data_1cur_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1cur _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.45 -0.464 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.4 m -79.2 61.51 3.34 Favored 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.37 -0.831 . . . . 0.0 110.115 -178.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.7 m95 -79.46 136.16 36.85 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.988 1.715 . . . . 0.0 110.572 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -149.92 171.38 16.89 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -139.64 127.89 22.59 Favored 'General case' 0 C--N 1.341 0.213 0 CA-C-N 118.826 0.739 . . . . 0.0 109.826 171.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.17 -152.47 0.43 Allowed 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 125.551 1.54 . . . . 0.0 107.121 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.2 p -136.64 170.99 15.16 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 124.179 0.992 . . . . 0.0 108.482 173.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -39.06 -55.17 3.03 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 114.528 1.306 . . . . 0.0 114.528 -174.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -55.45 -33.53 86.27 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.517 1.478 . . . . 0.0 113.633 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -68.67 -29.36 67.81 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 119.118 0.872 . . . . 0.0 111.072 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 t -62.13 -50.2 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 174.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -54.43 -49.3 70.31 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.55 -61.53 2.14 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.034 0.534 . . . . 0.0 111.066 176.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 74.4 mtm -55.14 -45.84 75.65 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.202 0.601 . . . . 0.0 110.801 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.3 mt -53.28 -38.01 62.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.19 -0.433 . . . . 0.0 111.747 176.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -72.0 -45.69 60.0 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 175.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.5 mtpt -80.31 62.36 4.42 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 122.709 0.404 . . . . 0.0 110.791 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -134.94 134.64 40.8 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.375 1.07 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.2 p -96.48 24.02 6.27 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.935 0.894 . . . . 0.0 112.951 -175.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.21 100.0 2.43 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 125.727 1.632 . . . . 0.0 110.986 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -78.51 159.13 28.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.626 1.171 . . . . 0.0 109.322 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 63.2 t -93.53 93.47 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.715 0.806 . . . . 0.0 110.34 -174.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.3 p -77.74 70.47 4.12 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 60.98 -96.72 0.11 Allowed Glycine 0 CA--C 1.527 0.835 0 C-N-CA 124.741 1.162 . . . . 0.0 111.045 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -86.98 -36.61 18.16 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.027 0.931 . . . . 0.0 110.543 178.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.3 m -89.88 166.54 13.45 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.728 1.611 . . . . 0.0 108.787 -172.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.12 144.17 18.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 172.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.7 m -134.07 117.36 16.54 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.687 1.195 . . . . 0.0 108.236 -175.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 -79.59 162.25 25.43 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.182 0.515 . . . . 0.0 110.778 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 67.2 m -154.24 159.59 41.39 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.103 0.961 . . . . 0.0 108.629 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.22 165.23 29.43 Favored Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 -174.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.2 mtpm? -73.54 -18.28 61.1 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 122.004 -0.704 . . . . 0.0 111.753 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.4 p -95.68 87.63 4.75 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.132 0.973 . . . . 0.0 109.064 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.0 t -81.84 77.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -86.3 87.65 7.47 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.089 -175.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.67 95.87 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 124.39 1.076 . . . . 0.0 109.173 -174.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.65 109.99 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 175.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -127.84 164.28 22.56 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.827 1.251 . . . . 0.0 109.365 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.77 167.43 24.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 176.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -136.18 114.03 11.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -174.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.7 t 34.38 69.01 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 C-N-CA 127.11 2.164 . . . . 0.0 112.339 174.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 90.9 mt -76.67 144.98 74.22 Favored Pre-proline 0 N--CA 1.453 -0.286 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo . . . . . 0 N--CA 1.457 -0.633 0 C-N-CA 123.21 2.607 . . . . 0.0 110.947 -174.585 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 . . . . . 0 CA--C 1.538 0.486 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -112.38 7.32 3.12 Favored 'Cis proline' 0 CA--C 1.535 0.532 0 CA-C-N 119.641 0.907 . . . . 0.0 113.09 0.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.4 p -83.71 154.9 23.38 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 115.043 1.497 . . . . 0.0 115.043 -171.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -79.37 139.06 37.86 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.747 1.219 . . . . 0.0 109.526 173.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.94 132.38 34.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 123.922 0.889 . . . . 0.0 110.094 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 t -125.97 83.47 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 172.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 55.7 p-80 42.08 -78.59 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 128.587 2.755 . . . . 0.0 115.008 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -84.37 -24.81 29.53 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 124.18 0.992 . . . . 0.0 111.723 -176.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -130.83 -174.9 3.5 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.584 1.153 . . . . 0.0 109.58 -174.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -128.91 92.1 3.34 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 26.73 69.82 0.45 Allowed Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 127.459 2.303 . . . . 0.0 115.882 -174.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -66.41 -55.56 0.36 Allowed 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.537 2.158 . . . . 0.0 108.674 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.2 m 169.53 154.63 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 129.257 3.023 . . . . 0.0 105.697 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.3 mp -117.22 124.79 49.95 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.969 1.308 . . . . 0.0 110.204 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -98.42 137.09 37.63 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 171.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.08 136.0 25.4 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.213 1.005 . . . . 0.0 110.867 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -76.47 112.06 3.38 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.705 2.937 . . . . 0.0 109.271 173.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.39 -41.37 9.06 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -173.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -72.75 -7.51 69.92 Favored Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.41 -0.661 . . . . 0.0 114.068 -175.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -85.94 165.07 17.04 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.741 1.271 . . . . 0.0 113.38 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 63.1 m -93.72 127.41 39.42 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 172.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 94.9 t -92.13 132.29 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -127.77 108.1 10.44 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.752 -1.574 . . . . 0.0 106.752 173.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.09 115.36 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 16.4 m -107.71 96.01 6.09 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 126.059 1.743 . . . . 0.0 107.181 174.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . 0.279 4.3 m-85 -78.79 151.57 31.9 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 172.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -127.79 69.6 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 102.595 -3.113 . . . . 0.0 102.595 162.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -80.64 113.08 18.58 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 171.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 52.3 m -137.93 45.38 2.13 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -78.55 113.71 16.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 172.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -72.8 69.8 0.95 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.166 0.586 . . . . 0.0 110.113 -178.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 174.43 -67.72 0.1 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -96.71 122.69 39.93 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -174.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.26 71.03 0.63 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.864 -1.695 . . . . 0.0 108.864 171.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -57.06 143.82 36.9 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.511 1.156 . . . . 0.0 111.356 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.3 p -106.76 161.25 14.84 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 125.435 1.494 . . . . 0.0 108.845 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -129.89 101.11 5.71 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 102.755 -3.054 . . . . 0.0 102.755 172.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -118.89 114.44 22.61 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -173.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 6.7 mt -95.2 125.31 47.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 C-N-CA 125.44 1.496 . . . . 0.0 110.297 -174.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -161.17 -145.46 0.11 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -113.0 -98.95 0.43 Allowed 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 174.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt 67.42 -67.32 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.887 1.275 . . . . 0.0 111.184 -174.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.78 170.35 28.9 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -174.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -75.1 147.01 32.99 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.634 2.223 . . . . 0.0 109.388 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.82 136.76 45.48 Favored 'Cis proline' 0 N--CA 1.454 -0.813 0 CA-C-N 119.48 0.85 . . . . 0.0 109.995 -5.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -79.03 149.24 32.24 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.93 144.03 39.12 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 121.188 0.518 . . . . 0.0 112.155 -173.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.15 -43.28 98.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.9 mtp -78.1 133.18 65.33 Favored Pre-proline 0 N--CA 1.45 -0.425 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 173.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -75.65 85.24 1.63 Allowed 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.669 1.579 . . . . 0.0 109.307 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.8 t -76.41 105.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -178.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 23.4 pt -78.91 72.98 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 123.241 1.495 . . . . 0.0 110.534 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -62.57 154.5 73.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 113.328 -1.76 . . . . 0.0 106.398 171.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_exo -37.62 104.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 124.031 3.154 . . . . 0.0 113.835 -176.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 31.4 mm -78.95 131.27 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.97 -88.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 104.753 -2.314 . . . . 0.0 104.753 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.3 150.3 20.72 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 170.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.89 168.08 39.8 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.8 174.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 2.8 p -120.77 127.61 52.13 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.291 1.036 . . . . 0.0 109.991 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.62 57.0 5.04 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 119.502 -0.61 . . . . 0.0 111.985 -176.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 73.33 99.68 0.07 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 126.256 1.822 . . . . 0.0 111.488 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.3 p -74.13 160.32 81.87 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 118.767 -0.635 . . . . 0.0 110.578 -176.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 169.08 2.07 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 123.559 2.839 . . . . 0.0 116.032 -173.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 92.6 t -121.38 97.08 47.54 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 126.641 1.976 . . . . 0.0 107.627 178.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -70.52 -179.77 3.5 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.936 3.091 . . . . 0.0 114.005 -176.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -109.88 -164.87 0.96 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.814 1.646 . . . . 0.0 107.305 172.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -60.99 153.43 25.18 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.518 -0.739 . . . . 0.0 111.003 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.71 3.1 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 123.808 0.718 . . . . 0.0 113.276 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -80.02 156.06 27.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.196 0.598 . . . . 0.0 111.798 -175.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -135.88 106.87 6.68 Favored 'General case' 0 CA--C 1.513 -0.456 0 C-N-CA 125.677 1.591 . . . . 0.0 110.289 -172.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -64.41 123.27 27.09 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.269 -1.932 . . . . 0.0 108.269 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -130.98 165.04 24.04 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 122.127 0.965 . . . . 0.0 109.886 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.0 m -152.62 120.76 6.23 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -103.57 104.6 14.68 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -118.74 147.74 43.53 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 28.6 m -104.14 152.05 22.58 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.804 0.842 . . . . 0.0 109.731 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -151.38 147.72 27.25 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.824 1.25 . . . . 0.0 109.161 175.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 44.8 m80 -116.15 111.37 42.64 Favored Pre-proline 0 N--CA 1.454 -0.256 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 172.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -82.64 -170.98 1.03 Allowed 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.892 2.395 . . . . 0.0 110.688 -173.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.0 p -140.95 147.9 39.53 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.69 152.46 35.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -174.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.55 -129.68 8.14 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 126.508 2.004 . . . . 0.0 108.982 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.8 m -142.82 137.48 29.69 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 117.437 0.618 . . . . 0.0 109.667 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.4 m-85 -130.42 176.75 7.88 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.484 1.914 . . . . 0.0 106.182 172.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -142.53 147.85 36.64 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 173.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -115.21 147.03 40.84 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 172.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.2 m -144.96 154.46 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 125.042 1.337 . . . . 0.0 109.735 -174.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.43 107.64 19.8 Favored 'General case' 0 C--N 1.333 -0.125 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 171.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.1 mm-40 -74.72 38.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -174.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 16.5 mt -93.24 142.73 25.67 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 104.305 -2.479 . . . . 0.0 104.305 168.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -48.24 138.85 22.48 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.028 1.818 . . . . 0.0 112.94 178.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.0 -46.67 2.45 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.312 0.958 . . . . 0.0 113.193 176.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.2 m170 -42.55 -55.8 3.34 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.814 1.646 . . . . 0.0 113.882 -173.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.88 -53.54 57.02 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.71 0.29 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.71 -38.67 88.72 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 124.117 0.967 . . . . 0.0 111.684 -176.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 31.0 p -78.31 -32.32 49.24 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 118.731 -0.652 . . . . 0.0 111.293 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.12 -30.61 0.1 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 118.355 -1.879 . . . . 0.0 116.234 173.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.315 10.3 ptp -80.4 84.46 6.03 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 120.053 1.927 . . . . 0.0 112.707 -174.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -141.93 174.49 10.54 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 126.532 1.933 . . . . 0.0 107.296 172.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -156.28 128.28 2.18 Favored Glycine 0 C--N 1.331 0.285 0 N-CA-C 108.482 -1.847 . . . . 0.0 108.482 173.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -76.99 130.12 37.05 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 174.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.0 mt -110.87 100.91 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 25.7 t -88.84 110.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 174.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.8 t -97.66 94.66 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 63.9 mttp . . . . . 0 C--N 1.332 -0.165 0 O-C-N 121.525 -0.734 . . . . 0.0 109.041 176.373 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.6 p . . . . . 0 CA--C 1.537 0.457 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.9 m -78.05 68.93 4.19 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 32.6 m95 -103.45 129.01 50.5 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 126.853 2.061 . . . . 0.0 109.772 -176.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -151.92 178.4 9.45 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -131.27 127.04 36.96 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 171.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.75 -150.62 0.27 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.6 p -137.34 170.41 16.13 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 119.475 1.034 . . . . 0.0 108.563 172.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.6 tt -39.53 -55.74 3.23 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 124.316 1.046 . . . . 0.0 113.582 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -56.54 -33.23 92.29 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 CA-C-N 121.011 1.397 . . . . 0.0 113.861 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -64.94 -25.25 67.8 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 118.946 0.794 . . . . 0.0 111.452 177.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.2 t -53.91 -46.94 64.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.651 0.659 . . . . 0.0 109.277 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 mtmm -59.12 -54.17 50.04 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.27 -47.66 62.42 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.84 0.456 . . . . 0.0 111.378 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -62.3 -54.78 35.65 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 119.47 -0.3 . . . . 0.0 110.672 177.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.6 mt -50.58 -47.8 57.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 118.423 0.556 . . . . 0.0 111.392 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -54.06 -25.94 24.19 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.003 0.921 . . . . 0.0 113.093 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -88.21 -9.12 54.06 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 118.9 0.773 . . . . 0.0 112.116 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -49.48 145.8 4.52 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -176.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.7 p -121.0 166.4 13.9 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.599 1.159 . . . . 0.0 108.851 171.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.69 116.71 2.92 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 124.521 1.058 . . . . 0.0 110.787 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 49.4 mtmt -81.68 144.35 31.24 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.558 1.143 . . . . 0.0 108.989 176.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 81.4 t -67.78 145.32 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 122.781 0.432 . . . . 0.0 110.603 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.9 m -150.82 68.95 0.96 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.767 1.227 . . . . 0.0 109.132 174.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.28 -115.45 7.14 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -79.01 -31.22 44.63 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 118.054 0.927 . . . . 0.0 109.109 172.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -79.54 153.39 29.56 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.742 -173.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -120.47 135.32 61.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 171.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 74.2 m -121.7 133.49 54.95 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.302 1.041 . . . . 0.0 110.459 -169.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 79.2 m-85 -105.55 177.72 4.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 124.086 0.954 . . . . 0.0 109.589 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.8 m -154.36 -50.0 0.09 Allowed 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.468 0.707 . . . . 0.0 109.609 177.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -65.63 145.22 48.2 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -60.6 -31.69 70.84 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.179 0.592 . . . . 0.0 111.088 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.8 m -78.1 76.21 4.62 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -78.04 102.59 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 30.9 t-80 -106.95 102.94 12.26 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 123.818 0.847 . . . . 0.0 109.563 -178.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 86.0 t -99.89 151.03 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 125.231 1.413 . . . . 0.0 108.777 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.6 t -130.72 100.49 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 124.618 1.167 . . . . 0.0 108.494 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -106.14 155.46 19.42 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 125.362 1.465 . . . . 0.0 110.731 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.73 158.41 44.01 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 124.511 1.125 . . . . 0.0 109.3 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.84 117.77 24.86 Favored 'General case' 0 N--CA 1.456 -0.157 0 C-N-CA 123.556 0.742 . . . . 0.0 111.032 -173.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.9 t 42.29 66.92 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 C-N-CA 125.323 1.449 . . . . 0.0 111.618 173.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.5 mt -77.88 153.43 80.44 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo . . . . . 0 N--CA 1.456 -0.716 0 C-N-CA 123.054 2.502 . . . . 0.0 111.704 175.58 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 . . . . . 0 CA--C 1.533 0.309 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -111.69 67.48 0.23 Allowed 'Cis proline' 0 N--CA 1.455 -0.791 0 N-CA-C 107.726 -1.682 . . . . 0.0 107.726 -6.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 79.0 p -92.19 133.66 35.59 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -86.34 122.4 30.25 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 169.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -93.32 131.01 38.87 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 104.57 -2.382 . . . . 0.0 104.57 171.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.5 t -137.5 114.92 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 120.226 1.375 . . . . 0.0 110.61 -173.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 36.79 -114.31 0.1 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.771 1.628 . . . . 0.0 112.837 -178.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -81.61 7.1 13.08 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -174.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -146.66 -169.77 3.36 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.526 1.13 . . . . 0.0 110.518 -172.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? -135.22 128.14 31.38 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 172.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 45.99 49.86 7.21 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 125.076 1.35 . . . . 0.0 111.963 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -81.71 173.7 11.05 Favored 'Trans proline' 0 N--CA 1.452 -0.942 0 C-N-CA 122.811 2.34 . . . . 0.0 111.998 -174.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.4 m -94.92 144.8 25.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 113.923 -1.49 . . . . 0.0 107.123 172.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.6 mp -113.23 139.47 48.76 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.093 -1.005 . . . . 0.0 109.983 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -115.37 98.75 6.92 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.531 1.533 . . . . 0.0 107.739 173.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.8 mt -101.16 138.08 19.87 Favored Pre-proline 0 CA--C 1.535 0.379 0 C-N-CA 126.408 1.883 . . . . 0.0 110.788 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.85 123.48 6.33 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 122.384 2.056 . . . . 0.0 107.65 171.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.64 138.46 17.98 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.578 0.751 . . . . 0.0 111.645 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 85.75 -1.57 88.04 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.521 -0.599 . . . . 0.0 112.691 -176.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.41 21.48 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 118.759 1.279 . . . . 0.0 112.065 174.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 89.3 m -91.73 91.3 7.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 171.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.0 t -79.15 99.46 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.298 1.039 . . . . 0.0 108.633 -172.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -98.64 107.35 19.78 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 126.113 1.765 . . . . 0.0 107.854 -178.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.1 t -101.83 116.92 46.33 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.0 m -88.25 137.29 32.45 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.21 146.33 39.49 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 123.712 0.805 . . . . 0.0 111.735 174.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.17 59.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 N-CA-C 101.222 -3.622 . . . . 0.0 101.222 163.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -92.93 73.2 4.81 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 104.635 -2.357 . . . . 0.0 104.635 -174.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.7 p -95.25 -77.46 0.47 Allowed 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.95 -171.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 51.71 -142.47 0.73 Allowed 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -172.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.4 mtpm? -149.01 123.58 9.76 Favored 'General case' 0 C--N 1.34 0.174 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.31 -55.19 3.22 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 118.883 0.765 . . . . 0.0 112.054 178.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -77.64 84.92 3.98 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 121.73 -0.865 . . . . 0.0 109.804 -174.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.26 75.59 0.01 OUTLIER Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.513 1.054 . . . . 0.0 110.697 172.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -55.51 163.81 1.18 Allowed 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.448 1.124 . . . . 0.0 110.096 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 93.0 p -131.91 165.95 22.74 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -132.31 93.03 3.18 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -98.38 130.76 45.03 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.748 1.219 . . . . 0.0 107.781 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 21.8 mt -102.49 133.53 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 124.635 1.174 . . . . 0.0 109.289 -173.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.9 t -157.88 -161.36 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -129.05 -0.0 5.24 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 124.324 1.05 . . . . 0.0 111.695 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -66.52 129.42 39.8 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -84.61 168.66 44.09 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 174.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -69.84 160.82 48.28 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.288 2.659 . . . . 0.0 110.114 174.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -75.74 163.96 89.08 Favored 'Cis proline' 0 N--CA 1.455 -0.745 0 N-CA-C 110.502 -0.615 . . . . 0.0 110.502 -4.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -111.14 152.79 26.59 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 176.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.16 153.32 34.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.3 t -59.11 -39.2 77.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 62.1 mtt -78.15 117.66 67.45 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.92 113.81 1.73 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.448 2.098 . . . . 0.0 111.924 -175.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 19.1 t -79.81 66.99 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 7.5 pt -79.42 -21.56 12.37 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.183 0 N-CA-C 115.145 1.535 . . . . 0.0 115.145 -172.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -49.55 -59.03 7.41 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 119.18 0.9 . . . . 0.0 111.597 177.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.92 62.7 6.64 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 122.796 2.33 . . . . 0.0 112.766 174.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.5 mm -113.62 145.77 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 172.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 48.9 t -97.19 -94.69 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 177.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.48 -176.5 3.95 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.76 0.824 . . . . 0.0 109.673 174.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.93 174.91 36.6 Favored Glycine 0 N--CA 1.443 -0.847 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 175.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 73.2 p -85.5 -50.68 7.06 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.354 0.597 . . . . 0.0 109.726 174.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 96.17 -176.79 33.3 Favored Glycine 0 CA--C 1.535 1.34 0 N-CA-C 105.559 -3.016 . . . . 0.0 105.559 -168.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -77.38 139.01 39.63 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.286 1.043 . . . . 0.0 109.667 -179.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.7 p -88.83 156.09 49.9 Favored Pre-proline 0 CA--C 1.537 0.451 0 N-CA-C 115.037 1.495 . . . . 0.0 115.037 -172.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.63 89.12 1.36 Allowed 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.321 2.681 . . . . 0.0 107.336 171.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 30.6 m -53.71 163.3 1.11 Allowed Pre-proline 0 CA--C 1.545 0.76 0 C-N-CA 124.774 1.23 . . . . 0.0 113.563 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.72 144.07 66.95 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 123.313 2.675 . . . . 0.0 113.775 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -108.62 21.77 16.82 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.851 1.26 . . . . 0.0 108.627 171.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 50.4 t0 79.31 139.7 0.07 Allowed 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 128.558 2.743 . . . . 0.0 107.953 -171.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 73.39 -50.03 1.64 Allowed Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.572 0.606 . . . . 0.0 112.102 -173.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -79.22 153.53 29.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.045 0.938 . . . . 0.0 112.194 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -130.23 95.68 3.97 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 127.233 2.213 . . . . 0.0 108.986 -173.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -45.54 112.87 0.84 Allowed Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.752 1.168 . . . . 0.0 111.506 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -131.63 175.21 9.37 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 122.504 1.145 . . . . 0.0 110.998 -176.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -167.84 156.13 9.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -141.11 90.91 2.35 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 172.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -110.23 153.53 24.68 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 25.0 m -118.5 140.91 49.13 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 124.659 1.184 . . . . 0.0 110.237 -173.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 2.8 p-90 -146.86 161.31 40.96 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.896 0.878 . . . . 0.0 110.676 174.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -133.71 89.18 31.29 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 125.467 1.507 . . . . 0.0 108.306 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -78.98 151.71 24.2 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.579 2.186 . . . . 0.0 110.239 -176.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.5 p -79.63 164.54 23.71 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.974 0.51 . . . . 0.0 110.172 174.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -67.02 157.03 34.48 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.939 -0.476 . . . . 0.0 111.976 -176.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.33 -118.86 4.1 Favored Glycine 0 C--N 1.335 0.499 0 C-N-CA 126.123 1.821 . . . . 0.0 109.084 -178.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -149.72 127.77 11.95 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.833 0.817 . . . . 0.0 109.606 -178.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -110.03 171.61 7.35 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 127.494 2.318 . . . . 0.0 106.912 174.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -142.0 144.11 33.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.867 1.267 . . . . 0.0 108.517 177.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -107.33 134.14 50.84 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.2 m -138.34 144.01 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 C-N-CA 124.218 1.007 . . . . 0.0 109.35 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.2 t -86.21 139.8 30.72 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -113.24 36.52 3.51 Favored 'General case' 0 CA--C 1.523 -0.088 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 -171.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 45.6 mt -91.59 133.54 30.91 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 103.798 -2.667 . . . . 0.0 103.798 168.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -39.11 128.37 1.41 Allowed 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.751 2.967 . . . . 0.0 113.968 -176.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.33 -23.59 5.35 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 118.981 -0.899 . . . . 0.0 114.337 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -62.25 -53.32 56.91 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 120.079 1.939 . . . . 0.0 111.62 -172.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -55.31 -48.51 74.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.896 -0.503 . . . . 0.0 110.559 175.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.96 -40.4 80.48 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.768 0.827 . . . . 0.0 111.923 -176.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 19.1 p -78.2 -40.48 37.42 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 119.054 -0.498 . . . . 0.0 109.997 -178.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 147.08 20.58 0.1 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 115.9 1.12 . . . . 0.0 115.9 172.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 15.6 ttt -80.02 76.71 6.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 119.66 1.73 . . . . 0.0 107.709 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.71 6.29 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 122.812 0.445 . . . . 0.0 111.734 -174.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -175.68 165.81 36.78 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 171.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -104.29 147.76 27.13 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 124.39 1.076 . . . . 0.0 109.341 -173.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.9 mt -128.18 96.84 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.5 131.9 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 174.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 35.2 t -118.66 93.93 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 106.995 -1.483 . . . . 0.0 106.995 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--N 1.332 -0.179 0 O-C-N 121.679 -0.638 . . . . 0.0 109.354 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.8 p . . . . . 0 CA--C 1.543 0.687 0 N-CA-C 114.453 1.279 . . . . 0.0 114.453 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 89.8 m -77.53 73.77 4.1 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.601 1.16 . . . . 0.0 108.301 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -107.09 134.42 50.25 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 127.588 2.355 . . . . 0.0 107.645 -177.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -151.38 -177.42 6.06 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 119.846 1.203 . . . . 0.0 109.601 176.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -136.5 149.07 47.98 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 172.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.29 -152.17 0.5 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.642 1.977 . . . . 0.0 106.573 174.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.6 p -135.79 173.01 12.19 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 119.152 0.887 . . . . 0.0 108.744 172.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.17 -56.89 2.41 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 114.455 1.279 . . . . 0.0 114.455 -175.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -54.67 -34.04 82.08 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.53 1.487 . . . . 0.0 113.456 -178.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -68.36 -26.88 65.8 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.215 -0.928 . . . . 0.0 111.38 177.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.2 t -59.44 -51.83 68.1 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 174.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.0 mtpp -56.43 -52.04 66.14 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.078 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.88 -54.71 17.86 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.607 0.363 . . . . 0.0 111.566 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.7 mtm -57.46 -53.8 54.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 119.343 -0.36 . . . . 0.0 110.27 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.4 mt -51.37 -48.14 62.62 Favored 'General case' 0 N--CA 1.463 0.217 0 C-N-CA 122.811 0.444 . . . . 0.0 111.334 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -55.11 -31.87 61.59 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 122.813 0.445 . . . . 0.0 111.929 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.5 11.13 25.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.33 0.652 . . . . 0.0 111.663 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.41 109.36 4.72 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 120.387 -1.446 . . . . 0.0 110.01 175.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 36.49 0.25 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.599 0.76 . . . . 0.0 112.706 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.67 108.09 2.36 Favored Glycine 0 C--N 1.338 0.651 0 C-N-CA 125.658 1.599 . . . . 0.0 110.224 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -78.89 150.67 32.1 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.352 1.061 . . . . 0.0 108.872 178.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 70.4 t -70.46 145.98 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.803 -0.561 . . . . 0.0 110.612 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 38.2 m -150.26 68.31 0.98 Allowed 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.623 1.169 . . . . 0.0 108.758 174.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.69 -110.99 3.82 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.3 -28.56 38.22 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 117.876 0.838 . . . . 0.0 110.388 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.8 m -86.81 155.13 20.42 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.702 1.201 . . . . 0.0 109.237 -172.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.9 t -119.64 134.52 62.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 171.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -122.96 120.05 32.24 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.666 1.186 . . . . 0.0 108.576 -172.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -87.48 170.84 11.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.151 0.5 . . . . 0.0 109.98 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 51.0 m -152.24 151.58 31.13 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -177.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.64 177.21 27.19 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -173.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 mttm -76.94 -26.13 53.67 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 122.035 -0.685 . . . . 0.0 111.827 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.3 m -78.77 73.61 5.32 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.846 0.748 . . . . 0.0 110.201 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -82.37 83.36 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -88.13 86.0 7.03 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.438 -174.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.4 t -81.0 111.71 18.04 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.115 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 -177.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.62 97.75 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 123.251 0.62 . . . . 0.0 109.33 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.07 101.6 13.28 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.703 1.201 . . . . 0.0 110.101 -176.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.77 102.17 14.92 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.801 1.24 . . . . 0.0 108.435 177.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.71 111.78 23.44 Favored 'General case' 0 CA--C 1.529 0.162 0 O-C-N 121.042 -1.036 . . . . 0.0 111.12 -174.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 8.5 t 38.21 73.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.648 1.579 . . . . 0.0 112.743 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.85 155.53 82.96 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -177.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo . . . . . 0 C--N 1.347 0.5 0 C-N-CA 124.717 3.611 . . . . 0.0 116.397 -173.509 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 . . . . . 0 CA--C 1.537 0.465 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -117.26 -9.1 0.34 Allowed 'Cis proline' 0 CA--C 1.535 0.572 0 N-CA-C 114.451 0.904 . . . . 0.0 114.451 -4.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.4 p -90.04 157.78 17.64 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 121.134 3.753 . . . . 0.0 121.134 -165.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -77.75 121.6 24.25 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 103.476 -2.786 . . . . 0.0 103.476 169.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -106.61 134.95 48.97 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.0 t -132.84 83.43 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 123.539 0.736 . . . . 0.0 109.204 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.278 1.0 OUTLIER 44.11 -70.07 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 130.224 3.409 . . . . 0.0 115.587 179.165 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -95.51 -23.86 16.9 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 124.186 0.994 . . . . 0.0 111.243 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -131.32 -172.94 2.97 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.549 1.139 . . . . 0.0 108.967 -175.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -139.4 134.72 32.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 172.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 49.48 41.43 0.99 Allowed Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 123.895 0.878 . . . . 0.0 112.111 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -72.77 162.88 39.99 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 CA-C-N 120.982 1.386 . . . . 0.0 111.247 -176.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.1 m -78.41 127.15 31.77 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 171.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 7.7 mp -97.38 127.37 43.29 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 119.249 0.932 . . . . 0.0 109.634 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -107.78 120.71 43.0 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 171.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 40.9 mt -123.24 134.61 25.26 Favored Pre-proline 0 CA--C 1.537 0.456 0 C-N-CA 124.691 1.196 . . . . 0.0 111.964 -171.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -65.1 113.46 2.41 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.396 2.064 . . . . 0.0 109.661 170.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.17 132.02 19.53 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.526 0.73 . . . . 0.0 111.133 174.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 88.94 -4.24 84.81 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.455 -0.636 . . . . 0.0 112.573 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.81 164.63 24.84 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 118.846 1.323 . . . . 0.0 111.641 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 53.9 m -98.21 103.27 15.2 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.667 1.587 . . . . 0.0 108.197 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.7 t -83.07 112.15 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 124.118 0.967 . . . . 0.0 108.768 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -103.31 100.69 10.58 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 174.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.5 t -79.23 93.25 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 37.6 m -90.95 99.74 12.73 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.622 1.569 . . . . 0.0 109.134 -176.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -79.64 159.57 26.69 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.492 173.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.9 mp -142.28 82.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 N-CA-C 101.019 -3.697 . . . . 0.0 101.019 162.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -108.3 115.17 29.61 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 105.383 -2.08 . . . . 0.0 105.383 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.3 m -140.41 39.55 1.89 Allowed 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 -79.77 70.62 6.33 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.986 177.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.4 mttm -1.62 94.94 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.402 3.081 . . . . 0.0 113.904 -176.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 96.14 -36.72 3.71 Favored Glycine 0 CA--C 1.532 1.15 0 O-C-N 121.92 -0.487 . . . . 0.0 113.418 175.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -79.92 95.11 6.0 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.6 1.2 . . . . 0.0 110.922 -178.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.78 54.02 0.36 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.243 1.402 . . . . 0.0 113.226 174.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -47.27 129.67 12.81 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-N 118.907 1.354 . . . . 0.0 110.228 177.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.4 p -108.26 112.59 25.15 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 -176.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -79.34 94.75 5.55 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -101.29 130.87 47.53 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 124.584 1.154 . . . . 0.0 109.538 -172.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -109.75 130.43 62.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 119.059 0.845 . . . . 0.0 110.468 -175.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.2 t -159.12 -153.18 0.35 Allowed 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -121.39 42.55 3.05 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 119.577 1.08 . . . . 0.0 110.234 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -76.09 94.8 3.52 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.6 157.2 52.52 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.1 160.24 45.64 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.105 1.87 . . . . 0.0 110.206 174.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -78.19 142.79 71.01 Favored 'Cis proline' 0 N--CA 1.456 -0.717 0 CA-C-N 118.901 0.643 . . . . 0.0 110.538 -2.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -79.85 151.89 29.99 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 176.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.54 148.64 24.97 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.542 0.737 . . . . 0.0 109.849 -178.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 25.5 t -63.47 -31.76 54.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 173.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -78.18 119.28 76.75 Favored Pre-proline 0 N--CA 1.45 -0.447 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.44 77.37 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.341 2.027 . . . . 0.0 108.89 -174.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 90.9 t -76.12 108.57 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 -175.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 15.6 pt -79.0 75.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-O 122.956 1.36 . . . . 0.0 111.194 -175.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -67.03 154.28 92.84 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 170.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -40.45 109.15 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.812 3.008 . . . . 0.0 114.363 -170.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 29.0 mm -78.6 121.83 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 175.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 87.6 t -84.67 -83.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.77 167.46 11.42 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 171.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.06 160.36 13.23 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.0 p -79.6 -46.3 17.53 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.173 177.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 93.61 -173.06 33.44 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 104.651 -3.38 . . . . 0.0 104.651 -167.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -82.96 131.67 35.18 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 120.404 2.102 . . . . 0.0 109.691 -174.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 p -90.48 153.43 46.07 Favored Pre-proline 0 CA--C 1.534 0.327 0 N-CA-C 116.113 1.894 . . . . 0.0 116.113 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -75.34 143.36 27.91 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.905 2.403 . . . . 0.0 106.099 169.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.5 m -141.16 95.57 7.43 Favored Pre-proline 0 CA--C 1.534 0.328 0 CA-C-N 118.456 0.571 . . . . 0.0 111.956 -172.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -55.97 168.53 1.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.816 3.011 . . . . 0.0 113.068 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -113.71 -5.25 13.34 Favored 'General case' 0 C--N 1.34 0.169 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -176.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 18.0 t0 178.05 154.16 0.33 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 126.236 1.815 . . . . 0.0 109.285 176.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 68.29 -62.66 0.4 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.522 2.011 . . . . 0.0 113.675 174.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -78.88 155.88 28.89 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 123.973 0.909 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -135.84 107.83 7.15 Favored 'General case' 0 CA--C 1.517 -0.303 0 C-N-CA 125.116 1.366 . . . . 0.0 110.778 -173.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -61.52 110.88 3.42 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.748 1.166 . . . . 0.0 110.604 176.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -116.51 170.55 8.48 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 122.658 1.218 . . . . 0.0 110.172 174.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 2.8 m -159.01 146.48 17.54 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 -174.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.21 96.25 2.75 Favored 'General case' 0 CA--C 1.521 -0.157 0 O-C-N 124.017 0.823 . . . . 0.0 111.866 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -103.82 147.93 26.72 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 169.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 37.4 m -104.15 134.3 47.63 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 177.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -136.54 140.67 43.11 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.522 1.129 . . . . 0.0 108.947 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -110.66 90.12 10.12 Favored Pre-proline 0 N--CA 1.455 -0.203 0 N-CA-C 105.174 -2.158 . . . . 0.0 105.174 173.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.16 147.55 42.78 Favored 'Trans proline' 0 N--CA 1.445 -1.354 0 C-N-CA 121.664 1.576 . . . . 0.0 110.285 -173.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.3 p -79.66 162.98 24.92 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.83 171.95 1.91 Allowed 'General case' 0 CA--C 1.537 0.455 0 O-C-N 121.307 -0.871 . . . . 0.0 112.13 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 100.95 -127.05 9.13 Favored Glycine 0 CA--C 1.522 0.496 0 C-N-CA 125.227 1.394 . . . . 0.0 110.158 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.2 m -153.04 144.4 23.25 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.352 1.076 . . . . 0.0 110.928 -174.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -134.21 -177.33 4.53 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 126.719 2.008 . . . . 0.0 106.71 173.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -144.62 141.6 29.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.223 1.009 . . . . 0.0 109.109 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -101.3 143.58 31.18 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.8 m -150.71 151.96 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 125.169 1.388 . . . . 0.0 109.789 -177.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 52.6 t -97.72 102.32 14.05 Favored 'General case' 0 C--O 1.231 0.111 0 C-N-CA 124.407 1.083 . . . . 0.0 109.754 171.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -73.52 33.61 0.08 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 29.4 mt -92.63 142.09 25.34 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 169.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 99.1 Cg_exo -46.11 136.67 14.14 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.335 2.023 . . . . 0.0 113.093 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.26 -52.41 4.05 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 123.676 0.655 . . . . 0.0 112.661 179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -39.83 -55.64 1.93 Allowed 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.855 1.662 . . . . 0.0 114.849 -171.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -50.89 -41.49 58.45 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.451 0.569 . . . . 0.0 111.635 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.27 -50.86 19.99 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.217 0.607 . . . . 0.0 109.943 174.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.7 p -79.85 62.39 4.07 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.691 -0.631 . . . . 0.0 111.377 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.38 93.39 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 117.622 1.809 . . . . 0.0 117.622 171.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 7.5 mtp -122.35 68.6 0.95 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 119.862 1.831 . . . . 0.0 109.154 170.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -159.48 -177.71 6.61 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.493 0.717 . . . . 0.0 111.883 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.73 171.47 33.74 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 172.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.7 mttm -101.6 152.46 20.78 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 123.784 0.834 . . . . 0.0 109.495 -174.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.9 mt -124.35 94.14 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 174.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 27.1 t -88.53 131.76 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 36.1 t -128.1 109.65 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt . . . . . 0 N--CA 1.465 0.294 0 CA-C-N 119.001 0.818 . . . . 0.0 110.464 -179.132 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.1 p . . . . . 0 CA--C 1.536 0.408 0 CA-C-O 121.007 0.432 . . . . 0.0 111.701 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 m -78.69 58.53 2.29 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 -169.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -89.09 130.28 35.56 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.754 1.222 . . . . 0.0 107.916 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -149.8 176.2 10.93 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -137.93 151.99 48.53 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 170.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.34 -153.76 0.57 Allowed 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 127.355 2.262 . . . . 0.0 105.998 173.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.3 p -138.21 169.12 18.34 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.958 0.799 . . . . 0.0 109.684 175.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.72 -54.39 4.09 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -174.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -57.73 -33.52 96.91 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.6 1.534 . . . . 0.0 111.936 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.8 mm100 -67.67 -23.8 65.35 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 121.765 -0.584 . . . . 0.0 111.103 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 t -64.14 -49.67 80.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 173.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.5 mttp -58.89 -39.82 82.58 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 122.684 0.393 . . . . 0.0 110.321 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.21 -62.83 1.44 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 122.042 -0.411 . . . . 0.0 109.963 174.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -54.08 -43.52 70.41 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.642 0.777 . . . . 0.0 111.897 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.7 mt -54.76 -33.09 60.85 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 176.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.54 -14.98 62.22 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 119.396 0.998 . . . . 0.0 112.392 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.98 17.57 20.65 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.008 0.822 . . . . 0.0 110.129 173.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.05 154.07 42.12 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.432 -0.793 . . . . 0.0 109.108 172.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.82 165.34 34.81 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.547 0.739 . . . . 0.0 109.766 -172.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.12 136.8 5.95 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 124.347 0.975 . . . . 0.0 111.335 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -79.26 126.75 31.19 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.299 1.039 . . . . 0.0 108.483 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.96 83.95 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 125.46 1.504 . . . . 0.0 109.261 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.9 m -85.89 68.06 10.22 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.087 1.355 . . . . 0.0 108.451 -175.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.54 -105.95 1.31 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -87.43 -22.34 25.04 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.78 0.832 . . . . 0.0 111.536 176.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.4 m -97.35 155.74 16.76 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 124.928 1.291 . . . . 0.0 108.517 -173.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.0 t -114.56 135.5 54.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 174.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -124.03 122.93 39.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 119.191 0.905 . . . . 0.0 110.375 -173.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -79.55 174.55 11.46 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.243 0.544 . . . . 0.0 111.208 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.5 m -158.93 49.88 0.36 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.723 0.809 . . . . 0.0 110.186 -174.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.26 170.44 38.94 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 -177.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -82.11 -33.71 29.58 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.978 0.511 . . . . 0.0 111.304 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.5 p -83.2 84.46 7.48 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 121.301 -0.874 . . . . 0.0 108.767 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.6 t -86.07 83.35 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 C-N-CA 124.196 0.998 . . . . 0.0 108.894 -174.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -84.96 104.78 15.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 124.705 1.202 . . . . 0.0 109.765 -176.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.44 104.49 16.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.7 t -81.9 112.09 19.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 174.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -125.81 160.39 29.96 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.978 1.311 . . . . 0.0 110.267 -176.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.22 163.54 38.01 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.274 1.03 . . . . 0.0 109.65 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -129.35 122.62 29.88 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 124.017 0.927 . . . . 0.0 109.668 -179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.4 t 26.1 65.16 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 128.418 2.687 . . . . 0.0 113.12 174.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.9 mt -77.23 146.91 75.44 Favored Pre-proline 0 CA--C 1.534 0.36 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo . . . . . 0 N--CA 1.458 -0.609 0 C-N-CA 124.712 3.608 . . . . 0.0 113.679 -177.465 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -109.76 50.54 1.22 Allowed 'Cis proline' 0 CA--C 1.54 0.79 0 N-CA-C 108.087 -1.543 . . . . 0.0 108.087 -5.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 87.0 p -73.19 127.2 31.94 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 115.958 1.836 . . . . 0.0 115.958 -170.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -81.81 108.85 15.67 Favored 'General case' 0 C--N 1.343 0.318 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 168.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -84.31 136.66 33.82 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 120.011 1.278 . . . . 0.0 107.93 177.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -135.59 87.53 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 CA-C-N 119.128 0.876 . . . . 0.0 109.64 -174.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.0 p-80 39.27 -97.15 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.575 1.95 . . . . 0.0 113.632 -176.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.0 -27.24 64.53 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.882 0.473 . . . . 0.0 111.844 -174.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -127.19 -171.55 2.45 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.505 1.122 . . . . 0.0 110.718 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -135.6 127.45 29.36 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 172.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 51.16 44.15 2.02 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 125.044 1.338 . . . . 0.0 111.76 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.01 -178.0 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 122.87 2.38 . . . . 0.0 112.733 -173.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.9 m -104.45 136.2 44.47 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 113.079 -1.873 . . . . 0.0 106.44 172.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.7 mp -116.5 122.3 44.33 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 118.875 0.761 . . . . 0.0 112.038 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -93.27 127.09 38.71 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 171.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 25.4 mt -130.83 140.96 40.27 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 125.176 1.391 . . . . 0.0 111.711 -170.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -81.37 122.78 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.664 2.243 . . . . 0.0 109.137 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.98 143.06 3.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 125.205 1.402 . . . . 0.0 112.652 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 78.02 -12.08 19.44 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.28 -0.733 . . . . 0.0 113.695 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.68 148.66 23.89 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 119.035 1.418 . . . . 0.0 111.074 174.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 59.8 m -81.61 102.06 10.41 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 173.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.28 127.19 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -124.45 103.3 8.11 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.76 105.44 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.9 m -91.33 98.04 11.47 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.99 1.316 . . . . 0.0 107.93 175.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.69 156.04 30.94 Favored 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 120.916 -0.313 . . . . 0.0 110.902 173.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.1 mp -136.99 73.43 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 102.172 -3.27 . . . . 0.0 102.172 164.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.57 110.93 21.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 173.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 41.4 m -141.25 46.28 1.73 Allowed 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 173.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -68.43 -48.91 63.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.6 mtmm 93.34 155.33 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 129.709 3.204 . . . . 0.0 109.42 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 -66.89 1.59 Allowed Glycine 0 CA--C 1.53 1.029 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -172.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -79.8 104.03 10.1 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 124.222 1.009 . . . . 0.0 110.705 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.42 73.36 0.59 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 107.964 -2.054 . . . . 0.0 107.964 171.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -55.26 136.49 48.82 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.792 1.296 . . . . 0.0 111.506 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.3 p -96.43 157.01 16.1 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.242 1.417 . . . . 0.0 108.32 174.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -128.38 115.83 18.84 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 103.623 -2.732 . . . . 0.0 103.623 171.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.13 121.46 22.64 Favored 'General case' 0 C--O 1.226 -0.164 0 CA-C-N 119.151 0.887 . . . . 0.0 109.975 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 53.3 mt -97.8 132.87 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 125.651 1.58 . . . . 0.0 109.275 -174.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -157.39 -155.8 0.54 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.757 1.223 . . . . 0.0 107.963 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.8 mtpt -132.6 -2.85 3.36 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -174.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -74.84 134.53 41.69 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 118.844 0.747 . . . . 0.0 109.453 176.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.35 42.3 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 123.285 0.469 . . . . 0.0 112.14 -178.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -70.95 166.0 30.5 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.617 2.878 . . . . 0.0 109.792 174.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -78.39 139.19 54.08 Favored 'Cis proline' 0 N--CA 1.454 -0.805 0 N-CA-C 110.392 -0.657 . . . . 0.0 110.392 -3.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -81.93 151.44 27.23 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.39 153.29 31.71 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 56.6 t -57.77 -43.67 84.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -77.92 131.66 69.6 Favored Pre-proline 0 N--CA 1.451 -0.379 0 N-CA-C 104.535 -2.394 . . . . 0.0 104.535 172.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.87 75.43 2.68 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.25 1.967 . . . . 0.0 112.197 -172.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 t -79.21 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 172.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -86.71 -34.82 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 126.834 2.054 . . . . 0.0 113.289 -173.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -51.27 138.9 26.78 Favored Pre-proline 0 CA--C 1.535 0.389 0 C-N-CA 124.301 1.04 . . . . 0.0 111.901 -173.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.22 170.98 56.71 Favored 'Cis proline' 0 N--CA 1.459 -0.507 0 CA-C-N 119.629 0.903 . . . . 0.0 110.981 0.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 26.1 mm -124.05 144.33 34.19 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.109 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 174.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.9 t -95.39 -88.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 174.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.23 158.55 15.41 Favored 'General case' 0 N--CA 1.461 0.11 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 173.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.45 172.84 40.68 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 119.272 -1.442 . . . . 0.0 113.025 173.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.8 p -126.94 116.49 20.87 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.587 1.155 . . . . 0.0 110.653 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -76.17 65.11 2.71 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.515 1.055 . . . . 0.0 111.314 -179.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 76.24 98.75 0.07 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 127.186 2.194 . . . . 0.0 112.073 173.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.9 p -68.67 169.28 11.29 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-O 118.951 -0.547 . . . . 0.0 110.552 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -54.27 167.02 1.41 Allowed 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 123.295 2.663 . . . . 0.0 117.014 -172.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 79.0 t -124.67 92.02 48.52 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 126.78 2.032 . . . . 0.0 106.632 173.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -72.33 -170.2 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 123.376 2.717 . . . . 0.0 113.467 -176.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -128.82 172.93 10.81 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 172.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -49.71 147.47 3.6 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-O 121.077 0.465 . . . . 0.0 112.166 -174.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.04 -44.85 2.67 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.346 -0.697 . . . . 0.0 112.738 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -79.69 153.05 29.57 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.226 1.01 . . . . 0.0 110.839 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -135.51 114.66 12.3 Favored 'General case' 0 C--O 1.224 -0.25 0 C-N-CA 124.903 1.281 . . . . 0.0 111.079 -173.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -75.95 113.56 3.92 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 125.507 1.527 . . . . 0.0 110.281 -174.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -113.9 163.02 15.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 122.766 1.27 . . . . 0.0 110.882 175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.3 m -150.91 126.66 10.28 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.702 -1.962 . . . . 0.0 105.702 174.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.63 89.6 3.12 Favored 'General case' 0 CA--C 1.518 -0.267 0 C-N-CA 124.46 1.104 . . . . 0.0 108.069 178.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -101.2 143.97 30.63 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 27.2 m -106.25 149.26 27.04 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.353 1.061 . . . . 0.0 109.686 -174.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -147.78 145.95 28.99 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.235 1.014 . . . . 0.0 109.762 174.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.4 m80 -114.1 107.46 51.94 Favored Pre-proline 0 CA--C 1.531 0.233 0 N-CA-C 105.033 -2.21 . . . . 0.0 105.033 173.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -90.79 133.74 1.75 Allowed 'Trans proline' 0 N--CA 1.444 -1.388 0 C-N-CA 123.743 2.962 . . . . 0.0 113.447 -170.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -84.54 158.86 20.82 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.528 1.531 . . . . 0.0 107.05 170.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.18 167.73 3.84 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.104 0.865 . . . . 0.0 113.025 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 107.12 -177.08 21.5 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 126.263 1.887 . . . . 0.0 112.916 174.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 12.7 m -87.82 137.56 32.23 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 124.213 1.005 . . . . 0.0 109.483 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -133.26 167.32 20.58 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 125.302 1.441 . . . . 0.0 107.24 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -134.0 147.75 51.03 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.987 1.315 . . . . 0.0 108.134 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . 0.422 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 47.6 p90 -114.14 138.99 49.7 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.3 m -142.52 156.23 18.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.345 1.458 . . . . 0.0 110.258 -178.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 13.4 t -96.62 114.75 26.43 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.552 1.141 . . . . 0.0 109.033 172.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -61.92 -14.44 34.4 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 125.42 1.488 . . . . 0.0 114.738 -176.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 26.2 mt -58.78 130.41 85.7 Favored Pre-proline 0 CA--C 1.541 0.606 0 CA-C-N 120.002 1.274 . . . . 0.0 108.317 174.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.71 145.86 4.19 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 123.12 2.547 . . . . 0.0 112.972 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.18 -43.75 2.06 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-O 119.58 -0.566 . . . . 0.0 112.798 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -52.67 -55.21 24.15 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.534 1.167 . . . . 0.0 112.602 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -53.93 -52.7 59.78 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.098 0.408 . . . . 0.0 110.103 177.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.46 -42.92 71.22 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 124.016 0.927 . . . . 0.0 111.402 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.1 p -81.24 10.92 4.76 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 12.93 37.73 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.475 -1.18 . . . . 0.0 116.026 170.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 2.9 ttt -79.31 73.88 5.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.995 1.897 . . . . 0.0 108.426 174.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.24 -166.92 2.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.511 0.324 . . . . 0.0 111.425 -174.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.422 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.76 177.44 40.2 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 174.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -116.43 152.89 33.08 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.5 1.12 . . . . 0.0 110.879 -172.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.6 mt -129.12 141.11 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 105.297 -2.112 . . . . 0.0 105.297 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 28.9 t -132.48 108.94 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.63 113.98 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 -176.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 67.9 mttm . . . . . 0 N--CA 1.461 0.119 0 CA-C-N 118.495 0.589 . . . . 0.0 109.847 174.702 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.2 p . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.0 m -79.8 64.19 4.58 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 122.323 1.059 . . . . 0.0 108.164 178.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -80.49 121.48 25.81 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 125.859 1.664 . . . . 0.0 110.987 -173.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.3 mmtp -142.01 170.39 15.81 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 172.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -134.8 129.06 33.96 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 171.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.6 -156.76 0.53 Allowed 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 172.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 70.9 p -137.65 170.98 15.13 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 119.413 1.006 . . . . 0.0 109.876 174.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.15 -60.36 1.02 Allowed Pre-proline 0 CA--C 1.543 0.677 0 N-CA-C 115.325 1.602 . . . . 0.0 115.325 -173.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -60.06 -29.26 88.82 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 CA-C-N 121.588 1.603 . . . . 0.0 112.335 -178.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -67.03 -25.74 66.42 Favored 'General case' 0 N--CA 1.45 -0.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.533 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.83 -46.52 96.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 173.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -60.54 -49.27 78.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.68 -49.32 57.6 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 122.141 0.177 . . . . 0.0 111.358 177.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.3 mtm -63.7 -50.42 69.24 Favored 'General case' 0 C--O 1.224 -0.27 0 CA-C-O 118.907 -0.568 . . . . 0.0 110.767 177.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 mt -52.57 -40.96 63.16 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.45 1.023 . . . . 0.0 111.942 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -57.36 -36.04 70.7 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 122.848 0.459 . . . . 0.0 110.752 174.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.41 50.38 0.93 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.827 0.851 . . . . 0.0 109.601 174.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.77 -51.23 35.77 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.603 0.761 . . . . 0.0 110.174 -174.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . 0.299 70.3 p 65.3 -44.31 0.35 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.154 2.182 . . . . 0.0 114.932 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.4 118.45 13.72 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 119.535 1.061 . . . . 0.0 110.975 174.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -79.88 163.96 23.94 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 124.979 1.312 . . . . 0.0 109.158 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -85.27 151.24 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 C-N-CA 122.957 0.503 . . . . 0.0 110.156 -179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 60.4 m -150.89 72.23 1.06 Allowed 'General case' 0 C--O 1.227 -0.116 0 C-N-CA 124.918 1.287 . . . . 0.0 108.581 174.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.15 -144.31 47.62 Favored Glycine 0 CA--C 1.528 0.866 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -80.01 57.24 2.59 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.913 1.357 . . . . 0.0 109.743 174.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.9 m -160.89 153.93 21.37 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 178.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.92 152.16 15.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -140.98 136.78 32.5 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.328 -172.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -107.46 164.42 12.22 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.065 0.946 . . . . 0.0 109.907 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 m -159.19 47.45 0.3 Allowed 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.311 0.644 . . . . 0.0 110.069 -174.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -175.47 171.6 44.69 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 107.637 -2.185 . . . . 0.0 107.637 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -75.41 -32.33 60.71 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 117.69 0.745 . . . . 0.0 111.005 -177.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.06 71.41 5.53 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.42 0.629 . . . . 0.0 110.241 -174.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -81.79 77.95 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -176.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -80.78 111.86 17.62 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.891 0.876 . . . . 0.0 109.034 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.18 106.68 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.5 t -89.57 95.45 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 118.068 0.395 . . . . 0.0 109.967 -174.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.0 99.95 10.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.329 1.452 . . . . 0.0 111.47 -174.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.22 108.45 18.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 O-C-N 121.673 -0.642 . . . . 0.0 109.971 175.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.45 82.78 8.16 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 121.259 -0.901 . . . . 0.0 109.057 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 34.3 t 68.24 96.05 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 C-N-CA 125.167 1.387 . . . . 0.0 109.68 175.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.9 mt -77.23 144.0 70.41 Favored Pre-proline 0 CA--C 1.531 0.213 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo . . . . . 0 N--CA 1.453 -0.863 0 C-N-CA 123.397 2.732 . . . . 0.0 109.125 -179.122 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 . . . . . 0 CA--C 1.538 0.512 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -118.15 -23.54 0.09 OUTLIER 'Cis proline' 0 C--N 1.347 0.471 0 CA-C-N 120.701 1.286 . . . . 0.0 114.599 -5.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 p -86.17 160.37 19.24 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.959 2.948 . . . . 0.0 118.959 -166.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -76.68 117.25 18.12 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 171.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -101.98 103.18 13.79 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 104.248 -2.501 . . . . 0.0 104.248 -179.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.7 t -108.89 113.07 43.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 O-C-N 122.086 -0.384 . . . . 0.0 110.079 -171.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 30.59 -104.24 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 126.078 1.751 . . . . 0.0 113.869 -174.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -67.09 -24.16 65.92 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -173.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -139.37 -164.67 1.72 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 119.35 0.977 . . . . 0.0 111.335 -173.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.1 mtmt -125.33 130.99 53.07 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 172.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 47.58 45.31 2.6 Favored Pre-proline 0 CA--C 1.545 0.768 0 C-N-CA 124.227 1.011 . . . . 0.0 112.025 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -67.37 154.75 72.99 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.273 1.315 . . . . 0.0 111.114 -179.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.5 m -87.56 133.73 33.74 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 171.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -111.71 128.51 56.1 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.922 0.783 . . . . 0.0 110.824 -174.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -99.33 115.94 30.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 171.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 27.2 mt -120.64 142.34 34.03 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 124.552 1.141 . . . . 0.0 113.379 -169.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -78.89 119.46 4.36 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 122.532 2.155 . . . . 0.0 109.137 171.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.2 140.6 3.88 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 125.816 1.646 . . . . 0.0 111.95 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.97 -5.46 48.59 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-O 119.092 -0.838 . . . . 0.0 113.613 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 155.22 26.17 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 119.45 1.625 . . . . 0.0 111.049 174.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 73.7 m -83.76 96.85 8.86 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 174.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.65 100.12 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 C-N-CA 124.877 1.271 . . . . 0.0 108.046 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -92.52 91.52 7.63 Favored 'General case' 0 C--O 1.237 0.441 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 40.7 t -77.08 103.13 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 176.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 43.3 m -101.04 98.22 8.69 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.011 1.724 . . . . 0.0 109.232 -172.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.412 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.8 m-85 -77.91 156.58 30.21 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.574 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -139.21 78.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 101.576 -3.49 . . . . 0.0 101.576 164.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -97.1 101.83 13.48 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 178.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.2 m -148.37 54.38 1.02 Allowed 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 122.182 0.992 . . . . 0.0 108.721 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.83 -19.64 61.28 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.822 173.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mttm 81.5 121.49 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 127.649 2.38 . . . . 0.0 107.323 -173.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.38 -54.05 3.18 Favored Glycine 0 CA--C 1.534 1.233 0 O-C-N 121.595 -0.691 . . . . 0.0 112.921 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -78.53 79.42 4.96 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 121.444 -1.033 . . . . 0.0 110.718 -174.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -51.69 77.33 0.01 OUTLIER Glycine 0 CA--C 1.527 0.794 0 C-N-CA 126.603 2.049 . . . . 0.0 112.635 174.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -63.18 144.17 57.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 118.66 1.23 . . . . 0.0 111.251 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.9 p -106.51 154.73 20.43 Favored 'General case' 0 N--CA 1.444 -0.757 0 C-N-CA 127.024 2.13 . . . . 0.0 106.048 172.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.412 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 8.2 t80 -134.52 110.33 9.29 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 105.37 -2.085 . . . . 0.0 105.37 172.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -130.81 148.39 52.58 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.292 0.496 . . . . 0.0 110.397 -174.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.2 mt -114.56 137.93 46.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 C-N-CA 126.22 1.808 . . . . 0.0 110.048 -172.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.5 t -160.93 -155.0 0.39 Allowed 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.909 1.284 . . . . 0.0 107.714 177.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -122.2 8.45 9.75 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.905 0.882 . . . . 0.0 111.595 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? -63.0 114.11 3.49 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.29 170.25 38.88 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -68.67 164.06 34.64 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.072 2.514 . . . . 0.0 109.196 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.81 131.12 23.04 Favored 'Cis proline' 0 N--CA 1.455 -0.749 0 CA-C-N 119.464 0.844 . . . . 0.0 110.828 0.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -79.56 158.53 27.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 174.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -138.33 167.28 22.21 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.364 1.066 . . . . 0.0 108.15 -177.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.55 60.42 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 C-N-CA 124.324 1.049 . . . . 0.0 108.664 -176.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 52.3 mtm -147.09 103.96 3.83 Favored Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 124.51 1.124 . . . . 0.0 110.473 -174.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -64.93 75.49 0.22 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.191 2.594 . . . . 0.0 112.692 174.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.6 t -78.98 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 173.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 24.9 pt -83.05 -23.66 8.39 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 C-N-CA 124.713 1.205 . . . . 0.0 114.134 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -45.35 -56.96 8.29 Favored Pre-proline 0 CA--C 1.543 0.694 0 CA-C-O 118.92 -0.562 . . . . 0.0 111.779 176.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -76.07 67.76 6.73 Favored 'Trans proline' 0 CA--C 1.537 0.663 0 C-N-CA 122.178 1.918 . . . . 0.0 111.597 172.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.1 mm -118.65 142.08 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 172.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.0 t -98.61 -92.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.94 161.39 14.48 Favored 'General case' 0 C--N 1.334 -0.088 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 174.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.38 173.71 28.18 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 120.134 -1.031 . . . . 0.0 113.374 174.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 3.0 p -109.41 125.52 52.5 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.909 1.284 . . . . 0.0 110.152 -178.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -80.21 58.95 4.6 Favored Glycine 0 CA--C 1.535 1.314 0 CA-C-O 119.496 -0.613 . . . . 0.0 111.817 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 71.58 98.8 0.07 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.617 1.967 . . . . 0.0 112.263 174.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 p -78.61 165.15 51.69 Favored Pre-proline 0 CA--C 1.544 0.732 0 O-C-N 121.077 -1.014 . . . . 0.0 112.5 -175.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -60.79 159.64 28.11 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 123.252 2.635 . . . . 0.0 112.098 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.51 86.19 14.37 Favored Pre-proline 0 CA--C 1.533 0.313 0 C-N-CA 124.217 1.007 . . . . 0.0 110.896 -179.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -55.74 163.72 5.21 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.528 2.819 . . . . 0.0 113.024 173.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -92.98 -23.53 18.68 Favored 'General case' 0 C--N 1.338 0.086 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 178.19 159.93 0.53 Allowed 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.7 2.0 . . . . 0.0 109.32 -176.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 70.26 -63.41 0.78 Allowed Glycine 0 C--N 1.338 0.644 0 C-N-CA 125.524 1.535 . . . . 0.0 112.839 174.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -78.68 157.84 28.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 124.263 1.025 . . . . 0.0 109.609 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -139.71 107.67 5.71 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.237 1.415 . . . . 0.0 110.826 -172.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -60.76 109.65 2.51 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.576 1.084 . . . . 0.0 110.852 -178.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -127.55 156.48 42.15 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.849 0.833 . . . . 0.0 111.455 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 18.1 m -159.72 109.93 1.9 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.97 -1.468 . . . . 0.0 107.449 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -86.75 69.61 10.33 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.164 1.386 . . . . 0.0 107.333 173.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -72.19 129.66 38.98 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 118.304 -1.358 . . . . 0.0 108.331 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.9 m -101.95 126.99 49.0 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.411 -171.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -134.68 157.78 45.78 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.481 1.512 . . . . 0.0 109.522 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -123.35 115.43 28.64 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 174.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -92.36 148.2 2.93 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 124.301 3.334 . . . . 0.0 111.809 -172.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.7 p -95.02 149.62 21.05 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 124.888 1.275 . . . . 0.0 108.763 173.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.98 151.9 13.99 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.122 0.419 . . . . 0.0 111.733 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.3 -124.13 5.89 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.937 2.208 . . . . 0.0 109.592 -176.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.0 m -153.61 147.95 25.93 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.314 1.057 . . . . 0.0 110.222 -174.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -139.87 173.87 11.08 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 127.825 2.45 . . . . 0.0 106.912 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -136.15 148.75 48.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 126.402 1.881 . . . . 0.0 107.259 174.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -109.47 147.87 32.14 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 172.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.39 150.9 12.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.117 1.367 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 42.6 t -84.75 140.34 31.33 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 169.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -78.08 -20.71 51.75 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -173.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 54.7 mt -61.35 124.38 80.46 Favored Pre-proline 0 CA--C 1.544 0.739 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -25.28 -76.01 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.567 1 C-N-CA 126.011 4.474 . . . . 0.0 117.446 -172.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -77.45 -2.29 79.32 Favored Glycine 0 CA--C 1.525 0.679 0 O-C-N 121.691 -0.631 . . . . 0.0 114.046 -173.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -72.69 -48.29 40.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 119.364 1.582 . . . . 0.0 110.558 -173.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.15 -41.86 93.68 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 173.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.24 78.29 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.823 0.449 . . . . 0.0 111.51 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 26.3 p -79.38 -58.29 3.28 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -174.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 176.87 37.79 0.05 OUTLIER Glycine 0 C--N 1.339 0.7 0 C-N-CA 119.187 -1.482 . . . . 0.0 115.196 -174.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 10.4 mtp -116.39 72.39 0.81 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 118.193 0.996 . . . . 0.0 108.405 173.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -159.56 -174.72 4.79 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.318 0.647 . . . . 0.0 112.16 -177.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 164.53 171.01 30.26 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 174.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 42.9 mtmt -99.94 146.86 26.2 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 124.998 1.319 . . . . 0.0 110.609 -176.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.8 mt -124.59 101.77 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 173.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.5 t -92.42 137.64 21.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 172.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 11.5 t -127.9 123.55 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -175.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt . . . . . 0 N--CA 1.466 0.328 0 CA-C-N 119.823 1.192 . . . . 0.0 111.422 179.481 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 25.2 p . . . . . 0 CA--C 1.538 0.481 0 CA-C-O 120.316 0.103 . . . . 0.0 110.829 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.9 m -79.77 64.18 4.55 Favored 'General case' 0 CA--C 1.536 0.409 0 O-C-N 121.161 -0.962 . . . . 0.0 110.277 -174.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -85.91 134.55 33.88 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 126.34 1.856 . . . . 0.0 110.212 -173.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -149.55 173.04 14.05 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -138.77 151.16 46.85 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 172.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.31 -153.02 0.54 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.898 1.679 . . . . 0.0 106.664 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.7 p -135.65 173.95 11.15 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 119.462 1.028 . . . . 0.0 108.512 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -39.41 -57.05 2.51 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -54.76 -34.18 83.54 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 121.963 1.775 . . . . 0.0 113.531 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 21.0 mp0 -67.41 -25.73 66.08 Favored 'General case' 0 N--CA 1.456 -0.172 0 O-C-N 121.134 -0.979 . . . . 0.0 111.258 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.82 -46.91 93.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 174.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.1 -50.11 74.98 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.21 -48.36 62.06 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.7 mtm -62.93 -50.63 70.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.606 0.362 . . . . 0.0 110.516 177.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.8 mt -52.08 -41.95 62.8 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.436 0.562 . . . . 0.0 111.875 177.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -56.51 -23.62 40.95 Favored 'General case' 0 CA--C 1.538 0.513 0 O-C-N 121.542 -0.724 . . . . 0.0 112.678 177.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -100.95 12.55 37.46 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.653 0.781 . . . . 0.0 111.787 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -65.85 -46.27 79.1 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -174.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.4 p 63.8 -139.12 0.32 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.455 1.502 . . . . 0.0 109.27 -171.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.48 104.18 0.2 Allowed Glycine 0 CA--C 1.528 0.893 0 CA-C-N 118.593 0.633 . . . . 0.0 111.741 -177.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 37.3 mtpt -78.7 120.26 23.11 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 62.5 t -63.04 148.51 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -148.85 64.17 1.05 Allowed 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.15 -141.26 35.51 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -79.55 54.74 1.82 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 118.603 1.202 . . . . 0.0 109.642 174.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.7 m -161.31 147.12 14.17 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -118.18 137.87 50.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 175.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 93.2 m -120.57 119.22 32.29 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.832 1.253 . . . . 0.0 109.623 -173.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -83.07 169.43 15.91 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 122.083 0.944 . . . . 0.0 111.606 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 75.1 m -156.86 152.17 26.48 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.36 166.95 33.05 Favored Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -174.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 35.4 mtmm -82.82 -28.48 30.18 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 122.282 -0.54 . . . . 0.0 112.241 -174.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.2 p -81.59 78.01 8.39 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.484 -0.76 . . . . 0.0 109.588 -178.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -80.07 75.39 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -80.89 93.19 6.24 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.788 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -88.49 102.42 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.049 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -176.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 43.1 t -83.74 88.42 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.08 164.23 12.78 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.267 1.427 . . . . 0.0 110.227 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -159.62 169.31 24.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 123.96 0.904 . . . . 0.0 109.23 178.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.56 132.7 28.01 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 26.13 72.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 127.263 2.225 . . . . 0.0 113.009 173.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.1 mt -77.29 148.27 77.4 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 N--CA 1.455 -0.745 0 C-N-CA 122.999 2.466 . . . . 0.0 110.519 -175.083 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 . . . . . 0 CA--C 1.534 0.355 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -113.47 -11.92 0.64 Allowed 'Cis proline' 0 CA--C 1.539 0.774 0 CA-C-N 118.947 0.66 . . . . 0.0 113.535 -4.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.5 p -44.68 143.46 1.38 Allowed 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 118.586 2.81 . . . . 0.0 118.586 -170.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -77.27 129.14 35.49 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 168.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -104.33 132.52 50.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 177.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.5 t -139.91 123.67 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -14.74 111.32 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.515 1.926 . . . . 0.0 115.37 -173.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.4 t70 89.67 -28.02 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 127.309 2.244 . . . . 0.0 113.419 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -136.69 -168.97 2.36 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.524 1.154 . . . . 0.0 111.015 -173.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.5 mttp -137.5 134.88 36.25 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 171.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 48.82 40.62 0.8 Allowed Pre-proline 0 CA--C 1.548 0.882 0 C-N-CA 124.081 0.952 . . . . 0.0 112.69 -176.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.25 159.67 46.64 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 CA-C-N 120.993 1.39 . . . . 0.0 113.349 -171.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.58 121.23 25.55 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 127.647 2.379 . . . . 0.0 106.297 173.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.2 mp -103.99 117.94 35.5 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 119.862 1.21 . . . . 0.0 111.5 -178.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -93.36 120.09 33.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 171.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.0 mt -122.32 139.7 31.2 Favored Pre-proline 0 CA--C 1.538 0.514 0 C-N-CA 124.431 1.092 . . . . 0.0 112.906 -170.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -76.34 116.26 4.3 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 122.805 2.336 . . . . 0.0 108.728 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -48.69 139.58 9.43 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 125.12 1.368 . . . . 0.0 112.302 -178.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.25 -9.78 38.7 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.072 -0.849 . . . . 0.0 113.457 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 157.52 20.02 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.42 1.61 . . . . 0.0 110.52 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 50.2 m -83.71 101.68 11.72 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.1 t -79.64 99.81 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 174.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -96.59 97.16 9.17 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 174.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -80.02 108.02 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.2 m -99.7 96.71 7.8 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.009 1.724 . . . . 0.0 107.972 175.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.278 5.7 m-85 -79.26 148.1 32.29 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 118.726 -0.654 . . . . 0.0 110.31 172.66 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.07 79.38 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 102.514 -3.143 . . . . 0.0 102.514 163.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -99.48 104.7 16.55 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 172.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.0 m -121.77 38.44 4.11 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 173.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -78.39 73.23 4.94 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.245 -0.91 . . . . 0.0 109.12 175.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.4 mttm 0.16 97.32 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 129.126 2.97 . . . . 0.0 114.557 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.05 -34.29 3.62 Favored Glycine 0 CA--C 1.534 1.243 0 O-C-N 121.605 -0.685 . . . . 0.0 114.07 175.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -82.24 88.12 6.52 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 119.073 1.436 . . . . 0.0 110.171 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.29 63.04 0.4 Allowed Glycine 0 CA--C 1.533 1.168 0 C-N-CA 123.785 0.707 . . . . 0.0 112.545 175.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -51.06 120.78 5.23 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 118.941 1.37 . . . . 0.0 110.084 175.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.87 165.11 25.48 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.581 0.752 . . . . 0.0 109.628 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.422 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 21.4 t80 -133.15 103.37 5.98 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 106.376 -1.712 . . . . 0.0 106.376 172.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -118.38 137.34 53.19 Favored 'General case' 0 CA--C 1.516 -0.333 0 C-N-CA 123.434 0.694 . . . . 0.0 109.819 -176.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 25.8 mt -110.0 134.71 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 126.041 1.737 . . . . 0.0 109.075 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.2 t -158.65 -158.22 0.68 Allowed 'General case' 0 C--O 1.223 -0.301 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.0 mtmm -129.6 6.67 5.21 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 119.564 1.075 . . . . 0.0 112.5 -179.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.9 mtpt -67.51 160.71 27.08 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.08 160.06 16.18 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -72.78 159.5 48.29 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 122.791 2.327 . . . . 0.0 109.893 174.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.79 134.83 34.28 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 N-CA-C 108.75 -1.288 . . . . 0.0 108.75 -5.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -83.13 31.36 0.44 Allowed 'General case' 0 N--CA 1.468 0.463 0 O-C-N 120.979 -1.075 . . . . 0.0 113.377 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . 70.05 156.0 0.14 Allowed 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 127.703 2.401 . . . . 0.0 113.084 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.98 -46.25 85.26 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.386 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.1 mmt -78.92 160.1 72.19 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 174.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -70.25 59.12 1.85 Allowed 'Trans proline' 0 CA--C 1.538 0.725 0 C-N-CA 123.08 2.52 . . . . 0.0 114.153 -174.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.8 t -82.46 55.79 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 O-C-N 120.238 -1.539 . . . . 0.0 108.664 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -80.88 -38.6 17.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 C-N-CA 123.101 0.561 . . . . 0.0 110.998 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -55.48 147.43 38.73 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 124.445 1.098 . . . . 0.0 111.826 -174.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 79.1 Cg_endo -74.13 150.38 95.47 Favored 'Cis proline' 0 N--CA 1.459 -0.537 0 CA-C-N 118.851 0.625 . . . . 0.0 111.127 -0.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.2 mm -109.45 143.7 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 C-N-CA 124.42 1.088 . . . . 0.0 108.406 175.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.73 -89.49 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 174.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.89 156.48 16.33 Favored 'General case' 0 C--N 1.332 -0.155 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 173.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.29 173.51 41.11 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 119.063 -1.541 . . . . 0.0 112.817 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.9 p -123.15 137.09 54.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.398 1.479 . . . . 0.0 109.625 176.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.47 -164.34 7.49 Favored Glycine 0 CA--C 1.54 1.654 0 N-CA-C 108.136 -1.986 . . . . 0.0 108.136 170.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -67.63 118.66 11.21 Favored 'General case' 0 CA--C 1.537 0.47 0 O-C-N 120.8 -1.412 . . . . 0.0 112.286 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 p -69.71 161.08 77.01 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 126.201 1.8 . . . . 0.0 113.413 -173.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -74.4 144.96 33.3 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.023 2.482 . . . . 0.0 107.969 174.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.18 80.15 9.49 Favored Pre-proline 0 CA--C 1.536 0.442 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -53.89 164.69 2.29 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 124.627 3.551 . . . . 0.0 112.588 172.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -119.35 -0.05 11.02 Favored 'General case' 0 C--N 1.34 0.173 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -174.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -175.28 148.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.191 1.396 . . . . 0.0 109.026 176.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 66.15 -62.85 0.15 Allowed Glycine 0 CA--C 1.527 0.79 0 C-N-CA 126.579 2.038 . . . . 0.0 113.47 177.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -78.66 157.39 28.64 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-O 121.352 0.596 . . . . 0.0 110.018 -177.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -129.55 108.63 10.39 Favored 'General case' 0 CA--C 1.512 -0.481 0 C-N-CA 127.014 2.125 . . . . 0.0 107.943 -174.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.04 123.71 18.63 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 19.8 p90 -130.89 168.57 17.07 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.724 1.25 . . . . 0.0 110.701 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.8 m -155.53 124.68 6.21 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.83 106.63 16.3 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -119.06 150.61 39.68 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.3 m -114.69 145.29 42.21 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.882 0.873 . . . . 0.0 111.007 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 26.1 t90 -145.02 153.23 41.26 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.887 1.275 . . . . 0.0 109.236 174.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.9 93.96 44.96 Favored Pre-proline 0 CA--C 1.53 0.174 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -81.6 146.01 14.93 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.467 2.112 . . . . 0.0 111.358 -173.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 10.6 p -96.3 156.37 16.37 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 172.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.93 144.65 27.56 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -174.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 139.97 -132.58 5.62 Favored Glycine 0 C--N 1.337 0.611 0 C-N-CA 126.215 1.864 . . . . 0.0 109.984 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 33.5 m -150.52 145.07 25.73 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 118.026 0.913 . . . . 0.0 109.132 -174.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -147.02 175.64 10.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.738 2.015 . . . . 0.0 107.181 -175.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -142.57 155.37 44.98 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 125.354 1.462 . . . . 0.0 108.557 179.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -121.46 147.2 46.07 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 124.275 1.03 . . . . 0.0 110.915 175.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.65 160.66 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 124.855 1.262 . . . . 0.0 112.308 -174.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 7.1 t -102.82 133.49 47.8 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.876 1.67 . . . . 0.0 108.738 171.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -70.65 -34.67 72.3 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 113.816 1.043 . . . . 0.0 113.816 -173.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 70.8 mt -48.62 128.38 13.71 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.781 0.832 . . . . 0.0 109.993 -172.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -42.32 142.82 1.61 Allowed 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 124.26 3.307 . . . . 0.0 114.968 -173.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.45 -40.55 1.78 Allowed Glycine 0 CA--C 1.529 0.951 0 C-N-CA 123.995 0.807 . . . . 0.0 112.634 177.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -54.6 -47.26 73.6 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.568 0.747 . . . . 0.0 111.624 -173.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -81.84 -11.67 58.85 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.631 0.65 . . . . 0.0 112.4 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.56 -57.82 4.72 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 173.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.5 p -151.63 87.04 1.34 Allowed 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.91 -66.47 0.06 OUTLIER Glycine 0 CA--C 1.524 0.631 0 C-N-CA 119.82 -1.181 . . . . 0.0 113.951 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.0 ptm -141.59 113.19 7.7 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 117.671 0.736 . . . . 0.0 111.948 -173.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -163.56 -166.73 1.26 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.716 1.206 . . . . 0.0 108.169 176.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.14 173.33 36.71 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 175.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 29.9 mttp -109.78 150.31 28.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.709 1.204 . . . . 0.0 110.869 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 17.1 mt -128.33 130.01 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 174.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 6.2 t -118.01 135.81 57.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 173.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.03 123.11 64.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -174.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 53.3 mtmt . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 118.81 0.732 . . . . 0.0 111.093 -174.288 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.0 p . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.1 m -79.59 62.62 3.94 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.879 0.847 . . . . 0.0 108.729 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -78.48 123.81 27.45 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.188 1.395 . . . . 0.0 110.392 -172.428 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -142.64 173.55 11.44 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 174.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -141.15 148.76 40.54 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.847 -0.533 . . . . 0.0 109.607 171.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.74 -153.77 0.56 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 126.633 1.973 . . . . 0.0 106.212 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -134.97 172.22 13.32 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 119.084 0.856 . . . . 0.0 108.991 172.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -38.64 -57.44 1.95 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -174.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.24 -32.46 87.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.473 1.449 . . . . 0.0 113.318 -178.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.6 mp0 -65.7 -31.57 72.64 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.7 t -55.42 -49.74 70.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.954 0.797 . . . . 0.0 109.14 176.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 mtpp -57.03 -51.39 69.47 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.87 -51.58 39.33 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -61.18 -53.1 61.19 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.219 0.463 . . . . 0.0 110.708 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 58.4 mt -51.7 -40.7 60.6 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.672 0.669 . . . . 0.0 111.78 -177.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -59.36 -23.53 62.61 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.842 0.857 . . . . 0.0 112.726 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -70.88 -66.31 0.63 Allowed 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.315 0.961 . . . . 0.0 109.514 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 58.6 -62.22 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 126.716 2.006 . . . . 0.0 115.622 176.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 19.3 p 53.89 37.66 27.04 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.174 1.79 . . . . 0.0 112.301 179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -141.6 121.66 1.89 Allowed Glycine 0 CA--C 1.528 0.854 0 C-N-CA 124.88 1.229 . . . . 0.0 110.535 -174.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.3 mtpt -79.81 118.14 21.33 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.892 1.677 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.4 t -68.83 77.48 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 C-N-CA 124.939 1.296 . . . . 0.0 110.257 -174.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 m -81.09 70.08 7.84 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.687 1.195 . . . . 0.0 107.784 -179.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 62.95 -113.55 6.0 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -174.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -78.45 -19.1 53.87 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.856 0.828 . . . . 0.0 111.238 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 59.6 m -98.62 110.06 22.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -172.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.9 t -79.19 114.17 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 104.298 -2.482 . . . . 0.0 104.298 172.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.5 m -106.72 121.48 44.46 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 124.577 1.151 . . . . 0.0 111.679 -170.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -81.36 167.68 19.21 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.513 0.673 . . . . 0.0 110.752 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.0 m -159.55 46.97 0.28 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.992 0.917 . . . . 0.0 109.275 -177.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.52 170.35 42.77 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -78.62 -32.14 47.32 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 117.45 0.625 . . . . 0.0 111.602 -177.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.6 m -78.87 72.94 5.42 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.49 0.662 . . . . 0.0 109.617 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.4 t -80.31 86.08 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-O 121.788 0.804 . . . . 0.0 109.118 -174.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -85.69 101.96 13.2 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.938 1.295 . . . . 0.0 110.401 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.3 t -102.79 110.62 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 C-N-CA 124.484 1.114 . . . . 0.0 108.918 -176.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.06 101.64 12.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 CA-C-N 118.183 0.447 . . . . 0.0 110.267 -176.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -101.93 104.39 15.09 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.437 1.495 . . . . 0.0 111.244 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.6 110.57 21.42 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.486 1.514 . . . . 0.0 109.259 175.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -97.48 95.54 7.72 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.79 -0.569 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 46.68 69.74 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 C-N-CA 127.238 2.215 . . . . 0.0 111.153 173.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 27.3 mt -77.26 152.54 81.75 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-O 118.514 -0.755 . . . . 0.0 109.556 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_exo . . . . . 0 N--CA 1.457 -0.656 0 C-N-CA 124.139 3.226 . . . . 0.0 111.446 175.331 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 . . . . . 0 CA--C 1.535 0.398 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -115.7 -21.65 0.15 OUTLIER 'Cis proline' 0 N--CA 1.458 -0.592 0 CA-C-N 120.305 1.145 . . . . 0.0 113.631 -5.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.0 p -67.55 148.54 51.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -167.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -75.54 131.48 40.07 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 173.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -102.23 131.1 48.99 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 172.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 t -138.33 122.01 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 CA-C-N 119.245 0.93 . . . . 0.0 108.809 -174.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 12.58 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 127.756 2.422 . . . . 0.0 115.335 -178.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 t70 76.21 -32.45 0.2 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.078 1.351 . . . . 0.0 113.595 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.2 mmmp? -121.58 -173.29 2.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 122.351 1.072 . . . . 0.0 112.367 -171.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -133.12 125.5 29.66 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 105.332 -2.099 . . . . 0.0 105.332 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 43.85 50.18 6.17 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.195 0.998 . . . . 0.0 111.83 -173.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.76 157.87 58.91 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 121.717 1.611 . . . . 0.0 110.485 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.2 m -84.44 145.88 27.93 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 105.893 -1.892 . . . . 0.0 105.893 170.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.0 mp -114.24 121.47 43.81 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.506 -0.747 . . . . 0.0 109.542 -177.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -98.94 118.54 35.95 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 171.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.9 mt -122.14 133.68 24.45 Favored Pre-proline 0 N--CA 1.453 -0.289 0 C-N-CA 124.978 1.311 . . . . 0.0 110.448 -172.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.93 118.39 5.02 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.127 1.885 . . . . 0.0 108.137 172.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.38 136.37 20.5 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.883 0.873 . . . . 0.0 111.196 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -12.71 67.65 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.672 -0.516 . . . . 0.0 112.156 -175.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.97 154.14 16.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 118.481 1.14 . . . . 0.0 112.909 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 99.5 m -92.15 105.72 17.88 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.472 -2.047 . . . . 0.0 105.472 171.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.2 t -88.04 93.78 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 C-N-CA 124.344 1.058 . . . . 0.0 108.178 -175.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.87 94.9 6.56 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 173.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.9 t -79.6 94.6 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 174.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 96.5 m -86.43 97.06 10.25 Favored 'General case' 0 N--CA 1.444 -0.732 0 C-N-CA 126.085 1.754 . . . . 0.0 108.539 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -77.29 156.73 31.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.169 0.509 . . . . 0.0 111.607 173.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -140.59 86.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 100.857 -3.757 . . . . 0.0 100.857 164.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -105.13 113.83 27.66 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.7 m -143.4 37.48 1.36 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -78.96 65.28 4.11 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.581 -0.699 . . . . 0.0 109.369 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.5 mttm 17.7 81.18 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 128.424 2.689 . . . . 0.0 114.688 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 95.15 -29.91 8.82 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.885 176.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -78.38 99.02 6.2 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 119.265 1.532 . . . . 0.0 109.917 -174.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.81 60.97 0.94 Allowed Glycine 0 CA--C 1.523 0.591 0 C-N-CA 124.806 1.194 . . . . 0.0 110.614 176.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -33.68 -52.29 0.41 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 126.114 1.766 . . . . 0.0 115.411 -172.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 17.5 p 78.43 134.06 0.06 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 125.889 1.676 . . . . 0.0 108.742 -172.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -114.44 108.7 17.23 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.638 -2.727 . . . . 0.0 103.638 172.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.86 139.12 47.61 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -173.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 mt -124.75 134.42 66.87 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.838 0.828 . . . . 0.0 110.39 -173.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -160.22 -163.08 1.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -175.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -120.97 5.69 10.39 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.814 0.846 . . . . 0.0 111.788 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -71.67 130.14 40.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 174.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.92 169.18 25.25 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.016 0.817 . . . . 0.0 112.158 -176.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -72.51 167.13 27.86 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.507 2.804 . . . . 0.0 109.698 174.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -68.2 130.74 15.47 Favored 'Cis proline' 0 N--CA 1.459 -0.544 0 CA-C-N 119.483 0.851 . . . . 0.0 111.218 -5.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -79.93 148.72 31.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 175.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.27 156.7 24.19 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.347 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 73.9 t -61.26 -34.75 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 55.2 mtm -78.05 128.13 79.61 Favored Pre-proline 0 CA--C 1.534 0.344 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 173.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.25 101.91 1.3 Allowed 'Trans proline' 0 N--CA 1.451 -0.971 0 C-N-CA 122.542 2.161 . . . . 0.0 110.602 -173.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 22.0 t -77.69 93.5 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.0 pt -78.49 -85.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.702 0.801 . . . . 0.0 112.788 -173.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -67.82 150.16 97.92 Favored Pre-proline 0 N--CA 1.454 -0.242 0 O-C-N 121.723 -0.611 . . . . 0.0 112.237 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.61 113.24 2.88 Favored 'Cis proline' 0 CA--C 1.537 0.645 0 CA-C-N 118.579 0.528 . . . . 0.0 112.878 1.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.7 mm -86.66 139.05 17.95 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.5 t -95.76 -87.2 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 174.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -93.64 166.65 12.13 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 173.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 179.6 41.55 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.3 p -124.68 124.57 42.47 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.696 1.199 . . . . 0.0 108.984 175.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.27 59.75 4.31 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.564 -0.575 . . . . 0.0 112.809 -173.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 71.17 93.66 0.08 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.244 1.818 . . . . 0.0 110.501 175.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 p -65.9 161.36 55.11 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 126.875 2.07 . . . . 0.0 115.357 -172.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -67.02 154.88 73.17 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 123.795 2.997 . . . . 0.0 108.995 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.4 t -147.19 85.31 6.92 Favored Pre-proline 0 CA--C 1.54 0.561 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -172.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -57.78 165.34 6.55 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.16 2.573 . . . . 0.0 112.722 174.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -101.43 6.39 42.48 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 -174.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.7 p30 143.38 166.45 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 130.355 3.462 . . . . 0.0 109.376 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.3 -66.54 0.95 Allowed Glycine 0 C--N 1.34 0.755 0 C-N-CA 125.431 1.491 . . . . 0.0 111.28 177.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -78.58 155.15 29.8 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 124.075 0.95 . . . . 0.0 108.466 174.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -137.61 109.78 7.3 Favored 'General case' 0 CA--C 1.518 -0.258 0 C-N-CA 125.063 1.345 . . . . 0.0 110.829 -172.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.11 114.02 5.79 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 124.63 1.109 . . . . 0.0 111.102 -177.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 22.1 p90 -122.21 164.67 17.42 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 122.292 1.044 . . . . 0.0 111.65 178.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 74.3 m -159.57 119.22 2.95 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -95.99 67.95 2.7 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 124.104 0.962 . . . . 0.0 108.501 176.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . 0.254 40.4 p90 -70.81 114.13 8.57 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 118.003 -1.479 . . . . 0.0 108.019 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.2 m -91.66 87.08 6.18 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.498 1.519 . . . . 0.0 109.974 -171.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.5 t90 -93.27 143.55 26.16 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.026 0.93 . . . . 0.0 110.951 -175.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -111.23 109.72 56.55 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 105.344 -2.095 . . . . 0.0 105.344 171.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -84.76 178.95 4.57 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 123.884 3.056 . . . . 0.0 111.462 -172.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 58.7 p -124.21 159.97 28.94 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 170.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.61 156.98 33.61 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 113.823 1.045 . . . . 0.0 113.823 -172.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 114.55 -176.86 17.2 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 126.254 1.883 . . . . 0.0 112.329 174.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 5.5 m -82.76 87.48 6.77 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.115 0.966 . . . . 0.0 110.262 -175.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -78.96 175.31 10.68 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 171.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -150.78 149.34 29.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.932 1.293 . . . . 0.0 109.541 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -112.31 146.52 38.1 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.233 1.013 . . . . 0.0 108.286 172.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -153.13 150.5 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 124.872 1.269 . . . . 0.0 110.404 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.82 106.99 19.19 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 169.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 34.3 mm-40 -75.17 34.32 0.11 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 114.695 1.368 . . . . 0.0 114.695 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 25.7 mt -92.21 137.2 25.0 Favored Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 169.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -43.94 129.2 7.54 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.596 2.197 . . . . 0.0 113.207 -178.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.65 -24.73 3.62 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.361 -0.688 . . . . 0.0 114.095 178.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -65.13 -52.53 54.74 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 119.796 1.798 . . . . 0.0 111.617 -172.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.62 -44.1 80.86 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 174.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.92 -42.9 99.02 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.777 0.431 . . . . 0.0 111.654 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.2 p -79.05 -59.93 2.58 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -174.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -178.9 31.43 0.06 OUTLIER Glycine 0 C--N 1.337 0.621 0 C-N-CA 119.296 -1.43 . . . . 0.0 115.033 -174.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.2 mtp -111.39 68.73 0.67 Allowed 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 118.2 1.0 . . . . 0.0 108.531 173.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -158.37 -177.52 6.6 Favored 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.09 165.48 24.56 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 173.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.2 mtmm -100.18 149.43 23.55 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.681 0.793 . . . . 0.0 109.492 -174.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.3 mt -125.96 93.96 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.102 1.761 . . . . 0.0 107.361 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.97 95.8 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 29.6 t -85.74 91.19 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 C--N 1.332 -0.193 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 177.094 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.448 -0.531 0 N-CA-C 110.627 -0.138 . . . . 0.0 110.627 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.4 m -79.01 63.96 3.81 Favored 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.259 -0.901 . . . . 0.0 109.956 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -78.25 125.57 29.55 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 125.157 1.383 . . . . 0.0 109.511 -173.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -144.23 -179.74 6.71 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.918 0.887 . . . . 0.0 108.672 174.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -142.65 154.21 44.15 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.671 0.669 . . . . 0.0 111.088 172.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.46 -152.43 0.51 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 128.19 2.596 . . . . 0.0 105.65 173.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -138.73 170.81 15.34 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 119.082 0.855 . . . . 0.0 110.042 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -38.85 -59.64 1.34 Allowed Pre-proline 0 CA--C 1.538 0.512 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -174.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -58.78 -30.73 93.48 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 CA-C-N 121.248 1.481 . . . . 0.0 112.074 -178.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -67.07 -25.33 66.19 Favored 'General case' 0 N--CA 1.449 -0.523 0 O-C-N 121.819 -0.551 . . . . 0.0 111.254 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.2 t -59.1 -54.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -57.73 -49.61 75.98 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.558 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.2 -57.91 6.75 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.05 0.54 . . . . 0.0 110.953 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.9 mtm -56.82 -50.21 73.07 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 122.816 0.446 . . . . 0.0 110.096 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.1 mt -53.35 -45.31 69.08 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.612 0.642 . . . . 0.0 110.92 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.79 -30.9 70.32 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 118.249 0.477 . . . . 0.0 111.146 177.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 mmpt? -80.42 1.57 28.6 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 123.214 0.606 . . . . 0.0 112.365 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.43 146.68 50.8 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.926 1.239 . . . . 0.0 110.381 175.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.6 p -109.65 32.4 5.07 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.424 0.69 . . . . 0.0 112.155 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.94 113.82 4.75 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 124.678 1.132 . . . . 0.0 110.802 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -79.45 145.72 33.14 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 174.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 t -73.57 148.73 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.769 -0.582 . . . . 0.0 109.623 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -150.76 65.68 0.93 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.753 0.821 . . . . 0.0 109.611 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.12 -138.49 41.52 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -174.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -79.82 50.58 1.19 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.74 1.27 . . . . 0.0 110.222 174.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 m -161.39 153.73 20.06 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -119.34 149.08 21.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.6 m -134.32 125.34 27.44 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.222 1.009 . . . . 0.0 108.974 -173.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -98.73 167.33 10.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 123.882 0.873 . . . . 0.0 110.0 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.1 m -156.7 161.53 39.84 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.904 1.282 . . . . 0.0 107.661 177.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 73.13 178.36 35.01 Favored Glycine 0 CA--C 1.529 0.969 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -78.04 -32.3 50.86 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 122.078 -0.66 . . . . 0.0 110.617 178.363 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 m -79.06 70.05 5.34 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.872 0.869 . . . . 0.0 110.777 -174.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 69.0 t -86.09 92.19 3.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.0 t-160 -94.49 94.94 8.51 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.852 0.861 . . . . 0.0 110.531 -173.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.4 t -92.26 94.29 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.2 t -89.83 103.54 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.99 112.23 21.51 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.146 0.978 . . . . 0.0 111.363 -173.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.16 148.44 23.65 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 121.593 -0.692 . . . . 0.0 109.559 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.52 109.18 16.92 Favored 'General case' 0 CA--C 1.527 0.058 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 174.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.5 t 40.52 81.59 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.408 1.883 . . . . 0.0 112.576 175.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 76.8 mt -76.91 147.59 77.62 Favored Pre-proline 0 CA--C 1.534 0.332 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -175.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo . . . . . 0 N--CA 1.455 -0.738 0 C-N-CA 123.876 3.051 . . . . 0.0 111.017 174.235 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 . . . . . 0 CA--C 1.539 0.525 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -116.73 -19.43 0.14 OUTLIER 'Cis proline' 0 CA--C 1.539 0.733 0 CA-C-N 119.108 0.717 . . . . 0.0 113.394 -6.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.52 151.22 47.69 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 118.964 2.95 . . . . 0.0 118.964 -168.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -77.35 128.92 35.11 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 104.249 -2.5 . . . . 0.0 104.249 169.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -111.62 115.34 28.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 -173.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 58.2 t -120.49 85.58 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 123.257 0.623 . . . . 0.0 109.517 -171.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 45.23 -97.19 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 126.177 1.791 . . . . 0.0 112.993 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -70.38 -23.61 62.8 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -134.36 -175.72 3.96 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.897 0.879 . . . . 0.0 110.903 -172.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.4 mtpp -131.07 129.58 42.12 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 172.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 50.58 42.95 1.42 Allowed Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 124.487 1.115 . . . . 0.0 113.115 -175.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -72.51 164.68 34.89 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.582 1.522 . . . . 0.0 114.291 -173.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . 0.266 0.2 OUTLIER -84.99 123.07 30.11 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 128.279 2.632 . . . . 0.0 106.088 173.571 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 8.9 mp -109.35 110.19 21.28 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.478 1.49 . . . . 0.0 113.221 -176.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -81.59 125.12 30.16 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 12.6 mt -127.29 140.34 37.65 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 124.283 1.033 . . . . 0.0 111.976 -171.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.05 118.18 4.01 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.287 2.658 . . . . 0.0 109.661 172.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.94 138.86 4.7 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.326 1.45 . . . . 0.0 112.175 176.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.17 -18.69 9.41 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-O 118.794 -1.004 . . . . 0.0 113.96 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.98 159.48 7.06 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.331 1.565 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.4 m -84.65 90.15 7.63 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.02 97.08 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -93.76 98.47 11.12 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.34 104.43 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.3 m -92.39 102.09 14.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.442 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.3 m-85 -77.67 154.91 31.71 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.422 173.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.2 mp -133.36 78.03 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 163.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -97.86 105.21 17.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 175.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.0 m -146.34 44.89 1.23 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -82.7 63.54 6.88 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -6.1 70.34 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 131.273 3.829 . . . . 0.0 114.82 -172.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 141.01 -47.46 0.86 Allowed Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.215 0.912 . . . . 0.0 111.062 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -85.33 100.18 11.65 Favored 'General case' 0 CA--C 1.528 0.13 0 O-C-N 122.076 -0.661 . . . . 0.0 111.125 -174.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.2 70.51 1.03 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 173.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -40.5 -49.21 2.9 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 116.164 1.913 . . . . 0.0 116.164 -171.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.7 p 78.22 148.28 0.1 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 120.027 1.285 . . . . 0.0 109.687 -172.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.442 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.9 t80 -138.39 108.31 6.33 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -115.52 135.85 53.67 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 118.798 0.727 . . . . 0.0 110.195 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.3 mt -110.26 130.53 63.35 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 126.186 1.794 . . . . 0.0 109.022 -177.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 t -159.39 -153.68 0.37 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -129.71 42.79 3.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 119.662 1.119 . . . . 0.0 110.573 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -91.69 110.92 22.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.143 0.577 . . . . 0.0 109.485 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.72 161.81 54.51 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 172.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.7 155.69 67.79 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.255 1.97 . . . . 0.0 109.62 174.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.51 167.87 78.0 Favored 'Cis proline' 0 N--CA 1.457 -0.667 0 CA-C-N 119.251 0.768 . . . . 0.0 111.301 -1.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -113.09 155.29 25.18 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.421 1.088 . . . . 0.0 109.106 177.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 156.56 26.68 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-O 121.378 0.608 . . . . 0.0 110.641 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 79.7 t -70.42 -36.9 68.58 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.743 175.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -78.34 152.04 78.45 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -38.85 111.9 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 124.996 3.797 . . . . 0.0 113.378 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.0 t -85.42 54.04 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 123.961 0.905 . . . . 0.0 109.021 -173.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.1 pp -88.0 91.05 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 122.519 1.152 . . . . 0.0 109.615 174.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.03 -157.55 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 126.254 1.822 . . . . 0.0 106.852 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -57.28 89.53 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 121.458 1.438 . . . . 0.0 109.34 153.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.1 mm -78.33 136.22 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 65.8 t -85.02 -88.81 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.556 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 175.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.42 155.71 16.63 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 171.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.51 166.34 33.52 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.312 -1.423 . . . . 0.0 111.438 174.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.6 p -118.44 142.28 47.71 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.251 1.42 . . . . 0.0 108.606 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.44 -161.45 6.79 Favored Glycine 0 CA--C 1.537 1.415 0 N-CA-C 108.174 -1.97 . . . . 0.0 108.174 172.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -67.17 106.38 1.99 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 120.842 -1.387 . . . . 0.0 109.899 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -62.5 156.68 61.3 Favored Pre-proline 0 CA--C 1.536 0.427 0 C-N-CA 126.731 2.013 . . . . 0.0 112.682 -174.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -67.27 151.28 81.13 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.999 2.466 . . . . 0.0 110.391 -175.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -129.95 74.5 80.52 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 123.821 0.848 . . . . 0.0 113.031 -175.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -60.91 174.89 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 122.419 2.079 . . . . 0.0 112.567 173.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 54.9 mttp -140.19 -168.46 2.54 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.891 1.277 . . . . 0.0 108.125 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 23.9 t70 55.65 -121.26 1.66 Allowed 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -174.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -112.71 9.98 25.7 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.716 -1.047 . . . . 0.0 112.856 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.1 mtpp -84.36 150.83 25.1 Favored 'General case' 0 C--N 1.341 0.233 0 CA-C-N 118.404 1.102 . . . . 0.0 109.007 175.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -132.87 110.32 10.23 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 124.292 1.037 . . . . 0.0 112.119 -173.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -66.88 116.07 7.85 Favored Glycine 0 CA--C 1.521 0.426 0 C-N-CA 125.178 1.37 . . . . 0.0 110.085 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -119.96 167.42 12.18 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 122.625 1.202 . . . . 0.0 110.804 175.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 61.7 m -154.69 115.23 3.91 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.02 83.6 5.19 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 172.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -90.42 151.52 21.38 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 35.7 m -121.54 145.57 47.83 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.021 0.528 . . . . 0.0 111.058 -173.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 24.0 t90 -143.61 144.17 31.8 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.45 1.1 . . . . 0.0 110.642 177.05 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 67.2 m-70 -109.6 109.93 59.74 Favored Pre-proline 0 CA--C 1.529 0.17 0 N-CA-C 104.857 -2.275 . . . . 0.0 104.857 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -90.73 133.6 1.76 Allowed 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.416 2.744 . . . . 0.0 113.606 -170.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.1 p -82.58 156.02 24.16 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.625 -1.621 . . . . 0.0 106.625 170.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -61.05 169.01 2.18 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 119.438 1.017 . . . . 0.0 112.438 -176.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 106.43 -177.98 22.37 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 125.636 1.589 . . . . 0.0 112.341 175.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 4.1 m -84.39 141.38 30.89 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.828 0.851 . . . . 0.0 110.073 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -137.35 170.11 16.64 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -142.57 146.83 34.99 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.961 1.304 . . . . 0.0 108.023 -178.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -115.59 140.87 48.77 Favored 'General case' 0 CA--C 1.528 0.097 0 O-C-N 123.984 0.803 . . . . 0.0 110.616 176.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.4 m -143.93 152.48 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 C-N-CA 124.548 1.139 . . . . 0.0 112.03 -174.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.1 t -98.8 125.7 44.24 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.58 1.552 . . . . 0.0 109.035 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 16.6 mm-40 -83.98 -4.26 58.59 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -173.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 30.8 mt -61.36 130.43 91.75 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 120.342 1.428 . . . . 0.0 108.239 175.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -39.44 125.08 1.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 124.118 3.212 . . . . 0.0 114.456 -174.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.94 -20.37 20.6 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 124.37 0.986 . . . . 0.0 113.226 176.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -66.98 -43.88 81.89 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 119.028 1.414 . . . . 0.0 112.303 -172.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -63.22 -48.7 77.17 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.703 0.683 . . . . 0.0 110.319 176.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.3 -54.57 43.88 Favored 'General case' 0 C--N 1.34 0.16 0 C-N-CA 123.755 0.822 . . . . 0.0 111.333 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.2 p -143.91 81.85 1.7 Allowed 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.226 1.011 . . . . 0.0 108.54 -174.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.49 -63.84 0.07 OUTLIER Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.246 176.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 4.0 ptm -157.9 129.5 6.8 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 117.795 0.797 . . . . 0.0 112.974 -172.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -162.74 -161.59 0.72 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.625 1.17 . . . . 0.0 108.349 175.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.49 171.36 33.42 Favored Glycine 0 C--N 1.334 0.452 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 172.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.0 mttm -110.95 153.69 25.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.373 1.069 . . . . 0.0 110.356 -173.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.9 mt -129.01 143.39 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.41 100.13 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -90.03 126.62 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 45.9 mtmt . . . . . 0 N--CA 1.46 0.052 0 CA-C-N 118.672 0.669 . . . . 0.0 110.828 -179.808 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 p . . . . . 0 CA--C 1.537 0.444 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.2 m -78.25 63.91 3.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.438 1.095 . . . . 0.0 112.155 -173.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 43.3 m95 -97.9 134.29 41.23 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.154 1.382 . . . . 0.0 109.538 174.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -149.57 -178.4 6.41 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -134.77 128.4 32.78 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 171.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.08 -151.82 0.31 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 172.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -142.03 168.13 20.49 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -39.58 -59.49 1.62 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -60.26 -28.74 87.48 Favored 'Trans proline' 0 N--CA 1.46 -0.496 0 CA-C-N 121.028 1.403 . . . . 0.0 112.19 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -66.93 -24.97 66.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 121.471 -0.768 . . . . 0.0 110.728 178.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 t -62.22 -50.28 80.61 Favored 'Isoleucine or valine' 0 C--N 1.34 0.177 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -58.1 -43.78 87.29 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -55.44 -58.3 8.32 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.903 -0.498 . . . . 0.0 110.988 175.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -58.33 -44.61 88.76 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 122.11 -0.369 . . . . 0.0 111.513 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.0 mt -50.52 -47.39 57.49 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.064 0.546 . . . . 0.0 110.746 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -61.89 -14.94 38.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.045 0.758 . . . . 0.0 113.045 178.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.5 mmmt -97.67 5.22 49.63 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 119.313 0.961 . . . . 0.0 111.651 176.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -74.65 125.16 28.08 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.051 -1.03 . . . . 0.0 110.507 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.9 p -93.27 29.33 1.94 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 123.306 0.642 . . . . 0.0 112.62 -176.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -104.32 111.71 3.91 Favored Glycine 0 C--N 1.339 0.726 0 C-N-CA 125.317 1.437 . . . . 0.0 111.139 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -79.63 159.83 26.61 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 173.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.0 t -81.56 150.73 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.5 m -147.72 65.57 1.12 Allowed 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.411 -0.805 . . . . 0.0 108.99 174.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 61.07 -109.34 2.37 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.546 -1.021 . . . . 0.0 110.546 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.2 p-10 -96.68 37.33 1.29 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.848 1.259 . . . . 0.0 110.325 177.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.1 m -160.64 161.98 32.58 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 105.806 -1.924 . . . . 0.0 105.806 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 t -120.27 151.65 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 126.969 2.108 . . . . 0.0 106.939 172.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.0 m -140.29 117.38 11.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.495 0.718 . . . . 0.0 109.18 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -83.06 166.99 18.29 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 174.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 57.3 m -152.29 156.17 39.13 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 175.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.37 165.44 20.53 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -173.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -72.64 -27.22 62.0 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.838 -0.801 . . . . 0.0 111.02 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -78.95 67.76 4.73 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.029 0.932 . . . . 0.0 110.269 -177.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.4 t -79.69 99.36 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.9 t-160 -107.4 94.65 5.21 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.7 107.0 17.27 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.154 0 C-N-CA 123.308 0.643 . . . . 0.0 109.486 -173.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.2 t -93.45 90.74 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -94.91 111.92 23.67 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.218 1.407 . . . . 0.0 110.282 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.98 143.39 27.12 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 174.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.7 104.41 5.77 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-O 121.23 0.538 . . . . 0.0 110.85 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 t 50.09 63.74 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 127.203 2.201 . . . . 0.0 111.216 173.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 22.5 mt -76.75 165.26 53.89 Favored Pre-proline 0 CA--C 1.536 0.433 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 99.7 Cg_exo . . . . . 0 CA--C 1.535 0.559 0 C-N-CA 122.888 2.392 . . . . 0.0 113.5 175.854 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 . . . . . 0 CA--C 1.536 0.425 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -109.32 -21.05 0.36 Allowed 'Cis proline' 0 CA--C 1.536 0.609 0 N-CA-C 114.507 0.926 . . . . 0.0 114.507 -3.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.3 p -92.11 170.24 9.99 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 -168.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.25 167.21 22.12 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.75 0.82 . . . . 0.0 109.136 178.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.29 148.25 50.75 Favored 'General case' 0 CA--C 1.538 0.485 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 173.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.1 t -134.89 79.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 123.745 0.818 . . . . 0.0 109.456 -170.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.7 p80 50.48 -74.51 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 127.821 2.448 . . . . 0.0 114.896 175.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -98.0 -37.38 9.79 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 124.643 1.177 . . . . 0.0 110.964 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -111.21 -159.95 0.7 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.876 1.27 . . . . 0.0 108.203 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -140.44 -165.27 1.89 Allowed 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 14.1 m-80 -12.57 -56.38 0.03 OUTLIER Pre-proline 0 N--CA 1.471 0.598 0 C-N-CA 128.433 2.693 . . . . 0.0 115.242 172.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.6 OUTLIER -15.5 125.64 0.01 OUTLIER 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.983 3.789 . . . . 0.0 116.272 161.083 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 55.5 m -31.78 144.04 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 129.911 3.284 . . . . 0.0 117.276 -174.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.42 134.68 54.52 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.907 1.683 . . . . 0.0 108.492 174.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -110.07 140.35 44.22 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.249 1.02 . . . . 0.0 108.685 173.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.4 mt -136.71 141.57 35.75 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 -172.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -78.35 125.7 7.18 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.796 2.33 . . . . 0.0 108.123 171.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.02 145.45 16.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.761 0.824 . . . . 0.0 112.553 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.45 2.87 81.45 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-O 119.498 -0.612 . . . . 0.0 112.986 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.88 157.97 20.2 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 118.745 1.273 . . . . 0.0 112.228 174.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 61.2 m -93.6 89.99 6.46 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 172.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 43.2 t -77.58 98.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -173.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -92.51 93.57 8.63 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.035 1.334 . . . . 0.0 107.88 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.95 107.05 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 78.9 m -99.94 103.84 15.43 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 125.326 1.45 . . . . 0.0 109.498 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -81.56 152.24 27.33 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.92 78.99 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 102.159 -3.275 . . . . 0.0 102.159 163.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -101.5 85.08 2.7 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 176.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.417 HG23 ' CD2' ' A' ' 120' ' ' PHE . 76.3 p -112.08 33.51 4.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.538 -174.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -79.61 70.95 6.19 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 177.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -33.49 103.46 0.03 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.133 2.173 . . . . 0.0 112.462 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.99 -46.05 1.13 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 125.215 1.388 . . . . 0.0 111.293 -177.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -97.76 107.49 20.0 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.483 1.113 . . . . 0.0 111.938 -173.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.89 -16.29 56.69 Favored Glycine 0 CA--C 1.538 1.503 0 CA-C-O 119.199 -0.779 . . . . 0.0 114.457 174.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 46.73 -72.28 0.0 OUTLIER 'General case' 0 C--N 1.343 0.307 0 C-N-CA 129.221 3.008 . . . . 0.0 116.46 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.0 p 88.62 155.98 0.06 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 129.228 3.011 . . . . 0.0 111.867 -172.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -125.13 131.74 53.21 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 103.339 -2.837 . . . . 0.0 103.339 171.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.26 116.42 11.08 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 108.569 -0.901 . . . . 0.0 108.569 -173.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -97.19 125.78 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 124.536 1.134 . . . . 0.0 109.392 -178.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -160.1 -141.94 0.08 Allowed 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -122.91 -110.65 0.32 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.143 0.883 . . . . 0.0 110.431 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt 65.62 -65.54 0.17 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.303 1.841 . . . . 0.0 112.397 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.48 162.56 33.36 Favored Glycine 0 CA--C 1.533 1.212 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -173.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -71.79 158.75 52.42 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.79 2.327 . . . . 0.0 109.804 177.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.22 132.38 27.09 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 CA-C-N 119.146 0.731 . . . . 0.0 110.222 -3.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -79.78 151.97 30.04 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.159 0.504 . . . . 0.0 109.695 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.01 151.65 28.33 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.313 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.8 t -61.45 -41.94 91.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 175.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.5 mmm -77.96 128.77 77.97 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 174.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -76.98 75.65 4.48 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.428 2.085 . . . . 0.0 110.397 -174.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.2 t -77.53 76.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 175.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.0 pt -77.96 89.66 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 122.394 1.092 . . . . 0.0 109.794 -176.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -55.57 146.69 43.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 171.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -25.63 116.26 0.03 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.698 1 C-N-CA 125.676 4.251 . . . . 0.0 115.625 -166.615 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 30.6 mm -78.46 131.6 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.4 t -82.15 -86.07 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.87 149.35 21.63 Favored 'General case' 0 C--N 1.333 -0.123 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 172.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.91 165.76 39.07 Favored Glycine 0 C--N 1.332 0.318 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 174.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.9 p -119.04 123.32 44.21 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.085 0.554 . . . . 0.0 111.792 -174.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -78.03 57.9 3.95 Favored Glycine 0 CA--C 1.535 1.34 0 CA-C-O 119.082 -0.843 . . . . 0.0 113.646 -175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 65.05 124.73 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 127.382 2.273 . . . . 0.0 113.719 174.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 92.0 p -74.23 136.54 75.64 Favored Pre-proline 0 CA--C 1.532 0.288 0 O-C-N 120.899 -1.125 . . . . 0.0 112.457 -173.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.49 84.96 0.92 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.312 2.008 . . . . 0.0 107.066 172.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.3 m -45.06 139.06 4.13 Favored Pre-proline 0 CA--C 1.539 0.533 0 C-N-CA 124.673 1.189 . . . . 0.0 112.851 -174.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -75.74 -178.27 4.2 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.636 2.891 . . . . 0.0 113.665 -173.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.93 176.73 7.1 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 127.043 2.137 . . . . 0.0 107.19 174.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -36.71 120.98 0.73 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.975 1.31 . . . . 0.0 113.269 -174.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 84.53 -27.05 4.85 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.968 0.794 . . . . 0.0 113.738 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 56.5 mttp -85.63 157.4 20.36 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.132 0.966 . . . . 0.0 109.97 -174.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.417 ' CD2' HG23 ' A' ' 79' ' ' THR . 10.1 m-85 -137.18 91.22 2.6 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.427 1.091 . . . . 0.0 111.414 -173.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -47.34 121.31 6.33 Favored Glycine 0 CA--C 1.529 0.924 0 C-N-CA 124.716 1.15 . . . . 0.0 111.74 174.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.7 p90 -144.24 176.32 9.42 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.312 1.053 . . . . 0.0 111.467 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.16 166.58 32.83 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 127.079 2.152 . . . . 0.0 105.757 -176.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -146.68 65.08 1.18 Allowed 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 19.4 p90 -77.99 135.83 37.86 Favored 'General case' 0 C--N 1.34 0.184 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.441 -174.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 14.8 m -99.13 132.6 44.32 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.508 0.723 . . . . 0.0 110.021 -175.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.6 t90 -137.95 143.25 40.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.459 1.104 . . . . 0.0 109.704 176.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 63.5 m80 -111.36 99.41 43.83 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -76.23 173.79 13.91 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 122.364 2.043 . . . . 0.0 109.397 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 81.3 p -119.06 153.6 34.49 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -57.62 142.26 45.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -172.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 135.45 -127.11 4.2 Favored Glycine 0 C--N 1.336 0.555 0 C-N-CA 126.208 1.861 . . . . 0.0 109.411 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -151.95 142.9 23.07 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 118.251 1.026 . . . . 0.0 110.006 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 20.5 m-85 -133.16 -179.28 5.4 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 126.243 1.817 . . . . 0.0 106.958 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -141.65 147.26 37.27 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 124.301 1.04 . . . . 0.0 108.43 174.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -102.46 145.76 29.09 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.0 m -146.64 160.72 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.842 1.257 . . . . 0.0 110.322 174.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.4 t -99.0 125.89 44.58 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.68 1.192 . . . . 0.0 109.691 171.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.69 -27.37 66.36 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 -177.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -57.26 128.94 79.25 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 120.541 1.519 . . . . 0.0 109.826 -174.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_exo -43.83 137.68 6.46 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.262 2.641 . . . . 0.0 113.15 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.59 -27.72 2.49 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.171 -0.794 . . . . 0.0 113.411 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -62.43 -51.53 67.16 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.734 1.767 . . . . 0.0 111.639 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.81 -44.0 86.07 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 117.82 0.282 . . . . 0.0 110.764 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.95 -43.04 99.27 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.135 -0.353 . . . . 0.0 111.364 -179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.6 p -79.14 -41.01 29.53 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 118.877 -0.582 . . . . 0.0 112.175 -174.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 178.26 -15.6 0.03 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 118.725 -1.702 . . . . 0.0 116.977 -176.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 13.3 mtp -79.04 77.03 5.53 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 120.118 1.959 . . . . 0.0 110.456 -174.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -160.17 -174.72 4.67 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.37 164.95 23.93 Favored Glycine 0 C--N 1.341 0.832 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 175.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 30.8 mttt -100.99 147.66 25.93 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.9 mt -121.52 100.65 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.15 121.15 38.92 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.064 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.6 t -109.38 95.06 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 -178.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 96.9 mttt . . . . . 0 C--N 1.332 -0.177 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.286 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.2 p . . . . . 0 CA--C 1.532 0.286 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.0 m -77.79 64.13 2.98 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -169.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 71.4 m95 -92.95 156.22 17.06 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 126.645 1.978 . . . . 0.0 110.766 175.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -154.68 179.36 9.14 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 172.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -139.68 150.26 44.68 Favored 'General case' 0 C--N 1.341 0.209 0 CA-C-N 119.557 1.072 . . . . 0.0 111.191 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -130.65 -154.52 0.64 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.009 2.123 . . . . 0.0 107.292 174.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -135.94 171.44 14.46 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.527 0.731 . . . . 0.0 110.198 176.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.67 -59.91 1.23 Allowed Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -174.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -59.77 -30.87 93.05 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 CA-C-N 121.515 1.577 . . . . 0.0 111.964 -178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -66.97 -22.94 65.9 Favored 'General case' 0 N--CA 1.448 -0.557 0 O-C-N 121.757 -0.589 . . . . 0.0 111.267 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.5 t -59.38 -51.5 71.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -59.78 -49.02 79.35 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.81 -55.69 13.19 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.043 0.214 . . . . 0.0 110.986 177.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 72.6 mtm -57.85 -52.49 65.25 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 123.223 0.609 . . . . 0.0 110.675 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.5 mt -50.67 -44.67 57.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 118.322 0.51 . . . . 0.0 111.057 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -58.81 -25.35 63.07 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 178.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.75 -1.02 36.75 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 119.934 1.243 . . . . 0.0 112.083 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.68 153.42 24.04 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 120.17 1.35 . . . . 0.0 110.782 175.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.2 p -117.94 27.77 8.81 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 123.269 0.628 . . . . 0.0 112.524 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.44 116.57 5.32 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -79.06 154.26 29.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 174.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 t -79.74 145.98 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 O-C-N 121.981 -0.449 . . . . 0.0 110.026 -175.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.2 m -149.08 64.32 1.04 Allowed 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.894 0.878 . . . . 0.0 109.404 174.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.04 -114.11 6.47 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.4 -17.0 55.28 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 123.178 0.591 . . . . 0.0 111.246 175.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -103.29 161.55 13.73 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 125.276 1.43 . . . . 0.0 107.841 -175.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.65 148.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.0 m -135.65 131.47 35.8 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -171.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -100.48 168.89 9.45 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.37 0.605 . . . . 0.0 110.663 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.0 m -155.01 155.0 33.38 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.76 174.35 32.96 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -174.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -77.84 -30.49 51.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 122.243 -0.563 . . . . 0.0 111.785 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.03 74.37 5.56 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.502 0.592 . . . . 0.0 109.968 -175.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.0 t -84.7 89.36 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -177.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -94.47 100.92 12.82 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.96 0.504 . . . . 0.0 110.642 -174.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -95.27 100.26 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 124.89 1.276 . . . . 0.0 108.315 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.1 t -95.7 122.89 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -133.31 116.48 16.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.621 0.646 . . . . 0.0 112.5 -173.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.85 112.56 24.53 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.981 0.913 . . . . 0.0 110.008 175.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.6 92.23 8.49 Favored 'General case' 0 N--CA 1.455 -0.178 0 O-C-N 121.58 -0.7 . . . . 0.0 110.038 -177.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.8 t 63.67 97.17 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 125.195 1.398 . . . . 0.0 111.324 174.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 75.2 mt -74.98 140.85 74.22 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -174.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo . . . . . 0 N--CA 1.457 -0.649 0 C-N-CA 123.629 2.886 . . . . 0.0 111.392 178.454 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.9 m-30 . . . . . 0 CA--C 1.543 0.679 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -124.45 29.62 0.16 OUTLIER 'Cis proline' 0 CA--C 1.537 0.664 0 CA-C-N 120.722 1.294 . . . . 0.0 109.999 -7.119 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.8 p -92.09 125.25 36.7 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 116.94 2.2 . . . . 0.0 116.94 -171.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.69 103.71 9.78 Favored 'General case' 0 C--N 1.342 0.243 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 166.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -88.03 112.03 22.18 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -176.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -111.49 84.7 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 125.14 1.376 . . . . 0.0 109.783 -171.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 46.98 -98.97 0.04 OUTLIER 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 125.78 1.632 . . . . 0.0 112.9 176.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -70.73 -24.69 62.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.565 0.346 . . . . 0.0 111.877 -176.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -130.57 -178.07 4.62 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.232 1.013 . . . . 0.0 110.679 -173.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.2 mtmp? -130.12 122.32 28.03 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 105.88 -1.896 . . . . 0.0 105.88 172.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 55.33 44.37 1.62 Allowed Pre-proline 0 CA--C 1.541 0.607 0 C-N-CA 124.705 1.202 . . . . 0.0 112.275 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.71 172.06 15.69 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.475 2.117 . . . . 0.0 111.567 -176.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.5 m -91.9 138.86 31.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 170.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.0 mp -112.25 126.99 55.83 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.83 0.852 . . . . 0.0 110.241 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -100.01 119.51 38.38 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 15.3 mt -124.04 142.24 39.2 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.392 1.077 . . . . 0.0 112.95 -171.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.15 118.71 4.07 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 122.935 2.423 . . . . 0.0 108.893 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.88 142.99 3.1 Favored 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 125.41 1.484 . . . . 0.0 112.31 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 80.49 -22.2 4.81 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 118.982 -0.899 . . . . 0.0 113.706 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.21 158.17 5.56 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.113 1.456 . . . . 0.0 111.969 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -79.84 96.68 6.4 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.5 t -78.68 90.36 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 174.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -84.36 119.3 24.94 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 174.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -111.79 114.36 46.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -176.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 94.4 m -107.47 104.35 13.9 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.541 1.137 . . . . 0.0 109.473 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.4 m-85 -79.53 162.9 25.1 Favored 'General case' 0 C--O 1.221 -0.414 0 O-C-N 121.662 -0.649 . . . . 0.0 112.429 174.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -137.61 78.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 101.651 -3.462 . . . . 0.0 101.651 163.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -99.94 96.51 7.6 Favored 'General case' 0 N--CA 1.457 -0.111 0 N-CA-C 106.811 -1.552 . . . . 0.0 106.811 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.7 m -147.44 59.32 1.15 Allowed 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 174.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -82.3 66.41 7.88 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 173.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 8.72 72.82 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.75 3.22 . . . . 0.0 113.927 -171.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.42 -44.83 1.29 Allowed Glycine 0 CA--C 1.527 0.796 0 C-N-CA 124.31 0.957 . . . . 0.0 111.382 178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -79.72 95.62 6.02 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.842 0.83 . . . . 0.0 110.091 -175.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.99 61.35 2.58 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.412 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -45.54 124.57 5.09 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.271 1.028 . . . . 0.0 110.857 173.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 96.8 p -87.2 167.06 14.47 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -134.05 112.5 11.23 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 172.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -131.27 127.59 38.08 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -173.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 47.5 mt -99.31 127.91 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 C-N-CA 125.818 1.647 . . . . 0.0 108.475 -174.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.48 -149.03 0.18 Allowed 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt -129.26 25.28 5.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.696 1.134 . . . . 0.0 111.994 -178.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -73.74 94.95 2.3 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 173.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -73.49 171.33 51.69 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 173.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.1 150.15 82.27 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.282 1.988 . . . . 0.0 109.65 175.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -75.31 130.75 22.13 Favored 'Cis proline' 0 N--CA 1.454 -0.807 0 N-CA-C 109.941 -0.83 . . . . 0.0 109.941 -3.255 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -78.75 145.82 34.21 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.4 145.59 39.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-O 121.382 0.61 . . . . 0.0 112.044 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -67.52 -43.41 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -78.85 144.95 65.15 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 177.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -64.01 68.83 0.2 Allowed 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.638 2.892 . . . . 0.0 113.685 175.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.43 75.52 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.4 pt -76.35 86.0 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 123.509 1.623 . . . . 0.0 110.816 -172.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.28 155.69 83.9 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 113.125 -1.852 . . . . 0.0 106.913 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -39.57 112.42 0.15 Allowed 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 123.91 3.073 . . . . 0.0 113.986 -176.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.1 mm -79.24 132.17 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -82.29 -87.11 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.49 156.16 16.46 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 123.394 0.678 . . . . 0.0 109.365 173.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.44 178.21 45.1 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 118.956 -1.592 . . . . 0.0 113.904 174.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 17.3 p -121.26 155.27 35.01 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 126.464 1.906 . . . . 0.0 109.424 175.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -90.09 -127.55 3.42 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 173.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -116.2 134.98 54.32 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 118.495 1.148 . . . . 0.0 108.61 176.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 4.5 p -76.58 177.56 2.5 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -172.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.56 -7.08 13.46 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.271 2.648 . . . . 0.0 113.015 172.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m 35.24 67.15 1.46 Allowed Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 126.285 1.834 . . . . 0.0 115.857 -178.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -60.72 178.59 0.46 Allowed 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.726 2.284 . . . . 0.0 113.796 174.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -142.45 -171.98 3.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.043 0.937 . . . . 0.0 110.187 -177.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 26.1 t70 62.65 -77.3 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 126.862 2.065 . . . . 0.0 111.549 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.75 15.66 0.3 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.966 0.793 . . . . 0.0 111.869 177.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 31.8 mtmm -87.59 155.9 19.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 174.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -140.07 104.07 4.76 Favored 'General case' 0 CA--C 1.517 -0.297 0 C-N-CA 123.765 0.826 . . . . 0.0 112.416 -171.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -67.38 107.85 2.2 Favored Glycine 0 CA--C 1.526 0.725 0 C-N-CA 125.299 1.428 . . . . 0.0 109.841 174.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -103.48 178.62 4.5 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.889 0.852 . . . . 0.0 109.374 173.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.87 157.75 43.66 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 -177.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.0 m-20 -139.46 87.5 2.19 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -100.59 168.78 9.49 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 172.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 16.6 m -151.86 148.94 28.42 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 120.952 -1.093 . . . . 0.0 108.976 -175.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 22.0 t90 -147.22 149.47 32.98 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 124.627 1.171 . . . . 0.0 110.225 -174.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -113.06 108.32 53.28 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 172.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -89.8 145.79 4.67 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 123.419 2.746 . . . . 0.0 112.693 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.8 p -89.55 154.94 19.61 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.983 1.313 . . . . 0.0 108.329 172.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.35 169.16 1.26 Allowed 'General case' 0 CA--C 1.538 0.484 0 O-C-N 121.603 -0.686 . . . . 0.0 112.225 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 108.09 -130.61 10.17 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 125.182 1.373 . . . . 0.0 110.192 178.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.7 m -151.56 144.48 24.48 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 118.28 1.04 . . . . 0.0 110.377 -175.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -137.57 174.94 10.05 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 126.221 1.809 . . . . 0.0 107.727 178.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -135.79 139.21 43.34 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.482 1.513 . . . . 0.0 108.6 179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -103.36 139.59 38.57 Favored 'General case' 0 N--CA 1.457 -0.116 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 172.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.7 m -147.15 168.62 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.229 1.011 . . . . 0.0 110.701 178.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 10.3 t -106.09 136.85 45.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 126.461 1.905 . . . . 0.0 108.485 173.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -77.49 -26.28 51.1 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 123.867 0.867 . . . . 0.0 113.22 -173.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 52.7 mt -57.92 130.82 82.97 Favored Pre-proline 0 CA--C 1.543 0.696 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.93 143.56 3.03 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 124.128 3.219 . . . . 0.0 114.778 -174.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.91 -39.73 1.37 Allowed Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.211 0.91 . . . . 0.0 113.958 174.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 25.0 m170 -50.24 -48.81 54.46 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.591 1.156 . . . . 0.0 114.062 -172.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.19 -49.83 74.24 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-O 120.736 0.303 . . . . 0.0 110.368 178.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -58.41 -42.1 86.4 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.256 0.622 . . . . 0.0 110.853 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 32.5 p -79.84 -41.29 26.66 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 118.129 -0.938 . . . . 0.0 113.196 -174.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -169.46 -41.13 0.03 OUTLIER Glycine 0 C--N 1.342 0.871 0 C-N-CA 118.028 -2.034 . . . . 0.0 117.881 -174.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.268 3.8 ptp -79.91 94.17 5.81 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 120.381 2.09 . . . . 0.0 112.196 -173.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -157.76 -178.28 7.21 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.083 0.953 . . . . 0.0 110.353 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.28 161.14 19.07 Favored Glycine 0 C--N 1.338 0.655 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 173.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -96.31 145.75 25.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.653 1.581 . . . . 0.0 109.553 -175.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.7 mt -122.4 101.09 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 173.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -89.67 132.19 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 25.7 t -123.94 125.98 71.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 24.1 mtpp . . . . . 0 N--CA 1.464 0.226 0 CA-C-N 118.898 0.772 . . . . 0.0 111.276 -177.932 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.5 p . . . . . 0 N--CA 1.446 -0.654 0 CA-C-O 119.413 -0.327 . . . . 0.0 111.645 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.2 m -79.71 62.71 4.06 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.155 0.889 . . . . 0.0 110.139 -174.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 73.6 m95 -94.49 122.26 36.88 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 125.177 1.391 . . . . 0.0 111.282 -174.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -142.11 -176.47 4.82 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -136.43 132.32 35.29 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 121.838 -0.539 . . . . 0.0 109.83 172.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -87.74 -154.56 0.26 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 104.303 -2.48 . . . . 0.0 104.303 169.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.8 p -142.61 165.19 28.09 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 120.921 -1.112 . . . . 0.0 108.713 174.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.3 tt -39.9 -53.02 4.99 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 114.687 1.365 . . . . 0.0 114.687 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -57.54 -31.19 90.91 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.865 1.71 . . . . 0.0 112.572 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -71.13 -33.63 70.28 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 122.995 0.518 . . . . 0.0 110.204 178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.6 t -62.74 -48.61 87.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -54.45 -44.96 72.96 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.988 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.91 -48.07 67.52 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.25 0.62 . . . . 0.0 111.437 175.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 68.8 mtm -70.1 -30.94 68.28 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 118.483 -0.77 . . . . 0.0 112.221 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.57 57.36 1.22 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-O 122.331 1.062 . . . . 0.0 109.757 172.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -137.29 -40.27 0.58 Allowed 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 129.383 3.073 . . . . 0.0 104.839 173.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . 0.294 0.0 OUTLIER 84.72 142.58 0.06 Allowed 'General case' 0 N--CA 1.442 -0.831 0 C-N-CA 128.974 2.91 . . . . 0.0 114.648 170.247 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -101.19 -147.8 0.36 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 111.688 -2.506 . . . . 0.0 109.091 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.2 p -44.16 131.66 5.94 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 126.717 2.007 . . . . 0.0 112.675 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 145.06 90.63 0.11 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.169 0.89 . . . . 0.0 110.928 174.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -79.13 137.79 37.63 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 174.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.5 t -63.69 146.89 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 33.0 m -148.52 64.66 1.07 Allowed 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 174.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 66.07 -142.99 44.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 107.642 -2.183 . . . . 0.0 107.642 -172.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -80.01 54.85 1.99 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.721 1.261 . . . . 0.0 109.733 174.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.9 m -160.86 153.9 21.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 178.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 93.5 t -123.46 142.08 41.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -125.77 129.44 49.47 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.963 1.305 . . . . 0.0 108.562 -174.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -93.18 167.07 12.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.493 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.6 m -156.26 61.58 0.56 Allowed 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.552 0.741 . . . . 0.0 109.621 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.87 166.07 38.58 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 108.234 -1.947 . . . . 0.0 108.234 177.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -75.18 -50.4 16.37 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 117.435 0.617 . . . . 0.0 109.659 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.3 p -79.83 93.62 5.66 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 42.5 t -82.82 98.53 4.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -94.11 116.01 28.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.8 122.47 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 124.864 1.265 . . . . 0.0 108.601 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 95.5 t -92.2 113.82 28.12 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 175.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.83 92.66 3.9 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.871 1.269 . . . . 0.0 110.392 -178.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.33 113.51 24.8 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.273 1.029 . . . . 0.0 109.999 178.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.1 114.45 24.73 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.209 -0.932 . . . . 0.0 110.409 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.4 t 32.89 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 126.67 1.988 . . . . 0.0 112.892 173.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.7 142.02 69.55 Favored Pre-proline 0 CA--C 1.533 0.31 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -178.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo . . . . . 0 N--CA 1.454 -0.802 0 C-N-CA 123.079 2.519 . . . . 0.0 110.429 -174.404 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 . . . . . 0 CA--C 1.534 0.358 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -116.64 50.95 0.65 Allowed 'Cis proline' 0 CA--C 1.536 0.591 0 N-CA-C 108.441 -1.407 . . . . 0.0 108.441 -5.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.7 p -93.05 129.3 39.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -173.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -77.95 121.69 24.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 N-CA-C 103.247 -2.871 . . . . 0.0 103.247 166.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -91.88 113.99 26.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -120.59 117.79 54.4 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 119.051 0.841 . . . . 0.0 110.584 -171.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 0.1 OUTLIER 36.93 -104.71 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.641 1.976 . . . . 0.0 113.067 -174.751 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.22 -17.68 39.04 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -124.5 -166.93 1.58 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 124.263 1.025 . . . . 0.0 110.833 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 51.2 mttm -133.95 124.74 26.86 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.192 -1.781 . . . . 0.0 106.192 172.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 52.91 44.24 1.91 Allowed Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.657 1.183 . . . . 0.0 112.354 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -79.28 173.72 12.91 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 122.372 2.048 . . . . 0.0 111.482 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 17.8 m -94.62 140.68 29.55 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 172.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.73 121.45 44.11 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.413 1.485 . . . . 0.0 112.305 -171.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -103.46 111.02 23.27 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.988 0.915 . . . . 0.0 108.737 173.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.9 mt -112.58 135.45 21.51 Favored Pre-proline 0 CA--C 1.537 0.447 0 C-N-CA 125.739 1.616 . . . . 0.0 110.289 -173.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.67 116.63 4.32 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 122.629 2.22 . . . . 0.0 108.747 172.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.03 133.58 27.21 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.593 0.757 . . . . 0.0 110.597 177.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.98 -26.63 16.75 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.986 -1.245 . . . . 0.0 109.986 -173.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.08 32.23 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.891 0.846 . . . . 0.0 111.845 174.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 95.2 m -105.08 130.22 53.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 t -100.53 99.28 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 124.253 1.021 . . . . 0.0 110.881 -172.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.53 93.71 8.4 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.0 t -83.93 100.64 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 174.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 93.3 m -86.75 100.07 12.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.497 1.119 . . . . 0.0 109.109 174.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -76.74 155.7 33.0 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.35 172.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.0 mp -137.96 92.2 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 101.868 -3.382 . . . . 0.0 101.868 163.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -113.54 113.31 24.93 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 172.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 49.1 m -146.17 45.89 1.24 Allowed 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 172.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -75.74 71.02 2.58 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 173.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.2 mtmm -17.74 87.96 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.527 3.131 . . . . 0.0 113.929 -173.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 133.32 -45.27 1.13 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.383 0.992 . . . . 0.0 111.507 178.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -97.33 111.99 24.0 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 117.506 0.653 . . . . 0.0 112.272 -173.06 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.62 54.96 2.5 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.937 0.78 . . . . 0.0 111.475 173.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -48.34 139.84 8.33 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.643 1.221 . . . . 0.0 111.347 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.4 p -104.51 165.99 10.69 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.53 1.132 . . . . 0.0 108.435 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -131.28 116.52 17.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 105.596 -2.002 . . . . 0.0 105.596 171.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -133.03 129.83 38.61 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 118.91 0.777 . . . . 0.0 110.642 -172.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 34.4 mt -104.38 134.04 46.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 C-N-CA 126.016 1.726 . . . . 0.0 108.864 -176.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.2 t -159.13 -154.61 0.42 Allowed 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 48.8 mtmt -126.56 21.88 7.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 119.232 0.924 . . . . 0.0 111.804 -179.154 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -70.37 118.87 13.73 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.05 159.33 43.38 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 174.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -72.5 164.53 35.34 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.969 2.446 . . . . 0.0 109.598 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -71.35 141.46 69.8 Favored 'Cis proline' 0 N--CA 1.459 -0.543 0 CA-C-N 119.333 0.798 . . . . 0.0 110.634 -5.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -79.91 150.86 30.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 121.289 0.566 . . . . 0.0 109.874 175.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.43 151.99 27.63 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.377 177.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 65.9 t -61.1 -39.18 81.47 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 174.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 92.3 mmm -78.2 133.1 65.02 Favored Pre-proline 0 N--CA 1.452 -0.373 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 174.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.87 75.57 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.751 2.301 . . . . 0.0 111.974 -173.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.9 t -79.02 65.5 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 172.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -88.43 -43.79 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.84 1.656 . . . . 0.0 111.801 -173.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -64.25 146.52 97.67 Favored Pre-proline 0 CA--C 1.531 0.215 0 C-N-CA 123.119 0.568 . . . . 0.0 111.515 -173.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.26 143.28 74.57 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 CA-C-N 119.038 0.692 . . . . 0.0 111.261 -2.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 mm -91.44 143.49 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 92.2 t -87.05 -92.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 104.432 -2.432 . . . . 0.0 104.432 173.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.17 145.65 24.87 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -178.6 161.5 28.09 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.264 -1.446 . . . . 0.0 111.237 174.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 34.6 p -103.02 149.25 24.74 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 125.186 1.395 . . . . 0.0 108.248 175.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.91 -156.7 8.78 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 173.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -74.74 139.12 43.18 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.506 1.153 . . . . 0.0 109.071 174.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 51.8 p -81.66 163.91 51.74 Favored Pre-proline 0 C--O 1.233 0.216 0 C-N-CA 122.497 0.319 . . . . 0.0 111.547 -174.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -64.97 166.33 18.84 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 N-CA-C 106.395 -2.194 . . . . 0.0 106.395 168.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.4 t -130.55 76.75 77.0 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -172.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -62.76 162.12 26.31 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 122.154 1.903 . . . . 0.0 110.256 172.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -137.19 5.95 2.8 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -178.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -174.33 148.94 1.3 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 125.469 1.508 . . . . 0.0 109.102 174.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.94 -66.21 0.13 Allowed Glycine 0 CA--C 1.527 0.832 0 C-N-CA 126.533 2.015 . . . . 0.0 113.935 174.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -79.02 151.53 31.46 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 125.22 1.408 . . . . 0.0 110.525 -176.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -134.76 101.98 5.11 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 125.46 1.504 . . . . 0.0 111.096 -174.013 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.95 112.28 1.87 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 125.272 1.415 . . . . 0.0 111.227 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -130.67 155.23 46.94 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.931 0.893 . . . . 0.0 111.29 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 6.6 m -154.78 114.4 3.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -174.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.09 62.55 4.21 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 125.199 1.399 . . . . 0.0 108.525 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -70.15 121.82 18.26 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 118.305 -1.358 . . . . 0.0 108.526 -174.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 41.0 m -96.86 84.73 3.63 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.389 -172.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -78.36 124.75 28.46 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -94.02 106.39 22.05 Favored Pre-proline 0 N--CA 1.451 -0.417 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 171.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -83.23 177.85 6.25 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.975 2.45 . . . . 0.0 112.169 -171.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.5 p -131.09 153.88 48.86 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 172.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.38 165.3 7.85 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.531 1.06 . . . . 0.0 111.935 -174.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 112.86 -168.18 12.54 Favored Glycine 0 CA--C 1.525 0.676 0 C-N-CA 124.718 1.151 . . . . 0.0 112.297 174.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 28.5 m -98.3 139.89 33.4 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 124.028 0.931 . . . . 0.0 109.08 -176.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -140.35 177.29 8.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 125.27 1.428 . . . . 0.0 107.235 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -145.44 152.7 40.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 176.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -116.74 149.13 40.39 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 123.489 0.716 . . . . 0.0 110.382 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 28.6 m -152.78 161.88 2.56 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 C-N-CA 125.052 1.341 . . . . 0.0 111.314 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 3.1 t -100.14 134.11 43.55 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.406 1.482 . . . . 0.0 107.892 170.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -74.05 -22.17 59.65 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -173.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 57.1 mt -60.78 126.98 86.6 Favored Pre-proline 0 CA--C 1.542 0.665 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -177.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -44.86 146.89 2.14 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 123.934 3.089 . . . . 0.0 114.056 -174.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.2 -39.01 1.61 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 123.304 0.478 . . . . 0.0 113.055 177.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.1 m170 -54.02 -51.55 63.63 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.491 1.145 . . . . 0.0 111.879 -173.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.28 -47.29 81.84 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 117.891 0.314 . . . . 0.0 110.986 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.47 97.27 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 122.783 0.433 . . . . 0.0 111.132 -178.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 40.4 p -79.99 -35.81 36.89 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -173.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.41 -27.34 0.04 OUTLIER Glycine 0 CA--C 1.528 0.898 0 N-CA-C 117.081 1.592 . . . . 0.0 117.081 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 3.6 mtt -78.12 80.43 4.55 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 120.07 1.935 . . . . 0.0 110.943 -173.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -162.28 -174.38 4.04 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.71 163.32 21.41 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 173.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 49.2 mttt -99.33 154.1 18.45 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.046 0.939 . . . . 0.0 108.954 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.4 mt -130.33 138.1 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 178.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 42.8 t -130.25 101.0 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 173.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 40.1 t -87.0 88.14 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 174.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.3 mttt . . . . . 0 C--N 1.332 -0.182 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 177.109 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 77.3 p . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 111.86 0.319 . . . . 0.0 111.86 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.8 m -98.84 122.33 41.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 123.846 0.858 . . . . 0.0 108.871 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -155.7 127.1 7.22 Favored 'General case' 0 C--N 1.341 0.233 0 C-N-CA 126.32 1.848 . . . . 0.0 108.417 173.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -150.07 170.62 18.45 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 173.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -135.91 148.14 48.43 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 172.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -118.24 -155.94 0.62 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 127.862 2.465 . . . . 0.0 106.357 174.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 29.9 p -134.43 173.04 12.07 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.577 0.751 . . . . 0.0 109.49 174.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.0 tt -39.05 -56.81 2.36 Favored Pre-proline 0 CA--C 1.538 0.481 0 N-CA-C 114.508 1.299 . . . . 0.0 114.508 -174.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -56.39 -31.46 85.38 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.32 1.347 . . . . 0.0 113.606 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.6 mp0 -68.28 -27.61 66.46 Favored 'General case' 0 N--CA 1.457 -0.115 0 O-C-N 121.177 -0.952 . . . . 0.0 111.249 176.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -61.31 -50.54 80.01 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -55.45 -47.11 76.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.889 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.68 -59.9 3.91 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 122.438 0.295 . . . . 0.0 110.978 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.5 mtm -54.59 -47.9 72.8 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.209 0.604 . . . . 0.0 111.153 -176.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.9 mt -50.51 -33.51 21.74 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 113.269 0.841 . . . . 0.0 113.269 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -73.09 -31.59 64.46 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.556 -0.715 . . . . 0.0 110.534 178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt -81.51 60.96 4.74 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 121.767 -0.583 . . . . 0.0 110.19 -176.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -125.42 102.12 7.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.116 0.566 . . . . 0.0 110.632 174.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.3 p -73.86 45.97 0.21 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.946 1.698 . . . . 0.0 111.197 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.24 112.6 2.42 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 125.508 1.528 . . . . 0.0 111.152 -174.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -79.12 -178.78 6.33 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.3 t -113.7 152.18 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 123.969 0.907 . . . . 0.0 108.89 177.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.7 m -149.1 73.41 1.21 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.373 1.069 . . . . 0.0 108.358 174.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.17 -144.36 39.27 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -172.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -79.46 59.1 2.83 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.653 1.226 . . . . 0.0 109.413 175.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -161.0 146.4 14.28 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.79 1.636 . . . . 0.0 106.708 -179.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 23.3 t -102.64 147.86 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 174.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 55.4 m -134.3 110.63 9.62 Favored 'General case' 0 CA--C 1.521 -0.172 0 C-N-CA 123.426 0.69 . . . . 0.0 109.954 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -82.8 169.01 16.6 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.564 0.697 . . . . 0.0 111.4 178.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -155.04 159.08 40.03 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 124.503 1.121 . . . . 0.0 107.988 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.39 -179.54 32.77 Favored Glycine 0 CA--C 1.53 1.019 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -176.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -85.63 -27.48 25.39 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.771 0.428 . . . . 0.0 111.211 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.6 m -79.18 69.2 5.34 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.107 0.963 . . . . 0.0 110.335 -176.083 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.44 78.55 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.975 0.893 . . . . 0.0 108.935 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 t-80 -83.4 105.61 14.49 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.9 t -107.36 95.75 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -174.07 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.6 t -83.66 123.32 38.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -174.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -132.52 114.61 14.48 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.461 1.104 . . . . 0.0 111.373 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.22 143.21 26.48 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.575 0.75 . . . . 0.0 109.819 174.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.25 96.54 5.59 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.012 0.525 . . . . 0.0 110.698 176.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.8 t 49.19 72.14 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.329 0 C-N-CA 128.407 2.683 . . . . 0.0 111.823 175.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.62 142.76 66.67 Favored Pre-proline 0 CA--C 1.533 0.32 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 176.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo . . . . . 0 N--CA 1.457 -0.637 0 C-N-CA 124.362 3.375 . . . . 0.0 112.819 178.41 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -92.13 -9.13 34.55 Favored 'Cis proline' 0 CA--C 1.538 0.687 0 CA-C-N 118.82 0.614 . . . . 0.0 111.423 -5.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -36.95 121.51 0.78 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -168.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -77.33 121.67 24.05 Favored 'General case' 0 C--N 1.346 0.447 0 C-N-CA 126.126 1.77 . . . . 0.0 107.161 171.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -94.53 112.07 23.83 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.182 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.47 81.71 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.226 0 C-N-CA 124.357 1.063 . . . . 0.0 109.344 -172.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 44.66 -84.74 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 127.367 2.267 . . . . 0.0 114.629 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -75.89 -29.46 58.47 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.336 0.654 . . . . 0.0 110.991 -175.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -136.72 -173.6 3.48 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.453 0.701 . . . . 0.0 109.777 -175.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -126.03 127.0 45.19 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 174.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.9 m-80 50.67 44.08 2.0 Allowed Pre-proline 0 CA--C 1.537 0.459 0 C-N-CA 124.915 1.286 . . . . 0.0 112.575 178.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -83.29 176.07 7.69 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.676 1.584 . . . . 0.0 110.863 -175.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 17.5 m -95.42 144.02 26.28 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 170.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.23 143.97 45.3 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.539 0.736 . . . . 0.0 110.806 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -110.18 125.33 52.94 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 170.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.6 mt -130.15 138.09 32.31 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 123.464 0.706 . . . . 0.0 111.893 -171.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.65 117.93 4.69 Favored 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 122.884 2.39 . . . . 0.0 109.233 172.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.73 141.41 10.01 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 125.053 1.341 . . . . 0.0 111.724 177.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.64 -2.07 55.38 Favored Glycine 0 CA--C 1.531 1.091 0 CA-C-O 118.936 -0.924 . . . . 0.0 113.719 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.76 158.77 31.63 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.708 1.754 . . . . 0.0 110.352 173.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 29.6 m -83.18 93.32 7.63 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 174.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 51.8 t -79.38 99.08 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -91.63 90.72 7.7 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.9 t -77.18 105.56 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 104.246 -2.501 . . . . 0.0 104.246 176.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 55.4 m -100.63 98.99 9.49 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 125.585 1.554 . . . . 0.0 109.797 -171.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.48 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.5 m-85 -77.38 158.77 29.92 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.38 68.26 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 101.652 -3.462 . . . . 0.0 101.652 164.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -87.24 67.06 9.48 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 -174.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.2 m -112.61 83.0 1.74 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 114.669 -1.15 . . . . 0.0 110.616 -175.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -120.14 119.91 34.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 172.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.33 72.82 1.31 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.109 0.564 . . . . 0.0 109.519 -175.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 162.82 -65.64 0.25 Allowed Glycine 0 CA--C 1.522 0.499 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -94.03 112.83 24.7 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.449 -0.442 . . . . 0.0 111.183 -174.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.68 38.99 0.91 Allowed Glycine 0 CA--C 1.537 1.418 0 CA-C-O 118.928 -0.929 . . . . 0.0 111.865 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 0.95 -78.42 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 129.86 3.264 . . . . 0.0 117.513 -172.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.5 p 99.13 155.08 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 129.967 3.307 . . . . 0.0 110.196 -173.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 6.7 t80 -134.01 110.42 9.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 173.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -122.94 140.94 52.46 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.5 mt -115.64 126.7 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.665 1.586 . . . . 0.0 110.257 -172.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -161.05 164.74 30.63 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -83.86 56.41 3.66 Favored 'General case' 0 CA--C 1.535 0.394 0 O-C-N 121.608 -0.682 . . . . 0.0 110.621 -174.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -105.56 107.91 19.15 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 175.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.05 160.12 52.62 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 175.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.67 162.11 43.31 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.986 2.458 . . . . 0.0 109.81 174.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 158.63 93.88 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 CA-C-N 119.006 0.681 . . . . 0.0 110.595 -3.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -96.32 153.56 17.75 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.1 151.1 35.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 175.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 60.3 t -60.38 -38.51 77.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 174.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -78.53 133.48 63.21 Favored Pre-proline 0 N--CA 1.451 -0.409 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 174.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -74.75 80.53 2.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.409 2.073 . . . . 0.0 109.739 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 70.2 t -77.0 84.24 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 178.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.3 pt -77.58 83.04 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-O 123.065 1.412 . . . . 0.0 111.625 -173.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -62.12 154.54 69.31 Favored Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 171.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -37.18 112.59 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 124.248 3.299 . . . . 0.0 114.375 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 32.1 mm -79.48 139.44 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 59.6 t -86.0 -88.32 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 174.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.29 146.5 23.98 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.49 -178.9 42.96 Favored Glycine 0 C--N 1.333 0.368 0 CA-C-N 120.153 1.342 . . . . 0.0 112.219 173.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.2 p -122.95 -37.96 2.67 Favored 'General case' 0 C--N 1.338 0.083 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -176.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 78.34 -175.45 54.71 Favored Glycine 0 CA--C 1.541 1.701 0 N-CA-C 107.658 -2.177 . . . . 0.0 107.658 -170.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.19 141.71 39.96 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.911 1.855 . . . . 0.0 114.513 -171.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.0 p -83.82 155.12 64.97 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -174.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -73.67 75.0 3.17 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.458 2.772 . . . . 0.0 110.688 175.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 66.9 t -20.34 96.16 0.05 OUTLIER Pre-proline 0 CA--C 1.542 0.665 0 C-N-CA 128.195 2.598 . . . . 0.0 112.846 175.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -66.47 171.71 10.2 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.723 2.948 . . . . 0.0 112.582 -178.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -124.76 151.94 44.48 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.653 1.181 . . . . 0.0 109.25 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 39.23 -103.4 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 127.219 2.208 . . . . 0.0 113.62 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -92.25 -2.11 68.74 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.496 -1.169 . . . . 0.0 114.476 -173.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -86.44 153.35 21.95 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.687 1.243 . . . . 0.0 110.442 -176.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -138.32 111.37 7.85 Favored 'General case' 0 C--O 1.224 -0.242 0 C-N-CA 124.987 1.315 . . . . 0.0 111.457 -172.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -78.92 113.15 3.6 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 125.459 1.504 . . . . 0.0 110.589 -174.019 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -121.59 164.46 17.24 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.798 0.839 . . . . 0.0 111.796 -176.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.2 m -165.94 115.61 0.99 Allowed 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 124.523 1.129 . . . . 0.0 108.103 178.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -84.99 67.25 10.14 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -66.79 122.45 17.7 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.1 m -97.98 130.12 44.84 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.704 -1.135 . . . . 0.0 110.379 -171.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -140.0 145.3 37.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.791 1.236 . . . . 0.0 109.669 -178.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -114.77 94.25 36.71 Favored Pre-proline 0 N--CA 1.454 -0.25 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -80.16 150.43 20.24 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 122.573 2.182 . . . . 0.0 111.287 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.3 p -101.31 155.21 18.17 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -53.58 141.56 25.33 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -173.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 136.61 176.49 14.39 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 126.198 1.856 . . . . 0.0 111.189 175.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.6 m -98.42 109.98 22.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.143 0.977 . . . . 0.0 110.317 -174.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -101.28 173.56 6.39 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 172.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -134.63 143.18 47.14 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -104.52 141.64 36.03 Favored 'General case' 0 CA--C 1.522 -0.126 0 CA-C-O 118.569 -0.729 . . . . 0.0 109.682 174.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 5.0 m -147.74 156.57 9.58 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 123.928 0.891 . . . . 0.0 111.77 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 11.2 t -94.9 131.58 40.66 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 126.595 1.958 . . . . 0.0 109.365 173.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -82.79 -1.39 51.54 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -172.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.33 136.42 93.52 Favored Pre-proline 0 CA--C 1.537 0.444 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 173.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.6 144.74 10.15 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.451 2.101 . . . . 0.0 112.554 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.07 -44.99 2.2 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.628 0.632 . . . . 0.0 112.995 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -48.41 -52.73 20.6 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 118.761 1.281 . . . . 0.0 113.989 -173.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.87 -52.11 66.41 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 120.877 0.37 . . . . 0.0 110.145 176.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.28 -39.74 91.56 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.684 1.194 . . . . 0.0 111.686 -175.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.2 p -79.01 -36.49 41.09 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 118.473 -0.775 . . . . 0.0 111.31 -174.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.33 -22.74 0.07 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 117.123 -2.465 . . . . 0.0 118.188 174.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.331 17.8 ptm -80.72 92.8 6.08 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 121.134 2.467 . . . . 0.0 112.93 -173.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.65 -175.1 4.78 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.188 0.995 . . . . 0.0 109.332 179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 176.23 170.6 39.1 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 173.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 38.0 mttt -107.08 146.56 31.06 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 124.447 1.099 . . . . 0.0 109.785 -173.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.5 mt -121.21 99.12 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 125.371 1.469 . . . . 0.0 107.062 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.5 t -90.82 100.66 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 24.1 t -89.62 127.49 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 178.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm . . . . . 0 N--CA 1.462 0.167 0 CA-C-N 119.136 0.88 . . . . 0.0 111.132 -178.151 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 m -79.88 60.1 3.37 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.2 m95 -99.66 131.84 45.39 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 126.029 1.732 . . . . 0.0 111.275 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -144.63 -170.89 3.49 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 172.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -136.21 130.12 32.66 Favored 'General case' 0 C--N 1.341 0.202 0 CA-C-N 119.216 0.916 . . . . 0.0 110.098 172.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -89.66 -156.62 0.42 Allowed 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 170.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.4 p -139.33 166.71 23.84 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 174.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -39.42 -54.97 3.49 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 115.594 1.702 . . . . 0.0 115.594 -172.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.75 -33.44 98.4 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 CA-C-N 120.92 1.364 . . . . 0.0 111.759 -177.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.94 -32.02 73.53 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 122.769 0.428 . . . . 0.0 110.454 -178.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -56.69 -51.04 71.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.231 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -58.22 -49.36 77.35 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.564 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -48.61 -57.15 6.65 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.738 0.415 . . . . 0.0 111.116 178.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -63.1 -45.13 93.52 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 118.432 -0.794 . . . . 0.0 111.605 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.4 mt -48.76 -47.77 41.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 119.414 1.007 . . . . 0.0 111.386 179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -55.35 -21.55 15.65 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 178.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -96.45 7.24 46.99 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 119.156 0.889 . . . . 0.0 112.414 -177.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.6 115.06 10.34 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 119.989 1.268 . . . . 0.0 110.226 -179.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 p -83.99 15.13 3.56 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.61 1.164 . . . . 0.0 113.875 -174.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.75 115.15 4.38 Favored Glycine 0 CA--C 1.527 0.819 0 O-C-N 121.214 -0.929 . . . . 0.0 111.446 -174.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -78.89 121.11 24.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.17 1.388 . . . . 0.0 108.995 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.97 122.5 6.27 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 C-N-CA 124.137 0.975 . . . . 0.0 109.592 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -132.12 68.93 1.48 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.689 1.596 . . . . 0.0 108.235 -174.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.84 -117.57 8.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 -174.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -78.89 -33.49 45.63 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.848 0.824 . . . . 0.0 109.559 173.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 27.8 m -78.88 155.96 28.85 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 123.739 0.816 . . . . 0.0 109.215 -173.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.7 t -118.67 132.62 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 173.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -121.14 126.88 50.84 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 123.204 0.602 . . . . 0.0 109.969 -173.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -97.84 175.9 5.99 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 122.826 0.45 . . . . 0.0 110.153 177.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 60.0 m -156.5 168.21 28.06 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.505 0.722 . . . . 0.0 109.811 -175.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 45.26 43.53 9.71 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 125.354 1.454 . . . . 0.0 113.018 174.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.1 mttp 50.55 12.02 0.09 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.093 1.757 . . . . 0.0 115.492 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.8 m -103.62 74.78 1.27 Allowed 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -173.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.1 t -89.56 96.79 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.3 t-160 -105.21 102.62 12.1 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 173.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.3 t -99.17 103.28 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.0 t -88.06 90.48 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 175.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.34 159.61 14.85 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.014 1.326 . . . . 0.0 109.841 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.9 166.44 33.53 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 0.0 108.841 177.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -147.69 115.15 6.3 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 122.251 0.22 . . . . 0.0 111.151 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t 54.27 53.35 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 125.868 1.667 . . . . 0.0 111.912 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 30.9 mt -78.36 151.78 78.19 Favored Pre-proline 0 CA--C 1.532 0.286 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 173.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_exo . . . . . 0 CA--C 1.534 0.511 0 C-N-CA 123.581 2.854 . . . . 0.0 112.91 -176.069 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 . . . . . 0 N--CA 1.451 -0.397 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -110.44 54.58 0.93 Allowed 'Cis proline' 0 N--CA 1.455 -0.782 0 N-CA-C 106.685 -2.083 . . . . 0.0 106.685 -6.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 85.8 p -79.49 121.59 25.4 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -170.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -78.57 115.89 18.58 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 103.284 -2.858 . . . . 0.0 103.284 167.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -100.25 138.52 37.19 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.3 t -135.25 100.35 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 118.354 0.524 . . . . 0.0 110.066 -174.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 1.5 p80 35.44 -69.62 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 130.227 3.411 . . . . 0.0 116.378 -173.429 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -101.84 -25.86 13.66 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 125.004 1.322 . . . . 0.0 112.218 -175.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -125.56 -169.85 2.07 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.81 1.244 . . . . 0.0 109.957 -173.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? -136.9 133.82 36.16 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 171.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 48.22 41.76 1.03 Allowed Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 124.235 1.014 . . . . 0.0 112.592 -174.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.59 169.03 22.0 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 CA-C-N 120.742 1.301 . . . . 0.0 112.872 -172.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.0 m -89.58 127.76 35.93 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 112.342 -2.208 . . . . 0.0 106.127 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -106.32 128.13 53.77 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.159 0.891 . . . . 0.0 110.101 -177.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 -104.68 117.91 35.26 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 171.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.6 mt -124.22 138.44 30.84 Favored Pre-proline 0 CA--C 1.538 0.496 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -67.95 125.32 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.727 2.284 . . . . 0.0 109.153 168.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.32 133.36 19.7 Favored 'General case' 0 C--N 1.332 -0.191 0 O-C-N 121.382 -0.824 . . . . 0.0 111.217 174.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.55 12.36 80.34 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.144 -0.809 . . . . 0.0 113.13 -176.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.41 148.7 47.79 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 119.375 1.588 . . . . 0.0 110.169 173.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 38.8 m -83.47 90.75 7.25 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 174.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 85.0 t -77.68 98.67 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 124.746 1.219 . . . . 0.0 108.068 -174.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -96.96 104.38 16.39 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 177.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.3 t -89.44 91.34 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 54.0 m -79.52 87.87 5.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.512 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.275 4.1 m-85 -79.73 138.6 37.35 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 117.876 -1.059 . . . . 0.0 109.934 172.584 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.8 mp -117.44 67.89 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 101.088 -3.671 . . . . 0.0 101.088 163.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -84.41 56.3 3.74 Favored 'General case' 0 C--O 1.231 0.109 0 O-C-N 121.117 -0.989 . . . . 0.0 108.626 -173.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 53.4 m -85.75 69.99 10.65 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.884 -176.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -97.43 156.82 16.3 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 171.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -93.17 124.14 36.94 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 75.42 -68.64 2.09 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.63 0.633 . . . . 0.0 112.392 175.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -79.08 81.07 5.38 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.873 -0.781 . . . . 0.0 110.001 -174.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -52.85 80.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 126.425 1.964 . . . . 0.0 112.52 174.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -57.47 162.52 2.85 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 119.232 1.516 . . . . 0.0 111.468 179.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.3 p -121.85 160.91 23.72 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.584 1.554 . . . . 0.0 107.388 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . 0.512 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -128.26 110.18 12.16 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 172.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -126.64 128.93 47.53 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.861 0.864 . . . . 0.0 108.716 -172.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 20.5 mt -106.21 134.32 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 C-N-CA 125.964 1.706 . . . . 0.0 110.054 -173.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.6 t -158.04 -152.08 0.33 Allowed 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 176.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -126.58 9.32 7.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.689 1.131 . . . . 0.0 113.286 -176.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -64.67 121.44 14.5 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.35 166.45 49.62 Favored Glycine 0 CA--C 1.532 1.117 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 161.89 44.15 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 122.856 2.37 . . . . 0.0 109.602 173.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -76.92 149.61 90.8 Favored 'Cis proline' 0 N--CA 1.454 -0.825 0 N-CA-C 110.27 -0.704 . . . . 0.0 110.27 -4.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -89.27 152.94 21.28 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 149.7 29.34 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.86 -42.09 87.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 174.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -78.89 130.35 70.49 Favored Pre-proline 0 N--CA 1.451 -0.391 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 174.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -75.02 85.07 1.57 Allowed 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 122.374 2.05 . . . . 0.0 109.829 -175.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.4 t -76.77 85.55 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.348 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 175.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 pt -75.43 87.43 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 CA-C-O 123.646 1.689 . . . . 0.0 110.653 -172.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -62.83 154.17 76.7 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 112.842 -1.981 . . . . 0.0 106.928 172.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -39.49 108.71 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 124.059 3.173 . . . . 0.0 113.794 -175.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.0 mm -78.46 126.84 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.37 -82.14 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 105.785 -1.932 . . . . 0.0 105.785 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.6 150.17 20.64 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.93 158.66 21.79 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 119.288 -1.434 . . . . 0.0 112.135 174.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.3 p -107.75 145.43 33.52 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.516 1.126 . . . . 0.0 110.544 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.63 158.38 37.19 Favored Glycine 0 CA--C 1.535 1.3 0 N-CA-C 107.342 -2.303 . . . . 0.0 107.342 172.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -41.88 133.07 2.95 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.558 1.543 . . . . 0.0 113.884 -173.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.5 p -68.53 158.5 84.99 Favored Pre-proline 0 CA--C 1.535 0.373 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -177.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.3 -177.96 2.66 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.075 1.85 . . . . 0.0 108.804 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 90.0 t -117.66 98.91 52.14 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 125.654 1.582 . . . . 0.0 108.83 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -62.45 173.59 3.36 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.737 3.625 . . . . 0.0 113.426 174.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -145.57 162.09 38.26 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.54 1.136 . . . . 0.0 109.355 176.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.58 -117.55 0.76 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.883 1.673 . . . . 0.0 110.967 177.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.63 17.43 42.72 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-O 118.899 -0.945 . . . . 0.0 112.445 -177.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -85.72 151.01 24.19 Favored 'General case' 0 C--N 1.341 0.234 0 CA-C-N 118.059 0.93 . . . . 0.0 108.876 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -133.98 93.63 3.13 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 124.373 1.069 . . . . 0.0 111.239 -172.37 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -49.03 118.15 4.82 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 125.926 1.726 . . . . 0.0 109.959 173.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.18 159.6 41.76 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 123.919 0.888 . . . . 0.0 112.223 -177.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -143.57 148.46 35.95 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 126.537 1.935 . . . . 0.0 107.114 178.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -134.1 65.16 1.58 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 178.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -76.93 150.65 35.94 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 31.4 m -118.18 142.77 47.1 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.872 0.869 . . . . 0.0 109.773 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -145.47 161.28 40.08 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.625 1.17 . . . . 0.0 109.98 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 69.6 m80 -129.81 92.25 37.8 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 125.885 1.674 . . . . 0.0 109.001 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -71.64 145.26 46.32 Favored 'Trans proline' 0 N--CA 1.454 -0.852 0 C-N-CA 123.093 2.528 . . . . 0.0 112.178 -175.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.8 p -93.56 155.25 17.42 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.834 1.254 . . . . 0.0 108.87 172.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.86 146.03 43.49 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.808 -0.558 . . . . 0.0 112.493 -174.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 128.41 -125.38 5.02 Favored Glycine 0 C--N 1.334 0.45 0 C-N-CA 126.79 2.138 . . . . 0.0 108.826 -178.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 35.6 m -153.5 144.59 22.91 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 118.226 1.013 . . . . 0.0 109.881 -175.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -134.74 175.27 9.7 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.506 1.922 . . . . 0.0 106.962 173.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -141.7 149.96 41.23 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.164 1.386 . . . . 0.0 108.199 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . 0.432 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 48.1 p90 -112.89 144.22 42.82 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.956 0.903 . . . . 0.0 109.893 175.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.1 m -148.71 162.64 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 C-N-CA 125.081 1.352 . . . . 0.0 110.68 178.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.29 136.94 41.23 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.643 1.577 . . . . 0.0 107.663 171.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -81.32 -16.5 52.23 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.317 1.228 . . . . 0.0 114.317 -172.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 53.7 mt -63.81 129.52 93.86 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_exo -46.79 150.09 2.76 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 123.947 3.098 . . . . 0.0 114.575 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.42 -43.01 2.01 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 124.092 0.853 . . . . 0.0 112.89 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -50.76 -53.68 29.68 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.671 1.188 . . . . 0.0 111.98 -173.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -54.8 -46.71 74.53 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.77 0.428 . . . . 0.0 111.16 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.73 -41.71 91.91 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 123.156 0.583 . . . . 0.0 111.201 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.1 p -79.67 -58.94 2.94 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.031 0.532 . . . . 0.0 112.124 -173.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.81 38.33 0.09 OUTLIER Glycine 0 CA--C 1.525 0.665 0 C-N-CA 119.65 -1.262 . . . . 0.0 114.685 -174.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.1 ttt -126.19 64.75 1.23 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -151.52 -174.47 4.84 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.806 0.843 . . . . 0.0 111.241 -177.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.432 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.83 174.39 38.06 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 174.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.4 146.67 45.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.417 1.487 . . . . 0.0 109.805 -170.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.2 mt -128.33 95.81 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 125.461 1.504 . . . . 0.0 107.651 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 t -88.03 132.22 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.7 t -122.19 120.99 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -176.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm . . . . . 0 N--CA 1.467 0.393 0 CA-C-N 119.671 1.123 . . . . 0.0 110.827 176.711 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.9 p . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -78.25 53.96 1.31 Allowed 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.725 1.148 . . . . 0.0 112.171 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -92.68 142.96 26.79 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 127.697 2.399 . . . . 0.0 108.405 175.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -152.29 177.08 10.94 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -140.05 140.72 36.21 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 169.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.61 -150.9 0.47 Allowed 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 174.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 19.0 p -136.03 173.43 11.72 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 172.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -39.56 -56.96 2.66 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 114.282 1.216 . . . . 0.0 114.282 -174.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -55.04 -35.31 89.97 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.572 1.515 . . . . 0.0 113.481 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.7 mp0 -65.55 -23.95 66.98 Favored 'General case' 0 N--CA 1.455 -0.184 0 O-C-N 121.339 -0.85 . . . . 0.0 111.379 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -55.72 -46.88 79.77 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 119.27 0.941 . . . . 0.0 108.972 173.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtmt -60.32 -51.25 70.31 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.56 -46.99 67.08 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.692 0.256 . . . . 0.0 111.692 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -62.65 -54.93 32.08 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.721 0.408 . . . . 0.0 110.274 177.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 62.1 mt -49.23 -46.88 46.56 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 122.883 0.473 . . . . 0.0 111.339 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -53.04 -27.0 17.66 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -90.5 -0.91 57.85 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.17 0.896 . . . . 0.0 112.503 -179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -57.02 154.52 9.56 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.897 0.771 . . . . 0.0 112.671 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.7 p -128.0 165.59 19.99 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 172.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 122.33 117.67 2.44 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -178.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.4 mtpt -79.08 121.51 25.07 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.31 1.444 . . . . 0.0 108.934 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.6 t -61.69 114.25 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 125.591 1.556 . . . . 0.0 109.485 -176.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.1 m -130.57 68.03 1.48 Allowed 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 124.159 0.983 . . . . 0.0 111.435 -174.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.18 -94.67 0.47 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 123.778 0.704 . . . . 0.0 112.476 174.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -101.07 -14.54 17.76 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.516 1.127 . . . . 0.0 110.127 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 29.4 m -108.39 151.79 25.55 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.811 1.244 . . . . 0.0 109.985 -172.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.44 130.71 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 170.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.7 m -115.39 119.66 37.0 Favored 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 123.187 0.595 . . . . 0.0 110.404 -170.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -91.8 153.09 19.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.9 m -155.79 51.49 0.56 Allowed 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.884 -0.51 . . . . 0.0 110.157 -175.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.89 166.27 39.46 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 108.276 -1.93 . . . . 0.0 108.276 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -73.61 -38.16 65.18 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 117.503 0.651 . . . . 0.0 110.584 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.7 p -80.09 103.46 9.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 174.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.5 t -107.69 128.37 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -132.15 101.36 5.36 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 123.941 0.897 . . . . 0.0 110.019 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.2 t -92.01 143.02 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.1 t -123.06 114.0 40.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 173.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -120.93 112.17 18.43 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 124.645 1.178 . . . . 0.0 111.976 -172.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.86 149.87 22.46 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 172.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.98 109.24 12.72 Favored 'General case' 0 C--O 1.226 -0.162 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 14.0 t 44.34 85.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.258 1.423 . . . . 0.0 112.189 -176.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 51.9 mt -76.67 128.95 80.7 Favored Pre-proline 0 CA--C 1.534 0.336 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo . . . . . 0 N--CA 1.456 -0.72 0 C-N-CA 124.071 3.181 . . . . 0.0 111.541 175.442 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 CA--C 1.541 0.6 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -117.61 34.46 0.58 Allowed 'Cis proline' 0 CA--C 1.536 0.611 0 N-CA-C 109.297 -1.078 . . . . 0.0 109.297 -6.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.1 p -90.64 143.13 27.04 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 118.519 2.785 . . . . 0.0 118.519 -168.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . 0.44 ' CD2' ' HB2' ' A' ' 148' ' ' MET . 3.2 m-85 -85.69 103.46 14.51 Favored 'General case' 0 C--N 1.34 0.176 0 N-CA-C 103.276 -2.861 . . . . 0.0 103.276 166.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -93.51 96.07 9.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -174.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.8 t -85.2 149.5 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -176.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -20.96 -57.31 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 116.732 2.123 . . . . 0.0 116.732 -172.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -114.31 -5.71 12.95 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 39.8 mttm -150.34 148.54 28.94 Favored 'General case' 0 C--O 1.223 -0.323 0 CA-C-N 119.845 1.202 . . . . 0.0 109.731 -174.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.5 mttm -97.07 123.79 40.91 Favored 'General case' 0 C--N 1.332 -0.181 0 O-C-N 121.351 -0.843 . . . . 0.0 109.595 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.59 46.29 1.88 Allowed Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.505 1.522 . . . . 0.0 111.435 176.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -83.92 174.29 8.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 122.31 2.007 . . . . 0.0 113.031 -171.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 52.9 m -86.54 148.66 25.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 170.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.5 mp -119.55 133.0 55.86 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 120.892 -1.13 . . . . 0.0 109.421 175.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -109.82 116.27 31.35 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.539 -2.022 . . . . 0.0 105.539 171.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 mt -124.56 145.77 50.32 Favored Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 124.29 1.036 . . . . 0.0 112.456 -171.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -85.37 128.48 3.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.678 2.252 . . . . 0.0 107.909 171.172 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.26 151.99 2.63 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.859 1.264 . . . . 0.0 112.034 178.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.7 -31.8 2.19 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-O 119.203 -0.776 . . . . 0.0 113.701 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -46.84 148.6 1.02 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.567 1.147 . . . . 0.0 112.811 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 17.2 m -79.68 96.06 6.11 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.4 t -79.53 89.51 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 177.098 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -82.68 133.49 35.16 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 173.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.3 t -132.78 110.83 16.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 98.4 m -91.39 125.94 36.3 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 174.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -94.27 158.64 15.49 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 174.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.6 mp -137.41 67.57 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 102.577 -3.12 . . . . 0.0 102.577 163.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 20.8 t30 -98.09 76.67 2.39 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 -175.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.0 p -94.79 -80.14 0.41 Allowed 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.501 1.12 . . . . 0.0 109.923 -173.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 68.35 -50.71 0.55 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.253 2.221 . . . . 0.0 114.649 177.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 87.4 mttt 96.42 33.14 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 130.079 3.352 . . . . 0.0 111.877 -179.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 171.22 -60.03 0.17 Allowed Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -83.12 91.35 7.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.97 83.39 0.02 OUTLIER Glycine 0 CA--C 1.528 0.9 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 173.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -68.87 74.66 0.29 Allowed 'General case' 0 N--CA 1.457 -0.111 0 C-N-CA 125.177 1.391 . . . . 0.0 112.878 -174.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.8 p -42.29 136.38 2.31 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 125.253 1.421 . . . . 0.0 111.281 177.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -107.68 119.95 40.86 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 173.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -129.62 108.79 10.49 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -172.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 32.3 mt -80.72 134.79 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 124.144 0.903 . . . . 0.0 108.824 176.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -160.33 -160.45 0.78 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.433 1.493 . . . . 0.0 107.42 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -126.43 13.31 7.61 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.692 0.797 . . . . 0.0 111.517 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -64.7 121.34 14.28 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 174.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -86.66 170.72 42.49 Favored Glycine 0 CA--C 1.532 1.114 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.85 164.16 36.59 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.208 2.605 . . . . 0.0 109.674 173.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.42 139.12 58.36 Favored 'Cis proline' 0 N--CA 1.455 -0.75 0 N-CA-C 110.163 -0.745 . . . . 0.0 110.163 -4.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -79.68 151.27 30.58 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.179 0.514 . . . . 0.0 110.011 178.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -98.96 149.71 22.69 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 124.135 0.974 . . . . 0.0 110.27 -174.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 18.2 t -62.52 -34.62 65.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 C-N-CA 123.706 0.803 . . . . 0.0 109.218 173.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.6 mmt -78.24 133.97 63.66 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -63.8 63.79 0.21 Allowed 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.889 3.059 . . . . 0.0 115.232 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 13.9 t -80.84 57.5 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 O-C-N 120.254 -1.529 . . . . 0.0 108.325 174.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -38.07 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 C-N-CA 123.529 0.732 . . . . 0.0 111.721 -174.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.04 143.45 32.08 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 125.017 1.327 . . . . 0.0 112.278 -172.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.18 162.45 92.7 Favored 'Cis proline' 0 N--CA 1.46 -0.444 0 N-CA-C 110.281 -0.7 . . . . 0.0 110.281 -6.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.5 mm -118.18 144.46 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 174.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.56 -86.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 174.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.41 87.64 6.09 Favored 'General case' 0 CA--C 1.52 -0.207 0 O-C-N 122.024 -0.423 . . . . 0.0 109.977 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -90.4 125.61 7.99 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 107.581 -2.208 . . . . 0.0 107.581 172.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.7 p -76.01 -41.48 50.97 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.261 1.531 . . . . 0.0 110.039 173.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.2 -170.09 21.25 Favored Glycine 0 CA--C 1.532 1.145 0 N-CA-C 108.673 -1.771 . . . . 0.0 108.673 -174.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -91.17 138.26 31.73 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.332 1.566 . . . . 0.0 109.215 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.0 p -83.21 159.31 62.48 Favored Pre-proline 0 CA--C 1.533 0.317 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -173.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.87 74.61 3.88 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.076 2.518 . . . . 0.0 107.987 172.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.8 m -53.67 128.9 54.1 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 123.278 0.631 . . . . 0.0 111.331 -175.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.98 176.36 9.92 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.286 2.657 . . . . 0.0 110.078 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.32 -29.38 6.24 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 176.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -174.02 155.85 2.6 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.715 2.006 . . . . 0.0 108.174 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.34 -59.05 1.15 Allowed Glycine 0 CA--C 1.527 0.789 0 C-N-CA 125.466 1.508 . . . . 0.0 113.06 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -78.92 158.77 27.98 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 123.417 0.687 . . . . 0.0 111.344 -174.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -135.23 94.42 3.12 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.804 2.041 . . . . 0.0 108.388 -174.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -53.27 113.29 2.84 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 173.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.1 p90 -119.32 177.03 5.05 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.537 1.135 . . . . 0.0 109.689 175.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.5 m -158.05 154.17 27.16 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 -177.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -131.82 89.54 2.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 173.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -96.9 170.08 9.41 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.8 m -150.79 146.56 26.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -150.56 153.53 35.94 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.884 0.874 . . . . 0.0 110.423 -176.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -116.47 114.44 40.33 Favored Pre-proline 0 CA--C 1.535 0.384 0 C-N-CA 125.584 1.554 . . . . 0.0 107.116 173.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.79 142.26 3.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 124.371 3.381 . . . . 0.0 111.503 -172.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.2 p -96.02 146.42 24.64 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 124.363 1.065 . . . . 0.0 108.845 173.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.83 149.08 19.08 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.164 0.438 . . . . 0.0 112.092 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 121.74 -123.96 5.63 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 126.754 2.121 . . . . 0.0 109.123 -175.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 46.1 m -153.84 145.7 23.49 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.351 1.075 . . . . 0.0 109.972 -174.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -132.95 176.45 8.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.336 2.254 . . . . 0.0 106.897 173.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -142.31 152.81 43.33 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 125.534 1.533 . . . . 0.0 107.551 175.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 55.1 p90 -114.83 140.59 48.82 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 123.223 0.609 . . . . 0.0 109.905 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.36 162.9 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.375 1.07 . . . . 0.0 111.093 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 8.8 t -107.69 136.09 48.02 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 127.121 2.169 . . . . 0.0 109.838 173.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -81.64 -19.0 42.65 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 -170.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.01 130.04 93.82 Favored Pre-proline 0 CA--C 1.544 0.721 0 CA-C-N 119.125 0.875 . . . . 0.0 108.989 -174.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -42.15 133.45 4.52 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.745 2.964 . . . . 0.0 113.424 178.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 90.07 -32.51 4.87 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.099 0.857 . . . . 0.0 111.795 -174.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -75.49 172.84 11.83 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -176.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 75.29 -60.6 0.5 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -170.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.2 -52.27 66.01 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.7 p -78.51 75.47 5.03 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 121.829 0.823 . . . . 0.0 112.272 -178.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 70.87 -44.71 0.67 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 118.189 2.035 . . . . 0.0 118.189 169.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' MET . . . . . 0.44 ' HB2' ' CD2' ' A' ' 54' ' ' PHE . 4.2 ptp -77.85 87.74 4.07 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 119.857 1.828 . . . . 0.0 114.271 -172.035 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -160.81 -179.91 7.97 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 126.053 1.741 . . . . 0.0 108.839 173.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 178.86 168.39 37.96 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 172.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -104.21 138.51 40.57 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 125.049 1.339 . . . . 0.0 108.356 -174.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.1 mt -114.76 100.44 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 19.6 t -84.16 136.37 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -123.02 115.65 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp . . . . . 0 N--CA 1.462 0.13 0 CA-C-N 119.091 0.86 . . . . 0.0 109.558 174.64 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p . . . . . 0 CA--C 1.54 0.568 0 CA-C-O 120.666 0.27 . . . . 0.0 111.337 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.2 m -79.16 66.57 4.64 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.568 1.147 . . . . 0.0 112.253 -171.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -96.34 146.83 24.4 Favored 'General case' 0 CA--C 1.522 -0.099 0 N-CA-C 114.875 1.435 . . . . 0.0 114.875 177.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -149.13 170.15 19.07 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 129.064 2.946 . . . . 0.0 103.706 171.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -124.8 126.55 45.79 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-N 119.645 1.111 . . . . 0.0 110.063 174.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -88.09 -150.22 0.18 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 172.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.9 p -142.39 166.07 25.7 Favored 'General case' 0 CA--C 1.532 0.274 0 O-C-N 121.389 -0.819 . . . . 0.0 109.277 174.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.45 -58.11 2.1 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -175.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -60.06 -28.84 87.9 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 CA-C-N 121.159 1.45 . . . . 0.0 112.224 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -66.83 -24.46 66.16 Favored 'General case' 0 N--CA 1.45 -0.465 0 O-C-N 121.462 -0.774 . . . . 0.0 111.013 177.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.0 t -63.34 -53.84 40.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -54.29 -42.81 70.47 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.468 178.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -58.25 -66.6 0.46 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.273 -0.267 . . . . 0.0 110.619 174.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 67.9 mtm -47.68 -50.2 25.55 Favored 'General case' 0 CA--C 1.528 0.1 0 C-N-CA 124.766 1.226 . . . . 0.0 112.182 -174.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.5 mt -47.14 -40.68 16.18 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.16 0.584 . . . . 0.0 112.192 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -67.86 -10.63 54.65 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.51 17.55 23.17 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.885 0.766 . . . . 0.0 110.999 175.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -65.6 106.06 1.37 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 119.132 0.878 . . . . 0.0 109.909 174.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.9 p -77.98 82.52 4.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.37 112.71 0.46 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 174.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.1 mmtp -78.98 162.78 25.72 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.793 1.237 . . . . 0.0 109.863 -177.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.4 t -69.11 141.42 17.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.653 1.181 . . . . 0.0 109.59 -178.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.5 m -147.85 67.22 1.1 Allowed 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.363 -0.835 . . . . 0.0 109.593 174.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.06 -94.66 0.12 Allowed Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.827 0.727 . . . . 0.0 111.785 175.022 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -109.19 25.54 11.68 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.856 1.663 . . . . 0.0 110.118 178.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -154.99 163.12 40.75 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -174.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.09 147.17 23.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.137 -1.801 . . . . 0.0 106.137 173.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.6 m -142.15 138.23 31.45 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 119.259 0.936 . . . . 0.0 111.168 -171.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -112.07 -167.88 1.24 Allowed 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.331 0.514 . . . . 0.0 111.522 173.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.3 m -157.75 -47.77 0.06 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.732 0.813 . . . . 0.0 112.268 -173.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.08 156.35 53.37 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 177.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -79.18 40.6 0.42 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.289 -1.124 . . . . 0.0 112.323 -174.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.3 m -156.18 102.31 2.12 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 120.771 -1.206 . . . . 0.0 107.877 -178.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.2 t -104.73 84.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -82.47 93.36 7.23 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 t -93.99 159.65 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.4 t -133.68 106.93 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 C-N-CA 124.97 1.308 . . . . 0.0 108.045 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -112.74 103.48 11.5 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.416 1.487 . . . . 0.0 109.836 -174.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.03 112.0 23.71 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.276 0.63 . . . . 0.0 109.304 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.57 102.87 15.55 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.502 -0.749 . . . . 0.0 110.15 -174.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.6 t 49.32 82.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 125.613 1.565 . . . . 0.0 112.389 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.3 mt -76.58 141.6 69.41 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 174.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo . . . . . 0 N--CA 1.454 -0.827 0 C-N-CA 123.093 2.529 . . . . 0.0 110.315 -174.361 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -109.86 65.09 0.34 Allowed 'Cis proline' 0 N--CA 1.455 -0.766 0 N-CA-C 107.115 -1.917 . . . . 0.0 107.115 -5.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 59.1 p -86.45 123.07 31.27 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 116.581 2.067 . . . . 0.0 116.581 -171.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -83.47 94.24 7.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 168.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -81.79 115.91 21.23 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -175.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.5 t -114.09 82.55 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 125.067 1.347 . . . . 0.0 109.479 -173.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.418 ' CG ' ' N ' ' A' ' 58' ' ' ASP . 1.0 OUTLIER 46.83 -69.21 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.594 3.557 . . . . 0.0 115.221 176.239 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.418 ' N ' ' CG ' ' A' ' 57' ' ' HIS . 21.2 t70 -95.51 -28.08 15.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.153 1.781 . . . . 0.0 110.838 -176.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -132.19 -176.92 4.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 123.787 0.835 . . . . 0.0 109.285 -176.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -134.4 121.27 20.9 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 175.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.64 43.41 0.9 Allowed Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 124.897 1.279 . . . . 0.0 111.18 -177.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.59 177.74 6.71 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 121.711 1.608 . . . . 0.0 111.412 -175.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.7 m -93.47 138.04 32.17 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 170.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.0 mp -111.3 140.17 46.09 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.111 0.964 . . . . 0.0 109.939 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -112.88 120.9 43.05 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.603 1.161 . . . . 0.0 108.167 172.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 16.5 mt -128.01 146.54 59.6 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -170.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -72.06 123.11 9.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.608 2.205 . . . . 0.0 110.587 170.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.39 134.65 28.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 124.22 1.008 . . . . 0.0 110.57 173.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.98 0.43 75.76 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 118.764 -1.02 . . . . 0.0 113.157 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.06 146.63 52.82 Favored 'General case' 0 N--CA 1.456 -0.169 0 CA-C-N 119.847 1.824 . . . . 0.0 109.628 173.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 58.5 m -78.37 99.76 6.5 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.25 134.71 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -139.47 95.07 2.86 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.754 1.621 . . . . 0.0 106.729 173.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.7 t -80.11 106.02 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 174.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.0 m -79.47 109.0 13.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -76.93 150.34 35.95 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.478 172.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 1.2 mp -132.74 69.1 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 165.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -102.3 77.94 1.7 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 -175.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.1 p -118.51 20.21 13.07 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.108 1.763 . . . . 0.0 112.627 -171.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -70.0 103.36 2.24 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 173.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -46.78 134.81 9.58 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.683 0.793 . . . . 0.0 111.692 -173.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.23 -59.45 3.6 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -174.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -78.89 67.8 4.69 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.338 0.655 . . . . 0.0 111.046 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.29 92.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.267 -1.933 . . . . 0.0 108.267 172.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.53 179.47 0.16 Allowed 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.059 0.944 . . . . 0.0 110.637 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 p -137.92 147.9 44.8 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.439 -2.06 . . . . 0.0 105.439 177.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -127.02 104.18 7.85 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 173.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 60.3 m-20 -120.62 127.24 51.91 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.989 0.916 . . . . 0.0 108.877 -174.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.2 mt -98.46 129.74 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 C-N-CA 125.999 1.719 . . . . 0.0 108.579 -174.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.96 -151.08 0.22 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.581 1.153 . . . . 0.0 108.153 -173.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt -133.92 -88.04 0.4 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.821 0.849 . . . . 0.0 109.783 178.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.6 mtmt 49.15 -126.74 2.09 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.216 1.006 . . . . 0.0 109.169 -173.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -175.65 161.88 30.92 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.191 -1.563 . . . . 0.0 109.191 175.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.82 154.44 30.17 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.613 2.876 . . . . 0.0 109.75 174.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.14 144.92 82.56 Favored 'Cis proline' 0 N--CA 1.453 -0.872 0 N-CA-C 108.994 -1.194 . . . . 0.0 108.994 -5.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -78.44 163.67 25.42 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-O 121.375 0.607 . . . . 0.0 110.054 -176.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.24 145.13 42.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.563 -173.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -49.56 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 174.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -78.79 149.55 74.34 Favored Pre-proline 0 CA--C 1.534 0.346 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -72.6 73.62 2.84 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.829 2.352 . . . . 0.0 111.494 -179.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 16.6 t -79.28 53.24 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 173.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.2 pt -84.33 68.71 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-O 122.874 1.321 . . . . 0.0 109.787 -176.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -88.48 -72.69 0.06 OUTLIER Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 113.743 -1.571 . . . . 0.0 110.597 -174.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -77.77 57.76 6.17 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 122.208 1.939 . . . . 0.0 111.48 -178.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 24.8 mm -78.41 126.56 38.64 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 O-C-N 121.228 -0.92 . . . . 0.0 108.8 177.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.1 t -84.78 -88.18 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.62 164.29 12.84 Favored 'General case' 0 CA--C 1.521 -0.162 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 173.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 172.26 -179.14 44.04 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 119.297 -1.43 . . . . 0.0 112.556 173.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 6.0 p -130.84 138.82 50.03 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 126.272 1.829 . . . . 0.0 108.749 176.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -75.04 -127.77 0.19 Allowed Glycine 0 CA--C 1.534 1.275 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 174.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -112.15 154.47 25.44 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 119.659 1.729 . . . . 0.0 110.465 176.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.6 p -90.31 155.83 46.33 Favored Pre-proline 0 N--CA 1.449 -0.488 0 C-N-CA 124.927 1.291 . . . . 0.0 112.397 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.52 98.82 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.192 0 C-N-CA 122.981 2.454 . . . . 0.0 107.468 173.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 40.3 t -37.85 123.49 1.0 Allowed Pre-proline 0 CA--C 1.538 0.502 0 C-N-CA 125.222 1.409 . . . . 0.0 110.421 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -67.79 156.71 64.91 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.66 2.24 . . . . 0.0 112.847 -172.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 29.2 mmmt -110.2 175.94 5.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 125.717 1.607 . . . . 0.0 106.824 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -36.91 104.02 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 125.119 1.368 . . . . 0.0 114.07 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.31 -8.5 46.33 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-O 118.456 -1.191 . . . . 0.0 115.148 173.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -84.48 156.0 21.92 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.866 1.333 . . . . 0.0 109.744 -178.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -139.37 94.17 2.76 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.6 116.14 4.5 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.214 1.387 . . . . 0.0 113.06 174.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -130.46 154.79 47.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.26 1.024 . . . . 0.0 111.486 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.8 m -145.36 118.84 9.05 Favored 'General case' 0 CA--C 1.518 -0.278 0 C-N-CA 124.419 1.088 . . . . 0.0 109.646 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -95.27 88.28 5.1 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 171.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -89.65 122.97 33.28 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 21.8 m -82.91 142.08 31.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.885 -174.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -151.38 155.77 39.33 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.458 1.103 . . . . 0.0 109.423 175.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 65.2 m80 -123.78 108.85 30.49 Favored Pre-proline 0 CA--C 1.532 0.288 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 173.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -89.57 144.24 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.909 3.073 . . . . 0.0 111.019 -172.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.8 p -95.86 155.02 16.92 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.052 0.941 . . . . 0.0 109.549 173.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -60.88 149.25 36.82 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -175.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 126.67 -128.04 6.17 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 126.39 1.948 . . . . 0.0 108.684 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 32.1 m -152.99 141.95 21.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 118.451 1.125 . . . . 0.0 110.201 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -128.29 174.84 8.95 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.893 1.677 . . . . 0.0 107.828 173.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -134.74 147.17 49.98 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.124 1.37 . . . . 0.0 107.904 174.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -109.06 142.88 39.15 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.561 0.745 . . . . 0.0 109.291 174.083 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 33.0 m -143.95 165.3 14.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 124.528 1.131 . . . . 0.0 111.452 -177.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.2 t -118.76 135.04 54.72 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 126.634 1.974 . . . . 0.0 110.091 173.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 64.9 mt-30 -64.47 -50.9 65.66 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 125.015 1.326 . . . . 0.0 113.49 -174.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 71.4 mt -39.95 121.91 1.55 Allowed Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 124.711 1.204 . . . . 0.0 111.526 -170.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -31.79 120.22 0.08 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.886 1 C-N-CA 125.472 4.115 . . . . 0.0 115.711 -173.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 86.74 -25.05 7.77 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 118.888 -0.951 . . . . 0.0 113.481 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 22.4 m170 -54.68 -59.99 3.97 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.203 1.501 . . . . 0.0 111.548 -172.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -49.12 -56.37 9.35 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.138 0.575 . . . . 0.0 110.934 177.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.27 -46.66 79.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.914 0.886 . . . . 0.0 112.336 -175.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.7 p -79.23 -36.31 40.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 113.186 0.809 . . . . 0.0 113.186 -172.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.56 -18.82 0.03 OUTLIER Glycine 0 C--N 1.34 0.771 0 C-N-CA 118.442 -1.837 . . . . 0.0 116.443 -175.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.4 ttt -79.73 65.11 4.8 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.093 1.446 . . . . 0.0 109.681 -174.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -161.53 167.96 24.47 Favored 'General case' 0 C--O 1.225 -0.236 0 C-N-CA 123.035 0.534 . . . . 0.0 111.53 -178.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -174.22 169.34 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 176.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -94.5 151.68 19.16 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.637 1.175 . . . . 0.0 110.526 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.4 mt -125.22 94.0 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 173.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.2 t -80.26 136.59 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 173.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.2 t -127.39 127.65 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 -176.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 49.8 mttp . . . . . 0 N--CA 1.464 0.243 0 CA-C-N 119.043 0.838 . . . . 0.0 111.383 -176.813 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.706 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.1 p -63.96 -64.97 0.75 Allowed 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 173.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.0 mp -112.59 179.85 3.86 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 128.052 2.541 . . . . 0.0 106.453 171.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -68.8 124.42 23.63 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p -118.18 32.91 5.89 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.738 1.215 . . . . 0.0 110.454 -175.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.4 m -79.2 61.51 3.34 Favored 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.37 -0.831 . . . . 0.0 110.115 -178.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.7 m95 -79.46 136.16 36.85 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.988 1.715 . . . . 0.0 110.572 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -149.92 171.38 16.89 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -139.64 127.89 22.59 Favored 'General case' 0 C--N 1.341 0.213 0 CA-C-N 118.826 0.739 . . . . 0.0 109.826 171.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.17 -152.47 0.43 Allowed 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 125.551 1.54 . . . . 0.0 107.121 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.2 p -136.64 170.99 15.16 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 124.179 0.992 . . . . 0.0 108.482 173.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -39.06 -55.17 3.03 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 114.528 1.306 . . . . 0.0 114.528 -174.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -55.45 -33.53 86.27 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.517 1.478 . . . . 0.0 113.633 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -68.67 -29.36 67.81 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 119.118 0.872 . . . . 0.0 111.072 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 t -62.13 -50.2 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 174.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -54.43 -49.3 70.31 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.55 -61.53 2.14 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.034 0.534 . . . . 0.0 111.066 176.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 74.4 mtm -55.14 -45.84 75.65 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.202 0.601 . . . . 0.0 110.801 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.3 mt -53.28 -38.01 62.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.19 -0.433 . . . . 0.0 111.747 176.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -72.0 -45.69 60.0 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 175.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.5 mtpt -80.31 62.36 4.42 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 122.709 0.404 . . . . 0.0 110.791 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -134.94 134.64 40.8 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.375 1.07 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.2 p -96.48 24.02 6.27 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.935 0.894 . . . . 0.0 112.951 -175.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.21 100.0 2.43 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 125.727 1.632 . . . . 0.0 110.986 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -78.51 159.13 28.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.626 1.171 . . . . 0.0 109.322 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 63.2 t -93.53 93.47 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.715 0.806 . . . . 0.0 110.34 -174.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.3 p -77.74 70.47 4.12 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 60.98 -96.72 0.11 Allowed Glycine 0 CA--C 1.527 0.835 0 C-N-CA 124.741 1.162 . . . . 0.0 111.045 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -86.98 -36.61 18.16 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.027 0.931 . . . . 0.0 110.543 178.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.3 m -89.88 166.54 13.45 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.728 1.611 . . . . 0.0 108.787 -172.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.12 144.17 18.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 172.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.7 m -134.07 117.36 16.54 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.687 1.195 . . . . 0.0 108.236 -175.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 -79.59 162.25 25.43 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.182 0.515 . . . . 0.0 110.778 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 67.2 m -154.24 159.59 41.39 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.103 0.961 . . . . 0.0 108.629 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.22 165.23 29.43 Favored Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 -174.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.2 mtpm? -73.54 -18.28 61.1 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 122.004 -0.704 . . . . 0.0 111.753 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.4 p -95.68 87.63 4.75 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.132 0.973 . . . . 0.0 109.064 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.0 t -81.84 77.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -86.3 87.65 7.47 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.089 -175.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.67 95.87 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 124.39 1.076 . . . . 0.0 109.173 -174.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.65 109.99 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 175.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -127.84 164.28 22.56 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.827 1.251 . . . . 0.0 109.365 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.77 167.43 24.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 176.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -136.18 114.03 11.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -174.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.7 t 34.38 69.01 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 C-N-CA 127.11 2.164 . . . . 0.0 112.339 174.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 90.9 mt -76.67 144.98 74.22 Favored Pre-proline 0 N--CA 1.453 -0.286 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.24 102.57 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.21 2.607 . . . . 0.0 110.947 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 138.24 -44.54 1.11 Allowed Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -174.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 -78.43 127.3 81.22 Favored Pre-proline 0 N--CA 1.453 -0.288 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -76.16 160.5 36.27 Favored 'Trans proline' 0 N--CA 1.45 -1.039 0 C-N-CA 121.933 1.755 . . . . 0.0 111.278 -176.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -67.77 164.74 37.13 Favored Pre-proline 0 CA--C 1.538 0.486 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 172.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -112.38 7.32 3.12 Favored 'Cis proline' 0 CA--C 1.535 0.532 0 CA-C-N 119.641 0.907 . . . . 0.0 113.09 0.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.4 p -83.71 154.9 23.38 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 115.043 1.497 . . . . 0.0 115.043 -171.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -79.37 139.06 37.86 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.747 1.219 . . . . 0.0 109.526 173.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.94 132.38 34.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 123.922 0.889 . . . . 0.0 110.094 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 t -125.97 83.47 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 172.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 55.7 p-80 42.08 -78.59 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 128.587 2.755 . . . . 0.0 115.008 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -84.37 -24.81 29.53 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 124.18 0.992 . . . . 0.0 111.723 -176.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -130.83 -174.9 3.5 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.584 1.153 . . . . 0.0 109.58 -174.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -128.91 92.1 3.34 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 26.73 69.82 0.45 Allowed Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 127.459 2.303 . . . . 0.0 115.882 -174.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -66.41 -55.56 0.36 Allowed 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.537 2.158 . . . . 0.0 108.674 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.2 m 169.53 154.63 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 129.257 3.023 . . . . 0.0 105.697 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.3 mp -117.22 124.79 49.95 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.969 1.308 . . . . 0.0 110.204 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -98.42 137.09 37.63 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 171.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.08 136.0 25.4 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.213 1.005 . . . . 0.0 110.867 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -76.47 112.06 3.38 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.705 2.937 . . . . 0.0 109.271 173.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.39 -41.37 9.06 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -173.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -72.75 -7.51 69.92 Favored Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.41 -0.661 . . . . 0.0 114.068 -175.031 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -85.94 165.07 17.04 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.741 1.271 . . . . 0.0 113.38 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 63.1 m -93.72 127.41 39.42 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 172.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 94.9 t -92.13 132.29 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -127.77 108.1 10.44 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.752 -1.574 . . . . 0.0 106.752 173.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.09 115.36 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 16.4 m -107.71 96.01 6.09 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 126.059 1.743 . . . . 0.0 107.181 174.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . 0.279 4.3 m-85 -78.79 151.57 31.9 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 172.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -127.79 69.6 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 102.595 -3.113 . . . . 0.0 102.595 162.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -80.64 113.08 18.58 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 171.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 52.3 m -137.93 45.38 2.13 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -78.55 113.71 16.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 172.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -72.8 69.8 0.95 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.166 0.586 . . . . 0.0 110.113 -178.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 174.43 -67.72 0.1 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -96.71 122.69 39.93 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -174.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.26 71.03 0.63 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.864 -1.695 . . . . 0.0 108.864 171.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -57.06 143.82 36.9 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.511 1.156 . . . . 0.0 111.356 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.3 p -106.76 161.25 14.84 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 125.435 1.494 . . . . 0.0 108.845 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -129.89 101.11 5.71 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 102.755 -3.054 . . . . 0.0 102.755 172.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -118.89 114.44 22.61 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -173.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 6.7 mt -95.2 125.31 47.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 C-N-CA 125.44 1.496 . . . . 0.0 110.297 -174.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -161.17 -145.46 0.11 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -113.0 -98.95 0.43 Allowed 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 174.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt 67.42 -67.32 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.887 1.275 . . . . 0.0 111.184 -174.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.78 170.35 28.9 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -174.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -75.1 147.01 32.99 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.634 2.223 . . . . 0.0 109.388 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.82 136.76 45.48 Favored 'Cis proline' 0 N--CA 1.454 -0.813 0 CA-C-N 119.48 0.85 . . . . 0.0 109.995 -5.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -79.03 149.24 32.24 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.93 144.03 39.12 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 121.188 0.518 . . . . 0.0 112.155 -173.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.15 -43.28 98.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.9 mtp -78.1 133.18 65.33 Favored Pre-proline 0 N--CA 1.45 -0.425 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 173.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -75.65 85.24 1.63 Allowed 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.669 1.579 . . . . 0.0 109.307 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.8 t -76.41 105.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -178.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 23.4 pt -78.91 72.98 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 123.241 1.495 . . . . 0.0 110.534 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -62.57 154.5 73.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 113.328 -1.76 . . . . 0.0 106.398 171.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_exo -37.62 104.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 124.031 3.154 . . . . 0.0 113.835 -176.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 31.4 mm -78.95 131.27 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.97 -88.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 104.753 -2.314 . . . . 0.0 104.753 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.3 150.3 20.72 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 170.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.89 168.08 39.8 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.8 174.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 2.8 p -120.77 127.61 52.13 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.291 1.036 . . . . 0.0 109.991 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.62 57.0 5.04 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 119.502 -0.61 . . . . 0.0 111.985 -176.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 73.33 99.68 0.07 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 126.256 1.822 . . . . 0.0 111.488 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.3 p -74.13 160.32 81.87 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 118.767 -0.635 . . . . 0.0 110.578 -176.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 169.08 2.07 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 123.559 2.839 . . . . 0.0 116.032 -173.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 92.6 t -121.38 97.08 47.54 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 126.641 1.976 . . . . 0.0 107.627 178.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -70.52 -179.77 3.5 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.936 3.091 . . . . 0.0 114.005 -176.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -109.88 -164.87 0.96 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.814 1.646 . . . . 0.0 107.305 172.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -60.99 153.43 25.18 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.518 -0.739 . . . . 0.0 111.003 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.71 3.1 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 123.808 0.718 . . . . 0.0 113.276 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -80.02 156.06 27.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.196 0.598 . . . . 0.0 111.798 -175.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -135.88 106.87 6.68 Favored 'General case' 0 CA--C 1.513 -0.456 0 C-N-CA 125.677 1.591 . . . . 0.0 110.289 -172.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -64.41 123.27 27.09 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.269 -1.932 . . . . 0.0 108.269 178.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -130.98 165.04 24.04 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 122.127 0.965 . . . . 0.0 109.886 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.0 m -152.62 120.76 6.23 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -103.57 104.6 14.68 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -118.74 147.74 43.53 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 28.6 m -104.14 152.05 22.58 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.804 0.842 . . . . 0.0 109.731 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -151.38 147.72 27.25 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.824 1.25 . . . . 0.0 109.161 175.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 44.8 m80 -116.15 111.37 42.64 Favored Pre-proline 0 N--CA 1.454 -0.256 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 172.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -82.64 -170.98 1.03 Allowed 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.892 2.395 . . . . 0.0 110.688 -173.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.0 p -140.95 147.9 39.53 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.69 152.46 35.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -174.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.55 -129.68 8.14 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 126.508 2.004 . . . . 0.0 108.982 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.8 m -142.82 137.48 29.69 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 117.437 0.618 . . . . 0.0 109.667 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.4 m-85 -130.42 176.75 7.88 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.484 1.914 . . . . 0.0 106.182 172.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -142.53 147.85 36.64 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 173.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -115.21 147.03 40.84 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 172.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.2 m -144.96 154.46 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 125.042 1.337 . . . . 0.0 109.735 -174.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.43 107.64 19.8 Favored 'General case' 0 C--N 1.333 -0.125 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 171.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.1 mm-40 -74.72 38.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -174.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 16.5 mt -93.24 142.73 25.67 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 104.305 -2.479 . . . . 0.0 104.305 168.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -48.24 138.85 22.48 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.028 1.818 . . . . 0.0 112.94 178.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.0 -46.67 2.45 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.312 0.958 . . . . 0.0 113.193 176.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.2 m170 -42.55 -55.8 3.34 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.814 1.646 . . . . 0.0 113.882 -173.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.88 -53.54 57.02 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.71 0.29 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.71 -38.67 88.72 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 124.117 0.967 . . . . 0.0 111.684 -176.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 31.0 p -78.31 -32.32 49.24 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 118.731 -0.652 . . . . 0.0 111.293 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.12 -30.61 0.1 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 118.355 -1.879 . . . . 0.0 116.234 173.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.315 10.3 ptp -80.4 84.46 6.03 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 120.053 1.927 . . . . 0.0 112.707 -174.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -141.93 174.49 10.54 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 126.532 1.933 . . . . 0.0 107.296 172.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -156.28 128.28 2.18 Favored Glycine 0 C--N 1.331 0.285 0 N-CA-C 108.482 -1.847 . . . . 0.0 108.482 173.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -76.99 130.12 37.05 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 174.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.0 mt -110.87 100.91 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 25.7 t -88.84 110.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 174.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.8 t -97.66 94.66 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 63.9 mttp . . . . . 0 C--N 1.332 -0.165 0 O-C-N 121.525 -0.734 . . . . 0.0 109.041 176.373 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.774 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.6 p -66.19 -79.69 0.04 OUTLIER 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 4.5 mt 37.26 -86.34 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.193 2.197 . . . . 0.0 114.638 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.47 -50.43 67.76 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.805 0.842 . . . . 0.0 111.838 174.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.6 p 67.79 -37.3 0.32 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.941 2.097 . . . . 0.0 113.296 -173.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.9 m -78.05 68.93 4.19 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 32.6 m95 -103.45 129.01 50.5 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 126.853 2.061 . . . . 0.0 109.772 -176.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -151.92 178.4 9.45 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -131.27 127.04 36.96 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 171.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.75 -150.62 0.27 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.6 p -137.34 170.41 16.13 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 119.475 1.034 . . . . 0.0 108.563 172.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.6 tt -39.53 -55.74 3.23 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 124.316 1.046 . . . . 0.0 113.582 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -56.54 -33.23 92.29 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 CA-C-N 121.011 1.397 . . . . 0.0 113.861 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -64.94 -25.25 67.8 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 118.946 0.794 . . . . 0.0 111.452 177.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.2 t -53.91 -46.94 64.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.651 0.659 . . . . 0.0 109.277 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 mtmm -59.12 -54.17 50.04 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.27 -47.66 62.42 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.84 0.456 . . . . 0.0 111.378 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -62.3 -54.78 35.65 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 119.47 -0.3 . . . . 0.0 110.672 177.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.6 mt -50.58 -47.8 57.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 118.423 0.556 . . . . 0.0 111.392 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -54.06 -25.94 24.19 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.003 0.921 . . . . 0.0 113.093 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -88.21 -9.12 54.06 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 118.9 0.773 . . . . 0.0 112.116 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -49.48 145.8 4.52 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -176.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.7 p -121.0 166.4 13.9 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.599 1.159 . . . . 0.0 108.851 171.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.69 116.71 2.92 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 124.521 1.058 . . . . 0.0 110.787 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 49.4 mtmt -81.68 144.35 31.24 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.558 1.143 . . . . 0.0 108.989 176.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 81.4 t -67.78 145.32 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 122.781 0.432 . . . . 0.0 110.603 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.9 m -150.82 68.95 0.96 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.767 1.227 . . . . 0.0 109.132 174.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.28 -115.45 7.14 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -79.01 -31.22 44.63 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 118.054 0.927 . . . . 0.0 109.109 172.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -79.54 153.39 29.56 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.742 -173.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -120.47 135.32 61.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 171.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 74.2 m -121.7 133.49 54.95 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.302 1.041 . . . . 0.0 110.459 -169.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 79.2 m-85 -105.55 177.72 4.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 124.086 0.954 . . . . 0.0 109.589 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.8 m -154.36 -50.0 0.09 Allowed 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.468 0.707 . . . . 0.0 109.609 177.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -65.63 145.22 48.2 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -60.6 -31.69 70.84 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.179 0.592 . . . . 0.0 111.088 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.8 m -78.1 76.21 4.62 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -78.04 102.59 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 30.9 t-80 -106.95 102.94 12.26 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 123.818 0.847 . . . . 0.0 109.563 -178.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 86.0 t -99.89 151.03 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 125.231 1.413 . . . . 0.0 108.777 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.6 t -130.72 100.49 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 124.618 1.167 . . . . 0.0 108.494 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -106.14 155.46 19.42 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 125.362 1.465 . . . . 0.0 110.731 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.73 158.41 44.01 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 124.511 1.125 . . . . 0.0 109.3 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.84 117.77 24.86 Favored 'General case' 0 N--CA 1.456 -0.157 0 C-N-CA 123.556 0.742 . . . . 0.0 111.032 -173.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.9 t 42.29 66.92 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 C-N-CA 125.323 1.449 . . . . 0.0 111.618 173.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.5 mt -77.88 153.43 80.44 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -44.54 125.27 5.99 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.054 2.502 . . . . 0.0 111.704 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.17 -32.36 7.42 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 123.747 0.689 . . . . 0.0 111.896 -176.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -99.78 112.98 64.81 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 118.183 0.992 . . . . 0.0 109.469 -175.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -58.74 160.1 18.74 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.764 2.309 . . . . 0.0 114.47 -176.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 -65.79 147.69 98.61 Favored Pre-proline 0 CA--C 1.533 0.309 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -111.69 67.48 0.23 Allowed 'Cis proline' 0 N--CA 1.455 -0.791 0 N-CA-C 107.726 -1.682 . . . . 0.0 107.726 -6.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 79.0 p -92.19 133.66 35.59 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -86.34 122.4 30.25 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 169.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -93.32 131.01 38.87 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 104.57 -2.382 . . . . 0.0 104.57 171.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.5 t -137.5 114.92 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 120.226 1.375 . . . . 0.0 110.61 -173.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 36.79 -114.31 0.1 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.771 1.628 . . . . 0.0 112.837 -178.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -81.61 7.1 13.08 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -174.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -146.66 -169.77 3.36 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.526 1.13 . . . . 0.0 110.518 -172.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? -135.22 128.14 31.38 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 172.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 45.99 49.86 7.21 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 125.076 1.35 . . . . 0.0 111.963 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -81.71 173.7 11.05 Favored 'Trans proline' 0 N--CA 1.452 -0.942 0 C-N-CA 122.811 2.34 . . . . 0.0 111.998 -174.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.4 m -94.92 144.8 25.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 113.923 -1.49 . . . . 0.0 107.123 172.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.6 mp -113.23 139.47 48.76 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.093 -1.005 . . . . 0.0 109.983 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -115.37 98.75 6.92 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.531 1.533 . . . . 0.0 107.739 173.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.8 mt -101.16 138.08 19.87 Favored Pre-proline 0 CA--C 1.535 0.379 0 C-N-CA 126.408 1.883 . . . . 0.0 110.788 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.85 123.48 6.33 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 122.384 2.056 . . . . 0.0 107.65 171.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.64 138.46 17.98 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.578 0.751 . . . . 0.0 111.645 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 85.75 -1.57 88.04 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.521 -0.599 . . . . 0.0 112.691 -176.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.41 21.48 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 118.759 1.279 . . . . 0.0 112.065 174.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 89.3 m -91.73 91.3 7.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 171.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.0 t -79.15 99.46 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.298 1.039 . . . . 0.0 108.633 -172.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -98.64 107.35 19.78 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 126.113 1.765 . . . . 0.0 107.854 -178.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.1 t -101.83 116.92 46.33 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.0 m -88.25 137.29 32.45 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.21 146.33 39.49 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 123.712 0.805 . . . . 0.0 111.735 174.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.17 59.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 N-CA-C 101.222 -3.622 . . . . 0.0 101.222 163.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -92.93 73.2 4.81 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 104.635 -2.357 . . . . 0.0 104.635 -174.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.7 p -95.25 -77.46 0.47 Allowed 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.95 -171.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 51.71 -142.47 0.73 Allowed 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -172.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.4 mtpm? -149.01 123.58 9.76 Favored 'General case' 0 C--N 1.34 0.174 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.31 -55.19 3.22 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 118.883 0.765 . . . . 0.0 112.054 178.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -77.64 84.92 3.98 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 121.73 -0.865 . . . . 0.0 109.804 -174.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.26 75.59 0.01 OUTLIER Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.513 1.054 . . . . 0.0 110.697 172.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -55.51 163.81 1.18 Allowed 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.448 1.124 . . . . 0.0 110.096 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 93.0 p -131.91 165.95 22.74 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -132.31 93.03 3.18 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -98.38 130.76 45.03 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.748 1.219 . . . . 0.0 107.781 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 21.8 mt -102.49 133.53 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 124.635 1.174 . . . . 0.0 109.289 -173.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.9 t -157.88 -161.36 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -129.05 -0.0 5.24 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 124.324 1.05 . . . . 0.0 111.695 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -66.52 129.42 39.8 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -84.61 168.66 44.09 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 174.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -69.84 160.82 48.28 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.288 2.659 . . . . 0.0 110.114 174.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -75.74 163.96 89.08 Favored 'Cis proline' 0 N--CA 1.455 -0.745 0 N-CA-C 110.502 -0.615 . . . . 0.0 110.502 -4.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -111.14 152.79 26.59 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 176.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.16 153.32 34.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.3 t -59.11 -39.2 77.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 62.1 mtt -78.15 117.66 67.45 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.92 113.81 1.73 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.448 2.098 . . . . 0.0 111.924 -175.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 19.1 t -79.81 66.99 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 7.5 pt -79.42 -21.56 12.37 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.183 0 N-CA-C 115.145 1.535 . . . . 0.0 115.145 -172.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -49.55 -59.03 7.41 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 119.18 0.9 . . . . 0.0 111.597 177.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.92 62.7 6.64 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 122.796 2.33 . . . . 0.0 112.766 174.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.5 mm -113.62 145.77 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 172.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 48.9 t -97.19 -94.69 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 177.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.48 -176.5 3.95 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.76 0.824 . . . . 0.0 109.673 174.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.93 174.91 36.6 Favored Glycine 0 N--CA 1.443 -0.847 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 175.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 73.2 p -85.5 -50.68 7.06 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.354 0.597 . . . . 0.0 109.726 174.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 96.17 -176.79 33.3 Favored Glycine 0 CA--C 1.535 1.34 0 N-CA-C 105.559 -3.016 . . . . 0.0 105.559 -168.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -77.38 139.01 39.63 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.286 1.043 . . . . 0.0 109.667 -179.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.7 p -88.83 156.09 49.9 Favored Pre-proline 0 CA--C 1.537 0.451 0 N-CA-C 115.037 1.495 . . . . 0.0 115.037 -172.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.63 89.12 1.36 Allowed 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.321 2.681 . . . . 0.0 107.336 171.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 30.6 m -53.71 163.3 1.11 Allowed Pre-proline 0 CA--C 1.545 0.76 0 C-N-CA 124.774 1.23 . . . . 0.0 113.563 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.72 144.07 66.95 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 123.313 2.675 . . . . 0.0 113.775 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -108.62 21.77 16.82 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.851 1.26 . . . . 0.0 108.627 171.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 50.4 t0 79.31 139.7 0.07 Allowed 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 128.558 2.743 . . . . 0.0 107.953 -171.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 73.39 -50.03 1.64 Allowed Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.572 0.606 . . . . 0.0 112.102 -173.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -79.22 153.53 29.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.045 0.938 . . . . 0.0 112.194 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -130.23 95.68 3.97 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 127.233 2.213 . . . . 0.0 108.986 -173.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -45.54 112.87 0.84 Allowed Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.752 1.168 . . . . 0.0 111.506 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -131.63 175.21 9.37 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 122.504 1.145 . . . . 0.0 110.998 -176.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -167.84 156.13 9.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -141.11 90.91 2.35 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 172.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -110.23 153.53 24.68 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 25.0 m -118.5 140.91 49.13 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 124.659 1.184 . . . . 0.0 110.237 -173.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 2.8 p-90 -146.86 161.31 40.96 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.896 0.878 . . . . 0.0 110.676 174.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -133.71 89.18 31.29 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 125.467 1.507 . . . . 0.0 108.306 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -78.98 151.71 24.2 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.579 2.186 . . . . 0.0 110.239 -176.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.5 p -79.63 164.54 23.71 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.974 0.51 . . . . 0.0 110.172 174.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -67.02 157.03 34.48 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.939 -0.476 . . . . 0.0 111.976 -176.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.33 -118.86 4.1 Favored Glycine 0 C--N 1.335 0.499 0 C-N-CA 126.123 1.821 . . . . 0.0 109.084 -178.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -149.72 127.77 11.95 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.833 0.817 . . . . 0.0 109.606 -178.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -110.03 171.61 7.35 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 127.494 2.318 . . . . 0.0 106.912 174.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -142.0 144.11 33.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.867 1.267 . . . . 0.0 108.517 177.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -107.33 134.14 50.84 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.2 m -138.34 144.01 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 C-N-CA 124.218 1.007 . . . . 0.0 109.35 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.2 t -86.21 139.8 30.72 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -113.24 36.52 3.51 Favored 'General case' 0 CA--C 1.523 -0.088 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 -171.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 45.6 mt -91.59 133.54 30.91 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 103.798 -2.667 . . . . 0.0 103.798 168.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -39.11 128.37 1.41 Allowed 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.751 2.967 . . . . 0.0 113.968 -176.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.33 -23.59 5.35 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 118.981 -0.899 . . . . 0.0 114.337 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -62.25 -53.32 56.91 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 120.079 1.939 . . . . 0.0 111.62 -172.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -55.31 -48.51 74.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.896 -0.503 . . . . 0.0 110.559 175.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.96 -40.4 80.48 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.768 0.827 . . . . 0.0 111.923 -176.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 19.1 p -78.2 -40.48 37.42 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 119.054 -0.498 . . . . 0.0 109.997 -178.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 147.08 20.58 0.1 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 115.9 1.12 . . . . 0.0 115.9 172.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 15.6 ttt -80.02 76.71 6.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 119.66 1.73 . . . . 0.0 107.709 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.71 6.29 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 122.812 0.445 . . . . 0.0 111.734 -174.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -175.68 165.81 36.78 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 171.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -104.29 147.76 27.13 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 124.39 1.076 . . . . 0.0 109.341 -173.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.9 mt -128.18 96.84 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.5 131.9 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 174.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 35.2 t -118.66 93.93 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 106.995 -1.483 . . . . 0.0 106.995 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--N 1.332 -0.179 0 O-C-N 121.679 -0.638 . . . . 0.0 109.354 -179.756 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.909 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 p -85.67 -21.63 28.27 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 126.246 1.818 . . . . 0.0 112.018 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 24.98 -83.38 0.0 OUTLIER 'General case' 0 C--N 1.346 0.455 0 C-N-CA 128.326 2.65 . . . . 0.0 116.079 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.413 ' HD2' ' C ' ' A' ' 6' ' ' THR . 0.1 OUTLIER -55.21 -42.19 73.01 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 113.348 -175.424 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.8 p 65.99 -40.9 0.34 Allowed 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.22 1.808 . . . . 0.0 114.453 -173.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.413 ' C ' ' HD2' ' A' ' 4' ' ' ASP . 89.8 m -77.53 73.77 4.1 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.601 1.16 . . . . 0.0 108.301 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -107.09 134.42 50.25 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 127.588 2.355 . . . . 0.0 107.645 -177.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -151.38 -177.42 6.06 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 119.846 1.203 . . . . 0.0 109.601 176.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -136.5 149.07 47.98 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 172.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.29 -152.17 0.5 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.642 1.977 . . . . 0.0 106.573 174.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.6 p -135.79 173.01 12.19 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 119.152 0.887 . . . . 0.0 108.744 172.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.17 -56.89 2.41 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 114.455 1.279 . . . . 0.0 114.455 -175.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -54.67 -34.04 82.08 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.53 1.487 . . . . 0.0 113.456 -178.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -68.36 -26.88 65.8 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.215 -0.928 . . . . 0.0 111.38 177.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.2 t -59.44 -51.83 68.1 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 174.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.0 mtpp -56.43 -52.04 66.14 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.078 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.88 -54.71 17.86 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.607 0.363 . . . . 0.0 111.566 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.7 mtm -57.46 -53.8 54.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 119.343 -0.36 . . . . 0.0 110.27 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.4 mt -51.37 -48.14 62.62 Favored 'General case' 0 N--CA 1.463 0.217 0 C-N-CA 122.811 0.444 . . . . 0.0 111.334 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -55.11 -31.87 61.59 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 122.813 0.445 . . . . 0.0 111.929 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.5 11.13 25.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.33 0.652 . . . . 0.0 111.663 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.41 109.36 4.72 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 120.387 -1.446 . . . . 0.0 110.01 175.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 36.49 0.25 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.599 0.76 . . . . 0.0 112.706 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.67 108.09 2.36 Favored Glycine 0 C--N 1.338 0.651 0 C-N-CA 125.658 1.599 . . . . 0.0 110.224 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -78.89 150.67 32.1 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.352 1.061 . . . . 0.0 108.872 178.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 70.4 t -70.46 145.98 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.803 -0.561 . . . . 0.0 110.612 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 38.2 m -150.26 68.31 0.98 Allowed 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.623 1.169 . . . . 0.0 108.758 174.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.69 -110.99 3.82 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.3 -28.56 38.22 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 117.876 0.838 . . . . 0.0 110.388 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.8 m -86.81 155.13 20.42 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.702 1.201 . . . . 0.0 109.237 -172.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.9 t -119.64 134.52 62.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 171.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -122.96 120.05 32.24 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.666 1.186 . . . . 0.0 108.576 -172.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -87.48 170.84 11.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.151 0.5 . . . . 0.0 109.98 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 51.0 m -152.24 151.58 31.13 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -177.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.64 177.21 27.19 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -173.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 mttm -76.94 -26.13 53.67 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 122.035 -0.685 . . . . 0.0 111.827 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.3 m -78.77 73.61 5.32 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.846 0.748 . . . . 0.0 110.201 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -82.37 83.36 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -88.13 86.0 7.03 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.438 -174.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.4 t -81.0 111.71 18.04 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.115 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 -177.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.62 97.75 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 123.251 0.62 . . . . 0.0 109.33 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.07 101.6 13.28 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.703 1.201 . . . . 0.0 110.101 -176.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.77 102.17 14.92 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.801 1.24 . . . . 0.0 108.435 177.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.71 111.78 23.44 Favored 'General case' 0 CA--C 1.529 0.162 0 O-C-N 121.042 -1.036 . . . . 0.0 111.12 -174.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 8.5 t 38.21 73.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.648 1.579 . . . . 0.0 112.743 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.85 155.53 82.96 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -177.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo -40.01 -44.82 3.83 Favored 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 124.717 3.611 . . . . 0.0 116.397 -173.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -60.13 -20.98 55.53 Favored Glycine 0 CA--C 1.534 1.255 0 CA-C-O 119.865 -0.408 . . . . 0.0 113.839 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -110.96 97.18 33.15 Favored Pre-proline 0 N--CA 1.453 -0.301 0 C-N-CA 125.465 1.506 . . . . 0.0 108.804 -175.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -73.91 76.1 3.02 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.293 1.995 . . . . 0.0 110.402 -178.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 70.28 165.9 0.13 Allowed Pre-proline 0 CA--C 1.537 0.465 0 C-N-CA 125.994 1.718 . . . . 0.0 112.261 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -117.26 -9.1 0.34 Allowed 'Cis proline' 0 CA--C 1.535 0.572 0 N-CA-C 114.451 0.904 . . . . 0.0 114.451 -4.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.4 p -90.04 157.78 17.64 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 121.134 3.753 . . . . 0.0 121.134 -165.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -77.75 121.6 24.25 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 103.476 -2.786 . . . . 0.0 103.476 169.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -106.61 134.95 48.97 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.0 t -132.84 83.43 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 123.539 0.736 . . . . 0.0 109.204 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.278 1.0 OUTLIER 44.11 -70.07 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 130.224 3.409 . . . . 0.0 115.587 179.165 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -95.51 -23.86 16.9 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 124.186 0.994 . . . . 0.0 111.243 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -131.32 -172.94 2.97 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.549 1.139 . . . . 0.0 108.967 -175.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -139.4 134.72 32.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 172.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 49.48 41.43 0.99 Allowed Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 123.895 0.878 . . . . 0.0 112.111 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -72.77 162.88 39.99 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 CA-C-N 120.982 1.386 . . . . 0.0 111.247 -176.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.1 m -78.41 127.15 31.77 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 171.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 7.7 mp -97.38 127.37 43.29 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 119.249 0.932 . . . . 0.0 109.634 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -107.78 120.71 43.0 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 171.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 40.9 mt -123.24 134.61 25.26 Favored Pre-proline 0 CA--C 1.537 0.456 0 C-N-CA 124.691 1.196 . . . . 0.0 111.964 -171.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -65.1 113.46 2.41 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.396 2.064 . . . . 0.0 109.661 170.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.17 132.02 19.53 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.526 0.73 . . . . 0.0 111.133 174.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 88.94 -4.24 84.81 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.455 -0.636 . . . . 0.0 112.573 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.81 164.63 24.84 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 118.846 1.323 . . . . 0.0 111.641 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 53.9 m -98.21 103.27 15.2 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.667 1.587 . . . . 0.0 108.197 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.7 t -83.07 112.15 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 124.118 0.967 . . . . 0.0 108.768 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -103.31 100.69 10.58 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 174.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.5 t -79.23 93.25 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 37.6 m -90.95 99.74 12.73 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.622 1.569 . . . . 0.0 109.134 -176.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -79.64 159.57 26.69 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.492 173.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.9 mp -142.28 82.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 N-CA-C 101.019 -3.697 . . . . 0.0 101.019 162.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -108.3 115.17 29.61 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 105.383 -2.08 . . . . 0.0 105.383 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.3 m -140.41 39.55 1.89 Allowed 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 -79.77 70.62 6.33 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.986 177.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.4 mttm -1.62 94.94 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.402 3.081 . . . . 0.0 113.904 -176.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 96.14 -36.72 3.71 Favored Glycine 0 CA--C 1.532 1.15 0 O-C-N 121.92 -0.487 . . . . 0.0 113.418 175.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -79.92 95.11 6.0 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.6 1.2 . . . . 0.0 110.922 -178.626 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.78 54.02 0.36 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.243 1.402 . . . . 0.0 113.226 174.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -47.27 129.67 12.81 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-N 118.907 1.354 . . . . 0.0 110.228 177.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.4 p -108.26 112.59 25.15 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 -176.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -79.34 94.75 5.55 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -101.29 130.87 47.53 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 124.584 1.154 . . . . 0.0 109.538 -172.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -109.75 130.43 62.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 119.059 0.845 . . . . 0.0 110.468 -175.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.2 t -159.12 -153.18 0.35 Allowed 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -121.39 42.55 3.05 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 119.577 1.08 . . . . 0.0 110.234 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -76.09 94.8 3.52 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.6 157.2 52.52 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.1 160.24 45.64 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.105 1.87 . . . . 0.0 110.206 174.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -78.19 142.79 71.01 Favored 'Cis proline' 0 N--CA 1.456 -0.717 0 CA-C-N 118.901 0.643 . . . . 0.0 110.538 -2.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -79.85 151.89 29.99 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 176.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.54 148.64 24.97 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.542 0.737 . . . . 0.0 109.849 -178.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 25.5 t -63.47 -31.76 54.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 173.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -78.18 119.28 76.75 Favored Pre-proline 0 N--CA 1.45 -0.447 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.44 77.37 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.341 2.027 . . . . 0.0 108.89 -174.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 90.9 t -76.12 108.57 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 -175.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 15.6 pt -79.0 75.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-O 122.956 1.36 . . . . 0.0 111.194 -175.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -67.03 154.28 92.84 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 170.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -40.45 109.15 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.812 3.008 . . . . 0.0 114.363 -170.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 29.0 mm -78.6 121.83 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 175.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 87.6 t -84.67 -83.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.77 167.46 11.42 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 171.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.06 160.36 13.23 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.0 p -79.6 -46.3 17.53 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.173 177.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 93.61 -173.06 33.44 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 104.651 -3.38 . . . . 0.0 104.651 -167.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -82.96 131.67 35.18 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 120.404 2.102 . . . . 0.0 109.691 -174.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 p -90.48 153.43 46.07 Favored Pre-proline 0 CA--C 1.534 0.327 0 N-CA-C 116.113 1.894 . . . . 0.0 116.113 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -75.34 143.36 27.91 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.905 2.403 . . . . 0.0 106.099 169.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.5 m -141.16 95.57 7.43 Favored Pre-proline 0 CA--C 1.534 0.328 0 CA-C-N 118.456 0.571 . . . . 0.0 111.956 -172.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -55.97 168.53 1.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.816 3.011 . . . . 0.0 113.068 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -113.71 -5.25 13.34 Favored 'General case' 0 C--N 1.34 0.169 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -176.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 18.0 t0 178.05 154.16 0.33 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 126.236 1.815 . . . . 0.0 109.285 176.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 68.29 -62.66 0.4 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.522 2.011 . . . . 0.0 113.675 174.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -78.88 155.88 28.89 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 123.973 0.909 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -135.84 107.83 7.15 Favored 'General case' 0 CA--C 1.517 -0.303 0 C-N-CA 125.116 1.366 . . . . 0.0 110.778 -173.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -61.52 110.88 3.42 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.748 1.166 . . . . 0.0 110.604 176.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -116.51 170.55 8.48 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 122.658 1.218 . . . . 0.0 110.172 174.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 2.8 m -159.01 146.48 17.54 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 -174.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.21 96.25 2.75 Favored 'General case' 0 CA--C 1.521 -0.157 0 O-C-N 124.017 0.823 . . . . 0.0 111.866 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -103.82 147.93 26.72 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 169.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 37.4 m -104.15 134.3 47.63 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 177.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -136.54 140.67 43.11 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.522 1.129 . . . . 0.0 108.947 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -110.66 90.12 10.12 Favored Pre-proline 0 N--CA 1.455 -0.203 0 N-CA-C 105.174 -2.158 . . . . 0.0 105.174 173.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.16 147.55 42.78 Favored 'Trans proline' 0 N--CA 1.445 -1.354 0 C-N-CA 121.664 1.576 . . . . 0.0 110.285 -173.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.3 p -79.66 162.98 24.92 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.83 171.95 1.91 Allowed 'General case' 0 CA--C 1.537 0.455 0 O-C-N 121.307 -0.871 . . . . 0.0 112.13 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 100.95 -127.05 9.13 Favored Glycine 0 CA--C 1.522 0.496 0 C-N-CA 125.227 1.394 . . . . 0.0 110.158 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.2 m -153.04 144.4 23.25 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.352 1.076 . . . . 0.0 110.928 -174.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -134.21 -177.33 4.53 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 126.719 2.008 . . . . 0.0 106.71 173.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -144.62 141.6 29.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.223 1.009 . . . . 0.0 109.109 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -101.3 143.58 31.18 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.8 m -150.71 151.96 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 125.169 1.388 . . . . 0.0 109.789 -177.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 52.6 t -97.72 102.32 14.05 Favored 'General case' 0 C--O 1.231 0.111 0 C-N-CA 124.407 1.083 . . . . 0.0 109.754 171.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -73.52 33.61 0.08 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 29.4 mt -92.63 142.09 25.34 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 169.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 99.1 Cg_exo -46.11 136.67 14.14 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.335 2.023 . . . . 0.0 113.093 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.26 -52.41 4.05 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 123.676 0.655 . . . . 0.0 112.661 179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -39.83 -55.64 1.93 Allowed 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.855 1.662 . . . . 0.0 114.849 -171.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -50.89 -41.49 58.45 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.451 0.569 . . . . 0.0 111.635 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.27 -50.86 19.99 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.217 0.607 . . . . 0.0 109.943 174.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.7 p -79.85 62.39 4.07 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.691 -0.631 . . . . 0.0 111.377 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.38 93.39 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 117.622 1.809 . . . . 0.0 117.622 171.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 7.5 mtp -122.35 68.6 0.95 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 119.862 1.831 . . . . 0.0 109.154 170.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -159.48 -177.71 6.61 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.493 0.717 . . . . 0.0 111.883 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.73 171.47 33.74 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 172.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.7 mttm -101.6 152.46 20.78 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 123.784 0.834 . . . . 0.0 109.495 -174.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.9 mt -124.35 94.14 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 174.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 27.1 t -88.53 131.76 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 36.1 t -128.1 109.65 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt . . . . . 0 N--CA 1.465 0.294 0 CA-C-N 119.001 0.818 . . . . 0.0 110.464 -179.132 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.778 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 p -51.93 -26.12 9.66 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.533 1.533 . . . . 0.0 112.472 178.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.7 mp -48.72 -38.61 22.06 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 125.604 1.561 . . . . 0.0 110.851 173.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.437 ' HA ' ' CH2' ' A' ' 7' ' ' TRP . 20.6 t0 -59.32 95.93 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.654 1.182 . . . . 0.0 111.693 178.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.1 p -134.03 -92.21 0.33 Allowed 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.92 1.288 . . . . 0.0 111.701 -174.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 m -78.69 58.53 2.29 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 -169.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.437 ' CH2' ' HA ' ' A' ' 4' ' ' ASP . 0.1 OUTLIER -89.09 130.28 35.56 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.754 1.222 . . . . 0.0 107.916 179.743 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -149.8 176.2 10.93 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -137.93 151.99 48.53 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 170.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.34 -153.76 0.57 Allowed 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 127.355 2.262 . . . . 0.0 105.998 173.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.3 p -138.21 169.12 18.34 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.958 0.799 . . . . 0.0 109.684 175.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.72 -54.39 4.09 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -174.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -57.73 -33.52 96.91 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.6 1.534 . . . . 0.0 111.936 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.8 mm100 -67.67 -23.8 65.35 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 121.765 -0.584 . . . . 0.0 111.103 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 t -64.14 -49.67 80.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 173.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.5 mttp -58.89 -39.82 82.58 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 122.684 0.393 . . . . 0.0 110.321 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.21 -62.83 1.44 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 122.042 -0.411 . . . . 0.0 109.963 174.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -54.08 -43.52 70.41 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.642 0.777 . . . . 0.0 111.897 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.7 mt -54.76 -33.09 60.85 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 176.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.54 -14.98 62.22 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 119.396 0.998 . . . . 0.0 112.392 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.98 17.57 20.65 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.008 0.822 . . . . 0.0 110.129 173.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.05 154.07 42.12 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.432 -0.793 . . . . 0.0 109.108 172.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.82 165.34 34.81 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.547 0.739 . . . . 0.0 109.766 -172.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.12 136.8 5.95 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 124.347 0.975 . . . . 0.0 111.335 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -79.26 126.75 31.19 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.299 1.039 . . . . 0.0 108.483 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.96 83.95 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 125.46 1.504 . . . . 0.0 109.261 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.9 m -85.89 68.06 10.22 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.087 1.355 . . . . 0.0 108.451 -175.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.54 -105.95 1.31 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -87.43 -22.34 25.04 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.78 0.832 . . . . 0.0 111.536 176.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.4 m -97.35 155.74 16.76 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 124.928 1.291 . . . . 0.0 108.517 -173.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.0 t -114.56 135.5 54.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 174.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -124.03 122.93 39.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 119.191 0.905 . . . . 0.0 110.375 -173.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -79.55 174.55 11.46 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.243 0.544 . . . . 0.0 111.208 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.5 m -158.93 49.88 0.36 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.723 0.809 . . . . 0.0 110.186 -174.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.26 170.44 38.94 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 -177.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -82.11 -33.71 29.58 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.978 0.511 . . . . 0.0 111.304 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.5 p -83.2 84.46 7.48 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 121.301 -0.874 . . . . 0.0 108.767 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.6 t -86.07 83.35 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 C-N-CA 124.196 0.998 . . . . 0.0 108.894 -174.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -84.96 104.78 15.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 124.705 1.202 . . . . 0.0 109.765 -176.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.44 104.49 16.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.7 t -81.9 112.09 19.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 174.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -125.81 160.39 29.96 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.978 1.311 . . . . 0.0 110.267 -176.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.22 163.54 38.01 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.274 1.03 . . . . 0.0 109.65 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -129.35 122.62 29.88 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 124.017 0.927 . . . . 0.0 109.668 -179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.4 t 26.1 65.16 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 128.418 2.687 . . . . 0.0 113.12 174.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.9 mt -77.23 146.91 75.44 Favored Pre-proline 0 CA--C 1.534 0.36 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -39.67 104.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 124.712 3.608 . . . . 0.0 113.679 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.28 -47.67 1.0 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -77.29 142.33 67.58 Favored Pre-proline 0 CA--C 1.531 0.24 0 O-C-N 122.244 -0.562 . . . . 0.0 109.93 -178.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -79.06 152.3 24.36 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.703 2.268 . . . . 0.0 111.512 -174.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -65.58 145.83 99.02 Favored Pre-proline 0 N--CA 1.45 -0.44 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -109.76 50.54 1.22 Allowed 'Cis proline' 0 CA--C 1.54 0.79 0 N-CA-C 108.087 -1.543 . . . . 0.0 108.087 -5.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 87.0 p -73.19 127.2 31.94 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 115.958 1.836 . . . . 0.0 115.958 -170.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -81.81 108.85 15.67 Favored 'General case' 0 C--N 1.343 0.318 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 168.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -84.31 136.66 33.82 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 120.011 1.278 . . . . 0.0 107.93 177.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -135.59 87.53 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 CA-C-N 119.128 0.876 . . . . 0.0 109.64 -174.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.0 p-80 39.27 -97.15 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.575 1.95 . . . . 0.0 113.632 -176.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.0 -27.24 64.53 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.882 0.473 . . . . 0.0 111.844 -174.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -127.19 -171.55 2.45 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.505 1.122 . . . . 0.0 110.718 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -135.6 127.45 29.36 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 172.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 51.16 44.15 2.02 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 125.044 1.338 . . . . 0.0 111.76 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.01 -178.0 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 122.87 2.38 . . . . 0.0 112.733 -173.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.9 m -104.45 136.2 44.47 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 113.079 -1.873 . . . . 0.0 106.44 172.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.7 mp -116.5 122.3 44.33 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 118.875 0.761 . . . . 0.0 112.038 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -93.27 127.09 38.71 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 171.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 25.4 mt -130.83 140.96 40.27 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 125.176 1.391 . . . . 0.0 111.711 -170.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -81.37 122.78 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.664 2.243 . . . . 0.0 109.137 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.98 143.06 3.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 125.205 1.402 . . . . 0.0 112.652 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 78.02 -12.08 19.44 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.28 -0.733 . . . . 0.0 113.695 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.68 148.66 23.89 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 119.035 1.418 . . . . 0.0 111.074 174.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 59.8 m -81.61 102.06 10.41 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 173.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.28 127.19 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -124.45 103.3 8.11 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.76 105.44 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.9 m -91.33 98.04 11.47 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.99 1.316 . . . . 0.0 107.93 175.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.69 156.04 30.94 Favored 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 120.916 -0.313 . . . . 0.0 110.902 173.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.1 mp -136.99 73.43 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 102.172 -3.27 . . . . 0.0 102.172 164.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.57 110.93 21.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 173.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 41.4 m -141.25 46.28 1.73 Allowed 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 173.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -68.43 -48.91 63.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.6 mtmm 93.34 155.33 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 129.709 3.204 . . . . 0.0 109.42 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 -66.89 1.59 Allowed Glycine 0 CA--C 1.53 1.029 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -172.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -79.8 104.03 10.1 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 124.222 1.009 . . . . 0.0 110.705 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.42 73.36 0.59 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 107.964 -2.054 . . . . 0.0 107.964 171.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -55.26 136.49 48.82 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.792 1.296 . . . . 0.0 111.506 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.3 p -96.43 157.01 16.1 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.242 1.417 . . . . 0.0 108.32 174.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -128.38 115.83 18.84 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 103.623 -2.732 . . . . 0.0 103.623 171.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.13 121.46 22.64 Favored 'General case' 0 C--O 1.226 -0.164 0 CA-C-N 119.151 0.887 . . . . 0.0 109.975 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 53.3 mt -97.8 132.87 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 125.651 1.58 . . . . 0.0 109.275 -174.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -157.39 -155.8 0.54 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.757 1.223 . . . . 0.0 107.963 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.8 mtpt -132.6 -2.85 3.36 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -174.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -74.84 134.53 41.69 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 118.844 0.747 . . . . 0.0 109.453 176.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.35 42.3 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 123.285 0.469 . . . . 0.0 112.14 -178.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -70.95 166.0 30.5 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.617 2.878 . . . . 0.0 109.792 174.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -78.39 139.19 54.08 Favored 'Cis proline' 0 N--CA 1.454 -0.805 0 N-CA-C 110.392 -0.657 . . . . 0.0 110.392 -3.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -81.93 151.44 27.23 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.39 153.29 31.71 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 56.6 t -57.77 -43.67 84.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -77.92 131.66 69.6 Favored Pre-proline 0 N--CA 1.451 -0.379 0 N-CA-C 104.535 -2.394 . . . . 0.0 104.535 172.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.87 75.43 2.68 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.25 1.967 . . . . 0.0 112.197 -172.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 t -79.21 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 172.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -86.71 -34.82 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 126.834 2.054 . . . . 0.0 113.289 -173.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -51.27 138.9 26.78 Favored Pre-proline 0 CA--C 1.535 0.389 0 C-N-CA 124.301 1.04 . . . . 0.0 111.901 -173.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.22 170.98 56.71 Favored 'Cis proline' 0 N--CA 1.459 -0.507 0 CA-C-N 119.629 0.903 . . . . 0.0 110.981 0.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 26.1 mm -124.05 144.33 34.19 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.109 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 174.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.9 t -95.39 -88.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 174.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.23 158.55 15.41 Favored 'General case' 0 N--CA 1.461 0.11 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 173.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.45 172.84 40.68 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 119.272 -1.442 . . . . 0.0 113.025 173.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.8 p -126.94 116.49 20.87 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.587 1.155 . . . . 0.0 110.653 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -76.17 65.11 2.71 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.515 1.055 . . . . 0.0 111.314 -179.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 76.24 98.75 0.07 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 127.186 2.194 . . . . 0.0 112.073 173.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.9 p -68.67 169.28 11.29 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-O 118.951 -0.547 . . . . 0.0 110.552 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -54.27 167.02 1.41 Allowed 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 123.295 2.663 . . . . 0.0 117.014 -172.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 79.0 t -124.67 92.02 48.52 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 126.78 2.032 . . . . 0.0 106.632 173.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -72.33 -170.2 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 123.376 2.717 . . . . 0.0 113.467 -176.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -128.82 172.93 10.81 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 172.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -49.71 147.47 3.6 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-O 121.077 0.465 . . . . 0.0 112.166 -174.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.04 -44.85 2.67 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.346 -0.697 . . . . 0.0 112.738 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -79.69 153.05 29.57 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.226 1.01 . . . . 0.0 110.839 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -135.51 114.66 12.3 Favored 'General case' 0 C--O 1.224 -0.25 0 C-N-CA 124.903 1.281 . . . . 0.0 111.079 -173.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -75.95 113.56 3.92 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 125.507 1.527 . . . . 0.0 110.281 -174.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -113.9 163.02 15.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 122.766 1.27 . . . . 0.0 110.882 175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.3 m -150.91 126.66 10.28 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.702 -1.962 . . . . 0.0 105.702 174.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.63 89.6 3.12 Favored 'General case' 0 CA--C 1.518 -0.267 0 C-N-CA 124.46 1.104 . . . . 0.0 108.069 178.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -101.2 143.97 30.63 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 27.2 m -106.25 149.26 27.04 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.353 1.061 . . . . 0.0 109.686 -174.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -147.78 145.95 28.99 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.235 1.014 . . . . 0.0 109.762 174.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.4 m80 -114.1 107.46 51.94 Favored Pre-proline 0 CA--C 1.531 0.233 0 N-CA-C 105.033 -2.21 . . . . 0.0 105.033 173.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -90.79 133.74 1.75 Allowed 'Trans proline' 0 N--CA 1.444 -1.388 0 C-N-CA 123.743 2.962 . . . . 0.0 113.447 -170.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -84.54 158.86 20.82 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.528 1.531 . . . . 0.0 107.05 170.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.18 167.73 3.84 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.104 0.865 . . . . 0.0 113.025 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 107.12 -177.08 21.5 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 126.263 1.887 . . . . 0.0 112.916 174.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 12.7 m -87.82 137.56 32.23 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 124.213 1.005 . . . . 0.0 109.483 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -133.26 167.32 20.58 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 125.302 1.441 . . . . 0.0 107.24 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -134.0 147.75 51.03 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.987 1.315 . . . . 0.0 108.134 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . 0.422 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 47.6 p90 -114.14 138.99 49.7 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.3 m -142.52 156.23 18.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.345 1.458 . . . . 0.0 110.258 -178.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 13.4 t -96.62 114.75 26.43 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.552 1.141 . . . . 0.0 109.033 172.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -61.92 -14.44 34.4 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 125.42 1.488 . . . . 0.0 114.738 -176.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 26.2 mt -58.78 130.41 85.7 Favored Pre-proline 0 CA--C 1.541 0.606 0 CA-C-N 120.002 1.274 . . . . 0.0 108.317 174.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.71 145.86 4.19 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 123.12 2.547 . . . . 0.0 112.972 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.18 -43.75 2.06 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-O 119.58 -0.566 . . . . 0.0 112.798 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -52.67 -55.21 24.15 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.534 1.167 . . . . 0.0 112.602 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -53.93 -52.7 59.78 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.098 0.408 . . . . 0.0 110.103 177.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.46 -42.92 71.22 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 124.016 0.927 . . . . 0.0 111.402 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.1 p -81.24 10.92 4.76 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 12.93 37.73 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.475 -1.18 . . . . 0.0 116.026 170.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 2.9 ttt -79.31 73.88 5.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.995 1.897 . . . . 0.0 108.426 174.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.24 -166.92 2.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.511 0.324 . . . . 0.0 111.425 -174.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.422 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.76 177.44 40.2 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 174.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -116.43 152.89 33.08 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.5 1.12 . . . . 0.0 110.879 -172.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.6 mt -129.12 141.11 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 105.297 -2.112 . . . . 0.0 105.297 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 28.9 t -132.48 108.94 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.63 113.98 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 -176.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 67.9 mttm . . . . . 0 N--CA 1.461 0.119 0 CA-C-N 118.495 0.589 . . . . 0.0 109.847 174.702 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.523 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.7 p -75.27 75.59 2.39 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 103.907 -2.627 . . . . 0.0 103.907 171.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.4 mt 60.03 -172.53 0.12 Allowed 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.248 1.019 . . . . 0.0 108.736 -169.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -71.52 133.46 45.83 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 121.135 -0.978 . . . . 0.0 109.298 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.2 p -130.26 41.1 3.45 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 123.965 0.906 . . . . 0.0 109.979 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.0 m -79.8 64.19 4.58 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 122.323 1.059 . . . . 0.0 108.164 178.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -80.49 121.48 25.81 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 125.859 1.664 . . . . 0.0 110.987 -173.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.3 mmtp -142.01 170.39 15.81 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 172.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -134.8 129.06 33.96 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 171.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.6 -156.76 0.53 Allowed 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 172.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 70.9 p -137.65 170.98 15.13 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 119.413 1.006 . . . . 0.0 109.876 174.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.15 -60.36 1.02 Allowed Pre-proline 0 CA--C 1.543 0.677 0 N-CA-C 115.325 1.602 . . . . 0.0 115.325 -173.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -60.06 -29.26 88.82 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 CA-C-N 121.588 1.603 . . . . 0.0 112.335 -178.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -67.03 -25.74 66.42 Favored 'General case' 0 N--CA 1.45 -0.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.533 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.83 -46.52 96.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 173.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -60.54 -49.27 78.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.68 -49.32 57.6 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 122.141 0.177 . . . . 0.0 111.358 177.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.3 mtm -63.7 -50.42 69.24 Favored 'General case' 0 C--O 1.224 -0.27 0 CA-C-O 118.907 -0.568 . . . . 0.0 110.767 177.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 mt -52.57 -40.96 63.16 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.45 1.023 . . . . 0.0 111.942 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -57.36 -36.04 70.7 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 122.848 0.459 . . . . 0.0 110.752 174.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.41 50.38 0.93 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.827 0.851 . . . . 0.0 109.601 174.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.77 -51.23 35.77 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.603 0.761 . . . . 0.0 110.174 -174.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . 0.299 70.3 p 65.3 -44.31 0.35 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.154 2.182 . . . . 0.0 114.932 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.4 118.45 13.72 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 119.535 1.061 . . . . 0.0 110.975 174.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -79.88 163.96 23.94 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 124.979 1.312 . . . . 0.0 109.158 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -85.27 151.24 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 C-N-CA 122.957 0.503 . . . . 0.0 110.156 -179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 60.4 m -150.89 72.23 1.06 Allowed 'General case' 0 C--O 1.227 -0.116 0 C-N-CA 124.918 1.287 . . . . 0.0 108.581 174.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.15 -144.31 47.62 Favored Glycine 0 CA--C 1.528 0.866 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -80.01 57.24 2.59 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.913 1.357 . . . . 0.0 109.743 174.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.9 m -160.89 153.93 21.37 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 178.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.92 152.16 15.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -140.98 136.78 32.5 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.328 -172.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -107.46 164.42 12.22 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.065 0.946 . . . . 0.0 109.907 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 m -159.19 47.45 0.3 Allowed 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.311 0.644 . . . . 0.0 110.069 -174.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -175.47 171.6 44.69 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 107.637 -2.185 . . . . 0.0 107.637 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -75.41 -32.33 60.71 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 117.69 0.745 . . . . 0.0 111.005 -177.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.06 71.41 5.53 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.42 0.629 . . . . 0.0 110.241 -174.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -81.79 77.95 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -176.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -80.78 111.86 17.62 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.891 0.876 . . . . 0.0 109.034 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.18 106.68 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.5 t -89.57 95.45 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 118.068 0.395 . . . . 0.0 109.967 -174.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.0 99.95 10.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.329 1.452 . . . . 0.0 111.47 -174.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.22 108.45 18.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 O-C-N 121.673 -0.642 . . . . 0.0 109.971 175.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.45 82.78 8.16 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 121.259 -0.901 . . . . 0.0 109.057 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 34.3 t 68.24 96.05 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 C-N-CA 125.167 1.387 . . . . 0.0 109.68 175.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.9 mt -77.23 144.0 70.41 Favored Pre-proline 0 CA--C 1.531 0.213 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -58.39 107.87 0.36 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.397 2.732 . . . . 0.0 109.125 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 147.59 -49.8 0.6 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 104.666 -3.373 . . . . 0.0 104.666 -171.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -80.13 126.51 79.25 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 170.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -70.51 -36.13 9.32 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 121.197 1.265 . . . . 0.0 109.935 174.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -173.43 179.82 0.51 Allowed Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 129.201 3.0 . . . . 0.0 105.136 -173.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -118.15 -23.54 0.09 OUTLIER 'Cis proline' 0 C--N 1.347 0.471 0 CA-C-N 120.701 1.286 . . . . 0.0 114.599 -5.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 p -86.17 160.37 19.24 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.959 2.948 . . . . 0.0 118.959 -166.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -76.68 117.25 18.12 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 171.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -101.98 103.18 13.79 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 104.248 -2.501 . . . . 0.0 104.248 -179.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.7 t -108.89 113.07 43.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 O-C-N 122.086 -0.384 . . . . 0.0 110.079 -171.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 30.59 -104.24 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 126.078 1.751 . . . . 0.0 113.869 -174.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -67.09 -24.16 65.92 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -173.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -139.37 -164.67 1.72 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 119.35 0.977 . . . . 0.0 111.335 -173.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.1 mtmt -125.33 130.99 53.07 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 172.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 47.58 45.31 2.6 Favored Pre-proline 0 CA--C 1.545 0.768 0 C-N-CA 124.227 1.011 . . . . 0.0 112.025 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -67.37 154.75 72.99 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.273 1.315 . . . . 0.0 111.114 -179.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.5 m -87.56 133.73 33.74 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 171.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -111.71 128.51 56.1 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.922 0.783 . . . . 0.0 110.824 -174.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -99.33 115.94 30.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 171.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 27.2 mt -120.64 142.34 34.03 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 124.552 1.141 . . . . 0.0 113.379 -169.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -78.89 119.46 4.36 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 122.532 2.155 . . . . 0.0 109.137 171.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.2 140.6 3.88 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 125.816 1.646 . . . . 0.0 111.95 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.97 -5.46 48.59 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-O 119.092 -0.838 . . . . 0.0 113.613 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 155.22 26.17 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 119.45 1.625 . . . . 0.0 111.049 174.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 73.7 m -83.76 96.85 8.86 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 174.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.65 100.12 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 C-N-CA 124.877 1.271 . . . . 0.0 108.046 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -92.52 91.52 7.63 Favored 'General case' 0 C--O 1.237 0.441 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 40.7 t -77.08 103.13 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 176.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 43.3 m -101.04 98.22 8.69 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.011 1.724 . . . . 0.0 109.232 -172.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.412 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.8 m-85 -77.91 156.58 30.21 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.574 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -139.21 78.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 101.576 -3.49 . . . . 0.0 101.576 164.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -97.1 101.83 13.48 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 178.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.2 m -148.37 54.38 1.02 Allowed 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 122.182 0.992 . . . . 0.0 108.721 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.83 -19.64 61.28 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.822 173.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mttm 81.5 121.49 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 127.649 2.38 . . . . 0.0 107.323 -173.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.38 -54.05 3.18 Favored Glycine 0 CA--C 1.534 1.233 0 O-C-N 121.595 -0.691 . . . . 0.0 112.921 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -78.53 79.42 4.96 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 121.444 -1.033 . . . . 0.0 110.718 -174.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -51.69 77.33 0.01 OUTLIER Glycine 0 CA--C 1.527 0.794 0 C-N-CA 126.603 2.049 . . . . 0.0 112.635 174.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -63.18 144.17 57.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 118.66 1.23 . . . . 0.0 111.251 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.9 p -106.51 154.73 20.43 Favored 'General case' 0 N--CA 1.444 -0.757 0 C-N-CA 127.024 2.13 . . . . 0.0 106.048 172.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.412 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 8.2 t80 -134.52 110.33 9.29 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 105.37 -2.085 . . . . 0.0 105.37 172.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -130.81 148.39 52.58 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.292 0.496 . . . . 0.0 110.397 -174.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.2 mt -114.56 137.93 46.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 C-N-CA 126.22 1.808 . . . . 0.0 110.048 -172.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.5 t -160.93 -155.0 0.39 Allowed 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.909 1.284 . . . . 0.0 107.714 177.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -122.2 8.45 9.75 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.905 0.882 . . . . 0.0 111.595 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? -63.0 114.11 3.49 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.29 170.25 38.88 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -68.67 164.06 34.64 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.072 2.514 . . . . 0.0 109.196 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.81 131.12 23.04 Favored 'Cis proline' 0 N--CA 1.455 -0.749 0 CA-C-N 119.464 0.844 . . . . 0.0 110.828 0.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -79.56 158.53 27.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 174.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -138.33 167.28 22.21 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.364 1.066 . . . . 0.0 108.15 -177.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.55 60.42 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 C-N-CA 124.324 1.049 . . . . 0.0 108.664 -176.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 52.3 mtm -147.09 103.96 3.83 Favored Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 124.51 1.124 . . . . 0.0 110.473 -174.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -64.93 75.49 0.22 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.191 2.594 . . . . 0.0 112.692 174.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.6 t -78.98 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 173.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 24.9 pt -83.05 -23.66 8.39 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 C-N-CA 124.713 1.205 . . . . 0.0 114.134 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -45.35 -56.96 8.29 Favored Pre-proline 0 CA--C 1.543 0.694 0 CA-C-O 118.92 -0.562 . . . . 0.0 111.779 176.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -76.07 67.76 6.73 Favored 'Trans proline' 0 CA--C 1.537 0.663 0 C-N-CA 122.178 1.918 . . . . 0.0 111.597 172.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.1 mm -118.65 142.08 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 172.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.0 t -98.61 -92.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.94 161.39 14.48 Favored 'General case' 0 C--N 1.334 -0.088 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 174.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.38 173.71 28.18 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 120.134 -1.031 . . . . 0.0 113.374 174.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 3.0 p -109.41 125.52 52.5 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.909 1.284 . . . . 0.0 110.152 -178.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -80.21 58.95 4.6 Favored Glycine 0 CA--C 1.535 1.314 0 CA-C-O 119.496 -0.613 . . . . 0.0 111.817 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 71.58 98.8 0.07 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.617 1.967 . . . . 0.0 112.263 174.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 p -78.61 165.15 51.69 Favored Pre-proline 0 CA--C 1.544 0.732 0 O-C-N 121.077 -1.014 . . . . 0.0 112.5 -175.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -60.79 159.64 28.11 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 123.252 2.635 . . . . 0.0 112.098 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.51 86.19 14.37 Favored Pre-proline 0 CA--C 1.533 0.313 0 C-N-CA 124.217 1.007 . . . . 0.0 110.896 -179.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -55.74 163.72 5.21 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.528 2.819 . . . . 0.0 113.024 173.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -92.98 -23.53 18.68 Favored 'General case' 0 C--N 1.338 0.086 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 178.19 159.93 0.53 Allowed 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.7 2.0 . . . . 0.0 109.32 -176.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 70.26 -63.41 0.78 Allowed Glycine 0 C--N 1.338 0.644 0 C-N-CA 125.524 1.535 . . . . 0.0 112.839 174.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -78.68 157.84 28.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 124.263 1.025 . . . . 0.0 109.609 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -139.71 107.67 5.71 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.237 1.415 . . . . 0.0 110.826 -172.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -60.76 109.65 2.51 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.576 1.084 . . . . 0.0 110.852 -178.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -127.55 156.48 42.15 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.849 0.833 . . . . 0.0 111.455 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 18.1 m -159.72 109.93 1.9 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.97 -1.468 . . . . 0.0 107.449 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -86.75 69.61 10.33 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.164 1.386 . . . . 0.0 107.333 173.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -72.19 129.66 38.98 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 118.304 -1.358 . . . . 0.0 108.331 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.9 m -101.95 126.99 49.0 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.411 -171.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -134.68 157.78 45.78 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.481 1.512 . . . . 0.0 109.522 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -123.35 115.43 28.64 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 174.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -92.36 148.2 2.93 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 124.301 3.334 . . . . 0.0 111.809 -172.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.7 p -95.02 149.62 21.05 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 124.888 1.275 . . . . 0.0 108.763 173.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.98 151.9 13.99 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.122 0.419 . . . . 0.0 111.733 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.3 -124.13 5.89 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.937 2.208 . . . . 0.0 109.592 -176.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.0 m -153.61 147.95 25.93 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.314 1.057 . . . . 0.0 110.222 -174.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -139.87 173.87 11.08 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 127.825 2.45 . . . . 0.0 106.912 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -136.15 148.75 48.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 126.402 1.881 . . . . 0.0 107.259 174.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -109.47 147.87 32.14 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 172.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.39 150.9 12.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.117 1.367 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 42.6 t -84.75 140.34 31.33 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 169.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -78.08 -20.71 51.75 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -173.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 54.7 mt -61.35 124.38 80.46 Favored Pre-proline 0 CA--C 1.544 0.739 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -25.28 -76.01 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.567 1 C-N-CA 126.011 4.474 . . . . 0.0 117.446 -172.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -77.45 -2.29 79.32 Favored Glycine 0 CA--C 1.525 0.679 0 O-C-N 121.691 -0.631 . . . . 0.0 114.046 -173.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -72.69 -48.29 40.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 119.364 1.582 . . . . 0.0 110.558 -173.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.15 -41.86 93.68 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 173.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.24 78.29 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.823 0.449 . . . . 0.0 111.51 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 26.3 p -79.38 -58.29 3.28 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -174.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 176.87 37.79 0.05 OUTLIER Glycine 0 C--N 1.339 0.7 0 C-N-CA 119.187 -1.482 . . . . 0.0 115.196 -174.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 10.4 mtp -116.39 72.39 0.81 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 118.193 0.996 . . . . 0.0 108.405 173.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -159.56 -174.72 4.79 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.318 0.647 . . . . 0.0 112.16 -177.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 164.53 171.01 30.26 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 174.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 42.9 mtmt -99.94 146.86 26.2 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 124.998 1.319 . . . . 0.0 110.609 -176.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.8 mt -124.59 101.77 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 173.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.5 t -92.42 137.64 21.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 172.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 11.5 t -127.9 123.55 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -175.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt . . . . . 0 N--CA 1.466 0.328 0 CA-C-N 119.823 1.192 . . . . 0.0 111.422 179.481 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.874 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.1 p -63.49 -51.45 65.53 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.287 1.035 . . . . 0.0 110.184 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 7.9 mp 54.5 -103.23 0.17 Allowed 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.461 1.105 . . . . 0.0 109.905 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -167.22 152.6 7.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 105.901 -1.889 . . . . 0.0 105.901 175.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 25.2 p -135.64 23.15 3.39 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.076 1.35 . . . . 0.0 110.829 -174.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.9 m -79.77 64.18 4.55 Favored 'General case' 0 CA--C 1.536 0.409 0 O-C-N 121.161 -0.962 . . . . 0.0 110.277 -174.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -85.91 134.55 33.88 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 126.34 1.856 . . . . 0.0 110.212 -173.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -149.55 173.04 14.05 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -138.77 151.16 46.85 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 172.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.31 -153.02 0.54 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.898 1.679 . . . . 0.0 106.664 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.7 p -135.65 173.95 11.15 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 119.462 1.028 . . . . 0.0 108.512 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -39.41 -57.05 2.51 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -54.76 -34.18 83.54 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 121.963 1.775 . . . . 0.0 113.531 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 21.0 mp0 -67.41 -25.73 66.08 Favored 'General case' 0 N--CA 1.456 -0.172 0 O-C-N 121.134 -0.979 . . . . 0.0 111.258 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.82 -46.91 93.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 174.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.1 -50.11 74.98 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.21 -48.36 62.06 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.7 mtm -62.93 -50.63 70.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.606 0.362 . . . . 0.0 110.516 177.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.8 mt -52.08 -41.95 62.8 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.436 0.562 . . . . 0.0 111.875 177.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -56.51 -23.62 40.95 Favored 'General case' 0 CA--C 1.538 0.513 0 O-C-N 121.542 -0.724 . . . . 0.0 112.678 177.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -100.95 12.55 37.46 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.653 0.781 . . . . 0.0 111.787 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -65.85 -46.27 79.1 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -174.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.4 p 63.8 -139.12 0.32 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.455 1.502 . . . . 0.0 109.27 -171.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.48 104.18 0.2 Allowed Glycine 0 CA--C 1.528 0.893 0 CA-C-N 118.593 0.633 . . . . 0.0 111.741 -177.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 37.3 mtpt -78.7 120.26 23.11 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 62.5 t -63.04 148.51 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -148.85 64.17 1.05 Allowed 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.15 -141.26 35.51 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -79.55 54.74 1.82 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 118.603 1.202 . . . . 0.0 109.642 174.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.7 m -161.31 147.12 14.17 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -118.18 137.87 50.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 175.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 93.2 m -120.57 119.22 32.29 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.832 1.253 . . . . 0.0 109.623 -173.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -83.07 169.43 15.91 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 122.083 0.944 . . . . 0.0 111.606 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 75.1 m -156.86 152.17 26.48 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.36 166.95 33.05 Favored Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -174.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 35.4 mtmm -82.82 -28.48 30.18 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 122.282 -0.54 . . . . 0.0 112.241 -174.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.2 p -81.59 78.01 8.39 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.484 -0.76 . . . . 0.0 109.588 -178.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -80.07 75.39 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -80.89 93.19 6.24 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.788 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -88.49 102.42 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.049 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -176.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 43.1 t -83.74 88.42 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.08 164.23 12.78 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.267 1.427 . . . . 0.0 110.227 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -159.62 169.31 24.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 123.96 0.904 . . . . 0.0 109.23 178.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.56 132.7 28.01 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 26.13 72.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 127.263 2.225 . . . . 0.0 113.009 173.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.1 mt -77.29 148.27 77.4 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -55.2 111.24 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.999 2.466 . . . . 0.0 110.519 -175.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 130.77 -40.33 1.67 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -174.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -87.93 125.08 65.74 Favored Pre-proline 0 N--CA 1.454 -0.272 0 C-N-CA 123.647 0.779 . . . . 0.0 109.453 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -59.08 161.95 14.89 Favored 'Trans proline' 0 N--CA 1.454 -0.84 0 C-N-CA 122.249 1.966 . . . . 0.0 111.744 173.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -62.66 164.6 11.72 Favored Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.953 173.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -113.47 -11.92 0.64 Allowed 'Cis proline' 0 CA--C 1.539 0.774 0 CA-C-N 118.947 0.66 . . . . 0.0 113.535 -4.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.5 p -44.68 143.46 1.38 Allowed 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 118.586 2.81 . . . . 0.0 118.586 -170.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -77.27 129.14 35.49 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 168.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -104.33 132.52 50.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 177.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.5 t -139.91 123.67 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -14.74 111.32 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.515 1.926 . . . . 0.0 115.37 -173.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.4 t70 89.67 -28.02 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 127.309 2.244 . . . . 0.0 113.419 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -136.69 -168.97 2.36 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.524 1.154 . . . . 0.0 111.015 -173.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.5 mttp -137.5 134.88 36.25 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 171.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 48.82 40.62 0.8 Allowed Pre-proline 0 CA--C 1.548 0.882 0 C-N-CA 124.081 0.952 . . . . 0.0 112.69 -176.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.25 159.67 46.64 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 CA-C-N 120.993 1.39 . . . . 0.0 113.349 -171.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.58 121.23 25.55 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 127.647 2.379 . . . . 0.0 106.297 173.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.2 mp -103.99 117.94 35.5 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 119.862 1.21 . . . . 0.0 111.5 -178.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -93.36 120.09 33.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 171.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.0 mt -122.32 139.7 31.2 Favored Pre-proline 0 CA--C 1.538 0.514 0 C-N-CA 124.431 1.092 . . . . 0.0 112.906 -170.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -76.34 116.26 4.3 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 122.805 2.336 . . . . 0.0 108.728 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -48.69 139.58 9.43 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 125.12 1.368 . . . . 0.0 112.302 -178.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.25 -9.78 38.7 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.072 -0.849 . . . . 0.0 113.457 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 157.52 20.02 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.42 1.61 . . . . 0.0 110.52 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 50.2 m -83.71 101.68 11.72 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.1 t -79.64 99.81 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 174.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -96.59 97.16 9.17 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 174.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -80.02 108.02 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.2 m -99.7 96.71 7.8 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.009 1.724 . . . . 0.0 107.972 175.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.278 5.7 m-85 -79.26 148.1 32.29 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 118.726 -0.654 . . . . 0.0 110.31 172.66 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.07 79.38 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 102.514 -3.143 . . . . 0.0 102.514 163.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -99.48 104.7 16.55 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 172.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.0 m -121.77 38.44 4.11 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 173.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -78.39 73.23 4.94 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.245 -0.91 . . . . 0.0 109.12 175.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.4 mttm 0.16 97.32 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 129.126 2.97 . . . . 0.0 114.557 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.05 -34.29 3.62 Favored Glycine 0 CA--C 1.534 1.243 0 O-C-N 121.605 -0.685 . . . . 0.0 114.07 175.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -82.24 88.12 6.52 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 119.073 1.436 . . . . 0.0 110.171 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.29 63.04 0.4 Allowed Glycine 0 CA--C 1.533 1.168 0 C-N-CA 123.785 0.707 . . . . 0.0 112.545 175.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -51.06 120.78 5.23 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 118.941 1.37 . . . . 0.0 110.084 175.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.87 165.11 25.48 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.581 0.752 . . . . 0.0 109.628 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.422 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 21.4 t80 -133.15 103.37 5.98 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 106.376 -1.712 . . . . 0.0 106.376 172.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -118.38 137.34 53.19 Favored 'General case' 0 CA--C 1.516 -0.333 0 C-N-CA 123.434 0.694 . . . . 0.0 109.819 -176.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 25.8 mt -110.0 134.71 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 126.041 1.737 . . . . 0.0 109.075 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.2 t -158.65 -158.22 0.68 Allowed 'General case' 0 C--O 1.223 -0.301 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.0 mtmm -129.6 6.67 5.21 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 119.564 1.075 . . . . 0.0 112.5 -179.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.9 mtpt -67.51 160.71 27.08 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.08 160.06 16.18 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -72.78 159.5 48.29 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 122.791 2.327 . . . . 0.0 109.893 174.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.79 134.83 34.28 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 N-CA-C 108.75 -1.288 . . . . 0.0 108.75 -5.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -83.13 31.36 0.44 Allowed 'General case' 0 N--CA 1.468 0.463 0 O-C-N 120.979 -1.075 . . . . 0.0 113.377 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . 70.05 156.0 0.14 Allowed 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 127.703 2.401 . . . . 0.0 113.084 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.98 -46.25 85.26 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.386 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.1 mmt -78.92 160.1 72.19 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 174.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -70.25 59.12 1.85 Allowed 'Trans proline' 0 CA--C 1.538 0.725 0 C-N-CA 123.08 2.52 . . . . 0.0 114.153 -174.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.8 t -82.46 55.79 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 O-C-N 120.238 -1.539 . . . . 0.0 108.664 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -80.88 -38.6 17.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 C-N-CA 123.101 0.561 . . . . 0.0 110.998 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -55.48 147.43 38.73 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 124.445 1.098 . . . . 0.0 111.826 -174.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 79.1 Cg_endo -74.13 150.38 95.47 Favored 'Cis proline' 0 N--CA 1.459 -0.537 0 CA-C-N 118.851 0.625 . . . . 0.0 111.127 -0.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.2 mm -109.45 143.7 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 C-N-CA 124.42 1.088 . . . . 0.0 108.406 175.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.73 -89.49 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 174.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.89 156.48 16.33 Favored 'General case' 0 C--N 1.332 -0.155 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 173.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.29 173.51 41.11 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 119.063 -1.541 . . . . 0.0 112.817 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.9 p -123.15 137.09 54.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.398 1.479 . . . . 0.0 109.625 176.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.47 -164.34 7.49 Favored Glycine 0 CA--C 1.54 1.654 0 N-CA-C 108.136 -1.986 . . . . 0.0 108.136 170.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -67.63 118.66 11.21 Favored 'General case' 0 CA--C 1.537 0.47 0 O-C-N 120.8 -1.412 . . . . 0.0 112.286 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 p -69.71 161.08 77.01 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 126.201 1.8 . . . . 0.0 113.413 -173.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -74.4 144.96 33.3 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.023 2.482 . . . . 0.0 107.969 174.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.18 80.15 9.49 Favored Pre-proline 0 CA--C 1.536 0.442 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -53.89 164.69 2.29 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 124.627 3.551 . . . . 0.0 112.588 172.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -119.35 -0.05 11.02 Favored 'General case' 0 C--N 1.34 0.173 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -174.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -175.28 148.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.191 1.396 . . . . 0.0 109.026 176.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 66.15 -62.85 0.15 Allowed Glycine 0 CA--C 1.527 0.79 0 C-N-CA 126.579 2.038 . . . . 0.0 113.47 177.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -78.66 157.39 28.64 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-O 121.352 0.596 . . . . 0.0 110.018 -177.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -129.55 108.63 10.39 Favored 'General case' 0 CA--C 1.512 -0.481 0 C-N-CA 127.014 2.125 . . . . 0.0 107.943 -174.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.04 123.71 18.63 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 19.8 p90 -130.89 168.57 17.07 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.724 1.25 . . . . 0.0 110.701 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.8 m -155.53 124.68 6.21 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.83 106.63 16.3 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -119.06 150.61 39.68 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.3 m -114.69 145.29 42.21 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.882 0.873 . . . . 0.0 111.007 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 26.1 t90 -145.02 153.23 41.26 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.887 1.275 . . . . 0.0 109.236 174.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.9 93.96 44.96 Favored Pre-proline 0 CA--C 1.53 0.174 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -81.6 146.01 14.93 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.467 2.112 . . . . 0.0 111.358 -173.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 10.6 p -96.3 156.37 16.37 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 172.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.93 144.65 27.56 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -174.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 139.97 -132.58 5.62 Favored Glycine 0 C--N 1.337 0.611 0 C-N-CA 126.215 1.864 . . . . 0.0 109.984 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 33.5 m -150.52 145.07 25.73 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 118.026 0.913 . . . . 0.0 109.132 -174.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -147.02 175.64 10.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.738 2.015 . . . . 0.0 107.181 -175.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -142.57 155.37 44.98 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 125.354 1.462 . . . . 0.0 108.557 179.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -121.46 147.2 46.07 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 124.275 1.03 . . . . 0.0 110.915 175.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.65 160.66 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 124.855 1.262 . . . . 0.0 112.308 -174.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 7.1 t -102.82 133.49 47.8 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.876 1.67 . . . . 0.0 108.738 171.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -70.65 -34.67 72.3 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 113.816 1.043 . . . . 0.0 113.816 -173.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 70.8 mt -48.62 128.38 13.71 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.781 0.832 . . . . 0.0 109.993 -172.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -42.32 142.82 1.61 Allowed 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 124.26 3.307 . . . . 0.0 114.968 -173.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.45 -40.55 1.78 Allowed Glycine 0 CA--C 1.529 0.951 0 C-N-CA 123.995 0.807 . . . . 0.0 112.634 177.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -54.6 -47.26 73.6 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.568 0.747 . . . . 0.0 111.624 -173.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -81.84 -11.67 58.85 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.631 0.65 . . . . 0.0 112.4 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.56 -57.82 4.72 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 173.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.5 p -151.63 87.04 1.34 Allowed 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.91 -66.47 0.06 OUTLIER Glycine 0 CA--C 1.524 0.631 0 C-N-CA 119.82 -1.181 . . . . 0.0 113.951 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.0 ptm -141.59 113.19 7.7 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 117.671 0.736 . . . . 0.0 111.948 -173.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -163.56 -166.73 1.26 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.716 1.206 . . . . 0.0 108.169 176.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.14 173.33 36.71 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 175.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 29.9 mttp -109.78 150.31 28.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.709 1.204 . . . . 0.0 110.869 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 17.1 mt -128.33 130.01 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 174.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 6.2 t -118.01 135.81 57.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 173.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.03 123.11 64.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -174.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 53.3 mtmt . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 118.81 0.732 . . . . 0.0 111.093 -174.288 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.741 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.1 p -76.43 71.39 3.09 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.8 mp -55.64 -81.98 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 125.16 1.384 . . . . 0.0 111.239 175.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -176.34 143.35 0.5 Allowed 'General case' 0 C--O 1.235 0.319 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.0 p -138.18 38.78 2.31 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 123.863 0.727 . . . . 0.0 110.495 -178.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.1 m -79.59 62.62 3.94 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.879 0.847 . . . . 0.0 108.729 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -78.48 123.81 27.45 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.188 1.395 . . . . 0.0 110.392 -172.428 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -142.64 173.55 11.44 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 174.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -141.15 148.76 40.54 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.847 -0.533 . . . . 0.0 109.607 171.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.74 -153.77 0.56 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 126.633 1.973 . . . . 0.0 106.212 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -134.97 172.22 13.32 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 119.084 0.856 . . . . 0.0 108.991 172.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -38.64 -57.44 1.95 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -174.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.24 -32.46 87.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.473 1.449 . . . . 0.0 113.318 -178.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.6 mp0 -65.7 -31.57 72.64 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.7 t -55.42 -49.74 70.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.954 0.797 . . . . 0.0 109.14 176.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 mtpp -57.03 -51.39 69.47 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.87 -51.58 39.33 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -61.18 -53.1 61.19 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.219 0.463 . . . . 0.0 110.708 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 58.4 mt -51.7 -40.7 60.6 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.672 0.669 . . . . 0.0 111.78 -177.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -59.36 -23.53 62.61 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.842 0.857 . . . . 0.0 112.726 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -70.88 -66.31 0.63 Allowed 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.315 0.961 . . . . 0.0 109.514 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 58.6 -62.22 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 126.716 2.006 . . . . 0.0 115.622 176.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 19.3 p 53.89 37.66 27.04 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.174 1.79 . . . . 0.0 112.301 179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -141.6 121.66 1.89 Allowed Glycine 0 CA--C 1.528 0.854 0 C-N-CA 124.88 1.229 . . . . 0.0 110.535 -174.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.3 mtpt -79.81 118.14 21.33 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.892 1.677 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.4 t -68.83 77.48 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 C-N-CA 124.939 1.296 . . . . 0.0 110.257 -174.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 m -81.09 70.08 7.84 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.687 1.195 . . . . 0.0 107.784 -179.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 62.95 -113.55 6.0 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -174.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -78.45 -19.1 53.87 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.856 0.828 . . . . 0.0 111.238 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 59.6 m -98.62 110.06 22.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -172.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.9 t -79.19 114.17 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 104.298 -2.482 . . . . 0.0 104.298 172.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.5 m -106.72 121.48 44.46 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 124.577 1.151 . . . . 0.0 111.679 -170.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -81.36 167.68 19.21 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.513 0.673 . . . . 0.0 110.752 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.0 m -159.55 46.97 0.28 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.992 0.917 . . . . 0.0 109.275 -177.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.52 170.35 42.77 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -78.62 -32.14 47.32 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 117.45 0.625 . . . . 0.0 111.602 -177.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.6 m -78.87 72.94 5.42 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.49 0.662 . . . . 0.0 109.617 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.4 t -80.31 86.08 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-O 121.788 0.804 . . . . 0.0 109.118 -174.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -85.69 101.96 13.2 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.938 1.295 . . . . 0.0 110.401 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.3 t -102.79 110.62 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 C-N-CA 124.484 1.114 . . . . 0.0 108.918 -176.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.06 101.64 12.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 CA-C-N 118.183 0.447 . . . . 0.0 110.267 -176.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -101.93 104.39 15.09 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.437 1.495 . . . . 0.0 111.244 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.6 110.57 21.42 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.486 1.514 . . . . 0.0 109.259 175.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -97.48 95.54 7.72 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.79 -0.569 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 46.68 69.74 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 C-N-CA 127.238 2.215 . . . . 0.0 111.153 173.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 27.3 mt -77.26 152.54 81.75 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-O 118.514 -0.755 . . . . 0.0 109.556 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_exo -43.52 108.83 0.12 Allowed 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.139 3.226 . . . . 0.0 111.446 175.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 139.12 -52.27 0.73 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 106.108 -2.797 . . . . 0.0 106.108 -172.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -81.36 121.44 80.14 Favored Pre-proline 0 N--CA 1.451 -0.405 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 171.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.98 -59.34 0.09 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.947 0 CA-C-N 120.686 1.281 . . . . 0.0 109.069 175.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -170.77 169.4 3.46 Favored Pre-proline 0 CA--C 1.535 0.398 0 C-N-CA 128.837 2.855 . . . . 0.0 105.558 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -115.7 -21.65 0.15 OUTLIER 'Cis proline' 0 N--CA 1.458 -0.592 0 CA-C-N 120.305 1.145 . . . . 0.0 113.631 -5.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.0 p -67.55 148.54 51.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -167.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -75.54 131.48 40.07 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 173.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -102.23 131.1 48.99 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 172.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 t -138.33 122.01 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 CA-C-N 119.245 0.93 . . . . 0.0 108.809 -174.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 12.58 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 127.756 2.422 . . . . 0.0 115.335 -178.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 t70 76.21 -32.45 0.2 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.078 1.351 . . . . 0.0 113.595 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.2 mmmp? -121.58 -173.29 2.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 122.351 1.072 . . . . 0.0 112.367 -171.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -133.12 125.5 29.66 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 105.332 -2.099 . . . . 0.0 105.332 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 43.85 50.18 6.17 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.195 0.998 . . . . 0.0 111.83 -173.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.76 157.87 58.91 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 121.717 1.611 . . . . 0.0 110.485 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.2 m -84.44 145.88 27.93 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 105.893 -1.892 . . . . 0.0 105.893 170.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.0 mp -114.24 121.47 43.81 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.506 -0.747 . . . . 0.0 109.542 -177.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -98.94 118.54 35.95 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 171.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.9 mt -122.14 133.68 24.45 Favored Pre-proline 0 N--CA 1.453 -0.289 0 C-N-CA 124.978 1.311 . . . . 0.0 110.448 -172.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.93 118.39 5.02 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.127 1.885 . . . . 0.0 108.137 172.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.38 136.37 20.5 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.883 0.873 . . . . 0.0 111.196 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -12.71 67.65 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.672 -0.516 . . . . 0.0 112.156 -175.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.97 154.14 16.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 118.481 1.14 . . . . 0.0 112.909 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 99.5 m -92.15 105.72 17.88 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.472 -2.047 . . . . 0.0 105.472 171.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.2 t -88.04 93.78 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 C-N-CA 124.344 1.058 . . . . 0.0 108.178 -175.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.87 94.9 6.56 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 173.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.9 t -79.6 94.6 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 174.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 96.5 m -86.43 97.06 10.25 Favored 'General case' 0 N--CA 1.444 -0.732 0 C-N-CA 126.085 1.754 . . . . 0.0 108.539 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -77.29 156.73 31.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.169 0.509 . . . . 0.0 111.607 173.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -140.59 86.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 100.857 -3.757 . . . . 0.0 100.857 164.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -105.13 113.83 27.66 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.7 m -143.4 37.48 1.36 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -78.96 65.28 4.11 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.581 -0.699 . . . . 0.0 109.369 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.5 mttm 17.7 81.18 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 128.424 2.689 . . . . 0.0 114.688 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 95.15 -29.91 8.82 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.885 176.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -78.38 99.02 6.2 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 119.265 1.532 . . . . 0.0 109.917 -174.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.81 60.97 0.94 Allowed Glycine 0 CA--C 1.523 0.591 0 C-N-CA 124.806 1.194 . . . . 0.0 110.614 176.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -33.68 -52.29 0.41 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 126.114 1.766 . . . . 0.0 115.411 -172.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 17.5 p 78.43 134.06 0.06 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 125.889 1.676 . . . . 0.0 108.742 -172.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -114.44 108.7 17.23 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.638 -2.727 . . . . 0.0 103.638 172.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.86 139.12 47.61 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -173.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 mt -124.75 134.42 66.87 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.838 0.828 . . . . 0.0 110.39 -173.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -160.22 -163.08 1.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -175.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -120.97 5.69 10.39 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.814 0.846 . . . . 0.0 111.788 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -71.67 130.14 40.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 174.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.92 169.18 25.25 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.016 0.817 . . . . 0.0 112.158 -176.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -72.51 167.13 27.86 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.507 2.804 . . . . 0.0 109.698 174.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -68.2 130.74 15.47 Favored 'Cis proline' 0 N--CA 1.459 -0.544 0 CA-C-N 119.483 0.851 . . . . 0.0 111.218 -5.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -79.93 148.72 31.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 175.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.27 156.7 24.19 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.347 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 73.9 t -61.26 -34.75 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 55.2 mtm -78.05 128.13 79.61 Favored Pre-proline 0 CA--C 1.534 0.344 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 173.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.25 101.91 1.3 Allowed 'Trans proline' 0 N--CA 1.451 -0.971 0 C-N-CA 122.542 2.161 . . . . 0.0 110.602 -173.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 22.0 t -77.69 93.5 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.0 pt -78.49 -85.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.702 0.801 . . . . 0.0 112.788 -173.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -67.82 150.16 97.92 Favored Pre-proline 0 N--CA 1.454 -0.242 0 O-C-N 121.723 -0.611 . . . . 0.0 112.237 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.61 113.24 2.88 Favored 'Cis proline' 0 CA--C 1.537 0.645 0 CA-C-N 118.579 0.528 . . . . 0.0 112.878 1.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.7 mm -86.66 139.05 17.95 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.5 t -95.76 -87.2 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 174.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -93.64 166.65 12.13 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 173.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 179.6 41.55 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.3 p -124.68 124.57 42.47 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.696 1.199 . . . . 0.0 108.984 175.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.27 59.75 4.31 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.564 -0.575 . . . . 0.0 112.809 -173.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 71.17 93.66 0.08 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.244 1.818 . . . . 0.0 110.501 175.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 p -65.9 161.36 55.11 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 126.875 2.07 . . . . 0.0 115.357 -172.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -67.02 154.88 73.17 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 123.795 2.997 . . . . 0.0 108.995 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.4 t -147.19 85.31 6.92 Favored Pre-proline 0 CA--C 1.54 0.561 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -172.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -57.78 165.34 6.55 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.16 2.573 . . . . 0.0 112.722 174.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -101.43 6.39 42.48 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 -174.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.7 p30 143.38 166.45 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 130.355 3.462 . . . . 0.0 109.376 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.3 -66.54 0.95 Allowed Glycine 0 C--N 1.34 0.755 0 C-N-CA 125.431 1.491 . . . . 0.0 111.28 177.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -78.58 155.15 29.8 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 124.075 0.95 . . . . 0.0 108.466 174.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -137.61 109.78 7.3 Favored 'General case' 0 CA--C 1.518 -0.258 0 C-N-CA 125.063 1.345 . . . . 0.0 110.829 -172.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.11 114.02 5.79 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 124.63 1.109 . . . . 0.0 111.102 -177.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 22.1 p90 -122.21 164.67 17.42 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 122.292 1.044 . . . . 0.0 111.65 178.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 74.3 m -159.57 119.22 2.95 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -95.99 67.95 2.7 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 124.104 0.962 . . . . 0.0 108.501 176.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . 0.254 40.4 p90 -70.81 114.13 8.57 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 118.003 -1.479 . . . . 0.0 108.019 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.2 m -91.66 87.08 6.18 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.498 1.519 . . . . 0.0 109.974 -171.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.5 t90 -93.27 143.55 26.16 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.026 0.93 . . . . 0.0 110.951 -175.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -111.23 109.72 56.55 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 105.344 -2.095 . . . . 0.0 105.344 171.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -84.76 178.95 4.57 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 123.884 3.056 . . . . 0.0 111.462 -172.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 58.7 p -124.21 159.97 28.94 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 170.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.61 156.98 33.61 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 113.823 1.045 . . . . 0.0 113.823 -172.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 114.55 -176.86 17.2 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 126.254 1.883 . . . . 0.0 112.329 174.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 5.5 m -82.76 87.48 6.77 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.115 0.966 . . . . 0.0 110.262 -175.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -78.96 175.31 10.68 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 171.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -150.78 149.34 29.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.932 1.293 . . . . 0.0 109.541 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -112.31 146.52 38.1 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.233 1.013 . . . . 0.0 108.286 172.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -153.13 150.5 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 124.872 1.269 . . . . 0.0 110.404 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.82 106.99 19.19 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 169.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 34.3 mm-40 -75.17 34.32 0.11 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 114.695 1.368 . . . . 0.0 114.695 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 25.7 mt -92.21 137.2 25.0 Favored Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 169.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -43.94 129.2 7.54 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.596 2.197 . . . . 0.0 113.207 -178.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.65 -24.73 3.62 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.361 -0.688 . . . . 0.0 114.095 178.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -65.13 -52.53 54.74 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 119.796 1.798 . . . . 0.0 111.617 -172.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.62 -44.1 80.86 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 174.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.92 -42.9 99.02 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.777 0.431 . . . . 0.0 111.654 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.2 p -79.05 -59.93 2.58 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -174.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -178.9 31.43 0.06 OUTLIER Glycine 0 C--N 1.337 0.621 0 C-N-CA 119.296 -1.43 . . . . 0.0 115.033 -174.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.2 mtp -111.39 68.73 0.67 Allowed 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 118.2 1.0 . . . . 0.0 108.531 173.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -158.37 -177.52 6.6 Favored 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.09 165.48 24.56 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 173.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.2 mtmm -100.18 149.43 23.55 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.681 0.793 . . . . 0.0 109.492 -174.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.3 mt -125.96 93.96 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.102 1.761 . . . . 0.0 107.361 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.97 95.8 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 29.6 t -85.74 91.19 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 C--N 1.332 -0.193 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 177.094 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.677 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 p -66.06 -67.18 0.46 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 173.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.5 mp -106.19 174.83 5.71 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 127.171 2.188 . . . . 0.0 106.425 171.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -72.83 118.87 16.3 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -176.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.3 p -112.77 31.46 6.36 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.973 1.309 . . . . 0.0 110.627 -174.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.4 m -79.01 63.96 3.81 Favored 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.259 -0.901 . . . . 0.0 109.956 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -78.25 125.57 29.55 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 125.157 1.383 . . . . 0.0 109.511 -173.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -144.23 -179.74 6.71 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.918 0.887 . . . . 0.0 108.672 174.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -142.65 154.21 44.15 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.671 0.669 . . . . 0.0 111.088 172.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.46 -152.43 0.51 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 128.19 2.596 . . . . 0.0 105.65 173.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -138.73 170.81 15.34 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 119.082 0.855 . . . . 0.0 110.042 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -38.85 -59.64 1.34 Allowed Pre-proline 0 CA--C 1.538 0.512 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -174.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -58.78 -30.73 93.48 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 CA-C-N 121.248 1.481 . . . . 0.0 112.074 -178.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -67.07 -25.33 66.19 Favored 'General case' 0 N--CA 1.449 -0.523 0 O-C-N 121.819 -0.551 . . . . 0.0 111.254 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.2 t -59.1 -54.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -57.73 -49.61 75.98 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.558 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.2 -57.91 6.75 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.05 0.54 . . . . 0.0 110.953 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.9 mtm -56.82 -50.21 73.07 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 122.816 0.446 . . . . 0.0 110.096 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.1 mt -53.35 -45.31 69.08 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.612 0.642 . . . . 0.0 110.92 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.79 -30.9 70.32 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 118.249 0.477 . . . . 0.0 111.146 177.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 mmpt? -80.42 1.57 28.6 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 123.214 0.606 . . . . 0.0 112.365 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.43 146.68 50.8 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.926 1.239 . . . . 0.0 110.381 175.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.6 p -109.65 32.4 5.07 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.424 0.69 . . . . 0.0 112.155 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.94 113.82 4.75 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 124.678 1.132 . . . . 0.0 110.802 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -79.45 145.72 33.14 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 174.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 t -73.57 148.73 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.769 -0.582 . . . . 0.0 109.623 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -150.76 65.68 0.93 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.753 0.821 . . . . 0.0 109.611 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.12 -138.49 41.52 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -174.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -79.82 50.58 1.19 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.74 1.27 . . . . 0.0 110.222 174.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 m -161.39 153.73 20.06 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -119.34 149.08 21.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.6 m -134.32 125.34 27.44 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.222 1.009 . . . . 0.0 108.974 -173.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -98.73 167.33 10.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 123.882 0.873 . . . . 0.0 110.0 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.1 m -156.7 161.53 39.84 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.904 1.282 . . . . 0.0 107.661 177.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 73.13 178.36 35.01 Favored Glycine 0 CA--C 1.529 0.969 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -78.04 -32.3 50.86 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 122.078 -0.66 . . . . 0.0 110.617 178.363 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 m -79.06 70.05 5.34 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.872 0.869 . . . . 0.0 110.777 -174.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 69.0 t -86.09 92.19 3.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.0 t-160 -94.49 94.94 8.51 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.852 0.861 . . . . 0.0 110.531 -173.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.4 t -92.26 94.29 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.2 t -89.83 103.54 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.99 112.23 21.51 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.146 0.978 . . . . 0.0 111.363 -173.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.16 148.44 23.65 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 121.593 -0.692 . . . . 0.0 109.559 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.52 109.18 16.92 Favored 'General case' 0 CA--C 1.527 0.058 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 174.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.5 t 40.52 81.59 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.408 1.883 . . . . 0.0 112.576 175.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 76.8 mt -76.91 147.59 77.62 Favored Pre-proline 0 CA--C 1.534 0.332 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -175.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -44.51 111.63 0.29 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 123.876 3.051 . . . . 0.0 111.017 174.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.73 -40.71 1.58 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -173.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -88.44 112.57 50.81 Favored Pre-proline 0 CA--C 1.53 0.203 0 CA-C-O 118.661 -0.685 . . . . 0.0 109.349 178.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -78.78 66.29 8.66 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.391 2.061 . . . . 0.0 109.702 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 64.9 170.64 0.1 OUTLIER Pre-proline 0 CA--C 1.539 0.525 0 C-N-CA 124.349 1.06 . . . . 0.0 112.362 -175.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -116.73 -19.43 0.14 OUTLIER 'Cis proline' 0 CA--C 1.539 0.733 0 CA-C-N 119.108 0.717 . . . . 0.0 113.394 -6.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.52 151.22 47.69 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 118.964 2.95 . . . . 0.0 118.964 -168.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -77.35 128.92 35.11 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 104.249 -2.5 . . . . 0.0 104.249 169.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -111.62 115.34 28.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 -173.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 58.2 t -120.49 85.58 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 123.257 0.623 . . . . 0.0 109.517 -171.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 45.23 -97.19 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 126.177 1.791 . . . . 0.0 112.993 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -70.38 -23.61 62.8 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.549 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -134.36 -175.72 3.96 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.897 0.879 . . . . 0.0 110.903 -172.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.4 mtpp -131.07 129.58 42.12 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 172.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 50.58 42.95 1.42 Allowed Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 124.487 1.115 . . . . 0.0 113.115 -175.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -72.51 164.68 34.89 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.582 1.522 . . . . 0.0 114.291 -173.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . 0.266 0.2 OUTLIER -84.99 123.07 30.11 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 128.279 2.632 . . . . 0.0 106.088 173.571 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 8.9 mp -109.35 110.19 21.28 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.478 1.49 . . . . 0.0 113.221 -176.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -81.59 125.12 30.16 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 12.6 mt -127.29 140.34 37.65 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 124.283 1.033 . . . . 0.0 111.976 -171.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.05 118.18 4.01 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.287 2.658 . . . . 0.0 109.661 172.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.94 138.86 4.7 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.326 1.45 . . . . 0.0 112.175 176.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.17 -18.69 9.41 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-O 118.794 -1.004 . . . . 0.0 113.96 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.98 159.48 7.06 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.331 1.565 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.4 m -84.65 90.15 7.63 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.02 97.08 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -93.76 98.47 11.12 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.34 104.43 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.3 m -92.39 102.09 14.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.442 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.3 m-85 -77.67 154.91 31.71 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.422 173.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.2 mp -133.36 78.03 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 163.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -97.86 105.21 17.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 175.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.0 m -146.34 44.89 1.23 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -82.7 63.54 6.88 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -6.1 70.34 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 131.273 3.829 . . . . 0.0 114.82 -172.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 141.01 -47.46 0.86 Allowed Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.215 0.912 . . . . 0.0 111.062 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -85.33 100.18 11.65 Favored 'General case' 0 CA--C 1.528 0.13 0 O-C-N 122.076 -0.661 . . . . 0.0 111.125 -174.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.2 70.51 1.03 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 173.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -40.5 -49.21 2.9 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 116.164 1.913 . . . . 0.0 116.164 -171.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.7 p 78.22 148.28 0.1 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 120.027 1.285 . . . . 0.0 109.687 -172.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.442 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.9 t80 -138.39 108.31 6.33 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -115.52 135.85 53.67 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 118.798 0.727 . . . . 0.0 110.195 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.3 mt -110.26 130.53 63.35 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 126.186 1.794 . . . . 0.0 109.022 -177.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 t -159.39 -153.68 0.37 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -129.71 42.79 3.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 119.662 1.119 . . . . 0.0 110.573 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -91.69 110.92 22.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.143 0.577 . . . . 0.0 109.485 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.72 161.81 54.51 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 172.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.7 155.69 67.79 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.255 1.97 . . . . 0.0 109.62 174.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.51 167.87 78.0 Favored 'Cis proline' 0 N--CA 1.457 -0.667 0 CA-C-N 119.251 0.768 . . . . 0.0 111.301 -1.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -113.09 155.29 25.18 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.421 1.088 . . . . 0.0 109.106 177.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 156.56 26.68 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-O 121.378 0.608 . . . . 0.0 110.641 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 79.7 t -70.42 -36.9 68.58 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.743 175.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -78.34 152.04 78.45 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -38.85 111.9 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 124.996 3.797 . . . . 0.0 113.378 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.0 t -85.42 54.04 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 123.961 0.905 . . . . 0.0 109.021 -173.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.1 pp -88.0 91.05 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 122.519 1.152 . . . . 0.0 109.615 174.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.03 -157.55 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 126.254 1.822 . . . . 0.0 106.852 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -57.28 89.53 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 121.458 1.438 . . . . 0.0 109.34 153.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.1 mm -78.33 136.22 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 65.8 t -85.02 -88.81 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.556 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 175.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.42 155.71 16.63 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 171.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.51 166.34 33.52 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.312 -1.423 . . . . 0.0 111.438 174.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.6 p -118.44 142.28 47.71 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.251 1.42 . . . . 0.0 108.606 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.44 -161.45 6.79 Favored Glycine 0 CA--C 1.537 1.415 0 N-CA-C 108.174 -1.97 . . . . 0.0 108.174 172.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -67.17 106.38 1.99 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 120.842 -1.387 . . . . 0.0 109.899 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -62.5 156.68 61.3 Favored Pre-proline 0 CA--C 1.536 0.427 0 C-N-CA 126.731 2.013 . . . . 0.0 112.682 -174.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -67.27 151.28 81.13 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.999 2.466 . . . . 0.0 110.391 -175.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -129.95 74.5 80.52 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 123.821 0.848 . . . . 0.0 113.031 -175.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -60.91 174.89 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 122.419 2.079 . . . . 0.0 112.567 173.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 54.9 mttp -140.19 -168.46 2.54 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.891 1.277 . . . . 0.0 108.125 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 23.9 t70 55.65 -121.26 1.66 Allowed 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -174.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -112.71 9.98 25.7 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.716 -1.047 . . . . 0.0 112.856 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.1 mtpp -84.36 150.83 25.1 Favored 'General case' 0 C--N 1.341 0.233 0 CA-C-N 118.404 1.102 . . . . 0.0 109.007 175.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -132.87 110.32 10.23 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 124.292 1.037 . . . . 0.0 112.119 -173.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -66.88 116.07 7.85 Favored Glycine 0 CA--C 1.521 0.426 0 C-N-CA 125.178 1.37 . . . . 0.0 110.085 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -119.96 167.42 12.18 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 122.625 1.202 . . . . 0.0 110.804 175.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 61.7 m -154.69 115.23 3.91 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.02 83.6 5.19 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 172.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -90.42 151.52 21.38 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 35.7 m -121.54 145.57 47.83 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.021 0.528 . . . . 0.0 111.058 -173.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 24.0 t90 -143.61 144.17 31.8 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.45 1.1 . . . . 0.0 110.642 177.05 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 67.2 m-70 -109.6 109.93 59.74 Favored Pre-proline 0 CA--C 1.529 0.17 0 N-CA-C 104.857 -2.275 . . . . 0.0 104.857 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -90.73 133.6 1.76 Allowed 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.416 2.744 . . . . 0.0 113.606 -170.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.1 p -82.58 156.02 24.16 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.625 -1.621 . . . . 0.0 106.625 170.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -61.05 169.01 2.18 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 119.438 1.017 . . . . 0.0 112.438 -176.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 106.43 -177.98 22.37 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 125.636 1.589 . . . . 0.0 112.341 175.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 4.1 m -84.39 141.38 30.89 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.828 0.851 . . . . 0.0 110.073 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -137.35 170.11 16.64 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -142.57 146.83 34.99 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.961 1.304 . . . . 0.0 108.023 -178.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -115.59 140.87 48.77 Favored 'General case' 0 CA--C 1.528 0.097 0 O-C-N 123.984 0.803 . . . . 0.0 110.616 176.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.4 m -143.93 152.48 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 C-N-CA 124.548 1.139 . . . . 0.0 112.03 -174.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.1 t -98.8 125.7 44.24 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.58 1.552 . . . . 0.0 109.035 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 16.6 mm-40 -83.98 -4.26 58.59 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -173.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 30.8 mt -61.36 130.43 91.75 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 120.342 1.428 . . . . 0.0 108.239 175.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -39.44 125.08 1.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 124.118 3.212 . . . . 0.0 114.456 -174.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.94 -20.37 20.6 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 124.37 0.986 . . . . 0.0 113.226 176.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -66.98 -43.88 81.89 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 119.028 1.414 . . . . 0.0 112.303 -172.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -63.22 -48.7 77.17 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.703 0.683 . . . . 0.0 110.319 176.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.3 -54.57 43.88 Favored 'General case' 0 C--N 1.34 0.16 0 C-N-CA 123.755 0.822 . . . . 0.0 111.333 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.2 p -143.91 81.85 1.7 Allowed 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.226 1.011 . . . . 0.0 108.54 -174.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.49 -63.84 0.07 OUTLIER Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.246 176.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 4.0 ptm -157.9 129.5 6.8 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 117.795 0.797 . . . . 0.0 112.974 -172.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -162.74 -161.59 0.72 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.625 1.17 . . . . 0.0 108.349 175.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.49 171.36 33.42 Favored Glycine 0 C--N 1.334 0.452 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 172.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.0 mttm -110.95 153.69 25.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.373 1.069 . . . . 0.0 110.356 -173.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.9 mt -129.01 143.39 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.41 100.13 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -90.03 126.62 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 45.9 mtmt . . . . . 0 N--CA 1.46 0.052 0 CA-C-N 118.672 0.669 . . . . 0.0 110.828 -179.808 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.802 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.2 p -75.87 67.22 2.24 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.916 0.887 . . . . 0.0 109.778 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.0 mp -61.66 150.34 36.76 Favored 'General case' 0 N--CA 1.455 -0.22 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 174.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 19.3 t0 25.59 82.4 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 127.79 2.436 . . . . 0.0 114.436 -176.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 p -65.19 -26.78 68.29 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 122.534 0.334 . . . . 0.0 110.283 172.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.2 m -78.25 63.91 3.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.438 1.095 . . . . 0.0 112.155 -173.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 43.3 m95 -97.9 134.29 41.23 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.154 1.382 . . . . 0.0 109.538 174.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -149.57 -178.4 6.41 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -134.77 128.4 32.78 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 171.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.08 -151.82 0.31 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 172.319 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -142.03 168.13 20.49 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -39.58 -59.49 1.62 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -60.26 -28.74 87.48 Favored 'Trans proline' 0 N--CA 1.46 -0.496 0 CA-C-N 121.028 1.403 . . . . 0.0 112.19 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -66.93 -24.97 66.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 121.471 -0.768 . . . . 0.0 110.728 178.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 t -62.22 -50.28 80.61 Favored 'Isoleucine or valine' 0 C--N 1.34 0.177 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -58.1 -43.78 87.29 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -55.44 -58.3 8.32 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.903 -0.498 . . . . 0.0 110.988 175.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -58.33 -44.61 88.76 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 122.11 -0.369 . . . . 0.0 111.513 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.0 mt -50.52 -47.39 57.49 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.064 0.546 . . . . 0.0 110.746 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -61.89 -14.94 38.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.045 0.758 . . . . 0.0 113.045 178.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.5 mmmt -97.67 5.22 49.63 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 119.313 0.961 . . . . 0.0 111.651 176.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -74.65 125.16 28.08 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.051 -1.03 . . . . 0.0 110.507 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.9 p -93.27 29.33 1.94 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 123.306 0.642 . . . . 0.0 112.62 -176.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -104.32 111.71 3.91 Favored Glycine 0 C--N 1.339 0.726 0 C-N-CA 125.317 1.437 . . . . 0.0 111.139 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -79.63 159.83 26.61 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 173.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.0 t -81.56 150.73 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.5 m -147.72 65.57 1.12 Allowed 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.411 -0.805 . . . . 0.0 108.99 174.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 61.07 -109.34 2.37 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.546 -1.021 . . . . 0.0 110.546 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.2 p-10 -96.68 37.33 1.29 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.848 1.259 . . . . 0.0 110.325 177.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.1 m -160.64 161.98 32.58 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 105.806 -1.924 . . . . 0.0 105.806 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 t -120.27 151.65 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 126.969 2.108 . . . . 0.0 106.939 172.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.0 m -140.29 117.38 11.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.495 0.718 . . . . 0.0 109.18 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -83.06 166.99 18.29 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 174.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 57.3 m -152.29 156.17 39.13 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 175.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.37 165.44 20.53 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -173.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -72.64 -27.22 62.0 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.838 -0.801 . . . . 0.0 111.02 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -78.95 67.76 4.73 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.029 0.932 . . . . 0.0 110.269 -177.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.4 t -79.69 99.36 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.9 t-160 -107.4 94.65 5.21 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.7 107.0 17.27 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.154 0 C-N-CA 123.308 0.643 . . . . 0.0 109.486 -173.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.2 t -93.45 90.74 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -94.91 111.92 23.67 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.218 1.407 . . . . 0.0 110.282 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.98 143.39 27.12 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 174.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.7 104.41 5.77 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-O 121.23 0.538 . . . . 0.0 110.85 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 t 50.09 63.74 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 127.203 2.201 . . . . 0.0 111.216 173.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 22.5 mt -76.75 165.26 53.89 Favored Pre-proline 0 CA--C 1.536 0.433 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 99.7 Cg_exo -47.59 -40.59 30.34 Favored 'Trans proline' 0 CA--C 1.535 0.559 0 C-N-CA 122.888 2.392 . . . . 0.0 113.5 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -61.56 -23.16 62.47 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 123.45 0.548 . . . . 0.0 113.537 177.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -120.6 77.62 28.37 Favored Pre-proline 0 CA--C 1.531 0.25 0 C-N-CA 125.425 1.49 . . . . 0.0 108.923 -179.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -73.46 73.73 3.32 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.256 2.638 . . . . 0.0 110.924 -175.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 71.45 161.61 0.15 Allowed Pre-proline 0 CA--C 1.536 0.425 0 C-N-CA 127.706 2.402 . . . . 0.0 111.925 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -109.32 -21.05 0.36 Allowed 'Cis proline' 0 CA--C 1.536 0.609 0 N-CA-C 114.507 0.926 . . . . 0.0 114.507 -3.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.3 p -92.11 170.24 9.99 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 -168.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.25 167.21 22.12 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.75 0.82 . . . . 0.0 109.136 178.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.29 148.25 50.75 Favored 'General case' 0 CA--C 1.538 0.485 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 173.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.1 t -134.89 79.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 123.745 0.818 . . . . 0.0 109.456 -170.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.7 p80 50.48 -74.51 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 127.821 2.448 . . . . 0.0 114.896 175.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -98.0 -37.38 9.79 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 124.643 1.177 . . . . 0.0 110.964 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -111.21 -159.95 0.7 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.876 1.27 . . . . 0.0 108.203 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -140.44 -165.27 1.89 Allowed 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 14.1 m-80 -12.57 -56.38 0.03 OUTLIER Pre-proline 0 N--CA 1.471 0.598 0 C-N-CA 128.433 2.693 . . . . 0.0 115.242 172.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.6 OUTLIER -15.5 125.64 0.01 OUTLIER 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.983 3.789 . . . . 0.0 116.272 161.083 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 55.5 m -31.78 144.04 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 129.911 3.284 . . . . 0.0 117.276 -174.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.42 134.68 54.52 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.907 1.683 . . . . 0.0 108.492 174.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -110.07 140.35 44.22 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.249 1.02 . . . . 0.0 108.685 173.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.4 mt -136.71 141.57 35.75 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 -172.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -78.35 125.7 7.18 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.796 2.33 . . . . 0.0 108.123 171.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.02 145.45 16.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.761 0.824 . . . . 0.0 112.553 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.45 2.87 81.45 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-O 119.498 -0.612 . . . . 0.0 112.986 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.88 157.97 20.2 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 118.745 1.273 . . . . 0.0 112.228 174.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 61.2 m -93.6 89.99 6.46 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 172.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 43.2 t -77.58 98.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -173.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -92.51 93.57 8.63 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.035 1.334 . . . . 0.0 107.88 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.95 107.05 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 78.9 m -99.94 103.84 15.43 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 125.326 1.45 . . . . 0.0 109.498 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -81.56 152.24 27.33 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.92 78.99 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 102.159 -3.275 . . . . 0.0 102.159 163.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -101.5 85.08 2.7 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 176.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.417 HG23 ' CD2' ' A' ' 120' ' ' PHE . 76.3 p -112.08 33.51 4.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.538 -174.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -79.61 70.95 6.19 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 177.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -33.49 103.46 0.03 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.133 2.173 . . . . 0.0 112.462 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.99 -46.05 1.13 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 125.215 1.388 . . . . 0.0 111.293 -177.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -97.76 107.49 20.0 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.483 1.113 . . . . 0.0 111.938 -173.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.89 -16.29 56.69 Favored Glycine 0 CA--C 1.538 1.503 0 CA-C-O 119.199 -0.779 . . . . 0.0 114.457 174.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 46.73 -72.28 0.0 OUTLIER 'General case' 0 C--N 1.343 0.307 0 C-N-CA 129.221 3.008 . . . . 0.0 116.46 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.0 p 88.62 155.98 0.06 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 129.228 3.011 . . . . 0.0 111.867 -172.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -125.13 131.74 53.21 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 103.339 -2.837 . . . . 0.0 103.339 171.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.26 116.42 11.08 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 108.569 -0.901 . . . . 0.0 108.569 -173.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -97.19 125.78 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 124.536 1.134 . . . . 0.0 109.392 -178.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -160.1 -141.94 0.08 Allowed 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -122.91 -110.65 0.32 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.143 0.883 . . . . 0.0 110.431 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt 65.62 -65.54 0.17 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.303 1.841 . . . . 0.0 112.397 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.48 162.56 33.36 Favored Glycine 0 CA--C 1.533 1.212 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -173.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -71.79 158.75 52.42 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.79 2.327 . . . . 0.0 109.804 177.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.22 132.38 27.09 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 CA-C-N 119.146 0.731 . . . . 0.0 110.222 -3.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -79.78 151.97 30.04 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.159 0.504 . . . . 0.0 109.695 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.01 151.65 28.33 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.313 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.8 t -61.45 -41.94 91.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 175.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.5 mmm -77.96 128.77 77.97 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 174.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -76.98 75.65 4.48 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.428 2.085 . . . . 0.0 110.397 -174.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.2 t -77.53 76.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 175.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.0 pt -77.96 89.66 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 122.394 1.092 . . . . 0.0 109.794 -176.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -55.57 146.69 43.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 171.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -25.63 116.26 0.03 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.698 1 C-N-CA 125.676 4.251 . . . . 0.0 115.625 -166.615 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 30.6 mm -78.46 131.6 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.4 t -82.15 -86.07 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.87 149.35 21.63 Favored 'General case' 0 C--N 1.333 -0.123 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 172.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.91 165.76 39.07 Favored Glycine 0 C--N 1.332 0.318 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 174.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.9 p -119.04 123.32 44.21 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.085 0.554 . . . . 0.0 111.792 -174.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -78.03 57.9 3.95 Favored Glycine 0 CA--C 1.535 1.34 0 CA-C-O 119.082 -0.843 . . . . 0.0 113.646 -175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 65.05 124.73 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 127.382 2.273 . . . . 0.0 113.719 174.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 92.0 p -74.23 136.54 75.64 Favored Pre-proline 0 CA--C 1.532 0.288 0 O-C-N 120.899 -1.125 . . . . 0.0 112.457 -173.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.49 84.96 0.92 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.312 2.008 . . . . 0.0 107.066 172.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.3 m -45.06 139.06 4.13 Favored Pre-proline 0 CA--C 1.539 0.533 0 C-N-CA 124.673 1.189 . . . . 0.0 112.851 -174.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -75.74 -178.27 4.2 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.636 2.891 . . . . 0.0 113.665 -173.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.93 176.73 7.1 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 127.043 2.137 . . . . 0.0 107.19 174.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -36.71 120.98 0.73 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.975 1.31 . . . . 0.0 113.269 -174.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 84.53 -27.05 4.85 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.968 0.794 . . . . 0.0 113.738 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 56.5 mttp -85.63 157.4 20.36 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.132 0.966 . . . . 0.0 109.97 -174.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.417 ' CD2' HG23 ' A' ' 79' ' ' THR . 10.1 m-85 -137.18 91.22 2.6 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.427 1.091 . . . . 0.0 111.414 -173.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -47.34 121.31 6.33 Favored Glycine 0 CA--C 1.529 0.924 0 C-N-CA 124.716 1.15 . . . . 0.0 111.74 174.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.7 p90 -144.24 176.32 9.42 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.312 1.053 . . . . 0.0 111.467 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.16 166.58 32.83 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 127.079 2.152 . . . . 0.0 105.757 -176.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -146.68 65.08 1.18 Allowed 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 19.4 p90 -77.99 135.83 37.86 Favored 'General case' 0 C--N 1.34 0.184 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.441 -174.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 14.8 m -99.13 132.6 44.32 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.508 0.723 . . . . 0.0 110.021 -175.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.6 t90 -137.95 143.25 40.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.459 1.104 . . . . 0.0 109.704 176.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 63.5 m80 -111.36 99.41 43.83 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -76.23 173.79 13.91 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 122.364 2.043 . . . . 0.0 109.397 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 81.3 p -119.06 153.6 34.49 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -57.62 142.26 45.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -172.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 135.45 -127.11 4.2 Favored Glycine 0 C--N 1.336 0.555 0 C-N-CA 126.208 1.861 . . . . 0.0 109.411 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -151.95 142.9 23.07 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 118.251 1.026 . . . . 0.0 110.006 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 20.5 m-85 -133.16 -179.28 5.4 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 126.243 1.817 . . . . 0.0 106.958 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -141.65 147.26 37.27 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 124.301 1.04 . . . . 0.0 108.43 174.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -102.46 145.76 29.09 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.0 m -146.64 160.72 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.842 1.257 . . . . 0.0 110.322 174.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.4 t -99.0 125.89 44.58 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.68 1.192 . . . . 0.0 109.691 171.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.69 -27.37 66.36 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 -177.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -57.26 128.94 79.25 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 120.541 1.519 . . . . 0.0 109.826 -174.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_exo -43.83 137.68 6.46 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.262 2.641 . . . . 0.0 113.15 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.59 -27.72 2.49 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.171 -0.794 . . . . 0.0 113.411 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -62.43 -51.53 67.16 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.734 1.767 . . . . 0.0 111.639 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.81 -44.0 86.07 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 117.82 0.282 . . . . 0.0 110.764 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.95 -43.04 99.27 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.135 -0.353 . . . . 0.0 111.364 -179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.6 p -79.14 -41.01 29.53 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 118.877 -0.582 . . . . 0.0 112.175 -174.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 178.26 -15.6 0.03 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 118.725 -1.702 . . . . 0.0 116.977 -176.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 13.3 mtp -79.04 77.03 5.53 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 120.118 1.959 . . . . 0.0 110.456 -174.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -160.17 -174.72 4.67 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.37 164.95 23.93 Favored Glycine 0 C--N 1.341 0.832 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 175.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 30.8 mttt -100.99 147.66 25.93 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.9 mt -121.52 100.65 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.15 121.15 38.92 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.064 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.6 t -109.38 95.06 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 -178.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 96.9 mttt . . . . . 0 C--N 1.332 -0.177 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.286 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.736 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.6 p -76.63 59.64 1.55 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.849 1.259 . . . . 0.0 109.616 178.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.6 mp 21.4 -90.15 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 128.189 2.596 . . . . 0.0 115.878 -174.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.34 76.14 2.58 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.306 -0.872 . . . . 0.0 111.427 -172.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.2 p -143.62 -77.44 0.23 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -176.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.0 m -77.79 64.13 2.98 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -169.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 71.4 m95 -92.95 156.22 17.06 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 126.645 1.978 . . . . 0.0 110.766 175.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -154.68 179.36 9.14 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 172.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -139.68 150.26 44.68 Favored 'General case' 0 C--N 1.341 0.209 0 CA-C-N 119.557 1.072 . . . . 0.0 111.191 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -130.65 -154.52 0.64 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.009 2.123 . . . . 0.0 107.292 174.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -135.94 171.44 14.46 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.527 0.731 . . . . 0.0 110.198 176.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.67 -59.91 1.23 Allowed Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -174.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -59.77 -30.87 93.05 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 CA-C-N 121.515 1.577 . . . . 0.0 111.964 -178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -66.97 -22.94 65.9 Favored 'General case' 0 N--CA 1.448 -0.557 0 O-C-N 121.757 -0.589 . . . . 0.0 111.267 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.5 t -59.38 -51.5 71.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -59.78 -49.02 79.35 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.81 -55.69 13.19 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.043 0.214 . . . . 0.0 110.986 177.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 72.6 mtm -57.85 -52.49 65.25 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 123.223 0.609 . . . . 0.0 110.675 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.5 mt -50.67 -44.67 57.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 118.322 0.51 . . . . 0.0 111.057 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -58.81 -25.35 63.07 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 178.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.75 -1.02 36.75 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 119.934 1.243 . . . . 0.0 112.083 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.68 153.42 24.04 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 120.17 1.35 . . . . 0.0 110.782 175.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.2 p -117.94 27.77 8.81 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 123.269 0.628 . . . . 0.0 112.524 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.44 116.57 5.32 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -79.06 154.26 29.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 174.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 t -79.74 145.98 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 O-C-N 121.981 -0.449 . . . . 0.0 110.026 -175.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.2 m -149.08 64.32 1.04 Allowed 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.894 0.878 . . . . 0.0 109.404 174.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.04 -114.11 6.47 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.4 -17.0 55.28 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 123.178 0.591 . . . . 0.0 111.246 175.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -103.29 161.55 13.73 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 125.276 1.43 . . . . 0.0 107.841 -175.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.65 148.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.0 m -135.65 131.47 35.8 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -171.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -100.48 168.89 9.45 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.37 0.605 . . . . 0.0 110.663 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.0 m -155.01 155.0 33.38 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.76 174.35 32.96 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -174.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -77.84 -30.49 51.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 122.243 -0.563 . . . . 0.0 111.785 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.03 74.37 5.56 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.502 0.592 . . . . 0.0 109.968 -175.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.0 t -84.7 89.36 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -177.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -94.47 100.92 12.82 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.96 0.504 . . . . 0.0 110.642 -174.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -95.27 100.26 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 124.89 1.276 . . . . 0.0 108.315 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.1 t -95.7 122.89 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -133.31 116.48 16.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.621 0.646 . . . . 0.0 112.5 -173.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.85 112.56 24.53 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.981 0.913 . . . . 0.0 110.008 175.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.6 92.23 8.49 Favored 'General case' 0 N--CA 1.455 -0.178 0 O-C-N 121.58 -0.7 . . . . 0.0 110.038 -177.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.8 t 63.67 97.17 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 125.195 1.398 . . . . 0.0 111.324 174.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 75.2 mt -74.98 140.85 74.22 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -174.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.55 116.87 1.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.629 2.886 . . . . 0.0 111.392 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 125.4 -41.06 1.74 Allowed Glycine 0 CA--C 1.527 0.803 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -173.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -74.0 116.19 49.9 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 176.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -81.05 63.9 8.81 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.479 2.119 . . . . 0.0 108.631 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.9 m-30 67.42 174.96 0.08 OUTLIER Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.353 1.061 . . . . 0.0 108.988 -172.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -124.45 29.62 0.16 OUTLIER 'Cis proline' 0 CA--C 1.537 0.664 0 CA-C-N 120.722 1.294 . . . . 0.0 109.999 -7.119 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.8 p -92.09 125.25 36.7 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 116.94 2.2 . . . . 0.0 116.94 -171.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.69 103.71 9.78 Favored 'General case' 0 C--N 1.342 0.243 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 166.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -88.03 112.03 22.18 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -176.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -111.49 84.7 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 125.14 1.376 . . . . 0.0 109.783 -171.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 46.98 -98.97 0.04 OUTLIER 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 125.78 1.632 . . . . 0.0 112.9 176.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -70.73 -24.69 62.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.565 0.346 . . . . 0.0 111.877 -176.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -130.57 -178.07 4.62 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.232 1.013 . . . . 0.0 110.679 -173.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.2 mtmp? -130.12 122.32 28.03 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 105.88 -1.896 . . . . 0.0 105.88 172.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 55.33 44.37 1.62 Allowed Pre-proline 0 CA--C 1.541 0.607 0 C-N-CA 124.705 1.202 . . . . 0.0 112.275 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.71 172.06 15.69 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.475 2.117 . . . . 0.0 111.567 -176.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.5 m -91.9 138.86 31.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 170.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.0 mp -112.25 126.99 55.83 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.83 0.852 . . . . 0.0 110.241 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -100.01 119.51 38.38 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 15.3 mt -124.04 142.24 39.2 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.392 1.077 . . . . 0.0 112.95 -171.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.15 118.71 4.07 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 122.935 2.423 . . . . 0.0 108.893 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.88 142.99 3.1 Favored 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 125.41 1.484 . . . . 0.0 112.31 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 80.49 -22.2 4.81 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 118.982 -0.899 . . . . 0.0 113.706 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.21 158.17 5.56 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.113 1.456 . . . . 0.0 111.969 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -79.84 96.68 6.4 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.5 t -78.68 90.36 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 174.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -84.36 119.3 24.94 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 174.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -111.79 114.36 46.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -176.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 94.4 m -107.47 104.35 13.9 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.541 1.137 . . . . 0.0 109.473 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.4 m-85 -79.53 162.9 25.1 Favored 'General case' 0 C--O 1.221 -0.414 0 O-C-N 121.662 -0.649 . . . . 0.0 112.429 174.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -137.61 78.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 101.651 -3.462 . . . . 0.0 101.651 163.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -99.94 96.51 7.6 Favored 'General case' 0 N--CA 1.457 -0.111 0 N-CA-C 106.811 -1.552 . . . . 0.0 106.811 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.7 m -147.44 59.32 1.15 Allowed 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 174.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -82.3 66.41 7.88 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 173.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 8.72 72.82 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.75 3.22 . . . . 0.0 113.927 -171.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.42 -44.83 1.29 Allowed Glycine 0 CA--C 1.527 0.796 0 C-N-CA 124.31 0.957 . . . . 0.0 111.382 178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -79.72 95.62 6.02 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.842 0.83 . . . . 0.0 110.091 -175.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.99 61.35 2.58 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.412 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -45.54 124.57 5.09 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.271 1.028 . . . . 0.0 110.857 173.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 96.8 p -87.2 167.06 14.47 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -134.05 112.5 11.23 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 172.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -131.27 127.59 38.08 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -173.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 47.5 mt -99.31 127.91 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 C-N-CA 125.818 1.647 . . . . 0.0 108.475 -174.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.48 -149.03 0.18 Allowed 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt -129.26 25.28 5.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.696 1.134 . . . . 0.0 111.994 -178.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -73.74 94.95 2.3 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 173.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -73.49 171.33 51.69 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 173.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.1 150.15 82.27 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.282 1.988 . . . . 0.0 109.65 175.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -75.31 130.75 22.13 Favored 'Cis proline' 0 N--CA 1.454 -0.807 0 N-CA-C 109.941 -0.83 . . . . 0.0 109.941 -3.255 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -78.75 145.82 34.21 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.4 145.59 39.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-O 121.382 0.61 . . . . 0.0 112.044 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -67.52 -43.41 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -78.85 144.95 65.15 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 177.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -64.01 68.83 0.2 Allowed 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.638 2.892 . . . . 0.0 113.685 175.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.43 75.52 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.4 pt -76.35 86.0 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 123.509 1.623 . . . . 0.0 110.816 -172.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.28 155.69 83.9 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 113.125 -1.852 . . . . 0.0 106.913 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -39.57 112.42 0.15 Allowed 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 123.91 3.073 . . . . 0.0 113.986 -176.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.1 mm -79.24 132.17 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -82.29 -87.11 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.49 156.16 16.46 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 123.394 0.678 . . . . 0.0 109.365 173.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.44 178.21 45.1 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 118.956 -1.592 . . . . 0.0 113.904 174.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 17.3 p -121.26 155.27 35.01 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 126.464 1.906 . . . . 0.0 109.424 175.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -90.09 -127.55 3.42 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 173.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -116.2 134.98 54.32 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 118.495 1.148 . . . . 0.0 108.61 176.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 4.5 p -76.58 177.56 2.5 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -172.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.56 -7.08 13.46 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.271 2.648 . . . . 0.0 113.015 172.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m 35.24 67.15 1.46 Allowed Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 126.285 1.834 . . . . 0.0 115.857 -178.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -60.72 178.59 0.46 Allowed 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.726 2.284 . . . . 0.0 113.796 174.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -142.45 -171.98 3.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.043 0.937 . . . . 0.0 110.187 -177.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 26.1 t70 62.65 -77.3 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 126.862 2.065 . . . . 0.0 111.549 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.75 15.66 0.3 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.966 0.793 . . . . 0.0 111.869 177.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 31.8 mtmm -87.59 155.9 19.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 174.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -140.07 104.07 4.76 Favored 'General case' 0 CA--C 1.517 -0.297 0 C-N-CA 123.765 0.826 . . . . 0.0 112.416 -171.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -67.38 107.85 2.2 Favored Glycine 0 CA--C 1.526 0.725 0 C-N-CA 125.299 1.428 . . . . 0.0 109.841 174.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -103.48 178.62 4.5 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.889 0.852 . . . . 0.0 109.374 173.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.87 157.75 43.66 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 -177.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.0 m-20 -139.46 87.5 2.19 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -100.59 168.78 9.49 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 172.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 16.6 m -151.86 148.94 28.42 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 120.952 -1.093 . . . . 0.0 108.976 -175.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 22.0 t90 -147.22 149.47 32.98 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 124.627 1.171 . . . . 0.0 110.225 -174.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -113.06 108.32 53.28 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 172.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -89.8 145.79 4.67 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 123.419 2.746 . . . . 0.0 112.693 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.8 p -89.55 154.94 19.61 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.983 1.313 . . . . 0.0 108.329 172.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.35 169.16 1.26 Allowed 'General case' 0 CA--C 1.538 0.484 0 O-C-N 121.603 -0.686 . . . . 0.0 112.225 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 108.09 -130.61 10.17 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 125.182 1.373 . . . . 0.0 110.192 178.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.7 m -151.56 144.48 24.48 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 118.28 1.04 . . . . 0.0 110.377 -175.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -137.57 174.94 10.05 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 126.221 1.809 . . . . 0.0 107.727 178.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -135.79 139.21 43.34 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.482 1.513 . . . . 0.0 108.6 179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -103.36 139.59 38.57 Favored 'General case' 0 N--CA 1.457 -0.116 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 172.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.7 m -147.15 168.62 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.229 1.011 . . . . 0.0 110.701 178.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 10.3 t -106.09 136.85 45.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 126.461 1.905 . . . . 0.0 108.485 173.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -77.49 -26.28 51.1 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 123.867 0.867 . . . . 0.0 113.22 -173.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 52.7 mt -57.92 130.82 82.97 Favored Pre-proline 0 CA--C 1.543 0.696 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.93 143.56 3.03 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 124.128 3.219 . . . . 0.0 114.778 -174.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.91 -39.73 1.37 Allowed Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.211 0.91 . . . . 0.0 113.958 174.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 25.0 m170 -50.24 -48.81 54.46 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.591 1.156 . . . . 0.0 114.062 -172.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.19 -49.83 74.24 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-O 120.736 0.303 . . . . 0.0 110.368 178.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -58.41 -42.1 86.4 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.256 0.622 . . . . 0.0 110.853 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 32.5 p -79.84 -41.29 26.66 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 118.129 -0.938 . . . . 0.0 113.196 -174.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -169.46 -41.13 0.03 OUTLIER Glycine 0 C--N 1.342 0.871 0 C-N-CA 118.028 -2.034 . . . . 0.0 117.881 -174.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.268 3.8 ptp -79.91 94.17 5.81 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 120.381 2.09 . . . . 0.0 112.196 -173.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -157.76 -178.28 7.21 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.083 0.953 . . . . 0.0 110.353 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.28 161.14 19.07 Favored Glycine 0 C--N 1.338 0.655 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 173.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -96.31 145.75 25.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.653 1.581 . . . . 0.0 109.553 -175.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.7 mt -122.4 101.09 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 173.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -89.67 132.19 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 25.7 t -123.94 125.98 71.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 24.1 mtpp . . . . . 0 N--CA 1.464 0.226 0 CA-C-N 118.898 0.772 . . . . 0.0 111.276 -177.932 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.864 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p 65.6 -57.97 0.31 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 127.855 2.462 . . . . 0.0 113.557 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 mp -55.17 151.3 9.57 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 171.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -34.52 106.97 0.05 OUTLIER 'General case' 0 C--O 1.232 0.171 0 C-N-CA 125.691 1.596 . . . . 0.0 112.458 -171.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.5 p -88.8 17.4 5.63 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 124.912 1.285 . . . . 0.0 111.645 -176.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.2 m -79.71 62.71 4.06 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.155 0.889 . . . . 0.0 110.139 -174.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 73.6 m95 -94.49 122.26 36.88 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 125.177 1.391 . . . . 0.0 111.282 -174.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -142.11 -176.47 4.82 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -136.43 132.32 35.29 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 121.838 -0.539 . . . . 0.0 109.83 172.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -87.74 -154.56 0.26 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 104.303 -2.48 . . . . 0.0 104.303 169.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.8 p -142.61 165.19 28.09 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 120.921 -1.112 . . . . 0.0 108.713 174.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.3 tt -39.9 -53.02 4.99 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 114.687 1.365 . . . . 0.0 114.687 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -57.54 -31.19 90.91 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.865 1.71 . . . . 0.0 112.572 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -71.13 -33.63 70.28 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 122.995 0.518 . . . . 0.0 110.204 178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.6 t -62.74 -48.61 87.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -54.45 -44.96 72.96 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.988 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.91 -48.07 67.52 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.25 0.62 . . . . 0.0 111.437 175.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 68.8 mtm -70.1 -30.94 68.28 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 118.483 -0.77 . . . . 0.0 112.221 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.57 57.36 1.22 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-O 122.331 1.062 . . . . 0.0 109.757 172.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -137.29 -40.27 0.58 Allowed 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 129.383 3.073 . . . . 0.0 104.839 173.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . 0.294 0.0 OUTLIER 84.72 142.58 0.06 Allowed 'General case' 0 N--CA 1.442 -0.831 0 C-N-CA 128.974 2.91 . . . . 0.0 114.648 170.247 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -101.19 -147.8 0.36 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 111.688 -2.506 . . . . 0.0 109.091 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.2 p -44.16 131.66 5.94 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 126.717 2.007 . . . . 0.0 112.675 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 145.06 90.63 0.11 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.169 0.89 . . . . 0.0 110.928 174.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -79.13 137.79 37.63 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 174.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.5 t -63.69 146.89 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 33.0 m -148.52 64.66 1.07 Allowed 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 174.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 66.07 -142.99 44.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 107.642 -2.183 . . . . 0.0 107.642 -172.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -80.01 54.85 1.99 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.721 1.261 . . . . 0.0 109.733 174.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.9 m -160.86 153.9 21.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 178.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 93.5 t -123.46 142.08 41.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -125.77 129.44 49.47 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.963 1.305 . . . . 0.0 108.562 -174.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -93.18 167.07 12.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.493 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.6 m -156.26 61.58 0.56 Allowed 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.552 0.741 . . . . 0.0 109.621 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.87 166.07 38.58 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 108.234 -1.947 . . . . 0.0 108.234 177.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -75.18 -50.4 16.37 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 117.435 0.617 . . . . 0.0 109.659 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.3 p -79.83 93.62 5.66 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 42.5 t -82.82 98.53 4.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -94.11 116.01 28.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.8 122.47 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 124.864 1.265 . . . . 0.0 108.601 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 95.5 t -92.2 113.82 28.12 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 175.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.83 92.66 3.9 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.871 1.269 . . . . 0.0 110.392 -178.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.33 113.51 24.8 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.273 1.029 . . . . 0.0 109.999 178.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.1 114.45 24.73 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.209 -0.932 . . . . 0.0 110.409 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.4 t 32.89 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 126.67 1.988 . . . . 0.0 112.892 173.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.7 142.02 69.55 Favored Pre-proline 0 CA--C 1.533 0.31 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -178.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -56.16 110.4 0.56 Allowed 'Trans proline' 0 N--CA 1.454 -0.802 0 C-N-CA 123.079 2.519 . . . . 0.0 110.429 -174.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 137.65 -42.71 1.27 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 107.917 -2.073 . . . . 0.0 107.917 -173.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -83.01 140.34 42.94 Favored Pre-proline 0 N--CA 1.453 -0.324 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 174.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.99 164.98 30.68 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 122.471 2.114 . . . . 0.0 110.631 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -72.02 166.33 41.77 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 173.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -116.64 50.95 0.65 Allowed 'Cis proline' 0 CA--C 1.536 0.591 0 N-CA-C 108.441 -1.407 . . . . 0.0 108.441 -5.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.7 p -93.05 129.3 39.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -173.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -77.95 121.69 24.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 N-CA-C 103.247 -2.871 . . . . 0.0 103.247 166.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -91.88 113.99 26.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -120.59 117.79 54.4 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 119.051 0.841 . . . . 0.0 110.584 -171.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 0.1 OUTLIER 36.93 -104.71 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.641 1.976 . . . . 0.0 113.067 -174.751 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.22 -17.68 39.04 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -124.5 -166.93 1.58 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 124.263 1.025 . . . . 0.0 110.833 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 51.2 mttm -133.95 124.74 26.86 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.192 -1.781 . . . . 0.0 106.192 172.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 52.91 44.24 1.91 Allowed Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.657 1.183 . . . . 0.0 112.354 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -79.28 173.72 12.91 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 122.372 2.048 . . . . 0.0 111.482 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 17.8 m -94.62 140.68 29.55 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 172.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.73 121.45 44.11 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.413 1.485 . . . . 0.0 112.305 -171.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -103.46 111.02 23.27 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.988 0.915 . . . . 0.0 108.737 173.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.9 mt -112.58 135.45 21.51 Favored Pre-proline 0 CA--C 1.537 0.447 0 C-N-CA 125.739 1.616 . . . . 0.0 110.289 -173.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.67 116.63 4.32 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 122.629 2.22 . . . . 0.0 108.747 172.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.03 133.58 27.21 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.593 0.757 . . . . 0.0 110.597 177.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.98 -26.63 16.75 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.986 -1.245 . . . . 0.0 109.986 -173.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.08 32.23 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.891 0.846 . . . . 0.0 111.845 174.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 95.2 m -105.08 130.22 53.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 t -100.53 99.28 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 124.253 1.021 . . . . 0.0 110.881 -172.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.53 93.71 8.4 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.0 t -83.93 100.64 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 174.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 93.3 m -86.75 100.07 12.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.497 1.119 . . . . 0.0 109.109 174.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -76.74 155.7 33.0 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.35 172.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.0 mp -137.96 92.2 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 101.868 -3.382 . . . . 0.0 101.868 163.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -113.54 113.31 24.93 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 172.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 49.1 m -146.17 45.89 1.24 Allowed 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 172.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -75.74 71.02 2.58 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 173.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.2 mtmm -17.74 87.96 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.527 3.131 . . . . 0.0 113.929 -173.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 133.32 -45.27 1.13 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.383 0.992 . . . . 0.0 111.507 178.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -97.33 111.99 24.0 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 117.506 0.653 . . . . 0.0 112.272 -173.06 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.62 54.96 2.5 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.937 0.78 . . . . 0.0 111.475 173.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -48.34 139.84 8.33 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.643 1.221 . . . . 0.0 111.347 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.4 p -104.51 165.99 10.69 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.53 1.132 . . . . 0.0 108.435 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -131.28 116.52 17.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 105.596 -2.002 . . . . 0.0 105.596 171.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 16.8 m-20 -133.03 129.83 38.61 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 118.91 0.777 . . . . 0.0 110.642 -172.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 34.4 mt -104.38 134.04 46.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 C-N-CA 126.016 1.726 . . . . 0.0 108.864 -176.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.2 t -159.13 -154.61 0.42 Allowed 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 48.8 mtmt -126.56 21.88 7.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 119.232 0.924 . . . . 0.0 111.804 -179.154 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -70.37 118.87 13.73 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.05 159.33 43.38 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 174.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -72.5 164.53 35.34 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.969 2.446 . . . . 0.0 109.598 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -71.35 141.46 69.8 Favored 'Cis proline' 0 N--CA 1.459 -0.543 0 CA-C-N 119.333 0.798 . . . . 0.0 110.634 -5.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -79.91 150.86 30.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 121.289 0.566 . . . . 0.0 109.874 175.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.43 151.99 27.63 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.377 177.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 65.9 t -61.1 -39.18 81.47 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 174.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 92.3 mmm -78.2 133.1 65.02 Favored Pre-proline 0 N--CA 1.452 -0.373 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 174.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.87 75.57 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.751 2.301 . . . . 0.0 111.974 -173.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.9 t -79.02 65.5 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 172.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -88.43 -43.79 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.84 1.656 . . . . 0.0 111.801 -173.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -64.25 146.52 97.67 Favored Pre-proline 0 CA--C 1.531 0.215 0 C-N-CA 123.119 0.568 . . . . 0.0 111.515 -173.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.26 143.28 74.57 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 CA-C-N 119.038 0.692 . . . . 0.0 111.261 -2.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 mm -91.44 143.49 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 92.2 t -87.05 -92.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 104.432 -2.432 . . . . 0.0 104.432 173.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.17 145.65 24.87 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -178.6 161.5 28.09 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.264 -1.446 . . . . 0.0 111.237 174.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 34.6 p -103.02 149.25 24.74 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 125.186 1.395 . . . . 0.0 108.248 175.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.91 -156.7 8.78 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 173.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -74.74 139.12 43.18 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.506 1.153 . . . . 0.0 109.071 174.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 51.8 p -81.66 163.91 51.74 Favored Pre-proline 0 C--O 1.233 0.216 0 C-N-CA 122.497 0.319 . . . . 0.0 111.547 -174.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -64.97 166.33 18.84 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 N-CA-C 106.395 -2.194 . . . . 0.0 106.395 168.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.4 t -130.55 76.75 77.0 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -172.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -62.76 162.12 26.31 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 122.154 1.903 . . . . 0.0 110.256 172.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -137.19 5.95 2.8 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -178.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -174.33 148.94 1.3 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 125.469 1.508 . . . . 0.0 109.102 174.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.94 -66.21 0.13 Allowed Glycine 0 CA--C 1.527 0.832 0 C-N-CA 126.533 2.015 . . . . 0.0 113.935 174.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -79.02 151.53 31.46 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 125.22 1.408 . . . . 0.0 110.525 -176.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -134.76 101.98 5.11 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 125.46 1.504 . . . . 0.0 111.096 -174.013 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.95 112.28 1.87 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 125.272 1.415 . . . . 0.0 111.227 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -130.67 155.23 46.94 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.931 0.893 . . . . 0.0 111.29 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 6.6 m -154.78 114.4 3.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -174.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.09 62.55 4.21 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 125.199 1.399 . . . . 0.0 108.525 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -70.15 121.82 18.26 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 118.305 -1.358 . . . . 0.0 108.526 -174.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 41.0 m -96.86 84.73 3.63 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.389 -172.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -78.36 124.75 28.46 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -94.02 106.39 22.05 Favored Pre-proline 0 N--CA 1.451 -0.417 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 171.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -83.23 177.85 6.25 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.975 2.45 . . . . 0.0 112.169 -171.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.5 p -131.09 153.88 48.86 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 172.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.38 165.3 7.85 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.531 1.06 . . . . 0.0 111.935 -174.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 112.86 -168.18 12.54 Favored Glycine 0 CA--C 1.525 0.676 0 C-N-CA 124.718 1.151 . . . . 0.0 112.297 174.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 28.5 m -98.3 139.89 33.4 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 124.028 0.931 . . . . 0.0 109.08 -176.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -140.35 177.29 8.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 125.27 1.428 . . . . 0.0 107.235 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -145.44 152.7 40.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 176.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -116.74 149.13 40.39 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 123.489 0.716 . . . . 0.0 110.382 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 28.6 m -152.78 161.88 2.56 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 C-N-CA 125.052 1.341 . . . . 0.0 111.314 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 3.1 t -100.14 134.11 43.55 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.406 1.482 . . . . 0.0 107.892 170.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -74.05 -22.17 59.65 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -173.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 57.1 mt -60.78 126.98 86.6 Favored Pre-proline 0 CA--C 1.542 0.665 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -177.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -44.86 146.89 2.14 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 123.934 3.089 . . . . 0.0 114.056 -174.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.2 -39.01 1.61 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 123.304 0.478 . . . . 0.0 113.055 177.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.1 m170 -54.02 -51.55 63.63 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.491 1.145 . . . . 0.0 111.879 -173.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.28 -47.29 81.84 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 117.891 0.314 . . . . 0.0 110.986 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.47 97.27 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 122.783 0.433 . . . . 0.0 111.132 -178.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 40.4 p -79.99 -35.81 36.89 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -173.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.41 -27.34 0.04 OUTLIER Glycine 0 CA--C 1.528 0.898 0 N-CA-C 117.081 1.592 . . . . 0.0 117.081 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 3.6 mtt -78.12 80.43 4.55 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 120.07 1.935 . . . . 0.0 110.943 -173.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -162.28 -174.38 4.04 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.71 163.32 21.41 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 173.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 49.2 mttt -99.33 154.1 18.45 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.046 0.939 . . . . 0.0 108.954 -175.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.4 mt -130.33 138.1 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 178.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 42.8 t -130.25 101.0 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 173.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 40.1 t -87.0 88.14 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 174.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.3 mttt . . . . . 0 C--N 1.332 -0.182 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 177.109 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.011 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.869 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 p -72.21 97.76 2.03 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 125.209 1.403 . . . . 0.0 108.687 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.8 mp -44.81 142.18 1.85 Allowed 'General case' 0 CA--C 1.529 0.16 0 CA-C-O 121.293 0.568 . . . . 0.0 111.957 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 20.3 t70 67.59 -31.57 0.18 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 127.239 2.216 . . . . 0.0 116.238 174.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 77.3 p -52.36 -43.75 64.84 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 119.243 0.928 . . . . 0.0 111.86 -176.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.8 m -98.84 122.33 41.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 123.846 0.858 . . . . 0.0 108.871 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -155.7 127.1 7.22 Favored 'General case' 0 C--N 1.341 0.233 0 C-N-CA 126.32 1.848 . . . . 0.0 108.417 173.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -150.07 170.62 18.45 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 173.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -135.91 148.14 48.43 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 172.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -118.24 -155.94 0.62 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 127.862 2.465 . . . . 0.0 106.357 174.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 29.9 p -134.43 173.04 12.07 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.577 0.751 . . . . 0.0 109.49 174.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.0 tt -39.05 -56.81 2.36 Favored Pre-proline 0 CA--C 1.538 0.481 0 N-CA-C 114.508 1.299 . . . . 0.0 114.508 -174.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -56.39 -31.46 85.38 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.32 1.347 . . . . 0.0 113.606 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.6 mp0 -68.28 -27.61 66.46 Favored 'General case' 0 N--CA 1.457 -0.115 0 O-C-N 121.177 -0.952 . . . . 0.0 111.249 176.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -61.31 -50.54 80.01 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -55.45 -47.11 76.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.889 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.68 -59.9 3.91 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 122.438 0.295 . . . . 0.0 110.978 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.5 mtm -54.59 -47.9 72.8 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.209 0.604 . . . . 0.0 111.153 -176.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.9 mt -50.51 -33.51 21.74 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 113.269 0.841 . . . . 0.0 113.269 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -73.09 -31.59 64.46 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.556 -0.715 . . . . 0.0 110.534 178.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt -81.51 60.96 4.74 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 121.767 -0.583 . . . . 0.0 110.19 -176.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -125.42 102.12 7.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.116 0.566 . . . . 0.0 110.632 174.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.3 p -73.86 45.97 0.21 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.946 1.698 . . . . 0.0 111.197 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.24 112.6 2.42 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 125.508 1.528 . . . . 0.0 111.152 -174.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -79.12 -178.78 6.33 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.3 t -113.7 152.18 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 123.969 0.907 . . . . 0.0 108.89 177.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.7 m -149.1 73.41 1.21 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.373 1.069 . . . . 0.0 108.358 174.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.17 -144.36 39.27 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -172.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -79.46 59.1 2.83 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.653 1.226 . . . . 0.0 109.413 175.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -161.0 146.4 14.28 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.79 1.636 . . . . 0.0 106.708 -179.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 23.3 t -102.64 147.86 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 174.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 55.4 m -134.3 110.63 9.62 Favored 'General case' 0 CA--C 1.521 -0.172 0 C-N-CA 123.426 0.69 . . . . 0.0 109.954 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -82.8 169.01 16.6 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.564 0.697 . . . . 0.0 111.4 178.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -155.04 159.08 40.03 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 124.503 1.121 . . . . 0.0 107.988 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.39 -179.54 32.77 Favored Glycine 0 CA--C 1.53 1.019 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -176.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -85.63 -27.48 25.39 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.771 0.428 . . . . 0.0 111.211 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.6 m -79.18 69.2 5.34 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.107 0.963 . . . . 0.0 110.335 -176.083 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.44 78.55 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.975 0.893 . . . . 0.0 108.935 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 t-80 -83.4 105.61 14.49 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.9 t -107.36 95.75 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -174.07 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.6 t -83.66 123.32 38.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -174.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -132.52 114.61 14.48 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.461 1.104 . . . . 0.0 111.373 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.22 143.21 26.48 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.575 0.75 . . . . 0.0 109.819 174.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.25 96.54 5.59 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.012 0.525 . . . . 0.0 110.698 176.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.8 t 49.19 72.14 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.329 0 C-N-CA 128.407 2.683 . . . . 0.0 111.823 175.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.62 142.76 66.67 Favored Pre-proline 0 CA--C 1.533 0.32 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 176.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -41.53 106.2 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.362 3.375 . . . . 0.0 112.819 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 133.04 -48.46 0.96 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -174.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -75.94 141.02 70.93 Favored Pre-proline 0 CA--C 1.53 0.191 0 CA-C-N 117.182 0.491 . . . . 0.0 109.789 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -75.16 155.86 42.23 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 122.352 2.034 . . . . 0.0 111.191 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -75.14 153.6 86.39 Favored Pre-proline 0 N--CA 1.452 -0.336 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 172.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -92.13 -9.13 34.55 Favored 'Cis proline' 0 CA--C 1.538 0.687 0 CA-C-N 118.82 0.614 . . . . 0.0 111.423 -5.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -36.95 121.51 0.78 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -168.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -77.33 121.67 24.05 Favored 'General case' 0 C--N 1.346 0.447 0 C-N-CA 126.126 1.77 . . . . 0.0 107.161 171.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -94.53 112.07 23.83 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.182 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.47 81.71 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.226 0 C-N-CA 124.357 1.063 . . . . 0.0 109.344 -172.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.9 p-80 44.66 -84.74 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 127.367 2.267 . . . . 0.0 114.629 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -75.89 -29.46 58.47 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.336 0.654 . . . . 0.0 110.991 -175.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -136.72 -173.6 3.48 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.453 0.701 . . . . 0.0 109.777 -175.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -126.03 127.0 45.19 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 174.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.9 m-80 50.67 44.08 2.0 Allowed Pre-proline 0 CA--C 1.537 0.459 0 C-N-CA 124.915 1.286 . . . . 0.0 112.575 178.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -83.29 176.07 7.69 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.676 1.584 . . . . 0.0 110.863 -175.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 17.5 m -95.42 144.02 26.28 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 170.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.23 143.97 45.3 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.539 0.736 . . . . 0.0 110.806 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -110.18 125.33 52.94 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 170.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.6 mt -130.15 138.09 32.31 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 123.464 0.706 . . . . 0.0 111.893 -171.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.65 117.93 4.69 Favored 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 122.884 2.39 . . . . 0.0 109.233 172.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.73 141.41 10.01 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 125.053 1.341 . . . . 0.0 111.724 177.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.64 -2.07 55.38 Favored Glycine 0 CA--C 1.531 1.091 0 CA-C-O 118.936 -0.924 . . . . 0.0 113.719 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.76 158.77 31.63 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.708 1.754 . . . . 0.0 110.352 173.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 29.6 m -83.18 93.32 7.63 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 174.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 51.8 t -79.38 99.08 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -91.63 90.72 7.7 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.9 t -77.18 105.56 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 104.246 -2.501 . . . . 0.0 104.246 176.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 55.4 m -100.63 98.99 9.49 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 125.585 1.554 . . . . 0.0 109.797 -171.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.48 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.5 m-85 -77.38 158.77 29.92 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.38 68.26 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 101.652 -3.462 . . . . 0.0 101.652 164.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -87.24 67.06 9.48 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 -174.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.2 m -112.61 83.0 1.74 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 114.669 -1.15 . . . . 0.0 110.616 -175.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -120.14 119.91 34.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 172.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.33 72.82 1.31 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.109 0.564 . . . . 0.0 109.519 -175.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 162.82 -65.64 0.25 Allowed Glycine 0 CA--C 1.522 0.499 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -94.03 112.83 24.7 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.449 -0.442 . . . . 0.0 111.183 -174.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.68 38.99 0.91 Allowed Glycine 0 CA--C 1.537 1.418 0 CA-C-O 118.928 -0.929 . . . . 0.0 111.865 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 0.95 -78.42 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 129.86 3.264 . . . . 0.0 117.513 -172.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.5 p 99.13 155.08 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 129.967 3.307 . . . . 0.0 110.196 -173.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 6.7 t80 -134.01 110.42 9.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 173.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -122.94 140.94 52.46 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.5 mt -115.64 126.7 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.665 1.586 . . . . 0.0 110.257 -172.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -161.05 164.74 30.63 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -83.86 56.41 3.66 Favored 'General case' 0 CA--C 1.535 0.394 0 O-C-N 121.608 -0.682 . . . . 0.0 110.621 -174.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -105.56 107.91 19.15 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 175.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.05 160.12 52.62 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 175.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.67 162.11 43.31 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.986 2.458 . . . . 0.0 109.81 174.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 158.63 93.88 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 CA-C-N 119.006 0.681 . . . . 0.0 110.595 -3.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -96.32 153.56 17.75 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.1 151.1 35.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 175.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 60.3 t -60.38 -38.51 77.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 174.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -78.53 133.48 63.21 Favored Pre-proline 0 N--CA 1.451 -0.409 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 174.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -74.75 80.53 2.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.409 2.073 . . . . 0.0 109.739 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 70.2 t -77.0 84.24 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 178.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.3 pt -77.58 83.04 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-O 123.065 1.412 . . . . 0.0 111.625 -173.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -62.12 154.54 69.31 Favored Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 171.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -37.18 112.59 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 124.248 3.299 . . . . 0.0 114.375 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 32.1 mm -79.48 139.44 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 59.6 t -86.0 -88.32 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 174.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.29 146.5 23.98 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.49 -178.9 42.96 Favored Glycine 0 C--N 1.333 0.368 0 CA-C-N 120.153 1.342 . . . . 0.0 112.219 173.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.2 p -122.95 -37.96 2.67 Favored 'General case' 0 C--N 1.338 0.083 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -176.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 78.34 -175.45 54.71 Favored Glycine 0 CA--C 1.541 1.701 0 N-CA-C 107.658 -2.177 . . . . 0.0 107.658 -170.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.19 141.71 39.96 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.911 1.855 . . . . 0.0 114.513 -171.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.0 p -83.82 155.12 64.97 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -174.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -73.67 75.0 3.17 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.458 2.772 . . . . 0.0 110.688 175.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 66.9 t -20.34 96.16 0.05 OUTLIER Pre-proline 0 CA--C 1.542 0.665 0 C-N-CA 128.195 2.598 . . . . 0.0 112.846 175.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -66.47 171.71 10.2 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.723 2.948 . . . . 0.0 112.582 -178.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -124.76 151.94 44.48 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.653 1.181 . . . . 0.0 109.25 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 39.23 -103.4 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 127.219 2.208 . . . . 0.0 113.62 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -92.25 -2.11 68.74 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.496 -1.169 . . . . 0.0 114.476 -173.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -86.44 153.35 21.95 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.687 1.243 . . . . 0.0 110.442 -176.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -138.32 111.37 7.85 Favored 'General case' 0 C--O 1.224 -0.242 0 C-N-CA 124.987 1.315 . . . . 0.0 111.457 -172.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -78.92 113.15 3.6 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 125.459 1.504 . . . . 0.0 110.589 -174.019 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -121.59 164.46 17.24 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.798 0.839 . . . . 0.0 111.796 -176.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.2 m -165.94 115.61 0.99 Allowed 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 124.523 1.129 . . . . 0.0 108.103 178.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -84.99 67.25 10.14 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -66.79 122.45 17.7 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.1 m -97.98 130.12 44.84 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.704 -1.135 . . . . 0.0 110.379 -171.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -140.0 145.3 37.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.791 1.236 . . . . 0.0 109.669 -178.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -114.77 94.25 36.71 Favored Pre-proline 0 N--CA 1.454 -0.25 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -80.16 150.43 20.24 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 122.573 2.182 . . . . 0.0 111.287 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.3 p -101.31 155.21 18.17 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -53.58 141.56 25.33 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -173.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 136.61 176.49 14.39 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 126.198 1.856 . . . . 0.0 111.189 175.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.6 m -98.42 109.98 22.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.143 0.977 . . . . 0.0 110.317 -174.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -101.28 173.56 6.39 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 172.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -134.63 143.18 47.14 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -104.52 141.64 36.03 Favored 'General case' 0 CA--C 1.522 -0.126 0 CA-C-O 118.569 -0.729 . . . . 0.0 109.682 174.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 5.0 m -147.74 156.57 9.58 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 123.928 0.891 . . . . 0.0 111.77 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 11.2 t -94.9 131.58 40.66 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 126.595 1.958 . . . . 0.0 109.365 173.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -82.79 -1.39 51.54 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -172.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.33 136.42 93.52 Favored Pre-proline 0 CA--C 1.537 0.444 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 173.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.6 144.74 10.15 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.451 2.101 . . . . 0.0 112.554 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.07 -44.99 2.2 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.628 0.632 . . . . 0.0 112.995 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -48.41 -52.73 20.6 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 118.761 1.281 . . . . 0.0 113.989 -173.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.87 -52.11 66.41 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 120.877 0.37 . . . . 0.0 110.145 176.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.28 -39.74 91.56 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.684 1.194 . . . . 0.0 111.686 -175.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.2 p -79.01 -36.49 41.09 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 118.473 -0.775 . . . . 0.0 111.31 -174.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.33 -22.74 0.07 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 117.123 -2.465 . . . . 0.0 118.188 174.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.331 17.8 ptm -80.72 92.8 6.08 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 121.134 2.467 . . . . 0.0 112.93 -173.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.65 -175.1 4.78 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.188 0.995 . . . . 0.0 109.332 179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 176.23 170.6 39.1 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 173.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 38.0 mttt -107.08 146.56 31.06 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 124.447 1.099 . . . . 0.0 109.785 -173.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.5 mt -121.21 99.12 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 125.371 1.469 . . . . 0.0 107.062 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.5 t -90.82 100.66 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 24.1 t -89.62 127.49 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 178.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm . . . . . 0 N--CA 1.462 0.167 0 CA-C-N 119.136 0.88 . . . . 0.0 111.132 -178.151 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.851 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.7 p -69.63 -63.74 1.01 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.437 1.095 . . . . 0.0 109.221 177.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 mp 58.17 179.84 0.06 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 125.378 1.471 . . . . 0.0 111.974 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -70.51 126.92 30.99 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.3 p -121.08 39.08 3.9 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 123.659 0.784 . . . . 0.0 109.358 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 m -79.88 60.1 3.37 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.2 m95 -99.66 131.84 45.39 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 126.029 1.732 . . . . 0.0 111.275 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -144.63 -170.89 3.49 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 172.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -136.21 130.12 32.66 Favored 'General case' 0 C--N 1.341 0.202 0 CA-C-N 119.216 0.916 . . . . 0.0 110.098 172.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -89.66 -156.62 0.42 Allowed 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 170.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.4 p -139.33 166.71 23.84 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 174.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -39.42 -54.97 3.49 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 115.594 1.702 . . . . 0.0 115.594 -172.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.75 -33.44 98.4 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 CA-C-N 120.92 1.364 . . . . 0.0 111.759 -177.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.94 -32.02 73.53 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 122.769 0.428 . . . . 0.0 110.454 -178.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -56.69 -51.04 71.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.231 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -58.22 -49.36 77.35 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.564 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -48.61 -57.15 6.65 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.738 0.415 . . . . 0.0 111.116 178.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -63.1 -45.13 93.52 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 118.432 -0.794 . . . . 0.0 111.605 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.4 mt -48.76 -47.77 41.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 119.414 1.007 . . . . 0.0 111.386 179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -55.35 -21.55 15.65 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 178.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -96.45 7.24 46.99 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 119.156 0.889 . . . . 0.0 112.414 -177.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.6 115.06 10.34 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 119.989 1.268 . . . . 0.0 110.226 -179.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 p -83.99 15.13 3.56 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.61 1.164 . . . . 0.0 113.875 -174.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.75 115.15 4.38 Favored Glycine 0 CA--C 1.527 0.819 0 O-C-N 121.214 -0.929 . . . . 0.0 111.446 -174.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -78.89 121.11 24.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.17 1.388 . . . . 0.0 108.995 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.97 122.5 6.27 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 C-N-CA 124.137 0.975 . . . . 0.0 109.592 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -132.12 68.93 1.48 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.689 1.596 . . . . 0.0 108.235 -174.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.84 -117.57 8.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 -174.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -78.89 -33.49 45.63 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.848 0.824 . . . . 0.0 109.559 173.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 27.8 m -78.88 155.96 28.85 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 123.739 0.816 . . . . 0.0 109.215 -173.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.7 t -118.67 132.62 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 173.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -121.14 126.88 50.84 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 123.204 0.602 . . . . 0.0 109.969 -173.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -97.84 175.9 5.99 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 122.826 0.45 . . . . 0.0 110.153 177.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 60.0 m -156.5 168.21 28.06 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.505 0.722 . . . . 0.0 109.811 -175.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 45.26 43.53 9.71 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 125.354 1.454 . . . . 0.0 113.018 174.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.1 mttp 50.55 12.02 0.09 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.093 1.757 . . . . 0.0 115.492 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.8 m -103.62 74.78 1.27 Allowed 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -173.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.1 t -89.56 96.79 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.3 t-160 -105.21 102.62 12.1 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 173.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.3 t -99.17 103.28 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.0 t -88.06 90.48 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 175.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.34 159.61 14.85 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.014 1.326 . . . . 0.0 109.841 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.9 166.44 33.53 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 0.0 108.841 177.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -147.69 115.15 6.3 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 122.251 0.22 . . . . 0.0 111.151 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t 54.27 53.35 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 125.868 1.667 . . . . 0.0 111.912 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 30.9 mt -78.36 151.78 78.19 Favored Pre-proline 0 CA--C 1.532 0.286 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 173.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_exo -47.01 103.88 0.06 OUTLIER 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 123.581 2.854 . . . . 0.0 112.91 -176.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 129.92 -48.8 0.95 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -174.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -79.16 127.56 78.85 Favored Pre-proline 0 CA--C 1.532 0.263 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.359 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.94 163.85 15.67 Favored 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.311 2.008 . . . . 0.0 112.029 -175.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -63.67 146.16 96.95 Favored Pre-proline 0 N--CA 1.451 -0.397 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -110.44 54.58 0.93 Allowed 'Cis proline' 0 N--CA 1.455 -0.782 0 N-CA-C 106.685 -2.083 . . . . 0.0 106.685 -6.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 85.8 p -79.49 121.59 25.4 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -170.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -78.57 115.89 18.58 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 103.284 -2.858 . . . . 0.0 103.284 167.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -100.25 138.52 37.19 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.3 t -135.25 100.35 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 118.354 0.524 . . . . 0.0 110.066 -174.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 1.5 p80 35.44 -69.62 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 130.227 3.411 . . . . 0.0 116.378 -173.429 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -101.84 -25.86 13.66 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 125.004 1.322 . . . . 0.0 112.218 -175.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -125.56 -169.85 2.07 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.81 1.244 . . . . 0.0 109.957 -173.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? -136.9 133.82 36.16 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 171.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 48.22 41.76 1.03 Allowed Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 124.235 1.014 . . . . 0.0 112.592 -174.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.59 169.03 22.0 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 CA-C-N 120.742 1.301 . . . . 0.0 112.872 -172.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.0 m -89.58 127.76 35.93 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 112.342 -2.208 . . . . 0.0 106.127 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -106.32 128.13 53.77 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.159 0.891 . . . . 0.0 110.101 -177.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 -104.68 117.91 35.26 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 171.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.6 mt -124.22 138.44 30.84 Favored Pre-proline 0 CA--C 1.538 0.496 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -67.95 125.32 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.727 2.284 . . . . 0.0 109.153 168.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.32 133.36 19.7 Favored 'General case' 0 C--N 1.332 -0.191 0 O-C-N 121.382 -0.824 . . . . 0.0 111.217 174.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.55 12.36 80.34 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.144 -0.809 . . . . 0.0 113.13 -176.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.41 148.7 47.79 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 119.375 1.588 . . . . 0.0 110.169 173.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 38.8 m -83.47 90.75 7.25 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 174.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 85.0 t -77.68 98.67 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 124.746 1.219 . . . . 0.0 108.068 -174.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -96.96 104.38 16.39 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 177.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.3 t -89.44 91.34 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 54.0 m -79.52 87.87 5.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.512 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.275 4.1 m-85 -79.73 138.6 37.35 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 117.876 -1.059 . . . . 0.0 109.934 172.584 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.8 mp -117.44 67.89 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 101.088 -3.671 . . . . 0.0 101.088 163.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -84.41 56.3 3.74 Favored 'General case' 0 C--O 1.231 0.109 0 O-C-N 121.117 -0.989 . . . . 0.0 108.626 -173.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 53.4 m -85.75 69.99 10.65 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.884 -176.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -97.43 156.82 16.3 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 171.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -93.17 124.14 36.94 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 75.42 -68.64 2.09 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.63 0.633 . . . . 0.0 112.392 175.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -79.08 81.07 5.38 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.873 -0.781 . . . . 0.0 110.001 -174.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -52.85 80.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 126.425 1.964 . . . . 0.0 112.52 174.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -57.47 162.52 2.85 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 119.232 1.516 . . . . 0.0 111.468 179.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.3 p -121.85 160.91 23.72 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.584 1.554 . . . . 0.0 107.388 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . 0.512 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -128.26 110.18 12.16 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 172.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -126.64 128.93 47.53 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.861 0.864 . . . . 0.0 108.716 -172.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 20.5 mt -106.21 134.32 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 C-N-CA 125.964 1.706 . . . . 0.0 110.054 -173.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.6 t -158.04 -152.08 0.33 Allowed 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 176.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -126.58 9.32 7.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.689 1.131 . . . . 0.0 113.286 -176.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -64.67 121.44 14.5 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.35 166.45 49.62 Favored Glycine 0 CA--C 1.532 1.117 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 161.89 44.15 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 122.856 2.37 . . . . 0.0 109.602 173.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -76.92 149.61 90.8 Favored 'Cis proline' 0 N--CA 1.454 -0.825 0 N-CA-C 110.27 -0.704 . . . . 0.0 110.27 -4.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -89.27 152.94 21.28 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 149.7 29.34 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.86 -42.09 87.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 174.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -78.89 130.35 70.49 Favored Pre-proline 0 N--CA 1.451 -0.391 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 174.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -75.02 85.07 1.57 Allowed 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 122.374 2.05 . . . . 0.0 109.829 -175.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.4 t -76.77 85.55 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.348 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 175.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 pt -75.43 87.43 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 CA-C-O 123.646 1.689 . . . . 0.0 110.653 -172.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -62.83 154.17 76.7 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 112.842 -1.981 . . . . 0.0 106.928 172.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -39.49 108.71 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 124.059 3.173 . . . . 0.0 113.794 -175.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.0 mm -78.46 126.84 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.37 -82.14 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 105.785 -1.932 . . . . 0.0 105.785 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.6 150.17 20.64 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.93 158.66 21.79 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 119.288 -1.434 . . . . 0.0 112.135 174.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.3 p -107.75 145.43 33.52 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.516 1.126 . . . . 0.0 110.544 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.63 158.38 37.19 Favored Glycine 0 CA--C 1.535 1.3 0 N-CA-C 107.342 -2.303 . . . . 0.0 107.342 172.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -41.88 133.07 2.95 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.558 1.543 . . . . 0.0 113.884 -173.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.5 p -68.53 158.5 84.99 Favored Pre-proline 0 CA--C 1.535 0.373 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -177.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.3 -177.96 2.66 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.075 1.85 . . . . 0.0 108.804 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 90.0 t -117.66 98.91 52.14 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 125.654 1.582 . . . . 0.0 108.83 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -62.45 173.59 3.36 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.737 3.625 . . . . 0.0 113.426 174.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -145.57 162.09 38.26 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.54 1.136 . . . . 0.0 109.355 176.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.58 -117.55 0.76 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.883 1.673 . . . . 0.0 110.967 177.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.63 17.43 42.72 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-O 118.899 -0.945 . . . . 0.0 112.445 -177.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -85.72 151.01 24.19 Favored 'General case' 0 C--N 1.341 0.234 0 CA-C-N 118.059 0.93 . . . . 0.0 108.876 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -133.98 93.63 3.13 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 124.373 1.069 . . . . 0.0 111.239 -172.37 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -49.03 118.15 4.82 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 125.926 1.726 . . . . 0.0 109.959 173.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.18 159.6 41.76 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 123.919 0.888 . . . . 0.0 112.223 -177.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -143.57 148.46 35.95 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 126.537 1.935 . . . . 0.0 107.114 178.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -134.1 65.16 1.58 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 178.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -76.93 150.65 35.94 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 31.4 m -118.18 142.77 47.1 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.872 0.869 . . . . 0.0 109.773 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -145.47 161.28 40.08 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.625 1.17 . . . . 0.0 109.98 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 69.6 m80 -129.81 92.25 37.8 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 125.885 1.674 . . . . 0.0 109.001 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -71.64 145.26 46.32 Favored 'Trans proline' 0 N--CA 1.454 -0.852 0 C-N-CA 123.093 2.528 . . . . 0.0 112.178 -175.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.8 p -93.56 155.25 17.42 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.834 1.254 . . . . 0.0 108.87 172.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.86 146.03 43.49 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.808 -0.558 . . . . 0.0 112.493 -174.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 128.41 -125.38 5.02 Favored Glycine 0 C--N 1.334 0.45 0 C-N-CA 126.79 2.138 . . . . 0.0 108.826 -178.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 35.6 m -153.5 144.59 22.91 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 118.226 1.013 . . . . 0.0 109.881 -175.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -134.74 175.27 9.7 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.506 1.922 . . . . 0.0 106.962 173.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -141.7 149.96 41.23 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.164 1.386 . . . . 0.0 108.199 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . 0.432 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 48.1 p90 -112.89 144.22 42.82 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.956 0.903 . . . . 0.0 109.893 175.765 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.1 m -148.71 162.64 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 C-N-CA 125.081 1.352 . . . . 0.0 110.68 178.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.29 136.94 41.23 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.643 1.577 . . . . 0.0 107.663 171.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -81.32 -16.5 52.23 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.317 1.228 . . . . 0.0 114.317 -172.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 53.7 mt -63.81 129.52 93.86 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_exo -46.79 150.09 2.76 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 123.947 3.098 . . . . 0.0 114.575 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.42 -43.01 2.01 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 124.092 0.853 . . . . 0.0 112.89 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -50.76 -53.68 29.68 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.671 1.188 . . . . 0.0 111.98 -173.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -54.8 -46.71 74.53 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.77 0.428 . . . . 0.0 111.16 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.73 -41.71 91.91 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 123.156 0.583 . . . . 0.0 111.201 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.1 p -79.67 -58.94 2.94 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.031 0.532 . . . . 0.0 112.124 -173.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.81 38.33 0.09 OUTLIER Glycine 0 CA--C 1.525 0.665 0 C-N-CA 119.65 -1.262 . . . . 0.0 114.685 -174.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.1 ttt -126.19 64.75 1.23 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -151.52 -174.47 4.84 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.806 0.843 . . . . 0.0 111.241 -177.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.432 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.83 174.39 38.06 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 174.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.4 146.67 45.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.417 1.487 . . . . 0.0 109.805 -170.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.2 mt -128.33 95.81 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 125.461 1.504 . . . . 0.0 107.651 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 t -88.03 132.22 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.7 t -122.19 120.99 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -176.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm . . . . . 0 N--CA 1.467 0.393 0 CA-C-N 119.671 1.123 . . . . 0.0 110.827 176.711 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.773 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.8 p -74.5 -46.35 40.0 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 124.754 1.222 . . . . 0.0 110.049 175.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.3 mm? 39.24 -103.37 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 127.013 2.125 . . . . 0.0 115.038 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -75.2 96.78 3.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 118.349 0.522 . . . . 0.0 110.605 -172.568 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.9 p -52.36 -16.97 0.98 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.653 1.181 . . . . 0.0 113.366 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -78.25 53.96 1.31 Allowed 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.725 1.148 . . . . 0.0 112.171 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -92.68 142.96 26.79 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 127.697 2.399 . . . . 0.0 108.405 175.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -152.29 177.08 10.94 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -140.05 140.72 36.21 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 169.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.61 -150.9 0.47 Allowed 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 174.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 19.0 p -136.03 173.43 11.72 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 172.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -39.56 -56.96 2.66 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 114.282 1.216 . . . . 0.0 114.282 -174.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -55.04 -35.31 89.97 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.572 1.515 . . . . 0.0 113.481 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.7 mp0 -65.55 -23.95 66.98 Favored 'General case' 0 N--CA 1.455 -0.184 0 O-C-N 121.339 -0.85 . . . . 0.0 111.379 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -55.72 -46.88 79.77 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 119.27 0.941 . . . . 0.0 108.972 173.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtmt -60.32 -51.25 70.31 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.56 -46.99 67.08 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.692 0.256 . . . . 0.0 111.692 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -62.65 -54.93 32.08 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.721 0.408 . . . . 0.0 110.274 177.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 62.1 mt -49.23 -46.88 46.56 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 122.883 0.473 . . . . 0.0 111.339 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -53.04 -27.0 17.66 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -90.5 -0.91 57.85 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.17 0.896 . . . . 0.0 112.503 -179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -57.02 154.52 9.56 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.897 0.771 . . . . 0.0 112.671 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.7 p -128.0 165.59 19.99 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 172.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 122.33 117.67 2.44 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -178.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.4 mtpt -79.08 121.51 25.07 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.31 1.444 . . . . 0.0 108.934 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.6 t -61.69 114.25 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 125.591 1.556 . . . . 0.0 109.485 -176.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.1 m -130.57 68.03 1.48 Allowed 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 124.159 0.983 . . . . 0.0 111.435 -174.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.18 -94.67 0.47 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 123.778 0.704 . . . . 0.0 112.476 174.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -101.07 -14.54 17.76 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.516 1.127 . . . . 0.0 110.127 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 29.4 m -108.39 151.79 25.55 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.811 1.244 . . . . 0.0 109.985 -172.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.44 130.71 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 170.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.7 m -115.39 119.66 37.0 Favored 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 123.187 0.595 . . . . 0.0 110.404 -170.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -91.8 153.09 19.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.9 m -155.79 51.49 0.56 Allowed 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.884 -0.51 . . . . 0.0 110.157 -175.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.89 166.27 39.46 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 108.276 -1.93 . . . . 0.0 108.276 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -73.61 -38.16 65.18 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 117.503 0.651 . . . . 0.0 110.584 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.7 p -80.09 103.46 9.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 174.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 29.5 t -107.69 128.37 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -132.15 101.36 5.36 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 123.941 0.897 . . . . 0.0 110.019 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.2 t -92.01 143.02 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.1 t -123.06 114.0 40.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 173.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -120.93 112.17 18.43 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 124.645 1.178 . . . . 0.0 111.976 -172.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.86 149.87 22.46 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 172.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.98 109.24 12.72 Favored 'General case' 0 C--O 1.226 -0.162 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 14.0 t 44.34 85.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.258 1.423 . . . . 0.0 112.189 -176.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 51.9 mt -76.67 128.95 80.7 Favored Pre-proline 0 CA--C 1.534 0.336 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo -42.07 111.24 0.18 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 124.071 3.181 . . . . 0.0 111.541 175.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 134.69 -45.91 1.08 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 -173.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -80.03 116.4 61.04 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -79.45 59.96 7.62 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.759 2.306 . . . . 0.0 111.247 -174.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 63.07 170.3 0.09 OUTLIER Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 124.906 1.282 . . . . 0.0 111.861 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -117.61 34.46 0.58 Allowed 'Cis proline' 0 CA--C 1.536 0.611 0 N-CA-C 109.297 -1.078 . . . . 0.0 109.297 -6.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.1 p -90.64 143.13 27.04 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 118.519 2.785 . . . . 0.0 118.519 -168.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . 0.44 ' CD2' ' HB2' ' A' ' 148' ' ' MET . 3.2 m-85 -85.69 103.46 14.51 Favored 'General case' 0 C--N 1.34 0.176 0 N-CA-C 103.276 -2.861 . . . . 0.0 103.276 166.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -93.51 96.07 9.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -174.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.8 t -85.2 149.5 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -176.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -20.96 -57.31 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 116.732 2.123 . . . . 0.0 116.732 -172.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -114.31 -5.71 12.95 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 39.8 mttm -150.34 148.54 28.94 Favored 'General case' 0 C--O 1.223 -0.323 0 CA-C-N 119.845 1.202 . . . . 0.0 109.731 -174.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.5 mttm -97.07 123.79 40.91 Favored 'General case' 0 C--N 1.332 -0.181 0 O-C-N 121.351 -0.843 . . . . 0.0 109.595 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.59 46.29 1.88 Allowed Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.505 1.522 . . . . 0.0 111.435 176.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -83.92 174.29 8.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 122.31 2.007 . . . . 0.0 113.031 -171.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 52.9 m -86.54 148.66 25.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 170.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.5 mp -119.55 133.0 55.86 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 120.892 -1.13 . . . . 0.0 109.421 175.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -109.82 116.27 31.35 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.539 -2.022 . . . . 0.0 105.539 171.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 mt -124.56 145.77 50.32 Favored Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 124.29 1.036 . . . . 0.0 112.456 -171.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -85.37 128.48 3.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.678 2.252 . . . . 0.0 107.909 171.172 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.26 151.99 2.63 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.859 1.264 . . . . 0.0 112.034 178.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.7 -31.8 2.19 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-O 119.203 -0.776 . . . . 0.0 113.701 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -46.84 148.6 1.02 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.567 1.147 . . . . 0.0 112.811 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 17.2 m -79.68 96.06 6.11 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.4 t -79.53 89.51 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 177.098 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -82.68 133.49 35.16 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 173.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.3 t -132.78 110.83 16.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 98.4 m -91.39 125.94 36.3 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 174.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -94.27 158.64 15.49 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 174.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.6 mp -137.41 67.57 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 102.577 -3.12 . . . . 0.0 102.577 163.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 20.8 t30 -98.09 76.67 2.39 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 -175.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.0 p -94.79 -80.14 0.41 Allowed 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.501 1.12 . . . . 0.0 109.923 -173.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 68.35 -50.71 0.55 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.253 2.221 . . . . 0.0 114.649 177.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 87.4 mttt 96.42 33.14 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 130.079 3.352 . . . . 0.0 111.877 -179.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 171.22 -60.03 0.17 Allowed Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -83.12 91.35 7.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.97 83.39 0.02 OUTLIER Glycine 0 CA--C 1.528 0.9 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 173.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -68.87 74.66 0.29 Allowed 'General case' 0 N--CA 1.457 -0.111 0 C-N-CA 125.177 1.391 . . . . 0.0 112.878 -174.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.8 p -42.29 136.38 2.31 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 125.253 1.421 . . . . 0.0 111.281 177.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -107.68 119.95 40.86 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 173.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -129.62 108.79 10.49 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -172.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 32.3 mt -80.72 134.79 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 124.144 0.903 . . . . 0.0 108.824 176.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -160.33 -160.45 0.78 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.433 1.493 . . . . 0.0 107.42 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -126.43 13.31 7.61 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.692 0.797 . . . . 0.0 111.517 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -64.7 121.34 14.28 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 174.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -86.66 170.72 42.49 Favored Glycine 0 CA--C 1.532 1.114 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.85 164.16 36.59 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.208 2.605 . . . . 0.0 109.674 173.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.42 139.12 58.36 Favored 'Cis proline' 0 N--CA 1.455 -0.75 0 N-CA-C 110.163 -0.745 . . . . 0.0 110.163 -4.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -79.68 151.27 30.58 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.179 0.514 . . . . 0.0 110.011 178.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -98.96 149.71 22.69 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 124.135 0.974 . . . . 0.0 110.27 -174.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 18.2 t -62.52 -34.62 65.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 C-N-CA 123.706 0.803 . . . . 0.0 109.218 173.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.6 mmt -78.24 133.97 63.66 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -63.8 63.79 0.21 Allowed 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.889 3.059 . . . . 0.0 115.232 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 13.9 t -80.84 57.5 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 O-C-N 120.254 -1.529 . . . . 0.0 108.325 174.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -38.07 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 C-N-CA 123.529 0.732 . . . . 0.0 111.721 -174.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.04 143.45 32.08 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 125.017 1.327 . . . . 0.0 112.278 -172.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.18 162.45 92.7 Favored 'Cis proline' 0 N--CA 1.46 -0.444 0 N-CA-C 110.281 -0.7 . . . . 0.0 110.281 -6.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 14.5 mm -118.18 144.46 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 174.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.56 -86.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 174.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.41 87.64 6.09 Favored 'General case' 0 CA--C 1.52 -0.207 0 O-C-N 122.024 -0.423 . . . . 0.0 109.977 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -90.4 125.61 7.99 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 107.581 -2.208 . . . . 0.0 107.581 172.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.7 p -76.01 -41.48 50.97 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.261 1.531 . . . . 0.0 110.039 173.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.2 -170.09 21.25 Favored Glycine 0 CA--C 1.532 1.145 0 N-CA-C 108.673 -1.771 . . . . 0.0 108.673 -174.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -91.17 138.26 31.73 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.332 1.566 . . . . 0.0 109.215 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.0 p -83.21 159.31 62.48 Favored Pre-proline 0 CA--C 1.533 0.317 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -173.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.87 74.61 3.88 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.076 2.518 . . . . 0.0 107.987 172.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.8 m -53.67 128.9 54.1 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 123.278 0.631 . . . . 0.0 111.331 -175.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.98 176.36 9.92 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.286 2.657 . . . . 0.0 110.078 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.32 -29.38 6.24 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 176.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -174.02 155.85 2.6 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.715 2.006 . . . . 0.0 108.174 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.34 -59.05 1.15 Allowed Glycine 0 CA--C 1.527 0.789 0 C-N-CA 125.466 1.508 . . . . 0.0 113.06 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -78.92 158.77 27.98 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 123.417 0.687 . . . . 0.0 111.344 -174.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -135.23 94.42 3.12 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.804 2.041 . . . . 0.0 108.388 -174.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -53.27 113.29 2.84 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 173.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.1 p90 -119.32 177.03 5.05 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.537 1.135 . . . . 0.0 109.689 175.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.5 m -158.05 154.17 27.16 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 -177.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -131.82 89.54 2.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 173.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -96.9 170.08 9.41 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.8 m -150.79 146.56 26.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -150.56 153.53 35.94 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.884 0.874 . . . . 0.0 110.423 -176.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -116.47 114.44 40.33 Favored Pre-proline 0 CA--C 1.535 0.384 0 C-N-CA 125.584 1.554 . . . . 0.0 107.116 173.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.79 142.26 3.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 124.371 3.381 . . . . 0.0 111.503 -172.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.2 p -96.02 146.42 24.64 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 124.363 1.065 . . . . 0.0 108.845 173.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.83 149.08 19.08 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.164 0.438 . . . . 0.0 112.092 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 121.74 -123.96 5.63 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 126.754 2.121 . . . . 0.0 109.123 -175.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 46.1 m -153.84 145.7 23.49 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.351 1.075 . . . . 0.0 109.972 -174.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -132.95 176.45 8.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.336 2.254 . . . . 0.0 106.897 173.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -142.31 152.81 43.33 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 125.534 1.533 . . . . 0.0 107.551 175.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 55.1 p90 -114.83 140.59 48.82 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 123.223 0.609 . . . . 0.0 109.905 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.36 162.9 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.375 1.07 . . . . 0.0 111.093 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 8.8 t -107.69 136.09 48.02 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 127.121 2.169 . . . . 0.0 109.838 173.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -81.64 -19.0 42.65 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 -170.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.01 130.04 93.82 Favored Pre-proline 0 CA--C 1.544 0.721 0 CA-C-N 119.125 0.875 . . . . 0.0 108.989 -174.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -42.15 133.45 4.52 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.745 2.964 . . . . 0.0 113.424 178.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 90.07 -32.51 4.87 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.099 0.857 . . . . 0.0 111.795 -174.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -75.49 172.84 11.83 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -176.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 75.29 -60.6 0.5 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -170.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.2 -52.27 66.01 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.7 p -78.51 75.47 5.03 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 121.829 0.823 . . . . 0.0 112.272 -178.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 70.87 -44.71 0.67 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 118.189 2.035 . . . . 0.0 118.189 169.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' MET . . . . . 0.44 ' HB2' ' CD2' ' A' ' 54' ' ' PHE . 4.2 ptp -77.85 87.74 4.07 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 119.857 1.828 . . . . 0.0 114.271 -172.035 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -160.81 -179.91 7.97 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 126.053 1.741 . . . . 0.0 108.839 173.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 178.86 168.39 37.96 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 172.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -104.21 138.51 40.57 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 125.049 1.339 . . . . 0.0 108.356 -174.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.1 mt -114.76 100.44 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 19.6 t -84.16 136.37 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -123.02 115.65 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp . . . . . 0 N--CA 1.462 0.13 0 CA-C-N 119.091 0.86 . . . . 0.0 109.558 174.64 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.829 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.1 p -76.61 86.09 3.28 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 175.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.3 mp -57.31 147.67 25.02 Favored 'General case' 0 C--O 1.23 0.056 0 CA-C-O 122.035 0.922 . . . . 0.0 108.907 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.42 143.34 42.76 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.667 -173.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -121.12 12.11 11.03 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.67 1.988 . . . . 0.0 111.337 -174.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.2 m -79.16 66.57 4.64 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.568 1.147 . . . . 0.0 112.253 -171.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -96.34 146.83 24.4 Favored 'General case' 0 CA--C 1.522 -0.099 0 N-CA-C 114.875 1.435 . . . . 0.0 114.875 177.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -149.13 170.15 19.07 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 129.064 2.946 . . . . 0.0 103.706 171.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -124.8 126.55 45.79 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-N 119.645 1.111 . . . . 0.0 110.063 174.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -88.09 -150.22 0.18 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 172.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.9 p -142.39 166.07 25.7 Favored 'General case' 0 CA--C 1.532 0.274 0 O-C-N 121.389 -0.819 . . . . 0.0 109.277 174.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.45 -58.11 2.1 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -175.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -60.06 -28.84 87.9 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 CA-C-N 121.159 1.45 . . . . 0.0 112.224 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -66.83 -24.46 66.16 Favored 'General case' 0 N--CA 1.45 -0.465 0 O-C-N 121.462 -0.774 . . . . 0.0 111.013 177.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.0 t -63.34 -53.84 40.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -54.29 -42.81 70.47 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.468 178.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -58.25 -66.6 0.46 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.273 -0.267 . . . . 0.0 110.619 174.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 67.9 mtm -47.68 -50.2 25.55 Favored 'General case' 0 CA--C 1.528 0.1 0 C-N-CA 124.766 1.226 . . . . 0.0 112.182 -174.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.5 mt -47.14 -40.68 16.18 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.16 0.584 . . . . 0.0 112.192 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -67.86 -10.63 54.65 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.51 17.55 23.17 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.885 0.766 . . . . 0.0 110.999 175.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -65.6 106.06 1.37 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 119.132 0.878 . . . . 0.0 109.909 174.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.9 p -77.98 82.52 4.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.37 112.71 0.46 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 174.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.1 mmtp -78.98 162.78 25.72 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.793 1.237 . . . . 0.0 109.863 -177.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.4 t -69.11 141.42 17.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.653 1.181 . . . . 0.0 109.59 -178.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.5 m -147.85 67.22 1.1 Allowed 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.363 -0.835 . . . . 0.0 109.593 174.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.06 -94.66 0.12 Allowed Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.827 0.727 . . . . 0.0 111.785 175.022 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -109.19 25.54 11.68 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.856 1.663 . . . . 0.0 110.118 178.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -154.99 163.12 40.75 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -174.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.09 147.17 23.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.137 -1.801 . . . . 0.0 106.137 173.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.6 m -142.15 138.23 31.45 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 119.259 0.936 . . . . 0.0 111.168 -171.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -112.07 -167.88 1.24 Allowed 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.331 0.514 . . . . 0.0 111.522 173.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.3 m -157.75 -47.77 0.06 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.732 0.813 . . . . 0.0 112.268 -173.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.08 156.35 53.37 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 177.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -79.18 40.6 0.42 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.289 -1.124 . . . . 0.0 112.323 -174.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.3 m -156.18 102.31 2.12 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 120.771 -1.206 . . . . 0.0 107.877 -178.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.2 t -104.73 84.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -82.47 93.36 7.23 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 t -93.99 159.65 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.4 t -133.68 106.93 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 C-N-CA 124.97 1.308 . . . . 0.0 108.045 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -112.74 103.48 11.5 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.416 1.487 . . . . 0.0 109.836 -174.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.03 112.0 23.71 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.276 0.63 . . . . 0.0 109.304 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.57 102.87 15.55 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.502 -0.749 . . . . 0.0 110.15 -174.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.6 t 49.32 82.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 125.613 1.565 . . . . 0.0 112.389 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.3 mt -76.58 141.6 69.41 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 174.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -56.22 113.85 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 123.093 2.529 . . . . 0.0 110.315 -174.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 128.19 -41.41 1.58 Allowed Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -174.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -81.14 146.05 57.75 Favored Pre-proline 0 N--CA 1.454 -0.238 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -75.71 152.28 37.37 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.513 2.142 . . . . 0.0 111.628 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -70.29 156.36 91.98 Favored Pre-proline 0 N--CA 1.453 -0.307 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 172.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -109.86 65.09 0.34 Allowed 'Cis proline' 0 N--CA 1.455 -0.766 0 N-CA-C 107.115 -1.917 . . . . 0.0 107.115 -5.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 59.1 p -86.45 123.07 31.27 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 116.581 2.067 . . . . 0.0 116.581 -171.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -83.47 94.24 7.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 168.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -81.79 115.91 21.23 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -175.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.5 t -114.09 82.55 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 125.067 1.347 . . . . 0.0 109.479 -173.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.418 ' CG ' ' N ' ' A' ' 58' ' ' ASP . 1.0 OUTLIER 46.83 -69.21 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.594 3.557 . . . . 0.0 115.221 176.239 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.418 ' N ' ' CG ' ' A' ' 57' ' ' HIS . 21.2 t70 -95.51 -28.08 15.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.153 1.781 . . . . 0.0 110.838 -176.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -132.19 -176.92 4.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 123.787 0.835 . . . . 0.0 109.285 -176.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -134.4 121.27 20.9 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 175.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.64 43.41 0.9 Allowed Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 124.897 1.279 . . . . 0.0 111.18 -177.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.59 177.74 6.71 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 121.711 1.608 . . . . 0.0 111.412 -175.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.7 m -93.47 138.04 32.17 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 170.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.0 mp -111.3 140.17 46.09 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.111 0.964 . . . . 0.0 109.939 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -112.88 120.9 43.05 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.603 1.161 . . . . 0.0 108.167 172.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 16.5 mt -128.01 146.54 59.6 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -170.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -72.06 123.11 9.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.608 2.205 . . . . 0.0 110.587 170.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.39 134.65 28.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 124.22 1.008 . . . . 0.0 110.57 173.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.98 0.43 75.76 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 118.764 -1.02 . . . . 0.0 113.157 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.06 146.63 52.82 Favored 'General case' 0 N--CA 1.456 -0.169 0 CA-C-N 119.847 1.824 . . . . 0.0 109.628 173.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 58.5 m -78.37 99.76 6.5 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.25 134.71 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -139.47 95.07 2.86 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.754 1.621 . . . . 0.0 106.729 173.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.7 t -80.11 106.02 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 174.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.0 m -79.47 109.0 13.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -76.93 150.34 35.95 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.478 172.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 1.2 mp -132.74 69.1 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 165.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -102.3 77.94 1.7 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 -175.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.1 p -118.51 20.21 13.07 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.108 1.763 . . . . 0.0 112.627 -171.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -70.0 103.36 2.24 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 173.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -46.78 134.81 9.58 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.683 0.793 . . . . 0.0 111.692 -173.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.23 -59.45 3.6 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -174.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -78.89 67.8 4.69 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.338 0.655 . . . . 0.0 111.046 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.29 92.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.267 -1.933 . . . . 0.0 108.267 172.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.53 179.47 0.16 Allowed 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.059 0.944 . . . . 0.0 110.637 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 p -137.92 147.9 44.8 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.439 -2.06 . . . . 0.0 105.439 177.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -127.02 104.18 7.85 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 173.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 60.3 m-20 -120.62 127.24 51.91 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.989 0.916 . . . . 0.0 108.877 -174.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.2 mt -98.46 129.74 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 C-N-CA 125.999 1.719 . . . . 0.0 108.579 -174.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.96 -151.08 0.22 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.581 1.153 . . . . 0.0 108.153 -173.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt -133.92 -88.04 0.4 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.821 0.849 . . . . 0.0 109.783 178.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.6 mtmt 49.15 -126.74 2.09 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.216 1.006 . . . . 0.0 109.169 -173.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -175.65 161.88 30.92 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.191 -1.563 . . . . 0.0 109.191 175.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.82 154.44 30.17 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.613 2.876 . . . . 0.0 109.75 174.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.14 144.92 82.56 Favored 'Cis proline' 0 N--CA 1.453 -0.872 0 N-CA-C 108.994 -1.194 . . . . 0.0 108.994 -5.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -78.44 163.67 25.42 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-O 121.375 0.607 . . . . 0.0 110.054 -176.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.24 145.13 42.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.563 -173.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -49.56 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 174.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -78.79 149.55 74.34 Favored Pre-proline 0 CA--C 1.534 0.346 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -72.6 73.62 2.84 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.829 2.352 . . . . 0.0 111.494 -179.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 16.6 t -79.28 53.24 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 173.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.2 pt -84.33 68.71 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-O 122.874 1.321 . . . . 0.0 109.787 -176.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -88.48 -72.69 0.06 OUTLIER Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 113.743 -1.571 . . . . 0.0 110.597 -174.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -77.77 57.76 6.17 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 122.208 1.939 . . . . 0.0 111.48 -178.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 24.8 mm -78.41 126.56 38.64 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 O-C-N 121.228 -0.92 . . . . 0.0 108.8 177.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.1 t -84.78 -88.18 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.62 164.29 12.84 Favored 'General case' 0 CA--C 1.521 -0.162 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 173.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 172.26 -179.14 44.04 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 119.297 -1.43 . . . . 0.0 112.556 173.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 6.0 p -130.84 138.82 50.03 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 126.272 1.829 . . . . 0.0 108.749 176.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -75.04 -127.77 0.19 Allowed Glycine 0 CA--C 1.534 1.275 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 174.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -112.15 154.47 25.44 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 119.659 1.729 . . . . 0.0 110.465 176.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.6 p -90.31 155.83 46.33 Favored Pre-proline 0 N--CA 1.449 -0.488 0 C-N-CA 124.927 1.291 . . . . 0.0 112.397 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.52 98.82 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.192 0 C-N-CA 122.981 2.454 . . . . 0.0 107.468 173.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 40.3 t -37.85 123.49 1.0 Allowed Pre-proline 0 CA--C 1.538 0.502 0 C-N-CA 125.222 1.409 . . . . 0.0 110.421 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -67.79 156.71 64.91 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.66 2.24 . . . . 0.0 112.847 -172.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 29.2 mmmt -110.2 175.94 5.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 125.717 1.607 . . . . 0.0 106.824 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -36.91 104.02 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 125.119 1.368 . . . . 0.0 114.07 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.31 -8.5 46.33 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-O 118.456 -1.191 . . . . 0.0 115.148 173.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -84.48 156.0 21.92 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.866 1.333 . . . . 0.0 109.744 -178.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -139.37 94.17 2.76 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.6 116.14 4.5 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.214 1.387 . . . . 0.0 113.06 174.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -130.46 154.79 47.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.26 1.024 . . . . 0.0 111.486 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.8 m -145.36 118.84 9.05 Favored 'General case' 0 CA--C 1.518 -0.278 0 C-N-CA 124.419 1.088 . . . . 0.0 109.646 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -95.27 88.28 5.1 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 171.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -89.65 122.97 33.28 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 21.8 m -82.91 142.08 31.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.885 -174.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -151.38 155.77 39.33 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.458 1.103 . . . . 0.0 109.423 175.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 65.2 m80 -123.78 108.85 30.49 Favored Pre-proline 0 CA--C 1.532 0.288 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 173.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -89.57 144.24 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.909 3.073 . . . . 0.0 111.019 -172.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.8 p -95.86 155.02 16.92 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.052 0.941 . . . . 0.0 109.549 173.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -60.88 149.25 36.82 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -175.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 126.67 -128.04 6.17 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 126.39 1.948 . . . . 0.0 108.684 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 32.1 m -152.99 141.95 21.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 118.451 1.125 . . . . 0.0 110.201 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -128.29 174.84 8.95 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.893 1.677 . . . . 0.0 107.828 173.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -134.74 147.17 49.98 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.124 1.37 . . . . 0.0 107.904 174.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -109.06 142.88 39.15 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.561 0.745 . . . . 0.0 109.291 174.083 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 33.0 m -143.95 165.3 14.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 124.528 1.131 . . . . 0.0 111.452 -177.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.2 t -118.76 135.04 54.72 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 126.634 1.974 . . . . 0.0 110.091 173.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 64.9 mt-30 -64.47 -50.9 65.66 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 125.015 1.326 . . . . 0.0 113.49 -174.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 71.4 mt -39.95 121.91 1.55 Allowed Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 124.711 1.204 . . . . 0.0 111.526 -170.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -31.79 120.22 0.08 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.886 1 C-N-CA 125.472 4.115 . . . . 0.0 115.711 -173.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 86.74 -25.05 7.77 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 118.888 -0.951 . . . . 0.0 113.481 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 22.4 m170 -54.68 -59.99 3.97 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.203 1.501 . . . . 0.0 111.548 -172.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -49.12 -56.37 9.35 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.138 0.575 . . . . 0.0 110.934 177.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.27 -46.66 79.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.914 0.886 . . . . 0.0 112.336 -175.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.7 p -79.23 -36.31 40.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 113.186 0.809 . . . . 0.0 113.186 -172.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.56 -18.82 0.03 OUTLIER Glycine 0 C--N 1.34 0.771 0 C-N-CA 118.442 -1.837 . . . . 0.0 116.443 -175.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.4 ttt -79.73 65.11 4.8 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.093 1.446 . . . . 0.0 109.681 -174.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -161.53 167.96 24.47 Favored 'General case' 0 C--O 1.225 -0.236 0 C-N-CA 123.035 0.534 . . . . 0.0 111.53 -178.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -174.22 169.34 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 176.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -94.5 151.68 19.16 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.637 1.175 . . . . 0.0 110.526 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.4 mt -125.22 94.0 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 173.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.2 t -80.26 136.59 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 173.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.2 t -127.39 127.65 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 -176.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 49.8 mttp . . . . . 0 N--CA 1.464 0.243 0 CA-C-N 119.043 0.838 . . . . 0.0 111.383 -176.813 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.45 -0.464 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.4 m -79.2 61.51 3.34 Favored 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.37 -0.831 . . . . 0.0 110.115 -178.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.7 m95 -79.46 136.16 36.85 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.988 1.715 . . . . 0.0 110.572 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -149.92 171.38 16.89 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -139.64 127.89 22.59 Favored 'General case' 0 C--N 1.341 0.213 0 CA-C-N 118.826 0.739 . . . . 0.0 109.826 171.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.17 -152.47 0.43 Allowed 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 125.551 1.54 . . . . 0.0 107.121 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.2 p -136.64 170.99 15.16 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 124.179 0.992 . . . . 0.0 108.482 173.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -39.06 -55.17 3.03 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 114.528 1.306 . . . . 0.0 114.528 -174.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -55.45 -33.53 86.27 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.517 1.478 . . . . 0.0 113.633 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -68.67 -29.36 67.81 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 119.118 0.872 . . . . 0.0 111.072 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 t -62.13 -50.2 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 174.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -54.43 -49.3 70.31 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.55 -61.53 2.14 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.034 0.534 . . . . 0.0 111.066 176.218 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 74.4 mtm -55.14 -45.84 75.65 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.202 0.601 . . . . 0.0 110.801 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.3 mt -53.28 -38.01 62.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.19 -0.433 . . . . 0.0 111.747 176.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -72.0 -45.69 60.0 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 175.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.5 mtpt -80.31 62.36 4.42 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 122.709 0.404 . . . . 0.0 110.791 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -134.94 134.64 40.8 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.375 1.07 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.2 p -96.48 24.02 6.27 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.935 0.894 . . . . 0.0 112.951 -175.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.21 100.0 2.43 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 125.727 1.632 . . . . 0.0 110.986 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -78.51 159.13 28.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.626 1.171 . . . . 0.0 109.322 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 63.2 t -93.53 93.47 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.715 0.806 . . . . 0.0 110.34 -174.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.3 p -77.74 70.47 4.12 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.002 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 60.98 -96.72 0.11 Allowed Glycine 0 CA--C 1.527 0.835 0 C-N-CA 124.741 1.162 . . . . 0.0 111.045 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -86.98 -36.61 18.16 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.027 0.931 . . . . 0.0 110.543 178.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.3 m -89.88 166.54 13.45 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.728 1.611 . . . . 0.0 108.787 -172.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.12 144.17 18.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 172.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.7 m -134.07 117.36 16.54 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.687 1.195 . . . . 0.0 108.236 -175.027 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 -79.59 162.25 25.43 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.182 0.515 . . . . 0.0 110.778 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 67.2 m -154.24 159.59 41.39 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.103 0.961 . . . . 0.0 108.629 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.22 165.23 29.43 Favored Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 -174.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.2 mtpm? -73.54 -18.28 61.1 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 122.004 -0.704 . . . . 0.0 111.753 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.4 p -95.68 87.63 4.75 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.132 0.973 . . . . 0.0 109.064 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.0 t -81.84 77.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.219 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -86.3 87.65 7.47 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.089 -175.242 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.67 95.87 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 124.39 1.076 . . . . 0.0 109.173 -174.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.65 109.99 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 175.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -127.84 164.28 22.56 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.827 1.251 . . . . 0.0 109.365 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.77 167.43 24.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 176.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -136.18 114.03 11.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -174.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.7 t 34.38 69.01 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 C-N-CA 127.11 2.164 . . . . 0.0 112.339 174.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 90.9 mt -76.67 144.98 74.22 Favored Pre-proline 0 N--CA 1.453 -0.286 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo . . . . . 0 N--CA 1.457 -0.633 0 C-N-CA 123.21 2.607 . . . . 0.0 110.947 -174.585 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 . . . . . 0 CA--C 1.538 0.486 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -112.38 7.32 3.12 Favored 'Cis proline' 0 CA--C 1.535 0.532 0 CA-C-N 119.641 0.907 . . . . 0.0 113.09 0.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.4 p -83.71 154.9 23.38 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 115.043 1.497 . . . . 0.0 115.043 -171.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -79.37 139.06 37.86 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.747 1.219 . . . . 0.0 109.526 173.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.94 132.38 34.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 123.922 0.889 . . . . 0.0 110.094 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 t -125.97 83.47 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 172.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 55.7 p-80 42.08 -78.59 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 128.587 2.755 . . . . 0.0 115.008 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -84.37 -24.81 29.53 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 124.18 0.992 . . . . 0.0 111.723 -176.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -130.83 -174.9 3.5 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.584 1.153 . . . . 0.0 109.58 -174.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -128.91 92.1 3.34 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.43 HD21 ' HA3' ' A' ' 150' ' ' GLY . 6.2 m120 26.73 69.82 0.45 Allowed Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 127.459 2.303 . . . . 0.0 115.882 -174.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -66.41 -55.56 0.36 Allowed 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.537 2.158 . . . . 0.0 108.674 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.2 m 169.53 154.63 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 129.257 3.023 . . . . 0.0 105.697 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.3 mp -117.22 124.79 49.95 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.969 1.308 . . . . 0.0 110.204 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -98.42 137.09 37.63 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 171.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.08 136.0 25.4 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.213 1.005 . . . . 0.0 110.867 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -76.47 112.06 3.38 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.705 2.937 . . . . 0.0 109.271 173.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.39 -41.37 9.06 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -173.512 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -72.75 -7.51 69.92 Favored Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.41 -0.661 . . . . 0.0 114.068 -175.031 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -85.94 165.07 17.04 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.741 1.271 . . . . 0.0 113.38 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 63.1 m -93.72 127.41 39.42 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 172.102 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 94.9 t -92.13 132.29 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -127.77 108.1 10.44 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.752 -1.574 . . . . 0.0 106.752 173.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.09 115.36 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 16.4 m -107.71 96.01 6.09 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 126.059 1.743 . . . . 0.0 107.181 174.227 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . 0.279 4.3 m-85 -78.79 151.57 31.9 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 172.47 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -127.79 69.6 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 102.595 -3.113 . . . . 0.0 102.595 162.406 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -80.64 113.08 18.58 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 171.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 52.3 m -137.93 45.38 2.13 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -78.55 113.71 16.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 172.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -72.8 69.8 0.95 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.166 0.586 . . . . 0.0 110.113 -178.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 174.43 -67.72 0.1 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -96.71 122.69 39.93 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -174.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.26 71.03 0.63 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.864 -1.695 . . . . 0.0 108.864 171.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -57.06 143.82 36.9 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.511 1.156 . . . . 0.0 111.356 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.3 p -106.76 161.25 14.84 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 125.435 1.494 . . . . 0.0 108.845 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -129.89 101.11 5.71 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 102.755 -3.054 . . . . 0.0 102.755 172.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -118.89 114.44 22.61 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -173.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 6.7 mt -95.2 125.31 47.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 C-N-CA 125.44 1.496 . . . . 0.0 110.297 -174.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -161.17 -145.46 0.11 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -113.0 -98.95 0.43 Allowed 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 174.07 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt 67.42 -67.32 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.887 1.275 . . . . 0.0 111.184 -174.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.78 170.35 28.9 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -174.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -75.1 147.01 32.99 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.634 2.223 . . . . 0.0 109.388 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.82 136.76 45.48 Favored 'Cis proline' 0 N--CA 1.454 -0.813 0 CA-C-N 119.48 0.85 . . . . 0.0 109.995 -5.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -79.03 149.24 32.24 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.93 144.03 39.12 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 121.188 0.518 . . . . 0.0 112.155 -173.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.15 -43.28 98.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.9 mtp -78.1 133.18 65.33 Favored Pre-proline 0 N--CA 1.45 -0.425 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 173.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -75.65 85.24 1.63 Allowed 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.669 1.579 . . . . 0.0 109.307 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.8 t -76.41 105.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -178.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 23.4 pt -78.91 72.98 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 123.241 1.495 . . . . 0.0 110.534 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -62.57 154.5 73.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 113.328 -1.76 . . . . 0.0 106.398 171.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_exo -37.62 104.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 124.031 3.154 . . . . 0.0 113.835 -176.265 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 31.4 mm -78.95 131.27 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.97 -88.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 104.753 -2.314 . . . . 0.0 104.753 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.3 150.3 20.72 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 170.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.89 168.08 39.8 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.8 174.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 2.8 p -120.77 127.61 52.13 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.291 1.036 . . . . 0.0 109.991 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.62 57.0 5.04 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 119.502 -0.61 . . . . 0.0 111.985 -176.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 73.33 99.68 0.07 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 126.256 1.822 . . . . 0.0 111.488 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.3 p -74.13 160.32 81.87 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 118.767 -0.635 . . . . 0.0 110.578 -176.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 169.08 2.07 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 123.559 2.839 . . . . 0.0 116.032 -173.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 92.6 t -121.38 97.08 47.54 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 126.641 1.976 . . . . 0.0 107.627 178.245 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.554 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 37.4 Cg_exo -70.52 -179.77 3.5 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.936 3.091 . . . . 0.0 114.005 -176.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -109.88 -164.87 0.96 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.814 1.646 . . . . 0.0 107.305 172.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -60.99 153.43 25.18 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.518 -0.739 . . . . 0.0 111.003 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.71 3.1 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 123.808 0.718 . . . . 0.0 113.276 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -80.02 156.06 27.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.196 0.598 . . . . 0.0 111.798 -175.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -135.88 106.87 6.68 Favored 'General case' 0 CA--C 1.513 -0.456 0 C-N-CA 125.677 1.591 . . . . 0.0 110.289 -172.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.554 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -64.41 123.27 27.09 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.269 -1.932 . . . . 0.0 108.269 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -130.98 165.04 24.04 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 122.127 0.965 . . . . 0.0 109.886 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.0 m -152.62 120.76 6.23 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -103.57 104.6 14.68 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -118.74 147.74 43.53 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 28.6 m -104.14 152.05 22.58 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.804 0.842 . . . . 0.0 109.731 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -151.38 147.72 27.25 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.824 1.25 . . . . 0.0 109.161 175.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 44.8 m80 -116.15 111.37 42.64 Favored Pre-proline 0 N--CA 1.454 -0.256 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 172.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -82.64 -170.98 1.03 Allowed 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.892 2.395 . . . . 0.0 110.688 -173.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.0 p -140.95 147.9 39.53 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.69 152.46 35.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -174.193 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.55 -129.68 8.14 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 126.508 2.004 . . . . 0.0 108.982 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.8 m -142.82 137.48 29.69 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 117.437 0.618 . . . . 0.0 109.667 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.4 m-85 -130.42 176.75 7.88 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.484 1.914 . . . . 0.0 106.182 172.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -142.53 147.85 36.64 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 173.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -115.21 147.03 40.84 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 172.604 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.2 m -144.96 154.46 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 125.042 1.337 . . . . 0.0 109.735 -174.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.43 107.64 19.8 Favored 'General case' 0 C--N 1.333 -0.125 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 171.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.1 mm-40 -74.72 38.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -174.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 16.5 mt -93.24 142.73 25.67 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 104.305 -2.479 . . . . 0.0 104.305 168.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -48.24 138.85 22.48 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.028 1.818 . . . . 0.0 112.94 178.411 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.0 -46.67 2.45 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.312 0.958 . . . . 0.0 113.193 176.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.2 m170 -42.55 -55.8 3.34 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.814 1.646 . . . . 0.0 113.882 -173.012 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.88 -53.54 57.02 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.71 0.29 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.71 -38.67 88.72 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 124.117 0.967 . . . . 0.0 111.684 -176.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 31.0 p -78.31 -32.32 49.24 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 118.731 -0.652 . . . . 0.0 111.293 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.12 -30.61 0.1 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 118.355 -1.879 . . . . 0.0 116.234 173.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.315 10.3 ptp -80.4 84.46 6.03 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 120.053 1.927 . . . . 0.0 112.707 -174.288 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -141.93 174.49 10.54 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 126.532 1.933 . . . . 0.0 107.296 172.502 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.43 ' HA3' HD21 ' A' ' 61' ' ' ASN . . . -156.28 128.28 2.18 Favored Glycine 0 C--N 1.331 0.285 0 N-CA-C 108.482 -1.847 . . . . 0.0 108.482 173.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -76.99 130.12 37.05 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 174.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.0 mt -110.87 100.91 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 25.7 t -88.84 110.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 174.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.8 t -97.66 94.66 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 63.9 mttp . . . . . 0 C--N 1.332 -0.165 0 O-C-N 121.525 -0.734 . . . . 0.0 109.041 176.373 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.6 p . . . . . 0 CA--C 1.537 0.457 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.9 m -78.05 68.93 4.19 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 32.6 m95 -103.45 129.01 50.5 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 126.853 2.061 . . . . 0.0 109.772 -176.01 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -151.92 178.4 9.45 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -131.27 127.04 36.96 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 171.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.75 -150.62 0.27 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.6 p -137.34 170.41 16.13 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 119.475 1.034 . . . . 0.0 108.563 172.126 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.6 tt -39.53 -55.74 3.23 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 124.316 1.046 . . . . 0.0 113.582 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -56.54 -33.23 92.29 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 CA-C-N 121.011 1.397 . . . . 0.0 113.861 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -64.94 -25.25 67.8 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 118.946 0.794 . . . . 0.0 111.452 177.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.2 t -53.91 -46.94 64.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.651 0.659 . . . . 0.0 109.277 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 mtmm -59.12 -54.17 50.04 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.27 -47.66 62.42 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.84 0.456 . . . . 0.0 111.378 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -62.3 -54.78 35.65 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 119.47 -0.3 . . . . 0.0 110.672 177.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.6 mt -50.58 -47.8 57.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 118.423 0.556 . . . . 0.0 111.392 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -54.06 -25.94 24.19 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.003 0.921 . . . . 0.0 113.093 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -88.21 -9.12 54.06 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 118.9 0.773 . . . . 0.0 112.116 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -49.48 145.8 4.52 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -176.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.7 p -121.0 166.4 13.9 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.599 1.159 . . . . 0.0 108.851 171.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.69 116.71 2.92 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 124.521 1.058 . . . . 0.0 110.787 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 49.4 mtmt -81.68 144.35 31.24 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.558 1.143 . . . . 0.0 108.989 176.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 81.4 t -67.78 145.32 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 122.781 0.432 . . . . 0.0 110.603 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.9 m -150.82 68.95 0.96 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.767 1.227 . . . . 0.0 109.132 174.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.28 -115.45 7.14 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -79.01 -31.22 44.63 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 118.054 0.927 . . . . 0.0 109.109 172.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -79.54 153.39 29.56 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.742 -173.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -120.47 135.32 61.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 171.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 74.2 m -121.7 133.49 54.95 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.302 1.041 . . . . 0.0 110.459 -169.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 79.2 m-85 -105.55 177.72 4.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 124.086 0.954 . . . . 0.0 109.589 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.8 m -154.36 -50.0 0.09 Allowed 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.468 0.707 . . . . 0.0 109.609 177.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -65.63 145.22 48.2 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -60.6 -31.69 70.84 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.179 0.592 . . . . 0.0 111.088 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.8 m -78.1 76.21 4.62 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -78.04 102.59 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 30.9 t-80 -106.95 102.94 12.26 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 123.818 0.847 . . . . 0.0 109.563 -178.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 86.0 t -99.89 151.03 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 125.231 1.413 . . . . 0.0 108.777 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.6 t -130.72 100.49 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 124.618 1.167 . . . . 0.0 108.494 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -106.14 155.46 19.42 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 125.362 1.465 . . . . 0.0 110.731 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.73 158.41 44.01 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 124.511 1.125 . . . . 0.0 109.3 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.84 117.77 24.86 Favored 'General case' 0 N--CA 1.456 -0.157 0 C-N-CA 123.556 0.742 . . . . 0.0 111.032 -173.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.9 t 42.29 66.92 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 C-N-CA 125.323 1.449 . . . . 0.0 111.618 173.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.5 mt -77.88 153.43 80.44 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo . . . . . 0 N--CA 1.456 -0.716 0 C-N-CA 123.054 2.502 . . . . 0.0 111.704 175.58 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 . . . . . 0 CA--C 1.533 0.309 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -111.69 67.48 0.23 Allowed 'Cis proline' 0 N--CA 1.455 -0.791 0 N-CA-C 107.726 -1.682 . . . . 0.0 107.726 -6.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 79.0 p -92.19 133.66 35.59 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -86.34 122.4 30.25 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 169.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -93.32 131.01 38.87 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 104.57 -2.382 . . . . 0.0 104.57 171.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.5 t -137.5 114.92 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 120.226 1.375 . . . . 0.0 110.61 -173.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 36.79 -114.31 0.1 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.771 1.628 . . . . 0.0 112.837 -178.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -81.61 7.1 13.08 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -174.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -146.66 -169.77 3.36 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.526 1.13 . . . . 0.0 110.518 -172.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? -135.22 128.14 31.38 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 172.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 45.99 49.86 7.21 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 125.076 1.35 . . . . 0.0 111.963 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -81.71 173.7 11.05 Favored 'Trans proline' 0 N--CA 1.452 -0.942 0 C-N-CA 122.811 2.34 . . . . 0.0 111.998 -174.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.4 m -94.92 144.8 25.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 113.923 -1.49 . . . . 0.0 107.123 172.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.6 mp -113.23 139.47 48.76 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.093 -1.005 . . . . 0.0 109.983 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -115.37 98.75 6.92 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.531 1.533 . . . . 0.0 107.739 173.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.8 mt -101.16 138.08 19.87 Favored Pre-proline 0 CA--C 1.535 0.379 0 C-N-CA 126.408 1.883 . . . . 0.0 110.788 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.85 123.48 6.33 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 122.384 2.056 . . . . 0.0 107.65 171.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.64 138.46 17.98 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.578 0.751 . . . . 0.0 111.645 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 85.75 -1.57 88.04 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.521 -0.599 . . . . 0.0 112.691 -176.199 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.41 21.48 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 118.759 1.279 . . . . 0.0 112.065 174.336 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 89.3 m -91.73 91.3 7.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 171.701 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.0 t -79.15 99.46 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.298 1.039 . . . . 0.0 108.633 -172.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -98.64 107.35 19.78 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 126.113 1.765 . . . . 0.0 107.854 -178.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.1 t -101.83 116.92 46.33 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.0 m -88.25 137.29 32.45 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.21 146.33 39.49 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 123.712 0.805 . . . . 0.0 111.735 174.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.17 59.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 N-CA-C 101.222 -3.622 . . . . 0.0 101.222 163.494 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -92.93 73.2 4.81 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 104.635 -2.357 . . . . 0.0 104.635 -174.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.7 p -95.25 -77.46 0.47 Allowed 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.95 -171.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 51.71 -142.47 0.73 Allowed 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -172.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.4 mtpm? -149.01 123.58 9.76 Favored 'General case' 0 C--N 1.34 0.174 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.31 -55.19 3.22 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 118.883 0.765 . . . . 0.0 112.054 178.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -77.64 84.92 3.98 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 121.73 -0.865 . . . . 0.0 109.804 -174.7 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.26 75.59 0.01 OUTLIER Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.513 1.054 . . . . 0.0 110.697 172.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -55.51 163.81 1.18 Allowed 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.448 1.124 . . . . 0.0 110.096 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 93.0 p -131.91 165.95 22.74 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -132.31 93.03 3.18 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -98.38 130.76 45.03 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.748 1.219 . . . . 0.0 107.781 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 21.8 mt -102.49 133.53 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 124.635 1.174 . . . . 0.0 109.289 -173.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.9 t -157.88 -161.36 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -129.05 -0.0 5.24 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 124.324 1.05 . . . . 0.0 111.695 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -66.52 129.42 39.8 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.318 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -84.61 168.66 44.09 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 174.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -69.84 160.82 48.28 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.288 2.659 . . . . 0.0 110.114 174.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -75.74 163.96 89.08 Favored 'Cis proline' 0 N--CA 1.455 -0.745 0 N-CA-C 110.502 -0.615 . . . . 0.0 110.502 -4.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -111.14 152.79 26.59 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 176.373 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.16 153.32 34.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.3 t -59.11 -39.2 77.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 62.1 mtt -78.15 117.66 67.45 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.92 113.81 1.73 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.448 2.098 . . . . 0.0 111.924 -175.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 19.1 t -79.81 66.99 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 7.5 pt -79.42 -21.56 12.37 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.183 0 N-CA-C 115.145 1.535 . . . . 0.0 115.145 -172.318 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -49.55 -59.03 7.41 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 119.18 0.9 . . . . 0.0 111.597 177.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.92 62.7 6.64 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 122.796 2.33 . . . . 0.0 112.766 174.167 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.5 mm -113.62 145.77 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 172.109 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 48.9 t -97.19 -94.69 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 177.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.48 -176.5 3.95 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.76 0.824 . . . . 0.0 109.673 174.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.93 174.91 36.6 Favored Glycine 0 N--CA 1.443 -0.847 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 175.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 73.2 p -85.5 -50.68 7.06 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.354 0.597 . . . . 0.0 109.726 174.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 96.17 -176.79 33.3 Favored Glycine 0 CA--C 1.535 1.34 0 N-CA-C 105.559 -3.016 . . . . 0.0 105.559 -168.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -77.38 139.01 39.63 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.286 1.043 . . . . 0.0 109.667 -179.223 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.7 p -88.83 156.09 49.9 Favored Pre-proline 0 CA--C 1.537 0.451 0 N-CA-C 115.037 1.495 . . . . 0.0 115.037 -172.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.63 89.12 1.36 Allowed 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.321 2.681 . . . . 0.0 107.336 171.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 30.6 m -53.71 163.3 1.11 Allowed Pre-proline 0 CA--C 1.545 0.76 0 C-N-CA 124.774 1.23 . . . . 0.0 113.563 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.72 144.07 66.95 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 123.313 2.675 . . . . 0.0 113.775 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -108.62 21.77 16.82 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.851 1.26 . . . . 0.0 108.627 171.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 50.4 t0 79.31 139.7 0.07 Allowed 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 128.558 2.743 . . . . 0.0 107.953 -171.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 73.39 -50.03 1.64 Allowed Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.572 0.606 . . . . 0.0 112.102 -173.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -79.22 153.53 29.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.045 0.938 . . . . 0.0 112.194 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -130.23 95.68 3.97 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 127.233 2.213 . . . . 0.0 108.986 -173.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -45.54 112.87 0.84 Allowed Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.752 1.168 . . . . 0.0 111.506 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -131.63 175.21 9.37 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 122.504 1.145 . . . . 0.0 110.998 -176.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -167.84 156.13 9.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -141.11 90.91 2.35 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 172.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -110.23 153.53 24.68 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 25.0 m -118.5 140.91 49.13 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 124.659 1.184 . . . . 0.0 110.237 -173.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 2.8 p-90 -146.86 161.31 40.96 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.896 0.878 . . . . 0.0 110.676 174.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -133.71 89.18 31.29 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 125.467 1.507 . . . . 0.0 108.306 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -78.98 151.71 24.2 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.579 2.186 . . . . 0.0 110.239 -176.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.5 p -79.63 164.54 23.71 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.974 0.51 . . . . 0.0 110.172 174.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -67.02 157.03 34.48 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.939 -0.476 . . . . 0.0 111.976 -176.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.33 -118.86 4.1 Favored Glycine 0 C--N 1.335 0.499 0 C-N-CA 126.123 1.821 . . . . 0.0 109.084 -178.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -149.72 127.77 11.95 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.833 0.817 . . . . 0.0 109.606 -178.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -110.03 171.61 7.35 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 127.494 2.318 . . . . 0.0 106.912 174.4 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -142.0 144.11 33.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.867 1.267 . . . . 0.0 108.517 177.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -107.33 134.14 50.84 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.2 m -138.34 144.01 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 C-N-CA 124.218 1.007 . . . . 0.0 109.35 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.2 t -86.21 139.8 30.72 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -113.24 36.52 3.51 Favored 'General case' 0 CA--C 1.523 -0.088 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 -171.256 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 45.6 mt -91.59 133.54 30.91 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 103.798 -2.667 . . . . 0.0 103.798 168.067 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -39.11 128.37 1.41 Allowed 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.751 2.967 . . . . 0.0 113.968 -176.097 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.33 -23.59 5.35 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 118.981 -0.899 . . . . 0.0 114.337 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -62.25 -53.32 56.91 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 120.079 1.939 . . . . 0.0 111.62 -172.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -55.31 -48.51 74.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.896 -0.503 . . . . 0.0 110.559 175.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.96 -40.4 80.48 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.768 0.827 . . . . 0.0 111.923 -176.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 19.1 p -78.2 -40.48 37.42 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 119.054 -0.498 . . . . 0.0 109.997 -178.188 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 147.08 20.58 0.1 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 115.9 1.12 . . . . 0.0 115.9 172.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 15.6 ttt -80.02 76.71 6.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 119.66 1.73 . . . . 0.0 107.709 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.71 6.29 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 122.812 0.445 . . . . 0.0 111.734 -174.042 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -175.68 165.81 36.78 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 171.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -104.29 147.76 27.13 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 124.39 1.076 . . . . 0.0 109.341 -173.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.9 mt -128.18 96.84 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.5 131.9 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 174.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 35.2 t -118.66 93.93 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 106.995 -1.483 . . . . 0.0 106.995 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--N 1.332 -0.179 0 O-C-N 121.679 -0.638 . . . . 0.0 109.354 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.8 p . . . . . 0 CA--C 1.543 0.687 0 N-CA-C 114.453 1.279 . . . . 0.0 114.453 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 89.8 m -77.53 73.77 4.1 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.601 1.16 . . . . 0.0 108.301 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -107.09 134.42 50.25 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 127.588 2.355 . . . . 0.0 107.645 -177.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -151.38 -177.42 6.06 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 119.846 1.203 . . . . 0.0 109.601 176.2 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -136.5 149.07 47.98 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 172.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.29 -152.17 0.5 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.642 1.977 . . . . 0.0 106.573 174.247 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.6 p -135.79 173.01 12.19 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 119.152 0.887 . . . . 0.0 108.744 172.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.17 -56.89 2.41 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 114.455 1.279 . . . . 0.0 114.455 -175.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -54.67 -34.04 82.08 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.53 1.487 . . . . 0.0 113.456 -178.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -68.36 -26.88 65.8 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.215 -0.928 . . . . 0.0 111.38 177.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.2 t -59.44 -51.83 68.1 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 174.469 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.0 mtpp -56.43 -52.04 66.14 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.078 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.88 -54.71 17.86 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.607 0.363 . . . . 0.0 111.566 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.7 mtm -57.46 -53.8 54.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 119.343 -0.36 . . . . 0.0 110.27 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.4 mt -51.37 -48.14 62.62 Favored 'General case' 0 N--CA 1.463 0.217 0 C-N-CA 122.811 0.444 . . . . 0.0 111.334 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -55.11 -31.87 61.59 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 122.813 0.445 . . . . 0.0 111.929 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.5 11.13 25.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.33 0.652 . . . . 0.0 111.663 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.41 109.36 4.72 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 120.387 -1.446 . . . . 0.0 110.01 175.182 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 36.49 0.25 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.599 0.76 . . . . 0.0 112.706 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.67 108.09 2.36 Favored Glycine 0 C--N 1.338 0.651 0 C-N-CA 125.658 1.599 . . . . 0.0 110.224 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -78.89 150.67 32.1 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.352 1.061 . . . . 0.0 108.872 178.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 70.4 t -70.46 145.98 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.803 -0.561 . . . . 0.0 110.612 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 38.2 m -150.26 68.31 0.98 Allowed 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.623 1.169 . . . . 0.0 108.758 174.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.69 -110.99 3.82 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.3 -28.56 38.22 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 117.876 0.838 . . . . 0.0 110.388 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.8 m -86.81 155.13 20.42 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.702 1.201 . . . . 0.0 109.237 -172.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.9 t -119.64 134.52 62.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 171.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -122.96 120.05 32.24 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.666 1.186 . . . . 0.0 108.576 -172.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -87.48 170.84 11.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.151 0.5 . . . . 0.0 109.98 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 51.0 m -152.24 151.58 31.13 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -177.243 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.64 177.21 27.19 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -173.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 mttm -76.94 -26.13 53.67 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 122.035 -0.685 . . . . 0.0 111.827 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.3 m -78.77 73.61 5.32 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.846 0.748 . . . . 0.0 110.201 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -82.37 83.36 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -88.13 86.0 7.03 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.438 -174.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.4 t -81.0 111.71 18.04 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.115 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 -177.448 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.62 97.75 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 123.251 0.62 . . . . 0.0 109.33 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.07 101.6 13.28 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.703 1.201 . . . . 0.0 110.101 -176.052 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.77 102.17 14.92 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.801 1.24 . . . . 0.0 108.435 177.229 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.71 111.78 23.44 Favored 'General case' 0 CA--C 1.529 0.162 0 O-C-N 121.042 -1.036 . . . . 0.0 111.12 -174.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 8.5 t 38.21 73.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.648 1.579 . . . . 0.0 112.743 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.85 155.53 82.96 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -177.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo . . . . . 0 C--N 1.347 0.5 0 C-N-CA 124.717 3.611 . . . . 0.0 116.397 -173.509 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 . . . . . 0 CA--C 1.537 0.465 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -117.26 -9.1 0.34 Allowed 'Cis proline' 0 CA--C 1.535 0.572 0 N-CA-C 114.451 0.904 . . . . 0.0 114.451 -4.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.4 p -90.04 157.78 17.64 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 121.134 3.753 . . . . 0.0 121.134 -165.524 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -77.75 121.6 24.25 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 103.476 -2.786 . . . . 0.0 103.476 169.187 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -106.61 134.95 48.97 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.0 t -132.84 83.43 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 123.539 0.736 . . . . 0.0 109.204 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.278 1.0 OUTLIER 44.11 -70.07 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 130.224 3.409 . . . . 0.0 115.587 179.165 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -95.51 -23.86 16.9 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 124.186 0.994 . . . . 0.0 111.243 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -131.32 -172.94 2.97 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.549 1.139 . . . . 0.0 108.967 -175.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -139.4 134.72 32.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 172.104 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 49.48 41.43 0.99 Allowed Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 123.895 0.878 . . . . 0.0 112.111 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -72.77 162.88 39.99 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 CA-C-N 120.982 1.386 . . . . 0.0 111.247 -176.217 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.1 m -78.41 127.15 31.77 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 171.389 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 7.7 mp -97.38 127.37 43.29 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 119.249 0.932 . . . . 0.0 109.634 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -107.78 120.71 43.0 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 171.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 40.9 mt -123.24 134.61 25.26 Favored Pre-proline 0 CA--C 1.537 0.456 0 C-N-CA 124.691 1.196 . . . . 0.0 111.964 -171.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -65.1 113.46 2.41 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.396 2.064 . . . . 0.0 109.661 170.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.17 132.02 19.53 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.526 0.73 . . . . 0.0 111.133 174.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 88.94 -4.24 84.81 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.455 -0.636 . . . . 0.0 112.573 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.81 164.63 24.84 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 118.846 1.323 . . . . 0.0 111.641 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 53.9 m -98.21 103.27 15.2 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.667 1.587 . . . . 0.0 108.197 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.7 t -83.07 112.15 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 124.118 0.967 . . . . 0.0 108.768 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -103.31 100.69 10.58 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 174.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.5 t -79.23 93.25 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 37.6 m -90.95 99.74 12.73 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.622 1.569 . . . . 0.0 109.134 -176.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -79.64 159.57 26.69 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.492 173.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.9 mp -142.28 82.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 N-CA-C 101.019 -3.697 . . . . 0.0 101.019 162.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -108.3 115.17 29.61 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 105.383 -2.08 . . . . 0.0 105.383 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.3 m -140.41 39.55 1.89 Allowed 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 -79.77 70.62 6.33 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.986 177.057 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.4 mttm -1.62 94.94 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.402 3.081 . . . . 0.0 113.904 -176.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 96.14 -36.72 3.71 Favored Glycine 0 CA--C 1.532 1.15 0 O-C-N 121.92 -0.487 . . . . 0.0 113.418 175.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -79.92 95.11 6.0 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.6 1.2 . . . . 0.0 110.922 -178.626 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.78 54.02 0.36 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.243 1.402 . . . . 0.0 113.226 174.265 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -47.27 129.67 12.81 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-N 118.907 1.354 . . . . 0.0 110.228 177.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.4 p -108.26 112.59 25.15 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 -176.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -79.34 94.75 5.55 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -101.29 130.87 47.53 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 124.584 1.154 . . . . 0.0 109.538 -172.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -109.75 130.43 62.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 119.059 0.845 . . . . 0.0 110.468 -175.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.2 t -159.12 -153.18 0.35 Allowed 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -121.39 42.55 3.05 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 119.577 1.08 . . . . 0.0 110.234 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -76.09 94.8 3.52 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.6 157.2 52.52 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.1 160.24 45.64 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.105 1.87 . . . . 0.0 110.206 174.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -78.19 142.79 71.01 Favored 'Cis proline' 0 N--CA 1.456 -0.717 0 CA-C-N 118.901 0.643 . . . . 0.0 110.538 -2.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -79.85 151.89 29.99 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 176.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.54 148.64 24.97 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.542 0.737 . . . . 0.0 109.849 -178.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 25.5 t -63.47 -31.76 54.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 173.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -78.18 119.28 76.75 Favored Pre-proline 0 N--CA 1.45 -0.447 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.44 77.37 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.341 2.027 . . . . 0.0 108.89 -174.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 90.9 t -76.12 108.57 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 -175.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 15.6 pt -79.0 75.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-O 122.956 1.36 . . . . 0.0 111.194 -175.079 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -67.03 154.28 92.84 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 170.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -40.45 109.15 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.812 3.008 . . . . 0.0 114.363 -170.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 29.0 mm -78.6 121.83 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 175.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 87.6 t -84.67 -83.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.77 167.46 11.42 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 171.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.06 160.36 13.23 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.0 p -79.6 -46.3 17.53 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.173 177.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 93.61 -173.06 33.44 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 104.651 -3.38 . . . . 0.0 104.651 -167.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -82.96 131.67 35.18 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 120.404 2.102 . . . . 0.0 109.691 -174.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 p -90.48 153.43 46.07 Favored Pre-proline 0 CA--C 1.534 0.327 0 N-CA-C 116.113 1.894 . . . . 0.0 116.113 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -75.34 143.36 27.91 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.905 2.403 . . . . 0.0 106.099 169.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.5 m -141.16 95.57 7.43 Favored Pre-proline 0 CA--C 1.534 0.328 0 CA-C-N 118.456 0.571 . . . . 0.0 111.956 -172.667 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -55.97 168.53 1.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.816 3.011 . . . . 0.0 113.068 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -113.71 -5.25 13.34 Favored 'General case' 0 C--N 1.34 0.169 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -176.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 18.0 t0 178.05 154.16 0.33 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 126.236 1.815 . . . . 0.0 109.285 176.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 68.29 -62.66 0.4 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.522 2.011 . . . . 0.0 113.675 174.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -78.88 155.88 28.89 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 123.973 0.909 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -135.84 107.83 7.15 Favored 'General case' 0 CA--C 1.517 -0.303 0 C-N-CA 125.116 1.366 . . . . 0.0 110.778 -173.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -61.52 110.88 3.42 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.748 1.166 . . . . 0.0 110.604 176.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -116.51 170.55 8.48 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 122.658 1.218 . . . . 0.0 110.172 174.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 2.8 m -159.01 146.48 17.54 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 -174.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.21 96.25 2.75 Favored 'General case' 0 CA--C 1.521 -0.157 0 O-C-N 124.017 0.823 . . . . 0.0 111.866 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -103.82 147.93 26.72 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 169.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 37.4 m -104.15 134.3 47.63 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 177.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -136.54 140.67 43.11 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.522 1.129 . . . . 0.0 108.947 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -110.66 90.12 10.12 Favored Pre-proline 0 N--CA 1.455 -0.203 0 N-CA-C 105.174 -2.158 . . . . 0.0 105.174 173.021 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.16 147.55 42.78 Favored 'Trans proline' 0 N--CA 1.445 -1.354 0 C-N-CA 121.664 1.576 . . . . 0.0 110.285 -173.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.3 p -79.66 162.98 24.92 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.5 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.83 171.95 1.91 Allowed 'General case' 0 CA--C 1.537 0.455 0 O-C-N 121.307 -0.871 . . . . 0.0 112.13 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 100.95 -127.05 9.13 Favored Glycine 0 CA--C 1.522 0.496 0 C-N-CA 125.227 1.394 . . . . 0.0 110.158 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.2 m -153.04 144.4 23.25 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.352 1.076 . . . . 0.0 110.928 -174.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -134.21 -177.33 4.53 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 126.719 2.008 . . . . 0.0 106.71 173.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -144.62 141.6 29.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.223 1.009 . . . . 0.0 109.109 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -101.3 143.58 31.18 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.211 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.8 m -150.71 151.96 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 125.169 1.388 . . . . 0.0 109.789 -177.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 52.6 t -97.72 102.32 14.05 Favored 'General case' 0 C--O 1.231 0.111 0 C-N-CA 124.407 1.083 . . . . 0.0 109.754 171.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -73.52 33.61 0.08 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 29.4 mt -92.63 142.09 25.34 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 169.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 99.1 Cg_exo -46.11 136.67 14.14 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.335 2.023 . . . . 0.0 113.093 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.26 -52.41 4.05 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 123.676 0.655 . . . . 0.0 112.661 179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -39.83 -55.64 1.93 Allowed 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.855 1.662 . . . . 0.0 114.849 -171.251 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -50.89 -41.49 58.45 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.451 0.569 . . . . 0.0 111.635 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.27 -50.86 19.99 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.217 0.607 . . . . 0.0 109.943 174.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.7 p -79.85 62.39 4.07 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.691 -0.631 . . . . 0.0 111.377 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.38 93.39 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 117.622 1.809 . . . . 0.0 117.622 171.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 7.5 mtp -122.35 68.6 0.95 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 119.862 1.831 . . . . 0.0 109.154 170.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -159.48 -177.71 6.61 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.493 0.717 . . . . 0.0 111.883 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.73 171.47 33.74 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 172.642 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.7 mttm -101.6 152.46 20.78 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 123.784 0.834 . . . . 0.0 109.495 -174.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.9 mt -124.35 94.14 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 174.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 27.1 t -88.53 131.76 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 36.1 t -128.1 109.65 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt . . . . . 0 N--CA 1.465 0.294 0 CA-C-N 119.001 0.818 . . . . 0.0 110.464 -179.132 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.1 p . . . . . 0 CA--C 1.536 0.408 0 CA-C-O 121.007 0.432 . . . . 0.0 111.701 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 m -78.69 58.53 2.29 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 -169.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -89.09 130.28 35.56 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.754 1.222 . . . . 0.0 107.916 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -149.8 176.2 10.93 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -137.93 151.99 48.53 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 170.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.34 -153.76 0.57 Allowed 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 127.355 2.262 . . . . 0.0 105.998 173.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.3 p -138.21 169.12 18.34 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.958 0.799 . . . . 0.0 109.684 175.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.72 -54.39 4.09 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -174.508 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -57.73 -33.52 96.91 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.6 1.534 . . . . 0.0 111.936 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.8 mm100 -67.67 -23.8 65.35 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 121.765 -0.584 . . . . 0.0 111.103 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 t -64.14 -49.67 80.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 173.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.5 mttp -58.89 -39.82 82.58 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 122.684 0.393 . . . . 0.0 110.321 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.21 -62.83 1.44 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 122.042 -0.411 . . . . 0.0 109.963 174.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -54.08 -43.52 70.41 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.642 0.777 . . . . 0.0 111.897 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.7 mt -54.76 -33.09 60.85 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 176.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.54 -14.98 62.22 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 119.396 0.998 . . . . 0.0 112.392 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.98 17.57 20.65 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.008 0.822 . . . . 0.0 110.129 173.165 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.05 154.07 42.12 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.432 -0.793 . . . . 0.0 109.108 172.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.82 165.34 34.81 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.547 0.739 . . . . 0.0 109.766 -172.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.12 136.8 5.95 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 124.347 0.975 . . . . 0.0 111.335 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -79.26 126.75 31.19 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.299 1.039 . . . . 0.0 108.483 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.96 83.95 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 125.46 1.504 . . . . 0.0 109.261 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.9 m -85.89 68.06 10.22 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.087 1.355 . . . . 0.0 108.451 -175.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.54 -105.95 1.31 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -87.43 -22.34 25.04 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.78 0.832 . . . . 0.0 111.536 176.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.4 m -97.35 155.74 16.76 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 124.928 1.291 . . . . 0.0 108.517 -173.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.0 t -114.56 135.5 54.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 174.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -124.03 122.93 39.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 119.191 0.905 . . . . 0.0 110.375 -173.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 38' ' ' VAL . 0.6 OUTLIER -79.55 174.55 11.46 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.243 0.544 . . . . 0.0 111.208 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.5 m -158.93 49.88 0.36 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.723 0.809 . . . . 0.0 110.186 -174.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.26 170.44 38.94 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 -177.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -82.11 -33.71 29.58 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.978 0.511 . . . . 0.0 111.304 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.5 p -83.2 84.46 7.48 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 121.301 -0.874 . . . . 0.0 108.767 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 33' ' ' TYR . 77.6 t -86.07 83.35 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 C-N-CA 124.196 0.998 . . . . 0.0 108.894 -174.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -84.96 104.78 15.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 124.705 1.202 . . . . 0.0 109.765 -176.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.44 104.49 16.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.7 t -81.9 112.09 19.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 174.655 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -125.81 160.39 29.96 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.978 1.311 . . . . 0.0 110.267 -176.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.22 163.54 38.01 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.274 1.03 . . . . 0.0 109.65 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -129.35 122.62 29.88 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 124.017 0.927 . . . . 0.0 109.668 -179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.4 t 26.1 65.16 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 128.418 2.687 . . . . 0.0 113.12 174.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.9 mt -77.23 146.91 75.44 Favored Pre-proline 0 CA--C 1.534 0.36 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo . . . . . 0 N--CA 1.458 -0.609 0 C-N-CA 124.712 3.608 . . . . 0.0 113.679 -177.465 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -109.76 50.54 1.22 Allowed 'Cis proline' 0 CA--C 1.54 0.79 0 N-CA-C 108.087 -1.543 . . . . 0.0 108.087 -5.08 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 87.0 p -73.19 127.2 31.94 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 115.958 1.836 . . . . 0.0 115.958 -170.377 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -81.81 108.85 15.67 Favored 'General case' 0 C--N 1.343 0.318 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 168.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -84.31 136.66 33.82 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 120.011 1.278 . . . . 0.0 107.93 177.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -135.59 87.53 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 CA-C-N 119.128 0.876 . . . . 0.0 109.64 -174.214 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.0 p-80 39.27 -97.15 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.575 1.95 . . . . 0.0 113.632 -176.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.0 -27.24 64.53 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.882 0.473 . . . . 0.0 111.844 -174.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -127.19 -171.55 2.45 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.505 1.122 . . . . 0.0 110.718 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -135.6 127.45 29.36 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 172.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 51.16 44.15 2.02 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 125.044 1.338 . . . . 0.0 111.76 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.01 -178.0 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 122.87 2.38 . . . . 0.0 112.733 -173.172 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.9 m -104.45 136.2 44.47 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 113.079 -1.873 . . . . 0.0 106.44 172.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.7 mp -116.5 122.3 44.33 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 118.875 0.761 . . . . 0.0 112.038 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -93.27 127.09 38.71 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 171.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 25.4 mt -130.83 140.96 40.27 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 125.176 1.391 . . . . 0.0 111.711 -170.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -81.37 122.78 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.664 2.243 . . . . 0.0 109.137 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.98 143.06 3.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 125.205 1.402 . . . . 0.0 112.652 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 78.02 -12.08 19.44 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.28 -0.733 . . . . 0.0 113.695 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.68 148.66 23.89 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 119.035 1.418 . . . . 0.0 111.074 174.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 59.8 m -81.61 102.06 10.41 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 173.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.28 127.19 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -124.45 103.3 8.11 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.76 105.44 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.9 m -91.33 98.04 11.47 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.99 1.316 . . . . 0.0 107.93 175.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.69 156.04 30.94 Favored 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 120.916 -0.313 . . . . 0.0 110.902 173.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.1 mp -136.99 73.43 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 102.172 -3.27 . . . . 0.0 102.172 164.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.57 110.93 21.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 173.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 41.4 m -141.25 46.28 1.73 Allowed 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 173.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -68.43 -48.91 63.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.6 mtmm 93.34 155.33 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 129.709 3.204 . . . . 0.0 109.42 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 -66.89 1.59 Allowed Glycine 0 CA--C 1.53 1.029 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -172.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -79.8 104.03 10.1 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 124.222 1.009 . . . . 0.0 110.705 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.42 73.36 0.59 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 107.964 -2.054 . . . . 0.0 107.964 171.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -55.26 136.49 48.82 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.792 1.296 . . . . 0.0 111.506 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.3 p -96.43 157.01 16.1 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.242 1.417 . . . . 0.0 108.32 174.649 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -128.38 115.83 18.84 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 103.623 -2.732 . . . . 0.0 103.623 171.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.13 121.46 22.64 Favored 'General case' 0 C--O 1.226 -0.164 0 CA-C-N 119.151 0.887 . . . . 0.0 109.975 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 53.3 mt -97.8 132.87 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 125.651 1.58 . . . . 0.0 109.275 -174.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -157.39 -155.8 0.54 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.757 1.223 . . . . 0.0 107.963 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.8 mtpt -132.6 -2.85 3.36 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -174.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -74.84 134.53 41.69 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 118.844 0.747 . . . . 0.0 109.453 176.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.35 42.3 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 123.285 0.469 . . . . 0.0 112.14 -178.274 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -70.95 166.0 30.5 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.617 2.878 . . . . 0.0 109.792 174.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -78.39 139.19 54.08 Favored 'Cis proline' 0 N--CA 1.454 -0.805 0 N-CA-C 110.392 -0.657 . . . . 0.0 110.392 -3.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -81.93 151.44 27.23 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.39 153.29 31.71 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 56.6 t -57.77 -43.67 84.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.41 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -77.92 131.66 69.6 Favored Pre-proline 0 N--CA 1.451 -0.379 0 N-CA-C 104.535 -2.394 . . . . 0.0 104.535 172.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.87 75.43 2.68 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.25 1.967 . . . . 0.0 112.197 -172.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 t -79.21 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 172.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.413 ' H ' HG13 ' A' ' 102' ' ' ILE . 1.8 pp -86.71 -34.82 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 126.834 2.054 . . . . 0.0 113.289 -173.07 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -51.27 138.9 26.78 Favored Pre-proline 0 CA--C 1.535 0.389 0 C-N-CA 124.301 1.04 . . . . 0.0 111.901 -173.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.22 170.98 56.71 Favored 'Cis proline' 0 N--CA 1.459 -0.507 0 CA-C-N 119.629 0.903 . . . . 0.0 110.981 0.022 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 26.1 mm -124.05 144.33 34.19 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.109 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 174.016 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.9 t -95.39 -88.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 174.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.23 158.55 15.41 Favored 'General case' 0 N--CA 1.461 0.11 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 173.399 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.45 172.84 40.68 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 119.272 -1.442 . . . . 0.0 113.025 173.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.8 p -126.94 116.49 20.87 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.587 1.155 . . . . 0.0 110.653 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -76.17 65.11 2.71 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.515 1.055 . . . . 0.0 111.314 -179.021 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 76.24 98.75 0.07 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 127.186 2.194 . . . . 0.0 112.073 173.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.9 p -68.67 169.28 11.29 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-O 118.951 -0.547 . . . . 0.0 110.552 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -54.27 167.02 1.41 Allowed 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 123.295 2.663 . . . . 0.0 117.014 -172.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 79.0 t -124.67 92.02 48.52 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 126.78 2.032 . . . . 0.0 106.632 173.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.407 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 31.6 Cg_exo -72.33 -170.2 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 123.376 2.717 . . . . 0.0 113.467 -176.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -128.82 172.93 10.81 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 172.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -49.71 147.47 3.6 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-O 121.077 0.465 . . . . 0.0 112.166 -174.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.04 -44.85 2.67 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.346 -0.697 . . . . 0.0 112.738 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -79.69 153.05 29.57 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.226 1.01 . . . . 0.0 110.839 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -135.51 114.66 12.3 Favored 'General case' 0 C--O 1.224 -0.25 0 C-N-CA 124.903 1.281 . . . . 0.0 111.079 -173.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.407 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -75.95 113.56 3.92 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 125.507 1.527 . . . . 0.0 110.281 -174.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -113.9 163.02 15.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 122.766 1.27 . . . . 0.0 110.882 175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.3 m -150.91 126.66 10.28 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.702 -1.962 . . . . 0.0 105.702 174.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.63 89.6 3.12 Favored 'General case' 0 CA--C 1.518 -0.267 0 C-N-CA 124.46 1.104 . . . . 0.0 108.069 178.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -101.2 143.97 30.63 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 27.2 m -106.25 149.26 27.04 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.353 1.061 . . . . 0.0 109.686 -174.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -147.78 145.95 28.99 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.235 1.014 . . . . 0.0 109.762 174.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.4 m80 -114.1 107.46 51.94 Favored Pre-proline 0 CA--C 1.531 0.233 0 N-CA-C 105.033 -2.21 . . . . 0.0 105.033 173.045 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -90.79 133.74 1.75 Allowed 'Trans proline' 0 N--CA 1.444 -1.388 0 C-N-CA 123.743 2.962 . . . . 0.0 113.447 -170.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -84.54 158.86 20.82 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.528 1.531 . . . . 0.0 107.05 170.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.18 167.73 3.84 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.104 0.865 . . . . 0.0 113.025 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 107.12 -177.08 21.5 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 126.263 1.887 . . . . 0.0 112.916 174.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 12.7 m -87.82 137.56 32.23 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 124.213 1.005 . . . . 0.0 109.483 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -133.26 167.32 20.58 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 125.302 1.441 . . . . 0.0 107.24 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -134.0 147.75 51.03 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.987 1.315 . . . . 0.0 108.134 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' TYR . . . . . 0.45 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 47.6 p90 -114.14 138.99 49.7 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.283 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.3 m -142.52 156.23 18.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.345 1.458 . . . . 0.0 110.258 -178.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 13.4 t -96.62 114.75 26.43 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.552 1.141 . . . . 0.0 109.033 172.46 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -61.92 -14.44 34.4 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 125.42 1.488 . . . . 0.0 114.738 -176.058 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 26.2 mt -58.78 130.41 85.7 Favored Pre-proline 0 CA--C 1.541 0.606 0 CA-C-N 120.002 1.274 . . . . 0.0 108.317 174.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.71 145.86 4.19 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 123.12 2.547 . . . . 0.0 112.972 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.18 -43.75 2.06 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-O 119.58 -0.566 . . . . 0.0 112.798 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -52.67 -55.21 24.15 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.534 1.167 . . . . 0.0 112.602 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -53.93 -52.7 59.78 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.098 0.408 . . . . 0.0 110.103 177.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.46 -42.92 71.22 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 124.016 0.927 . . . . 0.0 111.402 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.1 p -81.24 10.92 4.76 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 12.93 37.73 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.475 -1.18 . . . . 0.0 116.026 170.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 2.9 ttt -79.31 73.88 5.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.995 1.897 . . . . 0.0 108.426 174.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.24 -166.92 2.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.511 0.324 . . . . 0.0 111.425 -174.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.45 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.76 177.44 40.2 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 174.044 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -116.43 152.89 33.08 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.5 1.12 . . . . 0.0 110.879 -172.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.6 mt -129.12 141.11 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 105.297 -2.112 . . . . 0.0 105.297 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 28.9 t -132.48 108.94 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.63 113.98 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 -176.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 67.9 mttm . . . . . 0 N--CA 1.461 0.119 0 CA-C-N 118.495 0.589 . . . . 0.0 109.847 174.702 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.2 p . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.0 m -79.8 64.19 4.58 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 122.323 1.059 . . . . 0.0 108.164 178.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -80.49 121.48 25.81 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 125.859 1.664 . . . . 0.0 110.987 -173.412 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.3 mmtp -142.01 170.39 15.81 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 172.507 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -134.8 129.06 33.96 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 171.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.6 -156.76 0.53 Allowed 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 172.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 70.9 p -137.65 170.98 15.13 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 119.413 1.006 . . . . 0.0 109.876 174.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.15 -60.36 1.02 Allowed Pre-proline 0 CA--C 1.543 0.677 0 N-CA-C 115.325 1.602 . . . . 0.0 115.325 -173.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -60.06 -29.26 88.82 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 CA-C-N 121.588 1.603 . . . . 0.0 112.335 -178.108 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -67.03 -25.74 66.42 Favored 'General case' 0 N--CA 1.45 -0.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.533 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.83 -46.52 96.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 173.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -60.54 -49.27 78.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.233 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.68 -49.32 57.6 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 122.141 0.177 . . . . 0.0 111.358 177.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.3 mtm -63.7 -50.42 69.24 Favored 'General case' 0 C--O 1.224 -0.27 0 CA-C-O 118.907 -0.568 . . . . 0.0 110.767 177.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 mt -52.57 -40.96 63.16 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.45 1.023 . . . . 0.0 111.942 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -57.36 -36.04 70.7 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 122.848 0.459 . . . . 0.0 110.752 174.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.41 50.38 0.93 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.827 0.851 . . . . 0.0 109.601 174.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.77 -51.23 35.77 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.603 0.761 . . . . 0.0 110.174 -174.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . 0.299 70.3 p 65.3 -44.31 0.35 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.154 2.182 . . . . 0.0 114.932 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.4 118.45 13.72 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 119.535 1.061 . . . . 0.0 110.975 174.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -79.88 163.96 23.94 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 124.979 1.312 . . . . 0.0 109.158 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -85.27 151.24 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 C-N-CA 122.957 0.503 . . . . 0.0 110.156 -179.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 60.4 m -150.89 72.23 1.06 Allowed 'General case' 0 C--O 1.227 -0.116 0 C-N-CA 124.918 1.287 . . . . 0.0 108.581 174.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.15 -144.31 47.62 Favored Glycine 0 CA--C 1.528 0.866 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -80.01 57.24 2.59 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.913 1.357 . . . . 0.0 109.743 174.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.9 m -160.89 153.93 21.37 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 178.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.92 152.16 15.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -140.98 136.78 32.5 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.328 -172.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -107.46 164.42 12.22 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.065 0.946 . . . . 0.0 109.907 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 m -159.19 47.45 0.3 Allowed 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.311 0.644 . . . . 0.0 110.069 -174.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -175.47 171.6 44.69 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 107.637 -2.185 . . . . 0.0 107.637 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -75.41 -32.33 60.71 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 117.69 0.745 . . . . 0.0 111.005 -177.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.06 71.41 5.53 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.42 0.629 . . . . 0.0 110.241 -174.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -81.79 77.95 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -176.202 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -80.78 111.86 17.62 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.891 0.876 . . . . 0.0 109.034 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.18 106.68 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.5 t -89.57 95.45 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 118.068 0.395 . . . . 0.0 109.967 -174.425 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.0 99.95 10.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.329 1.452 . . . . 0.0 111.47 -174.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.22 108.45 18.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 O-C-N 121.673 -0.642 . . . . 0.0 109.971 175.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.45 82.78 8.16 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 121.259 -0.901 . . . . 0.0 109.057 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 34.3 t 68.24 96.05 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 C-N-CA 125.167 1.387 . . . . 0.0 109.68 175.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.9 mt -77.23 144.0 70.41 Favored Pre-proline 0 CA--C 1.531 0.213 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo . . . . . 0 N--CA 1.453 -0.863 0 C-N-CA 123.397 2.732 . . . . 0.0 109.125 -179.122 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 . . . . . 0 CA--C 1.538 0.512 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -118.15 -23.54 0.09 OUTLIER 'Cis proline' 0 C--N 1.347 0.471 0 CA-C-N 120.701 1.286 . . . . 0.0 114.599 -5.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 p -86.17 160.37 19.24 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.959 2.948 . . . . 0.0 118.959 -166.429 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -76.68 117.25 18.12 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 171.221 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -101.98 103.18 13.79 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 104.248 -2.501 . . . . 0.0 104.248 -179.056 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.7 t -108.89 113.07 43.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 O-C-N 122.086 -0.384 . . . . 0.0 110.079 -171.025 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 30.59 -104.24 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 126.078 1.751 . . . . 0.0 113.869 -174.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -67.09 -24.16 65.92 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -173.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -139.37 -164.67 1.72 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 119.35 0.977 . . . . 0.0 111.335 -173.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.1 mtmt -125.33 130.99 53.07 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 172.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 47.58 45.31 2.6 Favored Pre-proline 0 CA--C 1.545 0.768 0 C-N-CA 124.227 1.011 . . . . 0.0 112.025 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -67.37 154.75 72.99 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.273 1.315 . . . . 0.0 111.114 -179.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.5 m -87.56 133.73 33.74 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 171.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -111.71 128.51 56.1 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.922 0.783 . . . . 0.0 110.824 -174.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -99.33 115.94 30.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 171.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.427 HD12 HG23 ' A' ' 152' ' ' ILE . 27.2 mt -120.64 142.34 34.03 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 124.552 1.141 . . . . 0.0 113.379 -169.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -78.89 119.46 4.36 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 122.532 2.155 . . . . 0.0 109.137 171.398 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.2 140.6 3.88 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 125.816 1.646 . . . . 0.0 111.95 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.97 -5.46 48.59 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-O 119.092 -0.838 . . . . 0.0 113.613 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 155.22 26.17 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 119.45 1.625 . . . . 0.0 111.049 174.43 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 73.7 m -83.76 96.85 8.86 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 174.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.65 100.12 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 C-N-CA 124.877 1.271 . . . . 0.0 108.046 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -92.52 91.52 7.63 Favored 'General case' 0 C--O 1.237 0.441 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 40.7 t -77.08 103.13 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 176.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 43.3 m -101.04 98.22 8.69 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.011 1.724 . . . . 0.0 109.232 -172.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.8 m-85 -77.91 156.58 30.21 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.574 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -139.21 78.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 101.576 -3.49 . . . . 0.0 101.576 164.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -97.1 101.83 13.48 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 178.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.2 m -148.37 54.38 1.02 Allowed 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 122.182 0.992 . . . . 0.0 108.721 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.83 -19.64 61.28 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.822 173.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mttm 81.5 121.49 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 127.649 2.38 . . . . 0.0 107.323 -173.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.38 -54.05 3.18 Favored Glycine 0 CA--C 1.534 1.233 0 O-C-N 121.595 -0.691 . . . . 0.0 112.921 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -78.53 79.42 4.96 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 121.444 -1.033 . . . . 0.0 110.718 -174.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -51.69 77.33 0.01 OUTLIER Glycine 0 CA--C 1.527 0.794 0 C-N-CA 126.603 2.049 . . . . 0.0 112.635 174.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -63.18 144.17 57.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 118.66 1.23 . . . . 0.0 111.251 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.9 p -106.51 154.73 20.43 Favored 'General case' 0 N--CA 1.444 -0.757 0 C-N-CA 127.024 2.13 . . . . 0.0 106.048 172.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 8.2 t80 -134.52 110.33 9.29 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 105.37 -2.085 . . . . 0.0 105.37 172.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ASP . . . . . 0.411 ' HB3' HD12 ' A' ' 105' ' ' ILE . 1.4 m-20 -130.81 148.39 52.58 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.292 0.496 . . . . 0.0 110.397 -174.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.2 mt -114.56 137.93 46.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 C-N-CA 126.22 1.808 . . . . 0.0 110.048 -172.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.5 t -160.93 -155.0 0.39 Allowed 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.909 1.284 . . . . 0.0 107.714 177.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -122.2 8.45 9.75 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.905 0.882 . . . . 0.0 111.595 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? -63.0 114.11 3.49 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.29 170.25 38.88 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -68.67 164.06 34.64 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.072 2.514 . . . . 0.0 109.196 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.81 131.12 23.04 Favored 'Cis proline' 0 N--CA 1.455 -0.749 0 CA-C-N 119.464 0.844 . . . . 0.0 110.828 0.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -79.56 158.53 27.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 174.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -138.33 167.28 22.21 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.364 1.066 . . . . 0.0 108.15 -177.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.55 60.42 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 C-N-CA 124.324 1.049 . . . . 0.0 108.664 -176.364 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 52.3 mtm -147.09 103.96 3.83 Favored Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 124.51 1.124 . . . . 0.0 110.473 -174.022 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -64.93 75.49 0.22 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.191 2.594 . . . . 0.0 112.692 174.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.6 t -78.98 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 173.121 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 24.9 pt -83.05 -23.66 8.39 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 C-N-CA 124.713 1.205 . . . . 0.0 114.134 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -45.35 -56.96 8.29 Favored Pre-proline 0 CA--C 1.543 0.694 0 CA-C-O 118.92 -0.562 . . . . 0.0 111.779 176.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -76.07 67.76 6.73 Favored 'Trans proline' 0 CA--C 1.537 0.663 0 C-N-CA 122.178 1.918 . . . . 0.0 111.597 172.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 88' ' ' ASP . 6.1 mm -118.65 142.08 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 172.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.0 t -98.61 -92.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.94 161.39 14.48 Favored 'General case' 0 C--N 1.334 -0.088 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 174.403 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.38 173.71 28.18 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 120.134 -1.031 . . . . 0.0 113.374 174.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.431 HG23 ' CD1' ' A' ' 125' ' ' PHE . 3.0 p -109.41 125.52 52.5 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.909 1.284 . . . . 0.0 110.152 -178.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -80.21 58.95 4.6 Favored Glycine 0 CA--C 1.535 1.314 0 CA-C-O 119.496 -0.613 . . . . 0.0 111.817 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 71.58 98.8 0.07 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.617 1.967 . . . . 0.0 112.263 174.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 p -78.61 165.15 51.69 Favored Pre-proline 0 CA--C 1.544 0.732 0 O-C-N 121.077 -1.014 . . . . 0.0 112.5 -175.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -60.79 159.64 28.11 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 123.252 2.635 . . . . 0.0 112.098 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.51 86.19 14.37 Favored Pre-proline 0 CA--C 1.533 0.313 0 C-N-CA 124.217 1.007 . . . . 0.0 110.896 -179.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -55.74 163.72 5.21 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.528 2.819 . . . . 0.0 113.024 173.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -92.98 -23.53 18.68 Favored 'General case' 0 C--N 1.338 0.086 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 178.19 159.93 0.53 Allowed 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.7 2.0 . . . . 0.0 109.32 -176.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 70.26 -63.41 0.78 Allowed Glycine 0 C--N 1.338 0.644 0 C-N-CA 125.524 1.535 . . . . 0.0 112.839 174.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -78.68 157.84 28.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 124.263 1.025 . . . . 0.0 109.609 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -139.71 107.67 5.71 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.237 1.415 . . . . 0.0 110.826 -172.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -60.76 109.65 2.51 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.576 1.084 . . . . 0.0 110.852 -178.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -127.55 156.48 42.15 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.849 0.833 . . . . 0.0 111.455 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 18.1 m -159.72 109.93 1.9 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.97 -1.468 . . . . 0.0 107.449 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -86.75 69.61 10.33 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.164 1.386 . . . . 0.0 107.333 173.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' PHE . . . . . 0.431 ' CD1' HG23 ' A' ' 109' ' ' THR . 17.2 p90 -72.19 129.66 38.98 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 118.304 -1.358 . . . . 0.0 108.331 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.9 m -101.95 126.99 49.0 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.411 -171.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -134.68 157.78 45.78 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.481 1.512 . . . . 0.0 109.522 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -123.35 115.43 28.64 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 174.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -92.36 148.2 2.93 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 124.301 3.334 . . . . 0.0 111.809 -172.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.7 p -95.02 149.62 21.05 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 124.888 1.275 . . . . 0.0 108.763 173.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.98 151.9 13.99 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.122 0.419 . . . . 0.0 111.733 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.3 -124.13 5.89 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.937 2.208 . . . . 0.0 109.592 -176.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.0 m -153.61 147.95 25.93 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.314 1.057 . . . . 0.0 110.222 -174.469 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -139.87 173.87 11.08 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 127.825 2.45 . . . . 0.0 106.912 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -136.15 148.75 48.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 126.402 1.881 . . . . 0.0 107.259 174.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -109.47 147.87 32.14 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 172.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.39 150.9 12.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.117 1.367 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 42.6 t -84.75 140.34 31.33 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 169.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -78.08 -20.71 51.75 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -173.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 54.7 mt -61.35 124.38 80.46 Favored Pre-proline 0 CA--C 1.544 0.739 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -25.28 -76.01 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.567 1 C-N-CA 126.011 4.474 . . . . 0.0 117.446 -172.471 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -77.45 -2.29 79.32 Favored Glycine 0 CA--C 1.525 0.679 0 O-C-N 121.691 -0.631 . . . . 0.0 114.046 -173.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -72.69 -48.29 40.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 119.364 1.582 . . . . 0.0 110.558 -173.335 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.15 -41.86 93.68 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 173.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.24 78.29 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.823 0.449 . . . . 0.0 111.51 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 26.3 p -79.38 -58.29 3.28 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -174.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 176.87 37.79 0.05 OUTLIER Glycine 0 C--N 1.339 0.7 0 C-N-CA 119.187 -1.482 . . . . 0.0 115.196 -174.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 10.4 mtp -116.39 72.39 0.81 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 118.193 0.996 . . . . 0.0 108.405 173.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -159.56 -174.72 4.79 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.318 0.647 . . . . 0.0 112.16 -177.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 164.53 171.01 30.26 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 174.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 42.9 mtmt -99.94 146.86 26.2 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 124.998 1.319 . . . . 0.0 110.609 -176.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ILE . . . . . 0.427 HG23 HD12 ' A' ' 66' ' ' ILE . 15.8 mt -124.59 101.77 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 173.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.5 t -92.42 137.64 21.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 172.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 11.5 t -127.9 123.55 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -175.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt . . . . . 0 N--CA 1.466 0.328 0 CA-C-N 119.823 1.192 . . . . 0.0 111.422 179.481 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 25.2 p . . . . . 0 CA--C 1.538 0.481 0 CA-C-O 120.316 0.103 . . . . 0.0 110.829 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.9 m -79.77 64.18 4.55 Favored 'General case' 0 CA--C 1.536 0.409 0 O-C-N 121.161 -0.962 . . . . 0.0 110.277 -174.687 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -85.91 134.55 33.88 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 126.34 1.856 . . . . 0.0 110.212 -173.488 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -149.55 173.04 14.05 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -138.77 151.16 46.85 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 172.134 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.31 -153.02 0.54 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.898 1.679 . . . . 0.0 106.664 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.7 p -135.65 173.95 11.15 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 119.462 1.028 . . . . 0.0 108.512 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -39.41 -57.05 2.51 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -54.76 -34.18 83.54 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 121.963 1.775 . . . . 0.0 113.531 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 21.0 mp0 -67.41 -25.73 66.08 Favored 'General case' 0 N--CA 1.456 -0.172 0 O-C-N 121.134 -0.979 . . . . 0.0 111.258 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.82 -46.91 93.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 174.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.1 -50.11 74.98 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.21 -48.36 62.06 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.7 mtm -62.93 -50.63 70.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.606 0.362 . . . . 0.0 110.516 177.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.8 mt -52.08 -41.95 62.8 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.436 0.562 . . . . 0.0 111.875 177.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -56.51 -23.62 40.95 Favored 'General case' 0 CA--C 1.538 0.513 0 O-C-N 121.542 -0.724 . . . . 0.0 112.678 177.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -100.95 12.55 37.46 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.653 0.781 . . . . 0.0 111.787 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -65.85 -46.27 79.1 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -174.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.4 p 63.8 -139.12 0.32 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.455 1.502 . . . . 0.0 109.27 -171.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.48 104.18 0.2 Allowed Glycine 0 CA--C 1.528 0.893 0 CA-C-N 118.593 0.633 . . . . 0.0 111.741 -177.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 37.3 mtpt -78.7 120.26 23.11 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.028 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 62.5 t -63.04 148.51 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -148.85 64.17 1.05 Allowed 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.15 -141.26 35.51 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -79.55 54.74 1.82 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 118.603 1.202 . . . . 0.0 109.642 174.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.7 m -161.31 147.12 14.17 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -118.18 137.87 50.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 175.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 93.2 m -120.57 119.22 32.29 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.832 1.253 . . . . 0.0 109.623 -173.151 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -83.07 169.43 15.91 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 122.083 0.944 . . . . 0.0 111.606 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 75.1 m -156.86 152.17 26.48 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.36 166.95 33.05 Favored Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -174.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 35.4 mtmm -82.82 -28.48 30.18 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 122.282 -0.54 . . . . 0.0 112.241 -174.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.2 p -81.59 78.01 8.39 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.484 -0.76 . . . . 0.0 109.588 -178.611 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -80.07 75.39 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -80.89 93.19 6.24 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.788 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -88.49 102.42 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.049 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -176.387 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 43.1 t -83.74 88.42 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.08 164.23 12.78 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.267 1.427 . . . . 0.0 110.227 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -159.62 169.31 24.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 123.96 0.904 . . . . 0.0 109.23 178.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.56 132.7 28.01 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 26.13 72.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 127.263 2.225 . . . . 0.0 113.009 173.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.1 mt -77.29 148.27 77.4 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 N--CA 1.455 -0.745 0 C-N-CA 122.999 2.466 . . . . 0.0 110.519 -175.083 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 . . . . . 0 CA--C 1.534 0.355 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -113.47 -11.92 0.64 Allowed 'Cis proline' 0 CA--C 1.539 0.774 0 CA-C-N 118.947 0.66 . . . . 0.0 113.535 -4.385 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.5 p -44.68 143.46 1.38 Allowed 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 118.586 2.81 . . . . 0.0 118.586 -170.126 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -77.27 129.14 35.49 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 168.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -104.33 132.52 50.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 177.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.5 t -139.91 123.67 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -14.74 111.32 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.515 1.926 . . . . 0.0 115.37 -173.346 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.4 t70 89.67 -28.02 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 127.309 2.244 . . . . 0.0 113.419 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -136.69 -168.97 2.36 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.524 1.154 . . . . 0.0 111.015 -173.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.5 mttp -137.5 134.88 36.25 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 171.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 48.82 40.62 0.8 Allowed Pre-proline 0 CA--C 1.548 0.882 0 C-N-CA 124.081 0.952 . . . . 0.0 112.69 -176.057 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.25 159.67 46.64 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 CA-C-N 120.993 1.39 . . . . 0.0 113.349 -171.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.58 121.23 25.55 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 127.647 2.379 . . . . 0.0 106.297 173.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.2 mp -103.99 117.94 35.5 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 119.862 1.21 . . . . 0.0 111.5 -178.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -93.36 120.09 33.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 171.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.0 mt -122.32 139.7 31.2 Favored Pre-proline 0 CA--C 1.538 0.514 0 C-N-CA 124.431 1.092 . . . . 0.0 112.906 -170.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -76.34 116.26 4.3 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 122.805 2.336 . . . . 0.0 108.728 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -48.69 139.58 9.43 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 125.12 1.368 . . . . 0.0 112.302 -178.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.25 -9.78 38.7 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.072 -0.849 . . . . 0.0 113.457 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 157.52 20.02 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.42 1.61 . . . . 0.0 110.52 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 50.2 m -83.71 101.68 11.72 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.1 t -79.64 99.81 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 174.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -96.59 97.16 9.17 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 174.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -80.02 108.02 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.2 m -99.7 96.71 7.8 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.009 1.724 . . . . 0.0 107.972 175.04 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.278 5.7 m-85 -79.26 148.1 32.29 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 118.726 -0.654 . . . . 0.0 110.31 172.66 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.07 79.38 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 102.514 -3.143 . . . . 0.0 102.514 163.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -99.48 104.7 16.55 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 172.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.0 m -121.77 38.44 4.11 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 173.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -78.39 73.23 4.94 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.245 -0.91 . . . . 0.0 109.12 175.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.4 mttm 0.16 97.32 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 129.126 2.97 . . . . 0.0 114.557 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.05 -34.29 3.62 Favored Glycine 0 CA--C 1.534 1.243 0 O-C-N 121.605 -0.685 . . . . 0.0 114.07 175.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -82.24 88.12 6.52 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 119.073 1.436 . . . . 0.0 110.171 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.29 63.04 0.4 Allowed Glycine 0 CA--C 1.533 1.168 0 C-N-CA 123.785 0.707 . . . . 0.0 112.545 175.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -51.06 120.78 5.23 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 118.941 1.37 . . . . 0.0 110.084 175.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.87 165.11 25.48 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.581 0.752 . . . . 0.0 109.628 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 21.4 t80 -133.15 103.37 5.98 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 106.376 -1.712 . . . . 0.0 106.376 172.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ASP . . . . . 0.443 ' HB3' HD12 ' A' ' 105' ' ' ILE . 81.0 m-20 -118.38 137.34 53.19 Favored 'General case' 0 CA--C 1.516 -0.333 0 C-N-CA 123.434 0.694 . . . . 0.0 109.819 -176.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 25.8 mt -110.0 134.71 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 126.041 1.737 . . . . 0.0 109.075 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.2 t -158.65 -158.22 0.68 Allowed 'General case' 0 C--O 1.223 -0.301 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.0 mtmm -129.6 6.67 5.21 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 119.564 1.075 . . . . 0.0 112.5 -179.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.9 mtpt -67.51 160.71 27.08 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.08 160.06 16.18 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -72.78 159.5 48.29 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 122.791 2.327 . . . . 0.0 109.893 174.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.79 134.83 34.28 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 N-CA-C 108.75 -1.288 . . . . 0.0 108.75 -5.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.542 ' HB2' ' HB1' ' A' ' 144' ' ' ALA . 92.9 m-85 -83.13 31.36 0.44 Allowed 'General case' 0 N--CA 1.468 0.463 0 O-C-N 120.979 -1.075 . . . . 0.0 113.377 -173.417 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . 70.05 156.0 0.14 Allowed 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 127.703 2.401 . . . . 0.0 113.084 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.98 -46.25 85.26 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.386 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.1 mmt -78.92 160.1 72.19 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 174.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -70.25 59.12 1.85 Allowed 'Trans proline' 0 CA--C 1.538 0.725 0 C-N-CA 123.08 2.52 . . . . 0.0 114.153 -174.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.8 t -82.46 55.79 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 O-C-N 120.238 -1.539 . . . . 0.0 108.664 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -80.88 -38.6 17.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 C-N-CA 123.101 0.561 . . . . 0.0 110.998 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -55.48 147.43 38.73 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 124.445 1.098 . . . . 0.0 111.826 -174.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 79.1 Cg_endo -74.13 150.38 95.47 Favored 'Cis proline' 0 N--CA 1.459 -0.537 0 CA-C-N 118.851 0.625 . . . . 0.0 111.127 -0.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.443 HD12 ' HB3' ' A' ' 88' ' ' ASP . 20.2 mm -109.45 143.7 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 C-N-CA 124.42 1.088 . . . . 0.0 108.406 175.522 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.73 -89.49 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 174.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.89 156.48 16.33 Favored 'General case' 0 C--N 1.332 -0.155 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 173.054 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.29 173.51 41.11 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 119.063 -1.541 . . . . 0.0 112.817 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.9 p -123.15 137.09 54.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.398 1.479 . . . . 0.0 109.625 176.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.47 -164.34 7.49 Favored Glycine 0 CA--C 1.54 1.654 0 N-CA-C 108.136 -1.986 . . . . 0.0 108.136 170.669 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -67.63 118.66 11.21 Favored 'General case' 0 CA--C 1.537 0.47 0 O-C-N 120.8 -1.412 . . . . 0.0 112.286 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 p -69.71 161.08 77.01 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 126.201 1.8 . . . . 0.0 113.413 -173.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -74.4 144.96 33.3 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.023 2.482 . . . . 0.0 107.969 174.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.18 80.15 9.49 Favored Pre-proline 0 CA--C 1.536 0.442 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -53.89 164.69 2.29 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 124.627 3.551 . . . . 0.0 112.588 172.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -119.35 -0.05 11.02 Favored 'General case' 0 C--N 1.34 0.173 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -174.241 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -175.28 148.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.191 1.396 . . . . 0.0 109.026 176.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 66.15 -62.85 0.15 Allowed Glycine 0 CA--C 1.527 0.79 0 C-N-CA 126.579 2.038 . . . . 0.0 113.47 177.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -78.66 157.39 28.64 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-O 121.352 0.596 . . . . 0.0 110.018 -177.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -129.55 108.63 10.39 Favored 'General case' 0 CA--C 1.512 -0.481 0 C-N-CA 127.014 2.125 . . . . 0.0 107.943 -174.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.04 123.71 18.63 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 19.8 p90 -130.89 168.57 17.07 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.724 1.25 . . . . 0.0 110.701 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.8 m -155.53 124.68 6.21 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.83 106.63 16.3 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -119.06 150.61 39.68 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.3 m -114.69 145.29 42.21 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.882 0.873 . . . . 0.0 111.007 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 26.1 t90 -145.02 153.23 41.26 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.887 1.275 . . . . 0.0 109.236 174.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.9 93.96 44.96 Favored Pre-proline 0 CA--C 1.53 0.174 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -81.6 146.01 14.93 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.467 2.112 . . . . 0.0 111.358 -173.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 10.6 p -96.3 156.37 16.37 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 172.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.93 144.65 27.56 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -174.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 139.97 -132.58 5.62 Favored Glycine 0 C--N 1.337 0.611 0 C-N-CA 126.215 1.864 . . . . 0.0 109.984 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 33.5 m -150.52 145.07 25.73 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 118.026 0.913 . . . . 0.0 109.132 -174.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -147.02 175.64 10.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.738 2.015 . . . . 0.0 107.181 -175.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -142.57 155.37 44.98 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 125.354 1.462 . . . . 0.0 108.557 179.149 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -121.46 147.2 46.07 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 124.275 1.03 . . . . 0.0 110.915 175.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.65 160.66 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 124.855 1.262 . . . . 0.0 112.308 -174.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 7.1 t -102.82 133.49 47.8 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.876 1.67 . . . . 0.0 108.738 171.17 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -70.65 -34.67 72.3 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 113.816 1.043 . . . . 0.0 113.816 -173.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 70.8 mt -48.62 128.38 13.71 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.781 0.832 . . . . 0.0 109.993 -172.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -42.32 142.82 1.61 Allowed 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 124.26 3.307 . . . . 0.0 114.968 -173.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.45 -40.55 1.78 Allowed Glycine 0 CA--C 1.529 0.951 0 C-N-CA 123.995 0.807 . . . . 0.0 112.634 177.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -54.6 -47.26 73.6 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.568 0.747 . . . . 0.0 111.624 -173.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ALA . . . . . 0.542 ' HB1' ' HB2' ' A' ' 96' ' ' TYR . . . -81.84 -11.67 58.85 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.631 0.65 . . . . 0.0 112.4 175.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.56 -57.82 4.72 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 173.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.5 p -151.63 87.04 1.34 Allowed 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.91 -66.47 0.06 OUTLIER Glycine 0 CA--C 1.524 0.631 0 C-N-CA 119.82 -1.181 . . . . 0.0 113.951 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.0 ptm -141.59 113.19 7.7 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 117.671 0.736 . . . . 0.0 111.948 -173.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -163.56 -166.73 1.26 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.716 1.206 . . . . 0.0 108.169 176.547 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.14 173.33 36.71 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 175.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 29.9 mttp -109.78 150.31 28.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.709 1.204 . . . . 0.0 110.869 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 17.1 mt -128.33 130.01 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 174.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 6.2 t -118.01 135.81 57.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 173.197 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.03 123.11 64.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -174.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 53.3 mtmt . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 118.81 0.732 . . . . 0.0 111.093 -174.288 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.0 p . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.1 m -79.59 62.62 3.94 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.879 0.847 . . . . 0.0 108.729 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -78.48 123.81 27.45 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.188 1.395 . . . . 0.0 110.392 -172.428 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -142.64 173.55 11.44 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 174.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -141.15 148.76 40.54 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.847 -0.533 . . . . 0.0 109.607 171.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.74 -153.77 0.56 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 126.633 1.973 . . . . 0.0 106.212 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -134.97 172.22 13.32 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 119.084 0.856 . . . . 0.0 108.991 172.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -38.64 -57.44 1.95 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -174.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.24 -32.46 87.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.473 1.449 . . . . 0.0 113.318 -178.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.6 mp0 -65.7 -31.57 72.64 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.7 t -55.42 -49.74 70.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.954 0.797 . . . . 0.0 109.14 176.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 mtpp -57.03 -51.39 69.47 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.87 -51.58 39.33 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -61.18 -53.1 61.19 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.219 0.463 . . . . 0.0 110.708 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 58.4 mt -51.7 -40.7 60.6 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.672 0.669 . . . . 0.0 111.78 -177.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -59.36 -23.53 62.61 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.842 0.857 . . . . 0.0 112.726 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -70.88 -66.31 0.63 Allowed 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.315 0.961 . . . . 0.0 109.514 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 58.6 -62.22 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 126.716 2.006 . . . . 0.0 115.622 176.134 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 19.3 p 53.89 37.66 27.04 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.174 1.79 . . . . 0.0 112.301 179.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -141.6 121.66 1.89 Allowed Glycine 0 CA--C 1.528 0.854 0 C-N-CA 124.88 1.229 . . . . 0.0 110.535 -174.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.3 mtpt -79.81 118.14 21.33 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.892 1.677 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.4 t -68.83 77.48 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 C-N-CA 124.939 1.296 . . . . 0.0 110.257 -174.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 m -81.09 70.08 7.84 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.687 1.195 . . . . 0.0 107.784 -179.008 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 62.95 -113.55 6.0 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -174.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -78.45 -19.1 53.87 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.856 0.828 . . . . 0.0 111.238 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 59.6 m -98.62 110.06 22.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -172.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.9 t -79.19 114.17 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 104.298 -2.482 . . . . 0.0 104.298 172.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.5 m -106.72 121.48 44.46 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 124.577 1.151 . . . . 0.0 111.679 -170.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -81.36 167.68 19.21 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.513 0.673 . . . . 0.0 110.752 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.0 m -159.55 46.97 0.28 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.992 0.917 . . . . 0.0 109.275 -177.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.52 170.35 42.77 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -78.62 -32.14 47.32 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 117.45 0.625 . . . . 0.0 111.602 -177.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.6 m -78.87 72.94 5.42 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.49 0.662 . . . . 0.0 109.617 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.4 t -80.31 86.08 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-O 121.788 0.804 . . . . 0.0 109.118 -174.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -85.69 101.96 13.2 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.938 1.295 . . . . 0.0 110.401 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.3 t -102.79 110.62 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 C-N-CA 124.484 1.114 . . . . 0.0 108.918 -176.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.06 101.64 12.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 CA-C-N 118.183 0.447 . . . . 0.0 110.267 -176.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -101.93 104.39 15.09 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.437 1.495 . . . . 0.0 111.244 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.6 110.57 21.42 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.486 1.514 . . . . 0.0 109.259 175.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -97.48 95.54 7.72 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.79 -0.569 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 46.68 69.74 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 C-N-CA 127.238 2.215 . . . . 0.0 111.153 173.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 27.3 mt -77.26 152.54 81.75 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-O 118.514 -0.755 . . . . 0.0 109.556 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_exo . . . . . 0 N--CA 1.457 -0.656 0 C-N-CA 124.139 3.226 . . . . 0.0 111.446 175.331 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 . . . . . 0 CA--C 1.535 0.398 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -115.7 -21.65 0.15 OUTLIER 'Cis proline' 0 N--CA 1.458 -0.592 0 CA-C-N 120.305 1.145 . . . . 0.0 113.631 -5.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.0 p -67.55 148.54 51.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -167.28 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -75.54 131.48 40.07 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 173.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -102.23 131.1 48.99 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 172.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 t -138.33 122.01 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 CA-C-N 119.245 0.93 . . . . 0.0 108.809 -174.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 12.58 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 127.756 2.422 . . . . 0.0 115.335 -178.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 t70 76.21 -32.45 0.2 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.078 1.351 . . . . 0.0 113.595 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.2 mmmp? -121.58 -173.29 2.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 122.351 1.072 . . . . 0.0 112.367 -171.484 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -133.12 125.5 29.66 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 105.332 -2.099 . . . . 0.0 105.332 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 43.85 50.18 6.17 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.195 0.998 . . . . 0.0 111.83 -173.405 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.76 157.87 58.91 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 121.717 1.611 . . . . 0.0 110.485 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 151' ' ' LYS . 50.2 m -84.44 145.88 27.93 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 105.893 -1.892 . . . . 0.0 105.893 170.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.0 mp -114.24 121.47 43.81 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.506 -0.747 . . . . 0.0 109.542 -177.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -98.94 118.54 35.95 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 171.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.41 HD12 ' CG2' ' A' ' 152' ' ' ILE . 17.9 mt -122.14 133.68 24.45 Favored Pre-proline 0 N--CA 1.453 -0.289 0 C-N-CA 124.978 1.311 . . . . 0.0 110.448 -172.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.93 118.39 5.02 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.127 1.885 . . . . 0.0 108.137 172.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.38 136.37 20.5 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.883 0.873 . . . . 0.0 111.196 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -12.71 67.65 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.672 -0.516 . . . . 0.0 112.156 -175.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.97 154.14 16.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 118.481 1.14 . . . . 0.0 112.909 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 99.5 m -92.15 105.72 17.88 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.472 -2.047 . . . . 0.0 105.472 171.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.2 t -88.04 93.78 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 C-N-CA 124.344 1.058 . . . . 0.0 108.178 -175.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.87 94.9 6.56 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 173.368 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.9 t -79.6 94.6 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 174.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 96.5 m -86.43 97.06 10.25 Favored 'General case' 0 N--CA 1.444 -0.732 0 C-N-CA 126.085 1.754 . . . . 0.0 108.539 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.403 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.5 m-85 -77.29 156.73 31.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.169 0.509 . . . . 0.0 111.607 173.306 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -140.59 86.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 100.857 -3.757 . . . . 0.0 100.857 164.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -105.13 113.83 27.66 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.7 m -143.4 37.48 1.36 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -78.96 65.28 4.11 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.581 -0.699 . . . . 0.0 109.369 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.5 mttm 17.7 81.18 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 128.424 2.689 . . . . 0.0 114.688 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 95.15 -29.91 8.82 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.885 176.008 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -78.38 99.02 6.2 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 119.265 1.532 . . . . 0.0 109.917 -174.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.81 60.97 0.94 Allowed Glycine 0 CA--C 1.523 0.591 0 C-N-CA 124.806 1.194 . . . . 0.0 110.614 176.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -33.68 -52.29 0.41 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 126.114 1.766 . . . . 0.0 115.411 -172.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 17.5 p 78.43 134.06 0.06 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 125.889 1.676 . . . . 0.0 108.742 -172.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.2 t80 -114.44 108.7 17.23 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.638 -2.727 . . . . 0.0 103.638 172.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.86 139.12 47.61 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -173.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 mt -124.75 134.42 66.87 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.838 0.828 . . . . 0.0 110.39 -173.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -160.22 -163.08 1.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -175.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -120.97 5.69 10.39 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.814 0.846 . . . . 0.0 111.788 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -71.67 130.14 40.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 174.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.92 169.18 25.25 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.016 0.817 . . . . 0.0 112.158 -176.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -72.51 167.13 27.86 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.507 2.804 . . . . 0.0 109.698 174.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -68.2 130.74 15.47 Favored 'Cis proline' 0 N--CA 1.459 -0.544 0 CA-C-N 119.483 0.851 . . . . 0.0 111.218 -5.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -79.93 148.72 31.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 175.554 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.27 156.7 24.19 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.347 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 73.9 t -61.26 -34.75 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 55.2 mtm -78.05 128.13 79.61 Favored Pre-proline 0 CA--C 1.534 0.344 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 173.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.25 101.91 1.3 Allowed 'Trans proline' 0 N--CA 1.451 -0.971 0 C-N-CA 122.542 2.161 . . . . 0.0 110.602 -173.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 22.0 t -77.69 93.5 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.0 pt -78.49 -85.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.702 0.801 . . . . 0.0 112.788 -173.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -67.82 150.16 97.92 Favored Pre-proline 0 N--CA 1.454 -0.242 0 O-C-N 121.723 -0.611 . . . . 0.0 112.237 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.61 113.24 2.88 Favored 'Cis proline' 0 CA--C 1.537 0.645 0 CA-C-N 118.579 0.528 . . . . 0.0 112.878 1.404 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.7 mm -86.66 139.05 17.95 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.006 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.5 t -95.76 -87.2 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 174.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -93.64 166.65 12.13 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 173.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 179.6 41.55 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.3 p -124.68 124.57 42.47 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.696 1.199 . . . . 0.0 108.984 175.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.27 59.75 4.31 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.564 -0.575 . . . . 0.0 112.809 -173.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 71.17 93.66 0.08 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.244 1.818 . . . . 0.0 110.501 175.041 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 p -65.9 161.36 55.11 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 126.875 2.07 . . . . 0.0 115.357 -172.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -67.02 154.88 73.17 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 123.795 2.997 . . . . 0.0 108.995 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.4 t -147.19 85.31 6.92 Favored Pre-proline 0 CA--C 1.54 0.561 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -172.412 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -57.78 165.34 6.55 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.16 2.573 . . . . 0.0 112.722 174.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -101.43 6.39 42.48 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 -174.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.7 p30 143.38 166.45 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 130.355 3.462 . . . . 0.0 109.376 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.3 -66.54 0.95 Allowed Glycine 0 C--N 1.34 0.755 0 C-N-CA 125.431 1.491 . . . . 0.0 111.28 177.118 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -78.58 155.15 29.8 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 124.075 0.95 . . . . 0.0 108.466 174.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -137.61 109.78 7.3 Favored 'General case' 0 CA--C 1.518 -0.258 0 C-N-CA 125.063 1.345 . . . . 0.0 110.829 -172.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.11 114.02 5.79 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 124.63 1.109 . . . . 0.0 111.102 -177.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 22.1 p90 -122.21 164.67 17.42 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 122.292 1.044 . . . . 0.0 111.65 178.23 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 74.3 m -159.57 119.22 2.95 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -95.99 67.95 2.7 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 124.104 0.962 . . . . 0.0 108.501 176.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . 0.254 40.4 p90 -70.81 114.13 8.57 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 118.003 -1.479 . . . . 0.0 108.019 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.2 m -91.66 87.08 6.18 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.498 1.519 . . . . 0.0 109.974 -171.222 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.5 t90 -93.27 143.55 26.16 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.026 0.93 . . . . 0.0 110.951 -175.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -111.23 109.72 56.55 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 105.344 -2.095 . . . . 0.0 105.344 171.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -84.76 178.95 4.57 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 123.884 3.056 . . . . 0.0 111.462 -172.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 58.7 p -124.21 159.97 28.94 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 170.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.61 156.98 33.61 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 113.823 1.045 . . . . 0.0 113.823 -172.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 114.55 -176.86 17.2 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 126.254 1.883 . . . . 0.0 112.329 174.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 5.5 m -82.76 87.48 6.77 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.115 0.966 . . . . 0.0 110.262 -175.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -78.96 175.31 10.68 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 171.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -150.78 149.34 29.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.932 1.293 . . . . 0.0 109.541 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -112.31 146.52 38.1 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.233 1.013 . . . . 0.0 108.286 172.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -153.13 150.5 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 124.872 1.269 . . . . 0.0 110.404 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.82 106.99 19.19 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 169.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 34.3 mm-40 -75.17 34.32 0.11 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 114.695 1.368 . . . . 0.0 114.695 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 25.7 mt -92.21 137.2 25.0 Favored Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 169.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -43.94 129.2 7.54 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.596 2.197 . . . . 0.0 113.207 -178.261 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.65 -24.73 3.62 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.361 -0.688 . . . . 0.0 114.095 178.833 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -65.13 -52.53 54.74 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 119.796 1.798 . . . . 0.0 111.617 -172.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.62 -44.1 80.86 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 174.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.92 -42.9 99.02 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.777 0.431 . . . . 0.0 111.654 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.2 p -79.05 -59.93 2.58 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -174.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -178.9 31.43 0.06 OUTLIER Glycine 0 C--N 1.337 0.621 0 C-N-CA 119.296 -1.43 . . . . 0.0 115.033 -174.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.2 mtp -111.39 68.73 0.67 Allowed 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 118.2 1.0 . . . . 0.0 108.531 173.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -158.37 -177.52 6.6 Favored 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.09 165.48 24.56 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 173.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB2' HG23 ' A' ' 63' ' ' THR . 13.2 mtmm -100.18 149.43 23.55 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.681 0.793 . . . . 0.0 109.492 -174.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ILE . . . . . 0.41 ' CG2' HD12 ' A' ' 66' ' ' ILE . 13.3 mt -125.96 93.96 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.102 1.761 . . . . 0.0 107.361 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.97 95.8 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 29.6 t -85.74 91.19 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 C--N 1.332 -0.193 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 177.094 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.448 -0.531 0 N-CA-C 110.627 -0.138 . . . . 0.0 110.627 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.4 m -79.01 63.96 3.81 Favored 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.259 -0.901 . . . . 0.0 109.956 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -78.25 125.57 29.55 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 125.157 1.383 . . . . 0.0 109.511 -173.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -144.23 -179.74 6.71 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.918 0.887 . . . . 0.0 108.672 174.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -142.65 154.21 44.15 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.671 0.669 . . . . 0.0 111.088 172.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.46 -152.43 0.51 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 128.19 2.596 . . . . 0.0 105.65 173.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -138.73 170.81 15.34 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 119.082 0.855 . . . . 0.0 110.042 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -38.85 -59.64 1.34 Allowed Pre-proline 0 CA--C 1.538 0.512 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -174.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -58.78 -30.73 93.48 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 CA-C-N 121.248 1.481 . . . . 0.0 112.074 -178.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -67.07 -25.33 66.19 Favored 'General case' 0 N--CA 1.449 -0.523 0 O-C-N 121.819 -0.551 . . . . 0.0 111.254 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.2 t -59.1 -54.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -57.73 -49.61 75.98 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.558 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.2 -57.91 6.75 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.05 0.54 . . . . 0.0 110.953 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.9 mtm -56.82 -50.21 73.07 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 122.816 0.446 . . . . 0.0 110.096 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.1 mt -53.35 -45.31 69.08 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.612 0.642 . . . . 0.0 110.92 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.79 -30.9 70.32 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 118.249 0.477 . . . . 0.0 111.146 177.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 mmpt? -80.42 1.57 28.6 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 123.214 0.606 . . . . 0.0 112.365 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.43 146.68 50.8 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.926 1.239 . . . . 0.0 110.381 175.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.6 p -109.65 32.4 5.07 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.424 0.69 . . . . 0.0 112.155 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.94 113.82 4.75 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 124.678 1.132 . . . . 0.0 110.802 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -79.45 145.72 33.14 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 174.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 t -73.57 148.73 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.769 -0.582 . . . . 0.0 109.623 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -150.76 65.68 0.93 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.753 0.821 . . . . 0.0 109.611 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.12 -138.49 41.52 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -174.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -79.82 50.58 1.19 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.74 1.27 . . . . 0.0 110.222 174.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 m -161.39 153.73 20.06 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -119.34 149.08 21.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.6 m -134.32 125.34 27.44 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.222 1.009 . . . . 0.0 108.974 -173.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -98.73 167.33 10.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 123.882 0.873 . . . . 0.0 110.0 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.1 m -156.7 161.53 39.84 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.904 1.282 . . . . 0.0 107.661 177.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 73.13 178.36 35.01 Favored Glycine 0 CA--C 1.529 0.969 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -78.04 -32.3 50.86 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 122.078 -0.66 . . . . 0.0 110.617 178.363 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 m -79.06 70.05 5.34 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.872 0.869 . . . . 0.0 110.777 -174.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 69.0 t -86.09 92.19 3.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.0 t-160 -94.49 94.94 8.51 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.852 0.861 . . . . 0.0 110.531 -173.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.4 t -92.26 94.29 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.124 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.2 t -89.83 103.54 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.99 112.23 21.51 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.146 0.978 . . . . 0.0 111.363 -173.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.16 148.44 23.65 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 121.593 -0.692 . . . . 0.0 109.559 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.52 109.18 16.92 Favored 'General case' 0 CA--C 1.527 0.058 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 174.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.5 t 40.52 81.59 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.408 1.883 . . . . 0.0 112.576 175.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 76.8 mt -76.91 147.59 77.62 Favored Pre-proline 0 CA--C 1.534 0.332 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -175.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo . . . . . 0 N--CA 1.455 -0.738 0 C-N-CA 123.876 3.051 . . . . 0.0 111.017 174.235 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 . . . . . 0 CA--C 1.539 0.525 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -116.73 -19.43 0.14 OUTLIER 'Cis proline' 0 CA--C 1.539 0.733 0 CA-C-N 119.108 0.717 . . . . 0.0 113.394 -6.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.52 151.22 47.69 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 118.964 2.95 . . . . 0.0 118.964 -168.118 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -77.35 128.92 35.11 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 104.249 -2.5 . . . . 0.0 104.249 169.082 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -111.62 115.34 28.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 -173.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 58.2 t -120.49 85.58 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 123.257 0.623 . . . . 0.0 109.517 -171.033 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 45.23 -97.19 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 126.177 1.791 . . . . 0.0 112.993 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -70.38 -23.61 62.8 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.549 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -134.36 -175.72 3.96 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.897 0.879 . . . . 0.0 110.903 -172.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.4 mtpp -131.07 129.58 42.12 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 172.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 50.58 42.95 1.42 Allowed Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 124.487 1.115 . . . . 0.0 113.115 -175.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -72.51 164.68 34.89 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.582 1.522 . . . . 0.0 114.291 -173.304 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . 0.266 0.2 OUTLIER -84.99 123.07 30.11 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 128.279 2.632 . . . . 0.0 106.088 173.571 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 8.9 mp -109.35 110.19 21.28 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.478 1.49 . . . . 0.0 113.221 -176.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -81.59 125.12 30.16 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 12.6 mt -127.29 140.34 37.65 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 124.283 1.033 . . . . 0.0 111.976 -171.106 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.05 118.18 4.01 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.287 2.658 . . . . 0.0 109.661 172.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.94 138.86 4.7 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.326 1.45 . . . . 0.0 112.175 176.416 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.17 -18.69 9.41 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-O 118.794 -1.004 . . . . 0.0 113.96 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.98 159.48 7.06 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.331 1.565 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.4 m -84.65 90.15 7.63 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.02 97.08 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -93.76 98.47 11.12 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.34 104.43 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.241 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.3 m -92.39 102.09 14.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.3 m-85 -77.67 154.91 31.71 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.422 173.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.2 mp -133.36 78.03 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 163.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -97.86 105.21 17.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 175.815 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.0 m -146.34 44.89 1.23 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -82.7 63.54 6.88 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -6.1 70.34 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 131.273 3.829 . . . . 0.0 114.82 -172.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 141.01 -47.46 0.86 Allowed Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.215 0.912 . . . . 0.0 111.062 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -85.33 100.18 11.65 Favored 'General case' 0 CA--C 1.528 0.13 0 O-C-N 122.076 -0.661 . . . . 0.0 111.125 -174.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.2 70.51 1.03 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 173.323 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -40.5 -49.21 2.9 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 116.164 1.913 . . . . 0.0 116.164 -171.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.7 p 78.22 148.28 0.1 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 120.027 1.285 . . . . 0.0 109.687 -172.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.9 t80 -138.39 108.31 6.33 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -115.52 135.85 53.67 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 118.798 0.727 . . . . 0.0 110.195 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.3 mt -110.26 130.53 63.35 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 126.186 1.794 . . . . 0.0 109.022 -177.233 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 t -159.39 -153.68 0.37 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -129.71 42.79 3.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 119.662 1.119 . . . . 0.0 110.573 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -91.69 110.92 22.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.143 0.577 . . . . 0.0 109.485 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.72 161.81 54.51 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 172.197 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.7 155.69 67.79 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.255 1.97 . . . . 0.0 109.62 174.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.51 167.87 78.0 Favored 'Cis proline' 0 N--CA 1.457 -0.667 0 CA-C-N 119.251 0.768 . . . . 0.0 111.301 -1.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -113.09 155.29 25.18 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.421 1.088 . . . . 0.0 109.106 177.428 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 156.56 26.68 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-O 121.378 0.608 . . . . 0.0 110.641 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 79.7 t -70.42 -36.9 68.58 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.743 175.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -78.34 152.04 78.45 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -38.85 111.9 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 124.996 3.797 . . . . 0.0 113.378 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.0 t -85.42 54.04 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 123.961 0.905 . . . . 0.0 109.021 -173.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.1 pp -88.0 91.05 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 122.519 1.152 . . . . 0.0 109.615 174.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.03 -157.55 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 126.254 1.822 . . . . 0.0 106.852 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -57.28 89.53 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 121.458 1.438 . . . . 0.0 109.34 153.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.1 mm -78.33 136.22 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 65.8 t -85.02 -88.81 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.556 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 175.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.42 155.71 16.63 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 171.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.51 166.34 33.52 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.312 -1.423 . . . . 0.0 111.438 174.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.6 p -118.44 142.28 47.71 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.251 1.42 . . . . 0.0 108.606 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.44 -161.45 6.79 Favored Glycine 0 CA--C 1.537 1.415 0 N-CA-C 108.174 -1.97 . . . . 0.0 108.174 172.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -67.17 106.38 1.99 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 120.842 -1.387 . . . . 0.0 109.899 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -62.5 156.68 61.3 Favored Pre-proline 0 CA--C 1.536 0.427 0 C-N-CA 126.731 2.013 . . . . 0.0 112.682 -174.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -67.27 151.28 81.13 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.999 2.466 . . . . 0.0 110.391 -175.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -129.95 74.5 80.52 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 123.821 0.848 . . . . 0.0 113.031 -175.082 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -60.91 174.89 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 122.419 2.079 . . . . 0.0 112.567 173.028 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 54.9 mttp -140.19 -168.46 2.54 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.891 1.277 . . . . 0.0 108.125 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 23.9 t70 55.65 -121.26 1.66 Allowed 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -174.47 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -112.71 9.98 25.7 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.716 -1.047 . . . . 0.0 112.856 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.1 mtpp -84.36 150.83 25.1 Favored 'General case' 0 C--N 1.341 0.233 0 CA-C-N 118.404 1.102 . . . . 0.0 109.007 175.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -132.87 110.32 10.23 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 124.292 1.037 . . . . 0.0 112.119 -173.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -66.88 116.07 7.85 Favored Glycine 0 CA--C 1.521 0.426 0 C-N-CA 125.178 1.37 . . . . 0.0 110.085 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -119.96 167.42 12.18 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 122.625 1.202 . . . . 0.0 110.804 175.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 61.7 m -154.69 115.23 3.91 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.02 83.6 5.19 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 172.789 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -90.42 151.52 21.38 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 35.7 m -121.54 145.57 47.83 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.021 0.528 . . . . 0.0 111.058 -173.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 24.0 t90 -143.61 144.17 31.8 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.45 1.1 . . . . 0.0 110.642 177.05 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 67.2 m-70 -109.6 109.93 59.74 Favored Pre-proline 0 CA--C 1.529 0.17 0 N-CA-C 104.857 -2.275 . . . . 0.0 104.857 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -90.73 133.6 1.76 Allowed 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.416 2.744 . . . . 0.0 113.606 -170.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.1 p -82.58 156.02 24.16 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.625 -1.621 . . . . 0.0 106.625 170.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -61.05 169.01 2.18 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 119.438 1.017 . . . . 0.0 112.438 -176.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 106.43 -177.98 22.37 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 125.636 1.589 . . . . 0.0 112.341 175.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 4.1 m -84.39 141.38 30.89 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.828 0.851 . . . . 0.0 110.073 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -137.35 170.11 16.64 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -142.57 146.83 34.99 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.961 1.304 . . . . 0.0 108.023 -178.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' TYR . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 46.8 p90 -115.59 140.87 48.77 Favored 'General case' 0 CA--C 1.528 0.097 0 O-C-N 123.984 0.803 . . . . 0.0 110.616 176.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.4 m -143.93 152.48 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 C-N-CA 124.548 1.139 . . . . 0.0 112.03 -174.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.1 t -98.8 125.7 44.24 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.58 1.552 . . . . 0.0 109.035 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 16.6 mm-40 -83.98 -4.26 58.59 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -173.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 30.8 mt -61.36 130.43 91.75 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 120.342 1.428 . . . . 0.0 108.239 175.485 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -39.44 125.08 1.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 124.118 3.212 . . . . 0.0 114.456 -174.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.94 -20.37 20.6 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 124.37 0.986 . . . . 0.0 113.226 176.334 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -66.98 -43.88 81.89 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 119.028 1.414 . . . . 0.0 112.303 -172.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -63.22 -48.7 77.17 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.703 0.683 . . . . 0.0 110.319 176.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.3 -54.57 43.88 Favored 'General case' 0 C--N 1.34 0.16 0 C-N-CA 123.755 0.822 . . . . 0.0 111.333 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.2 p -143.91 81.85 1.7 Allowed 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.226 1.011 . . . . 0.0 108.54 -174.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.49 -63.84 0.07 OUTLIER Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.246 176.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 4.0 ptm -157.9 129.5 6.8 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 117.795 0.797 . . . . 0.0 112.974 -172.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -162.74 -161.59 0.72 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.625 1.17 . . . . 0.0 108.349 175.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 167.49 171.36 33.42 Favored Glycine 0 C--N 1.334 0.452 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 172.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.0 mttm -110.95 153.69 25.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.373 1.069 . . . . 0.0 110.356 -173.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.9 mt -129.01 143.39 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.41 100.13 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -90.03 126.62 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 45.9 mtmt . . . . . 0 N--CA 1.46 0.052 0 CA-C-N 118.672 0.669 . . . . 0.0 110.828 -179.808 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 p . . . . . 0 CA--C 1.537 0.444 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.2 m -78.25 63.91 3.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.438 1.095 . . . . 0.0 112.155 -173.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 43.3 m95 -97.9 134.29 41.23 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.154 1.382 . . . . 0.0 109.538 174.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -149.57 -178.4 6.41 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -134.77 128.4 32.78 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 171.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.08 -151.82 0.31 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 172.319 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -142.03 168.13 20.49 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.147 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -39.58 -59.49 1.62 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -60.26 -28.74 87.48 Favored 'Trans proline' 0 N--CA 1.46 -0.496 0 CA-C-N 121.028 1.403 . . . . 0.0 112.19 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -66.93 -24.97 66.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 121.471 -0.768 . . . . 0.0 110.728 178.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.428 HG21 ' CD2' ' A' ' 120' ' ' PHE . 24.1 t -62.22 -50.28 80.61 Favored 'Isoleucine or valine' 0 C--N 1.34 0.177 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.448 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -58.1 -43.78 87.29 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -55.44 -58.3 8.32 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.903 -0.498 . . . . 0.0 110.988 175.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -58.33 -44.61 88.76 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 122.11 -0.369 . . . . 0.0 111.513 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.0 mt -50.52 -47.39 57.49 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.064 0.546 . . . . 0.0 110.746 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -61.89 -14.94 38.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.045 0.758 . . . . 0.0 113.045 178.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.5 mmmt -97.67 5.22 49.63 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 119.313 0.961 . . . . 0.0 111.651 176.034 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -74.65 125.16 28.08 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.051 -1.03 . . . . 0.0 110.507 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.9 p -93.27 29.33 1.94 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 123.306 0.642 . . . . 0.0 112.62 -176.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -104.32 111.71 3.91 Favored Glycine 0 C--N 1.339 0.726 0 C-N-CA 125.317 1.437 . . . . 0.0 111.139 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -79.63 159.83 26.61 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 173.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.0 t -81.56 150.73 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.5 m -147.72 65.57 1.12 Allowed 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.411 -0.805 . . . . 0.0 108.99 174.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 61.07 -109.34 2.37 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.546 -1.021 . . . . 0.0 110.546 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.2 p-10 -96.68 37.33 1.29 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.848 1.259 . . . . 0.0 110.325 177.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.1 m -160.64 161.98 32.58 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 105.806 -1.924 . . . . 0.0 105.806 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 t -120.27 151.65 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 126.969 2.108 . . . . 0.0 106.939 172.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.0 m -140.29 117.38 11.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.495 0.718 . . . . 0.0 109.18 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -83.06 166.99 18.29 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 174.088 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 57.3 m -152.29 156.17 39.13 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 175.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.37 165.44 20.53 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -173.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -72.64 -27.22 62.0 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.838 -0.801 . . . . 0.0 111.02 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -78.95 67.76 4.73 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.029 0.932 . . . . 0.0 110.269 -177.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.4 t -79.69 99.36 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.9 t-160 -107.4 94.65 5.21 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.7 107.0 17.27 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.154 0 C-N-CA 123.308 0.643 . . . . 0.0 109.486 -173.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.2 t -93.45 90.74 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -94.91 111.92 23.67 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.218 1.407 . . . . 0.0 110.282 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.98 143.39 27.12 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 174.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.7 104.41 5.77 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-O 121.23 0.538 . . . . 0.0 110.85 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 t 50.09 63.74 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 127.203 2.201 . . . . 0.0 111.216 173.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 22.5 mt -76.75 165.26 53.89 Favored Pre-proline 0 CA--C 1.536 0.433 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 99.7 Cg_exo . . . . . 0 CA--C 1.535 0.559 0 C-N-CA 122.888 2.392 . . . . 0.0 113.5 175.854 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 . . . . . 0 CA--C 1.536 0.425 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -109.32 -21.05 0.36 Allowed 'Cis proline' 0 CA--C 1.536 0.609 0 N-CA-C 114.507 0.926 . . . . 0.0 114.507 -3.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.3 p -92.11 170.24 9.99 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 -168.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.25 167.21 22.12 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.75 0.82 . . . . 0.0 109.136 178.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.29 148.25 50.75 Favored 'General case' 0 CA--C 1.538 0.485 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 173.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.1 t -134.89 79.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 123.745 0.818 . . . . 0.0 109.456 -170.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.7 p80 50.48 -74.51 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 127.821 2.448 . . . . 0.0 114.896 175.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -98.0 -37.38 9.79 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 124.643 1.177 . . . . 0.0 110.964 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -111.21 -159.95 0.7 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.876 1.27 . . . . 0.0 108.203 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -140.44 -165.27 1.89 Allowed 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.41 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 14.1 m-80 -12.57 -56.38 0.03 OUTLIER Pre-proline 0 N--CA 1.471 0.598 0 C-N-CA 128.433 2.693 . . . . 0.0 115.242 172.175 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.6 OUTLIER -15.5 125.64 0.01 OUTLIER 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.983 3.789 . . . . 0.0 116.272 161.083 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.44 HG23 ' HB2' ' A' ' 151' ' ' LYS . 55.5 m -31.78 144.04 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 129.911 3.284 . . . . 0.0 117.276 -174.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.42 134.68 54.52 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.907 1.683 . . . . 0.0 108.492 174.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -110.07 140.35 44.22 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.249 1.02 . . . . 0.0 108.685 173.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.4 mt -136.71 141.57 35.75 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 -172.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -78.35 125.7 7.18 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.796 2.33 . . . . 0.0 108.123 171.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.02 145.45 16.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.761 0.824 . . . . 0.0 112.553 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.45 2.87 81.45 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-O 119.498 -0.612 . . . . 0.0 112.986 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.88 157.97 20.2 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 118.745 1.273 . . . . 0.0 112.228 174.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 61.2 m -93.6 89.99 6.46 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 172.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 43.2 t -77.58 98.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -173.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -92.51 93.57 8.63 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.035 1.334 . . . . 0.0 107.88 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.95 107.05 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 78.9 m -99.94 103.84 15.43 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 125.326 1.45 . . . . 0.0 109.498 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -81.56 152.24 27.33 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 174.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.92 78.99 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 102.159 -3.275 . . . . 0.0 102.159 163.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -101.5 85.08 2.7 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 176.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.471 HG21 ' CD2' ' A' ' 120' ' ' PHE . 76.3 p -112.08 33.51 4.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.538 -174.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -79.61 70.95 6.19 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 177.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -33.49 103.46 0.03 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.133 2.173 . . . . 0.0 112.462 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.99 -46.05 1.13 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 125.215 1.388 . . . . 0.0 111.293 -177.194 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -97.76 107.49 20.0 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.483 1.113 . . . . 0.0 111.938 -173.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.89 -16.29 56.69 Favored Glycine 0 CA--C 1.538 1.503 0 CA-C-O 119.199 -0.779 . . . . 0.0 114.457 174.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 46.73 -72.28 0.0 OUTLIER 'General case' 0 C--N 1.343 0.307 0 C-N-CA 129.221 3.008 . . . . 0.0 116.46 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.0 p 88.62 155.98 0.06 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 129.228 3.011 . . . . 0.0 111.867 -172.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -125.13 131.74 53.21 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 103.339 -2.837 . . . . 0.0 103.339 171.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.26 116.42 11.08 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 108.569 -0.901 . . . . 0.0 108.569 -173.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -97.19 125.78 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 124.536 1.134 . . . . 0.0 109.392 -178.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -160.1 -141.94 0.08 Allowed 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -122.91 -110.65 0.32 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.143 0.883 . . . . 0.0 110.431 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt 65.62 -65.54 0.17 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.303 1.841 . . . . 0.0 112.397 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.48 162.56 33.36 Favored Glycine 0 CA--C 1.533 1.212 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -173.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -71.79 158.75 52.42 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.79 2.327 . . . . 0.0 109.804 177.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.22 132.38 27.09 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 CA-C-N 119.146 0.731 . . . . 0.0 110.222 -3.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -79.78 151.97 30.04 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.159 0.504 . . . . 0.0 109.695 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.01 151.65 28.33 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.313 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.8 t -61.45 -41.94 91.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 175.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.5 mmm -77.96 128.77 77.97 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 174.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -76.98 75.65 4.48 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.428 2.085 . . . . 0.0 110.397 -174.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.2 t -77.53 76.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 175.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.0 pt -77.96 89.66 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 122.394 1.092 . . . . 0.0 109.794 -176.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -55.57 146.69 43.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 171.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -25.63 116.26 0.03 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.698 1 C-N-CA 125.676 4.251 . . . . 0.0 115.625 -166.615 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 30.6 mm -78.46 131.6 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.4 t -82.15 -86.07 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.87 149.35 21.63 Favored 'General case' 0 C--N 1.333 -0.123 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 172.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.91 165.76 39.07 Favored Glycine 0 C--N 1.332 0.318 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 174.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.9 p -119.04 123.32 44.21 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.085 0.554 . . . . 0.0 111.792 -174.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -78.03 57.9 3.95 Favored Glycine 0 CA--C 1.535 1.34 0 CA-C-O 119.082 -0.843 . . . . 0.0 113.646 -175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 65.05 124.73 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 127.382 2.273 . . . . 0.0 113.719 174.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 92.0 p -74.23 136.54 75.64 Favored Pre-proline 0 CA--C 1.532 0.288 0 O-C-N 120.899 -1.125 . . . . 0.0 112.457 -173.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.49 84.96 0.92 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.312 2.008 . . . . 0.0 107.066 172.134 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.3 m -45.06 139.06 4.13 Favored Pre-proline 0 CA--C 1.539 0.533 0 C-N-CA 124.673 1.189 . . . . 0.0 112.851 -174.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -75.74 -178.27 4.2 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.636 2.891 . . . . 0.0 113.665 -173.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.93 176.73 7.1 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 127.043 2.137 . . . . 0.0 107.19 174.066 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -36.71 120.98 0.73 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.975 1.31 . . . . 0.0 113.269 -174.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 84.53 -27.05 4.85 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.968 0.794 . . . . 0.0 113.738 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 56.5 mttp -85.63 157.4 20.36 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.132 0.966 . . . . 0.0 109.97 -174.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.471 ' CD2' HG21 ' A' ' 79' ' ' THR . 10.1 m-85 -137.18 91.22 2.6 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.427 1.091 . . . . 0.0 111.414 -173.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -47.34 121.31 6.33 Favored Glycine 0 CA--C 1.529 0.924 0 C-N-CA 124.716 1.15 . . . . 0.0 111.74 174.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.7 p90 -144.24 176.32 9.42 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.312 1.053 . . . . 0.0 111.467 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.16 166.58 32.83 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 127.079 2.152 . . . . 0.0 105.757 -176.113 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -146.68 65.08 1.18 Allowed 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.177 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 19.4 p90 -77.99 135.83 37.86 Favored 'General case' 0 C--N 1.34 0.184 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.441 -174.25 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 14.8 m -99.13 132.6 44.32 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.508 0.723 . . . . 0.0 110.021 -175.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.6 t90 -137.95 143.25 40.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.459 1.104 . . . . 0.0 109.704 176.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 63.5 m80 -111.36 99.41 43.83 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -76.23 173.79 13.91 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 122.364 2.043 . . . . 0.0 109.397 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 81.3 p -119.06 153.6 34.49 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -57.62 142.26 45.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -172.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 135.45 -127.11 4.2 Favored Glycine 0 C--N 1.336 0.555 0 C-N-CA 126.208 1.861 . . . . 0.0 109.411 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -151.95 142.9 23.07 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 118.251 1.026 . . . . 0.0 110.006 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 20.5 m-85 -133.16 -179.28 5.4 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 126.243 1.817 . . . . 0.0 106.958 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -141.65 147.26 37.27 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 124.301 1.04 . . . . 0.0 108.43 174.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -102.46 145.76 29.09 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.104 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.0 m -146.64 160.72 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.842 1.257 . . . . 0.0 110.322 174.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.4 t -99.0 125.89 44.58 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.68 1.192 . . . . 0.0 109.691 171.11 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.69 -27.37 66.36 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 -177.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -57.26 128.94 79.25 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 120.541 1.519 . . . . 0.0 109.826 -174.444 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_exo -43.83 137.68 6.46 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.262 2.641 . . . . 0.0 113.15 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.59 -27.72 2.49 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.171 -0.794 . . . . 0.0 113.411 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -62.43 -51.53 67.16 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.734 1.767 . . . . 0.0 111.639 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.81 -44.0 86.07 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 117.82 0.282 . . . . 0.0 110.764 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.95 -43.04 99.27 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.135 -0.353 . . . . 0.0 111.364 -179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.6 p -79.14 -41.01 29.53 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 118.877 -0.582 . . . . 0.0 112.175 -174.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 178.26 -15.6 0.03 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 118.725 -1.702 . . . . 0.0 116.977 -176.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 13.3 mtp -79.04 77.03 5.53 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 120.118 1.959 . . . . 0.0 110.456 -174.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -160.17 -174.72 4.67 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.37 164.95 23.93 Favored Glycine 0 C--N 1.341 0.832 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 175.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.44 ' HB2' HG23 ' A' ' 63' ' ' THR . 30.8 mttt -100.99 147.66 25.93 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.9 mt -121.52 100.65 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.15 121.15 38.92 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.064 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.6 t -109.38 95.06 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 -178.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 96.9 mttt . . . . . 0 C--N 1.332 -0.177 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.286 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.2 p . . . . . 0 CA--C 1.532 0.286 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.0 m -77.79 64.13 2.98 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -169.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 71.4 m95 -92.95 156.22 17.06 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 126.645 1.978 . . . . 0.0 110.766 175.424 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -154.68 179.36 9.14 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 172.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -139.68 150.26 44.68 Favored 'General case' 0 C--N 1.341 0.209 0 CA-C-N 119.557 1.072 . . . . 0.0 111.191 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -130.65 -154.52 0.64 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.009 2.123 . . . . 0.0 107.292 174.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -135.94 171.44 14.46 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.527 0.731 . . . . 0.0 110.198 176.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.67 -59.91 1.23 Allowed Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -174.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -59.77 -30.87 93.05 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 CA-C-N 121.515 1.577 . . . . 0.0 111.964 -178.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -66.97 -22.94 65.9 Favored 'General case' 0 N--CA 1.448 -0.557 0 O-C-N 121.757 -0.589 . . . . 0.0 111.267 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.5 t -59.38 -51.5 71.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -59.78 -49.02 79.35 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.81 -55.69 13.19 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.043 0.214 . . . . 0.0 110.986 177.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 72.6 mtm -57.85 -52.49 65.25 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 123.223 0.609 . . . . 0.0 110.675 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.5 mt -50.67 -44.67 57.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 118.322 0.51 . . . . 0.0 111.057 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -58.81 -25.35 63.07 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 178.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.75 -1.02 36.75 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 119.934 1.243 . . . . 0.0 112.083 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.68 153.42 24.04 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 120.17 1.35 . . . . 0.0 110.782 175.257 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.2 p -117.94 27.77 8.81 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 123.269 0.628 . . . . 0.0 112.524 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.44 116.57 5.32 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -79.06 154.26 29.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 174.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 t -79.74 145.98 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 O-C-N 121.981 -0.449 . . . . 0.0 110.026 -175.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.2 m -149.08 64.32 1.04 Allowed 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.894 0.878 . . . . 0.0 109.404 174.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.04 -114.11 6.47 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.4 -17.0 55.28 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 123.178 0.591 . . . . 0.0 111.246 175.163 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -103.29 161.55 13.73 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 125.276 1.43 . . . . 0.0 107.841 -175.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.65 148.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.0 m -135.65 131.47 35.8 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -171.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -100.48 168.89 9.45 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.37 0.605 . . . . 0.0 110.663 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.0 m -155.01 155.0 33.38 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.248 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.76 174.35 32.96 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -174.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -77.84 -30.49 51.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 122.243 -0.563 . . . . 0.0 111.785 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.03 74.37 5.56 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.502 0.592 . . . . 0.0 109.968 -175.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.0 t -84.7 89.36 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -177.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -94.47 100.92 12.82 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.96 0.504 . . . . 0.0 110.642 -174.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -95.27 100.26 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 124.89 1.276 . . . . 0.0 108.315 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.1 t -95.7 122.89 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -133.31 116.48 16.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.621 0.646 . . . . 0.0 112.5 -173.499 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.85 112.56 24.53 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.981 0.913 . . . . 0.0 110.008 175.531 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.6 92.23 8.49 Favored 'General case' 0 N--CA 1.455 -0.178 0 O-C-N 121.58 -0.7 . . . . 0.0 110.038 -177.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.8 t 63.67 97.17 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 125.195 1.398 . . . . 0.0 111.324 174.595 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 75.2 mt -74.98 140.85 74.22 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -174.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo . . . . . 0 N--CA 1.457 -0.649 0 C-N-CA 123.629 2.886 . . . . 0.0 111.392 178.454 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.9 m-30 . . . . . 0 CA--C 1.543 0.679 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -124.45 29.62 0.16 OUTLIER 'Cis proline' 0 CA--C 1.537 0.664 0 CA-C-N 120.722 1.294 . . . . 0.0 109.999 -7.119 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.8 p -92.09 125.25 36.7 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 116.94 2.2 . . . . 0.0 116.94 -171.263 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.69 103.71 9.78 Favored 'General case' 0 C--N 1.342 0.243 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 166.572 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -88.03 112.03 22.18 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -176.174 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -111.49 84.7 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 125.14 1.376 . . . . 0.0 109.783 -171.208 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 46.98 -98.97 0.04 OUTLIER 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 125.78 1.632 . . . . 0.0 112.9 176.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -70.73 -24.69 62.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.565 0.346 . . . . 0.0 111.877 -176.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -130.57 -178.07 4.62 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.232 1.013 . . . . 0.0 110.679 -173.076 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.2 mtmp? -130.12 122.32 28.03 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 105.88 -1.896 . . . . 0.0 105.88 172.172 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 55.33 44.37 1.62 Allowed Pre-proline 0 CA--C 1.541 0.607 0 C-N-CA 124.705 1.202 . . . . 0.0 112.275 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.71 172.06 15.69 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.475 2.117 . . . . 0.0 111.567 -176.274 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 151' ' ' LYS . 28.5 m -91.9 138.86 31.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 170.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.0 mp -112.25 126.99 55.83 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.83 0.852 . . . . 0.0 110.241 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -100.01 119.51 38.38 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 15.3 mt -124.04 142.24 39.2 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.392 1.077 . . . . 0.0 112.95 -171.035 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.15 118.71 4.07 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 122.935 2.423 . . . . 0.0 108.893 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.88 142.99 3.1 Favored 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 125.41 1.484 . . . . 0.0 112.31 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 80.49 -22.2 4.81 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 118.982 -0.899 . . . . 0.0 113.706 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.21 158.17 5.56 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.113 1.456 . . . . 0.0 111.969 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -79.84 96.68 6.4 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.5 t -78.68 90.36 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 174.418 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -84.36 119.3 24.94 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 174.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -111.79 114.36 46.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -176.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 94.4 m -107.47 104.35 13.9 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.541 1.137 . . . . 0.0 109.473 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.4 m-85 -79.53 162.9 25.1 Favored 'General case' 0 C--O 1.221 -0.414 0 O-C-N 121.662 -0.649 . . . . 0.0 112.429 174.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -137.61 78.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 101.651 -3.462 . . . . 0.0 101.651 163.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -99.94 96.51 7.6 Favored 'General case' 0 N--CA 1.457 -0.111 0 N-CA-C 106.811 -1.552 . . . . 0.0 106.811 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.7 m -147.44 59.32 1.15 Allowed 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 174.28 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -82.3 66.41 7.88 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 173.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 8.72 72.82 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.75 3.22 . . . . 0.0 113.927 -171.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.42 -44.83 1.29 Allowed Glycine 0 CA--C 1.527 0.796 0 C-N-CA 124.31 0.957 . . . . 0.0 111.382 178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -79.72 95.62 6.02 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.842 0.83 . . . . 0.0 110.091 -175.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.99 61.35 2.58 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.412 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -45.54 124.57 5.09 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.271 1.028 . . . . 0.0 110.857 173.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 96.8 p -87.2 167.06 14.47 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -134.05 112.5 11.23 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 172.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -131.27 127.59 38.08 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -173.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 47.5 mt -99.31 127.91 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 C-N-CA 125.818 1.647 . . . . 0.0 108.475 -174.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.48 -149.03 0.18 Allowed 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt -129.26 25.28 5.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.696 1.134 . . . . 0.0 111.994 -178.044 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -73.74 94.95 2.3 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 173.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -73.49 171.33 51.69 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 173.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.1 150.15 82.27 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.282 1.988 . . . . 0.0 109.65 175.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -75.31 130.75 22.13 Favored 'Cis proline' 0 N--CA 1.454 -0.807 0 N-CA-C 109.941 -0.83 . . . . 0.0 109.941 -3.255 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -78.75 145.82 34.21 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.4 145.59 39.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-O 121.382 0.61 . . . . 0.0 112.044 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -67.52 -43.41 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -78.85 144.95 65.15 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 177.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -64.01 68.83 0.2 Allowed 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.638 2.892 . . . . 0.0 113.685 175.134 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.43 75.52 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.4 pt -76.35 86.0 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 123.509 1.623 . . . . 0.0 110.816 -172.213 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.28 155.69 83.9 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 113.125 -1.852 . . . . 0.0 106.913 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -39.57 112.42 0.15 Allowed 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 123.91 3.073 . . . . 0.0 113.986 -176.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.1 mm -79.24 132.17 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -82.29 -87.11 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.49 156.16 16.46 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 123.394 0.678 . . . . 0.0 109.365 173.3 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.44 178.21 45.1 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 118.956 -1.592 . . . . 0.0 113.904 174.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 17.3 p -121.26 155.27 35.01 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 126.464 1.906 . . . . 0.0 109.424 175.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -90.09 -127.55 3.42 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 173.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -116.2 134.98 54.32 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 118.495 1.148 . . . . 0.0 108.61 176.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 4.5 p -76.58 177.56 2.5 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -172.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.56 -7.08 13.46 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.271 2.648 . . . . 0.0 113.015 172.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m 35.24 67.15 1.46 Allowed Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 126.285 1.834 . . . . 0.0 115.857 -178.172 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -60.72 178.59 0.46 Allowed 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.726 2.284 . . . . 0.0 113.796 174.084 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -142.45 -171.98 3.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.043 0.937 . . . . 0.0 110.187 -177.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 26.1 t70 62.65 -77.3 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 126.862 2.065 . . . . 0.0 111.549 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.75 15.66 0.3 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.966 0.793 . . . . 0.0 111.869 177.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 31.8 mtmm -87.59 155.9 19.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 174.307 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -140.07 104.07 4.76 Favored 'General case' 0 CA--C 1.517 -0.297 0 C-N-CA 123.765 0.826 . . . . 0.0 112.416 -171.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -67.38 107.85 2.2 Favored Glycine 0 CA--C 1.526 0.725 0 C-N-CA 125.299 1.428 . . . . 0.0 109.841 174.183 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -103.48 178.62 4.5 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.889 0.852 . . . . 0.0 109.374 173.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.87 157.75 43.66 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 -177.695 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.0 m-20 -139.46 87.5 2.19 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -100.59 168.78 9.49 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 172.463 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 16.6 m -151.86 148.94 28.42 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 120.952 -1.093 . . . . 0.0 108.976 -175.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 22.0 t90 -147.22 149.47 32.98 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 124.627 1.171 . . . . 0.0 110.225 -174.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -113.06 108.32 53.28 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 172.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -89.8 145.79 4.67 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 123.419 2.746 . . . . 0.0 112.693 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.8 p -89.55 154.94 19.61 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.983 1.313 . . . . 0.0 108.329 172.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.35 169.16 1.26 Allowed 'General case' 0 CA--C 1.538 0.484 0 O-C-N 121.603 -0.686 . . . . 0.0 112.225 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 108.09 -130.61 10.17 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 125.182 1.373 . . . . 0.0 110.192 178.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.7 m -151.56 144.48 24.48 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 118.28 1.04 . . . . 0.0 110.377 -175.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -137.57 174.94 10.05 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 126.221 1.809 . . . . 0.0 107.727 178.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -135.79 139.21 43.34 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.482 1.513 . . . . 0.0 108.6 179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -103.36 139.59 38.57 Favored 'General case' 0 N--CA 1.457 -0.116 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 172.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.7 m -147.15 168.62 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.229 1.011 . . . . 0.0 110.701 178.51 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 10.3 t -106.09 136.85 45.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 126.461 1.905 . . . . 0.0 108.485 173.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -77.49 -26.28 51.1 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 123.867 0.867 . . . . 0.0 113.22 -173.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 52.7 mt -57.92 130.82 82.97 Favored Pre-proline 0 CA--C 1.543 0.696 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.93 143.56 3.03 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 124.128 3.219 . . . . 0.0 114.778 -174.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.91 -39.73 1.37 Allowed Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.211 0.91 . . . . 0.0 113.958 174.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 25.0 m170 -50.24 -48.81 54.46 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.591 1.156 . . . . 0.0 114.062 -172.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.19 -49.83 74.24 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-O 120.736 0.303 . . . . 0.0 110.368 178.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -58.41 -42.1 86.4 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.256 0.622 . . . . 0.0 110.853 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 32.5 p -79.84 -41.29 26.66 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 118.129 -0.938 . . . . 0.0 113.196 -174.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -169.46 -41.13 0.03 OUTLIER Glycine 0 C--N 1.342 0.871 0 C-N-CA 118.028 -2.034 . . . . 0.0 117.881 -174.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.268 3.8 ptp -79.91 94.17 5.81 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 120.381 2.09 . . . . 0.0 112.196 -173.286 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -157.76 -178.28 7.21 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.083 0.953 . . . . 0.0 110.353 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.28 161.14 19.07 Favored Glycine 0 C--N 1.338 0.655 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 173.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.467 ' HB2' HG23 ' A' ' 63' ' ' THR . 90.8 mttt -96.31 145.75 25.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.653 1.581 . . . . 0.0 109.553 -175.378 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.7 mt -122.4 101.09 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 173.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -89.67 132.19 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 25.7 t -123.94 125.98 71.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 24.1 mtpp . . . . . 0 N--CA 1.464 0.226 0 CA-C-N 118.898 0.772 . . . . 0.0 111.276 -177.932 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.5 p . . . . . 0 N--CA 1.446 -0.654 0 CA-C-O 119.413 -0.327 . . . . 0.0 111.645 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.2 m -79.71 62.71 4.06 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.155 0.889 . . . . 0.0 110.139 -174.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 73.6 m95 -94.49 122.26 36.88 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 125.177 1.391 . . . . 0.0 111.282 -174.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -142.11 -176.47 4.82 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -136.43 132.32 35.29 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 121.838 -0.539 . . . . 0.0 109.83 172.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -87.74 -154.56 0.26 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 104.303 -2.48 . . . . 0.0 104.303 169.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.8 p -142.61 165.19 28.09 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 120.921 -1.112 . . . . 0.0 108.713 174.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.3 tt -39.9 -53.02 4.99 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 114.687 1.365 . . . . 0.0 114.687 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -57.54 -31.19 90.91 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.865 1.71 . . . . 0.0 112.572 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -71.13 -33.63 70.28 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 122.995 0.518 . . . . 0.0 110.204 178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.427 HG21 ' CD2' ' A' ' 120' ' ' PHE . 13.6 t -62.74 -48.61 87.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.77 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -54.45 -44.96 72.96 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.988 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.91 -48.07 67.52 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.25 0.62 . . . . 0.0 111.437 175.193 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 68.8 mtm -70.1 -30.94 68.28 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 118.483 -0.77 . . . . 0.0 112.221 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.57 57.36 1.22 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-O 122.331 1.062 . . . . 0.0 109.757 172.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -137.29 -40.27 0.58 Allowed 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 129.383 3.073 . . . . 0.0 104.839 173.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . 0.294 0.0 OUTLIER 84.72 142.58 0.06 Allowed 'General case' 0 N--CA 1.442 -0.831 0 C-N-CA 128.974 2.91 . . . . 0.0 114.648 170.247 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -101.19 -147.8 0.36 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 111.688 -2.506 . . . . 0.0 109.091 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.2 p -44.16 131.66 5.94 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 126.717 2.007 . . . . 0.0 112.675 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 145.06 90.63 0.11 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.169 0.89 . . . . 0.0 110.928 174.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -79.13 137.79 37.63 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 174.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.5 t -63.69 146.89 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 33.0 m -148.52 64.66 1.07 Allowed 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 174.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 66.07 -142.99 44.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 107.642 -2.183 . . . . 0.0 107.642 -172.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -80.01 54.85 1.99 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.721 1.261 . . . . 0.0 109.733 174.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.9 m -160.86 153.9 21.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 178.191 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 93.5 t -123.46 142.08 41.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -125.77 129.44 49.47 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.963 1.305 . . . . 0.0 108.562 -174.273 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -93.18 167.07 12.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.493 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.6 m -156.26 61.58 0.56 Allowed 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.552 0.741 . . . . 0.0 109.621 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.87 166.07 38.58 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 108.234 -1.947 . . . . 0.0 108.234 177.64 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -75.18 -50.4 16.37 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 117.435 0.617 . . . . 0.0 109.659 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.3 p -79.83 93.62 5.66 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 42.5 t -82.82 98.53 4.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -94.11 116.01 28.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.8 122.47 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 124.864 1.265 . . . . 0.0 108.601 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 95.5 t -92.2 113.82 28.12 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 175.726 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.83 92.66 3.9 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.871 1.269 . . . . 0.0 110.392 -178.481 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.33 113.51 24.8 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.273 1.029 . . . . 0.0 109.999 178.484 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.1 114.45 24.73 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.209 -0.932 . . . . 0.0 110.409 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.4 t 32.89 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 126.67 1.988 . . . . 0.0 112.892 173.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.7 142.02 69.55 Favored Pre-proline 0 CA--C 1.533 0.31 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -178.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo . . . . . 0 N--CA 1.454 -0.802 0 C-N-CA 123.079 2.519 . . . . 0.0 110.429 -174.404 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 . . . . . 0 CA--C 1.534 0.358 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -116.64 50.95 0.65 Allowed 'Cis proline' 0 CA--C 1.536 0.591 0 N-CA-C 108.441 -1.407 . . . . 0.0 108.441 -5.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.7 p -93.05 129.3 39.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -173.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -77.95 121.69 24.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 N-CA-C 103.247 -2.871 . . . . 0.0 103.247 166.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -91.88 113.99 26.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -120.59 117.79 54.4 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 119.051 0.841 . . . . 0.0 110.584 -171.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 0.1 OUTLIER 36.93 -104.71 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.641 1.976 . . . . 0.0 113.067 -174.751 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.22 -17.68 39.04 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -124.5 -166.93 1.58 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 124.263 1.025 . . . . 0.0 110.833 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 51.2 mttm -133.95 124.74 26.86 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.192 -1.781 . . . . 0.0 106.192 172.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 52.91 44.24 1.91 Allowed Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.657 1.183 . . . . 0.0 112.354 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -79.28 173.72 12.91 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 122.372 2.048 . . . . 0.0 111.482 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.477 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.8 m -94.62 140.68 29.55 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.73 121.45 44.11 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.413 1.485 . . . . 0.0 112.305 -171.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -103.46 111.02 23.27 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.988 0.915 . . . . 0.0 108.737 173.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.9 mt -112.58 135.45 21.51 Favored Pre-proline 0 CA--C 1.537 0.447 0 C-N-CA 125.739 1.616 . . . . 0.0 110.289 -173.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.67 116.63 4.32 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 122.629 2.22 . . . . 0.0 108.747 172.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.03 133.58 27.21 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.593 0.757 . . . . 0.0 110.597 177.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.98 -26.63 16.75 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.986 -1.245 . . . . 0.0 109.986 -173.695 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.08 32.23 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.891 0.846 . . . . 0.0 111.845 174.625 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 95.2 m -105.08 130.22 53.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 t -100.53 99.28 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 124.253 1.021 . . . . 0.0 110.881 -172.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.53 93.71 8.4 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.0 t -83.93 100.64 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 174.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 93.3 m -86.75 100.07 12.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.497 1.119 . . . . 0.0 109.109 174.372 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 2.9 m-85 -76.74 155.7 33.0 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.35 172.282 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.0 mp -137.96 92.2 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 101.868 -3.382 . . . . 0.0 101.868 163.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -113.54 113.31 24.93 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 172.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 49.1 m -146.17 45.89 1.24 Allowed 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 172.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -75.74 71.02 2.58 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 173.035 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.2 mtmm -17.74 87.96 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.527 3.131 . . . . 0.0 113.929 -173.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.435 ' H ' ' CG1' ' A' ' 114' ' ' VAL . . . 133.32 -45.27 1.13 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.383 0.992 . . . . 0.0 111.507 178.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -97.33 111.99 24.0 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 117.506 0.653 . . . . 0.0 112.272 -173.06 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.62 54.96 2.5 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.937 0.78 . . . . 0.0 111.475 173.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -48.34 139.84 8.33 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.643 1.221 . . . . 0.0 111.347 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.4 p -104.51 165.99 10.69 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.53 1.132 . . . . 0.0 108.435 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 9.0 t80 -131.28 116.52 17.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 105.596 -2.002 . . . . 0.0 105.596 171.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ASP . . . . . 0.488 ' HB3' HD12 ' A' ' 105' ' ' ILE . 16.8 m-20 -133.03 129.83 38.61 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 118.91 0.777 . . . . 0.0 110.642 -172.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 34.4 mt -104.38 134.04 46.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 C-N-CA 126.016 1.726 . . . . 0.0 108.864 -176.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.2 t -159.13 -154.61 0.42 Allowed 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 48.8 mtmt -126.56 21.88 7.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 119.232 0.924 . . . . 0.0 111.804 -179.154 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -70.37 118.87 13.73 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.05 159.33 43.38 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 174.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -72.5 164.53 35.34 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.969 2.446 . . . . 0.0 109.598 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -71.35 141.46 69.8 Favored 'Cis proline' 0 N--CA 1.459 -0.543 0 CA-C-N 119.333 0.798 . . . . 0.0 110.634 -5.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -79.91 150.86 30.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 121.289 0.566 . . . . 0.0 109.874 175.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.43 151.99 27.63 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.377 177.448 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 65.9 t -61.1 -39.18 81.47 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 174.584 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 92.3 mmm -78.2 133.1 65.02 Favored Pre-proline 0 N--CA 1.452 -0.373 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 174.182 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.87 75.57 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.751 2.301 . . . . 0.0 111.974 -173.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.9 t -79.02 65.5 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 172.714 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -88.43 -43.79 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.84 1.656 . . . . 0.0 111.801 -173.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -64.25 146.52 97.67 Favored Pre-proline 0 CA--C 1.531 0.215 0 C-N-CA 123.119 0.568 . . . . 0.0 111.515 -173.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.26 143.28 74.57 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 CA-C-N 119.038 0.692 . . . . 0.0 111.261 -2.25 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.488 HD12 ' HB3' ' A' ' 88' ' ' ASP . 19.4 mm -91.44 143.49 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.447 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 92.2 t -87.05 -92.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 104.432 -2.432 . . . . 0.0 104.432 173.05 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.17 145.65 24.87 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -178.6 161.5 28.09 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.264 -1.446 . . . . 0.0 111.237 174.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 34.6 p -103.02 149.25 24.74 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 125.186 1.395 . . . . 0.0 108.248 175.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.91 -156.7 8.78 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 173.327 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -74.74 139.12 43.18 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.506 1.153 . . . . 0.0 109.071 174.251 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 51.8 p -81.66 163.91 51.74 Favored Pre-proline 0 C--O 1.233 0.216 0 C-N-CA 122.497 0.319 . . . . 0.0 111.547 -174.456 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -64.97 166.33 18.84 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 N-CA-C 106.395 -2.194 . . . . 0.0 106.395 168.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.435 ' CG1' ' H ' ' A' ' 82' ' ' GLY . 14.4 t -130.55 76.75 77.0 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -172.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -62.76 162.12 26.31 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 122.154 1.903 . . . . 0.0 110.256 172.507 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -137.19 5.95 2.8 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -178.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -174.33 148.94 1.3 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 125.469 1.508 . . . . 0.0 109.102 174.456 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.94 -66.21 0.13 Allowed Glycine 0 CA--C 1.527 0.832 0 C-N-CA 126.533 2.015 . . . . 0.0 113.935 174.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -79.02 151.53 31.46 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 125.22 1.408 . . . . 0.0 110.525 -176.226 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.427 ' CD2' HG21 ' A' ' 15' ' ' VAL . 10.1 m-85 -134.76 101.98 5.11 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 125.46 1.504 . . . . 0.0 111.096 -174.013 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.95 112.28 1.87 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 125.272 1.415 . . . . 0.0 111.227 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -130.67 155.23 46.94 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.931 0.893 . . . . 0.0 111.29 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 6.6 m -154.78 114.4 3.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -174.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.09 62.55 4.21 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 125.199 1.399 . . . . 0.0 108.525 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -70.15 121.82 18.26 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 118.305 -1.358 . . . . 0.0 108.526 -174.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 41.0 m -96.86 84.73 3.63 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.389 -172.281 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -78.36 124.75 28.46 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -94.02 106.39 22.05 Favored Pre-proline 0 N--CA 1.451 -0.417 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 171.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -83.23 177.85 6.25 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.975 2.45 . . . . 0.0 112.169 -171.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.5 p -131.09 153.88 48.86 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 172.546 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.38 165.3 7.85 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.531 1.06 . . . . 0.0 111.935 -174.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 112.86 -168.18 12.54 Favored Glycine 0 CA--C 1.525 0.676 0 C-N-CA 124.718 1.151 . . . . 0.0 112.297 174.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 28.5 m -98.3 139.89 33.4 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 124.028 0.931 . . . . 0.0 109.08 -176.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -140.35 177.29 8.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 125.27 1.428 . . . . 0.0 107.235 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -145.44 152.7 40.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 176.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -116.74 149.13 40.39 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 123.489 0.716 . . . . 0.0 110.382 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 28.6 m -152.78 161.88 2.56 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 C-N-CA 125.052 1.341 . . . . 0.0 111.314 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 3.1 t -100.14 134.11 43.55 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.406 1.482 . . . . 0.0 107.892 170.578 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -74.05 -22.17 59.65 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -173.439 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 57.1 mt -60.78 126.98 86.6 Favored Pre-proline 0 CA--C 1.542 0.665 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -177.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -44.86 146.89 2.14 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 123.934 3.089 . . . . 0.0 114.056 -174.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.2 -39.01 1.61 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 123.304 0.478 . . . . 0.0 113.055 177.143 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.1 m170 -54.02 -51.55 63.63 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.491 1.145 . . . . 0.0 111.879 -173.266 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.28 -47.29 81.84 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 117.891 0.314 . . . . 0.0 110.986 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.47 97.27 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 122.783 0.433 . . . . 0.0 111.132 -178.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 40.4 p -79.99 -35.81 36.89 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -173.356 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.41 -27.34 0.04 OUTLIER Glycine 0 CA--C 1.528 0.898 0 N-CA-C 117.081 1.592 . . . . 0.0 117.081 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 3.6 mtt -78.12 80.43 4.55 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 120.07 1.935 . . . . 0.0 110.943 -173.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -162.28 -174.38 4.04 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.71 163.32 21.41 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 173.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.477 ' HB2' HG23 ' A' ' 63' ' ' THR . 49.2 mttt -99.33 154.1 18.45 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.046 0.939 . . . . 0.0 108.954 -175.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.4 mt -130.33 138.1 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 178.397 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 42.8 t -130.25 101.0 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 173.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 40.1 t -87.0 88.14 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 174.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.3 mttt . . . . . 0 C--N 1.332 -0.182 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 177.109 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 77.3 p . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 111.86 0.319 . . . . 0.0 111.86 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.8 m -98.84 122.33 41.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 123.846 0.858 . . . . 0.0 108.871 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -155.7 127.1 7.22 Favored 'General case' 0 C--N 1.341 0.233 0 C-N-CA 126.32 1.848 . . . . 0.0 108.417 173.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -150.07 170.62 18.45 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 173.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -135.91 148.14 48.43 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 172.447 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -118.24 -155.94 0.62 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 127.862 2.465 . . . . 0.0 106.357 174.408 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 29.9 p -134.43 173.04 12.07 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.577 0.751 . . . . 0.0 109.49 174.142 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.0 tt -39.05 -56.81 2.36 Favored Pre-proline 0 CA--C 1.538 0.481 0 N-CA-C 114.508 1.299 . . . . 0.0 114.508 -174.391 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -56.39 -31.46 85.38 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.32 1.347 . . . . 0.0 113.606 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.6 mp0 -68.28 -27.61 66.46 Favored 'General case' 0 N--CA 1.457 -0.115 0 O-C-N 121.177 -0.952 . . . . 0.0 111.249 176.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -61.31 -50.54 80.01 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -55.45 -47.11 76.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.889 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.68 -59.9 3.91 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 122.438 0.295 . . . . 0.0 110.978 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.5 mtm -54.59 -47.9 72.8 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.209 0.604 . . . . 0.0 111.153 -176.736 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.9 mt -50.51 -33.51 21.74 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 113.269 0.841 . . . . 0.0 113.269 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -73.09 -31.59 64.46 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.556 -0.715 . . . . 0.0 110.534 178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt -81.51 60.96 4.74 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 121.767 -0.583 . . . . 0.0 110.19 -176.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -125.42 102.12 7.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.116 0.566 . . . . 0.0 110.632 174.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.3 p -73.86 45.97 0.21 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.946 1.698 . . . . 0.0 111.197 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.24 112.6 2.42 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 125.508 1.528 . . . . 0.0 111.152 -174.009 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -79.12 -178.78 6.33 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.3 t -113.7 152.18 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 123.969 0.907 . . . . 0.0 108.89 177.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.7 m -149.1 73.41 1.21 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.373 1.069 . . . . 0.0 108.358 174.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.17 -144.36 39.27 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -172.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -79.46 59.1 2.83 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.653 1.226 . . . . 0.0 109.413 175.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -161.0 146.4 14.28 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.79 1.636 . . . . 0.0 106.708 -179.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 23.3 t -102.64 147.86 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 174.469 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 55.4 m -134.3 110.63 9.62 Favored 'General case' 0 CA--C 1.521 -0.172 0 C-N-CA 123.426 0.69 . . . . 0.0 109.954 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -82.8 169.01 16.6 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.564 0.697 . . . . 0.0 111.4 178.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -155.04 159.08 40.03 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 124.503 1.121 . . . . 0.0 107.988 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.39 -179.54 32.77 Favored Glycine 0 CA--C 1.53 1.019 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -176.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -85.63 -27.48 25.39 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.771 0.428 . . . . 0.0 111.211 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.6 m -79.18 69.2 5.34 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.107 0.963 . . . . 0.0 110.335 -176.083 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.44 78.55 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.975 0.893 . . . . 0.0 108.935 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 t-80 -83.4 105.61 14.49 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.9 t -107.36 95.75 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -174.07 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.6 t -83.66 123.32 38.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -174.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -132.52 114.61 14.48 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.461 1.104 . . . . 0.0 111.373 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.22 143.21 26.48 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.575 0.75 . . . . 0.0 109.819 174.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.421 ' HB3' ' HA ' ' A' ' 78' ' ' ASN . . . -116.25 96.54 5.59 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.012 0.525 . . . . 0.0 110.698 176.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.8 t 49.19 72.14 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.329 0 C-N-CA 128.407 2.683 . . . . 0.0 111.823 175.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.62 142.76 66.67 Favored Pre-proline 0 CA--C 1.533 0.32 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 176.539 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo . . . . . 0 N--CA 1.457 -0.637 0 C-N-CA 124.362 3.375 . . . . 0.0 112.819 178.41 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -92.13 -9.13 34.55 Favored 'Cis proline' 0 CA--C 1.538 0.687 0 CA-C-N 118.82 0.614 . . . . 0.0 111.423 -5.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -36.95 121.51 0.78 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -168.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -77.33 121.67 24.05 Favored 'General case' 0 C--N 1.346 0.447 0 C-N-CA 126.126 1.77 . . . . 0.0 107.161 171.304 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -94.53 112.07 23.83 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.182 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.47 81.71 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.226 0 C-N-CA 124.357 1.063 . . . . 0.0 109.344 -172.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.434 ' CD2' ' H ' ' A' ' 58' ' ' ASP . 31.9 p-80 44.66 -84.74 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 127.367 2.267 . . . . 0.0 114.629 177.209 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.434 ' H ' ' CD2' ' A' ' 57' ' ' HIS . 30.1 t70 -75.89 -29.46 58.47 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.336 0.654 . . . . 0.0 110.991 -175.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -136.72 -173.6 3.48 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.453 0.701 . . . . 0.0 109.777 -175.018 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -126.03 127.0 45.19 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 174.197 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.9 m-80 50.67 44.08 2.0 Allowed Pre-proline 0 CA--C 1.537 0.459 0 C-N-CA 124.915 1.286 . . . . 0.0 112.575 178.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -83.29 176.07 7.69 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.676 1.584 . . . . 0.0 110.863 -175.165 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.5 m -95.42 144.02 26.28 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 170.389 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.23 143.97 45.3 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.539 0.736 . . . . 0.0 110.806 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -110.18 125.33 52.94 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 170.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.6 mt -130.15 138.09 32.31 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 123.464 0.706 . . . . 0.0 111.893 -171.349 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.65 117.93 4.69 Favored 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 122.884 2.39 . . . . 0.0 109.233 172.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.73 141.41 10.01 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 125.053 1.341 . . . . 0.0 111.724 177.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.64 -2.07 55.38 Favored Glycine 0 CA--C 1.531 1.091 0 CA-C-O 118.936 -0.924 . . . . 0.0 113.719 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.76 158.77 31.63 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.708 1.754 . . . . 0.0 110.352 173.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 29.6 m -83.18 93.32 7.63 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 174.346 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 51.8 t -79.38 99.08 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -91.63 90.72 7.7 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.9 t -77.18 105.56 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 104.246 -2.501 . . . . 0.0 104.246 176.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 55.4 m -100.63 98.99 9.49 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 125.585 1.554 . . . . 0.0 109.797 -171.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.496 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.5 m-85 -77.38 158.77 29.92 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.38 68.26 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 101.652 -3.462 . . . . 0.0 101.652 164.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.431 HD22 ' C ' ' A' ' 78' ' ' ASN . 0.2 OUTLIER -87.24 67.06 9.48 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 -174.728 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.2 m -112.61 83.0 1.74 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 114.669 -1.15 . . . . 0.0 110.616 -175.621 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -120.14 119.91 34.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 172.053 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.33 72.82 1.31 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.109 0.564 . . . . 0.0 109.519 -175.045 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 162.82 -65.64 0.25 Allowed Glycine 0 CA--C 1.522 0.499 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -94.03 112.83 24.7 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.449 -0.442 . . . . 0.0 111.183 -174.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.68 38.99 0.91 Allowed Glycine 0 CA--C 1.537 1.418 0 CA-C-O 118.928 -0.929 . . . . 0.0 111.865 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 0.95 -78.42 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 129.86 3.264 . . . . 0.0 117.513 -172.039 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.5 p 99.13 155.08 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 129.967 3.307 . . . . 0.0 110.196 -173.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.496 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 6.7 t80 -134.01 110.42 9.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 173.324 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -122.94 140.94 52.46 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.5 mt -115.64 126.7 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.665 1.586 . . . . 0.0 110.257 -172.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -161.05 164.74 30.63 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -83.86 56.41 3.66 Favored 'General case' 0 CA--C 1.535 0.394 0 O-C-N 121.608 -0.682 . . . . 0.0 110.621 -174.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -105.56 107.91 19.15 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 175.139 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.05 160.12 52.62 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 175.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.67 162.11 43.31 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.986 2.458 . . . . 0.0 109.81 174.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 158.63 93.88 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 CA-C-N 119.006 0.681 . . . . 0.0 110.595 -3.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -96.32 153.56 17.75 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.1 151.1 35.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 175.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 60.3 t -60.38 -38.51 77.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 174.535 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -78.53 133.48 63.21 Favored Pre-proline 0 N--CA 1.451 -0.409 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 174.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -74.75 80.53 2.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.409 2.073 . . . . 0.0 109.739 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 70.2 t -77.0 84.24 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 178.097 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.3 pt -77.58 83.04 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-O 123.065 1.412 . . . . 0.0 111.625 -173.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -62.12 154.54 69.31 Favored Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 171.133 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -37.18 112.59 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 124.248 3.299 . . . . 0.0 114.375 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 32.1 mm -79.48 139.44 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 59.6 t -86.0 -88.32 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 174.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.29 146.5 23.98 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.116 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.49 -178.9 42.96 Favored Glycine 0 C--N 1.333 0.368 0 CA-C-N 120.153 1.342 . . . . 0.0 112.219 173.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.2 p -122.95 -37.96 2.67 Favored 'General case' 0 C--N 1.338 0.083 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -176.666 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 78.34 -175.45 54.71 Favored Glycine 0 CA--C 1.541 1.701 0 N-CA-C 107.658 -2.177 . . . . 0.0 107.658 -170.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.19 141.71 39.96 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.911 1.855 . . . . 0.0 114.513 -171.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.0 p -83.82 155.12 64.97 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -174.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -73.67 75.0 3.17 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.458 2.772 . . . . 0.0 110.688 175.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 66.9 t -20.34 96.16 0.05 OUTLIER Pre-proline 0 CA--C 1.542 0.665 0 C-N-CA 128.195 2.598 . . . . 0.0 112.846 175.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.453 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 33.4 Cg_exo -66.47 171.71 10.2 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.723 2.948 . . . . 0.0 112.582 -178.221 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -124.76 151.94 44.48 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.653 1.181 . . . . 0.0 109.25 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 39.23 -103.4 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 127.219 2.208 . . . . 0.0 113.62 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -92.25 -2.11 68.74 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.496 -1.169 . . . . 0.0 114.476 -173.524 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -86.44 153.35 21.95 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.687 1.243 . . . . 0.0 110.442 -176.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -138.32 111.37 7.85 Favored 'General case' 0 C--O 1.224 -0.242 0 C-N-CA 124.987 1.315 . . . . 0.0 111.457 -172.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.453 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -78.92 113.15 3.6 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 125.459 1.504 . . . . 0.0 110.589 -174.019 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -121.59 164.46 17.24 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.798 0.839 . . . . 0.0 111.796 -176.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.2 m -165.94 115.61 0.99 Allowed 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 124.523 1.129 . . . . 0.0 108.103 178.023 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -84.99 67.25 10.14 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.16 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -66.79 122.45 17.7 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.1 m -97.98 130.12 44.84 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.704 -1.135 . . . . 0.0 110.379 -171.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -140.0 145.3 37.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.791 1.236 . . . . 0.0 109.669 -178.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -114.77 94.25 36.71 Favored Pre-proline 0 N--CA 1.454 -0.25 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -80.16 150.43 20.24 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 122.573 2.182 . . . . 0.0 111.287 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.3 p -101.31 155.21 18.17 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -53.58 141.56 25.33 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -173.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 136.61 176.49 14.39 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 126.198 1.856 . . . . 0.0 111.189 175.351 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.6 m -98.42 109.98 22.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.143 0.977 . . . . 0.0 110.317 -174.736 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -101.28 173.56 6.39 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 172.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -134.63 143.18 47.14 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.208 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -104.52 141.64 36.03 Favored 'General case' 0 CA--C 1.522 -0.126 0 CA-C-O 118.569 -0.729 . . . . 0.0 109.682 174.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 5.0 m -147.74 156.57 9.58 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 123.928 0.891 . . . . 0.0 111.77 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 11.2 t -94.9 131.58 40.66 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 126.595 1.958 . . . . 0.0 109.365 173.142 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -82.79 -1.39 51.54 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -172.267 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.33 136.42 93.52 Favored Pre-proline 0 CA--C 1.537 0.444 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 173.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.6 144.74 10.15 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.451 2.101 . . . . 0.0 112.554 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.07 -44.99 2.2 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.628 0.632 . . . . 0.0 112.995 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -48.41 -52.73 20.6 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 118.761 1.281 . . . . 0.0 113.989 -173.163 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.87 -52.11 66.41 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 120.877 0.37 . . . . 0.0 110.145 176.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.28 -39.74 91.56 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.684 1.194 . . . . 0.0 111.686 -175.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.2 p -79.01 -36.49 41.09 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 118.473 -0.775 . . . . 0.0 111.31 -174.323 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.33 -22.74 0.07 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 117.123 -2.465 . . . . 0.0 118.188 174.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.331 17.8 ptm -80.72 92.8 6.08 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 121.134 2.467 . . . . 0.0 112.93 -173.058 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.65 -175.1 4.78 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.188 0.995 . . . . 0.0 109.332 179.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 176.23 170.6 39.1 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 173.01 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.421 ' HB2' HG23 ' A' ' 63' ' ' THR . 38.0 mttt -107.08 146.56 31.06 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 124.447 1.099 . . . . 0.0 109.785 -173.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.5 mt -121.21 99.12 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 125.371 1.469 . . . . 0.0 107.062 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.5 t -90.82 100.66 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 24.1 t -89.62 127.49 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 178.346 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm . . . . . 0 N--CA 1.462 0.167 0 CA-C-N 119.136 0.88 . . . . 0.0 111.132 -178.151 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 m -79.88 60.1 3.37 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.2 m95 -99.66 131.84 45.39 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 126.029 1.732 . . . . 0.0 111.275 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -144.63 -170.89 3.49 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 172.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -136.21 130.12 32.66 Favored 'General case' 0 C--N 1.341 0.202 0 CA-C-N 119.216 0.916 . . . . 0.0 110.098 172.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -89.66 -156.62 0.42 Allowed 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 170.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.4 p -139.33 166.71 23.84 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 174.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -39.42 -54.97 3.49 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 115.594 1.702 . . . . 0.0 115.594 -172.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.75 -33.44 98.4 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 CA-C-N 120.92 1.364 . . . . 0.0 111.759 -177.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.94 -32.02 73.53 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 122.769 0.428 . . . . 0.0 110.454 -178.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -56.69 -51.04 71.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.231 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -58.22 -49.36 77.35 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.564 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -48.61 -57.15 6.65 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.738 0.415 . . . . 0.0 111.116 178.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -63.1 -45.13 93.52 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 118.432 -0.794 . . . . 0.0 111.605 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.4 mt -48.76 -47.77 41.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 119.414 1.007 . . . . 0.0 111.386 179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -55.35 -21.55 15.65 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 178.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -96.45 7.24 46.99 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 119.156 0.889 . . . . 0.0 112.414 -177.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.6 115.06 10.34 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 119.989 1.268 . . . . 0.0 110.226 -179.466 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 p -83.99 15.13 3.56 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.61 1.164 . . . . 0.0 113.875 -174.38 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.75 115.15 4.38 Favored Glycine 0 CA--C 1.527 0.819 0 O-C-N 121.214 -0.929 . . . . 0.0 111.446 -174.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -78.89 121.11 24.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.17 1.388 . . . . 0.0 108.995 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.97 122.5 6.27 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 C-N-CA 124.137 0.975 . . . . 0.0 109.592 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -132.12 68.93 1.48 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.689 1.596 . . . . 0.0 108.235 -174.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.84 -117.57 8.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 -174.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -78.89 -33.49 45.63 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.848 0.824 . . . . 0.0 109.559 173.367 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 27.8 m -78.88 155.96 28.85 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 123.739 0.816 . . . . 0.0 109.215 -173.223 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.7 t -118.67 132.62 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 173.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -121.14 126.88 50.84 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 123.204 0.602 . . . . 0.0 109.969 -173.2 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.478 ' CB ' HG22 ' A' ' 38' ' ' VAL . 67.7 m-85 -97.84 175.9 5.99 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 122.826 0.45 . . . . 0.0 110.153 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 60.0 m -156.5 168.21 28.06 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.505 0.722 . . . . 0.0 109.811 -175.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 45.26 43.53 9.71 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 125.354 1.454 . . . . 0.0 113.018 174.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.1 mttp 50.55 12.02 0.09 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.093 1.757 . . . . 0.0 115.492 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.8 m -103.62 74.78 1.27 Allowed 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -173.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.478 HG22 ' CB ' ' A' ' 33' ' ' TYR . 74.1 t -89.56 96.79 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.3 t-160 -105.21 102.62 12.1 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 173.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.3 t -99.17 103.28 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.0 t -88.06 90.48 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 175.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.34 159.61 14.85 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.014 1.326 . . . . 0.0 109.841 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.9 166.44 33.53 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 0.0 108.841 177.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -147.69 115.15 6.3 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 122.251 0.22 . . . . 0.0 111.151 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t 54.27 53.35 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 125.868 1.667 . . . . 0.0 111.912 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 30.9 mt -78.36 151.78 78.19 Favored Pre-proline 0 CA--C 1.532 0.286 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 173.058 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_exo . . . . . 0 CA--C 1.534 0.511 0 C-N-CA 123.581 2.854 . . . . 0.0 112.91 -176.069 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 . . . . . 0 N--CA 1.451 -0.397 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -110.44 54.58 0.93 Allowed 'Cis proline' 0 N--CA 1.455 -0.782 0 N-CA-C 106.685 -2.083 . . . . 0.0 106.685 -6.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 85.8 p -79.49 121.59 25.4 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -170.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -78.57 115.89 18.58 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 103.284 -2.858 . . . . 0.0 103.284 167.179 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -100.25 138.52 37.19 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.101 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.3 t -135.25 100.35 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 118.354 0.524 . . . . 0.0 110.066 -174.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 1.5 p80 35.44 -69.62 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 130.227 3.411 . . . . 0.0 116.378 -173.429 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -101.84 -25.86 13.66 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 125.004 1.322 . . . . 0.0 112.218 -175.17 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -125.56 -169.85 2.07 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.81 1.244 . . . . 0.0 109.957 -173.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? -136.9 133.82 36.16 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 171.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 48.22 41.76 1.03 Allowed Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 124.235 1.014 . . . . 0.0 112.592 -174.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.59 169.03 22.0 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 CA-C-N 120.742 1.301 . . . . 0.0 112.872 -172.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.0 m -89.58 127.76 35.93 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 112.342 -2.208 . . . . 0.0 106.127 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -106.32 128.13 53.77 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.159 0.891 . . . . 0.0 110.101 -177.285 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 -104.68 117.91 35.26 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 171.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.422 HD12 HG23 ' A' ' 152' ' ' ILE . 14.6 mt -124.22 138.44 30.84 Favored Pre-proline 0 CA--C 1.538 0.496 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.817 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -67.95 125.32 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.727 2.284 . . . . 0.0 109.153 168.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.32 133.36 19.7 Favored 'General case' 0 C--N 1.332 -0.191 0 O-C-N 121.382 -0.824 . . . . 0.0 111.217 174.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.55 12.36 80.34 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.144 -0.809 . . . . 0.0 113.13 -176.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.41 148.7 47.79 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 119.375 1.588 . . . . 0.0 110.169 173.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 38.8 m -83.47 90.75 7.25 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 174.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 85.0 t -77.68 98.67 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 124.746 1.219 . . . . 0.0 108.068 -174.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -96.96 104.38 16.39 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 177.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.3 t -89.44 91.34 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 54.0 m -79.52 87.87 5.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.473 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.275 4.1 m-85 -79.73 138.6 37.35 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 117.876 -1.059 . . . . 0.0 109.934 172.584 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.8 mp -117.44 67.89 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 101.088 -3.671 . . . . 0.0 101.088 163.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -84.41 56.3 3.74 Favored 'General case' 0 C--O 1.231 0.109 0 O-C-N 121.117 -0.989 . . . . 0.0 108.626 -173.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.522 HG23 ' HG2' ' A' ' 115' ' ' PRO . 53.4 m -85.75 69.99 10.65 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.884 -176.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -97.43 156.82 16.3 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 171.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -93.17 124.14 36.94 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 75.42 -68.64 2.09 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.63 0.633 . . . . 0.0 112.392 175.254 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -79.08 81.07 5.38 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.873 -0.781 . . . . 0.0 110.001 -174.25 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -52.85 80.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 126.425 1.964 . . . . 0.0 112.52 174.061 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -57.47 162.52 2.85 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 119.232 1.516 . . . . 0.0 111.468 179.175 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.3 p -121.85 160.91 23.72 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.584 1.554 . . . . 0.0 107.388 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PHE . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -128.26 110.18 12.16 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 172.204 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -126.64 128.93 47.53 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.861 0.864 . . . . 0.0 108.716 -172.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 20.5 mt -106.21 134.32 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 C-N-CA 125.964 1.706 . . . . 0.0 110.054 -173.263 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.6 t -158.04 -152.08 0.33 Allowed 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 176.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -126.58 9.32 7.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.689 1.131 . . . . 0.0 113.286 -176.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -64.67 121.44 14.5 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.35 166.45 49.62 Favored Glycine 0 CA--C 1.532 1.117 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 161.89 44.15 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 122.856 2.37 . . . . 0.0 109.602 173.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -76.92 149.61 90.8 Favored 'Cis proline' 0 N--CA 1.454 -0.825 0 N-CA-C 110.27 -0.704 . . . . 0.0 110.27 -4.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -89.27 152.94 21.28 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 149.7 29.34 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.86 -42.09 87.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 174.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -78.89 130.35 70.49 Favored Pre-proline 0 N--CA 1.451 -0.391 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 174.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -75.02 85.07 1.57 Allowed 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 122.374 2.05 . . . . 0.0 109.829 -175.085 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.4 t -76.77 85.55 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.348 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 175.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 pt -75.43 87.43 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 CA-C-O 123.646 1.689 . . . . 0.0 110.653 -172.28 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -62.83 154.17 76.7 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 112.842 -1.981 . . . . 0.0 106.928 172.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -39.49 108.71 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 124.059 3.173 . . . . 0.0 113.794 -175.424 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.0 mm -78.46 126.84 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.37 -82.14 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 105.785 -1.932 . . . . 0.0 105.785 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.6 150.17 20.64 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.93 158.66 21.79 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 119.288 -1.434 . . . . 0.0 112.135 174.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.3 p -107.75 145.43 33.52 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.516 1.126 . . . . 0.0 110.544 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.63 158.38 37.19 Favored Glycine 0 CA--C 1.535 1.3 0 N-CA-C 107.342 -2.303 . . . . 0.0 107.342 172.091 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -41.88 133.07 2.95 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.558 1.543 . . . . 0.0 113.884 -173.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.5 p -68.53 158.5 84.99 Favored Pre-proline 0 CA--C 1.535 0.373 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -177.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.3 -177.96 2.66 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.075 1.85 . . . . 0.0 108.804 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 90.0 t -117.66 98.91 52.14 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 125.654 1.582 . . . . 0.0 108.83 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.522 ' HG2' HG23 ' A' ' 79' ' ' THR . 85.9 Cg_exo -62.45 173.59 3.36 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.737 3.625 . . . . 0.0 113.426 174.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -145.57 162.09 38.26 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.54 1.136 . . . . 0.0 109.355 176.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.58 -117.55 0.76 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.883 1.673 . . . . 0.0 110.967 177.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.63 17.43 42.72 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-O 118.899 -0.945 . . . . 0.0 112.445 -177.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -85.72 151.01 24.19 Favored 'General case' 0 C--N 1.341 0.234 0 CA-C-N 118.059 0.93 . . . . 0.0 108.876 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -133.98 93.63 3.13 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 124.373 1.069 . . . . 0.0 111.239 -172.37 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.47 ' H ' ' CG ' ' A' ' 115' ' ' PRO . . . -49.03 118.15 4.82 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 125.926 1.726 . . . . 0.0 109.959 173.756 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.18 159.6 41.76 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 123.919 0.888 . . . . 0.0 112.223 -177.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -143.57 148.46 35.95 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 126.537 1.935 . . . . 0.0 107.114 178.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -134.1 65.16 1.58 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 178.185 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -76.93 150.65 35.94 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.411 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 31.4 m -118.18 142.77 47.1 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.872 0.869 . . . . 0.0 109.773 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -145.47 161.28 40.08 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.625 1.17 . . . . 0.0 109.98 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 69.6 m80 -129.81 92.25 37.8 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 125.885 1.674 . . . . 0.0 109.001 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -71.64 145.26 46.32 Favored 'Trans proline' 0 N--CA 1.454 -0.852 0 C-N-CA 123.093 2.528 . . . . 0.0 112.178 -175.429 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.8 p -93.56 155.25 17.42 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.834 1.254 . . . . 0.0 108.87 172.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.86 146.03 43.49 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.808 -0.558 . . . . 0.0 112.493 -174.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 128.41 -125.38 5.02 Favored Glycine 0 C--N 1.334 0.45 0 C-N-CA 126.79 2.138 . . . . 0.0 108.826 -178.353 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 35.6 m -153.5 144.59 22.91 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 118.226 1.013 . . . . 0.0 109.881 -175.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -134.74 175.27 9.7 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.506 1.922 . . . . 0.0 106.962 173.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -141.7 149.96 41.23 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.164 1.386 . . . . 0.0 108.199 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' TYR . . . . . 0.46 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 48.1 p90 -112.89 144.22 42.82 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.956 0.903 . . . . 0.0 109.893 175.765 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.1 m -148.71 162.64 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 C-N-CA 125.081 1.352 . . . . 0.0 110.68 178.191 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.29 136.94 41.23 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.643 1.577 . . . . 0.0 107.663 171.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -81.32 -16.5 52.23 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.317 1.228 . . . . 0.0 114.317 -172.644 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 53.7 mt -63.81 129.52 93.86 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_exo -46.79 150.09 2.76 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 123.947 3.098 . . . . 0.0 114.575 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.42 -43.01 2.01 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 124.092 0.853 . . . . 0.0 112.89 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -50.76 -53.68 29.68 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.671 1.188 . . . . 0.0 111.98 -173.468 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -54.8 -46.71 74.53 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.77 0.428 . . . . 0.0 111.16 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.73 -41.71 91.91 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 123.156 0.583 . . . . 0.0 111.201 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.1 p -79.67 -58.94 2.94 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.031 0.532 . . . . 0.0 112.124 -173.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.81 38.33 0.09 OUTLIER Glycine 0 CA--C 1.525 0.665 0 C-N-CA 119.65 -1.262 . . . . 0.0 114.685 -174.331 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.1 ttt -126.19 64.75 1.23 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.272 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -151.52 -174.47 4.84 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.806 0.843 . . . . 0.0 111.241 -177.732 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.46 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.83 174.39 38.06 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 174.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.4 146.67 45.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.417 1.487 . . . . 0.0 109.805 -170.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ILE . . . . . 0.422 HG23 HD12 ' A' ' 66' ' ' ILE . 10.2 mt -128.33 95.81 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 125.461 1.504 . . . . 0.0 107.651 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 t -88.03 132.22 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.224 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.7 t -122.19 120.99 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -176.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm . . . . . 0 N--CA 1.467 0.393 0 CA-C-N 119.671 1.123 . . . . 0.0 110.827 176.711 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.9 p . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -78.25 53.96 1.31 Allowed 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.725 1.148 . . . . 0.0 112.171 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -92.68 142.96 26.79 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 127.697 2.399 . . . . 0.0 108.405 175.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -152.29 177.08 10.94 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -140.05 140.72 36.21 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 169.749 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.61 -150.9 0.47 Allowed 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 174.036 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 19.0 p -136.03 173.43 11.72 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 172.319 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -39.56 -56.96 2.66 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 114.282 1.216 . . . . 0.0 114.282 -174.795 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -55.04 -35.31 89.97 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.572 1.515 . . . . 0.0 113.481 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.7 mp0 -65.55 -23.95 66.98 Favored 'General case' 0 N--CA 1.455 -0.184 0 O-C-N 121.339 -0.85 . . . . 0.0 111.379 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -55.72 -46.88 79.77 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 119.27 0.941 . . . . 0.0 108.972 173.594 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtmt -60.32 -51.25 70.31 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.166 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.56 -46.99 67.08 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.692 0.256 . . . . 0.0 111.692 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -62.65 -54.93 32.08 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.721 0.408 . . . . 0.0 110.274 177.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 62.1 mt -49.23 -46.88 46.56 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 122.883 0.473 . . . . 0.0 111.339 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -53.04 -27.0 17.66 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -90.5 -0.91 57.85 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.17 0.896 . . . . 0.0 112.503 -179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -57.02 154.52 9.56 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.897 0.771 . . . . 0.0 112.671 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.7 p -128.0 165.59 19.99 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 172.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 122.33 117.67 2.44 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -178.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.4 mtpt -79.08 121.51 25.07 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.31 1.444 . . . . 0.0 108.934 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.6 t -61.69 114.25 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 125.591 1.556 . . . . 0.0 109.485 -176.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.1 m -130.57 68.03 1.48 Allowed 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 124.159 0.983 . . . . 0.0 111.435 -174.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.18 -94.67 0.47 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 123.778 0.704 . . . . 0.0 112.476 174.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -101.07 -14.54 17.76 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.516 1.127 . . . . 0.0 110.127 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 29.4 m -108.39 151.79 25.55 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.811 1.244 . . . . 0.0 109.985 -172.495 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.44 130.71 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 170.429 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.7 m -115.39 119.66 37.0 Favored 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 123.187 0.595 . . . . 0.0 110.404 -170.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.411 ' CD1' HG13 ' A' ' 38' ' ' VAL . 96.7 m-85 -91.8 153.09 19.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.9 m -155.79 51.49 0.56 Allowed 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.884 -0.51 . . . . 0.0 110.157 -175.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.89 166.27 39.46 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 108.276 -1.93 . . . . 0.0 108.276 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -73.61 -38.16 65.18 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 117.503 0.651 . . . . 0.0 110.584 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.7 p -80.09 103.46 9.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 174.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.411 HG13 ' CD1' ' A' ' 33' ' ' TYR . 29.5 t -107.69 128.37 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.549 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -132.15 101.36 5.36 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 123.941 0.897 . . . . 0.0 110.019 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.2 t -92.01 143.02 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.1 t -123.06 114.0 40.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 173.382 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -120.93 112.17 18.43 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 124.645 1.178 . . . . 0.0 111.976 -172.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.86 149.87 22.46 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 172.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.98 109.24 12.72 Favored 'General case' 0 C--O 1.226 -0.162 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.047 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 14.0 t 44.34 85.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.258 1.423 . . . . 0.0 112.189 -176.199 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 51.9 mt -76.67 128.95 80.7 Favored Pre-proline 0 CA--C 1.534 0.336 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo . . . . . 0 N--CA 1.456 -0.72 0 C-N-CA 124.071 3.181 . . . . 0.0 111.541 175.442 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 CA--C 1.541 0.6 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -117.61 34.46 0.58 Allowed 'Cis proline' 0 CA--C 1.536 0.611 0 N-CA-C 109.297 -1.078 . . . . 0.0 109.297 -6.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.1 p -90.64 143.13 27.04 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 118.519 2.785 . . . . 0.0 118.519 -168.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' PHE . . . . . 0.445 ' CD2' ' HB2' ' A' ' 148' ' ' MET . 3.2 m-85 -85.69 103.46 14.51 Favored 'General case' 0 C--N 1.34 0.176 0 N-CA-C 103.276 -2.861 . . . . 0.0 103.276 166.374 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -93.51 96.07 9.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -174.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.8 t -85.2 149.5 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -176.125 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -20.96 -57.31 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 116.732 2.123 . . . . 0.0 116.732 -172.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -114.31 -5.71 12.95 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 39.8 mttm -150.34 148.54 28.94 Favored 'General case' 0 C--O 1.223 -0.323 0 CA-C-N 119.845 1.202 . . . . 0.0 109.731 -174.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.5 mttm -97.07 123.79 40.91 Favored 'General case' 0 C--N 1.332 -0.181 0 O-C-N 121.351 -0.843 . . . . 0.0 109.595 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.59 46.29 1.88 Allowed Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.505 1.522 . . . . 0.0 111.435 176.626 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -83.92 174.29 8.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 122.31 2.007 . . . . 0.0 113.031 -171.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 52.9 m -86.54 148.66 25.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 170.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.5 mp -119.55 133.0 55.86 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 120.892 -1.13 . . . . 0.0 109.421 175.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -109.82 116.27 31.35 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.539 -2.022 . . . . 0.0 105.539 171.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 mt -124.56 145.77 50.32 Favored Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 124.29 1.036 . . . . 0.0 112.456 -171.142 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -85.37 128.48 3.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.678 2.252 . . . . 0.0 107.909 171.172 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.26 151.99 2.63 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.859 1.264 . . . . 0.0 112.034 178.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.7 -31.8 2.19 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-O 119.203 -0.776 . . . . 0.0 113.701 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -46.84 148.6 1.02 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.567 1.147 . . . . 0.0 112.811 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 17.2 m -79.68 96.06 6.11 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.31 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.4 t -79.53 89.51 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 177.098 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -82.68 133.49 35.16 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 173.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.3 t -132.78 110.83 16.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.251 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 98.4 m -91.39 125.94 36.3 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 174.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -94.27 158.64 15.49 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 174.373 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.6 mp -137.41 67.57 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 102.577 -3.12 . . . . 0.0 102.577 163.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 20.8 t30 -98.09 76.67 2.39 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 -175.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.0 p -94.79 -80.14 0.41 Allowed 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.501 1.12 . . . . 0.0 109.923 -173.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 68.35 -50.71 0.55 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.253 2.221 . . . . 0.0 114.649 177.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 87.4 mttt 96.42 33.14 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 130.079 3.352 . . . . 0.0 111.877 -179.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 171.22 -60.03 0.17 Allowed Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -83.12 91.35 7.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.97 83.39 0.02 OUTLIER Glycine 0 CA--C 1.528 0.9 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 173.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -68.87 74.66 0.29 Allowed 'General case' 0 N--CA 1.457 -0.111 0 C-N-CA 125.177 1.391 . . . . 0.0 112.878 -174.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.8 p -42.29 136.38 2.31 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 125.253 1.421 . . . . 0.0 111.281 177.022 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -107.68 119.95 40.86 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 173.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ASP . . . . . 0.538 ' HB3' HD12 ' A' ' 105' ' ' ILE . 5.3 m-20 -129.62 108.79 10.49 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -172.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 32.3 mt -80.72 134.79 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 124.144 0.903 . . . . 0.0 108.824 176.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -160.33 -160.45 0.78 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.433 1.493 . . . . 0.0 107.42 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -126.43 13.31 7.61 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.692 0.797 . . . . 0.0 111.517 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -64.7 121.34 14.28 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 174.671 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -86.66 170.72 42.49 Favored Glycine 0 CA--C 1.532 1.114 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.85 164.16 36.59 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.208 2.605 . . . . 0.0 109.674 173.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.42 139.12 58.36 Favored 'Cis proline' 0 N--CA 1.455 -0.75 0 N-CA-C 110.163 -0.745 . . . . 0.0 110.163 -4.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -79.68 151.27 30.58 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.179 0.514 . . . . 0.0 110.011 178.394 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -98.96 149.71 22.69 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 124.135 0.974 . . . . 0.0 110.27 -174.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 18.2 t -62.52 -34.62 65.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 C-N-CA 123.706 0.803 . . . . 0.0 109.218 173.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.6 mmt -78.24 133.97 63.66 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -63.8 63.79 0.21 Allowed 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.889 3.059 . . . . 0.0 115.232 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 13.9 t -80.84 57.5 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 O-C-N 120.254 -1.529 . . . . 0.0 108.325 174.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -38.07 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 C-N-CA 123.529 0.732 . . . . 0.0 111.721 -174.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.04 143.45 32.08 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 125.017 1.327 . . . . 0.0 112.278 -172.442 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.18 162.45 92.7 Favored 'Cis proline' 0 N--CA 1.46 -0.444 0 N-CA-C 110.281 -0.7 . . . . 0.0 110.281 -6.071 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 88' ' ' ASP . 14.5 mm -118.18 144.46 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 174.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.56 -86.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 174.594 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.41 87.64 6.09 Favored 'General case' 0 CA--C 1.52 -0.207 0 O-C-N 122.024 -0.423 . . . . 0.0 109.977 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -90.4 125.61 7.99 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 107.581 -2.208 . . . . 0.0 107.581 172.298 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.7 p -76.01 -41.48 50.97 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.261 1.531 . . . . 0.0 110.039 173.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.2 -170.09 21.25 Favored Glycine 0 CA--C 1.532 1.145 0 N-CA-C 108.673 -1.771 . . . . 0.0 108.673 -174.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -91.17 138.26 31.73 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.332 1.566 . . . . 0.0 109.215 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.0 p -83.21 159.31 62.48 Favored Pre-proline 0 CA--C 1.533 0.317 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -173.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.87 74.61 3.88 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.076 2.518 . . . . 0.0 107.987 172.658 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.8 m -53.67 128.9 54.1 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 123.278 0.631 . . . . 0.0 111.331 -175.419 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.98 176.36 9.92 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.286 2.657 . . . . 0.0 110.078 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.32 -29.38 6.24 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 176.066 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -174.02 155.85 2.6 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.715 2.006 . . . . 0.0 108.174 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.34 -59.05 1.15 Allowed Glycine 0 CA--C 1.527 0.789 0 C-N-CA 125.466 1.508 . . . . 0.0 113.06 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -78.92 158.77 27.98 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 123.417 0.687 . . . . 0.0 111.344 -174.521 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -135.23 94.42 3.12 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.804 2.041 . . . . 0.0 108.388 -174.145 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -53.27 113.29 2.84 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 173.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.1 p90 -119.32 177.03 5.05 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.537 1.135 . . . . 0.0 109.689 175.154 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.5 m -158.05 154.17 27.16 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 -177.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -131.82 89.54 2.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 173.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -96.9 170.08 9.41 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.822 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.8 m -150.79 146.56 26.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -150.56 153.53 35.94 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.884 0.874 . . . . 0.0 110.423 -176.024 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -116.47 114.44 40.33 Favored Pre-proline 0 CA--C 1.535 0.384 0 C-N-CA 125.584 1.554 . . . . 0.0 107.116 173.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.79 142.26 3.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 124.371 3.381 . . . . 0.0 111.503 -172.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.2 p -96.02 146.42 24.64 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 124.363 1.065 . . . . 0.0 108.845 173.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.83 149.08 19.08 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.164 0.438 . . . . 0.0 112.092 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 121.74 -123.96 5.63 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 126.754 2.121 . . . . 0.0 109.123 -175.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 46.1 m -153.84 145.7 23.49 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.351 1.075 . . . . 0.0 109.972 -174.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -132.95 176.45 8.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.336 2.254 . . . . 0.0 106.897 173.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -142.31 152.81 43.33 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 125.534 1.533 . . . . 0.0 107.551 175.269 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 55.1 p90 -114.83 140.59 48.82 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 123.223 0.609 . . . . 0.0 109.905 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.36 162.9 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.375 1.07 . . . . 0.0 111.093 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 8.8 t -107.69 136.09 48.02 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 127.121 2.169 . . . . 0.0 109.838 173.228 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -81.64 -19.0 42.65 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 -170.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.01 130.04 93.82 Favored Pre-proline 0 CA--C 1.544 0.721 0 CA-C-N 119.125 0.875 . . . . 0.0 108.989 -174.15 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -42.15 133.45 4.52 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.745 2.964 . . . . 0.0 113.424 178.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 90.07 -32.51 4.87 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.099 0.857 . . . . 0.0 111.795 -174.879 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -75.49 172.84 11.83 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -176.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 75.29 -60.6 0.5 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -170.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.2 -52.27 66.01 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.7 p -78.51 75.47 5.03 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 121.829 0.823 . . . . 0.0 112.272 -178.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 70.87 -44.71 0.67 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 118.189 2.035 . . . . 0.0 118.189 169.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' MET . . . . . 0.445 ' HB2' ' CD2' ' A' ' 54' ' ' PHE . 4.2 ptp -77.85 87.74 4.07 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 119.857 1.828 . . . . 0.0 114.271 -172.035 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -160.81 -179.91 7.97 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 126.053 1.741 . . . . 0.0 108.839 173.497 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 178.86 168.39 37.96 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 172.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -104.21 138.51 40.57 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 125.049 1.339 . . . . 0.0 108.356 -174.762 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.1 mt -114.76 100.44 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 19.6 t -84.16 136.37 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -123.02 115.65 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp . . . . . 0 N--CA 1.462 0.13 0 CA-C-N 119.091 0.86 . . . . 0.0 109.558 174.64 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p . . . . . 0 CA--C 1.54 0.568 0 CA-C-O 120.666 0.27 . . . . 0.0 111.337 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.2 m -79.16 66.57 4.64 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.568 1.147 . . . . 0.0 112.253 -171.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -96.34 146.83 24.4 Favored 'General case' 0 CA--C 1.522 -0.099 0 N-CA-C 114.875 1.435 . . . . 0.0 114.875 177.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -149.13 170.15 19.07 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 129.064 2.946 . . . . 0.0 103.706 171.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -124.8 126.55 45.79 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-N 119.645 1.111 . . . . 0.0 110.063 174.301 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -88.09 -150.22 0.18 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 172.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.9 p -142.39 166.07 25.7 Favored 'General case' 0 CA--C 1.532 0.274 0 O-C-N 121.389 -0.819 . . . . 0.0 109.277 174.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.45 -58.11 2.1 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -175.067 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -60.06 -28.84 87.9 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 CA-C-N 121.159 1.45 . . . . 0.0 112.224 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -66.83 -24.46 66.16 Favored 'General case' 0 N--CA 1.45 -0.465 0 O-C-N 121.462 -0.774 . . . . 0.0 111.013 177.461 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.0 t -63.34 -53.84 40.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -54.29 -42.81 70.47 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.468 178.36 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -58.25 -66.6 0.46 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.273 -0.267 . . . . 0.0 110.619 174.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 67.9 mtm -47.68 -50.2 25.55 Favored 'General case' 0 CA--C 1.528 0.1 0 C-N-CA 124.766 1.226 . . . . 0.0 112.182 -174.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.5 mt -47.14 -40.68 16.18 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.16 0.584 . . . . 0.0 112.192 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -67.86 -10.63 54.65 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.51 17.55 23.17 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.885 0.766 . . . . 0.0 110.999 175.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -65.6 106.06 1.37 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 119.132 0.878 . . . . 0.0 109.909 174.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.9 p -77.98 82.52 4.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.37 112.71 0.46 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 174.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.1 mmtp -78.98 162.78 25.72 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.793 1.237 . . . . 0.0 109.863 -177.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.4 t -69.11 141.42 17.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.653 1.181 . . . . 0.0 109.59 -178.4 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.5 m -147.85 67.22 1.1 Allowed 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.363 -0.835 . . . . 0.0 109.593 174.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.06 -94.66 0.12 Allowed Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.827 0.727 . . . . 0.0 111.785 175.022 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -109.19 25.54 11.68 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.856 1.663 . . . . 0.0 110.118 178.202 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -154.99 163.12 40.75 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -174.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.09 147.17 23.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.137 -1.801 . . . . 0.0 106.137 173.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.6 m -142.15 138.23 31.45 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 119.259 0.936 . . . . 0.0 111.168 -171.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -112.07 -167.88 1.24 Allowed 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.331 0.514 . . . . 0.0 111.522 173.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.3 m -157.75 -47.77 0.06 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.732 0.813 . . . . 0.0 112.268 -173.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.08 156.35 53.37 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 177.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -79.18 40.6 0.42 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.289 -1.124 . . . . 0.0 112.323 -174.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.3 m -156.18 102.31 2.12 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 120.771 -1.206 . . . . 0.0 107.877 -178.247 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.2 t -104.73 84.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -82.47 93.36 7.23 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 t -93.99 159.65 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.4 t -133.68 106.93 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 C-N-CA 124.97 1.308 . . . . 0.0 108.045 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -112.74 103.48 11.5 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.416 1.487 . . . . 0.0 109.836 -174.576 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.03 112.0 23.71 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.276 0.63 . . . . 0.0 109.304 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.57 102.87 15.55 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.502 -0.749 . . . . 0.0 110.15 -174.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.6 t 49.32 82.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 125.613 1.565 . . . . 0.0 112.389 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.3 mt -76.58 141.6 69.41 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 174.602 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo . . . . . 0 N--CA 1.454 -0.827 0 C-N-CA 123.093 2.529 . . . . 0.0 110.315 -174.361 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -109.86 65.09 0.34 Allowed 'Cis proline' 0 N--CA 1.455 -0.766 0 N-CA-C 107.115 -1.917 . . . . 0.0 107.115 -5.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 59.1 p -86.45 123.07 31.27 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 116.581 2.067 . . . . 0.0 116.581 -171.12 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -83.47 94.24 7.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 168.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -81.79 115.91 21.23 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -175.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.5 t -114.09 82.55 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 125.067 1.347 . . . . 0.0 109.479 -173.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.418 ' CG ' ' N ' ' A' ' 58' ' ' ASP . 1.0 OUTLIER 46.83 -69.21 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.594 3.557 . . . . 0.0 115.221 176.239 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.418 ' N ' ' CG ' ' A' ' 57' ' ' HIS . 21.2 t70 -95.51 -28.08 15.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.153 1.781 . . . . 0.0 110.838 -176.054 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -132.19 -176.92 4.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 123.787 0.835 . . . . 0.0 109.285 -176.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -134.4 121.27 20.9 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 175.344 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.64 43.41 0.9 Allowed Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 124.897 1.279 . . . . 0.0 111.18 -177.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.59 177.74 6.71 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 121.711 1.608 . . . . 0.0 111.412 -175.25 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.7 m -93.47 138.04 32.17 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 170.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.0 mp -111.3 140.17 46.09 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.111 0.964 . . . . 0.0 109.939 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -112.88 120.9 43.05 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.603 1.161 . . . . 0.0 108.167 172.539 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 16.5 mt -128.01 146.54 59.6 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -170.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -72.06 123.11 9.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.608 2.205 . . . . 0.0 110.587 170.769 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.39 134.65 28.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 124.22 1.008 . . . . 0.0 110.57 173.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.98 0.43 75.76 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 118.764 -1.02 . . . . 0.0 113.157 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.06 146.63 52.82 Favored 'General case' 0 N--CA 1.456 -0.169 0 CA-C-N 119.847 1.824 . . . . 0.0 109.628 173.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 58.5 m -78.37 99.76 6.5 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.25 134.71 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -139.47 95.07 2.86 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.754 1.621 . . . . 0.0 106.729 173.081 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.7 t -80.11 106.02 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 174.623 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.0 m -79.47 109.0 13.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.507 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -76.93 150.34 35.95 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.478 172.587 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.408 ' O ' HG22 ' A' ' 77' ' ' ILE . 1.2 mp -132.74 69.1 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 165.426 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -102.3 77.94 1.7 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 -175.089 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.1 p -118.51 20.21 13.07 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.108 1.763 . . . . 0.0 112.627 -171.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -70.0 103.36 2.24 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 173.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -46.78 134.81 9.58 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.683 0.793 . . . . 0.0 111.692 -173.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.23 -59.45 3.6 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -174.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -78.89 67.8 4.69 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.338 0.655 . . . . 0.0 111.046 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.29 92.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.267 -1.933 . . . . 0.0 108.267 172.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.53 179.47 0.16 Allowed 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.059 0.944 . . . . 0.0 110.637 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 p -137.92 147.9 44.8 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.439 -2.06 . . . . 0.0 105.439 177.315 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -127.02 104.18 7.85 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 173.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ASP . . . . . 0.499 ' HB3' HD12 ' A' ' 105' ' ' ILE . 60.3 m-20 -120.62 127.24 51.91 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.989 0.916 . . . . 0.0 108.877 -174.207 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.2 mt -98.46 129.74 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 C-N-CA 125.999 1.719 . . . . 0.0 108.579 -174.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.96 -151.08 0.22 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.581 1.153 . . . . 0.0 108.153 -173.766 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt -133.92 -88.04 0.4 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.821 0.849 . . . . 0.0 109.783 178.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.6 mtmt 49.15 -126.74 2.09 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.216 1.006 . . . . 0.0 109.169 -173.367 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -175.65 161.88 30.92 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.191 -1.563 . . . . 0.0 109.191 175.046 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.82 154.44 30.17 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.613 2.876 . . . . 0.0 109.75 174.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.14 144.92 82.56 Favored 'Cis proline' 0 N--CA 1.453 -0.872 0 N-CA-C 108.994 -1.194 . . . . 0.0 108.994 -5.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -78.44 163.67 25.42 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-O 121.375 0.607 . . . . 0.0 110.054 -176.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.24 145.13 42.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.563 -173.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -49.56 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 174.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -78.79 149.55 74.34 Favored Pre-proline 0 CA--C 1.534 0.346 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.317 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -72.6 73.62 2.84 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.829 2.352 . . . . 0.0 111.494 -179.399 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 16.6 t -79.28 53.24 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 173.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.2 pt -84.33 68.71 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-O 122.874 1.321 . . . . 0.0 109.787 -176.085 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -88.48 -72.69 0.06 OUTLIER Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 113.743 -1.571 . . . . 0.0 110.597 -174.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -77.77 57.76 6.17 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 122.208 1.939 . . . . 0.0 111.48 -178.418 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 88' ' ' ASP . 24.8 mm -78.41 126.56 38.64 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 O-C-N 121.228 -0.92 . . . . 0.0 108.8 177.392 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.1 t -84.78 -88.18 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.62 164.29 12.84 Favored 'General case' 0 CA--C 1.521 -0.162 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 173.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 172.26 -179.14 44.04 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 119.297 -1.43 . . . . 0.0 112.556 173.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 6.0 p -130.84 138.82 50.03 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 126.272 1.829 . . . . 0.0 108.749 176.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -75.04 -127.77 0.19 Allowed Glycine 0 CA--C 1.534 1.275 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 174.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -112.15 154.47 25.44 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 119.659 1.729 . . . . 0.0 110.465 176.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.6 p -90.31 155.83 46.33 Favored Pre-proline 0 N--CA 1.449 -0.488 0 C-N-CA 124.927 1.291 . . . . 0.0 112.397 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.52 98.82 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.192 0 C-N-CA 122.981 2.454 . . . . 0.0 107.468 173.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 40.3 t -37.85 123.49 1.0 Allowed Pre-proline 0 CA--C 1.538 0.502 0 C-N-CA 125.222 1.409 . . . . 0.0 110.421 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -67.79 156.71 64.91 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.66 2.24 . . . . 0.0 112.847 -172.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 29.2 mmmt -110.2 175.94 5.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 125.717 1.607 . . . . 0.0 106.824 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -36.91 104.02 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 125.119 1.368 . . . . 0.0 114.07 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.31 -8.5 46.33 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-O 118.456 -1.191 . . . . 0.0 115.148 173.727 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -84.48 156.0 21.92 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.866 1.333 . . . . 0.0 109.744 -178.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -139.37 94.17 2.76 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.373 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.6 116.14 4.5 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.214 1.387 . . . . 0.0 113.06 174.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -130.46 154.79 47.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.26 1.024 . . . . 0.0 111.486 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.8 m -145.36 118.84 9.05 Favored 'General case' 0 CA--C 1.518 -0.278 0 C-N-CA 124.419 1.088 . . . . 0.0 109.646 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -95.27 88.28 5.1 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 171.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -89.65 122.97 33.28 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 21.8 m -82.91 142.08 31.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.885 -174.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -151.38 155.77 39.33 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.458 1.103 . . . . 0.0 109.423 175.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 65.2 m80 -123.78 108.85 30.49 Favored Pre-proline 0 CA--C 1.532 0.288 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 173.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -89.57 144.24 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.909 3.073 . . . . 0.0 111.019 -172.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.8 p -95.86 155.02 16.92 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.052 0.941 . . . . 0.0 109.549 173.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -60.88 149.25 36.82 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -175.473 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 126.67 -128.04 6.17 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 126.39 1.948 . . . . 0.0 108.684 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 32.1 m -152.99 141.95 21.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 118.451 1.125 . . . . 0.0 110.201 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -128.29 174.84 8.95 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.893 1.677 . . . . 0.0 107.828 173.435 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -134.74 147.17 49.98 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.124 1.37 . . . . 0.0 107.904 174.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -109.06 142.88 39.15 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.561 0.745 . . . . 0.0 109.291 174.083 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 33.0 m -143.95 165.3 14.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 124.528 1.131 . . . . 0.0 111.452 -177.371 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.2 t -118.76 135.04 54.72 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 126.634 1.974 . . . . 0.0 110.091 173.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 64.9 mt-30 -64.47 -50.9 65.66 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 125.015 1.326 . . . . 0.0 113.49 -174.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 71.4 mt -39.95 121.91 1.55 Allowed Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 124.711 1.204 . . . . 0.0 111.526 -170.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -31.79 120.22 0.08 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.886 1 C-N-CA 125.472 4.115 . . . . 0.0 115.711 -173.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 86.74 -25.05 7.77 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 118.888 -0.951 . . . . 0.0 113.481 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 22.4 m170 -54.68 -59.99 3.97 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.203 1.501 . . . . 0.0 111.548 -172.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -49.12 -56.37 9.35 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.138 0.575 . . . . 0.0 110.934 177.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.27 -46.66 79.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.914 0.886 . . . . 0.0 112.336 -175.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.7 p -79.23 -36.31 40.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 113.186 0.809 . . . . 0.0 113.186 -172.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.56 -18.82 0.03 OUTLIER Glycine 0 C--N 1.34 0.771 0 C-N-CA 118.442 -1.837 . . . . 0.0 116.443 -175.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.4 ttt -79.73 65.11 4.8 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.093 1.446 . . . . 0.0 109.681 -174.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -161.53 167.96 24.47 Favored 'General case' 0 C--O 1.225 -0.236 0 C-N-CA 123.035 0.534 . . . . 0.0 111.53 -178.097 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -174.22 169.34 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 176.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -94.5 151.68 19.16 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.637 1.175 . . . . 0.0 110.526 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.4 mt -125.22 94.0 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 173.461 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.2 t -80.26 136.59 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 173.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.2 t -127.39 127.65 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 -176.379 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 49.8 mttp . . . . . 0 N--CA 1.464 0.243 0 CA-C-N 119.043 0.838 . . . . 0.0 111.383 -176.813 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.706 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.1 p -63.96 -64.97 0.75 Allowed 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 173.159 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.0 mp -112.59 179.85 3.86 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 128.052 2.541 . . . . 0.0 106.453 171.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -68.8 124.42 23.63 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p -118.18 32.91 5.89 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.738 1.215 . . . . 0.0 110.454 -175.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.4 m -79.2 61.51 3.34 Favored 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.37 -0.831 . . . . 0.0 110.115 -178.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.7 m95 -79.46 136.16 36.85 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.988 1.715 . . . . 0.0 110.572 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -149.92 171.38 16.89 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -139.64 127.89 22.59 Favored 'General case' 0 C--N 1.341 0.213 0 CA-C-N 118.826 0.739 . . . . 0.0 109.826 171.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.17 -152.47 0.43 Allowed 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 125.551 1.54 . . . . 0.0 107.121 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.2 p -136.64 170.99 15.16 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 124.179 0.992 . . . . 0.0 108.482 173.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -39.06 -55.17 3.03 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 114.528 1.306 . . . . 0.0 114.528 -174.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -55.45 -33.53 86.27 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.517 1.478 . . . . 0.0 113.633 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -68.67 -29.36 67.81 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 119.118 0.872 . . . . 0.0 111.072 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 t -62.13 -50.2 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 174.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -54.43 -49.3 70.31 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.55 -61.53 2.14 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.034 0.534 . . . . 0.0 111.066 176.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 74.4 mtm -55.14 -45.84 75.65 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.202 0.601 . . . . 0.0 110.801 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.3 mt -53.28 -38.01 62.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.19 -0.433 . . . . 0.0 111.747 176.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -72.0 -45.69 60.0 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 175.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.5 mtpt -80.31 62.36 4.42 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 122.709 0.404 . . . . 0.0 110.791 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -134.94 134.64 40.8 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.375 1.07 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.2 p -96.48 24.02 6.27 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.935 0.894 . . . . 0.0 112.951 -175.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.21 100.0 2.43 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 125.727 1.632 . . . . 0.0 110.986 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -78.51 159.13 28.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.626 1.171 . . . . 0.0 109.322 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 63.2 t -93.53 93.47 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.715 0.806 . . . . 0.0 110.34 -174.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.3 p -77.74 70.47 4.12 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.002 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 60.98 -96.72 0.11 Allowed Glycine 0 CA--C 1.527 0.835 0 C-N-CA 124.741 1.162 . . . . 0.0 111.045 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -86.98 -36.61 18.16 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.027 0.931 . . . . 0.0 110.543 178.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.3 m -89.88 166.54 13.45 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.728 1.611 . . . . 0.0 108.787 -172.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.12 144.17 18.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 172.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.7 m -134.07 117.36 16.54 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.687 1.195 . . . . 0.0 108.236 -175.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 -79.59 162.25 25.43 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.182 0.515 . . . . 0.0 110.778 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 67.2 m -154.24 159.59 41.39 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.103 0.961 . . . . 0.0 108.629 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.22 165.23 29.43 Favored Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 -174.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.2 mtpm? -73.54 -18.28 61.1 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 122.004 -0.704 . . . . 0.0 111.753 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.4 p -95.68 87.63 4.75 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.132 0.973 . . . . 0.0 109.064 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.0 t -81.84 77.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -86.3 87.65 7.47 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.089 -175.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.67 95.87 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 124.39 1.076 . . . . 0.0 109.173 -174.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.65 109.99 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 175.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -127.84 164.28 22.56 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.827 1.251 . . . . 0.0 109.365 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.77 167.43 24.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 176.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -136.18 114.03 11.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -174.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.7 t 34.38 69.01 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 C-N-CA 127.11 2.164 . . . . 0.0 112.339 174.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 90.9 mt -76.67 144.98 74.22 Favored Pre-proline 0 N--CA 1.453 -0.286 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.24 102.57 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.21 2.607 . . . . 0.0 110.947 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 138.24 -44.54 1.11 Allowed Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -174.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 -78.43 127.3 81.22 Favored Pre-proline 0 N--CA 1.453 -0.288 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -76.16 160.5 36.27 Favored 'Trans proline' 0 N--CA 1.45 -1.039 0 C-N-CA 121.933 1.755 . . . . 0.0 111.278 -176.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -67.77 164.74 37.13 Favored Pre-proline 0 CA--C 1.538 0.486 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 172.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -112.38 7.32 3.12 Favored 'Cis proline' 0 CA--C 1.535 0.532 0 CA-C-N 119.641 0.907 . . . . 0.0 113.09 0.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.4 p -83.71 154.9 23.38 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 115.043 1.497 . . . . 0.0 115.043 -171.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -79.37 139.06 37.86 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.747 1.219 . . . . 0.0 109.526 173.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.94 132.38 34.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 123.922 0.889 . . . . 0.0 110.094 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.2 t -125.97 83.47 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 172.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 55.7 p-80 42.08 -78.59 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 128.587 2.755 . . . . 0.0 115.008 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -84.37 -24.81 29.53 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 124.18 0.992 . . . . 0.0 111.723 -176.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -130.83 -174.9 3.5 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.584 1.153 . . . . 0.0 109.58 -174.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -128.91 92.1 3.34 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.43 HD21 ' HA3' ' A' ' 150' ' ' GLY . 6.2 m120 26.73 69.82 0.45 Allowed Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 127.459 2.303 . . . . 0.0 115.882 -174.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -66.41 -55.56 0.36 Allowed 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.537 2.158 . . . . 0.0 108.674 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.2 m 169.53 154.63 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 129.257 3.023 . . . . 0.0 105.697 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.3 mp -117.22 124.79 49.95 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.969 1.308 . . . . 0.0 110.204 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -98.42 137.09 37.63 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 171.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.08 136.0 25.4 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.213 1.005 . . . . 0.0 110.867 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -76.47 112.06 3.38 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.705 2.937 . . . . 0.0 109.271 173.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.39 -41.37 9.06 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -173.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -72.75 -7.51 69.92 Favored Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.41 -0.661 . . . . 0.0 114.068 -175.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -85.94 165.07 17.04 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.741 1.271 . . . . 0.0 113.38 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 63.1 m -93.72 127.41 39.42 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 172.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 94.9 t -92.13 132.29 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -127.77 108.1 10.44 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.752 -1.574 . . . . 0.0 106.752 173.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.09 115.36 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 16.4 m -107.71 96.01 6.09 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 126.059 1.743 . . . . 0.0 107.181 174.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . 0.279 4.3 m-85 -78.79 151.57 31.9 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 172.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -127.79 69.6 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 102.595 -3.113 . . . . 0.0 102.595 162.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -80.64 113.08 18.58 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 171.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 52.3 m -137.93 45.38 2.13 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -78.55 113.71 16.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 172.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -72.8 69.8 0.95 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.166 0.586 . . . . 0.0 110.113 -178.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 174.43 -67.72 0.1 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -96.71 122.69 39.93 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -174.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.26 71.03 0.63 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.864 -1.695 . . . . 0.0 108.864 171.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -57.06 143.82 36.9 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.511 1.156 . . . . 0.0 111.356 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.3 p -106.76 161.25 14.84 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 125.435 1.494 . . . . 0.0 108.845 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -129.89 101.11 5.71 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 102.755 -3.054 . . . . 0.0 102.755 172.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -118.89 114.44 22.61 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -173.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 6.7 mt -95.2 125.31 47.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 C-N-CA 125.44 1.496 . . . . 0.0 110.297 -174.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -161.17 -145.46 0.11 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -113.0 -98.95 0.43 Allowed 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 174.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt 67.42 -67.32 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.887 1.275 . . . . 0.0 111.184 -174.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.78 170.35 28.9 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -174.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -75.1 147.01 32.99 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.634 2.223 . . . . 0.0 109.388 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.82 136.76 45.48 Favored 'Cis proline' 0 N--CA 1.454 -0.813 0 CA-C-N 119.48 0.85 . . . . 0.0 109.995 -5.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -79.03 149.24 32.24 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.93 144.03 39.12 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 121.188 0.518 . . . . 0.0 112.155 -173.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.15 -43.28 98.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.9 mtp -78.1 133.18 65.33 Favored Pre-proline 0 N--CA 1.45 -0.425 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 173.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -75.65 85.24 1.63 Allowed 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.669 1.579 . . . . 0.0 109.307 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.8 t -76.41 105.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -178.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 23.4 pt -78.91 72.98 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 123.241 1.495 . . . . 0.0 110.534 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -62.57 154.5 73.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 113.328 -1.76 . . . . 0.0 106.398 171.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_exo -37.62 104.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 124.031 3.154 . . . . 0.0 113.835 -176.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 31.4 mm -78.95 131.27 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.97 -88.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 104.753 -2.314 . . . . 0.0 104.753 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.3 150.3 20.72 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 170.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.89 168.08 39.8 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.8 174.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 2.8 p -120.77 127.61 52.13 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.291 1.036 . . . . 0.0 109.991 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.62 57.0 5.04 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 119.502 -0.61 . . . . 0.0 111.985 -176.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 73.33 99.68 0.07 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 126.256 1.822 . . . . 0.0 111.488 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.3 p -74.13 160.32 81.87 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 118.767 -0.635 . . . . 0.0 110.578 -176.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 169.08 2.07 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 123.559 2.839 . . . . 0.0 116.032 -173.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 92.6 t -121.38 97.08 47.54 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 126.641 1.976 . . . . 0.0 107.627 178.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.554 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 37.4 Cg_exo -70.52 -179.77 3.5 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.936 3.091 . . . . 0.0 114.005 -176.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -109.88 -164.87 0.96 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.814 1.646 . . . . 0.0 107.305 172.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -60.99 153.43 25.18 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.518 -0.739 . . . . 0.0 111.003 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.71 3.1 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 123.808 0.718 . . . . 0.0 113.276 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -80.02 156.06 27.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.196 0.598 . . . . 0.0 111.798 -175.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -135.88 106.87 6.68 Favored 'General case' 0 CA--C 1.513 -0.456 0 C-N-CA 125.677 1.591 . . . . 0.0 110.289 -172.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.554 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -64.41 123.27 27.09 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.269 -1.932 . . . . 0.0 108.269 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -130.98 165.04 24.04 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 122.127 0.965 . . . . 0.0 109.886 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.0 m -152.62 120.76 6.23 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -103.57 104.6 14.68 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -118.74 147.74 43.53 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 28.6 m -104.14 152.05 22.58 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.804 0.842 . . . . 0.0 109.731 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -151.38 147.72 27.25 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.824 1.25 . . . . 0.0 109.161 175.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 44.8 m80 -116.15 111.37 42.64 Favored Pre-proline 0 N--CA 1.454 -0.256 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 172.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -82.64 -170.98 1.03 Allowed 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.892 2.395 . . . . 0.0 110.688 -173.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.0 p -140.95 147.9 39.53 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.69 152.46 35.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -174.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.55 -129.68 8.14 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 126.508 2.004 . . . . 0.0 108.982 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.8 m -142.82 137.48 29.69 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 117.437 0.618 . . . . 0.0 109.667 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.4 m-85 -130.42 176.75 7.88 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.484 1.914 . . . . 0.0 106.182 172.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -142.53 147.85 36.64 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 173.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -115.21 147.03 40.84 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 172.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.2 m -144.96 154.46 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 125.042 1.337 . . . . 0.0 109.735 -174.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.43 107.64 19.8 Favored 'General case' 0 C--N 1.333 -0.125 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 171.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.1 mm-40 -74.72 38.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -174.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 16.5 mt -93.24 142.73 25.67 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 104.305 -2.479 . . . . 0.0 104.305 168.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -48.24 138.85 22.48 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.028 1.818 . . . . 0.0 112.94 178.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.0 -46.67 2.45 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.312 0.958 . . . . 0.0 113.193 176.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.2 m170 -42.55 -55.8 3.34 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.814 1.646 . . . . 0.0 113.882 -173.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.88 -53.54 57.02 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.71 0.29 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.71 -38.67 88.72 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 124.117 0.967 . . . . 0.0 111.684 -176.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 31.0 p -78.31 -32.32 49.24 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 118.731 -0.652 . . . . 0.0 111.293 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.12 -30.61 0.1 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 118.355 -1.879 . . . . 0.0 116.234 173.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.315 10.3 ptp -80.4 84.46 6.03 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 120.053 1.927 . . . . 0.0 112.707 -174.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -141.93 174.49 10.54 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 126.532 1.933 . . . . 0.0 107.296 172.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.43 ' HA3' HD21 ' A' ' 61' ' ' ASN . . . -156.28 128.28 2.18 Favored Glycine 0 C--N 1.331 0.285 0 N-CA-C 108.482 -1.847 . . . . 0.0 108.482 173.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -76.99 130.12 37.05 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 174.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.0 mt -110.87 100.91 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 25.7 t -88.84 110.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 174.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.8 t -97.66 94.66 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 63.9 mttp . . . . . 0 C--N 1.332 -0.165 0 O-C-N 121.525 -0.734 . . . . 0.0 109.041 176.373 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.774 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.6 p -66.19 -79.69 0.04 OUTLIER 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 4.5 mt 37.26 -86.34 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.193 2.197 . . . . 0.0 114.638 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.47 -50.43 67.76 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.805 0.842 . . . . 0.0 111.838 174.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.6 p 67.79 -37.3 0.32 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.941 2.097 . . . . 0.0 113.296 -173.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.9 m -78.05 68.93 4.19 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 32.6 m95 -103.45 129.01 50.5 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 126.853 2.061 . . . . 0.0 109.772 -176.01 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -151.92 178.4 9.45 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -131.27 127.04 36.96 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 171.156 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.75 -150.62 0.27 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.6 p -137.34 170.41 16.13 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 119.475 1.034 . . . . 0.0 108.563 172.126 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.6 tt -39.53 -55.74 3.23 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 124.316 1.046 . . . . 0.0 113.582 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -56.54 -33.23 92.29 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 CA-C-N 121.011 1.397 . . . . 0.0 113.861 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -64.94 -25.25 67.8 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 118.946 0.794 . . . . 0.0 111.452 177.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.2 t -53.91 -46.94 64.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.651 0.659 . . . . 0.0 109.277 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 mtmm -59.12 -54.17 50.04 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.27 -47.66 62.42 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.84 0.456 . . . . 0.0 111.378 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -62.3 -54.78 35.65 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 119.47 -0.3 . . . . 0.0 110.672 177.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.6 mt -50.58 -47.8 57.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 118.423 0.556 . . . . 0.0 111.392 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -54.06 -25.94 24.19 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.003 0.921 . . . . 0.0 113.093 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -88.21 -9.12 54.06 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 118.9 0.773 . . . . 0.0 112.116 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -49.48 145.8 4.52 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -176.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.7 p -121.0 166.4 13.9 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.599 1.159 . . . . 0.0 108.851 171.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.69 116.71 2.92 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 124.521 1.058 . . . . 0.0 110.787 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 49.4 mtmt -81.68 144.35 31.24 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.558 1.143 . . . . 0.0 108.989 176.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 81.4 t -67.78 145.32 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 122.781 0.432 . . . . 0.0 110.603 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.9 m -150.82 68.95 0.96 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.767 1.227 . . . . 0.0 109.132 174.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.28 -115.45 7.14 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -79.01 -31.22 44.63 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 118.054 0.927 . . . . 0.0 109.109 172.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -79.54 153.39 29.56 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.742 -173.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -120.47 135.32 61.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 171.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 74.2 m -121.7 133.49 54.95 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.302 1.041 . . . . 0.0 110.459 -169.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 79.2 m-85 -105.55 177.72 4.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 124.086 0.954 . . . . 0.0 109.589 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.8 m -154.36 -50.0 0.09 Allowed 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.468 0.707 . . . . 0.0 109.609 177.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -65.63 145.22 48.2 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -60.6 -31.69 70.84 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.179 0.592 . . . . 0.0 111.088 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.8 m -78.1 76.21 4.62 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -78.04 102.59 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 30.9 t-80 -106.95 102.94 12.26 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 123.818 0.847 . . . . 0.0 109.563 -178.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 86.0 t -99.89 151.03 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 125.231 1.413 . . . . 0.0 108.777 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.6 t -130.72 100.49 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 124.618 1.167 . . . . 0.0 108.494 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -106.14 155.46 19.42 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 125.362 1.465 . . . . 0.0 110.731 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.73 158.41 44.01 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 124.511 1.125 . . . . 0.0 109.3 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.84 117.77 24.86 Favored 'General case' 0 N--CA 1.456 -0.157 0 C-N-CA 123.556 0.742 . . . . 0.0 111.032 -173.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.9 t 42.29 66.92 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 C-N-CA 125.323 1.449 . . . . 0.0 111.618 173.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.5 mt -77.88 153.43 80.44 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -44.54 125.27 5.99 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.054 2.502 . . . . 0.0 111.704 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.17 -32.36 7.42 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 123.747 0.689 . . . . 0.0 111.896 -176.117 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -99.78 112.98 64.81 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 118.183 0.992 . . . . 0.0 109.469 -175.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -58.74 160.1 18.74 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.764 2.309 . . . . 0.0 114.47 -176.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 -65.79 147.69 98.61 Favored Pre-proline 0 CA--C 1.533 0.309 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -111.69 67.48 0.23 Allowed 'Cis proline' 0 N--CA 1.455 -0.791 0 N-CA-C 107.726 -1.682 . . . . 0.0 107.726 -6.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 79.0 p -92.19 133.66 35.59 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -86.34 122.4 30.25 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 169.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -93.32 131.01 38.87 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 104.57 -2.382 . . . . 0.0 104.57 171.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.5 t -137.5 114.92 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 120.226 1.375 . . . . 0.0 110.61 -173.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 36.79 -114.31 0.1 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.771 1.628 . . . . 0.0 112.837 -178.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -81.61 7.1 13.08 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -174.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -146.66 -169.77 3.36 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.526 1.13 . . . . 0.0 110.518 -172.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? -135.22 128.14 31.38 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 172.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 45.99 49.86 7.21 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 125.076 1.35 . . . . 0.0 111.963 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -81.71 173.7 11.05 Favored 'Trans proline' 0 N--CA 1.452 -0.942 0 C-N-CA 122.811 2.34 . . . . 0.0 111.998 -174.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.4 m -94.92 144.8 25.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 113.923 -1.49 . . . . 0.0 107.123 172.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.6 mp -113.23 139.47 48.76 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.093 -1.005 . . . . 0.0 109.983 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -115.37 98.75 6.92 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.531 1.533 . . . . 0.0 107.739 173.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.8 mt -101.16 138.08 19.87 Favored Pre-proline 0 CA--C 1.535 0.379 0 C-N-CA 126.408 1.883 . . . . 0.0 110.788 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.85 123.48 6.33 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 122.384 2.056 . . . . 0.0 107.65 171.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.64 138.46 17.98 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.578 0.751 . . . . 0.0 111.645 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 85.75 -1.57 88.04 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.521 -0.599 . . . . 0.0 112.691 -176.199 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.41 21.48 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 118.759 1.279 . . . . 0.0 112.065 174.336 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 89.3 m -91.73 91.3 7.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 171.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.0 t -79.15 99.46 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.298 1.039 . . . . 0.0 108.633 -172.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -98.64 107.35 19.78 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 126.113 1.765 . . . . 0.0 107.854 -178.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.1 t -101.83 116.92 46.33 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.0 m -88.25 137.29 32.45 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.21 146.33 39.49 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 123.712 0.805 . . . . 0.0 111.735 174.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.17 59.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 N-CA-C 101.222 -3.622 . . . . 0.0 101.222 163.494 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -92.93 73.2 4.81 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 104.635 -2.357 . . . . 0.0 104.635 -174.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.7 p -95.25 -77.46 0.47 Allowed 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.95 -171.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 51.71 -142.47 0.73 Allowed 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -172.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.4 mtpm? -149.01 123.58 9.76 Favored 'General case' 0 C--N 1.34 0.174 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.31 -55.19 3.22 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 118.883 0.765 . . . . 0.0 112.054 178.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -77.64 84.92 3.98 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 121.73 -0.865 . . . . 0.0 109.804 -174.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.26 75.59 0.01 OUTLIER Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.513 1.054 . . . . 0.0 110.697 172.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -55.51 163.81 1.18 Allowed 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.448 1.124 . . . . 0.0 110.096 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 93.0 p -131.91 165.95 22.74 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -132.31 93.03 3.18 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -98.38 130.76 45.03 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.748 1.219 . . . . 0.0 107.781 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 21.8 mt -102.49 133.53 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 124.635 1.174 . . . . 0.0 109.289 -173.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.9 t -157.88 -161.36 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -129.05 -0.0 5.24 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 124.324 1.05 . . . . 0.0 111.695 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -66.52 129.42 39.8 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -84.61 168.66 44.09 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 174.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -69.84 160.82 48.28 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.288 2.659 . . . . 0.0 110.114 174.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -75.74 163.96 89.08 Favored 'Cis proline' 0 N--CA 1.455 -0.745 0 N-CA-C 110.502 -0.615 . . . . 0.0 110.502 -4.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -111.14 152.79 26.59 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 176.373 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.16 153.32 34.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.3 t -59.11 -39.2 77.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 62.1 mtt -78.15 117.66 67.45 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.92 113.81 1.73 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.448 2.098 . . . . 0.0 111.924 -175.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 19.1 t -79.81 66.99 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 7.5 pt -79.42 -21.56 12.37 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.183 0 N-CA-C 115.145 1.535 . . . . 0.0 115.145 -172.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -49.55 -59.03 7.41 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 119.18 0.9 . . . . 0.0 111.597 177.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.92 62.7 6.64 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 122.796 2.33 . . . . 0.0 112.766 174.167 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.5 mm -113.62 145.77 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 172.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 48.9 t -97.19 -94.69 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 177.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.48 -176.5 3.95 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.76 0.824 . . . . 0.0 109.673 174.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.93 174.91 36.6 Favored Glycine 0 N--CA 1.443 -0.847 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 175.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 73.2 p -85.5 -50.68 7.06 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.354 0.597 . . . . 0.0 109.726 174.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 96.17 -176.79 33.3 Favored Glycine 0 CA--C 1.535 1.34 0 N-CA-C 105.559 -3.016 . . . . 0.0 105.559 -168.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -77.38 139.01 39.63 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.286 1.043 . . . . 0.0 109.667 -179.223 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.7 p -88.83 156.09 49.9 Favored Pre-proline 0 CA--C 1.537 0.451 0 N-CA-C 115.037 1.495 . . . . 0.0 115.037 -172.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.63 89.12 1.36 Allowed 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.321 2.681 . . . . 0.0 107.336 171.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 30.6 m -53.71 163.3 1.11 Allowed Pre-proline 0 CA--C 1.545 0.76 0 C-N-CA 124.774 1.23 . . . . 0.0 113.563 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.72 144.07 66.95 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 123.313 2.675 . . . . 0.0 113.775 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -108.62 21.77 16.82 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.851 1.26 . . . . 0.0 108.627 171.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 50.4 t0 79.31 139.7 0.07 Allowed 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 128.558 2.743 . . . . 0.0 107.953 -171.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 73.39 -50.03 1.64 Allowed Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.572 0.606 . . . . 0.0 112.102 -173.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -79.22 153.53 29.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.045 0.938 . . . . 0.0 112.194 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -130.23 95.68 3.97 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 127.233 2.213 . . . . 0.0 108.986 -173.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -45.54 112.87 0.84 Allowed Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.752 1.168 . . . . 0.0 111.506 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -131.63 175.21 9.37 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 122.504 1.145 . . . . 0.0 110.998 -176.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -167.84 156.13 9.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -141.11 90.91 2.35 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 172.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -110.23 153.53 24.68 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 25.0 m -118.5 140.91 49.13 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 124.659 1.184 . . . . 0.0 110.237 -173.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 2.8 p-90 -146.86 161.31 40.96 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.896 0.878 . . . . 0.0 110.676 174.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -133.71 89.18 31.29 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 125.467 1.507 . . . . 0.0 108.306 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -78.98 151.71 24.2 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.579 2.186 . . . . 0.0 110.239 -176.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.5 p -79.63 164.54 23.71 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.974 0.51 . . . . 0.0 110.172 174.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -67.02 157.03 34.48 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.939 -0.476 . . . . 0.0 111.976 -176.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.33 -118.86 4.1 Favored Glycine 0 C--N 1.335 0.499 0 C-N-CA 126.123 1.821 . . . . 0.0 109.084 -178.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -149.72 127.77 11.95 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.833 0.817 . . . . 0.0 109.606 -178.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -110.03 171.61 7.35 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 127.494 2.318 . . . . 0.0 106.912 174.4 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -142.0 144.11 33.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.867 1.267 . . . . 0.0 108.517 177.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -107.33 134.14 50.84 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.2 m -138.34 144.01 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 C-N-CA 124.218 1.007 . . . . 0.0 109.35 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.2 t -86.21 139.8 30.72 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -113.24 36.52 3.51 Favored 'General case' 0 CA--C 1.523 -0.088 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 -171.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 45.6 mt -91.59 133.54 30.91 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 103.798 -2.667 . . . . 0.0 103.798 168.067 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -39.11 128.37 1.41 Allowed 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.751 2.967 . . . . 0.0 113.968 -176.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.33 -23.59 5.35 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 118.981 -0.899 . . . . 0.0 114.337 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -62.25 -53.32 56.91 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 120.079 1.939 . . . . 0.0 111.62 -172.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -55.31 -48.51 74.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.896 -0.503 . . . . 0.0 110.559 175.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.96 -40.4 80.48 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.768 0.827 . . . . 0.0 111.923 -176.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 19.1 p -78.2 -40.48 37.42 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 119.054 -0.498 . . . . 0.0 109.997 -178.188 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 147.08 20.58 0.1 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 115.9 1.12 . . . . 0.0 115.9 172.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 15.6 ttt -80.02 76.71 6.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 119.66 1.73 . . . . 0.0 107.709 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.71 6.29 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 122.812 0.445 . . . . 0.0 111.734 -174.042 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -175.68 165.81 36.78 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 171.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -104.29 147.76 27.13 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 124.39 1.076 . . . . 0.0 109.341 -173.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.9 mt -128.18 96.84 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.5 131.9 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 174.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 35.2 t -118.66 93.93 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 106.995 -1.483 . . . . 0.0 106.995 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--N 1.332 -0.179 0 O-C-N 121.679 -0.638 . . . . 0.0 109.354 -179.756 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.909 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 p -85.67 -21.63 28.27 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 126.246 1.818 . . . . 0.0 112.018 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 24.98 -83.38 0.0 OUTLIER 'General case' 0 C--N 1.346 0.455 0 C-N-CA 128.326 2.65 . . . . 0.0 116.079 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.21 -42.19 73.01 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 113.348 -175.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.8 p 65.99 -40.9 0.34 Allowed 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.22 1.808 . . . . 0.0 114.453 -173.302 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 89.8 m -77.53 73.77 4.1 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.601 1.16 . . . . 0.0 108.301 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -107.09 134.42 50.25 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 127.588 2.355 . . . . 0.0 107.645 -177.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -151.38 -177.42 6.06 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 119.846 1.203 . . . . 0.0 109.601 176.2 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -136.5 149.07 47.98 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 172.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.29 -152.17 0.5 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.642 1.977 . . . . 0.0 106.573 174.247 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.6 p -135.79 173.01 12.19 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 119.152 0.887 . . . . 0.0 108.744 172.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.17 -56.89 2.41 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 114.455 1.279 . . . . 0.0 114.455 -175.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -54.67 -34.04 82.08 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.53 1.487 . . . . 0.0 113.456 -178.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -68.36 -26.88 65.8 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.215 -0.928 . . . . 0.0 111.38 177.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.2 t -59.44 -51.83 68.1 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 174.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.0 mtpp -56.43 -52.04 66.14 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.078 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.88 -54.71 17.86 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.607 0.363 . . . . 0.0 111.566 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.7 mtm -57.46 -53.8 54.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 119.343 -0.36 . . . . 0.0 110.27 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.4 mt -51.37 -48.14 62.62 Favored 'General case' 0 N--CA 1.463 0.217 0 C-N-CA 122.811 0.444 . . . . 0.0 111.334 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -55.11 -31.87 61.59 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 122.813 0.445 . . . . 0.0 111.929 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.5 11.13 25.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.33 0.652 . . . . 0.0 111.663 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.41 109.36 4.72 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 120.387 -1.446 . . . . 0.0 110.01 175.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 36.49 0.25 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.599 0.76 . . . . 0.0 112.706 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.67 108.09 2.36 Favored Glycine 0 C--N 1.338 0.651 0 C-N-CA 125.658 1.599 . . . . 0.0 110.224 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -78.89 150.67 32.1 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.352 1.061 . . . . 0.0 108.872 178.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 70.4 t -70.46 145.98 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.803 -0.561 . . . . 0.0 110.612 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 38.2 m -150.26 68.31 0.98 Allowed 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.623 1.169 . . . . 0.0 108.758 174.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.69 -110.99 3.82 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.3 -28.56 38.22 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 117.876 0.838 . . . . 0.0 110.388 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.8 m -86.81 155.13 20.42 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.702 1.201 . . . . 0.0 109.237 -172.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.9 t -119.64 134.52 62.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 171.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -122.96 120.05 32.24 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.666 1.186 . . . . 0.0 108.576 -172.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -87.48 170.84 11.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.151 0.5 . . . . 0.0 109.98 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 51.0 m -152.24 151.58 31.13 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -177.243 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.64 177.21 27.19 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -173.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 mttm -76.94 -26.13 53.67 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 122.035 -0.685 . . . . 0.0 111.827 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.3 m -78.77 73.61 5.32 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.846 0.748 . . . . 0.0 110.201 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -82.37 83.36 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -88.13 86.0 7.03 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.438 -174.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.4 t -81.0 111.71 18.04 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.115 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 -177.448 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.62 97.75 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 123.251 0.62 . . . . 0.0 109.33 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.07 101.6 13.28 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.703 1.201 . . . . 0.0 110.101 -176.052 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.77 102.17 14.92 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.801 1.24 . . . . 0.0 108.435 177.229 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.71 111.78 23.44 Favored 'General case' 0 CA--C 1.529 0.162 0 O-C-N 121.042 -1.036 . . . . 0.0 111.12 -174.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 8.5 t 38.21 73.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.648 1.579 . . . . 0.0 112.743 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.85 155.53 82.96 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -177.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo -40.01 -44.82 3.83 Favored 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 124.717 3.611 . . . . 0.0 116.397 -173.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -60.13 -20.98 55.53 Favored Glycine 0 CA--C 1.534 1.255 0 CA-C-O 119.865 -0.408 . . . . 0.0 113.839 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -110.96 97.18 33.15 Favored Pre-proline 0 N--CA 1.453 -0.301 0 C-N-CA 125.465 1.506 . . . . 0.0 108.804 -175.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -73.91 76.1 3.02 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.293 1.995 . . . . 0.0 110.402 -178.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 70.28 165.9 0.13 Allowed Pre-proline 0 CA--C 1.537 0.465 0 C-N-CA 125.994 1.718 . . . . 0.0 112.261 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -117.26 -9.1 0.34 Allowed 'Cis proline' 0 CA--C 1.535 0.572 0 N-CA-C 114.451 0.904 . . . . 0.0 114.451 -4.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.4 p -90.04 157.78 17.64 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 121.134 3.753 . . . . 0.0 121.134 -165.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -77.75 121.6 24.25 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 103.476 -2.786 . . . . 0.0 103.476 169.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -106.61 134.95 48.97 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.0 t -132.84 83.43 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 123.539 0.736 . . . . 0.0 109.204 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.278 1.0 OUTLIER 44.11 -70.07 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 130.224 3.409 . . . . 0.0 115.587 179.165 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -95.51 -23.86 16.9 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 124.186 0.994 . . . . 0.0 111.243 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -131.32 -172.94 2.97 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.549 1.139 . . . . 0.0 108.967 -175.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -139.4 134.72 32.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 172.104 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 49.48 41.43 0.99 Allowed Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 123.895 0.878 . . . . 0.0 112.111 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -72.77 162.88 39.99 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 CA-C-N 120.982 1.386 . . . . 0.0 111.247 -176.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.1 m -78.41 127.15 31.77 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 171.389 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 7.7 mp -97.38 127.37 43.29 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 119.249 0.932 . . . . 0.0 109.634 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -107.78 120.71 43.0 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 171.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 40.9 mt -123.24 134.61 25.26 Favored Pre-proline 0 CA--C 1.537 0.456 0 C-N-CA 124.691 1.196 . . . . 0.0 111.964 -171.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -65.1 113.46 2.41 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.396 2.064 . . . . 0.0 109.661 170.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.17 132.02 19.53 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.526 0.73 . . . . 0.0 111.133 174.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 88.94 -4.24 84.81 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.455 -0.636 . . . . 0.0 112.573 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.81 164.63 24.84 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 118.846 1.323 . . . . 0.0 111.641 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 53.9 m -98.21 103.27 15.2 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.667 1.587 . . . . 0.0 108.197 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.7 t -83.07 112.15 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 124.118 0.967 . . . . 0.0 108.768 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -103.31 100.69 10.58 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 174.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.5 t -79.23 93.25 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 37.6 m -90.95 99.74 12.73 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.622 1.569 . . . . 0.0 109.134 -176.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -79.64 159.57 26.69 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.492 173.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.9 mp -142.28 82.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 N-CA-C 101.019 -3.697 . . . . 0.0 101.019 162.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -108.3 115.17 29.61 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 105.383 -2.08 . . . . 0.0 105.383 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.3 m -140.41 39.55 1.89 Allowed 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 -79.77 70.62 6.33 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.986 177.057 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.4 mttm -1.62 94.94 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.402 3.081 . . . . 0.0 113.904 -176.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 96.14 -36.72 3.71 Favored Glycine 0 CA--C 1.532 1.15 0 O-C-N 121.92 -0.487 . . . . 0.0 113.418 175.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -79.92 95.11 6.0 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.6 1.2 . . . . 0.0 110.922 -178.626 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.78 54.02 0.36 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.243 1.402 . . . . 0.0 113.226 174.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -47.27 129.67 12.81 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-N 118.907 1.354 . . . . 0.0 110.228 177.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.4 p -108.26 112.59 25.15 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 -176.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -79.34 94.75 5.55 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -101.29 130.87 47.53 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 124.584 1.154 . . . . 0.0 109.538 -172.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -109.75 130.43 62.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 119.059 0.845 . . . . 0.0 110.468 -175.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.2 t -159.12 -153.18 0.35 Allowed 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -121.39 42.55 3.05 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 119.577 1.08 . . . . 0.0 110.234 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -76.09 94.8 3.52 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.6 157.2 52.52 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.1 160.24 45.64 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.105 1.87 . . . . 0.0 110.206 174.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -78.19 142.79 71.01 Favored 'Cis proline' 0 N--CA 1.456 -0.717 0 CA-C-N 118.901 0.643 . . . . 0.0 110.538 -2.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -79.85 151.89 29.99 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 176.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.54 148.64 24.97 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.542 0.737 . . . . 0.0 109.849 -178.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 25.5 t -63.47 -31.76 54.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 173.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -78.18 119.28 76.75 Favored Pre-proline 0 N--CA 1.45 -0.447 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.44 77.37 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.341 2.027 . . . . 0.0 108.89 -174.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 90.9 t -76.12 108.57 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 -175.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 15.6 pt -79.0 75.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-O 122.956 1.36 . . . . 0.0 111.194 -175.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -67.03 154.28 92.84 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 170.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -40.45 109.15 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.812 3.008 . . . . 0.0 114.363 -170.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 29.0 mm -78.6 121.83 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 175.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 87.6 t -84.67 -83.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.77 167.46 11.42 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 171.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.06 160.36 13.23 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.0 p -79.6 -46.3 17.53 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.173 177.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 93.61 -173.06 33.44 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 104.651 -3.38 . . . . 0.0 104.651 -167.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -82.96 131.67 35.18 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 120.404 2.102 . . . . 0.0 109.691 -174.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 p -90.48 153.43 46.07 Favored Pre-proline 0 CA--C 1.534 0.327 0 N-CA-C 116.113 1.894 . . . . 0.0 116.113 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -75.34 143.36 27.91 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.905 2.403 . . . . 0.0 106.099 169.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.5 m -141.16 95.57 7.43 Favored Pre-proline 0 CA--C 1.534 0.328 0 CA-C-N 118.456 0.571 . . . . 0.0 111.956 -172.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -55.97 168.53 1.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.816 3.011 . . . . 0.0 113.068 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -113.71 -5.25 13.34 Favored 'General case' 0 C--N 1.34 0.169 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -176.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 18.0 t0 178.05 154.16 0.33 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 126.236 1.815 . . . . 0.0 109.285 176.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 68.29 -62.66 0.4 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.522 2.011 . . . . 0.0 113.675 174.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -78.88 155.88 28.89 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 123.973 0.909 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -135.84 107.83 7.15 Favored 'General case' 0 CA--C 1.517 -0.303 0 C-N-CA 125.116 1.366 . . . . 0.0 110.778 -173.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -61.52 110.88 3.42 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.748 1.166 . . . . 0.0 110.604 176.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -116.51 170.55 8.48 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 122.658 1.218 . . . . 0.0 110.172 174.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 2.8 m -159.01 146.48 17.54 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 -174.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.21 96.25 2.75 Favored 'General case' 0 CA--C 1.521 -0.157 0 O-C-N 124.017 0.823 . . . . 0.0 111.866 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -103.82 147.93 26.72 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 169.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 37.4 m -104.15 134.3 47.63 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 177.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -136.54 140.67 43.11 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.522 1.129 . . . . 0.0 108.947 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -110.66 90.12 10.12 Favored Pre-proline 0 N--CA 1.455 -0.203 0 N-CA-C 105.174 -2.158 . . . . 0.0 105.174 173.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.16 147.55 42.78 Favored 'Trans proline' 0 N--CA 1.445 -1.354 0 C-N-CA 121.664 1.576 . . . . 0.0 110.285 -173.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.3 p -79.66 162.98 24.92 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.5 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.83 171.95 1.91 Allowed 'General case' 0 CA--C 1.537 0.455 0 O-C-N 121.307 -0.871 . . . . 0.0 112.13 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 100.95 -127.05 9.13 Favored Glycine 0 CA--C 1.522 0.496 0 C-N-CA 125.227 1.394 . . . . 0.0 110.158 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.2 m -153.04 144.4 23.25 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.352 1.076 . . . . 0.0 110.928 -174.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -134.21 -177.33 4.53 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 126.719 2.008 . . . . 0.0 106.71 173.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -144.62 141.6 29.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.223 1.009 . . . . 0.0 109.109 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -101.3 143.58 31.18 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.211 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.8 m -150.71 151.96 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 125.169 1.388 . . . . 0.0 109.789 -177.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 52.6 t -97.72 102.32 14.05 Favored 'General case' 0 C--O 1.231 0.111 0 C-N-CA 124.407 1.083 . . . . 0.0 109.754 171.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -73.52 33.61 0.08 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 29.4 mt -92.63 142.09 25.34 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 169.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 99.1 Cg_exo -46.11 136.67 14.14 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.335 2.023 . . . . 0.0 113.093 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.26 -52.41 4.05 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 123.676 0.655 . . . . 0.0 112.661 179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -39.83 -55.64 1.93 Allowed 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.855 1.662 . . . . 0.0 114.849 -171.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -50.89 -41.49 58.45 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.451 0.569 . . . . 0.0 111.635 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.27 -50.86 19.99 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.217 0.607 . . . . 0.0 109.943 174.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.7 p -79.85 62.39 4.07 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.691 -0.631 . . . . 0.0 111.377 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.38 93.39 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 117.622 1.809 . . . . 0.0 117.622 171.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 7.5 mtp -122.35 68.6 0.95 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 119.862 1.831 . . . . 0.0 109.154 170.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -159.48 -177.71 6.61 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.493 0.717 . . . . 0.0 111.883 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.73 171.47 33.74 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 172.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.7 mttm -101.6 152.46 20.78 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 123.784 0.834 . . . . 0.0 109.495 -174.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.9 mt -124.35 94.14 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 174.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 27.1 t -88.53 131.76 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 36.1 t -128.1 109.65 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt . . . . . 0 N--CA 1.465 0.294 0 CA-C-N 119.001 0.818 . . . . 0.0 110.464 -179.132 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.778 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 p -51.93 -26.12 9.66 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.533 1.533 . . . . 0.0 112.472 178.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.7 mp -48.72 -38.61 22.06 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 125.604 1.561 . . . . 0.0 110.851 173.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.45 ' HA ' ' CH2' ' A' ' 7' ' ' TRP . 20.6 t0 -59.32 95.93 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.654 1.182 . . . . 0.0 111.693 178.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.1 p -134.03 -92.21 0.33 Allowed 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.92 1.288 . . . . 0.0 111.701 -174.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 m -78.69 58.53 2.29 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 -169.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.45 ' CH2' ' HA ' ' A' ' 4' ' ' ASP . 0.1 OUTLIER -89.09 130.28 35.56 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.754 1.222 . . . . 0.0 107.916 179.743 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -149.8 176.2 10.93 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -137.93 151.99 48.53 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 170.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.34 -153.76 0.57 Allowed 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 127.355 2.262 . . . . 0.0 105.998 173.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.3 p -138.21 169.12 18.34 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.958 0.799 . . . . 0.0 109.684 175.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.72 -54.39 4.09 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -174.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -57.73 -33.52 96.91 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.6 1.534 . . . . 0.0 111.936 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.8 mm100 -67.67 -23.8 65.35 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 121.765 -0.584 . . . . 0.0 111.103 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 t -64.14 -49.67 80.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 173.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.5 mttp -58.89 -39.82 82.58 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 122.684 0.393 . . . . 0.0 110.321 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.21 -62.83 1.44 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 122.042 -0.411 . . . . 0.0 109.963 174.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -54.08 -43.52 70.41 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.642 0.777 . . . . 0.0 111.897 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.7 mt -54.76 -33.09 60.85 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 176.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.54 -14.98 62.22 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 119.396 0.998 . . . . 0.0 112.392 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.98 17.57 20.65 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.008 0.822 . . . . 0.0 110.129 173.165 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.05 154.07 42.12 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.432 -0.793 . . . . 0.0 109.108 172.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.82 165.34 34.81 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.547 0.739 . . . . 0.0 109.766 -172.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.12 136.8 5.95 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 124.347 0.975 . . . . 0.0 111.335 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -79.26 126.75 31.19 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.299 1.039 . . . . 0.0 108.483 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.96 83.95 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 125.46 1.504 . . . . 0.0 109.261 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.9 m -85.89 68.06 10.22 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.087 1.355 . . . . 0.0 108.451 -175.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.54 -105.95 1.31 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -87.43 -22.34 25.04 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.78 0.832 . . . . 0.0 111.536 176.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.4 m -97.35 155.74 16.76 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 124.928 1.291 . . . . 0.0 108.517 -173.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.0 t -114.56 135.5 54.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 174.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -124.03 122.93 39.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 119.191 0.905 . . . . 0.0 110.375 -173.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 38' ' ' VAL . 0.6 OUTLIER -79.55 174.55 11.46 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.243 0.544 . . . . 0.0 111.208 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.5 m -158.93 49.88 0.36 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.723 0.809 . . . . 0.0 110.186 -174.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.26 170.44 38.94 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 -177.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -82.11 -33.71 29.58 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.978 0.511 . . . . 0.0 111.304 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.5 p -83.2 84.46 7.48 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 121.301 -0.874 . . . . 0.0 108.767 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 33' ' ' TYR . 77.6 t -86.07 83.35 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 C-N-CA 124.196 0.998 . . . . 0.0 108.894 -174.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -84.96 104.78 15.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 124.705 1.202 . . . . 0.0 109.765 -176.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.44 104.49 16.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.7 t -81.9 112.09 19.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 174.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -125.81 160.39 29.96 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.978 1.311 . . . . 0.0 110.267 -176.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.22 163.54 38.01 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.274 1.03 . . . . 0.0 109.65 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -129.35 122.62 29.88 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 124.017 0.927 . . . . 0.0 109.668 -179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.4 t 26.1 65.16 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 128.418 2.687 . . . . 0.0 113.12 174.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.9 mt -77.23 146.91 75.44 Favored Pre-proline 0 CA--C 1.534 0.36 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -39.67 104.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 124.712 3.608 . . . . 0.0 113.679 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.28 -47.67 1.0 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -77.29 142.33 67.58 Favored Pre-proline 0 CA--C 1.531 0.24 0 O-C-N 122.244 -0.562 . . . . 0.0 109.93 -178.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -79.06 152.3 24.36 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.703 2.268 . . . . 0.0 111.512 -174.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -65.58 145.83 99.02 Favored Pre-proline 0 N--CA 1.45 -0.44 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -109.76 50.54 1.22 Allowed 'Cis proline' 0 CA--C 1.54 0.79 0 N-CA-C 108.087 -1.543 . . . . 0.0 108.087 -5.08 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 87.0 p -73.19 127.2 31.94 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 115.958 1.836 . . . . 0.0 115.958 -170.377 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -81.81 108.85 15.67 Favored 'General case' 0 C--N 1.343 0.318 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 168.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -84.31 136.66 33.82 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 120.011 1.278 . . . . 0.0 107.93 177.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -135.59 87.53 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 CA-C-N 119.128 0.876 . . . . 0.0 109.64 -174.214 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.0 p-80 39.27 -97.15 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.575 1.95 . . . . 0.0 113.632 -176.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.0 -27.24 64.53 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.882 0.473 . . . . 0.0 111.844 -174.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -127.19 -171.55 2.45 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.505 1.122 . . . . 0.0 110.718 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -135.6 127.45 29.36 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 172.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 51.16 44.15 2.02 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 125.044 1.338 . . . . 0.0 111.76 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.01 -178.0 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 122.87 2.38 . . . . 0.0 112.733 -173.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.9 m -104.45 136.2 44.47 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 113.079 -1.873 . . . . 0.0 106.44 172.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.7 mp -116.5 122.3 44.33 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 118.875 0.761 . . . . 0.0 112.038 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -93.27 127.09 38.71 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 171.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 25.4 mt -130.83 140.96 40.27 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 125.176 1.391 . . . . 0.0 111.711 -170.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -81.37 122.78 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.664 2.243 . . . . 0.0 109.137 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.98 143.06 3.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 125.205 1.402 . . . . 0.0 112.652 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 78.02 -12.08 19.44 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.28 -0.733 . . . . 0.0 113.695 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.68 148.66 23.89 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 119.035 1.418 . . . . 0.0 111.074 174.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 59.8 m -81.61 102.06 10.41 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 173.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.28 127.19 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -124.45 103.3 8.11 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.76 105.44 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.9 m -91.33 98.04 11.47 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.99 1.316 . . . . 0.0 107.93 175.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.69 156.04 30.94 Favored 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 120.916 -0.313 . . . . 0.0 110.902 173.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.1 mp -136.99 73.43 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 102.172 -3.27 . . . . 0.0 102.172 164.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.57 110.93 21.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 173.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 41.4 m -141.25 46.28 1.73 Allowed 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 173.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -68.43 -48.91 63.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.6 mtmm 93.34 155.33 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 129.709 3.204 . . . . 0.0 109.42 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 -66.89 1.59 Allowed Glycine 0 CA--C 1.53 1.029 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -172.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -79.8 104.03 10.1 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 124.222 1.009 . . . . 0.0 110.705 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.42 73.36 0.59 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 107.964 -2.054 . . . . 0.0 107.964 171.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -55.26 136.49 48.82 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.792 1.296 . . . . 0.0 111.506 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.3 p -96.43 157.01 16.1 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.242 1.417 . . . . 0.0 108.32 174.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -128.38 115.83 18.84 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 103.623 -2.732 . . . . 0.0 103.623 171.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.13 121.46 22.64 Favored 'General case' 0 C--O 1.226 -0.164 0 CA-C-N 119.151 0.887 . . . . 0.0 109.975 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 53.3 mt -97.8 132.87 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 125.651 1.58 . . . . 0.0 109.275 -174.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -157.39 -155.8 0.54 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.757 1.223 . . . . 0.0 107.963 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.8 mtpt -132.6 -2.85 3.36 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -174.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -74.84 134.53 41.69 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 118.844 0.747 . . . . 0.0 109.453 176.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.35 42.3 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 123.285 0.469 . . . . 0.0 112.14 -178.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -70.95 166.0 30.5 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.617 2.878 . . . . 0.0 109.792 174.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -78.39 139.19 54.08 Favored 'Cis proline' 0 N--CA 1.454 -0.805 0 N-CA-C 110.392 -0.657 . . . . 0.0 110.392 -3.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -81.93 151.44 27.23 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.39 153.29 31.71 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 56.6 t -57.77 -43.67 84.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -77.92 131.66 69.6 Favored Pre-proline 0 N--CA 1.451 -0.379 0 N-CA-C 104.535 -2.394 . . . . 0.0 104.535 172.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.87 75.43 2.68 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.25 1.967 . . . . 0.0 112.197 -172.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 t -79.21 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 172.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.413 ' H ' HG13 ' A' ' 102' ' ' ILE . 1.8 pp -86.71 -34.82 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 126.834 2.054 . . . . 0.0 113.289 -173.07 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -51.27 138.9 26.78 Favored Pre-proline 0 CA--C 1.535 0.389 0 C-N-CA 124.301 1.04 . . . . 0.0 111.901 -173.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.22 170.98 56.71 Favored 'Cis proline' 0 N--CA 1.459 -0.507 0 CA-C-N 119.629 0.903 . . . . 0.0 110.981 0.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 26.1 mm -124.05 144.33 34.19 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.109 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 174.016 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.9 t -95.39 -88.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 174.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.23 158.55 15.41 Favored 'General case' 0 N--CA 1.461 0.11 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 173.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.45 172.84 40.68 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 119.272 -1.442 . . . . 0.0 113.025 173.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.8 p -126.94 116.49 20.87 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.587 1.155 . . . . 0.0 110.653 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -76.17 65.11 2.71 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.515 1.055 . . . . 0.0 111.314 -179.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 76.24 98.75 0.07 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 127.186 2.194 . . . . 0.0 112.073 173.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.9 p -68.67 169.28 11.29 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-O 118.951 -0.547 . . . . 0.0 110.552 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -54.27 167.02 1.41 Allowed 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 123.295 2.663 . . . . 0.0 117.014 -172.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 79.0 t -124.67 92.02 48.52 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 126.78 2.032 . . . . 0.0 106.632 173.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.407 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 31.6 Cg_exo -72.33 -170.2 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 123.376 2.717 . . . . 0.0 113.467 -176.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -128.82 172.93 10.81 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 172.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -49.71 147.47 3.6 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-O 121.077 0.465 . . . . 0.0 112.166 -174.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.04 -44.85 2.67 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.346 -0.697 . . . . 0.0 112.738 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -79.69 153.05 29.57 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.226 1.01 . . . . 0.0 110.839 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -135.51 114.66 12.3 Favored 'General case' 0 C--O 1.224 -0.25 0 C-N-CA 124.903 1.281 . . . . 0.0 111.079 -173.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.407 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -75.95 113.56 3.92 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 125.507 1.527 . . . . 0.0 110.281 -174.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -113.9 163.02 15.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 122.766 1.27 . . . . 0.0 110.882 175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.3 m -150.91 126.66 10.28 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.702 -1.962 . . . . 0.0 105.702 174.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.63 89.6 3.12 Favored 'General case' 0 CA--C 1.518 -0.267 0 C-N-CA 124.46 1.104 . . . . 0.0 108.069 178.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -101.2 143.97 30.63 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 27.2 m -106.25 149.26 27.04 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.353 1.061 . . . . 0.0 109.686 -174.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -147.78 145.95 28.99 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.235 1.014 . . . . 0.0 109.762 174.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.4 m80 -114.1 107.46 51.94 Favored Pre-proline 0 CA--C 1.531 0.233 0 N-CA-C 105.033 -2.21 . . . . 0.0 105.033 173.045 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -90.79 133.74 1.75 Allowed 'Trans proline' 0 N--CA 1.444 -1.388 0 C-N-CA 123.743 2.962 . . . . 0.0 113.447 -170.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -84.54 158.86 20.82 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.528 1.531 . . . . 0.0 107.05 170.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.18 167.73 3.84 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.104 0.865 . . . . 0.0 113.025 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 107.12 -177.08 21.5 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 126.263 1.887 . . . . 0.0 112.916 174.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 12.7 m -87.82 137.56 32.23 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 124.213 1.005 . . . . 0.0 109.483 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -133.26 167.32 20.58 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 125.302 1.441 . . . . 0.0 107.24 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -134.0 147.75 51.03 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.987 1.315 . . . . 0.0 108.134 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' TYR . . . . . 0.45 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 47.6 p90 -114.14 138.99 49.7 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.283 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.3 m -142.52 156.23 18.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.345 1.458 . . . . 0.0 110.258 -178.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 13.4 t -96.62 114.75 26.43 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.552 1.141 . . . . 0.0 109.033 172.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -61.92 -14.44 34.4 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 125.42 1.488 . . . . 0.0 114.738 -176.058 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 26.2 mt -58.78 130.41 85.7 Favored Pre-proline 0 CA--C 1.541 0.606 0 CA-C-N 120.002 1.274 . . . . 0.0 108.317 174.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.71 145.86 4.19 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 123.12 2.547 . . . . 0.0 112.972 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.18 -43.75 2.06 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-O 119.58 -0.566 . . . . 0.0 112.798 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -52.67 -55.21 24.15 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.534 1.167 . . . . 0.0 112.602 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -53.93 -52.7 59.78 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.098 0.408 . . . . 0.0 110.103 177.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.46 -42.92 71.22 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 124.016 0.927 . . . . 0.0 111.402 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.1 p -81.24 10.92 4.76 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 12.93 37.73 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.475 -1.18 . . . . 0.0 116.026 170.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 2.9 ttt -79.31 73.88 5.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.995 1.897 . . . . 0.0 108.426 174.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.24 -166.92 2.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.511 0.324 . . . . 0.0 111.425 -174.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.45 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.76 177.44 40.2 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 174.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -116.43 152.89 33.08 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.5 1.12 . . . . 0.0 110.879 -172.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.6 mt -129.12 141.11 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 105.297 -2.112 . . . . 0.0 105.297 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 28.9 t -132.48 108.94 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.63 113.98 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 -176.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 67.9 mttm . . . . . 0 N--CA 1.461 0.119 0 CA-C-N 118.495 0.589 . . . . 0.0 109.847 174.702 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.523 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.7 p -75.27 75.59 2.39 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 103.907 -2.627 . . . . 0.0 103.907 171.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.4 mt 60.03 -172.53 0.12 Allowed 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.248 1.019 . . . . 0.0 108.736 -169.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -71.52 133.46 45.83 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 121.135 -0.978 . . . . 0.0 109.298 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.2 p -130.26 41.1 3.45 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 123.965 0.906 . . . . 0.0 109.979 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.0 m -79.8 64.19 4.58 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 122.323 1.059 . . . . 0.0 108.164 178.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -80.49 121.48 25.81 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 125.859 1.664 . . . . 0.0 110.987 -173.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.3 mmtp -142.01 170.39 15.81 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 172.507 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -134.8 129.06 33.96 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 171.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.6 -156.76 0.53 Allowed 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 172.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 70.9 p -137.65 170.98 15.13 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 119.413 1.006 . . . . 0.0 109.876 174.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.15 -60.36 1.02 Allowed Pre-proline 0 CA--C 1.543 0.677 0 N-CA-C 115.325 1.602 . . . . 0.0 115.325 -173.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -60.06 -29.26 88.82 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 CA-C-N 121.588 1.603 . . . . 0.0 112.335 -178.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -67.03 -25.74 66.42 Favored 'General case' 0 N--CA 1.45 -0.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.533 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.83 -46.52 96.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 173.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -60.54 -49.27 78.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.68 -49.32 57.6 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 122.141 0.177 . . . . 0.0 111.358 177.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.3 mtm -63.7 -50.42 69.24 Favored 'General case' 0 C--O 1.224 -0.27 0 CA-C-O 118.907 -0.568 . . . . 0.0 110.767 177.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 mt -52.57 -40.96 63.16 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.45 1.023 . . . . 0.0 111.942 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -57.36 -36.04 70.7 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 122.848 0.459 . . . . 0.0 110.752 174.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.41 50.38 0.93 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.827 0.851 . . . . 0.0 109.601 174.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.77 -51.23 35.77 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.603 0.761 . . . . 0.0 110.174 -174.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . 0.299 70.3 p 65.3 -44.31 0.35 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.154 2.182 . . . . 0.0 114.932 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.4 118.45 13.72 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 119.535 1.061 . . . . 0.0 110.975 174.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -79.88 163.96 23.94 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 124.979 1.312 . . . . 0.0 109.158 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -85.27 151.24 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 C-N-CA 122.957 0.503 . . . . 0.0 110.156 -179.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 60.4 m -150.89 72.23 1.06 Allowed 'General case' 0 C--O 1.227 -0.116 0 C-N-CA 124.918 1.287 . . . . 0.0 108.581 174.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.15 -144.31 47.62 Favored Glycine 0 CA--C 1.528 0.866 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -80.01 57.24 2.59 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.913 1.357 . . . . 0.0 109.743 174.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.9 m -160.89 153.93 21.37 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 178.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.92 152.16 15.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -140.98 136.78 32.5 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.328 -172.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -107.46 164.42 12.22 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.065 0.946 . . . . 0.0 109.907 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 m -159.19 47.45 0.3 Allowed 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.311 0.644 . . . . 0.0 110.069 -174.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -175.47 171.6 44.69 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 107.637 -2.185 . . . . 0.0 107.637 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -75.41 -32.33 60.71 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 117.69 0.745 . . . . 0.0 111.005 -177.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.06 71.41 5.53 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.42 0.629 . . . . 0.0 110.241 -174.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -81.79 77.95 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -176.202 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -80.78 111.86 17.62 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.891 0.876 . . . . 0.0 109.034 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.18 106.68 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.5 t -89.57 95.45 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 118.068 0.395 . . . . 0.0 109.967 -174.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.0 99.95 10.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.329 1.452 . . . . 0.0 111.47 -174.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.22 108.45 18.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 O-C-N 121.673 -0.642 . . . . 0.0 109.971 175.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.45 82.78 8.16 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 121.259 -0.901 . . . . 0.0 109.057 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 34.3 t 68.24 96.05 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 C-N-CA 125.167 1.387 . . . . 0.0 109.68 175.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.9 mt -77.23 144.0 70.41 Favored Pre-proline 0 CA--C 1.531 0.213 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -58.39 107.87 0.36 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.397 2.732 . . . . 0.0 109.125 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 147.59 -49.8 0.6 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 104.666 -3.373 . . . . 0.0 104.666 -171.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -80.13 126.51 79.25 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 170.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -70.51 -36.13 9.32 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 121.197 1.265 . . . . 0.0 109.935 174.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -173.43 179.82 0.51 Allowed Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 129.201 3.0 . . . . 0.0 105.136 -173.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -118.15 -23.54 0.09 OUTLIER 'Cis proline' 0 C--N 1.347 0.471 0 CA-C-N 120.701 1.286 . . . . 0.0 114.599 -5.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 p -86.17 160.37 19.24 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.959 2.948 . . . . 0.0 118.959 -166.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -76.68 117.25 18.12 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 171.221 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -101.98 103.18 13.79 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 104.248 -2.501 . . . . 0.0 104.248 -179.056 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.7 t -108.89 113.07 43.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 O-C-N 122.086 -0.384 . . . . 0.0 110.079 -171.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 30.59 -104.24 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 126.078 1.751 . . . . 0.0 113.869 -174.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -67.09 -24.16 65.92 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -173.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -139.37 -164.67 1.72 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 119.35 0.977 . . . . 0.0 111.335 -173.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.1 mtmt -125.33 130.99 53.07 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 172.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 47.58 45.31 2.6 Favored Pre-proline 0 CA--C 1.545 0.768 0 C-N-CA 124.227 1.011 . . . . 0.0 112.025 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -67.37 154.75 72.99 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.273 1.315 . . . . 0.0 111.114 -179.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.5 m -87.56 133.73 33.74 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 171.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -111.71 128.51 56.1 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.922 0.783 . . . . 0.0 110.824 -174.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -99.33 115.94 30.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 171.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.427 HD12 HG23 ' A' ' 152' ' ' ILE . 27.2 mt -120.64 142.34 34.03 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 124.552 1.141 . . . . 0.0 113.379 -169.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -78.89 119.46 4.36 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 122.532 2.155 . . . . 0.0 109.137 171.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.2 140.6 3.88 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 125.816 1.646 . . . . 0.0 111.95 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.97 -5.46 48.59 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-O 119.092 -0.838 . . . . 0.0 113.613 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 155.22 26.17 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 119.45 1.625 . . . . 0.0 111.049 174.43 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 73.7 m -83.76 96.85 8.86 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 174.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.65 100.12 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 C-N-CA 124.877 1.271 . . . . 0.0 108.046 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -92.52 91.52 7.63 Favored 'General case' 0 C--O 1.237 0.441 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 40.7 t -77.08 103.13 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 176.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 43.3 m -101.04 98.22 8.69 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.011 1.724 . . . . 0.0 109.232 -172.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.8 m-85 -77.91 156.58 30.21 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.574 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -139.21 78.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 101.576 -3.49 . . . . 0.0 101.576 164.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -97.1 101.83 13.48 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 178.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.2 m -148.37 54.38 1.02 Allowed 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 122.182 0.992 . . . . 0.0 108.721 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.83 -19.64 61.28 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.822 173.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mttm 81.5 121.49 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 127.649 2.38 . . . . 0.0 107.323 -173.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.38 -54.05 3.18 Favored Glycine 0 CA--C 1.534 1.233 0 O-C-N 121.595 -0.691 . . . . 0.0 112.921 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -78.53 79.42 4.96 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 121.444 -1.033 . . . . 0.0 110.718 -174.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -51.69 77.33 0.01 OUTLIER Glycine 0 CA--C 1.527 0.794 0 C-N-CA 126.603 2.049 . . . . 0.0 112.635 174.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -63.18 144.17 57.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 118.66 1.23 . . . . 0.0 111.251 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.9 p -106.51 154.73 20.43 Favored 'General case' 0 N--CA 1.444 -0.757 0 C-N-CA 127.024 2.13 . . . . 0.0 106.048 172.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 8.2 t80 -134.52 110.33 9.29 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 105.37 -2.085 . . . . 0.0 105.37 172.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASP . . . . . 0.411 ' HB3' HD12 ' A' ' 105' ' ' ILE . 1.4 m-20 -130.81 148.39 52.58 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.292 0.496 . . . . 0.0 110.397 -174.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.2 mt -114.56 137.93 46.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 C-N-CA 126.22 1.808 . . . . 0.0 110.048 -172.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.5 t -160.93 -155.0 0.39 Allowed 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.909 1.284 . . . . 0.0 107.714 177.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -122.2 8.45 9.75 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.905 0.882 . . . . 0.0 111.595 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? -63.0 114.11 3.49 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.29 170.25 38.88 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -68.67 164.06 34.64 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.072 2.514 . . . . 0.0 109.196 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.81 131.12 23.04 Favored 'Cis proline' 0 N--CA 1.455 -0.749 0 CA-C-N 119.464 0.844 . . . . 0.0 110.828 0.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -79.56 158.53 27.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 174.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -138.33 167.28 22.21 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.364 1.066 . . . . 0.0 108.15 -177.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.55 60.42 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 C-N-CA 124.324 1.049 . . . . 0.0 108.664 -176.364 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 52.3 mtm -147.09 103.96 3.83 Favored Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 124.51 1.124 . . . . 0.0 110.473 -174.022 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -64.93 75.49 0.22 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.191 2.594 . . . . 0.0 112.692 174.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.6 t -78.98 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 173.121 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 24.9 pt -83.05 -23.66 8.39 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 C-N-CA 124.713 1.205 . . . . 0.0 114.134 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -45.35 -56.96 8.29 Favored Pre-proline 0 CA--C 1.543 0.694 0 CA-C-O 118.92 -0.562 . . . . 0.0 111.779 176.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -76.07 67.76 6.73 Favored 'Trans proline' 0 CA--C 1.537 0.663 0 C-N-CA 122.178 1.918 . . . . 0.0 111.597 172.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 88' ' ' ASP . 6.1 mm -118.65 142.08 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 172.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.0 t -98.61 -92.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.94 161.39 14.48 Favored 'General case' 0 C--N 1.334 -0.088 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 174.403 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.38 173.71 28.18 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 120.134 -1.031 . . . . 0.0 113.374 174.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.431 HG23 ' CD1' ' A' ' 125' ' ' PHE . 3.0 p -109.41 125.52 52.5 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.909 1.284 . . . . 0.0 110.152 -178.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -80.21 58.95 4.6 Favored Glycine 0 CA--C 1.535 1.314 0 CA-C-O 119.496 -0.613 . . . . 0.0 111.817 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 71.58 98.8 0.07 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.617 1.967 . . . . 0.0 112.263 174.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 p -78.61 165.15 51.69 Favored Pre-proline 0 CA--C 1.544 0.732 0 O-C-N 121.077 -1.014 . . . . 0.0 112.5 -175.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -60.79 159.64 28.11 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 123.252 2.635 . . . . 0.0 112.098 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.51 86.19 14.37 Favored Pre-proline 0 CA--C 1.533 0.313 0 C-N-CA 124.217 1.007 . . . . 0.0 110.896 -179.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -55.74 163.72 5.21 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.528 2.819 . . . . 0.0 113.024 173.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -92.98 -23.53 18.68 Favored 'General case' 0 C--N 1.338 0.086 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 178.19 159.93 0.53 Allowed 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.7 2.0 . . . . 0.0 109.32 -176.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 70.26 -63.41 0.78 Allowed Glycine 0 C--N 1.338 0.644 0 C-N-CA 125.524 1.535 . . . . 0.0 112.839 174.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -78.68 157.84 28.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 124.263 1.025 . . . . 0.0 109.609 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -139.71 107.67 5.71 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.237 1.415 . . . . 0.0 110.826 -172.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -60.76 109.65 2.51 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.576 1.084 . . . . 0.0 110.852 -178.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -127.55 156.48 42.15 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.849 0.833 . . . . 0.0 111.455 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 18.1 m -159.72 109.93 1.9 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.97 -1.468 . . . . 0.0 107.449 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -86.75 69.61 10.33 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.164 1.386 . . . . 0.0 107.333 173.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PHE . . . . . 0.431 ' CD1' HG23 ' A' ' 109' ' ' THR . 17.2 p90 -72.19 129.66 38.98 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 118.304 -1.358 . . . . 0.0 108.331 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.9 m -101.95 126.99 49.0 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.411 -171.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -134.68 157.78 45.78 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.481 1.512 . . . . 0.0 109.522 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -123.35 115.43 28.64 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 174.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -92.36 148.2 2.93 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 124.301 3.334 . . . . 0.0 111.809 -172.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.7 p -95.02 149.62 21.05 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 124.888 1.275 . . . . 0.0 108.763 173.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.98 151.9 13.99 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.122 0.419 . . . . 0.0 111.733 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.3 -124.13 5.89 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.937 2.208 . . . . 0.0 109.592 -176.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.0 m -153.61 147.95 25.93 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.314 1.057 . . . . 0.0 110.222 -174.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -139.87 173.87 11.08 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 127.825 2.45 . . . . 0.0 106.912 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -136.15 148.75 48.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 126.402 1.881 . . . . 0.0 107.259 174.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -109.47 147.87 32.14 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 172.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.39 150.9 12.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.117 1.367 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 42.6 t -84.75 140.34 31.33 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 169.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -78.08 -20.71 51.75 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -173.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 54.7 mt -61.35 124.38 80.46 Favored Pre-proline 0 CA--C 1.544 0.739 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -25.28 -76.01 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.567 1 C-N-CA 126.011 4.474 . . . . 0.0 117.446 -172.471 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -77.45 -2.29 79.32 Favored Glycine 0 CA--C 1.525 0.679 0 O-C-N 121.691 -0.631 . . . . 0.0 114.046 -173.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -72.69 -48.29 40.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 119.364 1.582 . . . . 0.0 110.558 -173.335 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.15 -41.86 93.68 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 173.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.24 78.29 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.823 0.449 . . . . 0.0 111.51 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 26.3 p -79.38 -58.29 3.28 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -174.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 176.87 37.79 0.05 OUTLIER Glycine 0 C--N 1.339 0.7 0 C-N-CA 119.187 -1.482 . . . . 0.0 115.196 -174.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 10.4 mtp -116.39 72.39 0.81 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 118.193 0.996 . . . . 0.0 108.405 173.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -159.56 -174.72 4.79 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.318 0.647 . . . . 0.0 112.16 -177.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 164.53 171.01 30.26 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 174.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 42.9 mtmt -99.94 146.86 26.2 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 124.998 1.319 . . . . 0.0 110.609 -176.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.427 HG23 HD12 ' A' ' 66' ' ' ILE . 15.8 mt -124.59 101.77 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 173.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.5 t -92.42 137.64 21.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 172.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 11.5 t -127.9 123.55 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -175.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt . . . . . 0 N--CA 1.466 0.328 0 CA-C-N 119.823 1.192 . . . . 0.0 111.422 179.481 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.874 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.1 p -63.49 -51.45 65.53 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.287 1.035 . . . . 0.0 110.184 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 7.9 mp 54.5 -103.23 0.17 Allowed 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.461 1.105 . . . . 0.0 109.905 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -167.22 152.6 7.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 105.901 -1.889 . . . . 0.0 105.901 175.331 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 25.2 p -135.64 23.15 3.39 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.076 1.35 . . . . 0.0 110.829 -174.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.9 m -79.77 64.18 4.55 Favored 'General case' 0 CA--C 1.536 0.409 0 O-C-N 121.161 -0.962 . . . . 0.0 110.277 -174.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -85.91 134.55 33.88 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 126.34 1.856 . . . . 0.0 110.212 -173.488 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -149.55 173.04 14.05 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -138.77 151.16 46.85 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 172.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.31 -153.02 0.54 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.898 1.679 . . . . 0.0 106.664 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.7 p -135.65 173.95 11.15 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 119.462 1.028 . . . . 0.0 108.512 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -39.41 -57.05 2.51 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -54.76 -34.18 83.54 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 121.963 1.775 . . . . 0.0 113.531 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 21.0 mp0 -67.41 -25.73 66.08 Favored 'General case' 0 N--CA 1.456 -0.172 0 O-C-N 121.134 -0.979 . . . . 0.0 111.258 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.82 -46.91 93.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 174.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.1 -50.11 74.98 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.21 -48.36 62.06 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.7 mtm -62.93 -50.63 70.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.606 0.362 . . . . 0.0 110.516 177.733 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.8 mt -52.08 -41.95 62.8 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.436 0.562 . . . . 0.0 111.875 177.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -56.51 -23.62 40.95 Favored 'General case' 0 CA--C 1.538 0.513 0 O-C-N 121.542 -0.724 . . . . 0.0 112.678 177.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -100.95 12.55 37.46 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.653 0.781 . . . . 0.0 111.787 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -65.85 -46.27 79.1 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -174.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.4 p 63.8 -139.12 0.32 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.455 1.502 . . . . 0.0 109.27 -171.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.48 104.18 0.2 Allowed Glycine 0 CA--C 1.528 0.893 0 CA-C-N 118.593 0.633 . . . . 0.0 111.741 -177.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 37.3 mtpt -78.7 120.26 23.11 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.028 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 62.5 t -63.04 148.51 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -148.85 64.17 1.05 Allowed 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.15 -141.26 35.51 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -79.55 54.74 1.82 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 118.603 1.202 . . . . 0.0 109.642 174.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.7 m -161.31 147.12 14.17 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -118.18 137.87 50.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 175.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 93.2 m -120.57 119.22 32.29 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.832 1.253 . . . . 0.0 109.623 -173.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -83.07 169.43 15.91 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 122.083 0.944 . . . . 0.0 111.606 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 75.1 m -156.86 152.17 26.48 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.36 166.95 33.05 Favored Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -174.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 35.4 mtmm -82.82 -28.48 30.18 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 122.282 -0.54 . . . . 0.0 112.241 -174.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.2 p -81.59 78.01 8.39 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.484 -0.76 . . . . 0.0 109.588 -178.611 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -80.07 75.39 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -80.89 93.19 6.24 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.788 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -88.49 102.42 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.049 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -176.387 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 43.1 t -83.74 88.42 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.08 164.23 12.78 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.267 1.427 . . . . 0.0 110.227 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -159.62 169.31 24.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 123.96 0.904 . . . . 0.0 109.23 178.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.56 132.7 28.01 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 26.13 72.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 127.263 2.225 . . . . 0.0 113.009 173.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.1 mt -77.29 148.27 77.4 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -55.2 111.24 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.999 2.466 . . . . 0.0 110.519 -175.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 130.77 -40.33 1.67 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -174.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -87.93 125.08 65.74 Favored Pre-proline 0 N--CA 1.454 -0.272 0 C-N-CA 123.647 0.779 . . . . 0.0 109.453 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -59.08 161.95 14.89 Favored 'Trans proline' 0 N--CA 1.454 -0.84 0 C-N-CA 122.249 1.966 . . . . 0.0 111.744 173.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -62.66 164.6 11.72 Favored Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.953 173.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -113.47 -11.92 0.64 Allowed 'Cis proline' 0 CA--C 1.539 0.774 0 CA-C-N 118.947 0.66 . . . . 0.0 113.535 -4.385 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.5 p -44.68 143.46 1.38 Allowed 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 118.586 2.81 . . . . 0.0 118.586 -170.126 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -77.27 129.14 35.49 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 168.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -104.33 132.52 50.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 177.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.5 t -139.91 123.67 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -14.74 111.32 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.515 1.926 . . . . 0.0 115.37 -173.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.4 t70 89.67 -28.02 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 127.309 2.244 . . . . 0.0 113.419 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -136.69 -168.97 2.36 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.524 1.154 . . . . 0.0 111.015 -173.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.5 mttp -137.5 134.88 36.25 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 171.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 48.82 40.62 0.8 Allowed Pre-proline 0 CA--C 1.548 0.882 0 C-N-CA 124.081 0.952 . . . . 0.0 112.69 -176.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.25 159.67 46.64 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 CA-C-N 120.993 1.39 . . . . 0.0 113.349 -171.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.58 121.23 25.55 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 127.647 2.379 . . . . 0.0 106.297 173.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.2 mp -103.99 117.94 35.5 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 119.862 1.21 . . . . 0.0 111.5 -178.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -93.36 120.09 33.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 171.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.0 mt -122.32 139.7 31.2 Favored Pre-proline 0 CA--C 1.538 0.514 0 C-N-CA 124.431 1.092 . . . . 0.0 112.906 -170.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -76.34 116.26 4.3 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 122.805 2.336 . . . . 0.0 108.728 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -48.69 139.58 9.43 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 125.12 1.368 . . . . 0.0 112.302 -178.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.25 -9.78 38.7 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.072 -0.849 . . . . 0.0 113.457 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 157.52 20.02 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.42 1.61 . . . . 0.0 110.52 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 50.2 m -83.71 101.68 11.72 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.1 t -79.64 99.81 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 174.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -96.59 97.16 9.17 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 174.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -80.02 108.02 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.2 m -99.7 96.71 7.8 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.009 1.724 . . . . 0.0 107.972 175.04 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.278 5.7 m-85 -79.26 148.1 32.29 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 118.726 -0.654 . . . . 0.0 110.31 172.66 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.07 79.38 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 102.514 -3.143 . . . . 0.0 102.514 163.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -99.48 104.7 16.55 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 172.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.0 m -121.77 38.44 4.11 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 173.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -78.39 73.23 4.94 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.245 -0.91 . . . . 0.0 109.12 175.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.4 mttm 0.16 97.32 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 129.126 2.97 . . . . 0.0 114.557 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.05 -34.29 3.62 Favored Glycine 0 CA--C 1.534 1.243 0 O-C-N 121.605 -0.685 . . . . 0.0 114.07 175.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -82.24 88.12 6.52 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 119.073 1.436 . . . . 0.0 110.171 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.29 63.04 0.4 Allowed Glycine 0 CA--C 1.533 1.168 0 C-N-CA 123.785 0.707 . . . . 0.0 112.545 175.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -51.06 120.78 5.23 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 118.941 1.37 . . . . 0.0 110.084 175.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.87 165.11 25.48 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.581 0.752 . . . . 0.0 109.628 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 21.4 t80 -133.15 103.37 5.98 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 106.376 -1.712 . . . . 0.0 106.376 172.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASP . . . . . 0.443 ' HB3' HD12 ' A' ' 105' ' ' ILE . 81.0 m-20 -118.38 137.34 53.19 Favored 'General case' 0 CA--C 1.516 -0.333 0 C-N-CA 123.434 0.694 . . . . 0.0 109.819 -176.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 25.8 mt -110.0 134.71 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 126.041 1.737 . . . . 0.0 109.075 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.2 t -158.65 -158.22 0.68 Allowed 'General case' 0 C--O 1.223 -0.301 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.0 mtmm -129.6 6.67 5.21 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 119.564 1.075 . . . . 0.0 112.5 -179.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.9 mtpt -67.51 160.71 27.08 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.08 160.06 16.18 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -72.78 159.5 48.29 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 122.791 2.327 . . . . 0.0 109.893 174.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.79 134.83 34.28 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 N-CA-C 108.75 -1.288 . . . . 0.0 108.75 -5.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.542 ' HB2' ' HB1' ' A' ' 144' ' ' ALA . 92.9 m-85 -83.13 31.36 0.44 Allowed 'General case' 0 N--CA 1.468 0.463 0 O-C-N 120.979 -1.075 . . . . 0.0 113.377 -173.417 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . 70.05 156.0 0.14 Allowed 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 127.703 2.401 . . . . 0.0 113.084 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.98 -46.25 85.26 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.386 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.1 mmt -78.92 160.1 72.19 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 174.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -70.25 59.12 1.85 Allowed 'Trans proline' 0 CA--C 1.538 0.725 0 C-N-CA 123.08 2.52 . . . . 0.0 114.153 -174.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.8 t -82.46 55.79 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 O-C-N 120.238 -1.539 . . . . 0.0 108.664 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -80.88 -38.6 17.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 C-N-CA 123.101 0.561 . . . . 0.0 110.998 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -55.48 147.43 38.73 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 124.445 1.098 . . . . 0.0 111.826 -174.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 79.1 Cg_endo -74.13 150.38 95.47 Favored 'Cis proline' 0 N--CA 1.459 -0.537 0 CA-C-N 118.851 0.625 . . . . 0.0 111.127 -0.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.443 HD12 ' HB3' ' A' ' 88' ' ' ASP . 20.2 mm -109.45 143.7 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 C-N-CA 124.42 1.088 . . . . 0.0 108.406 175.522 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.73 -89.49 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 174.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.89 156.48 16.33 Favored 'General case' 0 C--N 1.332 -0.155 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 173.054 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.29 173.51 41.11 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 119.063 -1.541 . . . . 0.0 112.817 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.9 p -123.15 137.09 54.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.398 1.479 . . . . 0.0 109.625 176.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.47 -164.34 7.49 Favored Glycine 0 CA--C 1.54 1.654 0 N-CA-C 108.136 -1.986 . . . . 0.0 108.136 170.669 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -67.63 118.66 11.21 Favored 'General case' 0 CA--C 1.537 0.47 0 O-C-N 120.8 -1.412 . . . . 0.0 112.286 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 p -69.71 161.08 77.01 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 126.201 1.8 . . . . 0.0 113.413 -173.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -74.4 144.96 33.3 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.023 2.482 . . . . 0.0 107.969 174.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.18 80.15 9.49 Favored Pre-proline 0 CA--C 1.536 0.442 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -53.89 164.69 2.29 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 124.627 3.551 . . . . 0.0 112.588 172.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -119.35 -0.05 11.02 Favored 'General case' 0 C--N 1.34 0.173 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -174.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -175.28 148.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.191 1.396 . . . . 0.0 109.026 176.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 66.15 -62.85 0.15 Allowed Glycine 0 CA--C 1.527 0.79 0 C-N-CA 126.579 2.038 . . . . 0.0 113.47 177.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -78.66 157.39 28.64 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-O 121.352 0.596 . . . . 0.0 110.018 -177.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -129.55 108.63 10.39 Favored 'General case' 0 CA--C 1.512 -0.481 0 C-N-CA 127.014 2.125 . . . . 0.0 107.943 -174.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.04 123.71 18.63 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 19.8 p90 -130.89 168.57 17.07 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.724 1.25 . . . . 0.0 110.701 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.8 m -155.53 124.68 6.21 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.83 106.63 16.3 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -119.06 150.61 39.68 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.3 m -114.69 145.29 42.21 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.882 0.873 . . . . 0.0 111.007 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 26.1 t90 -145.02 153.23 41.26 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.887 1.275 . . . . 0.0 109.236 174.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.9 93.96 44.96 Favored Pre-proline 0 CA--C 1.53 0.174 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -81.6 146.01 14.93 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.467 2.112 . . . . 0.0 111.358 -173.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 10.6 p -96.3 156.37 16.37 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 172.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.93 144.65 27.56 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -174.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 139.97 -132.58 5.62 Favored Glycine 0 C--N 1.337 0.611 0 C-N-CA 126.215 1.864 . . . . 0.0 109.984 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 33.5 m -150.52 145.07 25.73 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 118.026 0.913 . . . . 0.0 109.132 -174.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -147.02 175.64 10.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.738 2.015 . . . . 0.0 107.181 -175.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -142.57 155.37 44.98 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 125.354 1.462 . . . . 0.0 108.557 179.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -121.46 147.2 46.07 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 124.275 1.03 . . . . 0.0 110.915 175.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.65 160.66 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 124.855 1.262 . . . . 0.0 112.308 -174.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 7.1 t -102.82 133.49 47.8 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.876 1.67 . . . . 0.0 108.738 171.17 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -70.65 -34.67 72.3 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 113.816 1.043 . . . . 0.0 113.816 -173.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 70.8 mt -48.62 128.38 13.71 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.781 0.832 . . . . 0.0 109.993 -172.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -42.32 142.82 1.61 Allowed 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 124.26 3.307 . . . . 0.0 114.968 -173.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.45 -40.55 1.78 Allowed Glycine 0 CA--C 1.529 0.951 0 C-N-CA 123.995 0.807 . . . . 0.0 112.634 177.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -54.6 -47.26 73.6 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.568 0.747 . . . . 0.0 111.624 -173.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ALA . . . . . 0.542 ' HB1' ' HB2' ' A' ' 96' ' ' TYR . . . -81.84 -11.67 58.85 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.631 0.65 . . . . 0.0 112.4 175.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.56 -57.82 4.72 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 173.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.5 p -151.63 87.04 1.34 Allowed 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.91 -66.47 0.06 OUTLIER Glycine 0 CA--C 1.524 0.631 0 C-N-CA 119.82 -1.181 . . . . 0.0 113.951 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.0 ptm -141.59 113.19 7.7 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 117.671 0.736 . . . . 0.0 111.948 -173.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -163.56 -166.73 1.26 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.716 1.206 . . . . 0.0 108.169 176.547 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.14 173.33 36.71 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 175.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 29.9 mttp -109.78 150.31 28.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.709 1.204 . . . . 0.0 110.869 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 17.1 mt -128.33 130.01 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 174.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 6.2 t -118.01 135.81 57.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 173.197 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.03 123.11 64.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -174.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 53.3 mtmt . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 118.81 0.732 . . . . 0.0 111.093 -174.288 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.741 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.1 p -76.43 71.39 3.09 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.8 mp -55.64 -81.98 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 125.16 1.384 . . . . 0.0 111.239 175.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -176.34 143.35 0.5 Allowed 'General case' 0 C--O 1.235 0.319 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.0 p -138.18 38.78 2.31 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 123.863 0.727 . . . . 0.0 110.495 -178.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.1 m -79.59 62.62 3.94 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.879 0.847 . . . . 0.0 108.729 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -78.48 123.81 27.45 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.188 1.395 . . . . 0.0 110.392 -172.428 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -142.64 173.55 11.44 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 174.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -141.15 148.76 40.54 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.847 -0.533 . . . . 0.0 109.607 171.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.74 -153.77 0.56 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 126.633 1.973 . . . . 0.0 106.212 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -134.97 172.22 13.32 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 119.084 0.856 . . . . 0.0 108.991 172.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -38.64 -57.44 1.95 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -174.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.24 -32.46 87.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.473 1.449 . . . . 0.0 113.318 -178.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.6 mp0 -65.7 -31.57 72.64 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.7 t -55.42 -49.74 70.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.954 0.797 . . . . 0.0 109.14 176.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 mtpp -57.03 -51.39 69.47 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.87 -51.58 39.33 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -61.18 -53.1 61.19 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.219 0.463 . . . . 0.0 110.708 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 58.4 mt -51.7 -40.7 60.6 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.672 0.669 . . . . 0.0 111.78 -177.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -59.36 -23.53 62.61 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.842 0.857 . . . . 0.0 112.726 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -70.88 -66.31 0.63 Allowed 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.315 0.961 . . . . 0.0 109.514 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 58.6 -62.22 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 126.716 2.006 . . . . 0.0 115.622 176.134 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 19.3 p 53.89 37.66 27.04 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.174 1.79 . . . . 0.0 112.301 179.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -141.6 121.66 1.89 Allowed Glycine 0 CA--C 1.528 0.854 0 C-N-CA 124.88 1.229 . . . . 0.0 110.535 -174.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.3 mtpt -79.81 118.14 21.33 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.892 1.677 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.4 t -68.83 77.48 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 C-N-CA 124.939 1.296 . . . . 0.0 110.257 -174.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 m -81.09 70.08 7.84 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.687 1.195 . . . . 0.0 107.784 -179.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 62.95 -113.55 6.0 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -174.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -78.45 -19.1 53.87 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.856 0.828 . . . . 0.0 111.238 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 59.6 m -98.62 110.06 22.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -172.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.9 t -79.19 114.17 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 104.298 -2.482 . . . . 0.0 104.298 172.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.5 m -106.72 121.48 44.46 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 124.577 1.151 . . . . 0.0 111.679 -170.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -81.36 167.68 19.21 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.513 0.673 . . . . 0.0 110.752 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.0 m -159.55 46.97 0.28 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.992 0.917 . . . . 0.0 109.275 -177.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.52 170.35 42.77 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -78.62 -32.14 47.32 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 117.45 0.625 . . . . 0.0 111.602 -177.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.6 m -78.87 72.94 5.42 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.49 0.662 . . . . 0.0 109.617 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.4 t -80.31 86.08 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-O 121.788 0.804 . . . . 0.0 109.118 -174.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -85.69 101.96 13.2 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.938 1.295 . . . . 0.0 110.401 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.3 t -102.79 110.62 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 C-N-CA 124.484 1.114 . . . . 0.0 108.918 -176.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.06 101.64 12.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 CA-C-N 118.183 0.447 . . . . 0.0 110.267 -176.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -101.93 104.39 15.09 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.437 1.495 . . . . 0.0 111.244 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.6 110.57 21.42 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.486 1.514 . . . . 0.0 109.259 175.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -97.48 95.54 7.72 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.79 -0.569 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 46.68 69.74 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 C-N-CA 127.238 2.215 . . . . 0.0 111.153 173.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 27.3 mt -77.26 152.54 81.75 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-O 118.514 -0.755 . . . . 0.0 109.556 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_exo -43.52 108.83 0.12 Allowed 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.139 3.226 . . . . 0.0 111.446 175.331 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 139.12 -52.27 0.73 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 106.108 -2.797 . . . . 0.0 106.108 -172.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -81.36 121.44 80.14 Favored Pre-proline 0 N--CA 1.451 -0.405 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 171.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.98 -59.34 0.09 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.947 0 CA-C-N 120.686 1.281 . . . . 0.0 109.069 175.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -170.77 169.4 3.46 Favored Pre-proline 0 CA--C 1.535 0.398 0 C-N-CA 128.837 2.855 . . . . 0.0 105.558 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -115.7 -21.65 0.15 OUTLIER 'Cis proline' 0 N--CA 1.458 -0.592 0 CA-C-N 120.305 1.145 . . . . 0.0 113.631 -5.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.0 p -67.55 148.54 51.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -167.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -75.54 131.48 40.07 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 173.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -102.23 131.1 48.99 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 172.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 t -138.33 122.01 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 CA-C-N 119.245 0.93 . . . . 0.0 108.809 -174.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 12.58 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 127.756 2.422 . . . . 0.0 115.335 -178.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 t70 76.21 -32.45 0.2 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.078 1.351 . . . . 0.0 113.595 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.2 mmmp? -121.58 -173.29 2.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 122.351 1.072 . . . . 0.0 112.367 -171.484 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -133.12 125.5 29.66 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 105.332 -2.099 . . . . 0.0 105.332 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 43.85 50.18 6.17 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.195 0.998 . . . . 0.0 111.83 -173.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.76 157.87 58.91 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 121.717 1.611 . . . . 0.0 110.485 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 151' ' ' LYS . 50.2 m -84.44 145.88 27.93 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 105.893 -1.892 . . . . 0.0 105.893 170.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.0 mp -114.24 121.47 43.81 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.506 -0.747 . . . . 0.0 109.542 -177.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -98.94 118.54 35.95 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 171.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.41 HD12 ' CG2' ' A' ' 152' ' ' ILE . 17.9 mt -122.14 133.68 24.45 Favored Pre-proline 0 N--CA 1.453 -0.289 0 C-N-CA 124.978 1.311 . . . . 0.0 110.448 -172.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.93 118.39 5.02 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.127 1.885 . . . . 0.0 108.137 172.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.38 136.37 20.5 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.883 0.873 . . . . 0.0 111.196 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -12.71 67.65 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.672 -0.516 . . . . 0.0 112.156 -175.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.97 154.14 16.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 118.481 1.14 . . . . 0.0 112.909 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 99.5 m -92.15 105.72 17.88 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.472 -2.047 . . . . 0.0 105.472 171.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.2 t -88.04 93.78 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 C-N-CA 124.344 1.058 . . . . 0.0 108.178 -175.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.87 94.9 6.56 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 173.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.9 t -79.6 94.6 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 174.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 96.5 m -86.43 97.06 10.25 Favored 'General case' 0 N--CA 1.444 -0.732 0 C-N-CA 126.085 1.754 . . . . 0.0 108.539 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.403 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.5 m-85 -77.29 156.73 31.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.169 0.509 . . . . 0.0 111.607 173.306 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -140.59 86.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 100.857 -3.757 . . . . 0.0 100.857 164.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -105.13 113.83 27.66 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.7 m -143.4 37.48 1.36 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -78.96 65.28 4.11 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.581 -0.699 . . . . 0.0 109.369 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.5 mttm 17.7 81.18 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 128.424 2.689 . . . . 0.0 114.688 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 95.15 -29.91 8.82 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.885 176.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -78.38 99.02 6.2 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 119.265 1.532 . . . . 0.0 109.917 -174.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.81 60.97 0.94 Allowed Glycine 0 CA--C 1.523 0.591 0 C-N-CA 124.806 1.194 . . . . 0.0 110.614 176.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -33.68 -52.29 0.41 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 126.114 1.766 . . . . 0.0 115.411 -172.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 17.5 p 78.43 134.06 0.06 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 125.889 1.676 . . . . 0.0 108.742 -172.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.2 t80 -114.44 108.7 17.23 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.638 -2.727 . . . . 0.0 103.638 172.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.86 139.12 47.61 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -173.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 mt -124.75 134.42 66.87 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.838 0.828 . . . . 0.0 110.39 -173.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -160.22 -163.08 1.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -175.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -120.97 5.69 10.39 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.814 0.846 . . . . 0.0 111.788 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -71.67 130.14 40.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 174.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.92 169.18 25.25 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.016 0.817 . . . . 0.0 112.158 -176.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -72.51 167.13 27.86 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.507 2.804 . . . . 0.0 109.698 174.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -68.2 130.74 15.47 Favored 'Cis proline' 0 N--CA 1.459 -0.544 0 CA-C-N 119.483 0.851 . . . . 0.0 111.218 -5.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -79.93 148.72 31.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 175.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.27 156.7 24.19 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.347 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 73.9 t -61.26 -34.75 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 55.2 mtm -78.05 128.13 79.61 Favored Pre-proline 0 CA--C 1.534 0.344 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 173.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.25 101.91 1.3 Allowed 'Trans proline' 0 N--CA 1.451 -0.971 0 C-N-CA 122.542 2.161 . . . . 0.0 110.602 -173.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 22.0 t -77.69 93.5 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.0 pt -78.49 -85.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.702 0.801 . . . . 0.0 112.788 -173.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -67.82 150.16 97.92 Favored Pre-proline 0 N--CA 1.454 -0.242 0 O-C-N 121.723 -0.611 . . . . 0.0 112.237 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.61 113.24 2.88 Favored 'Cis proline' 0 CA--C 1.537 0.645 0 CA-C-N 118.579 0.528 . . . . 0.0 112.878 1.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.7 mm -86.66 139.05 17.95 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.006 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.5 t -95.76 -87.2 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 174.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -93.64 166.65 12.13 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 173.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 179.6 41.55 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.3 p -124.68 124.57 42.47 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.696 1.199 . . . . 0.0 108.984 175.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.27 59.75 4.31 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.564 -0.575 . . . . 0.0 112.809 -173.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 71.17 93.66 0.08 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.244 1.818 . . . . 0.0 110.501 175.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 p -65.9 161.36 55.11 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 126.875 2.07 . . . . 0.0 115.357 -172.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -67.02 154.88 73.17 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 123.795 2.997 . . . . 0.0 108.995 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.4 t -147.19 85.31 6.92 Favored Pre-proline 0 CA--C 1.54 0.561 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -172.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -57.78 165.34 6.55 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.16 2.573 . . . . 0.0 112.722 174.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -101.43 6.39 42.48 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 -174.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.7 p30 143.38 166.45 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 130.355 3.462 . . . . 0.0 109.376 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.3 -66.54 0.95 Allowed Glycine 0 C--N 1.34 0.755 0 C-N-CA 125.431 1.491 . . . . 0.0 111.28 177.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -78.58 155.15 29.8 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 124.075 0.95 . . . . 0.0 108.466 174.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -137.61 109.78 7.3 Favored 'General case' 0 CA--C 1.518 -0.258 0 C-N-CA 125.063 1.345 . . . . 0.0 110.829 -172.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.11 114.02 5.79 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 124.63 1.109 . . . . 0.0 111.102 -177.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 22.1 p90 -122.21 164.67 17.42 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 122.292 1.044 . . . . 0.0 111.65 178.23 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 74.3 m -159.57 119.22 2.95 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -95.99 67.95 2.7 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 124.104 0.962 . . . . 0.0 108.501 176.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . 0.254 40.4 p90 -70.81 114.13 8.57 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 118.003 -1.479 . . . . 0.0 108.019 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.2 m -91.66 87.08 6.18 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.498 1.519 . . . . 0.0 109.974 -171.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.5 t90 -93.27 143.55 26.16 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.026 0.93 . . . . 0.0 110.951 -175.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -111.23 109.72 56.55 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 105.344 -2.095 . . . . 0.0 105.344 171.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -84.76 178.95 4.57 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 123.884 3.056 . . . . 0.0 111.462 -172.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 58.7 p -124.21 159.97 28.94 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 170.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.61 156.98 33.61 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 113.823 1.045 . . . . 0.0 113.823 -172.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 114.55 -176.86 17.2 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 126.254 1.883 . . . . 0.0 112.329 174.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 5.5 m -82.76 87.48 6.77 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.115 0.966 . . . . 0.0 110.262 -175.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -78.96 175.31 10.68 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 171.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -150.78 149.34 29.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.932 1.293 . . . . 0.0 109.541 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -112.31 146.52 38.1 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.233 1.013 . . . . 0.0 108.286 172.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -153.13 150.5 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 124.872 1.269 . . . . 0.0 110.404 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.82 106.99 19.19 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 169.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 34.3 mm-40 -75.17 34.32 0.11 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 114.695 1.368 . . . . 0.0 114.695 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 25.7 mt -92.21 137.2 25.0 Favored Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 169.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -43.94 129.2 7.54 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.596 2.197 . . . . 0.0 113.207 -178.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.65 -24.73 3.62 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.361 -0.688 . . . . 0.0 114.095 178.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -65.13 -52.53 54.74 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 119.796 1.798 . . . . 0.0 111.617 -172.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.62 -44.1 80.86 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 174.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.92 -42.9 99.02 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.777 0.431 . . . . 0.0 111.654 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.2 p -79.05 -59.93 2.58 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -174.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -178.9 31.43 0.06 OUTLIER Glycine 0 C--N 1.337 0.621 0 C-N-CA 119.296 -1.43 . . . . 0.0 115.033 -174.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.2 mtp -111.39 68.73 0.67 Allowed 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 118.2 1.0 . . . . 0.0 108.531 173.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -158.37 -177.52 6.6 Favored 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.09 165.48 24.56 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 173.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB2' HG23 ' A' ' 63' ' ' THR . 13.2 mtmm -100.18 149.43 23.55 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.681 0.793 . . . . 0.0 109.492 -174.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.41 ' CG2' HD12 ' A' ' 66' ' ' ILE . 13.3 mt -125.96 93.96 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.102 1.761 . . . . 0.0 107.361 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.97 95.8 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 29.6 t -85.74 91.19 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 C--N 1.332 -0.193 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 177.094 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.677 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 p -66.06 -67.18 0.46 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 173.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.5 mp -106.19 174.83 5.71 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 127.171 2.188 . . . . 0.0 106.425 171.299 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -72.83 118.87 16.3 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -176.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.3 p -112.77 31.46 6.36 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.973 1.309 . . . . 0.0 110.627 -174.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.4 m -79.01 63.96 3.81 Favored 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.259 -0.901 . . . . 0.0 109.956 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -78.25 125.57 29.55 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 125.157 1.383 . . . . 0.0 109.511 -173.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -144.23 -179.74 6.71 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.918 0.887 . . . . 0.0 108.672 174.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -142.65 154.21 44.15 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.671 0.669 . . . . 0.0 111.088 172.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.46 -152.43 0.51 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 128.19 2.596 . . . . 0.0 105.65 173.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -138.73 170.81 15.34 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 119.082 0.855 . . . . 0.0 110.042 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -38.85 -59.64 1.34 Allowed Pre-proline 0 CA--C 1.538 0.512 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -174.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -58.78 -30.73 93.48 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 CA-C-N 121.248 1.481 . . . . 0.0 112.074 -178.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -67.07 -25.33 66.19 Favored 'General case' 0 N--CA 1.449 -0.523 0 O-C-N 121.819 -0.551 . . . . 0.0 111.254 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.2 t -59.1 -54.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -57.73 -49.61 75.98 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.558 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.2 -57.91 6.75 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.05 0.54 . . . . 0.0 110.953 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.9 mtm -56.82 -50.21 73.07 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 122.816 0.446 . . . . 0.0 110.096 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.1 mt -53.35 -45.31 69.08 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.612 0.642 . . . . 0.0 110.92 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.79 -30.9 70.32 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 118.249 0.477 . . . . 0.0 111.146 177.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 mmpt? -80.42 1.57 28.6 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 123.214 0.606 . . . . 0.0 112.365 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.43 146.68 50.8 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.926 1.239 . . . . 0.0 110.381 175.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.6 p -109.65 32.4 5.07 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.424 0.69 . . . . 0.0 112.155 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.94 113.82 4.75 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 124.678 1.132 . . . . 0.0 110.802 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -79.45 145.72 33.14 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 174.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 t -73.57 148.73 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.769 -0.582 . . . . 0.0 109.623 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -150.76 65.68 0.93 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.753 0.821 . . . . 0.0 109.611 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.12 -138.49 41.52 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -174.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -79.82 50.58 1.19 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.74 1.27 . . . . 0.0 110.222 174.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 m -161.39 153.73 20.06 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -119.34 149.08 21.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.6 m -134.32 125.34 27.44 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.222 1.009 . . . . 0.0 108.974 -173.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -98.73 167.33 10.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 123.882 0.873 . . . . 0.0 110.0 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.1 m -156.7 161.53 39.84 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.904 1.282 . . . . 0.0 107.661 177.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 73.13 178.36 35.01 Favored Glycine 0 CA--C 1.529 0.969 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -78.04 -32.3 50.86 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 122.078 -0.66 . . . . 0.0 110.617 178.363 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 m -79.06 70.05 5.34 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.872 0.869 . . . . 0.0 110.777 -174.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 69.0 t -86.09 92.19 3.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.0 t-160 -94.49 94.94 8.51 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.852 0.861 . . . . 0.0 110.531 -173.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.4 t -92.26 94.29 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.124 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.2 t -89.83 103.54 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.99 112.23 21.51 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.146 0.978 . . . . 0.0 111.363 -173.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.16 148.44 23.65 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 121.593 -0.692 . . . . 0.0 109.559 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.52 109.18 16.92 Favored 'General case' 0 CA--C 1.527 0.058 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 174.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.5 t 40.52 81.59 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.408 1.883 . . . . 0.0 112.576 175.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 76.8 mt -76.91 147.59 77.62 Favored Pre-proline 0 CA--C 1.534 0.332 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -175.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -44.51 111.63 0.29 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 123.876 3.051 . . . . 0.0 111.017 174.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.73 -40.71 1.58 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -173.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -88.44 112.57 50.81 Favored Pre-proline 0 CA--C 1.53 0.203 0 CA-C-O 118.661 -0.685 . . . . 0.0 109.349 178.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -78.78 66.29 8.66 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.391 2.061 . . . . 0.0 109.702 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 64.9 170.64 0.1 OUTLIER Pre-proline 0 CA--C 1.539 0.525 0 C-N-CA 124.349 1.06 . . . . 0.0 112.362 -175.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -116.73 -19.43 0.14 OUTLIER 'Cis proline' 0 CA--C 1.539 0.733 0 CA-C-N 119.108 0.717 . . . . 0.0 113.394 -6.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.52 151.22 47.69 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 118.964 2.95 . . . . 0.0 118.964 -168.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -77.35 128.92 35.11 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 104.249 -2.5 . . . . 0.0 104.249 169.082 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -111.62 115.34 28.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 -173.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 58.2 t -120.49 85.58 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 123.257 0.623 . . . . 0.0 109.517 -171.033 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 45.23 -97.19 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 126.177 1.791 . . . . 0.0 112.993 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -70.38 -23.61 62.8 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.549 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -134.36 -175.72 3.96 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.897 0.879 . . . . 0.0 110.903 -172.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.4 mtpp -131.07 129.58 42.12 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 172.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 50.58 42.95 1.42 Allowed Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 124.487 1.115 . . . . 0.0 113.115 -175.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -72.51 164.68 34.89 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.582 1.522 . . . . 0.0 114.291 -173.304 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . 0.266 0.2 OUTLIER -84.99 123.07 30.11 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 128.279 2.632 . . . . 0.0 106.088 173.571 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 8.9 mp -109.35 110.19 21.28 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.478 1.49 . . . . 0.0 113.221 -176.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -81.59 125.12 30.16 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 12.6 mt -127.29 140.34 37.65 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 124.283 1.033 . . . . 0.0 111.976 -171.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.05 118.18 4.01 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.287 2.658 . . . . 0.0 109.661 172.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.94 138.86 4.7 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.326 1.45 . . . . 0.0 112.175 176.416 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.17 -18.69 9.41 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-O 118.794 -1.004 . . . . 0.0 113.96 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.98 159.48 7.06 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.331 1.565 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.4 m -84.65 90.15 7.63 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.02 97.08 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -93.76 98.47 11.12 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.34 104.43 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.3 m -92.39 102.09 14.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.3 m-85 -77.67 154.91 31.71 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.422 173.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.2 mp -133.36 78.03 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 163.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -97.86 105.21 17.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 175.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.0 m -146.34 44.89 1.23 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -82.7 63.54 6.88 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -6.1 70.34 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 131.273 3.829 . . . . 0.0 114.82 -172.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 141.01 -47.46 0.86 Allowed Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.215 0.912 . . . . 0.0 111.062 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -85.33 100.18 11.65 Favored 'General case' 0 CA--C 1.528 0.13 0 O-C-N 122.076 -0.661 . . . . 0.0 111.125 -174.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.2 70.51 1.03 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 173.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -40.5 -49.21 2.9 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 116.164 1.913 . . . . 0.0 116.164 -171.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.7 p 78.22 148.28 0.1 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 120.027 1.285 . . . . 0.0 109.687 -172.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.9 t80 -138.39 108.31 6.33 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -115.52 135.85 53.67 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 118.798 0.727 . . . . 0.0 110.195 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.3 mt -110.26 130.53 63.35 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 126.186 1.794 . . . . 0.0 109.022 -177.233 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 t -159.39 -153.68 0.37 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -129.71 42.79 3.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 119.662 1.119 . . . . 0.0 110.573 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -91.69 110.92 22.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.143 0.577 . . . . 0.0 109.485 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.72 161.81 54.51 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 172.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.7 155.69 67.79 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.255 1.97 . . . . 0.0 109.62 174.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.51 167.87 78.0 Favored 'Cis proline' 0 N--CA 1.457 -0.667 0 CA-C-N 119.251 0.768 . . . . 0.0 111.301 -1.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -113.09 155.29 25.18 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.421 1.088 . . . . 0.0 109.106 177.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 156.56 26.68 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-O 121.378 0.608 . . . . 0.0 110.641 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 79.7 t -70.42 -36.9 68.58 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.743 175.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -78.34 152.04 78.45 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -38.85 111.9 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 124.996 3.797 . . . . 0.0 113.378 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.0 t -85.42 54.04 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 123.961 0.905 . . . . 0.0 109.021 -173.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.1 pp -88.0 91.05 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 122.519 1.152 . . . . 0.0 109.615 174.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.03 -157.55 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 126.254 1.822 . . . . 0.0 106.852 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -57.28 89.53 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 121.458 1.438 . . . . 0.0 109.34 153.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.1 mm -78.33 136.22 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 65.8 t -85.02 -88.81 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.556 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 175.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.42 155.71 16.63 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 171.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.51 166.34 33.52 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.312 -1.423 . . . . 0.0 111.438 174.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.6 p -118.44 142.28 47.71 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.251 1.42 . . . . 0.0 108.606 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.44 -161.45 6.79 Favored Glycine 0 CA--C 1.537 1.415 0 N-CA-C 108.174 -1.97 . . . . 0.0 108.174 172.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -67.17 106.38 1.99 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 120.842 -1.387 . . . . 0.0 109.899 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -62.5 156.68 61.3 Favored Pre-proline 0 CA--C 1.536 0.427 0 C-N-CA 126.731 2.013 . . . . 0.0 112.682 -174.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -67.27 151.28 81.13 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.999 2.466 . . . . 0.0 110.391 -175.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -129.95 74.5 80.52 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 123.821 0.848 . . . . 0.0 113.031 -175.082 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -60.91 174.89 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 122.419 2.079 . . . . 0.0 112.567 173.028 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 54.9 mttp -140.19 -168.46 2.54 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.891 1.277 . . . . 0.0 108.125 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 23.9 t70 55.65 -121.26 1.66 Allowed 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -174.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -112.71 9.98 25.7 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.716 -1.047 . . . . 0.0 112.856 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.1 mtpp -84.36 150.83 25.1 Favored 'General case' 0 C--N 1.341 0.233 0 CA-C-N 118.404 1.102 . . . . 0.0 109.007 175.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -132.87 110.32 10.23 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 124.292 1.037 . . . . 0.0 112.119 -173.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -66.88 116.07 7.85 Favored Glycine 0 CA--C 1.521 0.426 0 C-N-CA 125.178 1.37 . . . . 0.0 110.085 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -119.96 167.42 12.18 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 122.625 1.202 . . . . 0.0 110.804 175.27 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 61.7 m -154.69 115.23 3.91 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.02 83.6 5.19 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 172.789 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -90.42 151.52 21.38 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 35.7 m -121.54 145.57 47.83 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.021 0.528 . . . . 0.0 111.058 -173.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 24.0 t90 -143.61 144.17 31.8 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.45 1.1 . . . . 0.0 110.642 177.05 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 67.2 m-70 -109.6 109.93 59.74 Favored Pre-proline 0 CA--C 1.529 0.17 0 N-CA-C 104.857 -2.275 . . . . 0.0 104.857 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -90.73 133.6 1.76 Allowed 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.416 2.744 . . . . 0.0 113.606 -170.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.1 p -82.58 156.02 24.16 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.625 -1.621 . . . . 0.0 106.625 170.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -61.05 169.01 2.18 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 119.438 1.017 . . . . 0.0 112.438 -176.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 106.43 -177.98 22.37 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 125.636 1.589 . . . . 0.0 112.341 175.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 4.1 m -84.39 141.38 30.89 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.828 0.851 . . . . 0.0 110.073 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -137.35 170.11 16.64 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -142.57 146.83 34.99 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.961 1.304 . . . . 0.0 108.023 -178.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' TYR . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 46.8 p90 -115.59 140.87 48.77 Favored 'General case' 0 CA--C 1.528 0.097 0 O-C-N 123.984 0.803 . . . . 0.0 110.616 176.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.4 m -143.93 152.48 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 C-N-CA 124.548 1.139 . . . . 0.0 112.03 -174.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.1 t -98.8 125.7 44.24 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.58 1.552 . . . . 0.0 109.035 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 16.6 mm-40 -83.98 -4.26 58.59 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -173.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 30.8 mt -61.36 130.43 91.75 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 120.342 1.428 . . . . 0.0 108.239 175.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -39.44 125.08 1.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 124.118 3.212 . . . . 0.0 114.456 -174.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.94 -20.37 20.6 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 124.37 0.986 . . . . 0.0 113.226 176.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -66.98 -43.88 81.89 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 119.028 1.414 . . . . 0.0 112.303 -172.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -63.22 -48.7 77.17 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.703 0.683 . . . . 0.0 110.319 176.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.3 -54.57 43.88 Favored 'General case' 0 C--N 1.34 0.16 0 C-N-CA 123.755 0.822 . . . . 0.0 111.333 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.2 p -143.91 81.85 1.7 Allowed 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.226 1.011 . . . . 0.0 108.54 -174.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.49 -63.84 0.07 OUTLIER Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.246 176.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 4.0 ptm -157.9 129.5 6.8 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 117.795 0.797 . . . . 0.0 112.974 -172.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -162.74 -161.59 0.72 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.625 1.17 . . . . 0.0 108.349 175.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 167.49 171.36 33.42 Favored Glycine 0 C--N 1.334 0.452 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 172.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.0 mttm -110.95 153.69 25.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.373 1.069 . . . . 0.0 110.356 -173.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.9 mt -129.01 143.39 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.41 100.13 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -90.03 126.62 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 45.9 mtmt . . . . . 0 N--CA 1.46 0.052 0 CA-C-N 118.672 0.669 . . . . 0.0 110.828 -179.808 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.802 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.2 p -75.87 67.22 2.24 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.916 0.887 . . . . 0.0 109.778 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.0 mp -61.66 150.34 36.76 Favored 'General case' 0 N--CA 1.455 -0.22 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 174.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 19.3 t0 25.59 82.4 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 127.79 2.436 . . . . 0.0 114.436 -176.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 p -65.19 -26.78 68.29 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 122.534 0.334 . . . . 0.0 110.283 172.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.2 m -78.25 63.91 3.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.438 1.095 . . . . 0.0 112.155 -173.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 43.3 m95 -97.9 134.29 41.23 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.154 1.382 . . . . 0.0 109.538 174.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -149.57 -178.4 6.41 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -134.77 128.4 32.78 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 171.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.08 -151.82 0.31 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 172.319 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -142.03 168.13 20.49 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.147 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -39.58 -59.49 1.62 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -60.26 -28.74 87.48 Favored 'Trans proline' 0 N--CA 1.46 -0.496 0 CA-C-N 121.028 1.403 . . . . 0.0 112.19 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -66.93 -24.97 66.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 121.471 -0.768 . . . . 0.0 110.728 178.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.428 HG21 ' CD2' ' A' ' 120' ' ' PHE . 24.1 t -62.22 -50.28 80.61 Favored 'Isoleucine or valine' 0 C--N 1.34 0.177 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.448 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -58.1 -43.78 87.29 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -55.44 -58.3 8.32 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.903 -0.498 . . . . 0.0 110.988 175.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -58.33 -44.61 88.76 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 122.11 -0.369 . . . . 0.0 111.513 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.0 mt -50.52 -47.39 57.49 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.064 0.546 . . . . 0.0 110.746 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -61.89 -14.94 38.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.045 0.758 . . . . 0.0 113.045 178.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.5 mmmt -97.67 5.22 49.63 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 119.313 0.961 . . . . 0.0 111.651 176.034 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -74.65 125.16 28.08 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.051 -1.03 . . . . 0.0 110.507 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.9 p -93.27 29.33 1.94 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 123.306 0.642 . . . . 0.0 112.62 -176.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -104.32 111.71 3.91 Favored Glycine 0 C--N 1.339 0.726 0 C-N-CA 125.317 1.437 . . . . 0.0 111.139 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -79.63 159.83 26.61 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 173.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.0 t -81.56 150.73 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.5 m -147.72 65.57 1.12 Allowed 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.411 -0.805 . . . . 0.0 108.99 174.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 61.07 -109.34 2.37 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.546 -1.021 . . . . 0.0 110.546 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.2 p-10 -96.68 37.33 1.29 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.848 1.259 . . . . 0.0 110.325 177.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.1 m -160.64 161.98 32.58 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 105.806 -1.924 . . . . 0.0 105.806 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 t -120.27 151.65 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 126.969 2.108 . . . . 0.0 106.939 172.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.0 m -140.29 117.38 11.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.495 0.718 . . . . 0.0 109.18 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -83.06 166.99 18.29 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 174.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 57.3 m -152.29 156.17 39.13 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 175.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.37 165.44 20.53 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -173.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -72.64 -27.22 62.0 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.838 -0.801 . . . . 0.0 111.02 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -78.95 67.76 4.73 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.029 0.932 . . . . 0.0 110.269 -177.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.4 t -79.69 99.36 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.9 t-160 -107.4 94.65 5.21 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.7 107.0 17.27 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.154 0 C-N-CA 123.308 0.643 . . . . 0.0 109.486 -173.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.2 t -93.45 90.74 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -94.91 111.92 23.67 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.218 1.407 . . . . 0.0 110.282 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.98 143.39 27.12 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 174.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.7 104.41 5.77 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-O 121.23 0.538 . . . . 0.0 110.85 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.427 HG13 ' H ' ' A' ' 51' ' ' PHE . 4.7 t 50.09 63.74 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 127.203 2.201 . . . . 0.0 111.216 173.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 22.5 mt -76.75 165.26 53.89 Favored Pre-proline 0 CA--C 1.536 0.433 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 99.7 Cg_exo -47.59 -40.59 30.34 Favored 'Trans proline' 0 CA--C 1.535 0.559 0 C-N-CA 122.888 2.392 . . . . 0.0 113.5 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -61.56 -23.16 62.47 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 123.45 0.548 . . . . 0.0 113.537 177.566 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -120.6 77.62 28.37 Favored Pre-proline 0 CA--C 1.531 0.25 0 C-N-CA 125.425 1.49 . . . . 0.0 108.923 -179.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -73.46 73.73 3.32 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.256 2.638 . . . . 0.0 110.924 -175.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PHE . . . . . 0.427 ' H ' HG13 ' A' ' 45' ' ' VAL . 73.3 m-85 71.45 161.61 0.15 Allowed Pre-proline 0 CA--C 1.536 0.425 0 C-N-CA 127.706 2.402 . . . . 0.0 111.925 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -109.32 -21.05 0.36 Allowed 'Cis proline' 0 CA--C 1.536 0.609 0 N-CA-C 114.507 0.926 . . . . 0.0 114.507 -3.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.3 p -92.11 170.24 9.99 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 -168.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.25 167.21 22.12 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.75 0.82 . . . . 0.0 109.136 178.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.29 148.25 50.75 Favored 'General case' 0 CA--C 1.538 0.485 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 173.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.1 t -134.89 79.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 123.745 0.818 . . . . 0.0 109.456 -170.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.7 p80 50.48 -74.51 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 127.821 2.448 . . . . 0.0 114.896 175.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -98.0 -37.38 9.79 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 124.643 1.177 . . . . 0.0 110.964 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -111.21 -159.95 0.7 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.876 1.27 . . . . 0.0 108.203 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -140.44 -165.27 1.89 Allowed 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.41 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 14.1 m-80 -12.57 -56.38 0.03 OUTLIER Pre-proline 0 N--CA 1.471 0.598 0 C-N-CA 128.433 2.693 . . . . 0.0 115.242 172.175 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.6 OUTLIER -15.5 125.64 0.01 OUTLIER 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.983 3.789 . . . . 0.0 116.272 161.083 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.44 HG23 ' HB2' ' A' ' 151' ' ' LYS . 55.5 m -31.78 144.04 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 129.911 3.284 . . . . 0.0 117.276 -174.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.42 134.68 54.52 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.907 1.683 . . . . 0.0 108.492 174.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -110.07 140.35 44.22 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.249 1.02 . . . . 0.0 108.685 173.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.4 mt -136.71 141.57 35.75 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 -172.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -78.35 125.7 7.18 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.796 2.33 . . . . 0.0 108.123 171.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.02 145.45 16.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.761 0.824 . . . . 0.0 112.553 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.45 2.87 81.45 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-O 119.498 -0.612 . . . . 0.0 112.986 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.88 157.97 20.2 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 118.745 1.273 . . . . 0.0 112.228 174.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 61.2 m -93.6 89.99 6.46 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 172.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 43.2 t -77.58 98.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -173.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -92.51 93.57 8.63 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.035 1.334 . . . . 0.0 107.88 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.95 107.05 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 78.9 m -99.94 103.84 15.43 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 125.326 1.45 . . . . 0.0 109.498 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -81.56 152.24 27.33 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 174.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.92 78.99 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 102.159 -3.275 . . . . 0.0 102.159 163.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -101.5 85.08 2.7 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 176.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.471 HG21 ' CD2' ' A' ' 120' ' ' PHE . 76.3 p -112.08 33.51 4.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.538 -174.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -79.61 70.95 6.19 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 177.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -33.49 103.46 0.03 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.133 2.173 . . . . 0.0 112.462 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.99 -46.05 1.13 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 125.215 1.388 . . . . 0.0 111.293 -177.194 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -97.76 107.49 20.0 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.483 1.113 . . . . 0.0 111.938 -173.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.89 -16.29 56.69 Favored Glycine 0 CA--C 1.538 1.503 0 CA-C-O 119.199 -0.779 . . . . 0.0 114.457 174.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 46.73 -72.28 0.0 OUTLIER 'General case' 0 C--N 1.343 0.307 0 C-N-CA 129.221 3.008 . . . . 0.0 116.46 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.0 p 88.62 155.98 0.06 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 129.228 3.011 . . . . 0.0 111.867 -172.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -125.13 131.74 53.21 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 103.339 -2.837 . . . . 0.0 103.339 171.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.26 116.42 11.08 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 108.569 -0.901 . . . . 0.0 108.569 -173.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -97.19 125.78 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 124.536 1.134 . . . . 0.0 109.392 -178.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -160.1 -141.94 0.08 Allowed 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -122.91 -110.65 0.32 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.143 0.883 . . . . 0.0 110.431 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt 65.62 -65.54 0.17 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.303 1.841 . . . . 0.0 112.397 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.48 162.56 33.36 Favored Glycine 0 CA--C 1.533 1.212 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -173.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -71.79 158.75 52.42 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.79 2.327 . . . . 0.0 109.804 177.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.22 132.38 27.09 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 CA-C-N 119.146 0.731 . . . . 0.0 110.222 -3.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -79.78 151.97 30.04 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.159 0.504 . . . . 0.0 109.695 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.01 151.65 28.33 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.313 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.8 t -61.45 -41.94 91.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 175.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.5 mmm -77.96 128.77 77.97 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 174.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -76.98 75.65 4.48 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.428 2.085 . . . . 0.0 110.397 -174.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.2 t -77.53 76.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 175.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.0 pt -77.96 89.66 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 122.394 1.092 . . . . 0.0 109.794 -176.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -55.57 146.69 43.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 171.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -25.63 116.26 0.03 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.698 1 C-N-CA 125.676 4.251 . . . . 0.0 115.625 -166.615 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 30.6 mm -78.46 131.6 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.4 t -82.15 -86.07 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.87 149.35 21.63 Favored 'General case' 0 C--N 1.333 -0.123 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 172.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.91 165.76 39.07 Favored Glycine 0 C--N 1.332 0.318 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 174.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.9 p -119.04 123.32 44.21 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.085 0.554 . . . . 0.0 111.792 -174.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -78.03 57.9 3.95 Favored Glycine 0 CA--C 1.535 1.34 0 CA-C-O 119.082 -0.843 . . . . 0.0 113.646 -175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 65.05 124.73 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 127.382 2.273 . . . . 0.0 113.719 174.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 92.0 p -74.23 136.54 75.64 Favored Pre-proline 0 CA--C 1.532 0.288 0 O-C-N 120.899 -1.125 . . . . 0.0 112.457 -173.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.49 84.96 0.92 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.312 2.008 . . . . 0.0 107.066 172.134 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.3 m -45.06 139.06 4.13 Favored Pre-proline 0 CA--C 1.539 0.533 0 C-N-CA 124.673 1.189 . . . . 0.0 112.851 -174.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -75.74 -178.27 4.2 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.636 2.891 . . . . 0.0 113.665 -173.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.93 176.73 7.1 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 127.043 2.137 . . . . 0.0 107.19 174.066 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -36.71 120.98 0.73 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.975 1.31 . . . . 0.0 113.269 -174.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 84.53 -27.05 4.85 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.968 0.794 . . . . 0.0 113.738 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 56.5 mttp -85.63 157.4 20.36 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.132 0.966 . . . . 0.0 109.97 -174.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.471 ' CD2' HG21 ' A' ' 79' ' ' THR . 10.1 m-85 -137.18 91.22 2.6 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.427 1.091 . . . . 0.0 111.414 -173.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -47.34 121.31 6.33 Favored Glycine 0 CA--C 1.529 0.924 0 C-N-CA 124.716 1.15 . . . . 0.0 111.74 174.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.7 p90 -144.24 176.32 9.42 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.312 1.053 . . . . 0.0 111.467 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.16 166.58 32.83 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 127.079 2.152 . . . . 0.0 105.757 -176.113 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -146.68 65.08 1.18 Allowed 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 19.4 p90 -77.99 135.83 37.86 Favored 'General case' 0 C--N 1.34 0.184 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.441 -174.25 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 14.8 m -99.13 132.6 44.32 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.508 0.723 . . . . 0.0 110.021 -175.568 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.6 t90 -137.95 143.25 40.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.459 1.104 . . . . 0.0 109.704 176.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 63.5 m80 -111.36 99.41 43.83 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -76.23 173.79 13.91 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 122.364 2.043 . . . . 0.0 109.397 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 81.3 p -119.06 153.6 34.49 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -57.62 142.26 45.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -172.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 135.45 -127.11 4.2 Favored Glycine 0 C--N 1.336 0.555 0 C-N-CA 126.208 1.861 . . . . 0.0 109.411 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -151.95 142.9 23.07 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 118.251 1.026 . . . . 0.0 110.006 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 20.5 m-85 -133.16 -179.28 5.4 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 126.243 1.817 . . . . 0.0 106.958 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -141.65 147.26 37.27 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 124.301 1.04 . . . . 0.0 108.43 174.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -102.46 145.76 29.09 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.0 m -146.64 160.72 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.842 1.257 . . . . 0.0 110.322 174.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.4 t -99.0 125.89 44.58 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.68 1.192 . . . . 0.0 109.691 171.11 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.69 -27.37 66.36 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 -177.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -57.26 128.94 79.25 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 120.541 1.519 . . . . 0.0 109.826 -174.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_exo -43.83 137.68 6.46 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.262 2.641 . . . . 0.0 113.15 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.59 -27.72 2.49 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.171 -0.794 . . . . 0.0 113.411 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -62.43 -51.53 67.16 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.734 1.767 . . . . 0.0 111.639 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.81 -44.0 86.07 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 117.82 0.282 . . . . 0.0 110.764 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.95 -43.04 99.27 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.135 -0.353 . . . . 0.0 111.364 -179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.6 p -79.14 -41.01 29.53 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 118.877 -0.582 . . . . 0.0 112.175 -174.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 178.26 -15.6 0.03 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 118.725 -1.702 . . . . 0.0 116.977 -176.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 13.3 mtp -79.04 77.03 5.53 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 120.118 1.959 . . . . 0.0 110.456 -174.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -160.17 -174.72 4.67 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.37 164.95 23.93 Favored Glycine 0 C--N 1.341 0.832 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 175.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.44 ' HB2' HG23 ' A' ' 63' ' ' THR . 30.8 mttt -100.99 147.66 25.93 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.9 mt -121.52 100.65 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.15 121.15 38.92 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.064 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.6 t -109.38 95.06 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 -178.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 96.9 mttt . . . . . 0 C--N 1.332 -0.177 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.286 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.736 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.6 p -76.63 59.64 1.55 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.849 1.259 . . . . 0.0 109.616 178.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.6 mp 21.4 -90.15 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 128.189 2.596 . . . . 0.0 115.878 -174.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.34 76.14 2.58 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.306 -0.872 . . . . 0.0 111.427 -172.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.2 p -143.62 -77.44 0.23 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -176.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.0 m -77.79 64.13 2.98 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -169.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 71.4 m95 -92.95 156.22 17.06 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 126.645 1.978 . . . . 0.0 110.766 175.424 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -154.68 179.36 9.14 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 172.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -139.68 150.26 44.68 Favored 'General case' 0 C--N 1.341 0.209 0 CA-C-N 119.557 1.072 . . . . 0.0 111.191 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -130.65 -154.52 0.64 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.009 2.123 . . . . 0.0 107.292 174.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -135.94 171.44 14.46 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.527 0.731 . . . . 0.0 110.198 176.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.67 -59.91 1.23 Allowed Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -174.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -59.77 -30.87 93.05 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 CA-C-N 121.515 1.577 . . . . 0.0 111.964 -178.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -66.97 -22.94 65.9 Favored 'General case' 0 N--CA 1.448 -0.557 0 O-C-N 121.757 -0.589 . . . . 0.0 111.267 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.5 t -59.38 -51.5 71.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -59.78 -49.02 79.35 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.81 -55.69 13.19 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.043 0.214 . . . . 0.0 110.986 177.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 72.6 mtm -57.85 -52.49 65.25 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 123.223 0.609 . . . . 0.0 110.675 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.5 mt -50.67 -44.67 57.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 118.322 0.51 . . . . 0.0 111.057 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -58.81 -25.35 63.07 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 178.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.75 -1.02 36.75 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 119.934 1.243 . . . . 0.0 112.083 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.68 153.42 24.04 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 120.17 1.35 . . . . 0.0 110.782 175.257 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.2 p -117.94 27.77 8.81 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 123.269 0.628 . . . . 0.0 112.524 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.44 116.57 5.32 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -79.06 154.26 29.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 174.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 t -79.74 145.98 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 O-C-N 121.981 -0.449 . . . . 0.0 110.026 -175.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.2 m -149.08 64.32 1.04 Allowed 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.894 0.878 . . . . 0.0 109.404 174.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.04 -114.11 6.47 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.4 -17.0 55.28 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 123.178 0.591 . . . . 0.0 111.246 175.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -103.29 161.55 13.73 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 125.276 1.43 . . . . 0.0 107.841 -175.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.65 148.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.0 m -135.65 131.47 35.8 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -171.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -100.48 168.89 9.45 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.37 0.605 . . . . 0.0 110.663 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.0 m -155.01 155.0 33.38 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.248 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.76 174.35 32.96 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -174.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -77.84 -30.49 51.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 122.243 -0.563 . . . . 0.0 111.785 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.03 74.37 5.56 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.502 0.592 . . . . 0.0 109.968 -175.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.0 t -84.7 89.36 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -177.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -94.47 100.92 12.82 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.96 0.504 . . . . 0.0 110.642 -174.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -95.27 100.26 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 124.89 1.276 . . . . 0.0 108.315 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.1 t -95.7 122.89 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -133.31 116.48 16.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.621 0.646 . . . . 0.0 112.5 -173.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.85 112.56 24.53 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.981 0.913 . . . . 0.0 110.008 175.531 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.6 92.23 8.49 Favored 'General case' 0 N--CA 1.455 -0.178 0 O-C-N 121.58 -0.7 . . . . 0.0 110.038 -177.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.8 t 63.67 97.17 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 125.195 1.398 . . . . 0.0 111.324 174.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 75.2 mt -74.98 140.85 74.22 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -174.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.55 116.87 1.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.629 2.886 . . . . 0.0 111.392 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 125.4 -41.06 1.74 Allowed Glycine 0 CA--C 1.527 0.803 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -173.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -74.0 116.19 49.9 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 176.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -81.05 63.9 8.81 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.479 2.119 . . . . 0.0 108.631 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.9 m-30 67.42 174.96 0.08 OUTLIER Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.353 1.061 . . . . 0.0 108.988 -172.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -124.45 29.62 0.16 OUTLIER 'Cis proline' 0 CA--C 1.537 0.664 0 CA-C-N 120.722 1.294 . . . . 0.0 109.999 -7.119 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.8 p -92.09 125.25 36.7 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 116.94 2.2 . . . . 0.0 116.94 -171.263 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.69 103.71 9.78 Favored 'General case' 0 C--N 1.342 0.243 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 166.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -88.03 112.03 22.18 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -176.174 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -111.49 84.7 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 125.14 1.376 . . . . 0.0 109.783 -171.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 46.98 -98.97 0.04 OUTLIER 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 125.78 1.632 . . . . 0.0 112.9 176.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -70.73 -24.69 62.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.565 0.346 . . . . 0.0 111.877 -176.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -130.57 -178.07 4.62 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.232 1.013 . . . . 0.0 110.679 -173.076 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.2 mtmp? -130.12 122.32 28.03 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 105.88 -1.896 . . . . 0.0 105.88 172.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 55.33 44.37 1.62 Allowed Pre-proline 0 CA--C 1.541 0.607 0 C-N-CA 124.705 1.202 . . . . 0.0 112.275 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.71 172.06 15.69 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.475 2.117 . . . . 0.0 111.567 -176.274 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 151' ' ' LYS . 28.5 m -91.9 138.86 31.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 170.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.0 mp -112.25 126.99 55.83 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.83 0.852 . . . . 0.0 110.241 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -100.01 119.51 38.38 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 15.3 mt -124.04 142.24 39.2 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.392 1.077 . . . . 0.0 112.95 -171.035 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.15 118.71 4.07 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 122.935 2.423 . . . . 0.0 108.893 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.88 142.99 3.1 Favored 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 125.41 1.484 . . . . 0.0 112.31 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 80.49 -22.2 4.81 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 118.982 -0.899 . . . . 0.0 113.706 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.21 158.17 5.56 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.113 1.456 . . . . 0.0 111.969 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -79.84 96.68 6.4 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.5 t -78.68 90.36 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 174.418 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -84.36 119.3 24.94 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 174.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -111.79 114.36 46.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -176.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 94.4 m -107.47 104.35 13.9 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.541 1.137 . . . . 0.0 109.473 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.4 m-85 -79.53 162.9 25.1 Favored 'General case' 0 C--O 1.221 -0.414 0 O-C-N 121.662 -0.649 . . . . 0.0 112.429 174.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -137.61 78.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 101.651 -3.462 . . . . 0.0 101.651 163.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -99.94 96.51 7.6 Favored 'General case' 0 N--CA 1.457 -0.111 0 N-CA-C 106.811 -1.552 . . . . 0.0 106.811 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.7 m -147.44 59.32 1.15 Allowed 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 174.28 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -82.3 66.41 7.88 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 173.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 8.72 72.82 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.75 3.22 . . . . 0.0 113.927 -171.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.42 -44.83 1.29 Allowed Glycine 0 CA--C 1.527 0.796 0 C-N-CA 124.31 0.957 . . . . 0.0 111.382 178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -79.72 95.62 6.02 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.842 0.83 . . . . 0.0 110.091 -175.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.99 61.35 2.58 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.412 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -45.54 124.57 5.09 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.271 1.028 . . . . 0.0 110.857 173.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 96.8 p -87.2 167.06 14.47 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -134.05 112.5 11.23 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 172.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -131.27 127.59 38.08 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -173.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 47.5 mt -99.31 127.91 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 C-N-CA 125.818 1.647 . . . . 0.0 108.475 -174.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.48 -149.03 0.18 Allowed 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt -129.26 25.28 5.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.696 1.134 . . . . 0.0 111.994 -178.044 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -73.74 94.95 2.3 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 173.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -73.49 171.33 51.69 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 173.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.1 150.15 82.27 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.282 1.988 . . . . 0.0 109.65 175.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -75.31 130.75 22.13 Favored 'Cis proline' 0 N--CA 1.454 -0.807 0 N-CA-C 109.941 -0.83 . . . . 0.0 109.941 -3.255 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -78.75 145.82 34.21 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.4 145.59 39.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-O 121.382 0.61 . . . . 0.0 112.044 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -67.52 -43.41 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -78.85 144.95 65.15 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 177.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -64.01 68.83 0.2 Allowed 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.638 2.892 . . . . 0.0 113.685 175.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.43 75.52 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.4 pt -76.35 86.0 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 123.509 1.623 . . . . 0.0 110.816 -172.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.28 155.69 83.9 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 113.125 -1.852 . . . . 0.0 106.913 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -39.57 112.42 0.15 Allowed 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 123.91 3.073 . . . . 0.0 113.986 -176.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.1 mm -79.24 132.17 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -82.29 -87.11 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.49 156.16 16.46 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 123.394 0.678 . . . . 0.0 109.365 173.3 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.44 178.21 45.1 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 118.956 -1.592 . . . . 0.0 113.904 174.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 17.3 p -121.26 155.27 35.01 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 126.464 1.906 . . . . 0.0 109.424 175.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -90.09 -127.55 3.42 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 173.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -116.2 134.98 54.32 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 118.495 1.148 . . . . 0.0 108.61 176.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 4.5 p -76.58 177.56 2.5 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -172.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.56 -7.08 13.46 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.271 2.648 . . . . 0.0 113.015 172.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m 35.24 67.15 1.46 Allowed Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 126.285 1.834 . . . . 0.0 115.857 -178.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -60.72 178.59 0.46 Allowed 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.726 2.284 . . . . 0.0 113.796 174.084 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -142.45 -171.98 3.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.043 0.937 . . . . 0.0 110.187 -177.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 26.1 t70 62.65 -77.3 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 126.862 2.065 . . . . 0.0 111.549 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.75 15.66 0.3 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.966 0.793 . . . . 0.0 111.869 177.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 31.8 mtmm -87.59 155.9 19.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 174.307 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -140.07 104.07 4.76 Favored 'General case' 0 CA--C 1.517 -0.297 0 C-N-CA 123.765 0.826 . . . . 0.0 112.416 -171.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -67.38 107.85 2.2 Favored Glycine 0 CA--C 1.526 0.725 0 C-N-CA 125.299 1.428 . . . . 0.0 109.841 174.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -103.48 178.62 4.5 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.889 0.852 . . . . 0.0 109.374 173.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.87 157.75 43.66 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 -177.695 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.0 m-20 -139.46 87.5 2.19 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -100.59 168.78 9.49 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 172.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 16.6 m -151.86 148.94 28.42 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 120.952 -1.093 . . . . 0.0 108.976 -175.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 22.0 t90 -147.22 149.47 32.98 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 124.627 1.171 . . . . 0.0 110.225 -174.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -113.06 108.32 53.28 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 172.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -89.8 145.79 4.67 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 123.419 2.746 . . . . 0.0 112.693 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.8 p -89.55 154.94 19.61 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.983 1.313 . . . . 0.0 108.329 172.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.35 169.16 1.26 Allowed 'General case' 0 CA--C 1.538 0.484 0 O-C-N 121.603 -0.686 . . . . 0.0 112.225 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 108.09 -130.61 10.17 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 125.182 1.373 . . . . 0.0 110.192 178.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.7 m -151.56 144.48 24.48 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 118.28 1.04 . . . . 0.0 110.377 -175.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -137.57 174.94 10.05 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 126.221 1.809 . . . . 0.0 107.727 178.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -135.79 139.21 43.34 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.482 1.513 . . . . 0.0 108.6 179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -103.36 139.59 38.57 Favored 'General case' 0 N--CA 1.457 -0.116 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 172.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.7 m -147.15 168.62 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.229 1.011 . . . . 0.0 110.701 178.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 10.3 t -106.09 136.85 45.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 126.461 1.905 . . . . 0.0 108.485 173.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -77.49 -26.28 51.1 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 123.867 0.867 . . . . 0.0 113.22 -173.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 52.7 mt -57.92 130.82 82.97 Favored Pre-proline 0 CA--C 1.543 0.696 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.93 143.56 3.03 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 124.128 3.219 . . . . 0.0 114.778 -174.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.91 -39.73 1.37 Allowed Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.211 0.91 . . . . 0.0 113.958 174.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 25.0 m170 -50.24 -48.81 54.46 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.591 1.156 . . . . 0.0 114.062 -172.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.19 -49.83 74.24 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-O 120.736 0.303 . . . . 0.0 110.368 178.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -58.41 -42.1 86.4 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.256 0.622 . . . . 0.0 110.853 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 32.5 p -79.84 -41.29 26.66 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 118.129 -0.938 . . . . 0.0 113.196 -174.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -169.46 -41.13 0.03 OUTLIER Glycine 0 C--N 1.342 0.871 0 C-N-CA 118.028 -2.034 . . . . 0.0 117.881 -174.14 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.268 3.8 ptp -79.91 94.17 5.81 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 120.381 2.09 . . . . 0.0 112.196 -173.286 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -157.76 -178.28 7.21 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.083 0.953 . . . . 0.0 110.353 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.28 161.14 19.07 Favored Glycine 0 C--N 1.338 0.655 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 173.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.467 ' HB2' HG23 ' A' ' 63' ' ' THR . 90.8 mttt -96.31 145.75 25.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.653 1.581 . . . . 0.0 109.553 -175.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.7 mt -122.4 101.09 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 173.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -89.67 132.19 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 25.7 t -123.94 125.98 71.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 24.1 mtpp . . . . . 0 N--CA 1.464 0.226 0 CA-C-N 118.898 0.772 . . . . 0.0 111.276 -177.932 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.864 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p 65.6 -57.97 0.31 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 127.855 2.462 . . . . 0.0 113.557 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 mp -55.17 151.3 9.57 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 171.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -34.52 106.97 0.05 OUTLIER 'General case' 0 C--O 1.232 0.171 0 C-N-CA 125.691 1.596 . . . . 0.0 112.458 -171.348 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.5 p -88.8 17.4 5.63 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 124.912 1.285 . . . . 0.0 111.645 -176.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.2 m -79.71 62.71 4.06 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.155 0.889 . . . . 0.0 110.139 -174.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 73.6 m95 -94.49 122.26 36.88 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 125.177 1.391 . . . . 0.0 111.282 -174.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -142.11 -176.47 4.82 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -136.43 132.32 35.29 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 121.838 -0.539 . . . . 0.0 109.83 172.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -87.74 -154.56 0.26 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 104.303 -2.48 . . . . 0.0 104.303 169.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.8 p -142.61 165.19 28.09 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 120.921 -1.112 . . . . 0.0 108.713 174.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.3 tt -39.9 -53.02 4.99 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 114.687 1.365 . . . . 0.0 114.687 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -57.54 -31.19 90.91 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.865 1.71 . . . . 0.0 112.572 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -71.13 -33.63 70.28 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 122.995 0.518 . . . . 0.0 110.204 178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.427 HG21 ' CD2' ' A' ' 120' ' ' PHE . 13.6 t -62.74 -48.61 87.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.77 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -54.45 -44.96 72.96 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.988 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.91 -48.07 67.52 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.25 0.62 . . . . 0.0 111.437 175.193 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 68.8 mtm -70.1 -30.94 68.28 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 118.483 -0.77 . . . . 0.0 112.221 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.57 57.36 1.22 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-O 122.331 1.062 . . . . 0.0 109.757 172.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -137.29 -40.27 0.58 Allowed 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 129.383 3.073 . . . . 0.0 104.839 173.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . 0.294 0.0 OUTLIER 84.72 142.58 0.06 Allowed 'General case' 0 N--CA 1.442 -0.831 0 C-N-CA 128.974 2.91 . . . . 0.0 114.648 170.247 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -101.19 -147.8 0.36 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 111.688 -2.506 . . . . 0.0 109.091 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.2 p -44.16 131.66 5.94 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 126.717 2.007 . . . . 0.0 112.675 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 145.06 90.63 0.11 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.169 0.89 . . . . 0.0 110.928 174.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -79.13 137.79 37.63 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 174.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.5 t -63.69 146.89 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 33.0 m -148.52 64.66 1.07 Allowed 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 174.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 66.07 -142.99 44.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 107.642 -2.183 . . . . 0.0 107.642 -172.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -80.01 54.85 1.99 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.721 1.261 . . . . 0.0 109.733 174.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.9 m -160.86 153.9 21.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 178.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 93.5 t -123.46 142.08 41.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -125.77 129.44 49.47 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.963 1.305 . . . . 0.0 108.562 -174.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -93.18 167.07 12.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.493 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.6 m -156.26 61.58 0.56 Allowed 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.552 0.741 . . . . 0.0 109.621 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.87 166.07 38.58 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 108.234 -1.947 . . . . 0.0 108.234 177.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -75.18 -50.4 16.37 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 117.435 0.617 . . . . 0.0 109.659 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.3 p -79.83 93.62 5.66 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 42.5 t -82.82 98.53 4.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -94.11 116.01 28.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.8 122.47 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 124.864 1.265 . . . . 0.0 108.601 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 95.5 t -92.2 113.82 28.12 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 175.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.83 92.66 3.9 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.871 1.269 . . . . 0.0 110.392 -178.481 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.33 113.51 24.8 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.273 1.029 . . . . 0.0 109.999 178.484 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.1 114.45 24.73 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.209 -0.932 . . . . 0.0 110.409 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.4 t 32.89 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 126.67 1.988 . . . . 0.0 112.892 173.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.7 142.02 69.55 Favored Pre-proline 0 CA--C 1.533 0.31 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -178.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -56.16 110.4 0.56 Allowed 'Trans proline' 0 N--CA 1.454 -0.802 0 C-N-CA 123.079 2.519 . . . . 0.0 110.429 -174.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 137.65 -42.71 1.27 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 107.917 -2.073 . . . . 0.0 107.917 -173.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -83.01 140.34 42.94 Favored Pre-proline 0 N--CA 1.453 -0.324 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 174.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.99 164.98 30.68 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 122.471 2.114 . . . . 0.0 110.631 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -72.02 166.33 41.77 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 173.17 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -116.64 50.95 0.65 Allowed 'Cis proline' 0 CA--C 1.536 0.591 0 N-CA-C 108.441 -1.407 . . . . 0.0 108.441 -5.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.7 p -93.05 129.3 39.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -173.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -77.95 121.69 24.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 N-CA-C 103.247 -2.871 . . . . 0.0 103.247 166.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -91.88 113.99 26.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -120.59 117.79 54.4 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 119.051 0.841 . . . . 0.0 110.584 -171.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 0.1 OUTLIER 36.93 -104.71 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.641 1.976 . . . . 0.0 113.067 -174.751 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.22 -17.68 39.04 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -124.5 -166.93 1.58 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 124.263 1.025 . . . . 0.0 110.833 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 51.2 mttm -133.95 124.74 26.86 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.192 -1.781 . . . . 0.0 106.192 172.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 52.91 44.24 1.91 Allowed Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.657 1.183 . . . . 0.0 112.354 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -79.28 173.72 12.91 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 122.372 2.048 . . . . 0.0 111.482 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.477 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.8 m -94.62 140.68 29.55 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.73 121.45 44.11 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.413 1.485 . . . . 0.0 112.305 -171.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -103.46 111.02 23.27 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.988 0.915 . . . . 0.0 108.737 173.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.9 mt -112.58 135.45 21.51 Favored Pre-proline 0 CA--C 1.537 0.447 0 C-N-CA 125.739 1.616 . . . . 0.0 110.289 -173.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.67 116.63 4.32 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 122.629 2.22 . . . . 0.0 108.747 172.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.03 133.58 27.21 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.593 0.757 . . . . 0.0 110.597 177.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.98 -26.63 16.75 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.986 -1.245 . . . . 0.0 109.986 -173.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.08 32.23 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.891 0.846 . . . . 0.0 111.845 174.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 95.2 m -105.08 130.22 53.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 t -100.53 99.28 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 124.253 1.021 . . . . 0.0 110.881 -172.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.53 93.71 8.4 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.0 t -83.93 100.64 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 174.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 93.3 m -86.75 100.07 12.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.497 1.119 . . . . 0.0 109.109 174.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 2.9 m-85 -76.74 155.7 33.0 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.35 172.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.0 mp -137.96 92.2 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 101.868 -3.382 . . . . 0.0 101.868 163.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -113.54 113.31 24.93 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 172.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 49.1 m -146.17 45.89 1.24 Allowed 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 172.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -75.74 71.02 2.58 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 173.035 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.2 mtmm -17.74 87.96 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.527 3.131 . . . . 0.0 113.929 -173.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.435 ' H ' ' CG1' ' A' ' 114' ' ' VAL . . . 133.32 -45.27 1.13 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.383 0.992 . . . . 0.0 111.507 178.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -97.33 111.99 24.0 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 117.506 0.653 . . . . 0.0 112.272 -173.06 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.62 54.96 2.5 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.937 0.78 . . . . 0.0 111.475 173.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -48.34 139.84 8.33 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.643 1.221 . . . . 0.0 111.347 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.4 p -104.51 165.99 10.69 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.53 1.132 . . . . 0.0 108.435 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 9.0 t80 -131.28 116.52 17.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 105.596 -2.002 . . . . 0.0 105.596 171.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASP . . . . . 0.488 ' HB3' HD12 ' A' ' 105' ' ' ILE . 16.8 m-20 -133.03 129.83 38.61 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 118.91 0.777 . . . . 0.0 110.642 -172.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 34.4 mt -104.38 134.04 46.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 C-N-CA 126.016 1.726 . . . . 0.0 108.864 -176.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.2 t -159.13 -154.61 0.42 Allowed 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 48.8 mtmt -126.56 21.88 7.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 119.232 0.924 . . . . 0.0 111.804 -179.154 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -70.37 118.87 13.73 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.05 159.33 43.38 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 174.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -72.5 164.53 35.34 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.969 2.446 . . . . 0.0 109.598 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -71.35 141.46 69.8 Favored 'Cis proline' 0 N--CA 1.459 -0.543 0 CA-C-N 119.333 0.798 . . . . 0.0 110.634 -5.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -79.91 150.86 30.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 121.289 0.566 . . . . 0.0 109.874 175.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.43 151.99 27.63 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.377 177.448 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 65.9 t -61.1 -39.18 81.47 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 174.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 92.3 mmm -78.2 133.1 65.02 Favored Pre-proline 0 N--CA 1.452 -0.373 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 174.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.87 75.57 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.751 2.301 . . . . 0.0 111.974 -173.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.9 t -79.02 65.5 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 172.714 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -88.43 -43.79 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.84 1.656 . . . . 0.0 111.801 -173.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -64.25 146.52 97.67 Favored Pre-proline 0 CA--C 1.531 0.215 0 C-N-CA 123.119 0.568 . . . . 0.0 111.515 -173.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.26 143.28 74.57 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 CA-C-N 119.038 0.692 . . . . 0.0 111.261 -2.25 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.488 HD12 ' HB3' ' A' ' 88' ' ' ASP . 19.4 mm -91.44 143.49 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.447 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 92.2 t -87.05 -92.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 104.432 -2.432 . . . . 0.0 104.432 173.05 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.17 145.65 24.87 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -178.6 161.5 28.09 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.264 -1.446 . . . . 0.0 111.237 174.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 34.6 p -103.02 149.25 24.74 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 125.186 1.395 . . . . 0.0 108.248 175.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.91 -156.7 8.78 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 173.327 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -74.74 139.12 43.18 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.506 1.153 . . . . 0.0 109.071 174.251 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 51.8 p -81.66 163.91 51.74 Favored Pre-proline 0 C--O 1.233 0.216 0 C-N-CA 122.497 0.319 . . . . 0.0 111.547 -174.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -64.97 166.33 18.84 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 N-CA-C 106.395 -2.194 . . . . 0.0 106.395 168.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.435 ' CG1' ' H ' ' A' ' 82' ' ' GLY . 14.4 t -130.55 76.75 77.0 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -172.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -62.76 162.12 26.31 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 122.154 1.903 . . . . 0.0 110.256 172.507 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -137.19 5.95 2.8 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -178.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -174.33 148.94 1.3 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 125.469 1.508 . . . . 0.0 109.102 174.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.94 -66.21 0.13 Allowed Glycine 0 CA--C 1.527 0.832 0 C-N-CA 126.533 2.015 . . . . 0.0 113.935 174.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -79.02 151.53 31.46 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 125.22 1.408 . . . . 0.0 110.525 -176.226 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.427 ' CD2' HG21 ' A' ' 15' ' ' VAL . 10.1 m-85 -134.76 101.98 5.11 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 125.46 1.504 . . . . 0.0 111.096 -174.013 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.95 112.28 1.87 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 125.272 1.415 . . . . 0.0 111.227 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -130.67 155.23 46.94 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.931 0.893 . . . . 0.0 111.29 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 6.6 m -154.78 114.4 3.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -174.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.09 62.55 4.21 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 125.199 1.399 . . . . 0.0 108.525 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -70.15 121.82 18.26 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 118.305 -1.358 . . . . 0.0 108.526 -174.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 41.0 m -96.86 84.73 3.63 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.389 -172.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -78.36 124.75 28.46 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -94.02 106.39 22.05 Favored Pre-proline 0 N--CA 1.451 -0.417 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 171.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -83.23 177.85 6.25 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.975 2.45 . . . . 0.0 112.169 -171.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.5 p -131.09 153.88 48.86 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 172.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.38 165.3 7.85 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.531 1.06 . . . . 0.0 111.935 -174.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 112.86 -168.18 12.54 Favored Glycine 0 CA--C 1.525 0.676 0 C-N-CA 124.718 1.151 . . . . 0.0 112.297 174.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 28.5 m -98.3 139.89 33.4 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 124.028 0.931 . . . . 0.0 109.08 -176.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -140.35 177.29 8.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 125.27 1.428 . . . . 0.0 107.235 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -145.44 152.7 40.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 176.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -116.74 149.13 40.39 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 123.489 0.716 . . . . 0.0 110.382 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 28.6 m -152.78 161.88 2.56 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 C-N-CA 125.052 1.341 . . . . 0.0 111.314 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 3.1 t -100.14 134.11 43.55 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.406 1.482 . . . . 0.0 107.892 170.578 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -74.05 -22.17 59.65 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -173.439 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 57.1 mt -60.78 126.98 86.6 Favored Pre-proline 0 CA--C 1.542 0.665 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -177.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -44.86 146.89 2.14 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 123.934 3.089 . . . . 0.0 114.056 -174.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.2 -39.01 1.61 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 123.304 0.478 . . . . 0.0 113.055 177.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.1 m170 -54.02 -51.55 63.63 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.491 1.145 . . . . 0.0 111.879 -173.266 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.28 -47.29 81.84 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 117.891 0.314 . . . . 0.0 110.986 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.47 97.27 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 122.783 0.433 . . . . 0.0 111.132 -178.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 40.4 p -79.99 -35.81 36.89 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -173.356 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.41 -27.34 0.04 OUTLIER Glycine 0 CA--C 1.528 0.898 0 N-CA-C 117.081 1.592 . . . . 0.0 117.081 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 3.6 mtt -78.12 80.43 4.55 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 120.07 1.935 . . . . 0.0 110.943 -173.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -162.28 -174.38 4.04 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.71 163.32 21.41 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 173.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.477 ' HB2' HG23 ' A' ' 63' ' ' THR . 49.2 mttt -99.33 154.1 18.45 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.046 0.939 . . . . 0.0 108.954 -175.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.4 mt -130.33 138.1 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 178.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 42.8 t -130.25 101.0 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 173.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 40.1 t -87.0 88.14 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 174.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.3 mttt . . . . . 0 C--N 1.332 -0.182 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 177.109 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.011 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.869 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 p -72.21 97.76 2.03 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 125.209 1.403 . . . . 0.0 108.687 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.8 mp -44.81 142.18 1.85 Allowed 'General case' 0 CA--C 1.529 0.16 0 CA-C-O 121.293 0.568 . . . . 0.0 111.957 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 20.3 t70 67.59 -31.57 0.18 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 127.239 2.216 . . . . 0.0 116.238 174.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 77.3 p -52.36 -43.75 64.84 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 119.243 0.928 . . . . 0.0 111.86 -176.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.8 m -98.84 122.33 41.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 123.846 0.858 . . . . 0.0 108.871 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -155.7 127.1 7.22 Favored 'General case' 0 C--N 1.341 0.233 0 C-N-CA 126.32 1.848 . . . . 0.0 108.417 173.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -150.07 170.62 18.45 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 173.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -135.91 148.14 48.43 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 172.447 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -118.24 -155.94 0.62 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 127.862 2.465 . . . . 0.0 106.357 174.408 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 29.9 p -134.43 173.04 12.07 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.577 0.751 . . . . 0.0 109.49 174.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.0 tt -39.05 -56.81 2.36 Favored Pre-proline 0 CA--C 1.538 0.481 0 N-CA-C 114.508 1.299 . . . . 0.0 114.508 -174.391 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -56.39 -31.46 85.38 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.32 1.347 . . . . 0.0 113.606 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.6 mp0 -68.28 -27.61 66.46 Favored 'General case' 0 N--CA 1.457 -0.115 0 O-C-N 121.177 -0.952 . . . . 0.0 111.249 176.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -61.31 -50.54 80.01 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -55.45 -47.11 76.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.889 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.68 -59.9 3.91 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 122.438 0.295 . . . . 0.0 110.978 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.5 mtm -54.59 -47.9 72.8 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.209 0.604 . . . . 0.0 111.153 -176.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.9 mt -50.51 -33.51 21.74 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 113.269 0.841 . . . . 0.0 113.269 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -73.09 -31.59 64.46 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.556 -0.715 . . . . 0.0 110.534 178.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt -81.51 60.96 4.74 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 121.767 -0.583 . . . . 0.0 110.19 -176.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -125.42 102.12 7.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.116 0.566 . . . . 0.0 110.632 174.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.3 p -73.86 45.97 0.21 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.946 1.698 . . . . 0.0 111.197 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.24 112.6 2.42 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 125.508 1.528 . . . . 0.0 111.152 -174.009 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -79.12 -178.78 6.33 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.3 t -113.7 152.18 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 123.969 0.907 . . . . 0.0 108.89 177.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.7 m -149.1 73.41 1.21 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.373 1.069 . . . . 0.0 108.358 174.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.17 -144.36 39.27 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -172.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -79.46 59.1 2.83 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.653 1.226 . . . . 0.0 109.413 175.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -161.0 146.4 14.28 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.79 1.636 . . . . 0.0 106.708 -179.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 23.3 t -102.64 147.86 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 174.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 55.4 m -134.3 110.63 9.62 Favored 'General case' 0 CA--C 1.521 -0.172 0 C-N-CA 123.426 0.69 . . . . 0.0 109.954 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -82.8 169.01 16.6 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.564 0.697 . . . . 0.0 111.4 178.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -155.04 159.08 40.03 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 124.503 1.121 . . . . 0.0 107.988 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.39 -179.54 32.77 Favored Glycine 0 CA--C 1.53 1.019 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -176.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -85.63 -27.48 25.39 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.771 0.428 . . . . 0.0 111.211 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.6 m -79.18 69.2 5.34 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.107 0.963 . . . . 0.0 110.335 -176.083 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.44 78.55 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.975 0.893 . . . . 0.0 108.935 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 t-80 -83.4 105.61 14.49 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.9 t -107.36 95.75 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -174.07 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.6 t -83.66 123.32 38.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -174.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -132.52 114.61 14.48 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.461 1.104 . . . . 0.0 111.373 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.22 143.21 26.48 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.575 0.75 . . . . 0.0 109.819 174.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.421 ' HB3' ' HA ' ' A' ' 78' ' ' ASN . . . -116.25 96.54 5.59 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.012 0.525 . . . . 0.0 110.698 176.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.8 t 49.19 72.14 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.329 0 C-N-CA 128.407 2.683 . . . . 0.0 111.823 175.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.62 142.76 66.67 Favored Pre-proline 0 CA--C 1.533 0.32 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 176.539 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -41.53 106.2 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.362 3.375 . . . . 0.0 112.819 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 133.04 -48.46 0.96 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -174.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -75.94 141.02 70.93 Favored Pre-proline 0 CA--C 1.53 0.191 0 CA-C-N 117.182 0.491 . . . . 0.0 109.789 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -75.16 155.86 42.23 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 122.352 2.034 . . . . 0.0 111.191 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -75.14 153.6 86.39 Favored Pre-proline 0 N--CA 1.452 -0.336 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 172.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -92.13 -9.13 34.55 Favored 'Cis proline' 0 CA--C 1.538 0.687 0 CA-C-N 118.82 0.614 . . . . 0.0 111.423 -5.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -36.95 121.51 0.78 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -168.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -77.33 121.67 24.05 Favored 'General case' 0 C--N 1.346 0.447 0 C-N-CA 126.126 1.77 . . . . 0.0 107.161 171.304 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -94.53 112.07 23.83 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.182 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.47 81.71 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.226 0 C-N-CA 124.357 1.063 . . . . 0.0 109.344 -172.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.434 ' CD2' ' H ' ' A' ' 58' ' ' ASP . 31.9 p-80 44.66 -84.74 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 127.367 2.267 . . . . 0.0 114.629 177.209 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.434 ' H ' ' CD2' ' A' ' 57' ' ' HIS . 30.1 t70 -75.89 -29.46 58.47 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.336 0.654 . . . . 0.0 110.991 -175.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -136.72 -173.6 3.48 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.453 0.701 . . . . 0.0 109.777 -175.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -126.03 127.0 45.19 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 174.197 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.9 m-80 50.67 44.08 2.0 Allowed Pre-proline 0 CA--C 1.537 0.459 0 C-N-CA 124.915 1.286 . . . . 0.0 112.575 178.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -83.29 176.07 7.69 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.676 1.584 . . . . 0.0 110.863 -175.165 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.5 m -95.42 144.02 26.28 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 170.389 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.23 143.97 45.3 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.539 0.736 . . . . 0.0 110.806 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -110.18 125.33 52.94 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 170.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.6 mt -130.15 138.09 32.31 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 123.464 0.706 . . . . 0.0 111.893 -171.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.65 117.93 4.69 Favored 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 122.884 2.39 . . . . 0.0 109.233 172.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.73 141.41 10.01 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 125.053 1.341 . . . . 0.0 111.724 177.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.64 -2.07 55.38 Favored Glycine 0 CA--C 1.531 1.091 0 CA-C-O 118.936 -0.924 . . . . 0.0 113.719 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.76 158.77 31.63 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.708 1.754 . . . . 0.0 110.352 173.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 29.6 m -83.18 93.32 7.63 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 174.346 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 51.8 t -79.38 99.08 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -91.63 90.72 7.7 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.9 t -77.18 105.56 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 104.246 -2.501 . . . . 0.0 104.246 176.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 55.4 m -100.63 98.99 9.49 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 125.585 1.554 . . . . 0.0 109.797 -171.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.496 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.5 m-85 -77.38 158.77 29.92 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.38 68.26 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 101.652 -3.462 . . . . 0.0 101.652 164.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.431 HD22 ' C ' ' A' ' 78' ' ' ASN . 0.2 OUTLIER -87.24 67.06 9.48 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 -174.728 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.2 m -112.61 83.0 1.74 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 114.669 -1.15 . . . . 0.0 110.616 -175.621 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -120.14 119.91 34.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 172.053 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.33 72.82 1.31 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.109 0.564 . . . . 0.0 109.519 -175.045 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 162.82 -65.64 0.25 Allowed Glycine 0 CA--C 1.522 0.499 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -94.03 112.83 24.7 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.449 -0.442 . . . . 0.0 111.183 -174.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.68 38.99 0.91 Allowed Glycine 0 CA--C 1.537 1.418 0 CA-C-O 118.928 -0.929 . . . . 0.0 111.865 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 0.95 -78.42 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 129.86 3.264 . . . . 0.0 117.513 -172.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.5 p 99.13 155.08 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 129.967 3.307 . . . . 0.0 110.196 -173.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.496 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 6.7 t80 -134.01 110.42 9.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 173.324 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -122.94 140.94 52.46 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.5 mt -115.64 126.7 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.665 1.586 . . . . 0.0 110.257 -172.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -161.05 164.74 30.63 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -83.86 56.41 3.66 Favored 'General case' 0 CA--C 1.535 0.394 0 O-C-N 121.608 -0.682 . . . . 0.0 110.621 -174.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -105.56 107.91 19.15 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 175.139 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.05 160.12 52.62 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 175.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.67 162.11 43.31 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.986 2.458 . . . . 0.0 109.81 174.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 158.63 93.88 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 CA-C-N 119.006 0.681 . . . . 0.0 110.595 -3.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -96.32 153.56 17.75 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.1 151.1 35.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 175.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 60.3 t -60.38 -38.51 77.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 174.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -78.53 133.48 63.21 Favored Pre-proline 0 N--CA 1.451 -0.409 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 174.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -74.75 80.53 2.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.409 2.073 . . . . 0.0 109.739 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 70.2 t -77.0 84.24 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 178.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.3 pt -77.58 83.04 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-O 123.065 1.412 . . . . 0.0 111.625 -173.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -62.12 154.54 69.31 Favored Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 171.133 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -37.18 112.59 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 124.248 3.299 . . . . 0.0 114.375 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 32.1 mm -79.48 139.44 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 59.6 t -86.0 -88.32 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 174.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.29 146.5 23.98 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.116 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.49 -178.9 42.96 Favored Glycine 0 C--N 1.333 0.368 0 CA-C-N 120.153 1.342 . . . . 0.0 112.219 173.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.2 p -122.95 -37.96 2.67 Favored 'General case' 0 C--N 1.338 0.083 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -176.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 78.34 -175.45 54.71 Favored Glycine 0 CA--C 1.541 1.701 0 N-CA-C 107.658 -2.177 . . . . 0.0 107.658 -170.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.19 141.71 39.96 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.911 1.855 . . . . 0.0 114.513 -171.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.0 p -83.82 155.12 64.97 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -174.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -73.67 75.0 3.17 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.458 2.772 . . . . 0.0 110.688 175.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 66.9 t -20.34 96.16 0.05 OUTLIER Pre-proline 0 CA--C 1.542 0.665 0 C-N-CA 128.195 2.598 . . . . 0.0 112.846 175.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.453 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 33.4 Cg_exo -66.47 171.71 10.2 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.723 2.948 . . . . 0.0 112.582 -178.221 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -124.76 151.94 44.48 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.653 1.181 . . . . 0.0 109.25 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 39.23 -103.4 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 127.219 2.208 . . . . 0.0 113.62 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -92.25 -2.11 68.74 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.496 -1.169 . . . . 0.0 114.476 -173.524 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -86.44 153.35 21.95 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.687 1.243 . . . . 0.0 110.442 -176.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -138.32 111.37 7.85 Favored 'General case' 0 C--O 1.224 -0.242 0 C-N-CA 124.987 1.315 . . . . 0.0 111.457 -172.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.453 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -78.92 113.15 3.6 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 125.459 1.504 . . . . 0.0 110.589 -174.019 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -121.59 164.46 17.24 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.798 0.839 . . . . 0.0 111.796 -176.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.2 m -165.94 115.61 0.99 Allowed 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 124.523 1.129 . . . . 0.0 108.103 178.023 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -84.99 67.25 10.14 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.16 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -66.79 122.45 17.7 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.1 m -97.98 130.12 44.84 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.704 -1.135 . . . . 0.0 110.379 -171.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -140.0 145.3 37.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.791 1.236 . . . . 0.0 109.669 -178.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -114.77 94.25 36.71 Favored Pre-proline 0 N--CA 1.454 -0.25 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -80.16 150.43 20.24 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 122.573 2.182 . . . . 0.0 111.287 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.3 p -101.31 155.21 18.17 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -53.58 141.56 25.33 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -173.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 136.61 176.49 14.39 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 126.198 1.856 . . . . 0.0 111.189 175.351 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.6 m -98.42 109.98 22.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.143 0.977 . . . . 0.0 110.317 -174.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -101.28 173.56 6.39 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 172.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -134.63 143.18 47.14 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.208 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -104.52 141.64 36.03 Favored 'General case' 0 CA--C 1.522 -0.126 0 CA-C-O 118.569 -0.729 . . . . 0.0 109.682 174.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 5.0 m -147.74 156.57 9.58 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 123.928 0.891 . . . . 0.0 111.77 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 11.2 t -94.9 131.58 40.66 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 126.595 1.958 . . . . 0.0 109.365 173.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -82.79 -1.39 51.54 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -172.267 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.33 136.42 93.52 Favored Pre-proline 0 CA--C 1.537 0.444 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 173.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.6 144.74 10.15 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.451 2.101 . . . . 0.0 112.554 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.07 -44.99 2.2 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.628 0.632 . . . . 0.0 112.995 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -48.41 -52.73 20.6 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 118.761 1.281 . . . . 0.0 113.989 -173.163 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.87 -52.11 66.41 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 120.877 0.37 . . . . 0.0 110.145 176.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.28 -39.74 91.56 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.684 1.194 . . . . 0.0 111.686 -175.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.2 p -79.01 -36.49 41.09 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 118.473 -0.775 . . . . 0.0 111.31 -174.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.33 -22.74 0.07 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 117.123 -2.465 . . . . 0.0 118.188 174.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.331 17.8 ptm -80.72 92.8 6.08 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 121.134 2.467 . . . . 0.0 112.93 -173.058 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.65 -175.1 4.78 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.188 0.995 . . . . 0.0 109.332 179.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 176.23 170.6 39.1 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 173.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.421 ' HB2' HG23 ' A' ' 63' ' ' THR . 38.0 mttt -107.08 146.56 31.06 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 124.447 1.099 . . . . 0.0 109.785 -173.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.5 mt -121.21 99.12 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 125.371 1.469 . . . . 0.0 107.062 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.5 t -90.82 100.66 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 24.1 t -89.62 127.49 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 178.346 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm . . . . . 0 N--CA 1.462 0.167 0 CA-C-N 119.136 0.88 . . . . 0.0 111.132 -178.151 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.851 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.7 p -69.63 -63.74 1.01 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.437 1.095 . . . . 0.0 109.221 177.528 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 mp 58.17 179.84 0.06 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 125.378 1.471 . . . . 0.0 111.974 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -70.51 126.92 30.99 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.3 p -121.08 39.08 3.9 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 123.659 0.784 . . . . 0.0 109.358 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 m -79.88 60.1 3.37 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.2 m95 -99.66 131.84 45.39 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 126.029 1.732 . . . . 0.0 111.275 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -144.63 -170.89 3.49 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 172.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -136.21 130.12 32.66 Favored 'General case' 0 C--N 1.341 0.202 0 CA-C-N 119.216 0.916 . . . . 0.0 110.098 172.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -89.66 -156.62 0.42 Allowed 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 170.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.4 p -139.33 166.71 23.84 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 174.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -39.42 -54.97 3.49 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 115.594 1.702 . . . . 0.0 115.594 -172.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.75 -33.44 98.4 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 CA-C-N 120.92 1.364 . . . . 0.0 111.759 -177.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.94 -32.02 73.53 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 122.769 0.428 . . . . 0.0 110.454 -178.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -56.69 -51.04 71.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.231 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -58.22 -49.36 77.35 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.564 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -48.61 -57.15 6.65 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.738 0.415 . . . . 0.0 111.116 178.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -63.1 -45.13 93.52 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 118.432 -0.794 . . . . 0.0 111.605 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.4 mt -48.76 -47.77 41.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 119.414 1.007 . . . . 0.0 111.386 179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -55.35 -21.55 15.65 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 178.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -96.45 7.24 46.99 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 119.156 0.889 . . . . 0.0 112.414 -177.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.6 115.06 10.34 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 119.989 1.268 . . . . 0.0 110.226 -179.466 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 p -83.99 15.13 3.56 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.61 1.164 . . . . 0.0 113.875 -174.38 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.75 115.15 4.38 Favored Glycine 0 CA--C 1.527 0.819 0 O-C-N 121.214 -0.929 . . . . 0.0 111.446 -174.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -78.89 121.11 24.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.17 1.388 . . . . 0.0 108.995 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.97 122.5 6.27 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 C-N-CA 124.137 0.975 . . . . 0.0 109.592 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -132.12 68.93 1.48 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.689 1.596 . . . . 0.0 108.235 -174.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.84 -117.57 8.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 -174.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -78.89 -33.49 45.63 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.848 0.824 . . . . 0.0 109.559 173.367 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 27.8 m -78.88 155.96 28.85 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 123.739 0.816 . . . . 0.0 109.215 -173.223 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.7 t -118.67 132.62 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 173.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -121.14 126.88 50.84 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 123.204 0.602 . . . . 0.0 109.969 -173.2 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.478 ' CB ' HG22 ' A' ' 38' ' ' VAL . 67.7 m-85 -97.84 175.9 5.99 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 122.826 0.45 . . . . 0.0 110.153 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 60.0 m -156.5 168.21 28.06 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.505 0.722 . . . . 0.0 109.811 -175.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 45.26 43.53 9.71 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 125.354 1.454 . . . . 0.0 113.018 174.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.1 mttp 50.55 12.02 0.09 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.093 1.757 . . . . 0.0 115.492 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.8 m -103.62 74.78 1.27 Allowed 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -173.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.478 HG22 ' CB ' ' A' ' 33' ' ' TYR . 74.1 t -89.56 96.79 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.3 t-160 -105.21 102.62 12.1 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 173.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.3 t -99.17 103.28 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.0 t -88.06 90.48 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 175.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.34 159.61 14.85 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.014 1.326 . . . . 0.0 109.841 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.9 166.44 33.53 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 0.0 108.841 177.592 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -147.69 115.15 6.3 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 122.251 0.22 . . . . 0.0 111.151 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t 54.27 53.35 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 125.868 1.667 . . . . 0.0 111.912 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 30.9 mt -78.36 151.78 78.19 Favored Pre-proline 0 CA--C 1.532 0.286 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 173.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_exo -47.01 103.88 0.06 OUTLIER 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 123.581 2.854 . . . . 0.0 112.91 -176.069 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 129.92 -48.8 0.95 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -174.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -79.16 127.56 78.85 Favored Pre-proline 0 CA--C 1.532 0.263 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.359 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.94 163.85 15.67 Favored 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.311 2.008 . . . . 0.0 112.029 -175.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -63.67 146.16 96.95 Favored Pre-proline 0 N--CA 1.451 -0.397 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -110.44 54.58 0.93 Allowed 'Cis proline' 0 N--CA 1.455 -0.782 0 N-CA-C 106.685 -2.083 . . . . 0.0 106.685 -6.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 85.8 p -79.49 121.59 25.4 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -170.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -78.57 115.89 18.58 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 103.284 -2.858 . . . . 0.0 103.284 167.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -100.25 138.52 37.19 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.101 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.3 t -135.25 100.35 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 118.354 0.524 . . . . 0.0 110.066 -174.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 1.5 p80 35.44 -69.62 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 130.227 3.411 . . . . 0.0 116.378 -173.429 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -101.84 -25.86 13.66 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 125.004 1.322 . . . . 0.0 112.218 -175.17 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -125.56 -169.85 2.07 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.81 1.244 . . . . 0.0 109.957 -173.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? -136.9 133.82 36.16 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 171.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 48.22 41.76 1.03 Allowed Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 124.235 1.014 . . . . 0.0 112.592 -174.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.59 169.03 22.0 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 CA-C-N 120.742 1.301 . . . . 0.0 112.872 -172.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.0 m -89.58 127.76 35.93 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 112.342 -2.208 . . . . 0.0 106.127 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -106.32 128.13 53.77 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.159 0.891 . . . . 0.0 110.101 -177.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 -104.68 117.91 35.26 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 171.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.422 HD12 HG23 ' A' ' 152' ' ' ILE . 14.6 mt -124.22 138.44 30.84 Favored Pre-proline 0 CA--C 1.538 0.496 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.817 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -67.95 125.32 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.727 2.284 . . . . 0.0 109.153 168.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.32 133.36 19.7 Favored 'General case' 0 C--N 1.332 -0.191 0 O-C-N 121.382 -0.824 . . . . 0.0 111.217 174.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.55 12.36 80.34 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.144 -0.809 . . . . 0.0 113.13 -176.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.41 148.7 47.79 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 119.375 1.588 . . . . 0.0 110.169 173.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 38.8 m -83.47 90.75 7.25 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 174.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 85.0 t -77.68 98.67 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 124.746 1.219 . . . . 0.0 108.068 -174.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -96.96 104.38 16.39 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 177.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.3 t -89.44 91.34 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 54.0 m -79.52 87.87 5.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.275 4.1 m-85 -79.73 138.6 37.35 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 117.876 -1.059 . . . . 0.0 109.934 172.584 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.8 mp -117.44 67.89 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 101.088 -3.671 . . . . 0.0 101.088 163.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -84.41 56.3 3.74 Favored 'General case' 0 C--O 1.231 0.109 0 O-C-N 121.117 -0.989 . . . . 0.0 108.626 -173.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.522 HG23 ' HG2' ' A' ' 115' ' ' PRO . 53.4 m -85.75 69.99 10.65 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.884 -176.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -97.43 156.82 16.3 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 171.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -93.17 124.14 36.94 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 75.42 -68.64 2.09 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.63 0.633 . . . . 0.0 112.392 175.254 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -79.08 81.07 5.38 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.873 -0.781 . . . . 0.0 110.001 -174.25 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -52.85 80.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 126.425 1.964 . . . . 0.0 112.52 174.061 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -57.47 162.52 2.85 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 119.232 1.516 . . . . 0.0 111.468 179.175 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.3 p -121.85 160.91 23.72 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.584 1.554 . . . . 0.0 107.388 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PHE . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -128.26 110.18 12.16 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 172.204 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -126.64 128.93 47.53 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.861 0.864 . . . . 0.0 108.716 -172.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 20.5 mt -106.21 134.32 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 C-N-CA 125.964 1.706 . . . . 0.0 110.054 -173.263 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.6 t -158.04 -152.08 0.33 Allowed 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 176.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -126.58 9.32 7.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.689 1.131 . . . . 0.0 113.286 -176.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -64.67 121.44 14.5 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.35 166.45 49.62 Favored Glycine 0 CA--C 1.532 1.117 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 161.89 44.15 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 122.856 2.37 . . . . 0.0 109.602 173.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -76.92 149.61 90.8 Favored 'Cis proline' 0 N--CA 1.454 -0.825 0 N-CA-C 110.27 -0.704 . . . . 0.0 110.27 -4.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -89.27 152.94 21.28 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 149.7 29.34 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.86 -42.09 87.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 174.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -78.89 130.35 70.49 Favored Pre-proline 0 N--CA 1.451 -0.391 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 174.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -75.02 85.07 1.57 Allowed 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 122.374 2.05 . . . . 0.0 109.829 -175.085 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.4 t -76.77 85.55 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.348 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 175.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 pt -75.43 87.43 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 CA-C-O 123.646 1.689 . . . . 0.0 110.653 -172.28 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -62.83 154.17 76.7 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 112.842 -1.981 . . . . 0.0 106.928 172.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -39.49 108.71 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 124.059 3.173 . . . . 0.0 113.794 -175.424 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.0 mm -78.46 126.84 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.37 -82.14 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 105.785 -1.932 . . . . 0.0 105.785 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.6 150.17 20.64 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.93 158.66 21.79 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 119.288 -1.434 . . . . 0.0 112.135 174.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.3 p -107.75 145.43 33.52 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.516 1.126 . . . . 0.0 110.544 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.63 158.38 37.19 Favored Glycine 0 CA--C 1.535 1.3 0 N-CA-C 107.342 -2.303 . . . . 0.0 107.342 172.091 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -41.88 133.07 2.95 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.558 1.543 . . . . 0.0 113.884 -173.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.5 p -68.53 158.5 84.99 Favored Pre-proline 0 CA--C 1.535 0.373 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -177.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.3 -177.96 2.66 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.075 1.85 . . . . 0.0 108.804 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 90.0 t -117.66 98.91 52.14 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 125.654 1.582 . . . . 0.0 108.83 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.522 ' HG2' HG23 ' A' ' 79' ' ' THR . 85.9 Cg_exo -62.45 173.59 3.36 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.737 3.625 . . . . 0.0 113.426 174.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -145.57 162.09 38.26 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.54 1.136 . . . . 0.0 109.355 176.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.58 -117.55 0.76 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.883 1.673 . . . . 0.0 110.967 177.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.63 17.43 42.72 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-O 118.899 -0.945 . . . . 0.0 112.445 -177.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -85.72 151.01 24.19 Favored 'General case' 0 C--N 1.341 0.234 0 CA-C-N 118.059 0.93 . . . . 0.0 108.876 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -133.98 93.63 3.13 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 124.373 1.069 . . . . 0.0 111.239 -172.37 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.47 ' H ' ' CG ' ' A' ' 115' ' ' PRO . . . -49.03 118.15 4.82 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 125.926 1.726 . . . . 0.0 109.959 173.756 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.18 159.6 41.76 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 123.919 0.888 . . . . 0.0 112.223 -177.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -143.57 148.46 35.95 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 126.537 1.935 . . . . 0.0 107.114 178.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -134.1 65.16 1.58 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 178.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -76.93 150.65 35.94 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.411 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 31.4 m -118.18 142.77 47.1 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.872 0.869 . . . . 0.0 109.773 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -145.47 161.28 40.08 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.625 1.17 . . . . 0.0 109.98 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 69.6 m80 -129.81 92.25 37.8 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 125.885 1.674 . . . . 0.0 109.001 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -71.64 145.26 46.32 Favored 'Trans proline' 0 N--CA 1.454 -0.852 0 C-N-CA 123.093 2.528 . . . . 0.0 112.178 -175.429 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.8 p -93.56 155.25 17.42 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.834 1.254 . . . . 0.0 108.87 172.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.86 146.03 43.49 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.808 -0.558 . . . . 0.0 112.493 -174.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 128.41 -125.38 5.02 Favored Glycine 0 C--N 1.334 0.45 0 C-N-CA 126.79 2.138 . . . . 0.0 108.826 -178.353 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 35.6 m -153.5 144.59 22.91 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 118.226 1.013 . . . . 0.0 109.881 -175.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -134.74 175.27 9.7 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.506 1.922 . . . . 0.0 106.962 173.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -141.7 149.96 41.23 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.164 1.386 . . . . 0.0 108.199 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' TYR . . . . . 0.46 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 48.1 p90 -112.89 144.22 42.82 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.956 0.903 . . . . 0.0 109.893 175.765 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.1 m -148.71 162.64 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 C-N-CA 125.081 1.352 . . . . 0.0 110.68 178.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.29 136.94 41.23 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.643 1.577 . . . . 0.0 107.663 171.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -81.32 -16.5 52.23 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.317 1.228 . . . . 0.0 114.317 -172.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 53.7 mt -63.81 129.52 93.86 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_exo -46.79 150.09 2.76 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 123.947 3.098 . . . . 0.0 114.575 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.42 -43.01 2.01 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 124.092 0.853 . . . . 0.0 112.89 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -50.76 -53.68 29.68 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.671 1.188 . . . . 0.0 111.98 -173.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -54.8 -46.71 74.53 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.77 0.428 . . . . 0.0 111.16 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.73 -41.71 91.91 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 123.156 0.583 . . . . 0.0 111.201 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.1 p -79.67 -58.94 2.94 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.031 0.532 . . . . 0.0 112.124 -173.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.81 38.33 0.09 OUTLIER Glycine 0 CA--C 1.525 0.665 0 C-N-CA 119.65 -1.262 . . . . 0.0 114.685 -174.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.1 ttt -126.19 64.75 1.23 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.272 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -151.52 -174.47 4.84 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.806 0.843 . . . . 0.0 111.241 -177.732 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.46 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.83 174.39 38.06 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 174.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.4 146.67 45.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.417 1.487 . . . . 0.0 109.805 -170.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.422 HG23 HD12 ' A' ' 66' ' ' ILE . 10.2 mt -128.33 95.81 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 125.461 1.504 . . . . 0.0 107.651 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 t -88.03 132.22 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.224 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.7 t -122.19 120.99 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -176.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm . . . . . 0 N--CA 1.467 0.393 0 CA-C-N 119.671 1.123 . . . . 0.0 110.827 176.711 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.773 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.8 p -74.5 -46.35 40.0 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 124.754 1.222 . . . . 0.0 110.049 175.202 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.3 mm? 39.24 -103.37 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 127.013 2.125 . . . . 0.0 115.038 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -75.2 96.78 3.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 118.349 0.522 . . . . 0.0 110.605 -172.568 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.9 p -52.36 -16.97 0.98 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.653 1.181 . . . . 0.0 113.366 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -78.25 53.96 1.31 Allowed 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.725 1.148 . . . . 0.0 112.171 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -92.68 142.96 26.79 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 127.697 2.399 . . . . 0.0 108.405 175.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -152.29 177.08 10.94 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -140.05 140.72 36.21 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 169.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.61 -150.9 0.47 Allowed 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 174.036 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 19.0 p -136.03 173.43 11.72 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 172.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -39.56 -56.96 2.66 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 114.282 1.216 . . . . 0.0 114.282 -174.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -55.04 -35.31 89.97 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.572 1.515 . . . . 0.0 113.481 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.7 mp0 -65.55 -23.95 66.98 Favored 'General case' 0 N--CA 1.455 -0.184 0 O-C-N 121.339 -0.85 . . . . 0.0 111.379 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -55.72 -46.88 79.77 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 119.27 0.941 . . . . 0.0 108.972 173.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtmt -60.32 -51.25 70.31 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.56 -46.99 67.08 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.692 0.256 . . . . 0.0 111.692 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -62.65 -54.93 32.08 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.721 0.408 . . . . 0.0 110.274 177.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 62.1 mt -49.23 -46.88 46.56 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 122.883 0.473 . . . . 0.0 111.339 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -53.04 -27.0 17.66 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -90.5 -0.91 57.85 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.17 0.896 . . . . 0.0 112.503 -179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -57.02 154.52 9.56 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.897 0.771 . . . . 0.0 112.671 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.7 p -128.0 165.59 19.99 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 172.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 122.33 117.67 2.44 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -178.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.4 mtpt -79.08 121.51 25.07 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.31 1.444 . . . . 0.0 108.934 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.6 t -61.69 114.25 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 125.591 1.556 . . . . 0.0 109.485 -176.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.1 m -130.57 68.03 1.48 Allowed 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 124.159 0.983 . . . . 0.0 111.435 -174.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.18 -94.67 0.47 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 123.778 0.704 . . . . 0.0 112.476 174.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -101.07 -14.54 17.76 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.516 1.127 . . . . 0.0 110.127 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 29.4 m -108.39 151.79 25.55 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.811 1.244 . . . . 0.0 109.985 -172.495 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.44 130.71 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 170.429 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.7 m -115.39 119.66 37.0 Favored 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 123.187 0.595 . . . . 0.0 110.404 -170.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.411 ' CD1' HG13 ' A' ' 38' ' ' VAL . 96.7 m-85 -91.8 153.09 19.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.9 m -155.79 51.49 0.56 Allowed 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.884 -0.51 . . . . 0.0 110.157 -175.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.89 166.27 39.46 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 108.276 -1.93 . . . . 0.0 108.276 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -73.61 -38.16 65.18 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 117.503 0.651 . . . . 0.0 110.584 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.7 p -80.09 103.46 9.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 174.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.411 HG13 ' CD1' ' A' ' 33' ' ' TYR . 29.5 t -107.69 128.37 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.549 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -132.15 101.36 5.36 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 123.941 0.897 . . . . 0.0 110.019 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.2 t -92.01 143.02 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.1 t -123.06 114.0 40.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 173.382 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -120.93 112.17 18.43 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 124.645 1.178 . . . . 0.0 111.976 -172.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.86 149.87 22.46 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 172.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.98 109.24 12.72 Favored 'General case' 0 C--O 1.226 -0.162 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 14.0 t 44.34 85.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.258 1.423 . . . . 0.0 112.189 -176.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 51.9 mt -76.67 128.95 80.7 Favored Pre-proline 0 CA--C 1.534 0.336 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo -42.07 111.24 0.18 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 124.071 3.181 . . . . 0.0 111.541 175.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 134.69 -45.91 1.08 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 -173.031 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -80.03 116.4 61.04 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -79.45 59.96 7.62 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.759 2.306 . . . . 0.0 111.247 -174.137 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 63.07 170.3 0.09 OUTLIER Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 124.906 1.282 . . . . 0.0 111.861 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -117.61 34.46 0.58 Allowed 'Cis proline' 0 CA--C 1.536 0.611 0 N-CA-C 109.297 -1.078 . . . . 0.0 109.297 -6.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.1 p -90.64 143.13 27.04 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 118.519 2.785 . . . . 0.0 118.519 -168.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' PHE . . . . . 0.445 ' CD2' ' HB2' ' A' ' 148' ' ' MET . 3.2 m-85 -85.69 103.46 14.51 Favored 'General case' 0 C--N 1.34 0.176 0 N-CA-C 103.276 -2.861 . . . . 0.0 103.276 166.374 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -93.51 96.07 9.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -174.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.8 t -85.2 149.5 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -176.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -20.96 -57.31 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 116.732 2.123 . . . . 0.0 116.732 -172.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -114.31 -5.71 12.95 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 39.8 mttm -150.34 148.54 28.94 Favored 'General case' 0 C--O 1.223 -0.323 0 CA-C-N 119.845 1.202 . . . . 0.0 109.731 -174.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.5 mttm -97.07 123.79 40.91 Favored 'General case' 0 C--N 1.332 -0.181 0 O-C-N 121.351 -0.843 . . . . 0.0 109.595 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.59 46.29 1.88 Allowed Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.505 1.522 . . . . 0.0 111.435 176.626 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -83.92 174.29 8.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 122.31 2.007 . . . . 0.0 113.031 -171.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 52.9 m -86.54 148.66 25.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 170.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.5 mp -119.55 133.0 55.86 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 120.892 -1.13 . . . . 0.0 109.421 175.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -109.82 116.27 31.35 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.539 -2.022 . . . . 0.0 105.539 171.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 mt -124.56 145.77 50.32 Favored Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 124.29 1.036 . . . . 0.0 112.456 -171.142 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -85.37 128.48 3.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.678 2.252 . . . . 0.0 107.909 171.172 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.26 151.99 2.63 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.859 1.264 . . . . 0.0 112.034 178.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.7 -31.8 2.19 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-O 119.203 -0.776 . . . . 0.0 113.701 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -46.84 148.6 1.02 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.567 1.147 . . . . 0.0 112.811 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 17.2 m -79.68 96.06 6.11 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.4 t -79.53 89.51 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 177.098 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -82.68 133.49 35.16 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 173.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.3 t -132.78 110.83 16.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.251 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 98.4 m -91.39 125.94 36.3 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 174.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -94.27 158.64 15.49 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 174.373 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.6 mp -137.41 67.57 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 102.577 -3.12 . . . . 0.0 102.577 163.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 20.8 t30 -98.09 76.67 2.39 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 -175.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.0 p -94.79 -80.14 0.41 Allowed 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.501 1.12 . . . . 0.0 109.923 -173.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 68.35 -50.71 0.55 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.253 2.221 . . . . 0.0 114.649 177.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 87.4 mttt 96.42 33.14 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 130.079 3.352 . . . . 0.0 111.877 -179.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 171.22 -60.03 0.17 Allowed Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -83.12 91.35 7.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.97 83.39 0.02 OUTLIER Glycine 0 CA--C 1.528 0.9 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 173.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -68.87 74.66 0.29 Allowed 'General case' 0 N--CA 1.457 -0.111 0 C-N-CA 125.177 1.391 . . . . 0.0 112.878 -174.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.8 p -42.29 136.38 2.31 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 125.253 1.421 . . . . 0.0 111.281 177.022 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -107.68 119.95 40.86 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 173.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASP . . . . . 0.538 ' HB3' HD12 ' A' ' 105' ' ' ILE . 5.3 m-20 -129.62 108.79 10.49 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -172.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 32.3 mt -80.72 134.79 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 124.144 0.903 . . . . 0.0 108.824 176.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -160.33 -160.45 0.78 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.433 1.493 . . . . 0.0 107.42 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -126.43 13.31 7.61 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.692 0.797 . . . . 0.0 111.517 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -64.7 121.34 14.28 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 174.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -86.66 170.72 42.49 Favored Glycine 0 CA--C 1.532 1.114 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.85 164.16 36.59 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.208 2.605 . . . . 0.0 109.674 173.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.42 139.12 58.36 Favored 'Cis proline' 0 N--CA 1.455 -0.75 0 N-CA-C 110.163 -0.745 . . . . 0.0 110.163 -4.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -79.68 151.27 30.58 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.179 0.514 . . . . 0.0 110.011 178.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -98.96 149.71 22.69 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 124.135 0.974 . . . . 0.0 110.27 -174.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 18.2 t -62.52 -34.62 65.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 C-N-CA 123.706 0.803 . . . . 0.0 109.218 173.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.6 mmt -78.24 133.97 63.66 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -63.8 63.79 0.21 Allowed 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.889 3.059 . . . . 0.0 115.232 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 13.9 t -80.84 57.5 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 O-C-N 120.254 -1.529 . . . . 0.0 108.325 174.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -38.07 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 C-N-CA 123.529 0.732 . . . . 0.0 111.721 -174.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.04 143.45 32.08 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 125.017 1.327 . . . . 0.0 112.278 -172.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.18 162.45 92.7 Favored 'Cis proline' 0 N--CA 1.46 -0.444 0 N-CA-C 110.281 -0.7 . . . . 0.0 110.281 -6.071 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 88' ' ' ASP . 14.5 mm -118.18 144.46 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 174.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.56 -86.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 174.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.41 87.64 6.09 Favored 'General case' 0 CA--C 1.52 -0.207 0 O-C-N 122.024 -0.423 . . . . 0.0 109.977 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -90.4 125.61 7.99 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 107.581 -2.208 . . . . 0.0 107.581 172.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.7 p -76.01 -41.48 50.97 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.261 1.531 . . . . 0.0 110.039 173.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.2 -170.09 21.25 Favored Glycine 0 CA--C 1.532 1.145 0 N-CA-C 108.673 -1.771 . . . . 0.0 108.673 -174.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -91.17 138.26 31.73 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.332 1.566 . . . . 0.0 109.215 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.0 p -83.21 159.31 62.48 Favored Pre-proline 0 CA--C 1.533 0.317 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -173.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.87 74.61 3.88 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.076 2.518 . . . . 0.0 107.987 172.658 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.8 m -53.67 128.9 54.1 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 123.278 0.631 . . . . 0.0 111.331 -175.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.98 176.36 9.92 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.286 2.657 . . . . 0.0 110.078 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.32 -29.38 6.24 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 176.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -174.02 155.85 2.6 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.715 2.006 . . . . 0.0 108.174 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.34 -59.05 1.15 Allowed Glycine 0 CA--C 1.527 0.789 0 C-N-CA 125.466 1.508 . . . . 0.0 113.06 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -78.92 158.77 27.98 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 123.417 0.687 . . . . 0.0 111.344 -174.521 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -135.23 94.42 3.12 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.804 2.041 . . . . 0.0 108.388 -174.145 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -53.27 113.29 2.84 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 173.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.1 p90 -119.32 177.03 5.05 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.537 1.135 . . . . 0.0 109.689 175.154 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.5 m -158.05 154.17 27.16 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 -177.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -131.82 89.54 2.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 173.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -96.9 170.08 9.41 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.8 m -150.79 146.56 26.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -150.56 153.53 35.94 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.884 0.874 . . . . 0.0 110.423 -176.024 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -116.47 114.44 40.33 Favored Pre-proline 0 CA--C 1.535 0.384 0 C-N-CA 125.584 1.554 . . . . 0.0 107.116 173.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.79 142.26 3.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 124.371 3.381 . . . . 0.0 111.503 -172.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.2 p -96.02 146.42 24.64 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 124.363 1.065 . . . . 0.0 108.845 173.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.83 149.08 19.08 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.164 0.438 . . . . 0.0 112.092 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 121.74 -123.96 5.63 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 126.754 2.121 . . . . 0.0 109.123 -175.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 46.1 m -153.84 145.7 23.49 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.351 1.075 . . . . 0.0 109.972 -174.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -132.95 176.45 8.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.336 2.254 . . . . 0.0 106.897 173.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -142.31 152.81 43.33 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 125.534 1.533 . . . . 0.0 107.551 175.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 55.1 p90 -114.83 140.59 48.82 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 123.223 0.609 . . . . 0.0 109.905 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.36 162.9 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.375 1.07 . . . . 0.0 111.093 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 8.8 t -107.69 136.09 48.02 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 127.121 2.169 . . . . 0.0 109.838 173.228 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -81.64 -19.0 42.65 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 -170.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.01 130.04 93.82 Favored Pre-proline 0 CA--C 1.544 0.721 0 CA-C-N 119.125 0.875 . . . . 0.0 108.989 -174.15 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -42.15 133.45 4.52 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.745 2.964 . . . . 0.0 113.424 178.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 90.07 -32.51 4.87 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.099 0.857 . . . . 0.0 111.795 -174.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -75.49 172.84 11.83 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -176.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 75.29 -60.6 0.5 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -170.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.2 -52.27 66.01 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.7 p -78.51 75.47 5.03 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 121.829 0.823 . . . . 0.0 112.272 -178.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 70.87 -44.71 0.67 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 118.189 2.035 . . . . 0.0 118.189 169.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' MET . . . . . 0.445 ' HB2' ' CD2' ' A' ' 54' ' ' PHE . 4.2 ptp -77.85 87.74 4.07 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 119.857 1.828 . . . . 0.0 114.271 -172.035 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -160.81 -179.91 7.97 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 126.053 1.741 . . . . 0.0 108.839 173.497 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 178.86 168.39 37.96 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 172.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -104.21 138.51 40.57 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 125.049 1.339 . . . . 0.0 108.356 -174.762 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.1 mt -114.76 100.44 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 19.6 t -84.16 136.37 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -123.02 115.65 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp . . . . . 0 N--CA 1.462 0.13 0 CA-C-N 119.091 0.86 . . . . 0.0 109.558 174.64 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.829 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.1 p -76.61 86.09 3.28 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 175.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.3 mp -57.31 147.67 25.02 Favored 'General case' 0 C--O 1.23 0.056 0 CA-C-O 122.035 0.922 . . . . 0.0 108.907 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.42 143.34 42.76 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.667 -173.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -121.12 12.11 11.03 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.67 1.988 . . . . 0.0 111.337 -174.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.2 m -79.16 66.57 4.64 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.568 1.147 . . . . 0.0 112.253 -171.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -96.34 146.83 24.4 Favored 'General case' 0 CA--C 1.522 -0.099 0 N-CA-C 114.875 1.435 . . . . 0.0 114.875 177.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -149.13 170.15 19.07 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 129.064 2.946 . . . . 0.0 103.706 171.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -124.8 126.55 45.79 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-N 119.645 1.111 . . . . 0.0 110.063 174.301 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -88.09 -150.22 0.18 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 172.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.9 p -142.39 166.07 25.7 Favored 'General case' 0 CA--C 1.532 0.274 0 O-C-N 121.389 -0.819 . . . . 0.0 109.277 174.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.45 -58.11 2.1 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -175.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -60.06 -28.84 87.9 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 CA-C-N 121.159 1.45 . . . . 0.0 112.224 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -66.83 -24.46 66.16 Favored 'General case' 0 N--CA 1.45 -0.465 0 O-C-N 121.462 -0.774 . . . . 0.0 111.013 177.461 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.0 t -63.34 -53.84 40.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -54.29 -42.81 70.47 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.468 178.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -58.25 -66.6 0.46 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.273 -0.267 . . . . 0.0 110.619 174.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 67.9 mtm -47.68 -50.2 25.55 Favored 'General case' 0 CA--C 1.528 0.1 0 C-N-CA 124.766 1.226 . . . . 0.0 112.182 -174.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.5 mt -47.14 -40.68 16.18 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.16 0.584 . . . . 0.0 112.192 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -67.86 -10.63 54.65 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.51 17.55 23.17 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.885 0.766 . . . . 0.0 110.999 175.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -65.6 106.06 1.37 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 119.132 0.878 . . . . 0.0 109.909 174.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.9 p -77.98 82.52 4.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.37 112.71 0.46 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 174.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.1 mmtp -78.98 162.78 25.72 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.793 1.237 . . . . 0.0 109.863 -177.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.4 t -69.11 141.42 17.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.653 1.181 . . . . 0.0 109.59 -178.4 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.5 m -147.85 67.22 1.1 Allowed 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.363 -0.835 . . . . 0.0 109.593 174.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.06 -94.66 0.12 Allowed Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.827 0.727 . . . . 0.0 111.785 175.022 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -109.19 25.54 11.68 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.856 1.663 . . . . 0.0 110.118 178.202 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -154.99 163.12 40.75 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -174.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.09 147.17 23.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.137 -1.801 . . . . 0.0 106.137 173.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.6 m -142.15 138.23 31.45 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 119.259 0.936 . . . . 0.0 111.168 -171.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -112.07 -167.88 1.24 Allowed 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.331 0.514 . . . . 0.0 111.522 173.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.3 m -157.75 -47.77 0.06 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.732 0.813 . . . . 0.0 112.268 -173.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.08 156.35 53.37 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 177.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -79.18 40.6 0.42 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.289 -1.124 . . . . 0.0 112.323 -174.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.3 m -156.18 102.31 2.12 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 120.771 -1.206 . . . . 0.0 107.877 -178.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.2 t -104.73 84.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -82.47 93.36 7.23 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 t -93.99 159.65 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.4 t -133.68 106.93 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 C-N-CA 124.97 1.308 . . . . 0.0 108.045 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -112.74 103.48 11.5 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.416 1.487 . . . . 0.0 109.836 -174.576 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.03 112.0 23.71 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.276 0.63 . . . . 0.0 109.304 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.57 102.87 15.55 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.502 -0.749 . . . . 0.0 110.15 -174.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.6 t 49.32 82.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 125.613 1.565 . . . . 0.0 112.389 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.3 mt -76.58 141.6 69.41 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 174.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -56.22 113.85 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 123.093 2.529 . . . . 0.0 110.315 -174.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 128.19 -41.41 1.58 Allowed Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -174.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -81.14 146.05 57.75 Favored Pre-proline 0 N--CA 1.454 -0.238 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.025 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -75.71 152.28 37.37 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.513 2.142 . . . . 0.0 111.628 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -70.29 156.36 91.98 Favored Pre-proline 0 N--CA 1.453 -0.307 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 172.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -109.86 65.09 0.34 Allowed 'Cis proline' 0 N--CA 1.455 -0.766 0 N-CA-C 107.115 -1.917 . . . . 0.0 107.115 -5.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 59.1 p -86.45 123.07 31.27 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 116.581 2.067 . . . . 0.0 116.581 -171.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -83.47 94.24 7.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 168.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -81.79 115.91 21.23 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -175.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.5 t -114.09 82.55 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 125.067 1.347 . . . . 0.0 109.479 -173.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.418 ' CG ' ' N ' ' A' ' 58' ' ' ASP . 1.0 OUTLIER 46.83 -69.21 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.594 3.557 . . . . 0.0 115.221 176.239 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.418 ' N ' ' CG ' ' A' ' 57' ' ' HIS . 21.2 t70 -95.51 -28.08 15.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.153 1.781 . . . . 0.0 110.838 -176.054 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -132.19 -176.92 4.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 123.787 0.835 . . . . 0.0 109.285 -176.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -134.4 121.27 20.9 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 175.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.64 43.41 0.9 Allowed Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 124.897 1.279 . . . . 0.0 111.18 -177.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.59 177.74 6.71 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 121.711 1.608 . . . . 0.0 111.412 -175.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.7 m -93.47 138.04 32.17 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 170.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.0 mp -111.3 140.17 46.09 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.111 0.964 . . . . 0.0 109.939 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -112.88 120.9 43.05 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.603 1.161 . . . . 0.0 108.167 172.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 16.5 mt -128.01 146.54 59.6 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -170.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -72.06 123.11 9.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.608 2.205 . . . . 0.0 110.587 170.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.39 134.65 28.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 124.22 1.008 . . . . 0.0 110.57 173.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.98 0.43 75.76 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 118.764 -1.02 . . . . 0.0 113.157 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.06 146.63 52.82 Favored 'General case' 0 N--CA 1.456 -0.169 0 CA-C-N 119.847 1.824 . . . . 0.0 109.628 173.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 58.5 m -78.37 99.76 6.5 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.25 134.71 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -139.47 95.07 2.86 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.754 1.621 . . . . 0.0 106.729 173.081 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.7 t -80.11 106.02 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 174.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.0 m -79.47 109.0 13.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -76.93 150.34 35.95 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.478 172.587 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.408 ' O ' HG22 ' A' ' 77' ' ' ILE . 1.2 mp -132.74 69.1 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 165.426 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -102.3 77.94 1.7 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 -175.089 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.1 p -118.51 20.21 13.07 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.108 1.763 . . . . 0.0 112.627 -171.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -70.0 103.36 2.24 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 173.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -46.78 134.81 9.58 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.683 0.793 . . . . 0.0 111.692 -173.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.23 -59.45 3.6 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -174.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -78.89 67.8 4.69 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.338 0.655 . . . . 0.0 111.046 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.29 92.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.267 -1.933 . . . . 0.0 108.267 172.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.53 179.47 0.16 Allowed 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.059 0.944 . . . . 0.0 110.637 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 p -137.92 147.9 44.8 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.439 -2.06 . . . . 0.0 105.439 177.315 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -127.02 104.18 7.85 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 173.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASP . . . . . 0.499 ' HB3' HD12 ' A' ' 105' ' ' ILE . 60.3 m-20 -120.62 127.24 51.91 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.989 0.916 . . . . 0.0 108.877 -174.207 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.2 mt -98.46 129.74 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 C-N-CA 125.999 1.719 . . . . 0.0 108.579 -174.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.96 -151.08 0.22 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.581 1.153 . . . . 0.0 108.153 -173.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt -133.92 -88.04 0.4 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.821 0.849 . . . . 0.0 109.783 178.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.6 mtmt 49.15 -126.74 2.09 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.216 1.006 . . . . 0.0 109.169 -173.367 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -175.65 161.88 30.92 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.191 -1.563 . . . . 0.0 109.191 175.046 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.82 154.44 30.17 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.613 2.876 . . . . 0.0 109.75 174.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.14 144.92 82.56 Favored 'Cis proline' 0 N--CA 1.453 -0.872 0 N-CA-C 108.994 -1.194 . . . . 0.0 108.994 -5.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -78.44 163.67 25.42 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-O 121.375 0.607 . . . . 0.0 110.054 -176.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.24 145.13 42.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.563 -173.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -49.56 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 174.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -78.79 149.55 74.34 Favored Pre-proline 0 CA--C 1.534 0.346 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.317 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -72.6 73.62 2.84 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.829 2.352 . . . . 0.0 111.494 -179.399 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 16.6 t -79.28 53.24 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 173.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.2 pt -84.33 68.71 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-O 122.874 1.321 . . . . 0.0 109.787 -176.085 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -88.48 -72.69 0.06 OUTLIER Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 113.743 -1.571 . . . . 0.0 110.597 -174.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -77.77 57.76 6.17 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 122.208 1.939 . . . . 0.0 111.48 -178.418 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 88' ' ' ASP . 24.8 mm -78.41 126.56 38.64 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 O-C-N 121.228 -0.92 . . . . 0.0 108.8 177.392 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.1 t -84.78 -88.18 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.62 164.29 12.84 Favored 'General case' 0 CA--C 1.521 -0.162 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 173.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 172.26 -179.14 44.04 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 119.297 -1.43 . . . . 0.0 112.556 173.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 6.0 p -130.84 138.82 50.03 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 126.272 1.829 . . . . 0.0 108.749 176.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -75.04 -127.77 0.19 Allowed Glycine 0 CA--C 1.534 1.275 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 174.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -112.15 154.47 25.44 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 119.659 1.729 . . . . 0.0 110.465 176.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.6 p -90.31 155.83 46.33 Favored Pre-proline 0 N--CA 1.449 -0.488 0 C-N-CA 124.927 1.291 . . . . 0.0 112.397 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.52 98.82 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.192 0 C-N-CA 122.981 2.454 . . . . 0.0 107.468 173.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 40.3 t -37.85 123.49 1.0 Allowed Pre-proline 0 CA--C 1.538 0.502 0 C-N-CA 125.222 1.409 . . . . 0.0 110.421 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -67.79 156.71 64.91 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.66 2.24 . . . . 0.0 112.847 -172.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 29.2 mmmt -110.2 175.94 5.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 125.717 1.607 . . . . 0.0 106.824 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -36.91 104.02 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 125.119 1.368 . . . . 0.0 114.07 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.31 -8.5 46.33 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-O 118.456 -1.191 . . . . 0.0 115.148 173.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -84.48 156.0 21.92 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.866 1.333 . . . . 0.0 109.744 -178.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -139.37 94.17 2.76 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.373 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.6 116.14 4.5 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.214 1.387 . . . . 0.0 113.06 174.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -130.46 154.79 47.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.26 1.024 . . . . 0.0 111.486 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.8 m -145.36 118.84 9.05 Favored 'General case' 0 CA--C 1.518 -0.278 0 C-N-CA 124.419 1.088 . . . . 0.0 109.646 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -95.27 88.28 5.1 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 171.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -89.65 122.97 33.28 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 21.8 m -82.91 142.08 31.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.885 -174.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -151.38 155.77 39.33 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.458 1.103 . . . . 0.0 109.423 175.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 65.2 m80 -123.78 108.85 30.49 Favored Pre-proline 0 CA--C 1.532 0.288 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 173.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -89.57 144.24 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.909 3.073 . . . . 0.0 111.019 -172.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.8 p -95.86 155.02 16.92 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.052 0.941 . . . . 0.0 109.549 173.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -60.88 149.25 36.82 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -175.473 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 126.67 -128.04 6.17 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 126.39 1.948 . . . . 0.0 108.684 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 32.1 m -152.99 141.95 21.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 118.451 1.125 . . . . 0.0 110.201 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -128.29 174.84 8.95 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.893 1.677 . . . . 0.0 107.828 173.435 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -134.74 147.17 49.98 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.124 1.37 . . . . 0.0 107.904 174.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -109.06 142.88 39.15 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.561 0.745 . . . . 0.0 109.291 174.083 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 33.0 m -143.95 165.3 14.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 124.528 1.131 . . . . 0.0 111.452 -177.371 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.2 t -118.76 135.04 54.72 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 126.634 1.974 . . . . 0.0 110.091 173.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 64.9 mt-30 -64.47 -50.9 65.66 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 125.015 1.326 . . . . 0.0 113.49 -174.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 71.4 mt -39.95 121.91 1.55 Allowed Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 124.711 1.204 . . . . 0.0 111.526 -170.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -31.79 120.22 0.08 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.886 1 C-N-CA 125.472 4.115 . . . . 0.0 115.711 -173.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 86.74 -25.05 7.77 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 118.888 -0.951 . . . . 0.0 113.481 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 22.4 m170 -54.68 -59.99 3.97 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.203 1.501 . . . . 0.0 111.548 -172.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -49.12 -56.37 9.35 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.138 0.575 . . . . 0.0 110.934 177.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.27 -46.66 79.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.914 0.886 . . . . 0.0 112.336 -175.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.7 p -79.23 -36.31 40.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 113.186 0.809 . . . . 0.0 113.186 -172.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.56 -18.82 0.03 OUTLIER Glycine 0 C--N 1.34 0.771 0 C-N-CA 118.442 -1.837 . . . . 0.0 116.443 -175.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.4 ttt -79.73 65.11 4.8 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.093 1.446 . . . . 0.0 109.681 -174.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -161.53 167.96 24.47 Favored 'General case' 0 C--O 1.225 -0.236 0 C-N-CA 123.035 0.534 . . . . 0.0 111.53 -178.097 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -174.22 169.34 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 176.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -94.5 151.68 19.16 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.637 1.175 . . . . 0.0 110.526 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.4 mt -125.22 94.0 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 173.461 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.2 t -80.26 136.59 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 173.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.2 t -127.39 127.65 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 -176.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 49.8 mttp . . . . . 0 N--CA 1.464 0.243 0 CA-C-N 119.043 0.838 . . . . 0.0 111.383 -176.813 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.45 -0.464 0 N-CA-C 110.454 -0.202 . . . . 0.0 110.454 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.4 m -79.2 61.51 3.34 Favored 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.37 -0.831 . . . . 0.0 110.115 -178.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.7 m95 -79.46 136.16 36.85 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.988 1.715 . . . . 0.0 110.572 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -149.92 171.38 16.89 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -139.64 127.89 22.59 Favored 'General case' 0 C--N 1.341 0.213 0 CA-C-N 118.826 0.739 . . . . 0.0 109.826 171.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.17 -152.47 0.43 Allowed 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 125.551 1.54 . . . . 0.0 107.121 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.2 p -136.64 170.99 15.16 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 124.179 0.992 . . . . 0.0 108.482 173.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -39.06 -55.17 3.03 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 114.528 1.306 . . . . 0.0 114.528 -174.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -55.45 -33.53 86.27 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.517 1.478 . . . . 0.0 113.633 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -68.67 -29.36 67.81 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 119.118 0.872 . . . . 0.0 111.072 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 t -62.13 -50.2 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 174.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -54.43 -49.3 70.31 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.55 -61.53 2.14 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.034 0.534 . . . . 0.0 111.066 176.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 74.4 mtm -55.14 -45.84 75.65 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.202 0.601 . . . . 0.0 110.801 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.3 mt -53.28 -38.01 62.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.19 -0.433 . . . . 0.0 111.747 176.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -72.0 -45.69 60.0 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 175.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.5 mtpt -80.31 62.36 4.42 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 122.709 0.404 . . . . 0.0 110.791 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -134.94 134.64 40.8 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.375 1.07 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.2 p -96.48 24.02 6.27 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.935 0.894 . . . . 0.0 112.951 -175.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.21 100.0 2.43 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 125.727 1.632 . . . . 0.0 110.986 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -78.51 159.13 28.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.626 1.171 . . . . 0.0 109.322 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 63.2 t -93.53 93.47 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.715 0.806 . . . . 0.0 110.34 -174.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.3 p -77.74 70.47 4.12 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 60.98 -96.72 0.11 Allowed Glycine 0 CA--C 1.527 0.835 0 C-N-CA 124.741 1.162 . . . . 0.0 111.045 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -86.98 -36.61 18.16 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.027 0.931 . . . . 0.0 110.543 178.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.3 m -89.88 166.54 13.45 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.728 1.611 . . . . 0.0 108.787 -172.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.12 144.17 18.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 172.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.7 m -134.07 117.36 16.54 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.687 1.195 . . . . 0.0 108.236 -175.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 -79.59 162.25 25.43 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.182 0.515 . . . . 0.0 110.778 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 67.2 m -154.24 159.59 41.39 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.103 0.961 . . . . 0.0 108.629 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.22 165.23 29.43 Favored Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 -174.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.2 mtpm? -73.54 -18.28 61.1 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 122.004 -0.704 . . . . 0.0 111.753 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.4 p -95.68 87.63 4.75 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.132 0.973 . . . . 0.0 109.064 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.0 t -81.84 77.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -86.3 87.65 7.47 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.089 -175.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.67 95.87 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 124.39 1.076 . . . . 0.0 109.173 -174.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.65 109.99 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 175.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -127.84 164.28 22.56 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.827 1.251 . . . . 0.0 109.365 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.77 167.43 24.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 176.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -136.18 114.03 11.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -174.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.7 t 34.38 69.01 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 C-N-CA 127.11 2.164 . . . . 0.0 112.339 174.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 90.9 mt -76.67 144.98 74.22 Favored Pre-proline 0 N--CA 1.453 -0.286 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo . . . . . 0 N--CA 1.457 -0.633 0 C-N-CA 123.21 2.607 . . . . 0.0 110.947 -174.585 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 . . . . . 0 CA--C 1.538 0.486 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -112.38 7.32 3.12 Favored 'Cis proline' 0 CA--C 1.535 0.532 0 CA-C-N 119.641 0.907 . . . . 0.0 113.09 0.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.4 p -83.71 154.9 23.38 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 115.043 1.497 . . . . 0.0 115.043 -171.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -79.37 139.06 37.86 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.747 1.219 . . . . 0.0 109.526 173.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.94 132.38 34.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 123.922 0.889 . . . . 0.0 110.094 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.569 HG23 HD21 ' A' ' 61' ' ' ASN . 17.2 t -125.97 83.47 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 172.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 55.7 p-80 42.08 -78.59 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 128.587 2.755 . . . . 0.0 115.008 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -84.37 -24.81 29.53 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 124.18 0.992 . . . . 0.0 111.723 -176.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -130.83 -174.9 3.5 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.584 1.153 . . . . 0.0 109.58 -174.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -128.91 92.1 3.34 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.569 HD21 HG23 ' A' ' 56' ' ' VAL . 9.9 m-80 26.73 69.82 0.45 Allowed Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 127.459 2.303 . . . . 0.0 115.882 -174.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -66.41 -55.56 0.36 Allowed 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.537 2.158 . . . . 0.0 108.674 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.2 m 169.53 154.63 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 129.257 3.023 . . . . 0.0 105.697 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.3 mp -117.22 124.79 49.95 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.969 1.308 . . . . 0.0 110.204 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -98.42 137.09 37.63 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 171.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.08 136.0 25.4 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.213 1.005 . . . . 0.0 110.867 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -76.47 112.06 3.38 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.705 2.937 . . . . 0.0 109.271 173.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.39 -41.37 9.06 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -173.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -72.75 -7.51 69.92 Favored Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.41 -0.661 . . . . 0.0 114.068 -175.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -85.94 165.07 17.04 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.741 1.271 . . . . 0.0 113.38 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 63.1 m -93.72 127.41 39.42 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 172.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 94.9 t -92.13 132.29 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -127.77 108.1 10.44 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.752 -1.574 . . . . 0.0 106.752 173.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.09 115.36 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 16.4 m -107.71 96.01 6.09 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 126.059 1.743 . . . . 0.0 107.181 174.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . 0.279 4.3 m-85 -78.79 151.57 31.9 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 172.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -127.79 69.6 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 102.595 -3.113 . . . . 0.0 102.595 162.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -80.64 113.08 18.58 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 171.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 52.3 m -137.93 45.38 2.13 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -78.55 113.71 16.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 172.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -72.8 69.8 0.95 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.166 0.586 . . . . 0.0 110.113 -178.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 174.43 -67.72 0.1 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -96.71 122.69 39.93 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -174.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.26 71.03 0.63 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.864 -1.695 . . . . 0.0 108.864 171.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -57.06 143.82 36.9 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.511 1.156 . . . . 0.0 111.356 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.3 p -106.76 161.25 14.84 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 125.435 1.494 . . . . 0.0 108.845 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -129.89 101.11 5.71 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 102.755 -3.054 . . . . 0.0 102.755 172.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -118.89 114.44 22.61 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -173.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 6.7 mt -95.2 125.31 47.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 C-N-CA 125.44 1.496 . . . . 0.0 110.297 -174.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -161.17 -145.46 0.11 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -113.0 -98.95 0.43 Allowed 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 174.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt 67.42 -67.32 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.887 1.275 . . . . 0.0 111.184 -174.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.78 170.35 28.9 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -174.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -75.1 147.01 32.99 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.634 2.223 . . . . 0.0 109.388 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.82 136.76 45.48 Favored 'Cis proline' 0 N--CA 1.454 -0.813 0 CA-C-N 119.48 0.85 . . . . 0.0 109.995 -5.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -79.03 149.24 32.24 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.93 144.03 39.12 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 121.188 0.518 . . . . 0.0 112.155 -173.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.15 -43.28 98.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.9 mtp -78.1 133.18 65.33 Favored Pre-proline 0 N--CA 1.45 -0.425 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 173.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -75.65 85.24 1.63 Allowed 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.669 1.579 . . . . 0.0 109.307 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.8 t -76.41 105.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -178.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 23.4 pt -78.91 72.98 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 123.241 1.495 . . . . 0.0 110.534 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -62.57 154.5 73.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 113.328 -1.76 . . . . 0.0 106.398 171.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_exo -37.62 104.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 124.031 3.154 . . . . 0.0 113.835 -176.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 31.4 mm -78.95 131.27 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.97 -88.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 104.753 -2.314 . . . . 0.0 104.753 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.3 150.3 20.72 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 170.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.89 168.08 39.8 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.8 174.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 2.8 p -120.77 127.61 52.13 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.291 1.036 . . . . 0.0 109.991 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.62 57.0 5.04 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 119.502 -0.61 . . . . 0.0 111.985 -176.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 73.33 99.68 0.07 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 126.256 1.822 . . . . 0.0 111.488 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.3 p -74.13 160.32 81.87 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 118.767 -0.635 . . . . 0.0 110.578 -176.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 169.08 2.07 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 123.559 2.839 . . . . 0.0 116.032 -173.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 92.6 t -121.38 97.08 47.54 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 126.641 1.976 . . . . 0.0 107.627 178.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.554 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 37.4 Cg_exo -70.52 -179.77 3.5 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.936 3.091 . . . . 0.0 114.005 -176.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -109.88 -164.87 0.96 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.814 1.646 . . . . 0.0 107.305 172.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -60.99 153.43 25.18 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.518 -0.739 . . . . 0.0 111.003 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.71 3.1 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 123.808 0.718 . . . . 0.0 113.276 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -80.02 156.06 27.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.196 0.598 . . . . 0.0 111.798 -175.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -135.88 106.87 6.68 Favored 'General case' 0 CA--C 1.513 -0.456 0 C-N-CA 125.677 1.591 . . . . 0.0 110.289 -172.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.554 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -64.41 123.27 27.09 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.269 -1.932 . . . . 0.0 108.269 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -130.98 165.04 24.04 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 122.127 0.965 . . . . 0.0 109.886 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.0 m -152.62 120.76 6.23 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -103.57 104.6 14.68 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -118.74 147.74 43.53 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 28.6 m -104.14 152.05 22.58 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.804 0.842 . . . . 0.0 109.731 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -151.38 147.72 27.25 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.824 1.25 . . . . 0.0 109.161 175.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 44.8 m80 -116.15 111.37 42.64 Favored Pre-proline 0 N--CA 1.454 -0.256 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 172.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -82.64 -170.98 1.03 Allowed 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.892 2.395 . . . . 0.0 110.688 -173.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.0 p -140.95 147.9 39.53 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.69 152.46 35.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -174.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.55 -129.68 8.14 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 126.508 2.004 . . . . 0.0 108.982 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.8 m -142.82 137.48 29.69 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 117.437 0.618 . . . . 0.0 109.667 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.4 m-85 -130.42 176.75 7.88 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.484 1.914 . . . . 0.0 106.182 172.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -142.53 147.85 36.64 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 173.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -115.21 147.03 40.84 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 172.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.2 m -144.96 154.46 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 125.042 1.337 . . . . 0.0 109.735 -174.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.43 107.64 19.8 Favored 'General case' 0 C--N 1.333 -0.125 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 171.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.1 mm-40 -74.72 38.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -174.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 16.5 mt -93.24 142.73 25.67 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 104.305 -2.479 . . . . 0.0 104.305 168.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -48.24 138.85 22.48 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.028 1.818 . . . . 0.0 112.94 178.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.0 -46.67 2.45 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.312 0.958 . . . . 0.0 113.193 176.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.2 m170 -42.55 -55.8 3.34 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.814 1.646 . . . . 0.0 113.882 -173.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.88 -53.54 57.02 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.71 0.29 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.71 -38.67 88.72 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 124.117 0.967 . . . . 0.0 111.684 -176.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 31.0 p -78.31 -32.32 49.24 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 118.731 -0.652 . . . . 0.0 111.293 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.12 -30.61 0.1 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 118.355 -1.879 . . . . 0.0 116.234 173.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.315 10.3 ptp -80.4 84.46 6.03 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 120.053 1.927 . . . . 0.0 112.707 -174.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -141.93 174.49 10.54 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 126.532 1.933 . . . . 0.0 107.296 172.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -156.28 128.28 2.18 Favored Glycine 0 C--N 1.331 0.285 0 N-CA-C 108.482 -1.847 . . . . 0.0 108.482 173.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -76.99 130.12 37.05 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 174.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.0 mt -110.87 100.91 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 25.7 t -88.84 110.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 174.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.8 t -97.66 94.66 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 63.9 mttp . . . . . 0 C--N 1.332 -0.165 0 O-C-N 121.525 -0.734 . . . . 0.0 109.041 176.373 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.6 p . . . . . 0 CA--C 1.537 0.457 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.9 m -78.05 68.93 4.19 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 32.6 m95 -103.45 129.01 50.5 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 126.853 2.061 . . . . 0.0 109.772 -176.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -151.92 178.4 9.45 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -131.27 127.04 36.96 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 171.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.75 -150.62 0.27 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.6 p -137.34 170.41 16.13 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 119.475 1.034 . . . . 0.0 108.563 172.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.6 tt -39.53 -55.74 3.23 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 124.316 1.046 . . . . 0.0 113.582 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -56.54 -33.23 92.29 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 CA-C-N 121.011 1.397 . . . . 0.0 113.861 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -64.94 -25.25 67.8 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 118.946 0.794 . . . . 0.0 111.452 177.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.2 t -53.91 -46.94 64.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.651 0.659 . . . . 0.0 109.277 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 mtmm -59.12 -54.17 50.04 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.27 -47.66 62.42 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.84 0.456 . . . . 0.0 111.378 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -62.3 -54.78 35.65 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 119.47 -0.3 . . . . 0.0 110.672 177.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.6 mt -50.58 -47.8 57.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 118.423 0.556 . . . . 0.0 111.392 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -54.06 -25.94 24.19 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.003 0.921 . . . . 0.0 113.093 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -88.21 -9.12 54.06 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 118.9 0.773 . . . . 0.0 112.116 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -49.48 145.8 4.52 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -176.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.7 p -121.0 166.4 13.9 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.599 1.159 . . . . 0.0 108.851 171.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.69 116.71 2.92 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 124.521 1.058 . . . . 0.0 110.787 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 49.4 mtmt -81.68 144.35 31.24 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.558 1.143 . . . . 0.0 108.989 176.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 81.4 t -67.78 145.32 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 122.781 0.432 . . . . 0.0 110.603 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.9 m -150.82 68.95 0.96 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.767 1.227 . . . . 0.0 109.132 174.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.28 -115.45 7.14 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -79.01 -31.22 44.63 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 118.054 0.927 . . . . 0.0 109.109 172.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -79.54 153.39 29.56 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.742 -173.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -120.47 135.32 61.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 171.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 74.2 m -121.7 133.49 54.95 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.302 1.041 . . . . 0.0 110.459 -169.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 79.2 m-85 -105.55 177.72 4.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 124.086 0.954 . . . . 0.0 109.589 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.8 m -154.36 -50.0 0.09 Allowed 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.468 0.707 . . . . 0.0 109.609 177.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -65.63 145.22 48.2 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -60.6 -31.69 70.84 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.179 0.592 . . . . 0.0 111.088 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.8 m -78.1 76.21 4.62 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -78.04 102.59 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 30.9 t-80 -106.95 102.94 12.26 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 123.818 0.847 . . . . 0.0 109.563 -178.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 86.0 t -99.89 151.03 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 125.231 1.413 . . . . 0.0 108.777 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.6 t -130.72 100.49 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 124.618 1.167 . . . . 0.0 108.494 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -106.14 155.46 19.42 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 125.362 1.465 . . . . 0.0 110.731 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.73 158.41 44.01 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 124.511 1.125 . . . . 0.0 109.3 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.84 117.77 24.86 Favored 'General case' 0 N--CA 1.456 -0.157 0 C-N-CA 123.556 0.742 . . . . 0.0 111.032 -173.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.9 t 42.29 66.92 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 C-N-CA 125.323 1.449 . . . . 0.0 111.618 173.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.5 mt -77.88 153.43 80.44 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo . . . . . 0 N--CA 1.456 -0.716 0 C-N-CA 123.054 2.502 . . . . 0.0 111.704 175.58 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 . . . . . 0 CA--C 1.533 0.309 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -111.69 67.48 0.23 Allowed 'Cis proline' 0 N--CA 1.455 -0.791 0 N-CA-C 107.726 -1.682 . . . . 0.0 107.726 -6.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 79.0 p -92.19 133.66 35.59 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -86.34 122.4 30.25 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 169.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -93.32 131.01 38.87 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 104.57 -2.382 . . . . 0.0 104.57 171.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.5 t -137.5 114.92 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 120.226 1.375 . . . . 0.0 110.61 -173.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 36.79 -114.31 0.1 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.771 1.628 . . . . 0.0 112.837 -178.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -81.61 7.1 13.08 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -174.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -146.66 -169.77 3.36 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.526 1.13 . . . . 0.0 110.518 -172.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? -135.22 128.14 31.38 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 172.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 45.99 49.86 7.21 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 125.076 1.35 . . . . 0.0 111.963 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -81.71 173.7 11.05 Favored 'Trans proline' 0 N--CA 1.452 -0.942 0 C-N-CA 122.811 2.34 . . . . 0.0 111.998 -174.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.4 m -94.92 144.8 25.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 113.923 -1.49 . . . . 0.0 107.123 172.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.6 mp -113.23 139.47 48.76 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.093 -1.005 . . . . 0.0 109.983 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -115.37 98.75 6.92 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.531 1.533 . . . . 0.0 107.739 173.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.8 mt -101.16 138.08 19.87 Favored Pre-proline 0 CA--C 1.535 0.379 0 C-N-CA 126.408 1.883 . . . . 0.0 110.788 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.85 123.48 6.33 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 122.384 2.056 . . . . 0.0 107.65 171.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.64 138.46 17.98 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.578 0.751 . . . . 0.0 111.645 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 85.75 -1.57 88.04 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.521 -0.599 . . . . 0.0 112.691 -176.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.41 21.48 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 118.759 1.279 . . . . 0.0 112.065 174.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 89.3 m -91.73 91.3 7.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 171.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.0 t -79.15 99.46 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.298 1.039 . . . . 0.0 108.633 -172.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -98.64 107.35 19.78 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 126.113 1.765 . . . . 0.0 107.854 -178.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.1 t -101.83 116.92 46.33 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.0 m -88.25 137.29 32.45 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.21 146.33 39.49 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 123.712 0.805 . . . . 0.0 111.735 174.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.17 59.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 N-CA-C 101.222 -3.622 . . . . 0.0 101.222 163.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -92.93 73.2 4.81 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 104.635 -2.357 . . . . 0.0 104.635 -174.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.7 p -95.25 -77.46 0.47 Allowed 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.95 -171.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 51.71 -142.47 0.73 Allowed 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -172.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.4 mtpm? -149.01 123.58 9.76 Favored 'General case' 0 C--N 1.34 0.174 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.31 -55.19 3.22 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 118.883 0.765 . . . . 0.0 112.054 178.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -77.64 84.92 3.98 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 121.73 -0.865 . . . . 0.0 109.804 -174.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.26 75.59 0.01 OUTLIER Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.513 1.054 . . . . 0.0 110.697 172.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -55.51 163.81 1.18 Allowed 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.448 1.124 . . . . 0.0 110.096 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 93.0 p -131.91 165.95 22.74 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -132.31 93.03 3.18 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -98.38 130.76 45.03 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.748 1.219 . . . . 0.0 107.781 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 21.8 mt -102.49 133.53 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 124.635 1.174 . . . . 0.0 109.289 -173.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.9 t -157.88 -161.36 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -129.05 -0.0 5.24 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 124.324 1.05 . . . . 0.0 111.695 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -66.52 129.42 39.8 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -84.61 168.66 44.09 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 174.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -69.84 160.82 48.28 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.288 2.659 . . . . 0.0 110.114 174.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -75.74 163.96 89.08 Favored 'Cis proline' 0 N--CA 1.455 -0.745 0 N-CA-C 110.502 -0.615 . . . . 0.0 110.502 -4.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -111.14 152.79 26.59 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 176.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.16 153.32 34.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.3 t -59.11 -39.2 77.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 62.1 mtt -78.15 117.66 67.45 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.92 113.81 1.73 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.448 2.098 . . . . 0.0 111.924 -175.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 19.1 t -79.81 66.99 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 7.5 pt -79.42 -21.56 12.37 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.183 0 N-CA-C 115.145 1.535 . . . . 0.0 115.145 -172.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -49.55 -59.03 7.41 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 119.18 0.9 . . . . 0.0 111.597 177.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.92 62.7 6.64 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 122.796 2.33 . . . . 0.0 112.766 174.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.5 mm -113.62 145.77 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 172.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 48.9 t -97.19 -94.69 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 177.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.48 -176.5 3.95 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.76 0.824 . . . . 0.0 109.673 174.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.93 174.91 36.6 Favored Glycine 0 N--CA 1.443 -0.847 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 175.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 73.2 p -85.5 -50.68 7.06 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.354 0.597 . . . . 0.0 109.726 174.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 96.17 -176.79 33.3 Favored Glycine 0 CA--C 1.535 1.34 0 N-CA-C 105.559 -3.016 . . . . 0.0 105.559 -168.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -77.38 139.01 39.63 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.286 1.043 . . . . 0.0 109.667 -179.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.7 p -88.83 156.09 49.9 Favored Pre-proline 0 CA--C 1.537 0.451 0 N-CA-C 115.037 1.495 . . . . 0.0 115.037 -172.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.63 89.12 1.36 Allowed 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.321 2.681 . . . . 0.0 107.336 171.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 30.6 m -53.71 163.3 1.11 Allowed Pre-proline 0 CA--C 1.545 0.76 0 C-N-CA 124.774 1.23 . . . . 0.0 113.563 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.72 144.07 66.95 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 123.313 2.675 . . . . 0.0 113.775 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -108.62 21.77 16.82 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.851 1.26 . . . . 0.0 108.627 171.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 50.4 t0 79.31 139.7 0.07 Allowed 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 128.558 2.743 . . . . 0.0 107.953 -171.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 73.39 -50.03 1.64 Allowed Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.572 0.606 . . . . 0.0 112.102 -173.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -79.22 153.53 29.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.045 0.938 . . . . 0.0 112.194 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -130.23 95.68 3.97 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 127.233 2.213 . . . . 0.0 108.986 -173.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -45.54 112.87 0.84 Allowed Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.752 1.168 . . . . 0.0 111.506 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -131.63 175.21 9.37 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 122.504 1.145 . . . . 0.0 110.998 -176.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -167.84 156.13 9.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -141.11 90.91 2.35 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 172.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -110.23 153.53 24.68 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 25.0 m -118.5 140.91 49.13 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 124.659 1.184 . . . . 0.0 110.237 -173.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 2.8 p-90 -146.86 161.31 40.96 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.896 0.878 . . . . 0.0 110.676 174.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -133.71 89.18 31.29 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 125.467 1.507 . . . . 0.0 108.306 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -78.98 151.71 24.2 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.579 2.186 . . . . 0.0 110.239 -176.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.5 p -79.63 164.54 23.71 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.974 0.51 . . . . 0.0 110.172 174.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -67.02 157.03 34.48 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.939 -0.476 . . . . 0.0 111.976 -176.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.33 -118.86 4.1 Favored Glycine 0 C--N 1.335 0.499 0 C-N-CA 126.123 1.821 . . . . 0.0 109.084 -178.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -149.72 127.77 11.95 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.833 0.817 . . . . 0.0 109.606 -178.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -110.03 171.61 7.35 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 127.494 2.318 . . . . 0.0 106.912 174.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -142.0 144.11 33.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.867 1.267 . . . . 0.0 108.517 177.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -107.33 134.14 50.84 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.2 m -138.34 144.01 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 C-N-CA 124.218 1.007 . . . . 0.0 109.35 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.2 t -86.21 139.8 30.72 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -113.24 36.52 3.51 Favored 'General case' 0 CA--C 1.523 -0.088 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 -171.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 45.6 mt -91.59 133.54 30.91 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 103.798 -2.667 . . . . 0.0 103.798 168.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -39.11 128.37 1.41 Allowed 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.751 2.967 . . . . 0.0 113.968 -176.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.33 -23.59 5.35 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 118.981 -0.899 . . . . 0.0 114.337 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -62.25 -53.32 56.91 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 120.079 1.939 . . . . 0.0 111.62 -172.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -55.31 -48.51 74.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.896 -0.503 . . . . 0.0 110.559 175.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.96 -40.4 80.48 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.768 0.827 . . . . 0.0 111.923 -176.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 19.1 p -78.2 -40.48 37.42 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 119.054 -0.498 . . . . 0.0 109.997 -178.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 147.08 20.58 0.1 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 115.9 1.12 . . . . 0.0 115.9 172.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 15.6 ttt -80.02 76.71 6.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 119.66 1.73 . . . . 0.0 107.709 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.71 6.29 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 122.812 0.445 . . . . 0.0 111.734 -174.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -175.68 165.81 36.78 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 171.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -104.29 147.76 27.13 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 124.39 1.076 . . . . 0.0 109.341 -173.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.9 mt -128.18 96.84 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.5 131.9 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 174.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 35.2 t -118.66 93.93 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 106.995 -1.483 . . . . 0.0 106.995 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--N 1.332 -0.179 0 O-C-N 121.679 -0.638 . . . . 0.0 109.354 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.8 p . . . . . 0 CA--C 1.543 0.687 0 N-CA-C 114.453 1.279 . . . . 0.0 114.453 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 89.8 m -77.53 73.77 4.1 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.601 1.16 . . . . 0.0 108.301 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -107.09 134.42 50.25 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 127.588 2.355 . . . . 0.0 107.645 -177.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -151.38 -177.42 6.06 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 119.846 1.203 . . . . 0.0 109.601 176.2 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -136.5 149.07 47.98 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 172.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.29 -152.17 0.5 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.642 1.977 . . . . 0.0 106.573 174.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.6 p -135.79 173.01 12.19 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 119.152 0.887 . . . . 0.0 108.744 172.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.17 -56.89 2.41 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 114.455 1.279 . . . . 0.0 114.455 -175.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -54.67 -34.04 82.08 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.53 1.487 . . . . 0.0 113.456 -178.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -68.36 -26.88 65.8 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.215 -0.928 . . . . 0.0 111.38 177.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.2 t -59.44 -51.83 68.1 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 174.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.0 mtpp -56.43 -52.04 66.14 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.078 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.88 -54.71 17.86 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.607 0.363 . . . . 0.0 111.566 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.7 mtm -57.46 -53.8 54.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 119.343 -0.36 . . . . 0.0 110.27 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.4 mt -51.37 -48.14 62.62 Favored 'General case' 0 N--CA 1.463 0.217 0 C-N-CA 122.811 0.444 . . . . 0.0 111.334 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -55.11 -31.87 61.59 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 122.813 0.445 . . . . 0.0 111.929 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.5 11.13 25.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.33 0.652 . . . . 0.0 111.663 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.41 109.36 4.72 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 120.387 -1.446 . . . . 0.0 110.01 175.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 36.49 0.25 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.599 0.76 . . . . 0.0 112.706 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.67 108.09 2.36 Favored Glycine 0 C--N 1.338 0.651 0 C-N-CA 125.658 1.599 . . . . 0.0 110.224 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -78.89 150.67 32.1 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.352 1.061 . . . . 0.0 108.872 178.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 70.4 t -70.46 145.98 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.803 -0.561 . . . . 0.0 110.612 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 38.2 m -150.26 68.31 0.98 Allowed 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.623 1.169 . . . . 0.0 108.758 174.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.69 -110.99 3.82 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.3 -28.56 38.22 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 117.876 0.838 . . . . 0.0 110.388 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.8 m -86.81 155.13 20.42 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.702 1.201 . . . . 0.0 109.237 -172.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.9 t -119.64 134.52 62.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 171.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -122.96 120.05 32.24 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.666 1.186 . . . . 0.0 108.576 -172.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -87.48 170.84 11.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.151 0.5 . . . . 0.0 109.98 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 51.0 m -152.24 151.58 31.13 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -177.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.64 177.21 27.19 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -173.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 mttm -76.94 -26.13 53.67 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 122.035 -0.685 . . . . 0.0 111.827 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.3 m -78.77 73.61 5.32 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.846 0.748 . . . . 0.0 110.201 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -82.37 83.36 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -88.13 86.0 7.03 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.438 -174.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.4 t -81.0 111.71 18.04 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.115 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 -177.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.62 97.75 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 123.251 0.62 . . . . 0.0 109.33 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.07 101.6 13.28 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.703 1.201 . . . . 0.0 110.101 -176.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.77 102.17 14.92 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.801 1.24 . . . . 0.0 108.435 177.229 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.71 111.78 23.44 Favored 'General case' 0 CA--C 1.529 0.162 0 O-C-N 121.042 -1.036 . . . . 0.0 111.12 -174.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 8.5 t 38.21 73.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.648 1.579 . . . . 0.0 112.743 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.85 155.53 82.96 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -177.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo . . . . . 0 C--N 1.347 0.5 0 C-N-CA 124.717 3.611 . . . . 0.0 116.397 -173.509 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 . . . . . 0 CA--C 1.537 0.465 0 N-CA-C 112.261 0.467 . . . . 0.0 112.261 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -117.26 -9.1 0.34 Allowed 'Cis proline' 0 CA--C 1.535 0.572 0 N-CA-C 114.451 0.904 . . . . 0.0 114.451 -4.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.4 p -90.04 157.78 17.64 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 121.134 3.753 . . . . 0.0 121.134 -165.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -77.75 121.6 24.25 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 103.476 -2.786 . . . . 0.0 103.476 169.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -106.61 134.95 48.97 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.0 t -132.84 83.43 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 123.539 0.736 . . . . 0.0 109.204 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.278 1.0 OUTLIER 44.11 -70.07 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 130.224 3.409 . . . . 0.0 115.587 179.165 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -95.51 -23.86 16.9 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 124.186 0.994 . . . . 0.0 111.243 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -131.32 -172.94 2.97 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.549 1.139 . . . . 0.0 108.967 -175.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -139.4 134.72 32.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 172.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 49.48 41.43 0.99 Allowed Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 123.895 0.878 . . . . 0.0 112.111 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -72.77 162.88 39.99 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 CA-C-N 120.982 1.386 . . . . 0.0 111.247 -176.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.1 m -78.41 127.15 31.77 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 171.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 7.7 mp -97.38 127.37 43.29 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 119.249 0.932 . . . . 0.0 109.634 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -107.78 120.71 43.0 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 171.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 40.9 mt -123.24 134.61 25.26 Favored Pre-proline 0 CA--C 1.537 0.456 0 C-N-CA 124.691 1.196 . . . . 0.0 111.964 -171.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -65.1 113.46 2.41 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.396 2.064 . . . . 0.0 109.661 170.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.17 132.02 19.53 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.526 0.73 . . . . 0.0 111.133 174.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 88.94 -4.24 84.81 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.455 -0.636 . . . . 0.0 112.573 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.81 164.63 24.84 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 118.846 1.323 . . . . 0.0 111.641 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 53.9 m -98.21 103.27 15.2 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.667 1.587 . . . . 0.0 108.197 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.7 t -83.07 112.15 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 124.118 0.967 . . . . 0.0 108.768 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -103.31 100.69 10.58 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 174.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.5 t -79.23 93.25 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 37.6 m -90.95 99.74 12.73 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.622 1.569 . . . . 0.0 109.134 -176.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -79.64 159.57 26.69 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.492 173.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.9 mp -142.28 82.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 N-CA-C 101.019 -3.697 . . . . 0.0 101.019 162.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -108.3 115.17 29.61 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 105.383 -2.08 . . . . 0.0 105.383 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.3 m -140.41 39.55 1.89 Allowed 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 -79.77 70.62 6.33 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.986 177.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.4 mttm -1.62 94.94 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.402 3.081 . . . . 0.0 113.904 -176.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 96.14 -36.72 3.71 Favored Glycine 0 CA--C 1.532 1.15 0 O-C-N 121.92 -0.487 . . . . 0.0 113.418 175.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -79.92 95.11 6.0 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.6 1.2 . . . . 0.0 110.922 -178.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.78 54.02 0.36 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.243 1.402 . . . . 0.0 113.226 174.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -47.27 129.67 12.81 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-N 118.907 1.354 . . . . 0.0 110.228 177.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.4 p -108.26 112.59 25.15 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 -176.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -79.34 94.75 5.55 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -101.29 130.87 47.53 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 124.584 1.154 . . . . 0.0 109.538 -172.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -109.75 130.43 62.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 119.059 0.845 . . . . 0.0 110.468 -175.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.2 t -159.12 -153.18 0.35 Allowed 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -121.39 42.55 3.05 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 119.577 1.08 . . . . 0.0 110.234 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -76.09 94.8 3.52 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.6 157.2 52.52 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.1 160.24 45.64 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.105 1.87 . . . . 0.0 110.206 174.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -78.19 142.79 71.01 Favored 'Cis proline' 0 N--CA 1.456 -0.717 0 CA-C-N 118.901 0.643 . . . . 0.0 110.538 -2.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -79.85 151.89 29.99 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 176.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.54 148.64 24.97 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.542 0.737 . . . . 0.0 109.849 -178.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 25.5 t -63.47 -31.76 54.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 173.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -78.18 119.28 76.75 Favored Pre-proline 0 N--CA 1.45 -0.447 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.44 77.37 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.341 2.027 . . . . 0.0 108.89 -174.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 90.9 t -76.12 108.57 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 -175.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 15.6 pt -79.0 75.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-O 122.956 1.36 . . . . 0.0 111.194 -175.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -67.03 154.28 92.84 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 170.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -40.45 109.15 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.812 3.008 . . . . 0.0 114.363 -170.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 29.0 mm -78.6 121.83 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 175.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 87.6 t -84.67 -83.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.77 167.46 11.42 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 171.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.06 160.36 13.23 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.0 p -79.6 -46.3 17.53 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.173 177.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 93.61 -173.06 33.44 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 104.651 -3.38 . . . . 0.0 104.651 -167.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -82.96 131.67 35.18 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 120.404 2.102 . . . . 0.0 109.691 -174.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 p -90.48 153.43 46.07 Favored Pre-proline 0 CA--C 1.534 0.327 0 N-CA-C 116.113 1.894 . . . . 0.0 116.113 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -75.34 143.36 27.91 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.905 2.403 . . . . 0.0 106.099 169.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.5 m -141.16 95.57 7.43 Favored Pre-proline 0 CA--C 1.534 0.328 0 CA-C-N 118.456 0.571 . . . . 0.0 111.956 -172.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -55.97 168.53 1.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.816 3.011 . . . . 0.0 113.068 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -113.71 -5.25 13.34 Favored 'General case' 0 C--N 1.34 0.169 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -176.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 18.0 t0 178.05 154.16 0.33 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 126.236 1.815 . . . . 0.0 109.285 176.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 68.29 -62.66 0.4 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.522 2.011 . . . . 0.0 113.675 174.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -78.88 155.88 28.89 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 123.973 0.909 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -135.84 107.83 7.15 Favored 'General case' 0 CA--C 1.517 -0.303 0 C-N-CA 125.116 1.366 . . . . 0.0 110.778 -173.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -61.52 110.88 3.42 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.748 1.166 . . . . 0.0 110.604 176.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -116.51 170.55 8.48 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 122.658 1.218 . . . . 0.0 110.172 174.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 2.8 m -159.01 146.48 17.54 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 -174.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.21 96.25 2.75 Favored 'General case' 0 CA--C 1.521 -0.157 0 O-C-N 124.017 0.823 . . . . 0.0 111.866 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -103.82 147.93 26.72 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 169.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 37.4 m -104.15 134.3 47.63 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 177.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -136.54 140.67 43.11 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.522 1.129 . . . . 0.0 108.947 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -110.66 90.12 10.12 Favored Pre-proline 0 N--CA 1.455 -0.203 0 N-CA-C 105.174 -2.158 . . . . 0.0 105.174 173.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.16 147.55 42.78 Favored 'Trans proline' 0 N--CA 1.445 -1.354 0 C-N-CA 121.664 1.576 . . . . 0.0 110.285 -173.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.3 p -79.66 162.98 24.92 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.83 171.95 1.91 Allowed 'General case' 0 CA--C 1.537 0.455 0 O-C-N 121.307 -0.871 . . . . 0.0 112.13 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 100.95 -127.05 9.13 Favored Glycine 0 CA--C 1.522 0.496 0 C-N-CA 125.227 1.394 . . . . 0.0 110.158 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.2 m -153.04 144.4 23.25 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.352 1.076 . . . . 0.0 110.928 -174.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -134.21 -177.33 4.53 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 126.719 2.008 . . . . 0.0 106.71 173.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -144.62 141.6 29.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.223 1.009 . . . . 0.0 109.109 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -101.3 143.58 31.18 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.8 m -150.71 151.96 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 125.169 1.388 . . . . 0.0 109.789 -177.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 52.6 t -97.72 102.32 14.05 Favored 'General case' 0 C--O 1.231 0.111 0 C-N-CA 124.407 1.083 . . . . 0.0 109.754 171.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -73.52 33.61 0.08 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 29.4 mt -92.63 142.09 25.34 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 169.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 99.1 Cg_exo -46.11 136.67 14.14 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.335 2.023 . . . . 0.0 113.093 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.26 -52.41 4.05 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 123.676 0.655 . . . . 0.0 112.661 179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -39.83 -55.64 1.93 Allowed 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.855 1.662 . . . . 0.0 114.849 -171.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -50.89 -41.49 58.45 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.451 0.569 . . . . 0.0 111.635 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.27 -50.86 19.99 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.217 0.607 . . . . 0.0 109.943 174.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.7 p -79.85 62.39 4.07 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.691 -0.631 . . . . 0.0 111.377 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.38 93.39 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 117.622 1.809 . . . . 0.0 117.622 171.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 7.5 mtp -122.35 68.6 0.95 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 119.862 1.831 . . . . 0.0 109.154 170.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -159.48 -177.71 6.61 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.493 0.717 . . . . 0.0 111.883 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.73 171.47 33.74 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 172.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.7 mttm -101.6 152.46 20.78 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 123.784 0.834 . . . . 0.0 109.495 -174.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.9 mt -124.35 94.14 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 174.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 27.1 t -88.53 131.76 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 36.1 t -128.1 109.65 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt . . . . . 0 N--CA 1.465 0.294 0 CA-C-N 119.001 0.818 . . . . 0.0 110.464 -179.132 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.1 p . . . . . 0 CA--C 1.536 0.408 0 CA-C-O 121.007 0.432 . . . . 0.0 111.701 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 m -78.69 58.53 2.29 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 -169.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -89.09 130.28 35.56 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.754 1.222 . . . . 0.0 107.916 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -149.8 176.2 10.93 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -137.93 151.99 48.53 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 170.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.34 -153.76 0.57 Allowed 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 127.355 2.262 . . . . 0.0 105.998 173.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.3 p -138.21 169.12 18.34 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.958 0.799 . . . . 0.0 109.684 175.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.72 -54.39 4.09 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -174.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -57.73 -33.52 96.91 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.6 1.534 . . . . 0.0 111.936 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.8 mm100 -67.67 -23.8 65.35 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 121.765 -0.584 . . . . 0.0 111.103 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 t -64.14 -49.67 80.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 173.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.5 mttp -58.89 -39.82 82.58 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 122.684 0.393 . . . . 0.0 110.321 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.21 -62.83 1.44 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 122.042 -0.411 . . . . 0.0 109.963 174.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -54.08 -43.52 70.41 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.642 0.777 . . . . 0.0 111.897 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.7 mt -54.76 -33.09 60.85 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 176.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.54 -14.98 62.22 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 119.396 0.998 . . . . 0.0 112.392 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.98 17.57 20.65 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.008 0.822 . . . . 0.0 110.129 173.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.05 154.07 42.12 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.432 -0.793 . . . . 0.0 109.108 172.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.82 165.34 34.81 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.547 0.739 . . . . 0.0 109.766 -172.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.12 136.8 5.95 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 124.347 0.975 . . . . 0.0 111.335 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -79.26 126.75 31.19 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.299 1.039 . . . . 0.0 108.483 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.96 83.95 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 125.46 1.504 . . . . 0.0 109.261 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.9 m -85.89 68.06 10.22 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.087 1.355 . . . . 0.0 108.451 -175.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.54 -105.95 1.31 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -87.43 -22.34 25.04 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.78 0.832 . . . . 0.0 111.536 176.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.4 m -97.35 155.74 16.76 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 124.928 1.291 . . . . 0.0 108.517 -173.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.0 t -114.56 135.5 54.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 174.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -124.03 122.93 39.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 119.191 0.905 . . . . 0.0 110.375 -173.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 38' ' ' VAL . 0.6 OUTLIER -79.55 174.55 11.46 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.243 0.544 . . . . 0.0 111.208 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.5 m -158.93 49.88 0.36 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.723 0.809 . . . . 0.0 110.186 -174.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.26 170.44 38.94 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 -177.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -82.11 -33.71 29.58 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.978 0.511 . . . . 0.0 111.304 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.5 p -83.2 84.46 7.48 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 121.301 -0.874 . . . . 0.0 108.767 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 33' ' ' TYR . 77.6 t -86.07 83.35 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 C-N-CA 124.196 0.998 . . . . 0.0 108.894 -174.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -84.96 104.78 15.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 124.705 1.202 . . . . 0.0 109.765 -176.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.44 104.49 16.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.7 t -81.9 112.09 19.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 174.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -125.81 160.39 29.96 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.978 1.311 . . . . 0.0 110.267 -176.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.22 163.54 38.01 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.274 1.03 . . . . 0.0 109.65 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -129.35 122.62 29.88 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 124.017 0.927 . . . . 0.0 109.668 -179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.4 t 26.1 65.16 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 128.418 2.687 . . . . 0.0 113.12 174.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.9 mt -77.23 146.91 75.44 Favored Pre-proline 0 CA--C 1.534 0.36 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo . . . . . 0 N--CA 1.458 -0.609 0 C-N-CA 124.712 3.608 . . . . 0.0 113.679 -177.465 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -109.76 50.54 1.22 Allowed 'Cis proline' 0 CA--C 1.54 0.79 0 N-CA-C 108.087 -1.543 . . . . 0.0 108.087 -5.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 87.0 p -73.19 127.2 31.94 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 115.958 1.836 . . . . 0.0 115.958 -170.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -81.81 108.85 15.67 Favored 'General case' 0 C--N 1.343 0.318 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 168.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -84.31 136.66 33.82 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 120.011 1.278 . . . . 0.0 107.93 177.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -135.59 87.53 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 CA-C-N 119.128 0.876 . . . . 0.0 109.64 -174.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.0 p-80 39.27 -97.15 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.575 1.95 . . . . 0.0 113.632 -176.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.0 -27.24 64.53 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.882 0.473 . . . . 0.0 111.844 -174.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -127.19 -171.55 2.45 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.505 1.122 . . . . 0.0 110.718 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -135.6 127.45 29.36 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 172.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 51.16 44.15 2.02 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 125.044 1.338 . . . . 0.0 111.76 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.01 -178.0 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 122.87 2.38 . . . . 0.0 112.733 -173.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.9 m -104.45 136.2 44.47 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 113.079 -1.873 . . . . 0.0 106.44 172.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.7 mp -116.5 122.3 44.33 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 118.875 0.761 . . . . 0.0 112.038 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -93.27 127.09 38.71 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 171.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 25.4 mt -130.83 140.96 40.27 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 125.176 1.391 . . . . 0.0 111.711 -170.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -81.37 122.78 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.664 2.243 . . . . 0.0 109.137 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.98 143.06 3.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 125.205 1.402 . . . . 0.0 112.652 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 78.02 -12.08 19.44 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.28 -0.733 . . . . 0.0 113.695 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.68 148.66 23.89 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 119.035 1.418 . . . . 0.0 111.074 174.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 59.8 m -81.61 102.06 10.41 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 173.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.28 127.19 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -124.45 103.3 8.11 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.76 105.44 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.9 m -91.33 98.04 11.47 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.99 1.316 . . . . 0.0 107.93 175.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.69 156.04 30.94 Favored 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 120.916 -0.313 . . . . 0.0 110.902 173.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.1 mp -136.99 73.43 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 102.172 -3.27 . . . . 0.0 102.172 164.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.57 110.93 21.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 173.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 41.4 m -141.25 46.28 1.73 Allowed 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 173.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -68.43 -48.91 63.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.6 mtmm 93.34 155.33 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 129.709 3.204 . . . . 0.0 109.42 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 -66.89 1.59 Allowed Glycine 0 CA--C 1.53 1.029 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -172.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -79.8 104.03 10.1 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 124.222 1.009 . . . . 0.0 110.705 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.42 73.36 0.59 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 107.964 -2.054 . . . . 0.0 107.964 171.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -55.26 136.49 48.82 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.792 1.296 . . . . 0.0 111.506 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.3 p -96.43 157.01 16.1 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.242 1.417 . . . . 0.0 108.32 174.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -128.38 115.83 18.84 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 103.623 -2.732 . . . . 0.0 103.623 171.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.13 121.46 22.64 Favored 'General case' 0 C--O 1.226 -0.164 0 CA-C-N 119.151 0.887 . . . . 0.0 109.975 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 53.3 mt -97.8 132.87 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 125.651 1.58 . . . . 0.0 109.275 -174.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -157.39 -155.8 0.54 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.757 1.223 . . . . 0.0 107.963 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.8 mtpt -132.6 -2.85 3.36 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -174.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -74.84 134.53 41.69 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 118.844 0.747 . . . . 0.0 109.453 176.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.35 42.3 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 123.285 0.469 . . . . 0.0 112.14 -178.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -70.95 166.0 30.5 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.617 2.878 . . . . 0.0 109.792 174.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -78.39 139.19 54.08 Favored 'Cis proline' 0 N--CA 1.454 -0.805 0 N-CA-C 110.392 -0.657 . . . . 0.0 110.392 -3.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -81.93 151.44 27.23 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.39 153.29 31.71 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 56.6 t -57.77 -43.67 84.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -77.92 131.66 69.6 Favored Pre-proline 0 N--CA 1.451 -0.379 0 N-CA-C 104.535 -2.394 . . . . 0.0 104.535 172.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.87 75.43 2.68 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.25 1.967 . . . . 0.0 112.197 -172.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 t -79.21 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 172.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.413 ' H ' HG13 ' A' ' 102' ' ' ILE . 1.8 pp -86.71 -34.82 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 126.834 2.054 . . . . 0.0 113.289 -173.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -51.27 138.9 26.78 Favored Pre-proline 0 CA--C 1.535 0.389 0 C-N-CA 124.301 1.04 . . . . 0.0 111.901 -173.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.22 170.98 56.71 Favored 'Cis proline' 0 N--CA 1.459 -0.507 0 CA-C-N 119.629 0.903 . . . . 0.0 110.981 0.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 26.1 mm -124.05 144.33 34.19 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.109 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 174.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.9 t -95.39 -88.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 174.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.23 158.55 15.41 Favored 'General case' 0 N--CA 1.461 0.11 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 173.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.45 172.84 40.68 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 119.272 -1.442 . . . . 0.0 113.025 173.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.8 p -126.94 116.49 20.87 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.587 1.155 . . . . 0.0 110.653 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -76.17 65.11 2.71 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.515 1.055 . . . . 0.0 111.314 -179.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 76.24 98.75 0.07 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 127.186 2.194 . . . . 0.0 112.073 173.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.9 p -68.67 169.28 11.29 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-O 118.951 -0.547 . . . . 0.0 110.552 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -54.27 167.02 1.41 Allowed 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 123.295 2.663 . . . . 0.0 117.014 -172.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 79.0 t -124.67 92.02 48.52 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 126.78 2.032 . . . . 0.0 106.632 173.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.407 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 31.6 Cg_exo -72.33 -170.2 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 123.376 2.717 . . . . 0.0 113.467 -176.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -128.82 172.93 10.81 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 172.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -49.71 147.47 3.6 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-O 121.077 0.465 . . . . 0.0 112.166 -174.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.04 -44.85 2.67 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.346 -0.697 . . . . 0.0 112.738 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -79.69 153.05 29.57 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.226 1.01 . . . . 0.0 110.839 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -135.51 114.66 12.3 Favored 'General case' 0 C--O 1.224 -0.25 0 C-N-CA 124.903 1.281 . . . . 0.0 111.079 -173.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.407 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -75.95 113.56 3.92 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 125.507 1.527 . . . . 0.0 110.281 -174.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -113.9 163.02 15.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 122.766 1.27 . . . . 0.0 110.882 175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.3 m -150.91 126.66 10.28 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.702 -1.962 . . . . 0.0 105.702 174.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.63 89.6 3.12 Favored 'General case' 0 CA--C 1.518 -0.267 0 C-N-CA 124.46 1.104 . . . . 0.0 108.069 178.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -101.2 143.97 30.63 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 27.2 m -106.25 149.26 27.04 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.353 1.061 . . . . 0.0 109.686 -174.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -147.78 145.95 28.99 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.235 1.014 . . . . 0.0 109.762 174.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.4 m80 -114.1 107.46 51.94 Favored Pre-proline 0 CA--C 1.531 0.233 0 N-CA-C 105.033 -2.21 . . . . 0.0 105.033 173.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -90.79 133.74 1.75 Allowed 'Trans proline' 0 N--CA 1.444 -1.388 0 C-N-CA 123.743 2.962 . . . . 0.0 113.447 -170.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -84.54 158.86 20.82 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.528 1.531 . . . . 0.0 107.05 170.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.18 167.73 3.84 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.104 0.865 . . . . 0.0 113.025 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 107.12 -177.08 21.5 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 126.263 1.887 . . . . 0.0 112.916 174.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 12.7 m -87.82 137.56 32.23 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 124.213 1.005 . . . . 0.0 109.483 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -133.26 167.32 20.58 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 125.302 1.441 . . . . 0.0 107.24 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -134.0 147.75 51.03 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.987 1.315 . . . . 0.0 108.134 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . 0.45 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 47.6 p90 -114.14 138.99 49.7 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.3 m -142.52 156.23 18.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.345 1.458 . . . . 0.0 110.258 -178.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 13.4 t -96.62 114.75 26.43 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.552 1.141 . . . . 0.0 109.033 172.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -61.92 -14.44 34.4 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 125.42 1.488 . . . . 0.0 114.738 -176.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 26.2 mt -58.78 130.41 85.7 Favored Pre-proline 0 CA--C 1.541 0.606 0 CA-C-N 120.002 1.274 . . . . 0.0 108.317 174.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.71 145.86 4.19 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 123.12 2.547 . . . . 0.0 112.972 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.18 -43.75 2.06 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-O 119.58 -0.566 . . . . 0.0 112.798 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -52.67 -55.21 24.15 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.534 1.167 . . . . 0.0 112.602 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -53.93 -52.7 59.78 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.098 0.408 . . . . 0.0 110.103 177.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.46 -42.92 71.22 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 124.016 0.927 . . . . 0.0 111.402 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.1 p -81.24 10.92 4.76 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 12.93 37.73 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.475 -1.18 . . . . 0.0 116.026 170.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 2.9 ttt -79.31 73.88 5.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.995 1.897 . . . . 0.0 108.426 174.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.24 -166.92 2.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.511 0.324 . . . . 0.0 111.425 -174.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.45 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.76 177.44 40.2 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 174.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -116.43 152.89 33.08 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.5 1.12 . . . . 0.0 110.879 -172.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.6 mt -129.12 141.11 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 105.297 -2.112 . . . . 0.0 105.297 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 28.9 t -132.48 108.94 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.63 113.98 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 -176.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 67.9 mttm . . . . . 0 N--CA 1.461 0.119 0 CA-C-N 118.495 0.589 . . . . 0.0 109.847 174.702 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.2 p . . . . . 0 N--CA 1.452 -0.33 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.0 m -79.8 64.19 4.58 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 122.323 1.059 . . . . 0.0 108.164 178.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -80.49 121.48 25.81 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 125.859 1.664 . . . . 0.0 110.987 -173.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.3 mmtp -142.01 170.39 15.81 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 172.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -134.8 129.06 33.96 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 171.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.6 -156.76 0.53 Allowed 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 172.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 70.9 p -137.65 170.98 15.13 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 119.413 1.006 . . . . 0.0 109.876 174.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.15 -60.36 1.02 Allowed Pre-proline 0 CA--C 1.543 0.677 0 N-CA-C 115.325 1.602 . . . . 0.0 115.325 -173.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -60.06 -29.26 88.82 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 CA-C-N 121.588 1.603 . . . . 0.0 112.335 -178.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -67.03 -25.74 66.42 Favored 'General case' 0 N--CA 1.45 -0.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.533 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.83 -46.52 96.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 173.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -60.54 -49.27 78.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.68 -49.32 57.6 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 122.141 0.177 . . . . 0.0 111.358 177.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.3 mtm -63.7 -50.42 69.24 Favored 'General case' 0 C--O 1.224 -0.27 0 CA-C-O 118.907 -0.568 . . . . 0.0 110.767 177.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 mt -52.57 -40.96 63.16 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.45 1.023 . . . . 0.0 111.942 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -57.36 -36.04 70.7 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 122.848 0.459 . . . . 0.0 110.752 174.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.41 50.38 0.93 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.827 0.851 . . . . 0.0 109.601 174.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.77 -51.23 35.77 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.603 0.761 . . . . 0.0 110.174 -174.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . 0.299 70.3 p 65.3 -44.31 0.35 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.154 2.182 . . . . 0.0 114.932 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.4 118.45 13.72 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 119.535 1.061 . . . . 0.0 110.975 174.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -79.88 163.96 23.94 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 124.979 1.312 . . . . 0.0 109.158 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -85.27 151.24 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 C-N-CA 122.957 0.503 . . . . 0.0 110.156 -179.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 60.4 m -150.89 72.23 1.06 Allowed 'General case' 0 C--O 1.227 -0.116 0 C-N-CA 124.918 1.287 . . . . 0.0 108.581 174.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.15 -144.31 47.62 Favored Glycine 0 CA--C 1.528 0.866 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -80.01 57.24 2.59 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.913 1.357 . . . . 0.0 109.743 174.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.9 m -160.89 153.93 21.37 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 178.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.92 152.16 15.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -140.98 136.78 32.5 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.328 -172.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -107.46 164.42 12.22 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.065 0.946 . . . . 0.0 109.907 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 m -159.19 47.45 0.3 Allowed 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.311 0.644 . . . . 0.0 110.069 -174.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -175.47 171.6 44.69 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 107.637 -2.185 . . . . 0.0 107.637 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -75.41 -32.33 60.71 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 117.69 0.745 . . . . 0.0 111.005 -177.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.06 71.41 5.53 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.42 0.629 . . . . 0.0 110.241 -174.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -81.79 77.95 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -176.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -80.78 111.86 17.62 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.891 0.876 . . . . 0.0 109.034 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.18 106.68 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.5 t -89.57 95.45 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 118.068 0.395 . . . . 0.0 109.967 -174.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.0 99.95 10.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.329 1.452 . . . . 0.0 111.47 -174.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.22 108.45 18.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 O-C-N 121.673 -0.642 . . . . 0.0 109.971 175.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.45 82.78 8.16 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 121.259 -0.901 . . . . 0.0 109.057 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 34.3 t 68.24 96.05 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 C-N-CA 125.167 1.387 . . . . 0.0 109.68 175.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.9 mt -77.23 144.0 70.41 Favored Pre-proline 0 CA--C 1.531 0.213 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo . . . . . 0 N--CA 1.453 -0.863 0 C-N-CA 123.397 2.732 . . . . 0.0 109.125 -179.122 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 . . . . . 0 CA--C 1.538 0.512 0 N-CA-C 105.136 -2.172 . . . . 0.0 105.136 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -118.15 -23.54 0.09 OUTLIER 'Cis proline' 0 C--N 1.347 0.471 0 CA-C-N 120.701 1.286 . . . . 0.0 114.599 -5.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 p -86.17 160.37 19.24 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.959 2.948 . . . . 0.0 118.959 -166.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -76.68 117.25 18.12 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 171.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -101.98 103.18 13.79 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 104.248 -2.501 . . . . 0.0 104.248 -179.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.7 t -108.89 113.07 43.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 O-C-N 122.086 -0.384 . . . . 0.0 110.079 -171.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 30.59 -104.24 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 126.078 1.751 . . . . 0.0 113.869 -174.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -67.09 -24.16 65.92 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -173.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -139.37 -164.67 1.72 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 119.35 0.977 . . . . 0.0 111.335 -173.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.1 mtmt -125.33 130.99 53.07 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 172.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 47.58 45.31 2.6 Favored Pre-proline 0 CA--C 1.545 0.768 0 C-N-CA 124.227 1.011 . . . . 0.0 112.025 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -67.37 154.75 72.99 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.273 1.315 . . . . 0.0 111.114 -179.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.5 m -87.56 133.73 33.74 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 171.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -111.71 128.51 56.1 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.922 0.783 . . . . 0.0 110.824 -174.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -99.33 115.94 30.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 171.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.427 HD12 HG23 ' A' ' 152' ' ' ILE . 27.2 mt -120.64 142.34 34.03 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 124.552 1.141 . . . . 0.0 113.379 -169.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -78.89 119.46 4.36 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 122.532 2.155 . . . . 0.0 109.137 171.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.2 140.6 3.88 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 125.816 1.646 . . . . 0.0 111.95 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.97 -5.46 48.59 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-O 119.092 -0.838 . . . . 0.0 113.613 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 155.22 26.17 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 119.45 1.625 . . . . 0.0 111.049 174.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 73.7 m -83.76 96.85 8.86 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 174.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.65 100.12 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 C-N-CA 124.877 1.271 . . . . 0.0 108.046 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -92.52 91.52 7.63 Favored 'General case' 0 C--O 1.237 0.441 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 40.7 t -77.08 103.13 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 176.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 43.3 m -101.04 98.22 8.69 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.011 1.724 . . . . 0.0 109.232 -172.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.8 m-85 -77.91 156.58 30.21 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.574 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -139.21 78.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 101.576 -3.49 . . . . 0.0 101.576 164.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -97.1 101.83 13.48 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 178.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.2 m -148.37 54.38 1.02 Allowed 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 122.182 0.992 . . . . 0.0 108.721 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.83 -19.64 61.28 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.822 173.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mttm 81.5 121.49 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 127.649 2.38 . . . . 0.0 107.323 -173.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.38 -54.05 3.18 Favored Glycine 0 CA--C 1.534 1.233 0 O-C-N 121.595 -0.691 . . . . 0.0 112.921 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -78.53 79.42 4.96 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 121.444 -1.033 . . . . 0.0 110.718 -174.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -51.69 77.33 0.01 OUTLIER Glycine 0 CA--C 1.527 0.794 0 C-N-CA 126.603 2.049 . . . . 0.0 112.635 174.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -63.18 144.17 57.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 118.66 1.23 . . . . 0.0 111.251 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.9 p -106.51 154.73 20.43 Favored 'General case' 0 N--CA 1.444 -0.757 0 C-N-CA 127.024 2.13 . . . . 0.0 106.048 172.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 8.2 t80 -134.52 110.33 9.29 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 105.37 -2.085 . . . . 0.0 105.37 172.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . 0.411 ' HB3' HD12 ' A' ' 105' ' ' ILE . 1.4 m-20 -130.81 148.39 52.58 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.292 0.496 . . . . 0.0 110.397 -174.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.2 mt -114.56 137.93 46.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 C-N-CA 126.22 1.808 . . . . 0.0 110.048 -172.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.5 t -160.93 -155.0 0.39 Allowed 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.909 1.284 . . . . 0.0 107.714 177.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -122.2 8.45 9.75 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.905 0.882 . . . . 0.0 111.595 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? -63.0 114.11 3.49 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.29 170.25 38.88 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -68.67 164.06 34.64 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.072 2.514 . . . . 0.0 109.196 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.81 131.12 23.04 Favored 'Cis proline' 0 N--CA 1.455 -0.749 0 CA-C-N 119.464 0.844 . . . . 0.0 110.828 0.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -79.56 158.53 27.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 174.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -138.33 167.28 22.21 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.364 1.066 . . . . 0.0 108.15 -177.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.55 60.42 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 C-N-CA 124.324 1.049 . . . . 0.0 108.664 -176.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 52.3 mtm -147.09 103.96 3.83 Favored Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 124.51 1.124 . . . . 0.0 110.473 -174.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -64.93 75.49 0.22 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.191 2.594 . . . . 0.0 112.692 174.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.6 t -78.98 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 173.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 24.9 pt -83.05 -23.66 8.39 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 C-N-CA 124.713 1.205 . . . . 0.0 114.134 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -45.35 -56.96 8.29 Favored Pre-proline 0 CA--C 1.543 0.694 0 CA-C-O 118.92 -0.562 . . . . 0.0 111.779 176.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -76.07 67.76 6.73 Favored 'Trans proline' 0 CA--C 1.537 0.663 0 C-N-CA 122.178 1.918 . . . . 0.0 111.597 172.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 88' ' ' ASP . 6.1 mm -118.65 142.08 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 172.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.0 t -98.61 -92.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.94 161.39 14.48 Favored 'General case' 0 C--N 1.334 -0.088 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 174.403 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.38 173.71 28.18 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 120.134 -1.031 . . . . 0.0 113.374 174.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.431 HG23 ' CD1' ' A' ' 125' ' ' PHE . 3.0 p -109.41 125.52 52.5 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.909 1.284 . . . . 0.0 110.152 -178.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -80.21 58.95 4.6 Favored Glycine 0 CA--C 1.535 1.314 0 CA-C-O 119.496 -0.613 . . . . 0.0 111.817 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 71.58 98.8 0.07 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.617 1.967 . . . . 0.0 112.263 174.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 p -78.61 165.15 51.69 Favored Pre-proline 0 CA--C 1.544 0.732 0 O-C-N 121.077 -1.014 . . . . 0.0 112.5 -175.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -60.79 159.64 28.11 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 123.252 2.635 . . . . 0.0 112.098 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.51 86.19 14.37 Favored Pre-proline 0 CA--C 1.533 0.313 0 C-N-CA 124.217 1.007 . . . . 0.0 110.896 -179.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -55.74 163.72 5.21 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.528 2.819 . . . . 0.0 113.024 173.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -92.98 -23.53 18.68 Favored 'General case' 0 C--N 1.338 0.086 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 178.19 159.93 0.53 Allowed 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.7 2.0 . . . . 0.0 109.32 -176.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 70.26 -63.41 0.78 Allowed Glycine 0 C--N 1.338 0.644 0 C-N-CA 125.524 1.535 . . . . 0.0 112.839 174.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -78.68 157.84 28.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 124.263 1.025 . . . . 0.0 109.609 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -139.71 107.67 5.71 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.237 1.415 . . . . 0.0 110.826 -172.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -60.76 109.65 2.51 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.576 1.084 . . . . 0.0 110.852 -178.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -127.55 156.48 42.15 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.849 0.833 . . . . 0.0 111.455 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 18.1 m -159.72 109.93 1.9 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.97 -1.468 . . . . 0.0 107.449 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -86.75 69.61 10.33 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.164 1.386 . . . . 0.0 107.333 173.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . 0.431 ' CD1' HG23 ' A' ' 109' ' ' THR . 17.2 p90 -72.19 129.66 38.98 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 118.304 -1.358 . . . . 0.0 108.331 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.9 m -101.95 126.99 49.0 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.411 -171.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -134.68 157.78 45.78 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.481 1.512 . . . . 0.0 109.522 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -123.35 115.43 28.64 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 174.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -92.36 148.2 2.93 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 124.301 3.334 . . . . 0.0 111.809 -172.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.7 p -95.02 149.62 21.05 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 124.888 1.275 . . . . 0.0 108.763 173.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.98 151.9 13.99 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.122 0.419 . . . . 0.0 111.733 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.3 -124.13 5.89 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.937 2.208 . . . . 0.0 109.592 -176.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.0 m -153.61 147.95 25.93 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.314 1.057 . . . . 0.0 110.222 -174.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -139.87 173.87 11.08 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 127.825 2.45 . . . . 0.0 106.912 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -136.15 148.75 48.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 126.402 1.881 . . . . 0.0 107.259 174.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -109.47 147.87 32.14 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 172.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.39 150.9 12.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.117 1.367 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 42.6 t -84.75 140.34 31.33 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 169.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -78.08 -20.71 51.75 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -173.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 54.7 mt -61.35 124.38 80.46 Favored Pre-proline 0 CA--C 1.544 0.739 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -25.28 -76.01 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.567 1 C-N-CA 126.011 4.474 . . . . 0.0 117.446 -172.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -77.45 -2.29 79.32 Favored Glycine 0 CA--C 1.525 0.679 0 O-C-N 121.691 -0.631 . . . . 0.0 114.046 -173.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -72.69 -48.29 40.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 119.364 1.582 . . . . 0.0 110.558 -173.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.15 -41.86 93.68 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 173.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.24 78.29 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.823 0.449 . . . . 0.0 111.51 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 26.3 p -79.38 -58.29 3.28 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -174.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 176.87 37.79 0.05 OUTLIER Glycine 0 C--N 1.339 0.7 0 C-N-CA 119.187 -1.482 . . . . 0.0 115.196 -174.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 10.4 mtp -116.39 72.39 0.81 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 118.193 0.996 . . . . 0.0 108.405 173.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -159.56 -174.72 4.79 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.318 0.647 . . . . 0.0 112.16 -177.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 164.53 171.01 30.26 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 174.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 42.9 mtmt -99.94 146.86 26.2 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 124.998 1.319 . . . . 0.0 110.609 -176.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . 0.427 HG23 HD12 ' A' ' 66' ' ' ILE . 15.8 mt -124.59 101.77 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 173.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.5 t -92.42 137.64 21.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 172.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 11.5 t -127.9 123.55 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -175.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt . . . . . 0 N--CA 1.466 0.328 0 CA-C-N 119.823 1.192 . . . . 0.0 111.422 179.481 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 25.2 p . . . . . 0 CA--C 1.538 0.481 0 CA-C-O 120.316 0.103 . . . . 0.0 110.829 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.9 m -79.77 64.18 4.55 Favored 'General case' 0 CA--C 1.536 0.409 0 O-C-N 121.161 -0.962 . . . . 0.0 110.277 -174.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -85.91 134.55 33.88 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 126.34 1.856 . . . . 0.0 110.212 -173.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -149.55 173.04 14.05 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -138.77 151.16 46.85 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 172.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.31 -153.02 0.54 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.898 1.679 . . . . 0.0 106.664 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.7 p -135.65 173.95 11.15 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 119.462 1.028 . . . . 0.0 108.512 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -39.41 -57.05 2.51 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -54.76 -34.18 83.54 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 121.963 1.775 . . . . 0.0 113.531 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 21.0 mp0 -67.41 -25.73 66.08 Favored 'General case' 0 N--CA 1.456 -0.172 0 O-C-N 121.134 -0.979 . . . . 0.0 111.258 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.82 -46.91 93.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 174.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.1 -50.11 74.98 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.21 -48.36 62.06 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.7 mtm -62.93 -50.63 70.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.606 0.362 . . . . 0.0 110.516 177.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.8 mt -52.08 -41.95 62.8 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.436 0.562 . . . . 0.0 111.875 177.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -56.51 -23.62 40.95 Favored 'General case' 0 CA--C 1.538 0.513 0 O-C-N 121.542 -0.724 . . . . 0.0 112.678 177.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -100.95 12.55 37.46 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.653 0.781 . . . . 0.0 111.787 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -65.85 -46.27 79.1 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -174.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.4 p 63.8 -139.12 0.32 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.455 1.502 . . . . 0.0 109.27 -171.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.48 104.18 0.2 Allowed Glycine 0 CA--C 1.528 0.893 0 CA-C-N 118.593 0.633 . . . . 0.0 111.741 -177.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 37.3 mtpt -78.7 120.26 23.11 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 62.5 t -63.04 148.51 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -148.85 64.17 1.05 Allowed 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.15 -141.26 35.51 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -79.55 54.74 1.82 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 118.603 1.202 . . . . 0.0 109.642 174.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.7 m -161.31 147.12 14.17 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -118.18 137.87 50.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 175.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 93.2 m -120.57 119.22 32.29 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.832 1.253 . . . . 0.0 109.623 -173.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -83.07 169.43 15.91 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 122.083 0.944 . . . . 0.0 111.606 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 75.1 m -156.86 152.17 26.48 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.36 166.95 33.05 Favored Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -174.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 35.4 mtmm -82.82 -28.48 30.18 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 122.282 -0.54 . . . . 0.0 112.241 -174.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.2 p -81.59 78.01 8.39 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.484 -0.76 . . . . 0.0 109.588 -178.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -80.07 75.39 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -80.89 93.19 6.24 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.788 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -88.49 102.42 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.049 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -176.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 43.1 t -83.74 88.42 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.08 164.23 12.78 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.267 1.427 . . . . 0.0 110.227 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -159.62 169.31 24.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 123.96 0.904 . . . . 0.0 109.23 178.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.56 132.7 28.01 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 26.13 72.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 127.263 2.225 . . . . 0.0 113.009 173.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.1 mt -77.29 148.27 77.4 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 N--CA 1.455 -0.745 0 C-N-CA 122.999 2.466 . . . . 0.0 110.519 -175.083 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 . . . . . 0 CA--C 1.534 0.355 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -113.47 -11.92 0.64 Allowed 'Cis proline' 0 CA--C 1.539 0.774 0 CA-C-N 118.947 0.66 . . . . 0.0 113.535 -4.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.5 p -44.68 143.46 1.38 Allowed 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 118.586 2.81 . . . . 0.0 118.586 -170.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -77.27 129.14 35.49 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 168.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -104.33 132.52 50.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 177.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.5 t -139.91 123.67 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -14.74 111.32 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.515 1.926 . . . . 0.0 115.37 -173.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.4 t70 89.67 -28.02 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 127.309 2.244 . . . . 0.0 113.419 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -136.69 -168.97 2.36 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.524 1.154 . . . . 0.0 111.015 -173.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.5 mttp -137.5 134.88 36.25 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 171.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 48.82 40.62 0.8 Allowed Pre-proline 0 CA--C 1.548 0.882 0 C-N-CA 124.081 0.952 . . . . 0.0 112.69 -176.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.25 159.67 46.64 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 CA-C-N 120.993 1.39 . . . . 0.0 113.349 -171.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.58 121.23 25.55 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 127.647 2.379 . . . . 0.0 106.297 173.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.2 mp -103.99 117.94 35.5 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 119.862 1.21 . . . . 0.0 111.5 -178.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -93.36 120.09 33.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 171.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.0 mt -122.32 139.7 31.2 Favored Pre-proline 0 CA--C 1.538 0.514 0 C-N-CA 124.431 1.092 . . . . 0.0 112.906 -170.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -76.34 116.26 4.3 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 122.805 2.336 . . . . 0.0 108.728 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -48.69 139.58 9.43 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 125.12 1.368 . . . . 0.0 112.302 -178.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.25 -9.78 38.7 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.072 -0.849 . . . . 0.0 113.457 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 157.52 20.02 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.42 1.61 . . . . 0.0 110.52 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 50.2 m -83.71 101.68 11.72 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.1 t -79.64 99.81 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 174.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -96.59 97.16 9.17 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 174.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -80.02 108.02 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.2 m -99.7 96.71 7.8 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.009 1.724 . . . . 0.0 107.972 175.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.278 5.7 m-85 -79.26 148.1 32.29 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 118.726 -0.654 . . . . 0.0 110.31 172.66 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.07 79.38 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 102.514 -3.143 . . . . 0.0 102.514 163.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -99.48 104.7 16.55 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 172.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.0 m -121.77 38.44 4.11 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 173.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -78.39 73.23 4.94 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.245 -0.91 . . . . 0.0 109.12 175.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.4 mttm 0.16 97.32 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 129.126 2.97 . . . . 0.0 114.557 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.05 -34.29 3.62 Favored Glycine 0 CA--C 1.534 1.243 0 O-C-N 121.605 -0.685 . . . . 0.0 114.07 175.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -82.24 88.12 6.52 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 119.073 1.436 . . . . 0.0 110.171 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.29 63.04 0.4 Allowed Glycine 0 CA--C 1.533 1.168 0 C-N-CA 123.785 0.707 . . . . 0.0 112.545 175.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -51.06 120.78 5.23 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 118.941 1.37 . . . . 0.0 110.084 175.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.87 165.11 25.48 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.581 0.752 . . . . 0.0 109.628 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 21.4 t80 -133.15 103.37 5.98 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 106.376 -1.712 . . . . 0.0 106.376 172.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . 0.443 ' HB3' HD12 ' A' ' 105' ' ' ILE . 81.0 m-20 -118.38 137.34 53.19 Favored 'General case' 0 CA--C 1.516 -0.333 0 C-N-CA 123.434 0.694 . . . . 0.0 109.819 -176.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 25.8 mt -110.0 134.71 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 126.041 1.737 . . . . 0.0 109.075 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.2 t -158.65 -158.22 0.68 Allowed 'General case' 0 C--O 1.223 -0.301 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.0 mtmm -129.6 6.67 5.21 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 119.564 1.075 . . . . 0.0 112.5 -179.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.9 mtpt -67.51 160.71 27.08 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.08 160.06 16.18 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -72.78 159.5 48.29 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 122.791 2.327 . . . . 0.0 109.893 174.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.79 134.83 34.28 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 N-CA-C 108.75 -1.288 . . . . 0.0 108.75 -5.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.542 ' HB2' ' HB1' ' A' ' 144' ' ' ALA . 92.9 m-85 -83.13 31.36 0.44 Allowed 'General case' 0 N--CA 1.468 0.463 0 O-C-N 120.979 -1.075 . . . . 0.0 113.377 -173.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . 70.05 156.0 0.14 Allowed 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 127.703 2.401 . . . . 0.0 113.084 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.98 -46.25 85.26 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.386 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.1 mmt -78.92 160.1 72.19 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 174.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -70.25 59.12 1.85 Allowed 'Trans proline' 0 CA--C 1.538 0.725 0 C-N-CA 123.08 2.52 . . . . 0.0 114.153 -174.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.8 t -82.46 55.79 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 O-C-N 120.238 -1.539 . . . . 0.0 108.664 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -80.88 -38.6 17.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 C-N-CA 123.101 0.561 . . . . 0.0 110.998 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -55.48 147.43 38.73 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 124.445 1.098 . . . . 0.0 111.826 -174.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 79.1 Cg_endo -74.13 150.38 95.47 Favored 'Cis proline' 0 N--CA 1.459 -0.537 0 CA-C-N 118.851 0.625 . . . . 0.0 111.127 -0.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.443 HD12 ' HB3' ' A' ' 88' ' ' ASP . 20.2 mm -109.45 143.7 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 C-N-CA 124.42 1.088 . . . . 0.0 108.406 175.522 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.73 -89.49 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 174.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.89 156.48 16.33 Favored 'General case' 0 C--N 1.332 -0.155 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 173.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.29 173.51 41.11 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 119.063 -1.541 . . . . 0.0 112.817 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.9 p -123.15 137.09 54.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.398 1.479 . . . . 0.0 109.625 176.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.47 -164.34 7.49 Favored Glycine 0 CA--C 1.54 1.654 0 N-CA-C 108.136 -1.986 . . . . 0.0 108.136 170.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -67.63 118.66 11.21 Favored 'General case' 0 CA--C 1.537 0.47 0 O-C-N 120.8 -1.412 . . . . 0.0 112.286 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 p -69.71 161.08 77.01 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 126.201 1.8 . . . . 0.0 113.413 -173.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -74.4 144.96 33.3 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.023 2.482 . . . . 0.0 107.969 174.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.18 80.15 9.49 Favored Pre-proline 0 CA--C 1.536 0.442 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -53.89 164.69 2.29 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 124.627 3.551 . . . . 0.0 112.588 172.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -119.35 -0.05 11.02 Favored 'General case' 0 C--N 1.34 0.173 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -174.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -175.28 148.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.191 1.396 . . . . 0.0 109.026 176.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 66.15 -62.85 0.15 Allowed Glycine 0 CA--C 1.527 0.79 0 C-N-CA 126.579 2.038 . . . . 0.0 113.47 177.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -78.66 157.39 28.64 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-O 121.352 0.596 . . . . 0.0 110.018 -177.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -129.55 108.63 10.39 Favored 'General case' 0 CA--C 1.512 -0.481 0 C-N-CA 127.014 2.125 . . . . 0.0 107.943 -174.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.04 123.71 18.63 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 19.8 p90 -130.89 168.57 17.07 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.724 1.25 . . . . 0.0 110.701 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.8 m -155.53 124.68 6.21 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.83 106.63 16.3 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -119.06 150.61 39.68 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.3 m -114.69 145.29 42.21 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.882 0.873 . . . . 0.0 111.007 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 26.1 t90 -145.02 153.23 41.26 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.887 1.275 . . . . 0.0 109.236 174.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.9 93.96 44.96 Favored Pre-proline 0 CA--C 1.53 0.174 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -81.6 146.01 14.93 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.467 2.112 . . . . 0.0 111.358 -173.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 10.6 p -96.3 156.37 16.37 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 172.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.93 144.65 27.56 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -174.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 139.97 -132.58 5.62 Favored Glycine 0 C--N 1.337 0.611 0 C-N-CA 126.215 1.864 . . . . 0.0 109.984 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 33.5 m -150.52 145.07 25.73 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 118.026 0.913 . . . . 0.0 109.132 -174.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -147.02 175.64 10.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.738 2.015 . . . . 0.0 107.181 -175.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -142.57 155.37 44.98 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 125.354 1.462 . . . . 0.0 108.557 179.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -121.46 147.2 46.07 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 124.275 1.03 . . . . 0.0 110.915 175.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.65 160.66 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 124.855 1.262 . . . . 0.0 112.308 -174.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 7.1 t -102.82 133.49 47.8 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.876 1.67 . . . . 0.0 108.738 171.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -70.65 -34.67 72.3 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 113.816 1.043 . . . . 0.0 113.816 -173.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 70.8 mt -48.62 128.38 13.71 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.781 0.832 . . . . 0.0 109.993 -172.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -42.32 142.82 1.61 Allowed 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 124.26 3.307 . . . . 0.0 114.968 -173.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.45 -40.55 1.78 Allowed Glycine 0 CA--C 1.529 0.951 0 C-N-CA 123.995 0.807 . . . . 0.0 112.634 177.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -54.6 -47.26 73.6 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.568 0.747 . . . . 0.0 111.624 -173.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . 0.542 ' HB1' ' HB2' ' A' ' 96' ' ' TYR . . . -81.84 -11.67 58.85 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.631 0.65 . . . . 0.0 112.4 175.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.56 -57.82 4.72 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 173.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.5 p -151.63 87.04 1.34 Allowed 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.91 -66.47 0.06 OUTLIER Glycine 0 CA--C 1.524 0.631 0 C-N-CA 119.82 -1.181 . . . . 0.0 113.951 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.0 ptm -141.59 113.19 7.7 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 117.671 0.736 . . . . 0.0 111.948 -173.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -163.56 -166.73 1.26 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.716 1.206 . . . . 0.0 108.169 176.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.14 173.33 36.71 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 175.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 29.9 mttp -109.78 150.31 28.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.709 1.204 . . . . 0.0 110.869 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 17.1 mt -128.33 130.01 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 174.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 6.2 t -118.01 135.81 57.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 173.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.03 123.11 64.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -174.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 53.3 mtmt . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 118.81 0.732 . . . . 0.0 111.093 -174.288 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.0 p . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.1 m -79.59 62.62 3.94 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.879 0.847 . . . . 0.0 108.729 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -78.48 123.81 27.45 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.188 1.395 . . . . 0.0 110.392 -172.428 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -142.64 173.55 11.44 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 174.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -141.15 148.76 40.54 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.847 -0.533 . . . . 0.0 109.607 171.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.74 -153.77 0.56 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 126.633 1.973 . . . . 0.0 106.212 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -134.97 172.22 13.32 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 119.084 0.856 . . . . 0.0 108.991 172.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -38.64 -57.44 1.95 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -174.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.24 -32.46 87.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.473 1.449 . . . . 0.0 113.318 -178.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.6 mp0 -65.7 -31.57 72.64 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.7 t -55.42 -49.74 70.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.954 0.797 . . . . 0.0 109.14 176.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 mtpp -57.03 -51.39 69.47 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.87 -51.58 39.33 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -61.18 -53.1 61.19 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.219 0.463 . . . . 0.0 110.708 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 58.4 mt -51.7 -40.7 60.6 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.672 0.669 . . . . 0.0 111.78 -177.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -59.36 -23.53 62.61 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.842 0.857 . . . . 0.0 112.726 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -70.88 -66.31 0.63 Allowed 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.315 0.961 . . . . 0.0 109.514 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 58.6 -62.22 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 126.716 2.006 . . . . 0.0 115.622 176.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 19.3 p 53.89 37.66 27.04 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.174 1.79 . . . . 0.0 112.301 179.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -141.6 121.66 1.89 Allowed Glycine 0 CA--C 1.528 0.854 0 C-N-CA 124.88 1.229 . . . . 0.0 110.535 -174.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.3 mtpt -79.81 118.14 21.33 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.892 1.677 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.4 t -68.83 77.48 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 C-N-CA 124.939 1.296 . . . . 0.0 110.257 -174.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 m -81.09 70.08 7.84 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.687 1.195 . . . . 0.0 107.784 -179.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 62.95 -113.55 6.0 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -174.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -78.45 -19.1 53.87 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.856 0.828 . . . . 0.0 111.238 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 59.6 m -98.62 110.06 22.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -172.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.9 t -79.19 114.17 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 104.298 -2.482 . . . . 0.0 104.298 172.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.5 m -106.72 121.48 44.46 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 124.577 1.151 . . . . 0.0 111.679 -170.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -81.36 167.68 19.21 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.513 0.673 . . . . 0.0 110.752 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.0 m -159.55 46.97 0.28 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.992 0.917 . . . . 0.0 109.275 -177.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.52 170.35 42.77 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -78.62 -32.14 47.32 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 117.45 0.625 . . . . 0.0 111.602 -177.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.6 m -78.87 72.94 5.42 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.49 0.662 . . . . 0.0 109.617 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.4 t -80.31 86.08 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-O 121.788 0.804 . . . . 0.0 109.118 -174.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -85.69 101.96 13.2 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.938 1.295 . . . . 0.0 110.401 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.3 t -102.79 110.62 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 C-N-CA 124.484 1.114 . . . . 0.0 108.918 -176.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.06 101.64 12.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 CA-C-N 118.183 0.447 . . . . 0.0 110.267 -176.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -101.93 104.39 15.09 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.437 1.495 . . . . 0.0 111.244 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.6 110.57 21.42 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.486 1.514 . . . . 0.0 109.259 175.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -97.48 95.54 7.72 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.79 -0.569 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 46.68 69.74 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 C-N-CA 127.238 2.215 . . . . 0.0 111.153 173.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 27.3 mt -77.26 152.54 81.75 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-O 118.514 -0.755 . . . . 0.0 109.556 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_exo . . . . . 0 N--CA 1.457 -0.656 0 C-N-CA 124.139 3.226 . . . . 0.0 111.446 175.331 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 . . . . . 0 CA--C 1.535 0.398 0 N-CA-C 105.558 -2.016 . . . . 0.0 105.558 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -115.7 -21.65 0.15 OUTLIER 'Cis proline' 0 N--CA 1.458 -0.592 0 CA-C-N 120.305 1.145 . . . . 0.0 113.631 -5.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.0 p -67.55 148.54 51.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -167.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -75.54 131.48 40.07 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 173.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -102.23 131.1 48.99 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 172.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 t -138.33 122.01 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 CA-C-N 119.245 0.93 . . . . 0.0 108.809 -174.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 12.58 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 127.756 2.422 . . . . 0.0 115.335 -178.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 t70 76.21 -32.45 0.2 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.078 1.351 . . . . 0.0 113.595 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.2 mmmp? -121.58 -173.29 2.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 122.351 1.072 . . . . 0.0 112.367 -171.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -133.12 125.5 29.66 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 105.332 -2.099 . . . . 0.0 105.332 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 43.85 50.18 6.17 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.195 0.998 . . . . 0.0 111.83 -173.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.76 157.87 58.91 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 121.717 1.611 . . . . 0.0 110.485 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 151' ' ' LYS . 50.2 m -84.44 145.88 27.93 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 105.893 -1.892 . . . . 0.0 105.893 170.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.0 mp -114.24 121.47 43.81 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.506 -0.747 . . . . 0.0 109.542 -177.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -98.94 118.54 35.95 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 171.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.41 HD12 ' CG2' ' A' ' 152' ' ' ILE . 17.9 mt -122.14 133.68 24.45 Favored Pre-proline 0 N--CA 1.453 -0.289 0 C-N-CA 124.978 1.311 . . . . 0.0 110.448 -172.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.93 118.39 5.02 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.127 1.885 . . . . 0.0 108.137 172.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.38 136.37 20.5 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.883 0.873 . . . . 0.0 111.196 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -12.71 67.65 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.672 -0.516 . . . . 0.0 112.156 -175.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.97 154.14 16.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 118.481 1.14 . . . . 0.0 112.909 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 99.5 m -92.15 105.72 17.88 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.472 -2.047 . . . . 0.0 105.472 171.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.2 t -88.04 93.78 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 C-N-CA 124.344 1.058 . . . . 0.0 108.178 -175.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.87 94.9 6.56 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 173.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.9 t -79.6 94.6 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 174.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 96.5 m -86.43 97.06 10.25 Favored 'General case' 0 N--CA 1.444 -0.732 0 C-N-CA 126.085 1.754 . . . . 0.0 108.539 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.403 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.5 m-85 -77.29 156.73 31.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.169 0.509 . . . . 0.0 111.607 173.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -140.59 86.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 100.857 -3.757 . . . . 0.0 100.857 164.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -105.13 113.83 27.66 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.7 m -143.4 37.48 1.36 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -78.96 65.28 4.11 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.581 -0.699 . . . . 0.0 109.369 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.5 mttm 17.7 81.18 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 128.424 2.689 . . . . 0.0 114.688 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 95.15 -29.91 8.82 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.885 176.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -78.38 99.02 6.2 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 119.265 1.532 . . . . 0.0 109.917 -174.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.81 60.97 0.94 Allowed Glycine 0 CA--C 1.523 0.591 0 C-N-CA 124.806 1.194 . . . . 0.0 110.614 176.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -33.68 -52.29 0.41 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 126.114 1.766 . . . . 0.0 115.411 -172.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 17.5 p 78.43 134.06 0.06 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 125.889 1.676 . . . . 0.0 108.742 -172.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.2 t80 -114.44 108.7 17.23 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.638 -2.727 . . . . 0.0 103.638 172.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.86 139.12 47.61 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -173.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 mt -124.75 134.42 66.87 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.838 0.828 . . . . 0.0 110.39 -173.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -160.22 -163.08 1.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -175.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -120.97 5.69 10.39 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.814 0.846 . . . . 0.0 111.788 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -71.67 130.14 40.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 174.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.92 169.18 25.25 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.016 0.817 . . . . 0.0 112.158 -176.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -72.51 167.13 27.86 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.507 2.804 . . . . 0.0 109.698 174.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -68.2 130.74 15.47 Favored 'Cis proline' 0 N--CA 1.459 -0.544 0 CA-C-N 119.483 0.851 . . . . 0.0 111.218 -5.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -79.93 148.72 31.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 175.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.27 156.7 24.19 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.347 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 73.9 t -61.26 -34.75 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 55.2 mtm -78.05 128.13 79.61 Favored Pre-proline 0 CA--C 1.534 0.344 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 173.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.25 101.91 1.3 Allowed 'Trans proline' 0 N--CA 1.451 -0.971 0 C-N-CA 122.542 2.161 . . . . 0.0 110.602 -173.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 22.0 t -77.69 93.5 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.0 pt -78.49 -85.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.702 0.801 . . . . 0.0 112.788 -173.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -67.82 150.16 97.92 Favored Pre-proline 0 N--CA 1.454 -0.242 0 O-C-N 121.723 -0.611 . . . . 0.0 112.237 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.61 113.24 2.88 Favored 'Cis proline' 0 CA--C 1.537 0.645 0 CA-C-N 118.579 0.528 . . . . 0.0 112.878 1.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.7 mm -86.66 139.05 17.95 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.5 t -95.76 -87.2 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 174.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -93.64 166.65 12.13 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 173.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 179.6 41.55 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.3 p -124.68 124.57 42.47 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.696 1.199 . . . . 0.0 108.984 175.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.27 59.75 4.31 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.564 -0.575 . . . . 0.0 112.809 -173.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 71.17 93.66 0.08 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.244 1.818 . . . . 0.0 110.501 175.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 p -65.9 161.36 55.11 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 126.875 2.07 . . . . 0.0 115.357 -172.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -67.02 154.88 73.17 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 123.795 2.997 . . . . 0.0 108.995 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.4 t -147.19 85.31 6.92 Favored Pre-proline 0 CA--C 1.54 0.561 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -172.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -57.78 165.34 6.55 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.16 2.573 . . . . 0.0 112.722 174.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -101.43 6.39 42.48 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 -174.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.7 p30 143.38 166.45 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 130.355 3.462 . . . . 0.0 109.376 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.3 -66.54 0.95 Allowed Glycine 0 C--N 1.34 0.755 0 C-N-CA 125.431 1.491 . . . . 0.0 111.28 177.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -78.58 155.15 29.8 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 124.075 0.95 . . . . 0.0 108.466 174.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -137.61 109.78 7.3 Favored 'General case' 0 CA--C 1.518 -0.258 0 C-N-CA 125.063 1.345 . . . . 0.0 110.829 -172.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.11 114.02 5.79 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 124.63 1.109 . . . . 0.0 111.102 -177.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 22.1 p90 -122.21 164.67 17.42 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 122.292 1.044 . . . . 0.0 111.65 178.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 74.3 m -159.57 119.22 2.95 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -95.99 67.95 2.7 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 124.104 0.962 . . . . 0.0 108.501 176.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . 0.254 40.4 p90 -70.81 114.13 8.57 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 118.003 -1.479 . . . . 0.0 108.019 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.2 m -91.66 87.08 6.18 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.498 1.519 . . . . 0.0 109.974 -171.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.5 t90 -93.27 143.55 26.16 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.026 0.93 . . . . 0.0 110.951 -175.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -111.23 109.72 56.55 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 105.344 -2.095 . . . . 0.0 105.344 171.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -84.76 178.95 4.57 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 123.884 3.056 . . . . 0.0 111.462 -172.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 58.7 p -124.21 159.97 28.94 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 170.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.61 156.98 33.61 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 113.823 1.045 . . . . 0.0 113.823 -172.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 114.55 -176.86 17.2 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 126.254 1.883 . . . . 0.0 112.329 174.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 5.5 m -82.76 87.48 6.77 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.115 0.966 . . . . 0.0 110.262 -175.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -78.96 175.31 10.68 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 171.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -150.78 149.34 29.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.932 1.293 . . . . 0.0 109.541 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -112.31 146.52 38.1 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.233 1.013 . . . . 0.0 108.286 172.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -153.13 150.5 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 124.872 1.269 . . . . 0.0 110.404 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.82 106.99 19.19 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 169.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 34.3 mm-40 -75.17 34.32 0.11 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 114.695 1.368 . . . . 0.0 114.695 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 25.7 mt -92.21 137.2 25.0 Favored Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 169.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -43.94 129.2 7.54 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.596 2.197 . . . . 0.0 113.207 -178.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.65 -24.73 3.62 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.361 -0.688 . . . . 0.0 114.095 178.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -65.13 -52.53 54.74 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 119.796 1.798 . . . . 0.0 111.617 -172.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.62 -44.1 80.86 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 174.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.92 -42.9 99.02 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.777 0.431 . . . . 0.0 111.654 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.2 p -79.05 -59.93 2.58 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -174.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -178.9 31.43 0.06 OUTLIER Glycine 0 C--N 1.337 0.621 0 C-N-CA 119.296 -1.43 . . . . 0.0 115.033 -174.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.2 mtp -111.39 68.73 0.67 Allowed 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 118.2 1.0 . . . . 0.0 108.531 173.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -158.37 -177.52 6.6 Favored 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.09 165.48 24.56 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 173.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB2' HG23 ' A' ' 63' ' ' THR . 13.2 mtmm -100.18 149.43 23.55 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.681 0.793 . . . . 0.0 109.492 -174.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . 0.41 ' CG2' HD12 ' A' ' 66' ' ' ILE . 13.3 mt -125.96 93.96 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.102 1.761 . . . . 0.0 107.361 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.97 95.8 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 29.6 t -85.74 91.19 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 C--N 1.332 -0.193 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 177.094 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.448 -0.531 0 N-CA-C 110.627 -0.138 . . . . 0.0 110.627 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.4 m -79.01 63.96 3.81 Favored 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.259 -0.901 . . . . 0.0 109.956 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -78.25 125.57 29.55 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 125.157 1.383 . . . . 0.0 109.511 -173.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -144.23 -179.74 6.71 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.918 0.887 . . . . 0.0 108.672 174.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -142.65 154.21 44.15 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.671 0.669 . . . . 0.0 111.088 172.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.46 -152.43 0.51 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 128.19 2.596 . . . . 0.0 105.65 173.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -138.73 170.81 15.34 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 119.082 0.855 . . . . 0.0 110.042 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -38.85 -59.64 1.34 Allowed Pre-proline 0 CA--C 1.538 0.512 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -174.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -58.78 -30.73 93.48 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 CA-C-N 121.248 1.481 . . . . 0.0 112.074 -178.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -67.07 -25.33 66.19 Favored 'General case' 0 N--CA 1.449 -0.523 0 O-C-N 121.819 -0.551 . . . . 0.0 111.254 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.2 t -59.1 -54.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -57.73 -49.61 75.98 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.558 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.2 -57.91 6.75 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.05 0.54 . . . . 0.0 110.953 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.9 mtm -56.82 -50.21 73.07 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 122.816 0.446 . . . . 0.0 110.096 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.1 mt -53.35 -45.31 69.08 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.612 0.642 . . . . 0.0 110.92 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.79 -30.9 70.32 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 118.249 0.477 . . . . 0.0 111.146 177.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 mmpt? -80.42 1.57 28.6 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 123.214 0.606 . . . . 0.0 112.365 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.43 146.68 50.8 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.926 1.239 . . . . 0.0 110.381 175.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.6 p -109.65 32.4 5.07 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.424 0.69 . . . . 0.0 112.155 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.94 113.82 4.75 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 124.678 1.132 . . . . 0.0 110.802 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -79.45 145.72 33.14 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 174.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 t -73.57 148.73 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.769 -0.582 . . . . 0.0 109.623 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -150.76 65.68 0.93 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.753 0.821 . . . . 0.0 109.611 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.12 -138.49 41.52 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -174.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -79.82 50.58 1.19 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.74 1.27 . . . . 0.0 110.222 174.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 m -161.39 153.73 20.06 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -119.34 149.08 21.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.6 m -134.32 125.34 27.44 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.222 1.009 . . . . 0.0 108.974 -173.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -98.73 167.33 10.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 123.882 0.873 . . . . 0.0 110.0 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.1 m -156.7 161.53 39.84 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.904 1.282 . . . . 0.0 107.661 177.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 73.13 178.36 35.01 Favored Glycine 0 CA--C 1.529 0.969 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -78.04 -32.3 50.86 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 122.078 -0.66 . . . . 0.0 110.617 178.363 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 m -79.06 70.05 5.34 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.872 0.869 . . . . 0.0 110.777 -174.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 69.0 t -86.09 92.19 3.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.0 t-160 -94.49 94.94 8.51 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.852 0.861 . . . . 0.0 110.531 -173.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.4 t -92.26 94.29 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.124 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.2 t -89.83 103.54 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.99 112.23 21.51 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.146 0.978 . . . . 0.0 111.363 -173.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.16 148.44 23.65 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 121.593 -0.692 . . . . 0.0 109.559 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.52 109.18 16.92 Favored 'General case' 0 CA--C 1.527 0.058 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 174.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.5 t 40.52 81.59 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.408 1.883 . . . . 0.0 112.576 175.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 76.8 mt -76.91 147.59 77.62 Favored Pre-proline 0 CA--C 1.534 0.332 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -175.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo . . . . . 0 N--CA 1.455 -0.738 0 C-N-CA 123.876 3.051 . . . . 0.0 111.017 174.235 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 . . . . . 0 CA--C 1.539 0.525 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -116.73 -19.43 0.14 OUTLIER 'Cis proline' 0 CA--C 1.539 0.733 0 CA-C-N 119.108 0.717 . . . . 0.0 113.394 -6.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.52 151.22 47.69 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 118.964 2.95 . . . . 0.0 118.964 -168.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -77.35 128.92 35.11 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 104.249 -2.5 . . . . 0.0 104.249 169.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -111.62 115.34 28.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 -173.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 58.2 t -120.49 85.58 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 123.257 0.623 . . . . 0.0 109.517 -171.033 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 45.23 -97.19 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 126.177 1.791 . . . . 0.0 112.993 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -70.38 -23.61 62.8 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -134.36 -175.72 3.96 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.897 0.879 . . . . 0.0 110.903 -172.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.4 mtpp -131.07 129.58 42.12 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 172.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 50.58 42.95 1.42 Allowed Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 124.487 1.115 . . . . 0.0 113.115 -175.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -72.51 164.68 34.89 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.582 1.522 . . . . 0.0 114.291 -173.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . 0.266 0.2 OUTLIER -84.99 123.07 30.11 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 128.279 2.632 . . . . 0.0 106.088 173.571 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 8.9 mp -109.35 110.19 21.28 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.478 1.49 . . . . 0.0 113.221 -176.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -81.59 125.12 30.16 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 12.6 mt -127.29 140.34 37.65 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 124.283 1.033 . . . . 0.0 111.976 -171.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.05 118.18 4.01 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.287 2.658 . . . . 0.0 109.661 172.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.94 138.86 4.7 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.326 1.45 . . . . 0.0 112.175 176.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.17 -18.69 9.41 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-O 118.794 -1.004 . . . . 0.0 113.96 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.98 159.48 7.06 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.331 1.565 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.4 m -84.65 90.15 7.63 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.02 97.08 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -93.76 98.47 11.12 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.34 104.43 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.3 m -92.39 102.09 14.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.3 m-85 -77.67 154.91 31.71 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.422 173.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.2 mp -133.36 78.03 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 163.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -97.86 105.21 17.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 175.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.0 m -146.34 44.89 1.23 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -82.7 63.54 6.88 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -6.1 70.34 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 131.273 3.829 . . . . 0.0 114.82 -172.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 141.01 -47.46 0.86 Allowed Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.215 0.912 . . . . 0.0 111.062 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -85.33 100.18 11.65 Favored 'General case' 0 CA--C 1.528 0.13 0 O-C-N 122.076 -0.661 . . . . 0.0 111.125 -174.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.2 70.51 1.03 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 173.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -40.5 -49.21 2.9 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 116.164 1.913 . . . . 0.0 116.164 -171.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.7 p 78.22 148.28 0.1 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 120.027 1.285 . . . . 0.0 109.687 -172.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.9 t80 -138.39 108.31 6.33 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -115.52 135.85 53.67 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 118.798 0.727 . . . . 0.0 110.195 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.3 mt -110.26 130.53 63.35 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 126.186 1.794 . . . . 0.0 109.022 -177.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 t -159.39 -153.68 0.37 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -129.71 42.79 3.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 119.662 1.119 . . . . 0.0 110.573 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -91.69 110.92 22.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.143 0.577 . . . . 0.0 109.485 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.72 161.81 54.51 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 172.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.7 155.69 67.79 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.255 1.97 . . . . 0.0 109.62 174.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.51 167.87 78.0 Favored 'Cis proline' 0 N--CA 1.457 -0.667 0 CA-C-N 119.251 0.768 . . . . 0.0 111.301 -1.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -113.09 155.29 25.18 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.421 1.088 . . . . 0.0 109.106 177.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 156.56 26.68 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-O 121.378 0.608 . . . . 0.0 110.641 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 79.7 t -70.42 -36.9 68.58 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.743 175.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -78.34 152.04 78.45 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -38.85 111.9 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 124.996 3.797 . . . . 0.0 113.378 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.0 t -85.42 54.04 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 123.961 0.905 . . . . 0.0 109.021 -173.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.1 pp -88.0 91.05 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 122.519 1.152 . . . . 0.0 109.615 174.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.03 -157.55 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 126.254 1.822 . . . . 0.0 106.852 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -57.28 89.53 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 121.458 1.438 . . . . 0.0 109.34 153.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.1 mm -78.33 136.22 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 65.8 t -85.02 -88.81 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.556 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 175.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.42 155.71 16.63 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 171.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.51 166.34 33.52 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.312 -1.423 . . . . 0.0 111.438 174.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.6 p -118.44 142.28 47.71 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.251 1.42 . . . . 0.0 108.606 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.44 -161.45 6.79 Favored Glycine 0 CA--C 1.537 1.415 0 N-CA-C 108.174 -1.97 . . . . 0.0 108.174 172.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -67.17 106.38 1.99 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 120.842 -1.387 . . . . 0.0 109.899 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -62.5 156.68 61.3 Favored Pre-proline 0 CA--C 1.536 0.427 0 C-N-CA 126.731 2.013 . . . . 0.0 112.682 -174.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -67.27 151.28 81.13 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.999 2.466 . . . . 0.0 110.391 -175.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -129.95 74.5 80.52 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 123.821 0.848 . . . . 0.0 113.031 -175.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -60.91 174.89 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 122.419 2.079 . . . . 0.0 112.567 173.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 54.9 mttp -140.19 -168.46 2.54 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.891 1.277 . . . . 0.0 108.125 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 23.9 t70 55.65 -121.26 1.66 Allowed 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -174.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -112.71 9.98 25.7 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.716 -1.047 . . . . 0.0 112.856 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.1 mtpp -84.36 150.83 25.1 Favored 'General case' 0 C--N 1.341 0.233 0 CA-C-N 118.404 1.102 . . . . 0.0 109.007 175.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -132.87 110.32 10.23 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 124.292 1.037 . . . . 0.0 112.119 -173.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -66.88 116.07 7.85 Favored Glycine 0 CA--C 1.521 0.426 0 C-N-CA 125.178 1.37 . . . . 0.0 110.085 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -119.96 167.42 12.18 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 122.625 1.202 . . . . 0.0 110.804 175.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 61.7 m -154.69 115.23 3.91 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.02 83.6 5.19 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 172.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -90.42 151.52 21.38 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 35.7 m -121.54 145.57 47.83 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.021 0.528 . . . . 0.0 111.058 -173.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 24.0 t90 -143.61 144.17 31.8 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.45 1.1 . . . . 0.0 110.642 177.05 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 67.2 m-70 -109.6 109.93 59.74 Favored Pre-proline 0 CA--C 1.529 0.17 0 N-CA-C 104.857 -2.275 . . . . 0.0 104.857 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -90.73 133.6 1.76 Allowed 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.416 2.744 . . . . 0.0 113.606 -170.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.1 p -82.58 156.02 24.16 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.625 -1.621 . . . . 0.0 106.625 170.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -61.05 169.01 2.18 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 119.438 1.017 . . . . 0.0 112.438 -176.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 106.43 -177.98 22.37 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 125.636 1.589 . . . . 0.0 112.341 175.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 4.1 m -84.39 141.38 30.89 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.828 0.851 . . . . 0.0 110.073 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -137.35 170.11 16.64 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -142.57 146.83 34.99 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.961 1.304 . . . . 0.0 108.023 -178.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 46.8 p90 -115.59 140.87 48.77 Favored 'General case' 0 CA--C 1.528 0.097 0 O-C-N 123.984 0.803 . . . . 0.0 110.616 176.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.4 m -143.93 152.48 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 C-N-CA 124.548 1.139 . . . . 0.0 112.03 -174.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.1 t -98.8 125.7 44.24 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.58 1.552 . . . . 0.0 109.035 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 16.6 mm-40 -83.98 -4.26 58.59 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -173.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 30.8 mt -61.36 130.43 91.75 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 120.342 1.428 . . . . 0.0 108.239 175.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -39.44 125.08 1.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 124.118 3.212 . . . . 0.0 114.456 -174.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.94 -20.37 20.6 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 124.37 0.986 . . . . 0.0 113.226 176.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -66.98 -43.88 81.89 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 119.028 1.414 . . . . 0.0 112.303 -172.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -63.22 -48.7 77.17 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.703 0.683 . . . . 0.0 110.319 176.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.3 -54.57 43.88 Favored 'General case' 0 C--N 1.34 0.16 0 C-N-CA 123.755 0.822 . . . . 0.0 111.333 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.2 p -143.91 81.85 1.7 Allowed 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.226 1.011 . . . . 0.0 108.54 -174.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.49 -63.84 0.07 OUTLIER Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.246 176.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 4.0 ptm -157.9 129.5 6.8 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 117.795 0.797 . . . . 0.0 112.974 -172.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -162.74 -161.59 0.72 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.625 1.17 . . . . 0.0 108.349 175.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 167.49 171.36 33.42 Favored Glycine 0 C--N 1.334 0.452 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 172.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.0 mttm -110.95 153.69 25.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.373 1.069 . . . . 0.0 110.356 -173.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.9 mt -129.01 143.39 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.41 100.13 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -90.03 126.62 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 45.9 mtmt . . . . . 0 N--CA 1.46 0.052 0 CA-C-N 118.672 0.669 . . . . 0.0 110.828 -179.808 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 p . . . . . 0 CA--C 1.537 0.444 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.2 m -78.25 63.91 3.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.438 1.095 . . . . 0.0 112.155 -173.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 43.3 m95 -97.9 134.29 41.23 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.154 1.382 . . . . 0.0 109.538 174.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -149.57 -178.4 6.41 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -134.77 128.4 32.78 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 171.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.08 -151.82 0.31 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 172.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -142.03 168.13 20.49 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -39.58 -59.49 1.62 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -60.26 -28.74 87.48 Favored 'Trans proline' 0 N--CA 1.46 -0.496 0 CA-C-N 121.028 1.403 . . . . 0.0 112.19 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -66.93 -24.97 66.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 121.471 -0.768 . . . . 0.0 110.728 178.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.428 HG21 ' CD2' ' A' ' 120' ' ' PHE . 24.1 t -62.22 -50.28 80.61 Favored 'Isoleucine or valine' 0 C--N 1.34 0.177 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -58.1 -43.78 87.29 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -55.44 -58.3 8.32 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.903 -0.498 . . . . 0.0 110.988 175.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -58.33 -44.61 88.76 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 122.11 -0.369 . . . . 0.0 111.513 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.0 mt -50.52 -47.39 57.49 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.064 0.546 . . . . 0.0 110.746 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -61.89 -14.94 38.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.045 0.758 . . . . 0.0 113.045 178.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.5 mmmt -97.67 5.22 49.63 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 119.313 0.961 . . . . 0.0 111.651 176.034 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -74.65 125.16 28.08 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.051 -1.03 . . . . 0.0 110.507 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.9 p -93.27 29.33 1.94 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 123.306 0.642 . . . . 0.0 112.62 -176.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -104.32 111.71 3.91 Favored Glycine 0 C--N 1.339 0.726 0 C-N-CA 125.317 1.437 . . . . 0.0 111.139 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -79.63 159.83 26.61 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 173.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.0 t -81.56 150.73 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.5 m -147.72 65.57 1.12 Allowed 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.411 -0.805 . . . . 0.0 108.99 174.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 61.07 -109.34 2.37 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.546 -1.021 . . . . 0.0 110.546 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.2 p-10 -96.68 37.33 1.29 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.848 1.259 . . . . 0.0 110.325 177.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.1 m -160.64 161.98 32.58 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 105.806 -1.924 . . . . 0.0 105.806 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 t -120.27 151.65 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 126.969 2.108 . . . . 0.0 106.939 172.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.0 m -140.29 117.38 11.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.495 0.718 . . . . 0.0 109.18 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -83.06 166.99 18.29 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 174.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 57.3 m -152.29 156.17 39.13 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 175.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.37 165.44 20.53 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -173.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -72.64 -27.22 62.0 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.838 -0.801 . . . . 0.0 111.02 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -78.95 67.76 4.73 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.029 0.932 . . . . 0.0 110.269 -177.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.4 t -79.69 99.36 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.9 t-160 -107.4 94.65 5.21 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.7 107.0 17.27 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.154 0 C-N-CA 123.308 0.643 . . . . 0.0 109.486 -173.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.2 t -93.45 90.74 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -94.91 111.92 23.67 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.218 1.407 . . . . 0.0 110.282 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.98 143.39 27.12 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 174.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.7 104.41 5.77 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-O 121.23 0.538 . . . . 0.0 110.85 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.7 t 50.09 63.74 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 127.203 2.201 . . . . 0.0 111.216 173.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 22.5 mt -76.75 165.26 53.89 Favored Pre-proline 0 CA--C 1.536 0.433 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 99.7 Cg_exo . . . . . 0 CA--C 1.535 0.559 0 C-N-CA 122.888 2.392 . . . . 0.0 113.5 175.854 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 . . . . . 0 CA--C 1.536 0.425 0 N-CA-C 111.925 0.343 . . . . 0.0 111.925 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -109.32 -21.05 0.36 Allowed 'Cis proline' 0 CA--C 1.536 0.609 0 N-CA-C 114.507 0.926 . . . . 0.0 114.507 -3.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.3 p -92.11 170.24 9.99 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 -168.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.25 167.21 22.12 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.75 0.82 . . . . 0.0 109.136 178.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.29 148.25 50.75 Favored 'General case' 0 CA--C 1.538 0.485 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 173.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.1 t -134.89 79.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 123.745 0.818 . . . . 0.0 109.456 -170.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.7 p80 50.48 -74.51 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 127.821 2.448 . . . . 0.0 114.896 175.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -98.0 -37.38 9.79 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 124.643 1.177 . . . . 0.0 110.964 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -111.21 -159.95 0.7 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.876 1.27 . . . . 0.0 108.203 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -140.44 -165.27 1.89 Allowed 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.41 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 14.1 m-80 -12.57 -56.38 0.03 OUTLIER Pre-proline 0 N--CA 1.471 0.598 0 C-N-CA 128.433 2.693 . . . . 0.0 115.242 172.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.6 OUTLIER -15.5 125.64 0.01 OUTLIER 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.983 3.789 . . . . 0.0 116.272 161.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.44 HG23 ' HB2' ' A' ' 151' ' ' LYS . 55.5 m -31.78 144.04 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 129.911 3.284 . . . . 0.0 117.276 -174.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.42 134.68 54.52 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.907 1.683 . . . . 0.0 108.492 174.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -110.07 140.35 44.22 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.249 1.02 . . . . 0.0 108.685 173.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.4 mt -136.71 141.57 35.75 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 -172.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -78.35 125.7 7.18 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.796 2.33 . . . . 0.0 108.123 171.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.02 145.45 16.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.761 0.824 . . . . 0.0 112.553 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.45 2.87 81.45 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-O 119.498 -0.612 . . . . 0.0 112.986 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.88 157.97 20.2 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 118.745 1.273 . . . . 0.0 112.228 174.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 61.2 m -93.6 89.99 6.46 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 172.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 43.2 t -77.58 98.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -173.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -92.51 93.57 8.63 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.035 1.334 . . . . 0.0 107.88 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.95 107.05 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 78.9 m -99.94 103.84 15.43 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 125.326 1.45 . . . . 0.0 109.498 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -81.56 152.24 27.33 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 174.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.92 78.99 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 102.159 -3.275 . . . . 0.0 102.159 163.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -101.5 85.08 2.7 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 176.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.471 HG21 ' CD2' ' A' ' 120' ' ' PHE . 76.3 p -112.08 33.51 4.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.538 -174.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -79.61 70.95 6.19 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 177.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -33.49 103.46 0.03 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.133 2.173 . . . . 0.0 112.462 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.99 -46.05 1.13 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 125.215 1.388 . . . . 0.0 111.293 -177.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -97.76 107.49 20.0 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.483 1.113 . . . . 0.0 111.938 -173.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.89 -16.29 56.69 Favored Glycine 0 CA--C 1.538 1.503 0 CA-C-O 119.199 -0.779 . . . . 0.0 114.457 174.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 46.73 -72.28 0.0 OUTLIER 'General case' 0 C--N 1.343 0.307 0 C-N-CA 129.221 3.008 . . . . 0.0 116.46 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.0 p 88.62 155.98 0.06 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 129.228 3.011 . . . . 0.0 111.867 -172.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -125.13 131.74 53.21 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 103.339 -2.837 . . . . 0.0 103.339 171.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.26 116.42 11.08 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 108.569 -0.901 . . . . 0.0 108.569 -173.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -97.19 125.78 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 124.536 1.134 . . . . 0.0 109.392 -178.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -160.1 -141.94 0.08 Allowed 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -122.91 -110.65 0.32 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.143 0.883 . . . . 0.0 110.431 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt 65.62 -65.54 0.17 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.303 1.841 . . . . 0.0 112.397 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.48 162.56 33.36 Favored Glycine 0 CA--C 1.533 1.212 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -173.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -71.79 158.75 52.42 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.79 2.327 . . . . 0.0 109.804 177.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.22 132.38 27.09 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 CA-C-N 119.146 0.731 . . . . 0.0 110.222 -3.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -79.78 151.97 30.04 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.159 0.504 . . . . 0.0 109.695 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.01 151.65 28.33 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.313 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.8 t -61.45 -41.94 91.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 175.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.5 mmm -77.96 128.77 77.97 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 174.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -76.98 75.65 4.48 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.428 2.085 . . . . 0.0 110.397 -174.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.2 t -77.53 76.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 175.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.0 pt -77.96 89.66 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 122.394 1.092 . . . . 0.0 109.794 -176.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -55.57 146.69 43.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 171.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -25.63 116.26 0.03 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.698 1 C-N-CA 125.676 4.251 . . . . 0.0 115.625 -166.615 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 30.6 mm -78.46 131.6 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.4 t -82.15 -86.07 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.87 149.35 21.63 Favored 'General case' 0 C--N 1.333 -0.123 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 172.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.91 165.76 39.07 Favored Glycine 0 C--N 1.332 0.318 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 174.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.9 p -119.04 123.32 44.21 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.085 0.554 . . . . 0.0 111.792 -174.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -78.03 57.9 3.95 Favored Glycine 0 CA--C 1.535 1.34 0 CA-C-O 119.082 -0.843 . . . . 0.0 113.646 -175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 65.05 124.73 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 127.382 2.273 . . . . 0.0 113.719 174.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 92.0 p -74.23 136.54 75.64 Favored Pre-proline 0 CA--C 1.532 0.288 0 O-C-N 120.899 -1.125 . . . . 0.0 112.457 -173.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.49 84.96 0.92 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.312 2.008 . . . . 0.0 107.066 172.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.3 m -45.06 139.06 4.13 Favored Pre-proline 0 CA--C 1.539 0.533 0 C-N-CA 124.673 1.189 . . . . 0.0 112.851 -174.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -75.74 -178.27 4.2 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.636 2.891 . . . . 0.0 113.665 -173.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.93 176.73 7.1 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 127.043 2.137 . . . . 0.0 107.19 174.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -36.71 120.98 0.73 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.975 1.31 . . . . 0.0 113.269 -174.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 84.53 -27.05 4.85 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.968 0.794 . . . . 0.0 113.738 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 56.5 mttp -85.63 157.4 20.36 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.132 0.966 . . . . 0.0 109.97 -174.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.471 ' CD2' HG21 ' A' ' 79' ' ' THR . 10.1 m-85 -137.18 91.22 2.6 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.427 1.091 . . . . 0.0 111.414 -173.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -47.34 121.31 6.33 Favored Glycine 0 CA--C 1.529 0.924 0 C-N-CA 124.716 1.15 . . . . 0.0 111.74 174.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.7 p90 -144.24 176.32 9.42 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.312 1.053 . . . . 0.0 111.467 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.16 166.58 32.83 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 127.079 2.152 . . . . 0.0 105.757 -176.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -146.68 65.08 1.18 Allowed 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 19.4 p90 -77.99 135.83 37.86 Favored 'General case' 0 C--N 1.34 0.184 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.441 -174.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 14.8 m -99.13 132.6 44.32 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.508 0.723 . . . . 0.0 110.021 -175.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.6 t90 -137.95 143.25 40.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.459 1.104 . . . . 0.0 109.704 176.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 63.5 m80 -111.36 99.41 43.83 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -76.23 173.79 13.91 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 122.364 2.043 . . . . 0.0 109.397 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 81.3 p -119.06 153.6 34.49 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -57.62 142.26 45.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -172.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 135.45 -127.11 4.2 Favored Glycine 0 C--N 1.336 0.555 0 C-N-CA 126.208 1.861 . . . . 0.0 109.411 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -151.95 142.9 23.07 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 118.251 1.026 . . . . 0.0 110.006 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 20.5 m-85 -133.16 -179.28 5.4 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 126.243 1.817 . . . . 0.0 106.958 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -141.65 147.26 37.27 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 124.301 1.04 . . . . 0.0 108.43 174.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -102.46 145.76 29.09 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.0 m -146.64 160.72 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.842 1.257 . . . . 0.0 110.322 174.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.4 t -99.0 125.89 44.58 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.68 1.192 . . . . 0.0 109.691 171.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.69 -27.37 66.36 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 -177.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -57.26 128.94 79.25 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 120.541 1.519 . . . . 0.0 109.826 -174.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_exo -43.83 137.68 6.46 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.262 2.641 . . . . 0.0 113.15 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.59 -27.72 2.49 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.171 -0.794 . . . . 0.0 113.411 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -62.43 -51.53 67.16 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.734 1.767 . . . . 0.0 111.639 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.81 -44.0 86.07 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 117.82 0.282 . . . . 0.0 110.764 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.95 -43.04 99.27 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.135 -0.353 . . . . 0.0 111.364 -179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.6 p -79.14 -41.01 29.53 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 118.877 -0.582 . . . . 0.0 112.175 -174.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 178.26 -15.6 0.03 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 118.725 -1.702 . . . . 0.0 116.977 -176.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 13.3 mtp -79.04 77.03 5.53 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 120.118 1.959 . . . . 0.0 110.456 -174.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -160.17 -174.72 4.67 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.37 164.95 23.93 Favored Glycine 0 C--N 1.341 0.832 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 175.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.44 ' HB2' HG23 ' A' ' 63' ' ' THR . 30.8 mttt -100.99 147.66 25.93 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.9 mt -121.52 100.65 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.15 121.15 38.92 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.064 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.6 t -109.38 95.06 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 -178.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 96.9 mttt . . . . . 0 C--N 1.332 -0.177 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.286 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.2 p . . . . . 0 CA--C 1.532 0.286 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.0 m -77.79 64.13 2.98 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -169.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 71.4 m95 -92.95 156.22 17.06 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 126.645 1.978 . . . . 0.0 110.766 175.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -154.68 179.36 9.14 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 172.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -139.68 150.26 44.68 Favored 'General case' 0 C--N 1.341 0.209 0 CA-C-N 119.557 1.072 . . . . 0.0 111.191 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -130.65 -154.52 0.64 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.009 2.123 . . . . 0.0 107.292 174.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -135.94 171.44 14.46 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.527 0.731 . . . . 0.0 110.198 176.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.67 -59.91 1.23 Allowed Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -174.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -59.77 -30.87 93.05 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 CA-C-N 121.515 1.577 . . . . 0.0 111.964 -178.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -66.97 -22.94 65.9 Favored 'General case' 0 N--CA 1.448 -0.557 0 O-C-N 121.757 -0.589 . . . . 0.0 111.267 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.5 t -59.38 -51.5 71.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -59.78 -49.02 79.35 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.81 -55.69 13.19 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.043 0.214 . . . . 0.0 110.986 177.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 72.6 mtm -57.85 -52.49 65.25 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 123.223 0.609 . . . . 0.0 110.675 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.5 mt -50.67 -44.67 57.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 118.322 0.51 . . . . 0.0 111.057 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -58.81 -25.35 63.07 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 178.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.75 -1.02 36.75 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 119.934 1.243 . . . . 0.0 112.083 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.68 153.42 24.04 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 120.17 1.35 . . . . 0.0 110.782 175.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.2 p -117.94 27.77 8.81 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 123.269 0.628 . . . . 0.0 112.524 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.44 116.57 5.32 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -79.06 154.26 29.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 174.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 t -79.74 145.98 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 O-C-N 121.981 -0.449 . . . . 0.0 110.026 -175.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.2 m -149.08 64.32 1.04 Allowed 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.894 0.878 . . . . 0.0 109.404 174.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.04 -114.11 6.47 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.4 -17.0 55.28 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 123.178 0.591 . . . . 0.0 111.246 175.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -103.29 161.55 13.73 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 125.276 1.43 . . . . 0.0 107.841 -175.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.65 148.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.0 m -135.65 131.47 35.8 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -171.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -100.48 168.89 9.45 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.37 0.605 . . . . 0.0 110.663 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.0 m -155.01 155.0 33.38 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.76 174.35 32.96 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -174.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -77.84 -30.49 51.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 122.243 -0.563 . . . . 0.0 111.785 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.03 74.37 5.56 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.502 0.592 . . . . 0.0 109.968 -175.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.0 t -84.7 89.36 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -177.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -94.47 100.92 12.82 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.96 0.504 . . . . 0.0 110.642 -174.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -95.27 100.26 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 124.89 1.276 . . . . 0.0 108.315 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.1 t -95.7 122.89 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -133.31 116.48 16.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.621 0.646 . . . . 0.0 112.5 -173.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.85 112.56 24.53 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.981 0.913 . . . . 0.0 110.008 175.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.6 92.23 8.49 Favored 'General case' 0 N--CA 1.455 -0.178 0 O-C-N 121.58 -0.7 . . . . 0.0 110.038 -177.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.8 t 63.67 97.17 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 125.195 1.398 . . . . 0.0 111.324 174.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 75.2 mt -74.98 140.85 74.22 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -174.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo . . . . . 0 N--CA 1.457 -0.649 0 C-N-CA 123.629 2.886 . . . . 0.0 111.392 178.454 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.9 m-30 . . . . . 0 CA--C 1.543 0.679 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -124.45 29.62 0.16 OUTLIER 'Cis proline' 0 CA--C 1.537 0.664 0 CA-C-N 120.722 1.294 . . . . 0.0 109.999 -7.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.8 p -92.09 125.25 36.7 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 116.94 2.2 . . . . 0.0 116.94 -171.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.69 103.71 9.78 Favored 'General case' 0 C--N 1.342 0.243 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 166.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -88.03 112.03 22.18 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -176.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -111.49 84.7 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 125.14 1.376 . . . . 0.0 109.783 -171.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 46.98 -98.97 0.04 OUTLIER 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 125.78 1.632 . . . . 0.0 112.9 176.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -70.73 -24.69 62.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.565 0.346 . . . . 0.0 111.877 -176.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -130.57 -178.07 4.62 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.232 1.013 . . . . 0.0 110.679 -173.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.2 mtmp? -130.12 122.32 28.03 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 105.88 -1.896 . . . . 0.0 105.88 172.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 55.33 44.37 1.62 Allowed Pre-proline 0 CA--C 1.541 0.607 0 C-N-CA 124.705 1.202 . . . . 0.0 112.275 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.71 172.06 15.69 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.475 2.117 . . . . 0.0 111.567 -176.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 151' ' ' LYS . 28.5 m -91.9 138.86 31.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 170.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.0 mp -112.25 126.99 55.83 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.83 0.852 . . . . 0.0 110.241 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -100.01 119.51 38.38 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 15.3 mt -124.04 142.24 39.2 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.392 1.077 . . . . 0.0 112.95 -171.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.15 118.71 4.07 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 122.935 2.423 . . . . 0.0 108.893 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.88 142.99 3.1 Favored 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 125.41 1.484 . . . . 0.0 112.31 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 80.49 -22.2 4.81 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 118.982 -0.899 . . . . 0.0 113.706 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.21 158.17 5.56 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.113 1.456 . . . . 0.0 111.969 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -79.84 96.68 6.4 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.5 t -78.68 90.36 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 174.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -84.36 119.3 24.94 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 174.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -111.79 114.36 46.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -176.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 94.4 m -107.47 104.35 13.9 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.541 1.137 . . . . 0.0 109.473 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.4 m-85 -79.53 162.9 25.1 Favored 'General case' 0 C--O 1.221 -0.414 0 O-C-N 121.662 -0.649 . . . . 0.0 112.429 174.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -137.61 78.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 101.651 -3.462 . . . . 0.0 101.651 163.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -99.94 96.51 7.6 Favored 'General case' 0 N--CA 1.457 -0.111 0 N-CA-C 106.811 -1.552 . . . . 0.0 106.811 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.7 m -147.44 59.32 1.15 Allowed 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 174.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -82.3 66.41 7.88 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 173.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 8.72 72.82 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.75 3.22 . . . . 0.0 113.927 -171.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.42 -44.83 1.29 Allowed Glycine 0 CA--C 1.527 0.796 0 C-N-CA 124.31 0.957 . . . . 0.0 111.382 178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -79.72 95.62 6.02 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.842 0.83 . . . . 0.0 110.091 -175.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.99 61.35 2.58 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.412 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -45.54 124.57 5.09 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.271 1.028 . . . . 0.0 110.857 173.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 96.8 p -87.2 167.06 14.47 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -134.05 112.5 11.23 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 172.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -131.27 127.59 38.08 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -173.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 47.5 mt -99.31 127.91 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 C-N-CA 125.818 1.647 . . . . 0.0 108.475 -174.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.48 -149.03 0.18 Allowed 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt -129.26 25.28 5.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.696 1.134 . . . . 0.0 111.994 -178.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -73.74 94.95 2.3 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 173.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -73.49 171.33 51.69 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 173.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.1 150.15 82.27 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.282 1.988 . . . . 0.0 109.65 175.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -75.31 130.75 22.13 Favored 'Cis proline' 0 N--CA 1.454 -0.807 0 N-CA-C 109.941 -0.83 . . . . 0.0 109.941 -3.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -78.75 145.82 34.21 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.4 145.59 39.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-O 121.382 0.61 . . . . 0.0 112.044 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -67.52 -43.41 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -78.85 144.95 65.15 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 177.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -64.01 68.83 0.2 Allowed 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.638 2.892 . . . . 0.0 113.685 175.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.43 75.52 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.4 pt -76.35 86.0 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 123.509 1.623 . . . . 0.0 110.816 -172.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.28 155.69 83.9 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 113.125 -1.852 . . . . 0.0 106.913 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -39.57 112.42 0.15 Allowed 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 123.91 3.073 . . . . 0.0 113.986 -176.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.1 mm -79.24 132.17 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -82.29 -87.11 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.49 156.16 16.46 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 123.394 0.678 . . . . 0.0 109.365 173.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.44 178.21 45.1 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 118.956 -1.592 . . . . 0.0 113.904 174.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 17.3 p -121.26 155.27 35.01 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 126.464 1.906 . . . . 0.0 109.424 175.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -90.09 -127.55 3.42 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 173.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -116.2 134.98 54.32 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 118.495 1.148 . . . . 0.0 108.61 176.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 4.5 p -76.58 177.56 2.5 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -172.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.56 -7.08 13.46 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.271 2.648 . . . . 0.0 113.015 172.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m 35.24 67.15 1.46 Allowed Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 126.285 1.834 . . . . 0.0 115.857 -178.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -60.72 178.59 0.46 Allowed 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.726 2.284 . . . . 0.0 113.796 174.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -142.45 -171.98 3.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.043 0.937 . . . . 0.0 110.187 -177.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 26.1 t70 62.65 -77.3 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 126.862 2.065 . . . . 0.0 111.549 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.75 15.66 0.3 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.966 0.793 . . . . 0.0 111.869 177.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 31.8 mtmm -87.59 155.9 19.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 174.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -140.07 104.07 4.76 Favored 'General case' 0 CA--C 1.517 -0.297 0 C-N-CA 123.765 0.826 . . . . 0.0 112.416 -171.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -67.38 107.85 2.2 Favored Glycine 0 CA--C 1.526 0.725 0 C-N-CA 125.299 1.428 . . . . 0.0 109.841 174.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -103.48 178.62 4.5 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.889 0.852 . . . . 0.0 109.374 173.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.87 157.75 43.66 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 -177.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.0 m-20 -139.46 87.5 2.19 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -100.59 168.78 9.49 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 172.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 16.6 m -151.86 148.94 28.42 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 120.952 -1.093 . . . . 0.0 108.976 -175.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 22.0 t90 -147.22 149.47 32.98 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 124.627 1.171 . . . . 0.0 110.225 -174.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -113.06 108.32 53.28 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 172.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -89.8 145.79 4.67 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 123.419 2.746 . . . . 0.0 112.693 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.8 p -89.55 154.94 19.61 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.983 1.313 . . . . 0.0 108.329 172.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.35 169.16 1.26 Allowed 'General case' 0 CA--C 1.538 0.484 0 O-C-N 121.603 -0.686 . . . . 0.0 112.225 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 108.09 -130.61 10.17 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 125.182 1.373 . . . . 0.0 110.192 178.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.7 m -151.56 144.48 24.48 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 118.28 1.04 . . . . 0.0 110.377 -175.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -137.57 174.94 10.05 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 126.221 1.809 . . . . 0.0 107.727 178.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -135.79 139.21 43.34 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.482 1.513 . . . . 0.0 108.6 179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -103.36 139.59 38.57 Favored 'General case' 0 N--CA 1.457 -0.116 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 172.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.7 m -147.15 168.62 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.229 1.011 . . . . 0.0 110.701 178.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 10.3 t -106.09 136.85 45.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 126.461 1.905 . . . . 0.0 108.485 173.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -77.49 -26.28 51.1 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 123.867 0.867 . . . . 0.0 113.22 -173.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 52.7 mt -57.92 130.82 82.97 Favored Pre-proline 0 CA--C 1.543 0.696 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.93 143.56 3.03 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 124.128 3.219 . . . . 0.0 114.778 -174.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.91 -39.73 1.37 Allowed Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.211 0.91 . . . . 0.0 113.958 174.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 25.0 m170 -50.24 -48.81 54.46 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.591 1.156 . . . . 0.0 114.062 -172.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.19 -49.83 74.24 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-O 120.736 0.303 . . . . 0.0 110.368 178.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -58.41 -42.1 86.4 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.256 0.622 . . . . 0.0 110.853 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 32.5 p -79.84 -41.29 26.66 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 118.129 -0.938 . . . . 0.0 113.196 -174.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -169.46 -41.13 0.03 OUTLIER Glycine 0 C--N 1.342 0.871 0 C-N-CA 118.028 -2.034 . . . . 0.0 117.881 -174.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.268 3.8 ptp -79.91 94.17 5.81 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 120.381 2.09 . . . . 0.0 112.196 -173.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -157.76 -178.28 7.21 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.083 0.953 . . . . 0.0 110.353 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.28 161.14 19.07 Favored Glycine 0 C--N 1.338 0.655 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 173.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.467 ' HB2' HG23 ' A' ' 63' ' ' THR . 90.8 mttt -96.31 145.75 25.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.653 1.581 . . . . 0.0 109.553 -175.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.7 mt -122.4 101.09 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 173.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -89.67 132.19 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 25.7 t -123.94 125.98 71.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 24.1 mtpp . . . . . 0 N--CA 1.464 0.226 0 CA-C-N 118.898 0.772 . . . . 0.0 111.276 -177.932 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.5 p . . . . . 0 N--CA 1.446 -0.654 0 CA-C-O 119.413 -0.327 . . . . 0.0 111.645 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.2 m -79.71 62.71 4.06 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.155 0.889 . . . . 0.0 110.139 -174.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 73.6 m95 -94.49 122.26 36.88 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 125.177 1.391 . . . . 0.0 111.282 -174.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -142.11 -176.47 4.82 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -136.43 132.32 35.29 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 121.838 -0.539 . . . . 0.0 109.83 172.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -87.74 -154.56 0.26 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 104.303 -2.48 . . . . 0.0 104.303 169.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.8 p -142.61 165.19 28.09 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 120.921 -1.112 . . . . 0.0 108.713 174.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.3 tt -39.9 -53.02 4.99 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 114.687 1.365 . . . . 0.0 114.687 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -57.54 -31.19 90.91 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.865 1.71 . . . . 0.0 112.572 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -71.13 -33.63 70.28 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 122.995 0.518 . . . . 0.0 110.204 178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.427 HG21 ' CD2' ' A' ' 120' ' ' PHE . 13.6 t -62.74 -48.61 87.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -54.45 -44.96 72.96 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.988 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.91 -48.07 67.52 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.25 0.62 . . . . 0.0 111.437 175.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 68.8 mtm -70.1 -30.94 68.28 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 118.483 -0.77 . . . . 0.0 112.221 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.57 57.36 1.22 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-O 122.331 1.062 . . . . 0.0 109.757 172.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -137.29 -40.27 0.58 Allowed 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 129.383 3.073 . . . . 0.0 104.839 173.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . 0.294 0.0 OUTLIER 84.72 142.58 0.06 Allowed 'General case' 0 N--CA 1.442 -0.831 0 C-N-CA 128.974 2.91 . . . . 0.0 114.648 170.247 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -101.19 -147.8 0.36 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 111.688 -2.506 . . . . 0.0 109.091 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.2 p -44.16 131.66 5.94 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 126.717 2.007 . . . . 0.0 112.675 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 145.06 90.63 0.11 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.169 0.89 . . . . 0.0 110.928 174.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -79.13 137.79 37.63 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 174.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.5 t -63.69 146.89 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 33.0 m -148.52 64.66 1.07 Allowed 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 174.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 66.07 -142.99 44.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 107.642 -2.183 . . . . 0.0 107.642 -172.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -80.01 54.85 1.99 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.721 1.261 . . . . 0.0 109.733 174.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.9 m -160.86 153.9 21.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 178.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 93.5 t -123.46 142.08 41.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -125.77 129.44 49.47 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.963 1.305 . . . . 0.0 108.562 -174.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -93.18 167.07 12.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.493 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.6 m -156.26 61.58 0.56 Allowed 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.552 0.741 . . . . 0.0 109.621 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.87 166.07 38.58 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 108.234 -1.947 . . . . 0.0 108.234 177.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -75.18 -50.4 16.37 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 117.435 0.617 . . . . 0.0 109.659 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.3 p -79.83 93.62 5.66 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 42.5 t -82.82 98.53 4.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -94.11 116.01 28.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.8 122.47 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 124.864 1.265 . . . . 0.0 108.601 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 95.5 t -92.2 113.82 28.12 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 175.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.83 92.66 3.9 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.871 1.269 . . . . 0.0 110.392 -178.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.33 113.51 24.8 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.273 1.029 . . . . 0.0 109.999 178.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.1 114.45 24.73 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.209 -0.932 . . . . 0.0 110.409 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.4 t 32.89 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 126.67 1.988 . . . . 0.0 112.892 173.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.7 142.02 69.55 Favored Pre-proline 0 CA--C 1.533 0.31 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -178.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo . . . . . 0 N--CA 1.454 -0.802 0 C-N-CA 123.079 2.519 . . . . 0.0 110.429 -174.404 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 . . . . . 0 CA--C 1.534 0.358 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -116.64 50.95 0.65 Allowed 'Cis proline' 0 CA--C 1.536 0.591 0 N-CA-C 108.441 -1.407 . . . . 0.0 108.441 -5.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.7 p -93.05 129.3 39.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -173.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -77.95 121.69 24.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 N-CA-C 103.247 -2.871 . . . . 0.0 103.247 166.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -91.88 113.99 26.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -120.59 117.79 54.4 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 119.051 0.841 . . . . 0.0 110.584 -171.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 0.1 OUTLIER 36.93 -104.71 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.641 1.976 . . . . 0.0 113.067 -174.751 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.22 -17.68 39.04 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -124.5 -166.93 1.58 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 124.263 1.025 . . . . 0.0 110.833 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 51.2 mttm -133.95 124.74 26.86 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.192 -1.781 . . . . 0.0 106.192 172.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 52.91 44.24 1.91 Allowed Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.657 1.183 . . . . 0.0 112.354 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -79.28 173.72 12.91 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 122.372 2.048 . . . . 0.0 111.482 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.477 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.8 m -94.62 140.68 29.55 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.73 121.45 44.11 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.413 1.485 . . . . 0.0 112.305 -171.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -103.46 111.02 23.27 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.988 0.915 . . . . 0.0 108.737 173.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.9 mt -112.58 135.45 21.51 Favored Pre-proline 0 CA--C 1.537 0.447 0 C-N-CA 125.739 1.616 . . . . 0.0 110.289 -173.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.67 116.63 4.32 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 122.629 2.22 . . . . 0.0 108.747 172.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.03 133.58 27.21 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.593 0.757 . . . . 0.0 110.597 177.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.98 -26.63 16.75 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.986 -1.245 . . . . 0.0 109.986 -173.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.08 32.23 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.891 0.846 . . . . 0.0 111.845 174.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 95.2 m -105.08 130.22 53.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 t -100.53 99.28 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 124.253 1.021 . . . . 0.0 110.881 -172.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.53 93.71 8.4 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.0 t -83.93 100.64 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 174.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 93.3 m -86.75 100.07 12.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.497 1.119 . . . . 0.0 109.109 174.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 2.9 m-85 -76.74 155.7 33.0 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.35 172.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.0 mp -137.96 92.2 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 101.868 -3.382 . . . . 0.0 101.868 163.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -113.54 113.31 24.93 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 172.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 49.1 m -146.17 45.89 1.24 Allowed 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 172.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -75.74 71.02 2.58 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 173.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.2 mtmm -17.74 87.96 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.527 3.131 . . . . 0.0 113.929 -173.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.435 ' H ' ' CG1' ' A' ' 114' ' ' VAL . . . 133.32 -45.27 1.13 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.383 0.992 . . . . 0.0 111.507 178.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -97.33 111.99 24.0 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 117.506 0.653 . . . . 0.0 112.272 -173.06 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.62 54.96 2.5 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.937 0.78 . . . . 0.0 111.475 173.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -48.34 139.84 8.33 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.643 1.221 . . . . 0.0 111.347 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.4 p -104.51 165.99 10.69 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.53 1.132 . . . . 0.0 108.435 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 9.0 t80 -131.28 116.52 17.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 105.596 -2.002 . . . . 0.0 105.596 171.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . 0.488 ' HB3' HD12 ' A' ' 105' ' ' ILE . 16.8 m-20 -133.03 129.83 38.61 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 118.91 0.777 . . . . 0.0 110.642 -172.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 34.4 mt -104.38 134.04 46.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 C-N-CA 126.016 1.726 . . . . 0.0 108.864 -176.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.2 t -159.13 -154.61 0.42 Allowed 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 48.8 mtmt -126.56 21.88 7.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 119.232 0.924 . . . . 0.0 111.804 -179.154 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -70.37 118.87 13.73 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.05 159.33 43.38 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 174.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -72.5 164.53 35.34 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.969 2.446 . . . . 0.0 109.598 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -71.35 141.46 69.8 Favored 'Cis proline' 0 N--CA 1.459 -0.543 0 CA-C-N 119.333 0.798 . . . . 0.0 110.634 -5.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -79.91 150.86 30.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 121.289 0.566 . . . . 0.0 109.874 175.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.43 151.99 27.63 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.377 177.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 65.9 t -61.1 -39.18 81.47 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 174.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 92.3 mmm -78.2 133.1 65.02 Favored Pre-proline 0 N--CA 1.452 -0.373 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 174.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.87 75.57 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.751 2.301 . . . . 0.0 111.974 -173.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.9 t -79.02 65.5 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 172.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -88.43 -43.79 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.84 1.656 . . . . 0.0 111.801 -173.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -64.25 146.52 97.67 Favored Pre-proline 0 CA--C 1.531 0.215 0 C-N-CA 123.119 0.568 . . . . 0.0 111.515 -173.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.26 143.28 74.57 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 CA-C-N 119.038 0.692 . . . . 0.0 111.261 -2.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.488 HD12 ' HB3' ' A' ' 88' ' ' ASP . 19.4 mm -91.44 143.49 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 92.2 t -87.05 -92.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 104.432 -2.432 . . . . 0.0 104.432 173.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.17 145.65 24.87 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -178.6 161.5 28.09 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.264 -1.446 . . . . 0.0 111.237 174.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 34.6 p -103.02 149.25 24.74 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 125.186 1.395 . . . . 0.0 108.248 175.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.91 -156.7 8.78 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 173.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -74.74 139.12 43.18 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.506 1.153 . . . . 0.0 109.071 174.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 51.8 p -81.66 163.91 51.74 Favored Pre-proline 0 C--O 1.233 0.216 0 C-N-CA 122.497 0.319 . . . . 0.0 111.547 -174.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -64.97 166.33 18.84 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 N-CA-C 106.395 -2.194 . . . . 0.0 106.395 168.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.435 ' CG1' ' H ' ' A' ' 82' ' ' GLY . 14.4 t -130.55 76.75 77.0 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -172.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -62.76 162.12 26.31 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 122.154 1.903 . . . . 0.0 110.256 172.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -137.19 5.95 2.8 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -178.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -174.33 148.94 1.3 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 125.469 1.508 . . . . 0.0 109.102 174.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.94 -66.21 0.13 Allowed Glycine 0 CA--C 1.527 0.832 0 C-N-CA 126.533 2.015 . . . . 0.0 113.935 174.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -79.02 151.53 31.46 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 125.22 1.408 . . . . 0.0 110.525 -176.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.427 ' CD2' HG21 ' A' ' 15' ' ' VAL . 10.1 m-85 -134.76 101.98 5.11 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 125.46 1.504 . . . . 0.0 111.096 -174.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.95 112.28 1.87 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 125.272 1.415 . . . . 0.0 111.227 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -130.67 155.23 46.94 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.931 0.893 . . . . 0.0 111.29 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 6.6 m -154.78 114.4 3.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -174.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.09 62.55 4.21 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 125.199 1.399 . . . . 0.0 108.525 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -70.15 121.82 18.26 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 118.305 -1.358 . . . . 0.0 108.526 -174.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 41.0 m -96.86 84.73 3.63 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.389 -172.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -78.36 124.75 28.46 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -94.02 106.39 22.05 Favored Pre-proline 0 N--CA 1.451 -0.417 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 171.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -83.23 177.85 6.25 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.975 2.45 . . . . 0.0 112.169 -171.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.5 p -131.09 153.88 48.86 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 172.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.38 165.3 7.85 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.531 1.06 . . . . 0.0 111.935 -174.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 112.86 -168.18 12.54 Favored Glycine 0 CA--C 1.525 0.676 0 C-N-CA 124.718 1.151 . . . . 0.0 112.297 174.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 28.5 m -98.3 139.89 33.4 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 124.028 0.931 . . . . 0.0 109.08 -176.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -140.35 177.29 8.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 125.27 1.428 . . . . 0.0 107.235 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -145.44 152.7 40.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 176.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -116.74 149.13 40.39 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 123.489 0.716 . . . . 0.0 110.382 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 28.6 m -152.78 161.88 2.56 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 C-N-CA 125.052 1.341 . . . . 0.0 111.314 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 3.1 t -100.14 134.11 43.55 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.406 1.482 . . . . 0.0 107.892 170.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -74.05 -22.17 59.65 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -173.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 57.1 mt -60.78 126.98 86.6 Favored Pre-proline 0 CA--C 1.542 0.665 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -177.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -44.86 146.89 2.14 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 123.934 3.089 . . . . 0.0 114.056 -174.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.2 -39.01 1.61 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 123.304 0.478 . . . . 0.0 113.055 177.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.1 m170 -54.02 -51.55 63.63 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.491 1.145 . . . . 0.0 111.879 -173.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.28 -47.29 81.84 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 117.891 0.314 . . . . 0.0 110.986 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.47 97.27 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 122.783 0.433 . . . . 0.0 111.132 -178.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 40.4 p -79.99 -35.81 36.89 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -173.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.41 -27.34 0.04 OUTLIER Glycine 0 CA--C 1.528 0.898 0 N-CA-C 117.081 1.592 . . . . 0.0 117.081 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 3.6 mtt -78.12 80.43 4.55 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 120.07 1.935 . . . . 0.0 110.943 -173.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -162.28 -174.38 4.04 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.71 163.32 21.41 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 173.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.477 ' HB2' HG23 ' A' ' 63' ' ' THR . 49.2 mttt -99.33 154.1 18.45 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.046 0.939 . . . . 0.0 108.954 -175.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.4 mt -130.33 138.1 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 178.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 42.8 t -130.25 101.0 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 173.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 40.1 t -87.0 88.14 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 174.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.3 mttt . . . . . 0 C--N 1.332 -0.182 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 177.109 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 77.3 p . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 111.86 0.319 . . . . 0.0 111.86 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.8 m -98.84 122.33 41.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 123.846 0.858 . . . . 0.0 108.871 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -155.7 127.1 7.22 Favored 'General case' 0 C--N 1.341 0.233 0 C-N-CA 126.32 1.848 . . . . 0.0 108.417 173.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -150.07 170.62 18.45 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 173.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -135.91 148.14 48.43 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 172.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -118.24 -155.94 0.62 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 127.862 2.465 . . . . 0.0 106.357 174.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 29.9 p -134.43 173.04 12.07 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.577 0.751 . . . . 0.0 109.49 174.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.0 tt -39.05 -56.81 2.36 Favored Pre-proline 0 CA--C 1.538 0.481 0 N-CA-C 114.508 1.299 . . . . 0.0 114.508 -174.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -56.39 -31.46 85.38 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.32 1.347 . . . . 0.0 113.606 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.6 mp0 -68.28 -27.61 66.46 Favored 'General case' 0 N--CA 1.457 -0.115 0 O-C-N 121.177 -0.952 . . . . 0.0 111.249 176.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -61.31 -50.54 80.01 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -55.45 -47.11 76.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.889 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.68 -59.9 3.91 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 122.438 0.295 . . . . 0.0 110.978 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.5 mtm -54.59 -47.9 72.8 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.209 0.604 . . . . 0.0 111.153 -176.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.9 mt -50.51 -33.51 21.74 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 113.269 0.841 . . . . 0.0 113.269 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -73.09 -31.59 64.46 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.556 -0.715 . . . . 0.0 110.534 178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt -81.51 60.96 4.74 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 121.767 -0.583 . . . . 0.0 110.19 -176.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -125.42 102.12 7.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.116 0.566 . . . . 0.0 110.632 174.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.3 p -73.86 45.97 0.21 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.946 1.698 . . . . 0.0 111.197 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.24 112.6 2.42 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 125.508 1.528 . . . . 0.0 111.152 -174.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -79.12 -178.78 6.33 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.3 t -113.7 152.18 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 123.969 0.907 . . . . 0.0 108.89 177.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.7 m -149.1 73.41 1.21 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.373 1.069 . . . . 0.0 108.358 174.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.17 -144.36 39.27 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -172.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -79.46 59.1 2.83 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.653 1.226 . . . . 0.0 109.413 175.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -161.0 146.4 14.28 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.79 1.636 . . . . 0.0 106.708 -179.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 23.3 t -102.64 147.86 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 174.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 55.4 m -134.3 110.63 9.62 Favored 'General case' 0 CA--C 1.521 -0.172 0 C-N-CA 123.426 0.69 . . . . 0.0 109.954 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -82.8 169.01 16.6 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.564 0.697 . . . . 0.0 111.4 178.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -155.04 159.08 40.03 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 124.503 1.121 . . . . 0.0 107.988 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.39 -179.54 32.77 Favored Glycine 0 CA--C 1.53 1.019 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -176.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -85.63 -27.48 25.39 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.771 0.428 . . . . 0.0 111.211 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.6 m -79.18 69.2 5.34 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.107 0.963 . . . . 0.0 110.335 -176.083 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.44 78.55 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.975 0.893 . . . . 0.0 108.935 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 t-80 -83.4 105.61 14.49 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.9 t -107.36 95.75 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -174.07 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.6 t -83.66 123.32 38.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -174.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -132.52 114.61 14.48 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.461 1.104 . . . . 0.0 111.373 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.22 143.21 26.48 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.575 0.75 . . . . 0.0 109.819 174.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.421 ' HB3' ' HA ' ' A' ' 78' ' ' ASN . . . -116.25 96.54 5.59 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.012 0.525 . . . . 0.0 110.698 176.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.8 t 49.19 72.14 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.329 0 C-N-CA 128.407 2.683 . . . . 0.0 111.823 175.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.62 142.76 66.67 Favored Pre-proline 0 CA--C 1.533 0.32 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 176.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo . . . . . 0 N--CA 1.457 -0.637 0 C-N-CA 124.362 3.375 . . . . 0.0 112.819 178.41 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -92.13 -9.13 34.55 Favored 'Cis proline' 0 CA--C 1.538 0.687 0 CA-C-N 118.82 0.614 . . . . 0.0 111.423 -5.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -36.95 121.51 0.78 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -168.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -77.33 121.67 24.05 Favored 'General case' 0 C--N 1.346 0.447 0 C-N-CA 126.126 1.77 . . . . 0.0 107.161 171.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -94.53 112.07 23.83 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.182 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.47 81.71 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.226 0 C-N-CA 124.357 1.063 . . . . 0.0 109.344 -172.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.434 ' CD2' ' H ' ' A' ' 58' ' ' ASP . 31.9 p-80 44.66 -84.74 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 127.367 2.267 . . . . 0.0 114.629 177.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.434 ' H ' ' CD2' ' A' ' 57' ' ' HIS . 30.1 t70 -75.89 -29.46 58.47 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.336 0.654 . . . . 0.0 110.991 -175.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -136.72 -173.6 3.48 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.453 0.701 . . . . 0.0 109.777 -175.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -126.03 127.0 45.19 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 174.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.9 m-80 50.67 44.08 2.0 Allowed Pre-proline 0 CA--C 1.537 0.459 0 C-N-CA 124.915 1.286 . . . . 0.0 112.575 178.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -83.29 176.07 7.69 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.676 1.584 . . . . 0.0 110.863 -175.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.5 m -95.42 144.02 26.28 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 170.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.23 143.97 45.3 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.539 0.736 . . . . 0.0 110.806 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -110.18 125.33 52.94 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 170.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.6 mt -130.15 138.09 32.31 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 123.464 0.706 . . . . 0.0 111.893 -171.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.65 117.93 4.69 Favored 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 122.884 2.39 . . . . 0.0 109.233 172.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.73 141.41 10.01 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 125.053 1.341 . . . . 0.0 111.724 177.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.64 -2.07 55.38 Favored Glycine 0 CA--C 1.531 1.091 0 CA-C-O 118.936 -0.924 . . . . 0.0 113.719 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.76 158.77 31.63 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.708 1.754 . . . . 0.0 110.352 173.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 29.6 m -83.18 93.32 7.63 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 174.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 51.8 t -79.38 99.08 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -91.63 90.72 7.7 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.9 t -77.18 105.56 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 104.246 -2.501 . . . . 0.0 104.246 176.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 55.4 m -100.63 98.99 9.49 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 125.585 1.554 . . . . 0.0 109.797 -171.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.496 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.5 m-85 -77.38 158.77 29.92 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.38 68.26 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 101.652 -3.462 . . . . 0.0 101.652 164.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.431 HD22 ' C ' ' A' ' 78' ' ' ASN . 0.2 OUTLIER -87.24 67.06 9.48 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 -174.728 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.2 m -112.61 83.0 1.74 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 114.669 -1.15 . . . . 0.0 110.616 -175.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -120.14 119.91 34.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 172.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.33 72.82 1.31 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.109 0.564 . . . . 0.0 109.519 -175.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 162.82 -65.64 0.25 Allowed Glycine 0 CA--C 1.522 0.499 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -94.03 112.83 24.7 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.449 -0.442 . . . . 0.0 111.183 -174.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.68 38.99 0.91 Allowed Glycine 0 CA--C 1.537 1.418 0 CA-C-O 118.928 -0.929 . . . . 0.0 111.865 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 0.95 -78.42 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 129.86 3.264 . . . . 0.0 117.513 -172.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.5 p 99.13 155.08 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 129.967 3.307 . . . . 0.0 110.196 -173.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.496 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 6.7 t80 -134.01 110.42 9.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 173.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -122.94 140.94 52.46 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.5 mt -115.64 126.7 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.665 1.586 . . . . 0.0 110.257 -172.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -161.05 164.74 30.63 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -83.86 56.41 3.66 Favored 'General case' 0 CA--C 1.535 0.394 0 O-C-N 121.608 -0.682 . . . . 0.0 110.621 -174.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -105.56 107.91 19.15 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 175.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.05 160.12 52.62 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 175.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.67 162.11 43.31 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.986 2.458 . . . . 0.0 109.81 174.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 158.63 93.88 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 CA-C-N 119.006 0.681 . . . . 0.0 110.595 -3.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -96.32 153.56 17.75 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.1 151.1 35.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 175.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 60.3 t -60.38 -38.51 77.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 174.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -78.53 133.48 63.21 Favored Pre-proline 0 N--CA 1.451 -0.409 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 174.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -74.75 80.53 2.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.409 2.073 . . . . 0.0 109.739 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 70.2 t -77.0 84.24 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 178.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.3 pt -77.58 83.04 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-O 123.065 1.412 . . . . 0.0 111.625 -173.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -62.12 154.54 69.31 Favored Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 171.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -37.18 112.59 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 124.248 3.299 . . . . 0.0 114.375 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 32.1 mm -79.48 139.44 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 59.6 t -86.0 -88.32 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 174.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.29 146.5 23.98 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.49 -178.9 42.96 Favored Glycine 0 C--N 1.333 0.368 0 CA-C-N 120.153 1.342 . . . . 0.0 112.219 173.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.2 p -122.95 -37.96 2.67 Favored 'General case' 0 C--N 1.338 0.083 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -176.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 78.34 -175.45 54.71 Favored Glycine 0 CA--C 1.541 1.701 0 N-CA-C 107.658 -2.177 . . . . 0.0 107.658 -170.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.19 141.71 39.96 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.911 1.855 . . . . 0.0 114.513 -171.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.0 p -83.82 155.12 64.97 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -174.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -73.67 75.0 3.17 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.458 2.772 . . . . 0.0 110.688 175.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 66.9 t -20.34 96.16 0.05 OUTLIER Pre-proline 0 CA--C 1.542 0.665 0 C-N-CA 128.195 2.598 . . . . 0.0 112.846 175.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.453 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 33.4 Cg_exo -66.47 171.71 10.2 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.723 2.948 . . . . 0.0 112.582 -178.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -124.76 151.94 44.48 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.653 1.181 . . . . 0.0 109.25 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 39.23 -103.4 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 127.219 2.208 . . . . 0.0 113.62 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -92.25 -2.11 68.74 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.496 -1.169 . . . . 0.0 114.476 -173.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -86.44 153.35 21.95 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.687 1.243 . . . . 0.0 110.442 -176.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -138.32 111.37 7.85 Favored 'General case' 0 C--O 1.224 -0.242 0 C-N-CA 124.987 1.315 . . . . 0.0 111.457 -172.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.453 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -78.92 113.15 3.6 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 125.459 1.504 . . . . 0.0 110.589 -174.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -121.59 164.46 17.24 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.798 0.839 . . . . 0.0 111.796 -176.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.2 m -165.94 115.61 0.99 Allowed 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 124.523 1.129 . . . . 0.0 108.103 178.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -84.99 67.25 10.14 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -66.79 122.45 17.7 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.1 m -97.98 130.12 44.84 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.704 -1.135 . . . . 0.0 110.379 -171.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -140.0 145.3 37.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.791 1.236 . . . . 0.0 109.669 -178.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -114.77 94.25 36.71 Favored Pre-proline 0 N--CA 1.454 -0.25 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -80.16 150.43 20.24 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 122.573 2.182 . . . . 0.0 111.287 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.3 p -101.31 155.21 18.17 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -53.58 141.56 25.33 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -173.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 136.61 176.49 14.39 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 126.198 1.856 . . . . 0.0 111.189 175.351 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.6 m -98.42 109.98 22.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.143 0.977 . . . . 0.0 110.317 -174.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -101.28 173.56 6.39 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 172.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -134.63 143.18 47.14 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -104.52 141.64 36.03 Favored 'General case' 0 CA--C 1.522 -0.126 0 CA-C-O 118.569 -0.729 . . . . 0.0 109.682 174.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 5.0 m -147.74 156.57 9.58 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 123.928 0.891 . . . . 0.0 111.77 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 11.2 t -94.9 131.58 40.66 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 126.595 1.958 . . . . 0.0 109.365 173.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -82.79 -1.39 51.54 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -172.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.33 136.42 93.52 Favored Pre-proline 0 CA--C 1.537 0.444 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 173.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.6 144.74 10.15 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.451 2.101 . . . . 0.0 112.554 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.07 -44.99 2.2 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.628 0.632 . . . . 0.0 112.995 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -48.41 -52.73 20.6 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 118.761 1.281 . . . . 0.0 113.989 -173.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.87 -52.11 66.41 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 120.877 0.37 . . . . 0.0 110.145 176.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.28 -39.74 91.56 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.684 1.194 . . . . 0.0 111.686 -175.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.2 p -79.01 -36.49 41.09 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 118.473 -0.775 . . . . 0.0 111.31 -174.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.33 -22.74 0.07 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 117.123 -2.465 . . . . 0.0 118.188 174.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.331 17.8 ptm -80.72 92.8 6.08 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 121.134 2.467 . . . . 0.0 112.93 -173.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.65 -175.1 4.78 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.188 0.995 . . . . 0.0 109.332 179.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 176.23 170.6 39.1 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 173.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.421 ' HB2' HG23 ' A' ' 63' ' ' THR . 38.0 mttt -107.08 146.56 31.06 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 124.447 1.099 . . . . 0.0 109.785 -173.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.5 mt -121.21 99.12 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 125.371 1.469 . . . . 0.0 107.062 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.5 t -90.82 100.66 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 24.1 t -89.62 127.49 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 178.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm . . . . . 0 N--CA 1.462 0.167 0 CA-C-N 119.136 0.88 . . . . 0.0 111.132 -178.151 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.452 -0.336 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 m -79.88 60.1 3.37 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.2 m95 -99.66 131.84 45.39 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 126.029 1.732 . . . . 0.0 111.275 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -144.63 -170.89 3.49 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 172.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -136.21 130.12 32.66 Favored 'General case' 0 C--N 1.341 0.202 0 CA-C-N 119.216 0.916 . . . . 0.0 110.098 172.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -89.66 -156.62 0.42 Allowed 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 170.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.4 p -139.33 166.71 23.84 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 174.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -39.42 -54.97 3.49 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 115.594 1.702 . . . . 0.0 115.594 -172.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.75 -33.44 98.4 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 CA-C-N 120.92 1.364 . . . . 0.0 111.759 -177.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.94 -32.02 73.53 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 122.769 0.428 . . . . 0.0 110.454 -178.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -56.69 -51.04 71.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.231 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -58.22 -49.36 77.35 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.564 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -48.61 -57.15 6.65 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.738 0.415 . . . . 0.0 111.116 178.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -63.1 -45.13 93.52 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 118.432 -0.794 . . . . 0.0 111.605 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.4 mt -48.76 -47.77 41.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 119.414 1.007 . . . . 0.0 111.386 179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -55.35 -21.55 15.65 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 178.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -96.45 7.24 46.99 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 119.156 0.889 . . . . 0.0 112.414 -177.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.6 115.06 10.34 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 119.989 1.268 . . . . 0.0 110.226 -179.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 p -83.99 15.13 3.56 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.61 1.164 . . . . 0.0 113.875 -174.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.75 115.15 4.38 Favored Glycine 0 CA--C 1.527 0.819 0 O-C-N 121.214 -0.929 . . . . 0.0 111.446 -174.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -78.89 121.11 24.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.17 1.388 . . . . 0.0 108.995 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.97 122.5 6.27 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 C-N-CA 124.137 0.975 . . . . 0.0 109.592 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -132.12 68.93 1.48 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.689 1.596 . . . . 0.0 108.235 -174.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.84 -117.57 8.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 -174.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -78.89 -33.49 45.63 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.848 0.824 . . . . 0.0 109.559 173.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 27.8 m -78.88 155.96 28.85 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 123.739 0.816 . . . . 0.0 109.215 -173.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.7 t -118.67 132.62 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 173.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -121.14 126.88 50.84 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 123.204 0.602 . . . . 0.0 109.969 -173.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.478 ' CB ' HG22 ' A' ' 38' ' ' VAL . 67.7 m-85 -97.84 175.9 5.99 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 122.826 0.45 . . . . 0.0 110.153 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 60.0 m -156.5 168.21 28.06 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.505 0.722 . . . . 0.0 109.811 -175.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 45.26 43.53 9.71 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 125.354 1.454 . . . . 0.0 113.018 174.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.1 mttp 50.55 12.02 0.09 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.093 1.757 . . . . 0.0 115.492 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.8 m -103.62 74.78 1.27 Allowed 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -173.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.478 HG22 ' CB ' ' A' ' 33' ' ' TYR . 74.1 t -89.56 96.79 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.3 t-160 -105.21 102.62 12.1 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 173.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.3 t -99.17 103.28 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.0 t -88.06 90.48 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 175.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.34 159.61 14.85 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.014 1.326 . . . . 0.0 109.841 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.9 166.44 33.53 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 0.0 108.841 177.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -147.69 115.15 6.3 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 122.251 0.22 . . . . 0.0 111.151 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t 54.27 53.35 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 125.868 1.667 . . . . 0.0 111.912 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 30.9 mt -78.36 151.78 78.19 Favored Pre-proline 0 CA--C 1.532 0.286 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 173.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_exo . . . . . 0 CA--C 1.534 0.511 0 C-N-CA 123.581 2.854 . . . . 0.0 112.91 -176.069 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 . . . . . 0 N--CA 1.451 -0.397 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -110.44 54.58 0.93 Allowed 'Cis proline' 0 N--CA 1.455 -0.782 0 N-CA-C 106.685 -2.083 . . . . 0.0 106.685 -6.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 85.8 p -79.49 121.59 25.4 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -170.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -78.57 115.89 18.58 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 103.284 -2.858 . . . . 0.0 103.284 167.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -100.25 138.52 37.19 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.3 t -135.25 100.35 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 118.354 0.524 . . . . 0.0 110.066 -174.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 1.5 p80 35.44 -69.62 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 130.227 3.411 . . . . 0.0 116.378 -173.429 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -101.84 -25.86 13.66 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 125.004 1.322 . . . . 0.0 112.218 -175.17 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -125.56 -169.85 2.07 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.81 1.244 . . . . 0.0 109.957 -173.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? -136.9 133.82 36.16 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 171.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 48.22 41.76 1.03 Allowed Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 124.235 1.014 . . . . 0.0 112.592 -174.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.59 169.03 22.0 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 CA-C-N 120.742 1.301 . . . . 0.0 112.872 -172.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.0 m -89.58 127.76 35.93 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 112.342 -2.208 . . . . 0.0 106.127 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -106.32 128.13 53.77 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.159 0.891 . . . . 0.0 110.101 -177.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 -104.68 117.91 35.26 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 171.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.422 HD12 HG23 ' A' ' 152' ' ' ILE . 14.6 mt -124.22 138.44 30.84 Favored Pre-proline 0 CA--C 1.538 0.496 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.817 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -67.95 125.32 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.727 2.284 . . . . 0.0 109.153 168.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.32 133.36 19.7 Favored 'General case' 0 C--N 1.332 -0.191 0 O-C-N 121.382 -0.824 . . . . 0.0 111.217 174.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.55 12.36 80.34 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.144 -0.809 . . . . 0.0 113.13 -176.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.41 148.7 47.79 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 119.375 1.588 . . . . 0.0 110.169 173.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 38.8 m -83.47 90.75 7.25 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 174.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 85.0 t -77.68 98.67 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 124.746 1.219 . . . . 0.0 108.068 -174.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -96.96 104.38 16.39 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 177.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.3 t -89.44 91.34 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 54.0 m -79.52 87.87 5.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.275 4.1 m-85 -79.73 138.6 37.35 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 117.876 -1.059 . . . . 0.0 109.934 172.584 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.8 mp -117.44 67.89 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 101.088 -3.671 . . . . 0.0 101.088 163.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -84.41 56.3 3.74 Favored 'General case' 0 C--O 1.231 0.109 0 O-C-N 121.117 -0.989 . . . . 0.0 108.626 -173.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.522 HG23 ' HG2' ' A' ' 115' ' ' PRO . 53.4 m -85.75 69.99 10.65 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.884 -176.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -97.43 156.82 16.3 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 171.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -93.17 124.14 36.94 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 75.42 -68.64 2.09 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.63 0.633 . . . . 0.0 112.392 175.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -79.08 81.07 5.38 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.873 -0.781 . . . . 0.0 110.001 -174.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -52.85 80.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 126.425 1.964 . . . . 0.0 112.52 174.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -57.47 162.52 2.85 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 119.232 1.516 . . . . 0.0 111.468 179.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.3 p -121.85 160.91 23.72 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.584 1.554 . . . . 0.0 107.388 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -128.26 110.18 12.16 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 172.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -126.64 128.93 47.53 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.861 0.864 . . . . 0.0 108.716 -172.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 20.5 mt -106.21 134.32 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 C-N-CA 125.964 1.706 . . . . 0.0 110.054 -173.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.6 t -158.04 -152.08 0.33 Allowed 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 176.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -126.58 9.32 7.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.689 1.131 . . . . 0.0 113.286 -176.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -64.67 121.44 14.5 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.35 166.45 49.62 Favored Glycine 0 CA--C 1.532 1.117 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 161.89 44.15 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 122.856 2.37 . . . . 0.0 109.602 173.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -76.92 149.61 90.8 Favored 'Cis proline' 0 N--CA 1.454 -0.825 0 N-CA-C 110.27 -0.704 . . . . 0.0 110.27 -4.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -89.27 152.94 21.28 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 149.7 29.34 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.86 -42.09 87.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 174.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -78.89 130.35 70.49 Favored Pre-proline 0 N--CA 1.451 -0.391 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 174.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -75.02 85.07 1.57 Allowed 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 122.374 2.05 . . . . 0.0 109.829 -175.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.4 t -76.77 85.55 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.348 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 175.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 pt -75.43 87.43 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 CA-C-O 123.646 1.689 . . . . 0.0 110.653 -172.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -62.83 154.17 76.7 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 112.842 -1.981 . . . . 0.0 106.928 172.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -39.49 108.71 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 124.059 3.173 . . . . 0.0 113.794 -175.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.0 mm -78.46 126.84 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.37 -82.14 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 105.785 -1.932 . . . . 0.0 105.785 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.6 150.17 20.64 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.93 158.66 21.79 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 119.288 -1.434 . . . . 0.0 112.135 174.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.3 p -107.75 145.43 33.52 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.516 1.126 . . . . 0.0 110.544 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.63 158.38 37.19 Favored Glycine 0 CA--C 1.535 1.3 0 N-CA-C 107.342 -2.303 . . . . 0.0 107.342 172.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -41.88 133.07 2.95 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.558 1.543 . . . . 0.0 113.884 -173.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.5 p -68.53 158.5 84.99 Favored Pre-proline 0 CA--C 1.535 0.373 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -177.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.3 -177.96 2.66 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.075 1.85 . . . . 0.0 108.804 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 90.0 t -117.66 98.91 52.14 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 125.654 1.582 . . . . 0.0 108.83 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.522 ' HG2' HG23 ' A' ' 79' ' ' THR . 85.9 Cg_exo -62.45 173.59 3.36 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.737 3.625 . . . . 0.0 113.426 174.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -145.57 162.09 38.26 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.54 1.136 . . . . 0.0 109.355 176.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.58 -117.55 0.76 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.883 1.673 . . . . 0.0 110.967 177.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.63 17.43 42.72 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-O 118.899 -0.945 . . . . 0.0 112.445 -177.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -85.72 151.01 24.19 Favored 'General case' 0 C--N 1.341 0.234 0 CA-C-N 118.059 0.93 . . . . 0.0 108.876 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -133.98 93.63 3.13 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 124.373 1.069 . . . . 0.0 111.239 -172.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.47 ' H ' ' CG ' ' A' ' 115' ' ' PRO . . . -49.03 118.15 4.82 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 125.926 1.726 . . . . 0.0 109.959 173.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.18 159.6 41.76 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 123.919 0.888 . . . . 0.0 112.223 -177.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -143.57 148.46 35.95 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 126.537 1.935 . . . . 0.0 107.114 178.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -134.1 65.16 1.58 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 178.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -76.93 150.65 35.94 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 31.4 m -118.18 142.77 47.1 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.872 0.869 . . . . 0.0 109.773 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -145.47 161.28 40.08 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.625 1.17 . . . . 0.0 109.98 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 69.6 m80 -129.81 92.25 37.8 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 125.885 1.674 . . . . 0.0 109.001 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -71.64 145.26 46.32 Favored 'Trans proline' 0 N--CA 1.454 -0.852 0 C-N-CA 123.093 2.528 . . . . 0.0 112.178 -175.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.8 p -93.56 155.25 17.42 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.834 1.254 . . . . 0.0 108.87 172.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.86 146.03 43.49 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.808 -0.558 . . . . 0.0 112.493 -174.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 128.41 -125.38 5.02 Favored Glycine 0 C--N 1.334 0.45 0 C-N-CA 126.79 2.138 . . . . 0.0 108.826 -178.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 35.6 m -153.5 144.59 22.91 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 118.226 1.013 . . . . 0.0 109.881 -175.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -134.74 175.27 9.7 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.506 1.922 . . . . 0.0 106.962 173.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -141.7 149.96 41.23 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.164 1.386 . . . . 0.0 108.199 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . 0.46 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 48.1 p90 -112.89 144.22 42.82 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.956 0.903 . . . . 0.0 109.893 175.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.1 m -148.71 162.64 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 C-N-CA 125.081 1.352 . . . . 0.0 110.68 178.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.29 136.94 41.23 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.643 1.577 . . . . 0.0 107.663 171.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -81.32 -16.5 52.23 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.317 1.228 . . . . 0.0 114.317 -172.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 53.7 mt -63.81 129.52 93.86 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_exo -46.79 150.09 2.76 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 123.947 3.098 . . . . 0.0 114.575 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.42 -43.01 2.01 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 124.092 0.853 . . . . 0.0 112.89 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -50.76 -53.68 29.68 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.671 1.188 . . . . 0.0 111.98 -173.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -54.8 -46.71 74.53 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.77 0.428 . . . . 0.0 111.16 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.73 -41.71 91.91 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 123.156 0.583 . . . . 0.0 111.201 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.1 p -79.67 -58.94 2.94 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.031 0.532 . . . . 0.0 112.124 -173.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.81 38.33 0.09 OUTLIER Glycine 0 CA--C 1.525 0.665 0 C-N-CA 119.65 -1.262 . . . . 0.0 114.685 -174.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.1 ttt -126.19 64.75 1.23 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -151.52 -174.47 4.84 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.806 0.843 . . . . 0.0 111.241 -177.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.46 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.83 174.39 38.06 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 174.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.4 146.67 45.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.417 1.487 . . . . 0.0 109.805 -170.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . 0.422 HG23 HD12 ' A' ' 66' ' ' ILE . 10.2 mt -128.33 95.81 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 125.461 1.504 . . . . 0.0 107.651 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 t -88.03 132.22 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.7 t -122.19 120.99 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -176.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm . . . . . 0 N--CA 1.467 0.393 0 CA-C-N 119.671 1.123 . . . . 0.0 110.827 176.711 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.9 p . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 113.366 0.876 . . . . 0.0 113.366 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -78.25 53.96 1.31 Allowed 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.725 1.148 . . . . 0.0 112.171 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -92.68 142.96 26.79 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 127.697 2.399 . . . . 0.0 108.405 175.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -152.29 177.08 10.94 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -140.05 140.72 36.21 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 169.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.61 -150.9 0.47 Allowed 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 174.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 19.0 p -136.03 173.43 11.72 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 172.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -39.56 -56.96 2.66 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 114.282 1.216 . . . . 0.0 114.282 -174.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -55.04 -35.31 89.97 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.572 1.515 . . . . 0.0 113.481 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.7 mp0 -65.55 -23.95 66.98 Favored 'General case' 0 N--CA 1.455 -0.184 0 O-C-N 121.339 -0.85 . . . . 0.0 111.379 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -55.72 -46.88 79.77 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 119.27 0.941 . . . . 0.0 108.972 173.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtmt -60.32 -51.25 70.31 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.56 -46.99 67.08 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.692 0.256 . . . . 0.0 111.692 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -62.65 -54.93 32.08 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.721 0.408 . . . . 0.0 110.274 177.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 62.1 mt -49.23 -46.88 46.56 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 122.883 0.473 . . . . 0.0 111.339 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -53.04 -27.0 17.66 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -90.5 -0.91 57.85 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.17 0.896 . . . . 0.0 112.503 -179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -57.02 154.52 9.56 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.897 0.771 . . . . 0.0 112.671 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.7 p -128.0 165.59 19.99 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 172.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 122.33 117.67 2.44 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -178.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.4 mtpt -79.08 121.51 25.07 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.31 1.444 . . . . 0.0 108.934 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.6 t -61.69 114.25 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 125.591 1.556 . . . . 0.0 109.485 -176.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.1 m -130.57 68.03 1.48 Allowed 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 124.159 0.983 . . . . 0.0 111.435 -174.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.18 -94.67 0.47 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 123.778 0.704 . . . . 0.0 112.476 174.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -101.07 -14.54 17.76 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.516 1.127 . . . . 0.0 110.127 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 29.4 m -108.39 151.79 25.55 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.811 1.244 . . . . 0.0 109.985 -172.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.44 130.71 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 170.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.7 m -115.39 119.66 37.0 Favored 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 123.187 0.595 . . . . 0.0 110.404 -170.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.411 ' CD1' HG13 ' A' ' 38' ' ' VAL . 96.7 m-85 -91.8 153.09 19.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.9 m -155.79 51.49 0.56 Allowed 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.884 -0.51 . . . . 0.0 110.157 -175.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.89 166.27 39.46 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 108.276 -1.93 . . . . 0.0 108.276 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -73.61 -38.16 65.18 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 117.503 0.651 . . . . 0.0 110.584 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.7 p -80.09 103.46 9.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 174.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.411 HG13 ' CD1' ' A' ' 33' ' ' TYR . 29.5 t -107.69 128.37 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.549 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -132.15 101.36 5.36 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 123.941 0.897 . . . . 0.0 110.019 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.2 t -92.01 143.02 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.1 t -123.06 114.0 40.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 173.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -120.93 112.17 18.43 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 124.645 1.178 . . . . 0.0 111.976 -172.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.86 149.87 22.46 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 172.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.98 109.24 12.72 Favored 'General case' 0 C--O 1.226 -0.162 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 14.0 t 44.34 85.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.258 1.423 . . . . 0.0 112.189 -176.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 51.9 mt -76.67 128.95 80.7 Favored Pre-proline 0 CA--C 1.534 0.336 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo . . . . . 0 N--CA 1.456 -0.72 0 C-N-CA 124.071 3.181 . . . . 0.0 111.541 175.442 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 . . . . . 0 CA--C 1.541 0.6 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -117.61 34.46 0.58 Allowed 'Cis proline' 0 CA--C 1.536 0.611 0 N-CA-C 109.297 -1.078 . . . . 0.0 109.297 -6.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.1 p -90.64 143.13 27.04 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 118.519 2.785 . . . . 0.0 118.519 -168.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . 0.445 ' CD2' ' HB2' ' A' ' 148' ' ' MET . 3.2 m-85 -85.69 103.46 14.51 Favored 'General case' 0 C--N 1.34 0.176 0 N-CA-C 103.276 -2.861 . . . . 0.0 103.276 166.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -93.51 96.07 9.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -174.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.8 t -85.2 149.5 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -176.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -20.96 -57.31 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 116.732 2.123 . . . . 0.0 116.732 -172.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -114.31 -5.71 12.95 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 39.8 mttm -150.34 148.54 28.94 Favored 'General case' 0 C--O 1.223 -0.323 0 CA-C-N 119.845 1.202 . . . . 0.0 109.731 -174.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.5 mttm -97.07 123.79 40.91 Favored 'General case' 0 C--N 1.332 -0.181 0 O-C-N 121.351 -0.843 . . . . 0.0 109.595 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.59 46.29 1.88 Allowed Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.505 1.522 . . . . 0.0 111.435 176.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -83.92 174.29 8.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 122.31 2.007 . . . . 0.0 113.031 -171.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 52.9 m -86.54 148.66 25.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 170.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.5 mp -119.55 133.0 55.86 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 120.892 -1.13 . . . . 0.0 109.421 175.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -109.82 116.27 31.35 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.539 -2.022 . . . . 0.0 105.539 171.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 mt -124.56 145.77 50.32 Favored Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 124.29 1.036 . . . . 0.0 112.456 -171.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -85.37 128.48 3.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.678 2.252 . . . . 0.0 107.909 171.172 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.26 151.99 2.63 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.859 1.264 . . . . 0.0 112.034 178.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.7 -31.8 2.19 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-O 119.203 -0.776 . . . . 0.0 113.701 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -46.84 148.6 1.02 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.567 1.147 . . . . 0.0 112.811 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 17.2 m -79.68 96.06 6.11 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.4 t -79.53 89.51 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 177.098 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -82.68 133.49 35.16 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 173.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.3 t -132.78 110.83 16.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 98.4 m -91.39 125.94 36.3 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 174.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -94.27 158.64 15.49 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 174.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.6 mp -137.41 67.57 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 102.577 -3.12 . . . . 0.0 102.577 163.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 20.8 t30 -98.09 76.67 2.39 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 -175.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.0 p -94.79 -80.14 0.41 Allowed 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.501 1.12 . . . . 0.0 109.923 -173.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 68.35 -50.71 0.55 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.253 2.221 . . . . 0.0 114.649 177.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 87.4 mttt 96.42 33.14 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 130.079 3.352 . . . . 0.0 111.877 -179.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 171.22 -60.03 0.17 Allowed Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -83.12 91.35 7.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.97 83.39 0.02 OUTLIER Glycine 0 CA--C 1.528 0.9 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 173.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -68.87 74.66 0.29 Allowed 'General case' 0 N--CA 1.457 -0.111 0 C-N-CA 125.177 1.391 . . . . 0.0 112.878 -174.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.8 p -42.29 136.38 2.31 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 125.253 1.421 . . . . 0.0 111.281 177.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -107.68 119.95 40.86 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 173.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . 0.538 ' HB3' HD12 ' A' ' 105' ' ' ILE . 5.3 m-20 -129.62 108.79 10.49 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -172.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 32.3 mt -80.72 134.79 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 124.144 0.903 . . . . 0.0 108.824 176.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -160.33 -160.45 0.78 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.433 1.493 . . . . 0.0 107.42 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -126.43 13.31 7.61 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.692 0.797 . . . . 0.0 111.517 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -64.7 121.34 14.28 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 174.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -86.66 170.72 42.49 Favored Glycine 0 CA--C 1.532 1.114 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.85 164.16 36.59 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.208 2.605 . . . . 0.0 109.674 173.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.42 139.12 58.36 Favored 'Cis proline' 0 N--CA 1.455 -0.75 0 N-CA-C 110.163 -0.745 . . . . 0.0 110.163 -4.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -79.68 151.27 30.58 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.179 0.514 . . . . 0.0 110.011 178.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -98.96 149.71 22.69 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 124.135 0.974 . . . . 0.0 110.27 -174.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 18.2 t -62.52 -34.62 65.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 C-N-CA 123.706 0.803 . . . . 0.0 109.218 173.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.6 mmt -78.24 133.97 63.66 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -63.8 63.79 0.21 Allowed 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.889 3.059 . . . . 0.0 115.232 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 13.9 t -80.84 57.5 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 O-C-N 120.254 -1.529 . . . . 0.0 108.325 174.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -38.07 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 C-N-CA 123.529 0.732 . . . . 0.0 111.721 -174.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.04 143.45 32.08 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 125.017 1.327 . . . . 0.0 112.278 -172.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.18 162.45 92.7 Favored 'Cis proline' 0 N--CA 1.46 -0.444 0 N-CA-C 110.281 -0.7 . . . . 0.0 110.281 -6.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 88' ' ' ASP . 14.5 mm -118.18 144.46 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 174.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.56 -86.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 174.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.41 87.64 6.09 Favored 'General case' 0 CA--C 1.52 -0.207 0 O-C-N 122.024 -0.423 . . . . 0.0 109.977 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -90.4 125.61 7.99 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 107.581 -2.208 . . . . 0.0 107.581 172.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.7 p -76.01 -41.48 50.97 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.261 1.531 . . . . 0.0 110.039 173.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.2 -170.09 21.25 Favored Glycine 0 CA--C 1.532 1.145 0 N-CA-C 108.673 -1.771 . . . . 0.0 108.673 -174.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -91.17 138.26 31.73 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.332 1.566 . . . . 0.0 109.215 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.0 p -83.21 159.31 62.48 Favored Pre-proline 0 CA--C 1.533 0.317 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -173.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.87 74.61 3.88 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.076 2.518 . . . . 0.0 107.987 172.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.8 m -53.67 128.9 54.1 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 123.278 0.631 . . . . 0.0 111.331 -175.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.98 176.36 9.92 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.286 2.657 . . . . 0.0 110.078 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.32 -29.38 6.24 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 176.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -174.02 155.85 2.6 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.715 2.006 . . . . 0.0 108.174 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.34 -59.05 1.15 Allowed Glycine 0 CA--C 1.527 0.789 0 C-N-CA 125.466 1.508 . . . . 0.0 113.06 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -78.92 158.77 27.98 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 123.417 0.687 . . . . 0.0 111.344 -174.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -135.23 94.42 3.12 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.804 2.041 . . . . 0.0 108.388 -174.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -53.27 113.29 2.84 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 173.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.1 p90 -119.32 177.03 5.05 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.537 1.135 . . . . 0.0 109.689 175.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.5 m -158.05 154.17 27.16 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 -177.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -131.82 89.54 2.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 173.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -96.9 170.08 9.41 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.8 m -150.79 146.56 26.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -150.56 153.53 35.94 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.884 0.874 . . . . 0.0 110.423 -176.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -116.47 114.44 40.33 Favored Pre-proline 0 CA--C 1.535 0.384 0 C-N-CA 125.584 1.554 . . . . 0.0 107.116 173.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.79 142.26 3.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 124.371 3.381 . . . . 0.0 111.503 -172.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.2 p -96.02 146.42 24.64 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 124.363 1.065 . . . . 0.0 108.845 173.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.83 149.08 19.08 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.164 0.438 . . . . 0.0 112.092 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 121.74 -123.96 5.63 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 126.754 2.121 . . . . 0.0 109.123 -175.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 46.1 m -153.84 145.7 23.49 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.351 1.075 . . . . 0.0 109.972 -174.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -132.95 176.45 8.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.336 2.254 . . . . 0.0 106.897 173.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -142.31 152.81 43.33 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 125.534 1.533 . . . . 0.0 107.551 175.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 55.1 p90 -114.83 140.59 48.82 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 123.223 0.609 . . . . 0.0 109.905 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.36 162.9 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.375 1.07 . . . . 0.0 111.093 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 8.8 t -107.69 136.09 48.02 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 127.121 2.169 . . . . 0.0 109.838 173.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -81.64 -19.0 42.65 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 -170.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.01 130.04 93.82 Favored Pre-proline 0 CA--C 1.544 0.721 0 CA-C-N 119.125 0.875 . . . . 0.0 108.989 -174.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -42.15 133.45 4.52 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.745 2.964 . . . . 0.0 113.424 178.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 90.07 -32.51 4.87 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.099 0.857 . . . . 0.0 111.795 -174.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -75.49 172.84 11.83 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -176.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 75.29 -60.6 0.5 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -170.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.2 -52.27 66.01 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.7 p -78.51 75.47 5.03 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 121.829 0.823 . . . . 0.0 112.272 -178.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 70.87 -44.71 0.67 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 118.189 2.035 . . . . 0.0 118.189 169.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . 0.445 ' HB2' ' CD2' ' A' ' 54' ' ' PHE . 4.2 ptp -77.85 87.74 4.07 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 119.857 1.828 . . . . 0.0 114.271 -172.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -160.81 -179.91 7.97 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 126.053 1.741 . . . . 0.0 108.839 173.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 178.86 168.39 37.96 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 172.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -104.21 138.51 40.57 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 125.049 1.339 . . . . 0.0 108.356 -174.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.1 mt -114.76 100.44 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 19.6 t -84.16 136.37 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -123.02 115.65 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp . . . . . 0 N--CA 1.462 0.13 0 CA-C-N 119.091 0.86 . . . . 0.0 109.558 174.64 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p . . . . . 0 CA--C 1.54 0.568 0 CA-C-O 120.666 0.27 . . . . 0.0 111.337 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.2 m -79.16 66.57 4.64 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.568 1.147 . . . . 0.0 112.253 -171.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -96.34 146.83 24.4 Favored 'General case' 0 CA--C 1.522 -0.099 0 N-CA-C 114.875 1.435 . . . . 0.0 114.875 177.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -149.13 170.15 19.07 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 129.064 2.946 . . . . 0.0 103.706 171.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -124.8 126.55 45.79 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-N 119.645 1.111 . . . . 0.0 110.063 174.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -88.09 -150.22 0.18 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 172.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.9 p -142.39 166.07 25.7 Favored 'General case' 0 CA--C 1.532 0.274 0 O-C-N 121.389 -0.819 . . . . 0.0 109.277 174.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.45 -58.11 2.1 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -175.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -60.06 -28.84 87.9 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 CA-C-N 121.159 1.45 . . . . 0.0 112.224 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -66.83 -24.46 66.16 Favored 'General case' 0 N--CA 1.45 -0.465 0 O-C-N 121.462 -0.774 . . . . 0.0 111.013 177.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.0 t -63.34 -53.84 40.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -54.29 -42.81 70.47 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.468 178.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -58.25 -66.6 0.46 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.273 -0.267 . . . . 0.0 110.619 174.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 67.9 mtm -47.68 -50.2 25.55 Favored 'General case' 0 CA--C 1.528 0.1 0 C-N-CA 124.766 1.226 . . . . 0.0 112.182 -174.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.5 mt -47.14 -40.68 16.18 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.16 0.584 . . . . 0.0 112.192 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -67.86 -10.63 54.65 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.51 17.55 23.17 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.885 0.766 . . . . 0.0 110.999 175.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -65.6 106.06 1.37 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 119.132 0.878 . . . . 0.0 109.909 174.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.9 p -77.98 82.52 4.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.37 112.71 0.46 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 174.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.1 mmtp -78.98 162.78 25.72 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.793 1.237 . . . . 0.0 109.863 -177.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.4 t -69.11 141.42 17.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.653 1.181 . . . . 0.0 109.59 -178.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.5 m -147.85 67.22 1.1 Allowed 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.363 -0.835 . . . . 0.0 109.593 174.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.06 -94.66 0.12 Allowed Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.827 0.727 . . . . 0.0 111.785 175.022 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -109.19 25.54 11.68 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.856 1.663 . . . . 0.0 110.118 178.202 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -154.99 163.12 40.75 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -174.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.09 147.17 23.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.137 -1.801 . . . . 0.0 106.137 173.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.6 m -142.15 138.23 31.45 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 119.259 0.936 . . . . 0.0 111.168 -171.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -112.07 -167.88 1.24 Allowed 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.331 0.514 . . . . 0.0 111.522 173.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.3 m -157.75 -47.77 0.06 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.732 0.813 . . . . 0.0 112.268 -173.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.08 156.35 53.37 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 177.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -79.18 40.6 0.42 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.289 -1.124 . . . . 0.0 112.323 -174.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.3 m -156.18 102.31 2.12 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 120.771 -1.206 . . . . 0.0 107.877 -178.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.2 t -104.73 84.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -82.47 93.36 7.23 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 t -93.99 159.65 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.4 t -133.68 106.93 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 C-N-CA 124.97 1.308 . . . . 0.0 108.045 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -112.74 103.48 11.5 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.416 1.487 . . . . 0.0 109.836 -174.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.03 112.0 23.71 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.276 0.63 . . . . 0.0 109.304 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.57 102.87 15.55 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.502 -0.749 . . . . 0.0 110.15 -174.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.6 t 49.32 82.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 125.613 1.565 . . . . 0.0 112.389 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.3 mt -76.58 141.6 69.41 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 174.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo . . . . . 0 N--CA 1.454 -0.827 0 C-N-CA 123.093 2.529 . . . . 0.0 110.315 -174.361 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -109.86 65.09 0.34 Allowed 'Cis proline' 0 N--CA 1.455 -0.766 0 N-CA-C 107.115 -1.917 . . . . 0.0 107.115 -5.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 59.1 p -86.45 123.07 31.27 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 116.581 2.067 . . . . 0.0 116.581 -171.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -83.47 94.24 7.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 168.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -81.79 115.91 21.23 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -175.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.5 t -114.09 82.55 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 125.067 1.347 . . . . 0.0 109.479 -173.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.418 ' CG ' ' N ' ' A' ' 58' ' ' ASP . 1.0 OUTLIER 46.83 -69.21 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.594 3.557 . . . . 0.0 115.221 176.239 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.418 ' N ' ' CG ' ' A' ' 57' ' ' HIS . 21.2 t70 -95.51 -28.08 15.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.153 1.781 . . . . 0.0 110.838 -176.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -132.19 -176.92 4.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 123.787 0.835 . . . . 0.0 109.285 -176.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -134.4 121.27 20.9 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 175.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.64 43.41 0.9 Allowed Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 124.897 1.279 . . . . 0.0 111.18 -177.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.59 177.74 6.71 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 121.711 1.608 . . . . 0.0 111.412 -175.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.7 m -93.47 138.04 32.17 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 170.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.0 mp -111.3 140.17 46.09 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.111 0.964 . . . . 0.0 109.939 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -112.88 120.9 43.05 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.603 1.161 . . . . 0.0 108.167 172.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 16.5 mt -128.01 146.54 59.6 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -170.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -72.06 123.11 9.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.608 2.205 . . . . 0.0 110.587 170.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.39 134.65 28.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 124.22 1.008 . . . . 0.0 110.57 173.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.98 0.43 75.76 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 118.764 -1.02 . . . . 0.0 113.157 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.06 146.63 52.82 Favored 'General case' 0 N--CA 1.456 -0.169 0 CA-C-N 119.847 1.824 . . . . 0.0 109.628 173.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 58.5 m -78.37 99.76 6.5 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.25 134.71 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -139.47 95.07 2.86 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.754 1.621 . . . . 0.0 106.729 173.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.7 t -80.11 106.02 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 174.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.0 m -79.47 109.0 13.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -76.93 150.34 35.95 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.478 172.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.408 ' O ' HG22 ' A' ' 77' ' ' ILE . 1.2 mp -132.74 69.1 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 165.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -102.3 77.94 1.7 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 -175.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.1 p -118.51 20.21 13.07 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.108 1.763 . . . . 0.0 112.627 -171.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -70.0 103.36 2.24 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 173.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -46.78 134.81 9.58 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.683 0.793 . . . . 0.0 111.692 -173.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.23 -59.45 3.6 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -174.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -78.89 67.8 4.69 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.338 0.655 . . . . 0.0 111.046 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.29 92.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.267 -1.933 . . . . 0.0 108.267 172.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.53 179.47 0.16 Allowed 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.059 0.944 . . . . 0.0 110.637 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 p -137.92 147.9 44.8 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.439 -2.06 . . . . 0.0 105.439 177.315 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -127.02 104.18 7.85 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 173.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ASP . . . . . 0.499 ' HB3' HD12 ' A' ' 105' ' ' ILE . 60.3 m-20 -120.62 127.24 51.91 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.989 0.916 . . . . 0.0 108.877 -174.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.2 mt -98.46 129.74 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 C-N-CA 125.999 1.719 . . . . 0.0 108.579 -174.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.96 -151.08 0.22 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.581 1.153 . . . . 0.0 108.153 -173.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt -133.92 -88.04 0.4 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.821 0.849 . . . . 0.0 109.783 178.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.6 mtmt 49.15 -126.74 2.09 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.216 1.006 . . . . 0.0 109.169 -173.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -175.65 161.88 30.92 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.191 -1.563 . . . . 0.0 109.191 175.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.82 154.44 30.17 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.613 2.876 . . . . 0.0 109.75 174.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.14 144.92 82.56 Favored 'Cis proline' 0 N--CA 1.453 -0.872 0 N-CA-C 108.994 -1.194 . . . . 0.0 108.994 -5.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -78.44 163.67 25.42 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-O 121.375 0.607 . . . . 0.0 110.054 -176.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.24 145.13 42.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.563 -173.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -49.56 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 174.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -78.79 149.55 74.34 Favored Pre-proline 0 CA--C 1.534 0.346 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -72.6 73.62 2.84 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.829 2.352 . . . . 0.0 111.494 -179.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 16.6 t -79.28 53.24 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 173.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.2 pt -84.33 68.71 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-O 122.874 1.321 . . . . 0.0 109.787 -176.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -88.48 -72.69 0.06 OUTLIER Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 113.743 -1.571 . . . . 0.0 110.597 -174.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -77.77 57.76 6.17 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 122.208 1.939 . . . . 0.0 111.48 -178.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 88' ' ' ASP . 24.8 mm -78.41 126.56 38.64 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 O-C-N 121.228 -0.92 . . . . 0.0 108.8 177.392 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.1 t -84.78 -88.18 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.62 164.29 12.84 Favored 'General case' 0 CA--C 1.521 -0.162 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 173.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 172.26 -179.14 44.04 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 119.297 -1.43 . . . . 0.0 112.556 173.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 6.0 p -130.84 138.82 50.03 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 126.272 1.829 . . . . 0.0 108.749 176.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -75.04 -127.77 0.19 Allowed Glycine 0 CA--C 1.534 1.275 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 174.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -112.15 154.47 25.44 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 119.659 1.729 . . . . 0.0 110.465 176.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.6 p -90.31 155.83 46.33 Favored Pre-proline 0 N--CA 1.449 -0.488 0 C-N-CA 124.927 1.291 . . . . 0.0 112.397 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.52 98.82 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.192 0 C-N-CA 122.981 2.454 . . . . 0.0 107.468 173.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 40.3 t -37.85 123.49 1.0 Allowed Pre-proline 0 CA--C 1.538 0.502 0 C-N-CA 125.222 1.409 . . . . 0.0 110.421 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -67.79 156.71 64.91 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.66 2.24 . . . . 0.0 112.847 -172.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 29.2 mmmt -110.2 175.94 5.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 125.717 1.607 . . . . 0.0 106.824 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -36.91 104.02 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 125.119 1.368 . . . . 0.0 114.07 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.31 -8.5 46.33 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-O 118.456 -1.191 . . . . 0.0 115.148 173.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -84.48 156.0 21.92 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.866 1.333 . . . . 0.0 109.744 -178.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -139.37 94.17 2.76 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.6 116.14 4.5 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.214 1.387 . . . . 0.0 113.06 174.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -130.46 154.79 47.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.26 1.024 . . . . 0.0 111.486 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.8 m -145.36 118.84 9.05 Favored 'General case' 0 CA--C 1.518 -0.278 0 C-N-CA 124.419 1.088 . . . . 0.0 109.646 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -95.27 88.28 5.1 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 171.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -89.65 122.97 33.28 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 21.8 m -82.91 142.08 31.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.885 -174.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -151.38 155.77 39.33 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.458 1.103 . . . . 0.0 109.423 175.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 65.2 m80 -123.78 108.85 30.49 Favored Pre-proline 0 CA--C 1.532 0.288 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 173.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -89.57 144.24 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.909 3.073 . . . . 0.0 111.019 -172.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.8 p -95.86 155.02 16.92 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.052 0.941 . . . . 0.0 109.549 173.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -60.88 149.25 36.82 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -175.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 126.67 -128.04 6.17 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 126.39 1.948 . . . . 0.0 108.684 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 32.1 m -152.99 141.95 21.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 118.451 1.125 . . . . 0.0 110.201 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -128.29 174.84 8.95 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.893 1.677 . . . . 0.0 107.828 173.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -134.74 147.17 49.98 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.124 1.37 . . . . 0.0 107.904 174.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -109.06 142.88 39.15 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.561 0.745 . . . . 0.0 109.291 174.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 33.0 m -143.95 165.3 14.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 124.528 1.131 . . . . 0.0 111.452 -177.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.2 t -118.76 135.04 54.72 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 126.634 1.974 . . . . 0.0 110.091 173.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 64.9 mt-30 -64.47 -50.9 65.66 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 125.015 1.326 . . . . 0.0 113.49 -174.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 71.4 mt -39.95 121.91 1.55 Allowed Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 124.711 1.204 . . . . 0.0 111.526 -170.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -31.79 120.22 0.08 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.886 1 C-N-CA 125.472 4.115 . . . . 0.0 115.711 -173.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 86.74 -25.05 7.77 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 118.888 -0.951 . . . . 0.0 113.481 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 22.4 m170 -54.68 -59.99 3.97 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.203 1.501 . . . . 0.0 111.548 -172.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -49.12 -56.37 9.35 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.138 0.575 . . . . 0.0 110.934 177.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.27 -46.66 79.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.914 0.886 . . . . 0.0 112.336 -175.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.7 p -79.23 -36.31 40.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 113.186 0.809 . . . . 0.0 113.186 -172.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.56 -18.82 0.03 OUTLIER Glycine 0 C--N 1.34 0.771 0 C-N-CA 118.442 -1.837 . . . . 0.0 116.443 -175.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.4 ttt -79.73 65.11 4.8 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.093 1.446 . . . . 0.0 109.681 -174.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -161.53 167.96 24.47 Favored 'General case' 0 C--O 1.225 -0.236 0 C-N-CA 123.035 0.534 . . . . 0.0 111.53 -178.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -174.22 169.34 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 176.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -94.5 151.68 19.16 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.637 1.175 . . . . 0.0 110.526 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.4 mt -125.22 94.0 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 173.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.2 t -80.26 136.59 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 173.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.2 t -127.39 127.65 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 -176.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 49.8 mttp . . . . . 0 N--CA 1.464 0.243 0 CA-C-N 119.043 0.838 . . . . 0.0 111.383 -176.813 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.706 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.1 p -63.96 -64.97 0.75 Allowed 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 173.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.0 mp -112.59 179.85 3.86 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 128.052 2.541 . . . . 0.0 106.453 171.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -68.8 124.42 23.63 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p -118.18 32.91 5.89 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 124.738 1.215 . . . . 0.0 110.454 -175.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 10.4 m -79.2 61.51 3.34 Favored 'General case' 0 CA--C 1.535 0.381 0 O-C-N 121.37 -0.831 . . . . 0.0 110.115 -178.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 1.7 m95 -79.46 136.16 36.85 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 125.988 1.715 . . . . 0.0 110.572 -174.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.8 mtmt -149.92 171.38 16.89 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -139.64 127.89 22.59 Favored 'General case' 0 C--N 1.341 0.213 0 CA-C-N 118.826 0.739 . . . . 0.0 109.826 171.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.17 -152.47 0.43 Allowed 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 125.551 1.54 . . . . 0.0 107.121 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 30.2 p -136.64 170.99 15.16 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 124.179 0.992 . . . . 0.0 108.482 173.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tt -39.06 -55.17 3.03 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 114.528 1.306 . . . . 0.0 114.528 -174.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -55.45 -33.53 86.27 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.517 1.478 . . . . 0.0 113.633 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -68.67 -29.36 67.81 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 119.118 0.872 . . . . 0.0 111.072 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 t -62.13 -50.2 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 174.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -54.43 -49.3 70.31 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.55 -61.53 2.14 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.034 0.534 . . . . 0.0 111.066 176.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 74.4 mtm -55.14 -45.84 75.65 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 123.202 0.601 . . . . 0.0 110.801 -177.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.3 mt -53.28 -38.01 62.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.19 -0.433 . . . . 0.0 111.747 176.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -72.0 -45.69 60.0 Favored 'General case' 0 CA--C 1.529 0.162 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 175.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.5 mtpt -80.31 62.36 4.42 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 122.709 0.404 . . . . 0.0 110.791 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -134.94 134.64 40.8 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.375 1.07 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.2 p -96.48 24.02 6.27 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.935 0.894 . . . . 0.0 112.951 -175.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -96.21 100.0 2.43 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 125.727 1.632 . . . . 0.0 110.986 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mtpp -78.51 159.13 28.36 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.626 1.171 . . . . 0.0 109.322 178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 63.2 t -93.53 93.47 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 C-N-CA 123.715 0.806 . . . . 0.0 110.34 -174.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.3 p -77.74 70.47 4.12 Favored 'General case' 0 CA--C 1.532 0.282 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 60.98 -96.72 0.11 Allowed Glycine 0 CA--C 1.527 0.835 0 C-N-CA 124.741 1.162 . . . . 0.0 111.045 -179.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -86.98 -36.61 18.16 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.027 0.931 . . . . 0.0 110.543 178.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.3 m -89.88 166.54 13.45 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 125.728 1.611 . . . . 0.0 108.787 -172.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 3.8 t -110.12 144.17 18.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 172.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.7 m -134.07 117.36 16.54 Favored 'General case' 0 CA--C 1.517 -0.299 0 C-N-CA 124.687 1.195 . . . . 0.0 108.236 -175.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 m-85 -79.59 162.25 25.43 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.182 0.515 . . . . 0.0 110.778 175.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 67.2 m -154.24 159.59 41.39 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.103 0.961 . . . . 0.0 108.629 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.22 165.23 29.43 Favored Glycine 0 CA--C 1.529 0.946 0 N-CA-C 110.332 -1.107 . . . . 0.0 110.332 -174.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 7.2 mtpm? -73.54 -18.28 61.1 Favored 'General case' 0 CA--C 1.533 0.302 0 O-C-N 122.004 -0.704 . . . . 0.0 111.753 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.4 p -95.68 87.63 4.75 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.132 0.973 . . . . 0.0 109.064 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.0 t -81.84 77.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -86.3 87.65 7.47 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.089 -175.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 48.7 t -79.67 95.87 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 124.39 1.076 . . . . 0.0 109.173 -174.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.65 109.99 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 175.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -127.84 164.28 22.56 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.827 1.251 . . . . 0.0 109.365 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.77 167.43 24.72 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 176.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -136.18 114.03 11.2 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -174.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.7 t 34.38 69.01 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 C-N-CA 127.11 2.164 . . . . 0.0 112.339 174.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 90.9 mt -76.67 144.98 74.22 Favored Pre-proline 0 N--CA 1.453 -0.286 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 176.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -56.24 102.57 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 123.21 2.607 . . . . 0.0 110.947 -174.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 138.24 -44.54 1.11 Allowed Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.981 -1.647 . . . . 0.0 108.981 -174.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 -78.43 127.3 81.22 Favored Pre-proline 0 N--CA 1.453 -0.288 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -76.16 160.5 36.27 Favored 'Trans proline' 0 N--CA 1.45 -1.039 0 C-N-CA 121.933 1.755 . . . . 0.0 111.278 -176.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -67.77 164.74 37.13 Favored Pre-proline 0 CA--C 1.538 0.486 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 172.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -112.38 7.32 3.12 Favored 'Cis proline' 0 CA--C 1.535 0.532 0 CA-C-N 119.641 0.907 . . . . 0.0 113.09 0.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.4 p -83.71 154.9 23.38 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 115.043 1.497 . . . . 0.0 115.043 -171.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -79.37 139.06 37.86 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.747 1.219 . . . . 0.0 109.526 173.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.94 132.38 34.73 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 123.922 0.889 . . . . 0.0 110.094 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.569 HG23 HD21 ' A' ' 61' ' ' ASN . 17.2 t -125.97 83.47 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 172.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 55.7 p-80 42.08 -78.59 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 128.587 2.755 . . . . 0.0 115.008 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -84.37 -24.81 29.53 Favored 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 124.18 0.992 . . . . 0.0 111.723 -176.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -130.83 -174.9 3.5 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.584 1.153 . . . . 0.0 109.58 -174.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -128.91 92.1 3.34 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.569 HD21 HG23 ' A' ' 56' ' ' VAL . 9.9 m-80 26.73 69.82 0.45 Allowed Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 127.459 2.303 . . . . 0.0 115.882 -174.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -66.41 -55.56 0.36 Allowed 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.537 2.158 . . . . 0.0 108.674 165.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.2 m 169.53 154.63 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 129.257 3.023 . . . . 0.0 105.697 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.3 mp -117.22 124.79 49.95 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.969 1.308 . . . . 0.0 110.204 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -98.42 137.09 37.63 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 171.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.08 136.0 25.4 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.213 1.005 . . . . 0.0 110.867 -173.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -76.47 112.06 3.38 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 123.705 2.937 . . . . 0.0 109.271 173.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.39 -41.37 9.06 Favored 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -173.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -72.75 -7.51 69.92 Favored Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.41 -0.661 . . . . 0.0 114.068 -175.031 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -85.94 165.07 17.04 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 118.741 1.271 . . . . 0.0 113.38 -174.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 63.1 m -93.72 127.41 39.42 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 172.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 94.9 t -92.13 132.29 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -127.77 108.1 10.44 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.752 -1.574 . . . . 0.0 106.752 173.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.3 t -88.09 115.36 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 16.4 m -107.71 96.01 6.09 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 126.059 1.743 . . . . 0.0 107.181 174.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . 0.279 4.3 m-85 -78.79 151.57 31.9 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 172.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -127.79 69.6 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 102.595 -3.113 . . . . 0.0 102.595 162.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -80.64 113.08 18.58 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 171.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 52.3 m -137.93 45.38 2.13 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 173.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -78.55 113.71 16.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 105.927 -1.879 . . . . 0.0 105.927 172.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -72.8 69.8 0.95 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 123.166 0.586 . . . . 0.0 110.113 -178.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 174.43 -67.72 0.1 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -96.71 122.69 39.93 Favored 'General case' 0 N--CA 1.456 -0.146 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -174.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.26 71.03 0.63 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 108.864 -1.695 . . . . 0.0 108.864 171.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -57.06 143.82 36.9 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.511 1.156 . . . . 0.0 111.356 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.3 p -106.76 161.25 14.84 Favored 'General case' 0 N--CA 1.444 -0.749 0 C-N-CA 125.435 1.494 . . . . 0.0 108.845 175.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -129.89 101.11 5.71 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 102.755 -3.054 . . . . 0.0 102.755 172.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -118.89 114.44 22.61 Favored 'General case' 0 CA--C 1.522 -0.129 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -173.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 6.7 mt -95.2 125.31 47.9 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 C-N-CA 125.44 1.496 . . . . 0.0 110.297 -174.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -161.17 -145.46 0.11 Allowed 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -113.0 -98.95 0.43 Allowed 'General case' 0 N--CA 1.454 -0.257 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 174.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt 67.42 -67.32 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 124.887 1.275 . . . . 0.0 111.184 -174.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.78 170.35 28.9 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.277 -0.729 . . . . 0.0 111.277 -174.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -75.1 147.01 32.99 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 122.634 2.223 . . . . 0.0 109.388 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.82 136.76 45.48 Favored 'Cis proline' 0 N--CA 1.454 -0.813 0 CA-C-N 119.48 0.85 . . . . 0.0 109.995 -5.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 22.2 m-85 -79.03 149.24 32.24 Favored 'General case' 0 N--CA 1.456 -0.151 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.93 144.03 39.12 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 121.188 0.518 . . . . 0.0 112.155 -173.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.15 -43.28 98.78 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.9 mtp -78.1 133.18 65.33 Favored Pre-proline 0 N--CA 1.45 -0.425 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 173.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -75.65 85.24 1.63 Allowed 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.669 1.579 . . . . 0.0 109.307 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.8 t -76.41 105.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -178.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 23.4 pt -78.91 72.98 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 123.241 1.495 . . . . 0.0 110.534 177.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 19.9 m-20 -62.57 154.5 73.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 113.328 -1.76 . . . . 0.0 106.398 171.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_exo -37.62 104.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 124.031 3.154 . . . . 0.0 113.835 -176.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 31.4 mm -78.95 131.27 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.97 -88.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 N-CA-C 104.753 -2.314 . . . . 0.0 104.753 174.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.3 150.3 20.72 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 170.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.89 168.08 39.8 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.8 174.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 2.8 p -120.77 127.61 52.13 Favored 'General case' 0 C--O 1.234 0.253 0 C-N-CA 124.291 1.036 . . . . 0.0 109.991 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.62 57.0 5.04 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-O 119.502 -0.61 . . . . 0.0 111.985 -176.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 73.33 99.68 0.07 Allowed 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 126.256 1.822 . . . . 0.0 111.488 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.3 p -74.13 160.32 81.87 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 118.767 -0.635 . . . . 0.0 110.578 -176.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 169.08 2.07 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 123.559 2.839 . . . . 0.0 116.032 -173.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 92.6 t -121.38 97.08 47.54 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 126.641 1.976 . . . . 0.0 107.627 178.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.554 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 37.4 Cg_exo -70.52 -179.77 3.5 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.936 3.091 . . . . 0.0 114.005 -176.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.7 mmtt -109.88 -164.87 0.96 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 125.814 1.646 . . . . 0.0 107.305 172.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -60.99 153.43 25.18 Favored 'General case' 0 CA--C 1.534 0.329 0 O-C-N 121.518 -0.739 . . . . 0.0 111.003 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.71 3.1 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 123.808 0.718 . . . . 0.0 113.276 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 4.0 mtpm? -80.02 156.06 27.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.196 0.598 . . . . 0.0 111.798 -175.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -135.88 106.87 6.68 Favored 'General case' 0 CA--C 1.513 -0.456 0 C-N-CA 125.677 1.591 . . . . 0.0 110.289 -172.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.554 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -64.41 123.27 27.09 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 108.269 -1.932 . . . . 0.0 108.269 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -130.98 165.04 24.04 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 122.127 0.965 . . . . 0.0 109.886 174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 99.0 m -152.62 120.76 6.23 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -103.57 104.6 14.68 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 37.0 p90 -118.74 147.74 43.53 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 28.6 m -104.14 152.05 22.58 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.804 0.842 . . . . 0.0 109.731 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -151.38 147.72 27.25 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 124.824 1.25 . . . . 0.0 109.161 175.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 44.8 m80 -116.15 111.37 42.64 Favored Pre-proline 0 N--CA 1.454 -0.256 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 172.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -82.64 -170.98 1.03 Allowed 'Trans proline' 0 N--CA 1.45 -1.056 0 C-N-CA 122.892 2.395 . . . . 0.0 110.688 -173.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.0 p -140.95 147.9 39.53 Favored 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.69 152.46 35.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.754 0.65 . . . . 0.0 112.754 -174.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.55 -129.68 8.14 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 126.508 2.004 . . . . 0.0 108.982 -177.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.8 m -142.82 137.48 29.69 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 117.437 0.618 . . . . 0.0 109.667 -174.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.4 m-85 -130.42 176.75 7.88 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.484 1.914 . . . . 0.0 106.182 172.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -142.53 147.85 36.64 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 173.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -115.21 147.03 40.84 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 172.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.2 m -144.96 154.46 14.18 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 125.042 1.337 . . . . 0.0 109.735 -174.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.43 107.64 19.8 Favored 'General case' 0 C--N 1.333 -0.125 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 171.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.1 mm-40 -74.72 38.53 0.12 Allowed 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -174.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 16.5 mt -93.24 142.73 25.67 Favored Pre-proline 0 CA--C 1.537 0.463 0 N-CA-C 104.305 -2.479 . . . . 0.0 104.305 168.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -48.24 138.85 22.48 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.028 1.818 . . . . 0.0 112.94 178.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.0 -46.67 2.45 Favored Glycine 0 CA--C 1.529 0.928 0 C-N-CA 124.312 0.958 . . . . 0.0 113.193 176.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.2 m170 -42.55 -55.8 3.34 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.814 1.646 . . . . 0.0 113.882 -173.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.88 -53.54 57.02 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.71 0.29 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.71 -38.67 88.72 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 124.117 0.967 . . . . 0.0 111.684 -176.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 31.0 p -78.31 -32.32 49.24 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-O 118.731 -0.652 . . . . 0.0 111.293 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.12 -30.61 0.1 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 118.355 -1.879 . . . . 0.0 116.234 173.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.315 10.3 ptp -80.4 84.46 6.03 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 120.053 1.927 . . . . 0.0 112.707 -174.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -141.93 174.49 10.54 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 126.532 1.933 . . . . 0.0 107.296 172.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -156.28 128.28 2.18 Favored Glycine 0 C--N 1.331 0.285 0 N-CA-C 108.482 -1.847 . . . . 0.0 108.482 173.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -76.99 130.12 37.05 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 174.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 10.0 mt -110.87 100.91 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.378 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 25.7 t -88.84 110.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 174.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 42.8 t -97.66 94.66 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 -178.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 63.9 mttp . . . . . 0 C--N 1.332 -0.165 0 O-C-N 121.525 -0.734 . . . . 0.0 109.041 176.373 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.774 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.6 p -66.19 -79.69 0.04 OUTLIER 'General case' 0 N--CA 1.451 -0.376 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 4.5 mt 37.26 -86.34 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 127.193 2.197 . . . . 0.0 114.638 174.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -54.47 -50.43 67.76 Favored 'General case' 0 CA--C 1.529 0.151 0 C-N-CA 123.805 0.842 . . . . 0.0 111.838 174.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.6 p 67.79 -37.3 0.32 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 126.941 2.097 . . . . 0.0 113.296 -173.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.9 m -78.05 68.93 4.19 Favored 'General case' 0 CA--C 1.535 0.397 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 32.6 m95 -103.45 129.01 50.5 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 126.853 2.061 . . . . 0.0 109.772 -176.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -151.92 178.4 9.45 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 175.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -131.27 127.04 36.96 Favored 'General case' 0 CA--C 1.528 0.129 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 171.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.75 -150.62 0.27 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.6 p -137.34 170.41 16.13 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 119.475 1.034 . . . . 0.0 108.563 172.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.6 tt -39.53 -55.74 3.23 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 124.316 1.046 . . . . 0.0 113.582 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -56.54 -33.23 92.29 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 CA-C-N 121.011 1.397 . . . . 0.0 113.861 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -64.94 -25.25 67.8 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 118.946 0.794 . . . . 0.0 111.452 177.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.2 t -53.91 -46.94 64.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.651 0.659 . . . . 0.0 109.277 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 mtmm -59.12 -54.17 50.04 Favored 'General case' 0 N--CA 1.454 -0.253 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.27 -47.66 62.42 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 122.84 0.456 . . . . 0.0 111.378 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -62.3 -54.78 35.65 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-O 119.47 -0.3 . . . . 0.0 110.672 177.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 66.6 mt -50.58 -47.8 57.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 118.423 0.556 . . . . 0.0 111.392 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -54.06 -25.94 24.19 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.003 0.921 . . . . 0.0 113.093 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 19.9 mtpp -88.21 -9.12 54.06 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 118.9 0.773 . . . . 0.0 112.116 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -49.48 145.8 4.52 Favored 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 114.177 1.177 . . . . 0.0 114.177 -176.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 77.7 p -121.0 166.4 13.9 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.599 1.159 . . . . 0.0 108.851 171.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.69 116.71 2.92 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 124.521 1.058 . . . . 0.0 110.787 -177.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 49.4 mtmt -81.68 144.35 31.24 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 124.558 1.143 . . . . 0.0 108.989 176.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 81.4 t -67.78 145.32 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 C-N-CA 122.781 0.432 . . . . 0.0 110.603 -178.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.9 m -150.82 68.95 0.96 Allowed 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.767 1.227 . . . . 0.0 109.132 174.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.28 -115.45 7.14 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.176 -1.569 . . . . 0.0 109.176 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -79.01 -31.22 44.63 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 118.054 0.927 . . . . 0.0 109.109 172.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.9 m -79.54 153.39 29.56 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.742 -173.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -120.47 135.32 61.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 171.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 74.2 m -121.7 133.49 54.95 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 124.302 1.041 . . . . 0.0 110.459 -169.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 79.2 m-85 -105.55 177.72 4.77 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 124.086 0.954 . . . . 0.0 109.589 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.8 m -154.36 -50.0 0.09 Allowed 'General case' 0 N--CA 1.461 0.111 0 C-N-CA 123.468 0.707 . . . . 0.0 109.609 177.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -65.63 145.22 48.2 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.6 mmtt -60.6 -31.69 70.84 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.179 0.592 . . . . 0.0 111.088 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.8 m -78.1 76.21 4.62 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 35.6 t -78.04 102.59 4.46 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 30.9 t-80 -106.95 102.94 12.26 Favored 'General case' 0 C--O 1.235 0.306 0 C-N-CA 123.818 0.847 . . . . 0.0 109.563 -178.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 86.0 t -99.89 151.03 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 C-N-CA 125.231 1.413 . . . . 0.0 108.777 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.6 t -130.72 100.49 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 124.618 1.167 . . . . 0.0 108.494 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -106.14 155.46 19.42 Favored 'General case' 0 N--CA 1.455 -0.207 0 C-N-CA 125.362 1.465 . . . . 0.0 110.731 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -147.73 158.41 44.01 Favored 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 124.511 1.125 . . . . 0.0 109.3 178.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.84 117.77 24.86 Favored 'General case' 0 N--CA 1.456 -0.157 0 C-N-CA 123.556 0.742 . . . . 0.0 111.032 -173.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.9 t 42.29 66.92 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.28 0 C-N-CA 125.323 1.449 . . . . 0.0 111.618 173.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 86.5 mt -77.88 153.43 80.44 Favored Pre-proline 0 CA--C 1.535 0.37 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -44.54 125.27 5.99 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.054 2.502 . . . . 0.0 111.704 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.17 -32.36 7.42 Favored Glycine 0 CA--C 1.528 0.889 0 C-N-CA 123.747 0.689 . . . . 0.0 111.896 -176.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -99.78 112.98 64.81 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 118.183 0.992 . . . . 0.0 109.469 -175.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -58.74 160.1 18.74 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.764 2.309 . . . . 0.0 114.47 -176.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 -65.79 147.69 98.61 Favored Pre-proline 0 CA--C 1.533 0.309 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -111.69 67.48 0.23 Allowed 'Cis proline' 0 N--CA 1.455 -0.791 0 N-CA-C 107.726 -1.682 . . . . 0.0 107.726 -6.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 79.0 p -92.19 133.66 35.59 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -86.34 122.4 30.25 Favored 'General case' 0 C--N 1.34 0.167 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 169.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -93.32 131.01 38.87 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 104.57 -2.382 . . . . 0.0 104.57 171.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.5 t -137.5 114.92 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 120.226 1.375 . . . . 0.0 110.61 -173.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 36.79 -114.31 0.1 Allowed 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.771 1.628 . . . . 0.0 112.837 -178.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -81.61 7.1 13.08 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -174.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -146.66 -169.77 3.36 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.526 1.13 . . . . 0.0 110.518 -172.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? -135.22 128.14 31.38 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 172.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 45.99 49.86 7.21 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 125.076 1.35 . . . . 0.0 111.963 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -81.71 173.7 11.05 Favored 'Trans proline' 0 N--CA 1.452 -0.942 0 C-N-CA 122.811 2.34 . . . . 0.0 111.998 -174.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 73.4 m -94.92 144.8 25.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 113.923 -1.49 . . . . 0.0 107.123 172.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.6 mp -113.23 139.47 48.76 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.093 -1.005 . . . . 0.0 109.983 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.7 mm-40 -115.37 98.75 6.92 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.531 1.533 . . . . 0.0 107.739 173.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.8 mt -101.16 138.08 19.87 Favored Pre-proline 0 CA--C 1.535 0.379 0 C-N-CA 126.408 1.883 . . . . 0.0 110.788 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.85 123.48 6.33 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 122.384 2.056 . . . . 0.0 107.65 171.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.64 138.46 17.98 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.578 0.751 . . . . 0.0 111.645 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 85.75 -1.57 88.04 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.521 -0.599 . . . . 0.0 112.691 -176.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.41 21.48 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 118.759 1.279 . . . . 0.0 112.065 174.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 89.3 m -91.73 91.3 7.91 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 171.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 13.0 t -79.15 99.46 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 124.298 1.039 . . . . 0.0 108.633 -172.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -98.64 107.35 19.78 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 126.113 1.765 . . . . 0.0 107.854 -178.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.1 t -101.83 116.92 46.33 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.0 m -88.25 137.29 32.45 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.06 -1.83 . . . . 0.0 106.06 171.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -113.21 146.33 39.49 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 123.712 0.805 . . . . 0.0 111.735 174.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.17 59.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 N-CA-C 101.222 -3.622 . . . . 0.0 101.222 163.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -92.93 73.2 4.81 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 104.635 -2.357 . . . . 0.0 104.635 -174.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 30.7 p -95.25 -77.46 0.47 Allowed 'General case' 0 N--CA 1.446 -0.635 0 CA-C-N 114.419 -1.264 . . . . 0.0 111.95 -171.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 51.71 -142.47 0.73 Allowed 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -172.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 8.4 mtpm? -149.01 123.58 9.76 Favored 'General case' 0 C--N 1.34 0.174 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 174.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.31 -55.19 3.22 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 118.883 0.765 . . . . 0.0 112.054 178.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -77.64 84.92 3.98 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 121.73 -0.865 . . . . 0.0 109.804 -174.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.26 75.59 0.01 OUTLIER Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.513 1.054 . . . . 0.0 110.697 172.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -55.51 163.81 1.18 Allowed 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 118.448 1.124 . . . . 0.0 110.096 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 93.0 p -131.91 165.95 22.74 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -132.31 93.03 3.18 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -98.38 130.76 45.03 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 124.748 1.219 . . . . 0.0 107.781 -177.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 21.8 mt -102.49 133.53 45.9 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 124.635 1.174 . . . . 0.0 109.289 -173.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.9 t -157.88 -161.36 1.02 Allowed 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -129.05 -0.0 5.24 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 124.324 1.05 . . . . 0.0 111.695 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.6 mtmm -66.52 129.42 39.8 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -84.61 168.66 44.09 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 174.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -69.84 160.82 48.28 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 123.288 2.659 . . . . 0.0 110.114 174.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -75.74 163.96 89.08 Favored 'Cis proline' 0 N--CA 1.455 -0.745 0 N-CA-C 110.502 -0.615 . . . . 0.0 110.502 -4.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -111.14 152.79 26.59 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 176.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.16 153.32 34.3 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.3 t -59.11 -39.2 77.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.22 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 62.1 mtt -78.15 117.66 67.45 Favored Pre-proline 0 CA--C 1.537 0.461 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 174.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.92 113.81 1.73 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.448 2.098 . . . . 0.0 111.924 -175.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 19.1 t -79.81 66.99 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 7.5 pt -79.42 -21.56 12.37 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.183 0 N-CA-C 115.145 1.535 . . . . 0.0 115.145 -172.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -49.55 -59.03 7.41 Favored Pre-proline 0 CA--C 1.545 0.753 0 CA-C-N 119.18 0.9 . . . . 0.0 111.597 177.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.92 62.7 6.64 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 122.796 2.33 . . . . 0.0 112.766 174.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.5 mm -113.62 145.77 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.083 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 172.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 48.9 t -97.19 -94.69 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 106.867 -1.531 . . . . 0.0 106.867 177.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.48 -176.5 3.95 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 123.76 0.824 . . . . 0.0 109.673 174.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.93 174.91 36.6 Favored Glycine 0 N--CA 1.443 -0.847 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 175.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 73.2 p -85.5 -50.68 7.06 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.354 0.597 . . . . 0.0 109.726 174.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 96.17 -176.79 33.3 Favored Glycine 0 CA--C 1.535 1.34 0 N-CA-C 105.559 -3.016 . . . . 0.0 105.559 -168.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -77.38 139.01 39.63 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.286 1.043 . . . . 0.0 109.667 -179.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.7 p -88.83 156.09 49.9 Favored Pre-proline 0 CA--C 1.537 0.451 0 N-CA-C 115.037 1.495 . . . . 0.0 115.037 -172.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.63 89.12 1.36 Allowed 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.321 2.681 . . . . 0.0 107.336 171.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 30.6 m -53.71 163.3 1.11 Allowed Pre-proline 0 CA--C 1.545 0.76 0 C-N-CA 124.774 1.23 . . . . 0.0 113.563 -175.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -54.72 144.07 66.95 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 123.313 2.675 . . . . 0.0 113.775 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -108.62 21.77 16.82 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.851 1.26 . . . . 0.0 108.627 171.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 50.4 t0 79.31 139.7 0.07 Allowed 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 128.558 2.743 . . . . 0.0 107.953 -171.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 73.39 -50.03 1.64 Allowed Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.572 0.606 . . . . 0.0 112.102 -173.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -79.22 153.53 29.91 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 124.045 0.938 . . . . 0.0 112.194 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -130.23 95.68 3.97 Favored 'General case' 0 C--O 1.231 0.083 0 C-N-CA 127.233 2.213 . . . . 0.0 108.986 -173.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -45.54 112.87 0.84 Allowed Glycine 0 CA--C 1.528 0.853 0 C-N-CA 124.752 1.168 . . . . 0.0 111.506 173.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -131.63 175.21 9.37 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 122.504 1.145 . . . . 0.0 110.998 -176.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -167.84 156.13 9.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -141.11 90.91 2.35 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 172.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -110.23 153.53 24.68 Favored 'General case' 0 C--O 1.235 0.294 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 25.0 m -118.5 140.91 49.13 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 124.659 1.184 . . . . 0.0 110.237 -173.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 2.8 p-90 -146.86 161.31 40.96 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.896 0.878 . . . . 0.0 110.676 174.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -133.71 89.18 31.29 Favored Pre-proline 0 CA--C 1.533 0.292 0 C-N-CA 125.467 1.507 . . . . 0.0 108.306 -178.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -78.98 151.71 24.2 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.579 2.186 . . . . 0.0 110.239 -176.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.5 p -79.63 164.54 23.71 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.974 0.51 . . . . 0.0 110.172 174.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -67.02 157.03 34.48 Favored 'General case' 0 CA--C 1.533 0.307 0 O-C-N 121.939 -0.476 . . . . 0.0 111.976 -176.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.33 -118.86 4.1 Favored Glycine 0 C--N 1.335 0.499 0 C-N-CA 126.123 1.821 . . . . 0.0 109.084 -178.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -149.72 127.77 11.95 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 117.833 0.817 . . . . 0.0 109.606 -178.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -110.03 171.61 7.35 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 127.494 2.318 . . . . 0.0 106.912 174.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -142.0 144.11 33.51 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 124.867 1.267 . . . . 0.0 108.517 177.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.9 p90 -107.33 134.14 50.84 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.2 m -138.34 144.01 31.4 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.15 0 C-N-CA 124.218 1.007 . . . . 0.0 109.35 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.2 t -86.21 139.8 30.72 Favored 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -113.24 36.52 3.51 Favored 'General case' 0 CA--C 1.523 -0.088 0 N-CA-C 113.972 1.101 . . . . 0.0 113.972 -171.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 45.6 mt -91.59 133.54 30.91 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 103.798 -2.667 . . . . 0.0 103.798 168.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -39.11 128.37 1.41 Allowed 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.751 2.967 . . . . 0.0 113.968 -176.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.33 -23.59 5.35 Favored Glycine 0 CA--C 1.529 0.953 0 CA-C-O 118.981 -0.899 . . . . 0.0 114.337 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -62.25 -53.32 56.91 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 120.079 1.939 . . . . 0.0 111.62 -172.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -55.31 -48.51 74.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 121.896 -0.503 . . . . 0.0 110.559 175.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -57.96 -40.4 80.48 Favored 'General case' 0 CA--C 1.529 0.147 0 C-N-CA 123.768 0.827 . . . . 0.0 111.923 -176.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 19.1 p -78.2 -40.48 37.42 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 119.054 -0.498 . . . . 0.0 109.997 -178.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 147.08 20.58 0.1 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 115.9 1.12 . . . . 0.0 115.9 172.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 15.6 ttt -80.02 76.71 6.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 119.66 1.73 . . . . 0.0 107.709 174.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.71 6.29 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 122.812 0.445 . . . . 0.0 111.734 -174.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -175.68 165.81 36.78 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 171.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -104.29 147.76 27.13 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 124.39 1.076 . . . . 0.0 109.341 -173.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 15.9 mt -128.18 96.84 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -176.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 44.6 t -78.5 131.9 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 174.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 35.2 t -118.66 93.93 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 106.995 -1.483 . . . . 0.0 106.995 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 66.6 mttm . . . . . 0 C--N 1.332 -0.179 0 O-C-N 121.679 -0.638 . . . . 0.0 109.354 -179.756 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.909 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.1 p -85.67 -21.63 28.27 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 126.246 1.818 . . . . 0.0 112.018 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.8 mm? 24.98 -83.38 0.0 OUTLIER 'General case' 0 C--N 1.346 0.455 0 C-N-CA 128.326 2.65 . . . . 0.0 116.079 178.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -55.21 -42.19 73.01 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 113.348 -175.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.8 p 65.99 -40.9 0.34 Allowed 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 126.22 1.808 . . . . 0.0 114.453 -173.302 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 89.8 m -77.53 73.77 4.1 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.601 1.16 . . . . 0.0 108.301 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -107.09 134.42 50.25 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 127.588 2.355 . . . . 0.0 107.645 -177.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -151.38 -177.42 6.06 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 119.846 1.203 . . . . 0.0 109.601 176.2 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -136.5 149.07 47.98 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 172.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.29 -152.17 0.5 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.642 1.977 . . . . 0.0 106.573 174.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.6 p -135.79 173.01 12.19 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 119.152 0.887 . . . . 0.0 108.744 172.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.17 -56.89 2.41 Favored Pre-proline 0 CA--C 1.538 0.5 0 N-CA-C 114.455 1.279 . . . . 0.0 114.455 -175.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -54.67 -34.04 82.08 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.53 1.487 . . . . 0.0 113.456 -178.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -68.36 -26.88 65.8 Favored 'General case' 0 N--CA 1.455 -0.198 0 O-C-N 121.215 -0.928 . . . . 0.0 111.38 177.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 52.2 t -59.44 -51.83 68.1 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.069 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 174.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.0 mtpp -56.43 -52.04 66.14 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.078 177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.88 -54.71 17.86 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.607 0.363 . . . . 0.0 111.566 177.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.7 mtm -57.46 -53.8 54.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 119.343 -0.36 . . . . 0.0 110.27 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.4 mt -51.37 -48.14 62.62 Favored 'General case' 0 N--CA 1.463 0.217 0 C-N-CA 122.811 0.444 . . . . 0.0 111.334 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -55.11 -31.87 61.59 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 122.813 0.445 . . . . 0.0 111.929 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.5 11.13 25.06 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.33 0.652 . . . . 0.0 111.663 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.41 109.36 4.72 Favored 'General case' 0 CA--C 1.529 0.14 0 O-C-N 120.387 -1.446 . . . . 0.0 110.01 175.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.5 p -78.44 36.49 0.25 Allowed 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.599 0.76 . . . . 0.0 112.706 -175.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -110.67 108.09 2.36 Favored Glycine 0 C--N 1.338 0.651 0 C-N-CA 125.658 1.599 . . . . 0.0 110.224 -175.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -78.89 150.67 32.1 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.352 1.061 . . . . 0.0 108.872 178.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 70.4 t -70.46 145.98 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.803 -0.561 . . . . 0.0 110.612 -179.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 38.2 m -150.26 68.31 0.98 Allowed 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.623 1.169 . . . . 0.0 108.758 174.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.69 -110.99 3.82 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.3 -28.56 38.22 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 117.876 0.838 . . . . 0.0 110.388 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 31.8 m -86.81 155.13 20.42 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.702 1.201 . . . . 0.0 109.237 -172.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.9 t -119.64 134.52 62.93 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 171.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -122.96 120.05 32.24 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 124.666 1.186 . . . . 0.0 108.576 -172.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -87.48 170.84 11.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-O 121.151 0.5 . . . . 0.0 109.98 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 51.0 m -152.24 151.58 31.13 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -177.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.64 177.21 27.19 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -173.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 58.5 mttm -76.94 -26.13 53.67 Favored 'General case' 0 CA--C 1.53 0.198 0 O-C-N 122.035 -0.685 . . . . 0.0 111.827 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.3 m -78.77 73.61 5.32 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.846 0.748 . . . . 0.0 110.201 -175.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -82.37 83.36 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.9 t-80 -88.13 86.0 7.03 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 124.189 0.996 . . . . 0.0 109.438 -174.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 93.4 t -81.0 111.71 18.04 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.115 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 -177.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.62 97.75 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 123.251 0.62 . . . . 0.0 109.33 -177.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.07 101.6 13.28 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.703 1.201 . . . . 0.0 110.101 -176.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -90.77 102.17 14.92 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.801 1.24 . . . . 0.0 108.435 177.229 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.71 111.78 23.44 Favored 'General case' 0 CA--C 1.529 0.162 0 O-C-N 121.042 -1.036 . . . . 0.0 111.12 -174.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 8.5 t 38.21 73.96 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.648 1.579 . . . . 0.0 112.743 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.4 mp -76.85 155.53 82.96 Favored Pre-proline 0 CA--C 1.537 0.457 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 -177.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo -40.01 -44.82 3.83 Favored 'Trans proline' 0 C--N 1.347 0.5 0 C-N-CA 124.717 3.611 . . . . 0.0 116.397 -173.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -60.13 -20.98 55.53 Favored Glycine 0 CA--C 1.534 1.255 0 CA-C-O 119.865 -0.408 . . . . 0.0 113.839 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -110.96 97.18 33.15 Favored Pre-proline 0 N--CA 1.453 -0.301 0 C-N-CA 125.465 1.506 . . . . 0.0 108.804 -175.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_endo -73.91 76.1 3.02 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.293 1.995 . . . . 0.0 110.402 -178.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 70.28 165.9 0.13 Allowed Pre-proline 0 CA--C 1.537 0.465 0 C-N-CA 125.994 1.718 . . . . 0.0 112.261 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -117.26 -9.1 0.34 Allowed 'Cis proline' 0 CA--C 1.535 0.572 0 N-CA-C 114.451 0.904 . . . . 0.0 114.451 -4.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.4 p -90.04 157.78 17.64 Favored 'General case' 0 CA--C 1.535 0.367 0 N-CA-C 121.134 3.753 . . . . 0.0 121.134 -165.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -77.75 121.6 24.25 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 103.476 -2.786 . . . . 0.0 103.476 169.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -106.61 134.95 48.97 Favored 'General case' 0 N--CA 1.439 -0.99 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -174.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.0 t -132.84 83.43 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 123.539 0.736 . . . . 0.0 109.204 -173.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.278 1.0 OUTLIER 44.11 -70.07 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 130.224 3.409 . . . . 0.0 115.587 179.165 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -95.51 -23.86 16.9 Favored 'General case' 0 N--CA 1.456 -0.175 0 C-N-CA 124.186 0.994 . . . . 0.0 111.243 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -131.32 -172.94 2.97 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.549 1.139 . . . . 0.0 108.967 -175.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -139.4 134.72 32.82 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.381 -2.081 . . . . 0.0 105.381 172.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 49.48 41.43 0.99 Allowed Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 123.895 0.878 . . . . 0.0 112.111 -173.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -72.77 162.88 39.99 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 CA-C-N 120.982 1.386 . . . . 0.0 111.247 -176.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.1 m -78.41 127.15 31.77 Favored 'General case' 0 N--CA 1.44 -0.934 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 171.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 7.7 mp -97.38 127.37 43.29 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 119.249 0.932 . . . . 0.0 109.634 -179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -107.78 120.71 43.0 Favored 'General case' 0 C--O 1.232 0.168 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 171.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 40.9 mt -123.24 134.61 25.26 Favored Pre-proline 0 CA--C 1.537 0.456 0 C-N-CA 124.691 1.196 . . . . 0.0 111.964 -171.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -65.1 113.46 2.41 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.396 2.064 . . . . 0.0 109.661 170.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.17 132.02 19.53 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.526 0.73 . . . . 0.0 111.133 174.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 88.94 -4.24 84.81 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-O 119.455 -0.636 . . . . 0.0 112.573 -176.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.81 164.63 24.84 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 118.846 1.323 . . . . 0.0 111.641 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 53.9 m -98.21 103.27 15.2 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.667 1.587 . . . . 0.0 108.197 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.7 t -83.07 112.15 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.397 0 C-N-CA 124.118 0.967 . . . . 0.0 108.768 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -103.31 100.69 10.58 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 174.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.5 t -79.23 93.25 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 37.6 m -90.95 99.74 12.73 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.622 1.569 . . . . 0.0 109.134 -176.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -79.64 159.57 26.69 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.492 173.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.9 mp -142.28 82.77 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 N-CA-C 101.019 -3.697 . . . . 0.0 101.019 162.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 23.7 t30 -108.3 115.17 29.61 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 105.383 -2.08 . . . . 0.0 105.383 172.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 99.3 m -140.41 39.55 1.89 Allowed 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 175.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.7 t-20 -79.77 70.62 6.33 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.986 177.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.4 mttm -1.62 94.94 0.01 OUTLIER 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 129.402 3.081 . . . . 0.0 113.904 -176.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 96.14 -36.72 3.71 Favored Glycine 0 CA--C 1.532 1.15 0 O-C-N 121.92 -0.487 . . . . 0.0 113.418 175.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -79.92 95.11 6.0 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-N 118.6 1.2 . . . . 0.0 110.922 -178.626 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.78 54.02 0.36 Allowed Glycine 0 CA--C 1.534 1.273 0 C-N-CA 125.243 1.402 . . . . 0.0 113.226 174.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.3 m-70 -47.27 129.67 12.81 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-N 118.907 1.354 . . . . 0.0 110.228 177.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.4 p -108.26 112.59 25.15 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 -176.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 48.6 t80 -79.34 94.75 5.55 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 105.916 -1.883 . . . . 0.0 105.916 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -101.29 130.87 47.53 Favored 'General case' 0 N--CA 1.462 0.16 0 C-N-CA 124.584 1.154 . . . . 0.0 109.538 -172.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -109.75 130.43 62.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 119.059 0.845 . . . . 0.0 110.468 -175.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.2 t -159.12 -153.18 0.35 Allowed 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -121.39 42.55 3.05 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 119.577 1.08 . . . . 0.0 110.234 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 21.8 mmmt -76.09 94.8 3.52 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.6 157.2 52.52 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 172.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.1 160.24 45.64 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.105 1.87 . . . . 0.0 110.206 174.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -78.19 142.79 71.01 Favored 'Cis proline' 0 N--CA 1.456 -0.717 0 CA-C-N 118.901 0.643 . . . . 0.0 110.538 -2.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -79.85 151.89 29.99 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 176.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -101.54 148.64 24.97 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.542 0.737 . . . . 0.0 109.849 -178.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 25.5 t -63.47 -31.76 54.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 173.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.1 mpp? -78.18 119.28 76.75 Favored Pre-proline 0 N--CA 1.45 -0.447 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -79.44 77.37 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.341 2.027 . . . . 0.0 108.89 -174.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 90.9 t -76.12 108.57 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 -175.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 15.6 pt -79.0 75.71 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-O 122.956 1.36 . . . . 0.0 111.194 -175.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -67.03 154.28 92.84 Favored Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 170.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -40.45 109.15 0.09 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.812 3.008 . . . . 0.0 114.363 -170.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 29.0 mm -78.6 121.83 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 175.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 87.6 t -84.67 -83.75 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.478 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.77 167.46 11.42 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 171.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.06 160.36 13.23 Favored Glycine 0 N--CA 1.448 -0.551 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 175.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 75.0 p -79.6 -46.3 17.53 Favored 'General case' 0 N--CA 1.444 -0.758 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.173 177.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 93.61 -173.06 33.44 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 104.651 -3.38 . . . . 0.0 104.651 -167.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -82.96 131.67 35.18 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 120.404 2.102 . . . . 0.0 109.691 -174.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.6 p -90.48 153.43 46.07 Favored Pre-proline 0 CA--C 1.534 0.327 0 N-CA-C 116.113 1.894 . . . . 0.0 116.113 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -75.34 143.36 27.91 Favored 'Trans proline' 0 N--CA 1.451 -0.973 0 C-N-CA 122.905 2.403 . . . . 0.0 106.099 169.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.5 m -141.16 95.57 7.43 Favored Pre-proline 0 CA--C 1.534 0.328 0 CA-C-N 118.456 0.571 . . . . 0.0 111.956 -172.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -55.97 168.53 1.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.816 3.011 . . . . 0.0 113.068 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -113.71 -5.25 13.34 Favored 'General case' 0 C--N 1.34 0.169 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -176.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 18.0 t0 178.05 154.16 0.33 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 126.236 1.815 . . . . 0.0 109.285 176.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 68.29 -62.66 0.4 Allowed Glycine 0 C--N 1.339 0.703 0 C-N-CA 126.522 2.011 . . . . 0.0 113.675 174.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 70.6 mmtt -78.88 155.88 28.89 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 123.973 0.909 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -135.84 107.83 7.15 Favored 'General case' 0 CA--C 1.517 -0.303 0 C-N-CA 125.116 1.366 . . . . 0.0 110.778 -173.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -61.52 110.88 3.42 Favored Glycine 0 CA--C 1.526 0.726 0 C-N-CA 124.748 1.166 . . . . 0.0 110.604 176.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.6 p90 -116.51 170.55 8.48 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-O 122.658 1.218 . . . . 0.0 110.172 174.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 2.8 m -159.01 146.48 17.54 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 -174.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.21 96.25 2.75 Favored 'General case' 0 CA--C 1.521 -0.157 0 O-C-N 124.017 0.823 . . . . 0.0 111.866 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -103.82 147.93 26.72 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 169.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 37.4 m -104.15 134.3 47.63 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 177.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -136.54 140.67 43.11 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.522 1.129 . . . . 0.0 108.947 176.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -110.66 90.12 10.12 Favored Pre-proline 0 N--CA 1.455 -0.203 0 N-CA-C 105.174 -2.158 . . . . 0.0 105.174 173.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.16 147.55 42.78 Favored 'Trans proline' 0 N--CA 1.445 -1.354 0 C-N-CA 121.664 1.576 . . . . 0.0 110.285 -173.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.3 p -79.66 162.98 24.92 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 173.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.83 171.95 1.91 Allowed 'General case' 0 CA--C 1.537 0.455 0 O-C-N 121.307 -0.871 . . . . 0.0 112.13 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 100.95 -127.05 9.13 Favored Glycine 0 CA--C 1.522 0.496 0 C-N-CA 125.227 1.394 . . . . 0.0 110.158 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.2 m -153.04 144.4 23.25 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.352 1.076 . . . . 0.0 110.928 -174.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -134.21 -177.33 4.53 Favored 'General case' 0 N--CA 1.456 -0.163 0 C-N-CA 126.719 2.008 . . . . 0.0 106.71 173.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -144.62 141.6 29.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.223 1.009 . . . . 0.0 109.109 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -101.3 143.58 31.18 Favored 'General case' 0 N--CA 1.455 -0.206 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.8 m -150.71 151.96 11.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 125.169 1.388 . . . . 0.0 109.789 -177.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 52.6 t -97.72 102.32 14.05 Favored 'General case' 0 C--O 1.231 0.111 0 C-N-CA 124.407 1.083 . . . . 0.0 109.754 171.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 29.4 mm100 -73.52 33.61 0.08 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 114.176 1.176 . . . . 0.0 114.176 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 29.4 mt -92.63 142.09 25.34 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 169.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 99.1 Cg_exo -46.11 136.67 14.14 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 122.335 2.023 . . . . 0.0 113.093 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.26 -52.41 4.05 Favored Glycine 0 CA--C 1.527 0.801 0 C-N-CA 123.676 0.655 . . . . 0.0 112.661 179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -39.83 -55.64 1.93 Allowed 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 125.855 1.662 . . . . 0.0 114.849 -171.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -50.89 -41.49 58.45 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.451 0.569 . . . . 0.0 111.635 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -73.27 -50.86 19.99 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.217 0.607 . . . . 0.0 109.943 174.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 60.7 p -79.85 62.39 4.07 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 121.691 -0.631 . . . . 0.0 111.377 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.38 93.39 Favored Glycine 0 CA--C 1.53 0.999 0 N-CA-C 117.622 1.809 . . . . 0.0 117.622 171.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 7.5 mtp -122.35 68.6 0.95 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 119.862 1.831 . . . . 0.0 109.154 170.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 27.8 p90 -159.48 -177.71 6.61 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.493 0.717 . . . . 0.0 111.883 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.73 171.47 33.74 Favored Glycine 0 C--N 1.34 0.775 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 172.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.7 mttm -101.6 152.46 20.78 Favored 'General case' 0 CA--C 1.528 0.103 0 C-N-CA 123.784 0.834 . . . . 0.0 109.495 -174.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.9 mt -124.35 94.14 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 174.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 27.1 t -88.53 131.76 35.17 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 175.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 36.1 t -128.1 109.65 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -175.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt . . . . . 0 N--CA 1.465 0.294 0 CA-C-N 119.001 0.818 . . . . 0.0 110.464 -179.132 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.778 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.4 p -51.93 -26.12 9.66 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 125.533 1.533 . . . . 0.0 112.472 178.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.7 mp -48.72 -38.61 22.06 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 125.604 1.561 . . . . 0.0 110.851 173.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.45 ' HA ' ' CH2' ' A' ' 7' ' ' TRP . 20.6 t0 -59.32 95.93 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.654 1.182 . . . . 0.0 111.693 178.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.1 p -134.03 -92.21 0.33 Allowed 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.92 1.288 . . . . 0.0 111.701 -174.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.4 m -78.69 58.53 2.29 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 114.124 1.157 . . . . 0.0 114.124 -169.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.45 ' CH2' ' HA ' ' A' ' 4' ' ' ASP . 0.1 OUTLIER -89.09 130.28 35.56 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.754 1.222 . . . . 0.0 107.916 179.743 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -149.8 176.2 10.93 Favored 'General case' 0 CA--C 1.528 0.134 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -137.93 151.99 48.53 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 170.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.34 -153.76 0.57 Allowed 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 127.355 2.262 . . . . 0.0 105.998 173.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.3 p -138.21 169.12 18.34 Favored 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 118.958 0.799 . . . . 0.0 109.684 175.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.72 -54.39 4.09 Favored Pre-proline 0 CA--C 1.54 0.58 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 -174.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -57.73 -33.52 96.91 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.6 1.534 . . . . 0.0 111.936 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.8 mm100 -67.67 -23.8 65.35 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 121.765 -0.584 . . . . 0.0 111.103 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.5 t -64.14 -49.67 80.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 173.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.5 mttp -58.89 -39.82 82.58 Favored 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 122.684 0.393 . . . . 0.0 110.321 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -56.21 -62.83 1.44 Allowed 'General case' 0 CA--C 1.531 0.213 0 O-C-N 122.042 -0.411 . . . . 0.0 109.963 174.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.5 mtm -54.08 -43.52 70.41 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.642 0.777 . . . . 0.0 111.897 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.7 mt -54.76 -33.09 60.85 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 176.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 28.0 mt-10 -65.54 -14.98 62.22 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 119.396 0.998 . . . . 0.0 112.392 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.98 17.57 20.65 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 119.008 0.822 . . . . 0.0 110.129 173.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.05 154.07 42.12 Favored 'General case' 0 CA--C 1.531 0.249 0 O-C-N 121.432 -0.793 . . . . 0.0 109.108 172.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -151.82 165.34 34.81 Favored 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 123.547 0.739 . . . . 0.0 109.766 -172.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 116.12 136.8 5.95 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 124.347 0.975 . . . . 0.0 111.335 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -79.26 126.75 31.19 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.299 1.039 . . . . 0.0 108.483 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 50.9 t -68.96 83.95 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 C-N-CA 125.46 1.504 . . . . 0.0 109.261 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.9 m -85.89 68.06 10.22 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.087 1.355 . . . . 0.0 108.451 -175.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.54 -105.95 1.31 Allowed Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -87.43 -22.34 25.04 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.78 0.832 . . . . 0.0 111.536 176.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.4 m -97.35 155.74 16.76 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 124.928 1.291 . . . . 0.0 108.517 -173.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 71.0 t -114.56 135.5 54.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 106.196 -1.779 . . . . 0.0 106.196 174.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.8 m -124.03 122.93 39.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 119.191 0.905 . . . . 0.0 110.375 -173.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 38' ' ' VAL . 0.6 OUTLIER -79.55 174.55 11.46 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.243 0.544 . . . . 0.0 111.208 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.5 m -158.93 49.88 0.36 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 123.723 0.809 . . . . 0.0 110.186 -174.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 176.26 170.44 38.94 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 -177.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -82.11 -33.71 29.58 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 122.978 0.511 . . . . 0.0 111.304 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.5 p -83.2 84.46 7.48 Favored 'General case' 0 N--CA 1.454 -0.24 0 O-C-N 121.301 -0.874 . . . . 0.0 108.767 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 33' ' ' TYR . 77.6 t -86.07 83.35 2.1 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 C-N-CA 124.196 0.998 . . . . 0.0 108.894 -174.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.9 t-80 -84.96 104.78 15.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 C-N-CA 124.705 1.202 . . . . 0.0 109.765 -176.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.44 104.49 16.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.7 t -81.9 112.09 19.3 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 174.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -125.81 160.39 29.96 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.978 1.311 . . . . 0.0 110.267 -176.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.22 163.54 38.01 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.274 1.03 . . . . 0.0 109.65 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -129.35 122.62 29.88 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 124.017 0.927 . . . . 0.0 109.668 -179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 5.4 t 26.1 65.16 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 128.418 2.687 . . . . 0.0 113.12 174.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.9 mt -77.23 146.91 75.44 Favored Pre-proline 0 CA--C 1.534 0.36 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -39.67 104.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 124.712 3.608 . . . . 0.0 113.679 -177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.28 -47.67 1.0 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -175.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -77.29 142.33 67.58 Favored Pre-proline 0 CA--C 1.531 0.24 0 O-C-N 122.244 -0.562 . . . . 0.0 109.93 -178.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -79.06 152.3 24.36 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.703 2.268 . . . . 0.0 111.512 -174.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -65.58 145.83 99.02 Favored Pre-proline 0 N--CA 1.45 -0.44 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 173.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -109.76 50.54 1.22 Allowed 'Cis proline' 0 CA--C 1.54 0.79 0 N-CA-C 108.087 -1.543 . . . . 0.0 108.087 -5.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 87.0 p -73.19 127.2 31.94 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 115.958 1.836 . . . . 0.0 115.958 -170.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -81.81 108.85 15.67 Favored 'General case' 0 C--N 1.343 0.318 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 168.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -84.31 136.66 33.82 Favored 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 120.011 1.278 . . . . 0.0 107.93 177.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -135.59 87.53 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.185 0 CA-C-N 119.128 0.876 . . . . 0.0 109.64 -174.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.0 p-80 39.27 -97.15 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 126.575 1.95 . . . . 0.0 113.632 -176.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.0 -27.24 64.53 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.882 0.473 . . . . 0.0 111.844 -174.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 mmtt -127.19 -171.55 2.45 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.505 1.122 . . . . 0.0 110.718 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -135.6 127.45 29.36 Favored 'General case' 0 N--CA 1.447 -0.607 0 N-CA-C 105.221 -2.14 . . . . 0.0 105.221 172.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 51.16 44.15 2.02 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 125.044 1.338 . . . . 0.0 111.76 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.01 -178.0 4.24 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 122.87 2.38 . . . . 0.0 112.733 -173.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.9 m -104.45 136.2 44.47 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 113.079 -1.873 . . . . 0.0 106.44 172.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.7 mp -116.5 122.3 44.33 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 118.875 0.761 . . . . 0.0 112.038 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -93.27 127.09 38.71 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 171.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 25.4 mt -130.83 140.96 40.27 Favored Pre-proline 0 CA--C 1.538 0.497 0 C-N-CA 125.176 1.391 . . . . 0.0 111.711 -170.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -81.37 122.78 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.664 2.243 . . . . 0.0 109.137 171.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.98 143.06 3.15 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 125.205 1.402 . . . . 0.0 112.652 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 78.02 -12.08 19.44 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.28 -0.733 . . . . 0.0 113.695 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.68 148.66 23.89 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 119.035 1.418 . . . . 0.0 111.074 174.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 59.8 m -81.61 102.06 10.41 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 173.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.4 t -79.28 127.19 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -124.45 103.3 8.11 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 50.7 t -85.76 105.44 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.9 m -91.33 98.04 11.47 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.99 1.316 . . . . 0.0 107.93 175.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.69 156.04 30.94 Favored 'General case' 0 C--O 1.223 -0.308 0 C-N-CA 120.916 -0.313 . . . . 0.0 110.902 173.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.1 mp -136.99 73.43 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.415 0 N-CA-C 102.172 -3.27 . . . . 0.0 102.172 164.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -89.57 110.93 21.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 173.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 41.4 m -141.25 46.28 1.73 Allowed 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 173.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -68.43 -48.91 63.35 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.6 mtmm 93.34 155.33 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 129.709 3.204 . . . . 0.0 109.42 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 -66.89 1.59 Allowed Glycine 0 CA--C 1.53 1.029 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -172.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -79.8 104.03 10.1 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 124.222 1.009 . . . . 0.0 110.705 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.42 73.36 0.59 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 107.964 -2.054 . . . . 0.0 107.964 171.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -55.26 136.49 48.82 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 118.792 1.296 . . . . 0.0 111.506 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.3 p -96.43 157.01 16.1 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.242 1.417 . . . . 0.0 108.32 174.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -128.38 115.83 18.84 Favored 'General case' 0 CA--C 1.52 -0.193 0 N-CA-C 103.623 -2.732 . . . . 0.0 103.623 171.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -133.13 121.46 22.64 Favored 'General case' 0 C--O 1.226 -0.164 0 CA-C-N 119.151 0.887 . . . . 0.0 109.975 -171.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 53.3 mt -97.8 132.87 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 125.651 1.58 . . . . 0.0 109.275 -174.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -157.39 -155.8 0.54 Allowed 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 124.757 1.223 . . . . 0.0 107.963 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.8 mtpt -132.6 -2.85 3.36 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 113.335 0.865 . . . . 0.0 113.335 -174.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 35.7 mtmt -74.84 134.53 41.69 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 118.844 0.747 . . . . 0.0 109.453 176.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -87.15 171.35 42.3 Favored Glycine 0 CA--C 1.531 1.044 0 C-N-CA 123.285 0.469 . . . . 0.0 112.14 -178.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -70.95 166.0 30.5 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 123.617 2.878 . . . . 0.0 109.792 174.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -78.39 139.19 54.08 Favored 'Cis proline' 0 N--CA 1.454 -0.805 0 N-CA-C 110.392 -0.657 . . . . 0.0 110.392 -3.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -81.93 151.44 27.23 Favored 'General case' 0 N--CA 1.454 -0.231 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 175.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.39 153.29 31.71 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 56.6 t -57.77 -43.67 84.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -77.92 131.66 69.6 Favored Pre-proline 0 N--CA 1.451 -0.379 0 N-CA-C 104.535 -2.394 . . . . 0.0 104.535 172.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.87 75.43 2.68 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.25 1.967 . . . . 0.0 112.197 -172.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 t -79.21 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 105.448 -2.056 . . . . 0.0 105.448 172.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.413 ' H ' HG13 ' A' ' 102' ' ' ILE . 1.8 pp -86.71 -34.82 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 C-N-CA 126.834 2.054 . . . . 0.0 113.289 -173.07 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -51.27 138.9 26.78 Favored Pre-proline 0 CA--C 1.535 0.389 0 C-N-CA 124.301 1.04 . . . . 0.0 111.901 -173.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -82.22 170.98 56.71 Favored 'Cis proline' 0 N--CA 1.459 -0.507 0 CA-C-N 119.629 0.903 . . . . 0.0 110.981 0.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 26.1 mm -124.05 144.33 34.19 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.109 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 174.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.9 t -95.39 -88.76 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 106.056 -1.831 . . . . 0.0 106.056 174.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.23 158.55 15.41 Favored 'General case' 0 N--CA 1.461 0.11 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 173.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.45 172.84 40.68 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 119.272 -1.442 . . . . 0.0 113.025 173.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.8 p -126.94 116.49 20.87 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.587 1.155 . . . . 0.0 110.653 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -76.17 65.11 2.71 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.515 1.055 . . . . 0.0 111.314 -179.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 76.24 98.75 0.07 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 127.186 2.194 . . . . 0.0 112.073 173.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 93.9 p -68.67 169.28 11.29 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-O 118.951 -0.547 . . . . 0.0 110.552 -179.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -54.27 167.02 1.41 Allowed 'Trans proline' 0 C--N 1.349 0.566 0 C-N-CA 123.295 2.663 . . . . 0.0 117.014 -172.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 79.0 t -124.67 92.02 48.52 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 126.78 2.032 . . . . 0.0 106.632 173.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.407 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 31.6 Cg_exo -72.33 -170.2 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 123.376 2.717 . . . . 0.0 113.467 -176.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -128.82 172.93 10.81 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 172.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -49.71 147.47 3.6 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-O 121.077 0.465 . . . . 0.0 112.166 -174.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.04 -44.85 2.67 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-O 119.346 -0.697 . . . . 0.0 112.738 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -79.69 153.05 29.57 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 124.226 1.01 . . . . 0.0 110.839 -178.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -135.51 114.66 12.3 Favored 'General case' 0 C--O 1.224 -0.25 0 C-N-CA 124.903 1.281 . . . . 0.0 111.079 -173.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.407 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -75.95 113.56 3.92 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 125.507 1.527 . . . . 0.0 110.281 -174.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -113.9 163.02 15.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 122.766 1.27 . . . . 0.0 110.882 175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.3 m -150.91 126.66 10.28 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.702 -1.962 . . . . 0.0 105.702 174.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.63 89.6 3.12 Favored 'General case' 0 CA--C 1.518 -0.267 0 C-N-CA 124.46 1.104 . . . . 0.0 108.069 178.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -101.2 143.97 30.63 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 174.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 27.2 m -106.25 149.26 27.04 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.353 1.061 . . . . 0.0 109.686 -174.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -147.78 145.95 28.99 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.235 1.014 . . . . 0.0 109.762 174.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.4 m80 -114.1 107.46 51.94 Favored Pre-proline 0 CA--C 1.531 0.233 0 N-CA-C 105.033 -2.21 . . . . 0.0 105.033 173.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -90.79 133.74 1.75 Allowed 'Trans proline' 0 N--CA 1.444 -1.388 0 C-N-CA 123.743 2.962 . . . . 0.0 113.447 -170.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.4 p -84.54 158.86 20.82 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.528 1.531 . . . . 0.0 107.05 170.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -62.18 167.73 3.84 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 119.104 0.865 . . . . 0.0 113.025 -174.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 107.12 -177.08 21.5 Favored Glycine 0 CA--C 1.528 0.894 0 C-N-CA 126.263 1.887 . . . . 0.0 112.916 174.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 12.7 m -87.82 137.56 32.23 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 124.213 1.005 . . . . 0.0 109.483 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -133.26 167.32 20.58 Favored 'General case' 0 N--CA 1.453 -0.277 0 C-N-CA 125.302 1.441 . . . . 0.0 107.24 176.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -134.0 147.75 51.03 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.987 1.315 . . . . 0.0 108.134 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . 0.45 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 47.6 p90 -114.14 138.99 49.7 Favored 'General case' 0 N--CA 1.457 -0.08 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.3 m -142.52 156.23 18.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 C-N-CA 125.345 1.458 . . . . 0.0 110.258 -178.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 13.4 t -96.62 114.75 26.43 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 124.552 1.141 . . . . 0.0 109.033 172.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -61.92 -14.44 34.4 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 125.42 1.488 . . . . 0.0 114.738 -176.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 26.2 mt -58.78 130.41 85.7 Favored Pre-proline 0 CA--C 1.541 0.606 0 CA-C-N 120.002 1.274 . . . . 0.0 108.317 174.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -45.71 145.86 4.19 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 123.12 2.547 . . . . 0.0 112.972 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.18 -43.75 2.06 Favored Glycine 0 CA--C 1.528 0.881 0 CA-C-O 119.58 -0.566 . . . . 0.0 112.798 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 18.5 m170 -52.67 -55.21 24.15 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.534 1.167 . . . . 0.0 112.602 -172.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -53.93 -52.7 59.78 Favored 'General case' 0 CA--C 1.535 0.367 0 CA-C-N 118.098 0.408 . . . . 0.0 110.103 177.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -54.46 -42.92 71.22 Favored 'General case' 0 C--N 1.339 0.114 0 C-N-CA 124.016 0.927 . . . . 0.0 111.402 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.1 p -81.24 10.92 4.76 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 12.93 37.73 Favored Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.475 -1.18 . . . . 0.0 116.026 170.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 2.9 ttt -79.31 73.88 5.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 119.995 1.897 . . . . 0.0 108.426 174.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.24 -166.92 2.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.511 0.324 . . . . 0.0 111.425 -174.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.45 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.76 177.44 40.2 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 174.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -116.43 152.89 33.08 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.5 1.12 . . . . 0.0 110.879 -172.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.6 mt -129.12 141.11 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 105.297 -2.112 . . . . 0.0 105.297 174.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 28.9 t -132.48 108.94 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 174.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.63 113.98 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 -176.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 67.9 mttm . . . . . 0 N--CA 1.461 0.119 0 CA-C-N 118.495 0.589 . . . . 0.0 109.847 174.702 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.523 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 23.7 p -75.27 75.59 2.39 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 103.907 -2.627 . . . . 0.0 103.907 171.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.4 mt 60.03 -172.53 0.12 Allowed 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.248 1.019 . . . . 0.0 108.736 -169.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -71.52 133.46 45.83 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 121.135 -0.978 . . . . 0.0 109.298 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.2 p -130.26 41.1 3.45 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 123.965 0.906 . . . . 0.0 109.979 174.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.0 m -79.8 64.19 4.58 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 122.323 1.059 . . . . 0.0 108.164 178.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -80.49 121.48 25.81 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 125.859 1.664 . . . . 0.0 110.987 -173.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.3 mmtp -142.01 170.39 15.81 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 172.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -134.8 129.06 33.96 Favored 'General case' 0 N--CA 1.456 -0.172 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 171.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.6 -156.76 0.53 Allowed 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 105.444 -2.058 . . . . 0.0 105.444 172.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 70.9 p -137.65 170.98 15.13 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 119.413 1.006 . . . . 0.0 109.876 174.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.15 -60.36 1.02 Allowed Pre-proline 0 CA--C 1.543 0.677 0 N-CA-C 115.325 1.602 . . . . 0.0 115.325 -173.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -60.06 -29.26 88.82 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 CA-C-N 121.588 1.603 . . . . 0.0 112.335 -178.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -67.03 -25.74 66.42 Favored 'General case' 0 N--CA 1.45 -0.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.533 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.9 t -61.83 -46.52 96.33 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.139 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 173.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -60.54 -49.27 78.22 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 176.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.68 -49.32 57.6 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 122.141 0.177 . . . . 0.0 111.358 177.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.3 mtm -63.7 -50.42 69.24 Favored 'General case' 0 C--O 1.224 -0.27 0 CA-C-O 118.907 -0.568 . . . . 0.0 110.767 177.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 mt -52.57 -40.96 63.16 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.45 1.023 . . . . 0.0 111.942 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -57.36 -36.04 70.7 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 122.848 0.459 . . . . 0.0 110.752 174.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.41 50.38 0.93 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.827 0.851 . . . . 0.0 109.601 174.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -69.77 -51.23 35.77 Favored 'General case' 0 CA--C 1.528 0.109 0 C-N-CA 123.603 0.761 . . . . 0.0 110.174 -174.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . 0.299 70.3 p 65.3 -44.31 0.35 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.154 2.182 . . . . 0.0 114.932 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.4 118.45 13.72 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 119.535 1.061 . . . . 0.0 110.975 174.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mptp? -79.88 163.96 23.94 Favored 'General case' 0 N--CA 1.454 -0.261 0 C-N-CA 124.979 1.312 . . . . 0.0 109.158 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 58.6 t -85.27 151.24 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 C-N-CA 122.957 0.503 . . . . 0.0 110.156 -179.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 60.4 m -150.89 72.23 1.06 Allowed 'General case' 0 C--O 1.227 -0.116 0 C-N-CA 124.918 1.287 . . . . 0.0 108.581 174.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.15 -144.31 47.62 Favored Glycine 0 CA--C 1.528 0.866 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 -172.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -80.01 57.24 2.59 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 118.913 1.357 . . . . 0.0 109.743 174.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.9 m -160.89 153.93 21.37 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 178.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.92 152.16 15.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -140.98 136.78 32.5 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.328 -172.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -107.46 164.42 12.22 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.065 0.946 . . . . 0.0 109.907 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 m -159.19 47.45 0.3 Allowed 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.311 0.644 . . . . 0.0 110.069 -174.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -175.47 171.6 44.69 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 107.637 -2.185 . . . . 0.0 107.637 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -75.41 -32.33 60.71 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 117.69 0.745 . . . . 0.0 111.005 -177.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.06 71.41 5.53 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-O 121.42 0.629 . . . . 0.0 110.241 -174.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 77.7 t -81.79 77.95 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.218 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -176.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -80.78 111.86 17.62 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 123.891 0.876 . . . . 0.0 109.034 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.18 106.68 21.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -177.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 9.5 t -89.57 95.45 5.45 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 118.068 0.395 . . . . 0.0 109.967 -174.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.0 99.95 10.76 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 125.329 1.452 . . . . 0.0 111.47 -174.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.22 108.45 18.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 O-C-N 121.673 -0.642 . . . . 0.0 109.971 175.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.45 82.78 8.16 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 121.259 -0.901 . . . . 0.0 109.057 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 34.3 t 68.24 96.05 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 C-N-CA 125.167 1.387 . . . . 0.0 109.68 175.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.9 mt -77.23 144.0 70.41 Favored Pre-proline 0 CA--C 1.531 0.213 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -58.39 107.87 0.36 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 123.397 2.732 . . . . 0.0 109.125 -179.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 147.59 -49.8 0.6 Allowed Glycine 0 CA--C 1.523 0.556 0 N-CA-C 104.666 -3.373 . . . . 0.0 104.666 -171.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -80.13 126.51 79.25 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 104.586 -2.376 . . . . 0.0 104.586 170.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -70.51 -36.13 9.32 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 121.197 1.265 . . . . 0.0 109.935 174.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -173.43 179.82 0.51 Allowed Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 129.201 3.0 . . . . 0.0 105.136 -173.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -118.15 -23.54 0.09 OUTLIER 'Cis proline' 0 C--N 1.347 0.471 0 CA-C-N 120.701 1.286 . . . . 0.0 114.599 -5.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.4 p -86.17 160.37 19.24 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.959 2.948 . . . . 0.0 118.959 -166.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -76.68 117.25 18.12 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 104.33 -2.47 . . . . 0.0 104.33 171.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -101.98 103.18 13.79 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 104.248 -2.501 . . . . 0.0 104.248 -179.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.7 t -108.89 113.07 43.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 O-C-N 122.086 -0.384 . . . . 0.0 110.079 -171.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 30.59 -104.24 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 126.078 1.751 . . . . 0.0 113.869 -174.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -67.09 -24.16 65.92 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -173.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.7 mttm -139.37 -164.67 1.72 Allowed 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 119.35 0.977 . . . . 0.0 111.335 -173.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.1 mtmt -125.33 130.99 53.07 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 172.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 47.58 45.31 2.6 Favored Pre-proline 0 CA--C 1.545 0.768 0 C-N-CA 124.227 1.011 . . . . 0.0 112.025 -174.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -67.37 154.75 72.99 Favored 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.273 1.315 . . . . 0.0 111.114 -179.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.5 m -87.56 133.73 33.74 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 105.765 -1.939 . . . . 0.0 105.765 171.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -111.71 128.51 56.1 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.922 0.783 . . . . 0.0 110.824 -174.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -99.33 115.94 30.35 Favored 'General case' 0 CA--C 1.531 0.225 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 171.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.427 HD12 HG23 ' A' ' 152' ' ' ILE . 27.2 mt -120.64 142.34 34.03 Favored Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 124.552 1.141 . . . . 0.0 113.379 -169.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -78.89 119.46 4.36 Favored 'Trans proline' 0 N--CA 1.451 -0.995 0 C-N-CA 122.532 2.155 . . . . 0.0 109.137 171.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.2 140.6 3.88 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 125.816 1.646 . . . . 0.0 111.95 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 76.97 -5.46 48.59 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-O 119.092 -0.838 . . . . 0.0 113.613 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 155.22 26.17 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 119.45 1.625 . . . . 0.0 111.049 174.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 73.7 m -83.76 96.85 8.86 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 174.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -79.65 100.12 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.57 0 C-N-CA 124.877 1.271 . . . . 0.0 108.046 179.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -92.52 91.52 7.63 Favored 'General case' 0 C--O 1.237 0.441 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 174.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 40.7 t -77.08 103.13 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.654 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 176.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 43.3 m -101.04 98.22 8.69 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.011 1.724 . . . . 0.0 109.232 -172.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.8 m-85 -77.91 156.58 30.21 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.574 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -139.21 78.02 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 101.576 -3.49 . . . . 0.0 101.576 164.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -97.1 101.83 13.48 Favored 'General case' 0 C--O 1.226 -0.17 0 N-CA-C 106.433 -1.691 . . . . 0.0 106.433 178.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 46.2 m -148.37 54.38 1.02 Allowed 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 122.182 0.992 . . . . 0.0 108.721 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.83 -19.64 61.28 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 115.08 -0.964 . . . . 0.0 109.822 173.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mttm 81.5 121.49 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 127.649 2.38 . . . . 0.0 107.323 -173.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.38 -54.05 3.18 Favored Glycine 0 CA--C 1.534 1.233 0 O-C-N 121.595 -0.691 . . . . 0.0 112.921 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -78.53 79.42 4.96 Favored 'General case' 0 N--CA 1.455 -0.216 0 O-C-N 121.444 -1.033 . . . . 0.0 110.718 -174.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -51.69 77.33 0.01 OUTLIER Glycine 0 CA--C 1.527 0.794 0 C-N-CA 126.603 2.049 . . . . 0.0 112.635 174.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -63.18 144.17 57.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 118.66 1.23 . . . . 0.0 111.251 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.9 p -106.51 154.73 20.43 Favored 'General case' 0 N--CA 1.444 -0.757 0 C-N-CA 127.024 2.13 . . . . 0.0 106.048 172.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 8.2 t80 -134.52 110.33 9.29 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 105.37 -2.085 . . . . 0.0 105.37 172.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . 0.411 ' HB3' HD12 ' A' ' 105' ' ' ILE . 1.4 m-20 -130.81 148.39 52.58 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.292 0.496 . . . . 0.0 110.397 -174.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.2 mt -114.56 137.93 46.32 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 C-N-CA 126.22 1.808 . . . . 0.0 110.048 -172.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 4.5 t -160.93 -155.0 0.39 Allowed 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 124.909 1.284 . . . . 0.0 107.714 177.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -122.2 8.45 9.75 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.905 0.882 . . . . 0.0 111.595 177.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.6 mtmp? -63.0 114.11 3.49 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.29 170.25 38.88 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -68.67 164.06 34.64 Favored 'Trans proline' 0 N--CA 1.454 -0.815 0 C-N-CA 123.072 2.514 . . . . 0.0 109.196 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.81 131.12 23.04 Favored 'Cis proline' 0 N--CA 1.455 -0.749 0 CA-C-N 119.464 0.844 . . . . 0.0 110.828 0.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 71.5 m-85 -79.56 158.53 27.13 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 174.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -138.33 167.28 22.21 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 124.364 1.066 . . . . 0.0 108.15 -177.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 21.2 t -77.55 60.42 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 C-N-CA 124.324 1.049 . . . . 0.0 108.664 -176.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 52.3 mtm -147.09 103.96 3.83 Favored Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 124.51 1.124 . . . . 0.0 110.473 -174.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -64.93 75.49 0.22 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.191 2.594 . . . . 0.0 112.692 174.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.6 t -78.98 67.22 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 173.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 24.9 pt -83.05 -23.66 8.39 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 C-N-CA 124.713 1.205 . . . . 0.0 114.134 -172.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -45.35 -56.96 8.29 Favored Pre-proline 0 CA--C 1.543 0.694 0 CA-C-O 118.92 -0.562 . . . . 0.0 111.779 176.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -76.07 67.76 6.73 Favored 'Trans proline' 0 CA--C 1.537 0.663 0 C-N-CA 122.178 1.918 . . . . 0.0 111.597 172.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 88' ' ' ASP . 6.1 mm -118.65 142.08 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 172.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.0 t -98.61 -92.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -177.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.94 161.39 14.48 Favored 'General case' 0 C--N 1.334 -0.088 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 174.403 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.38 173.71 28.18 Favored Glycine 0 C--N 1.334 0.455 0 C-N-CA 120.134 -1.031 . . . . 0.0 113.374 174.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.431 HG23 ' CD1' ' A' ' 125' ' ' PHE . 3.0 p -109.41 125.52 52.5 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.909 1.284 . . . . 0.0 110.152 -178.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -80.21 58.95 4.6 Favored Glycine 0 CA--C 1.535 1.314 0 CA-C-O 119.496 -0.613 . . . . 0.0 111.817 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 71.58 98.8 0.07 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.617 1.967 . . . . 0.0 112.263 174.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.1 p -78.61 165.15 51.69 Favored Pre-proline 0 CA--C 1.544 0.732 0 O-C-N 121.077 -1.014 . . . . 0.0 112.5 -175.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -60.79 159.64 28.11 Favored 'Trans proline' 0 C--N 1.351 0.71 0 C-N-CA 123.252 2.635 . . . . 0.0 112.098 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.51 86.19 14.37 Favored Pre-proline 0 CA--C 1.533 0.313 0 C-N-CA 124.217 1.007 . . . . 0.0 110.896 -179.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -55.74 163.72 5.21 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 123.528 2.819 . . . . 0.0 113.024 173.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -92.98 -23.53 18.68 Favored 'General case' 0 C--N 1.338 0.086 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 178.19 159.93 0.53 Allowed 'General case' 0 C--N 1.327 -0.408 0 C-N-CA 126.7 2.0 . . . . 0.0 109.32 -176.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 70.26 -63.41 0.78 Allowed Glycine 0 C--N 1.338 0.644 0 C-N-CA 125.524 1.535 . . . . 0.0 112.839 174.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -78.68 157.84 28.51 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 124.263 1.025 . . . . 0.0 109.609 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -139.71 107.67 5.71 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 125.237 1.415 . . . . 0.0 110.826 -172.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -60.76 109.65 2.51 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 124.576 1.084 . . . . 0.0 110.852 -178.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 3.9 p90 -127.55 156.48 42.15 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 121.849 0.833 . . . . 0.0 111.455 -178.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 18.1 m -159.72 109.93 1.9 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 113.97 -1.468 . . . . 0.0 107.449 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -86.75 69.61 10.33 Favored 'General case' 0 C--O 1.233 0.225 0 C-N-CA 125.164 1.386 . . . . 0.0 107.333 173.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . 0.431 ' CD1' HG23 ' A' ' 109' ' ' THR . 17.2 p90 -72.19 129.66 38.98 Favored 'General case' 0 N--CA 1.455 -0.181 0 C-N-CA 118.304 -1.358 . . . . 0.0 108.331 179.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 40.9 m -101.95 126.99 49.0 Favored 'General case' 0 N--CA 1.451 -0.409 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.411 -171.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -134.68 157.78 45.78 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 125.481 1.512 . . . . 0.0 109.522 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 78.8 m80 -123.35 115.43 28.64 Favored Pre-proline 0 CA--C 1.536 0.421 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 174.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -92.36 148.2 2.93 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 124.301 3.334 . . . . 0.0 111.809 -172.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 37.7 p -95.02 149.62 21.05 Favored 'General case' 0 N--CA 1.457 -0.121 0 C-N-CA 124.888 1.275 . . . . 0.0 108.763 173.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.98 151.9 13.99 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.122 0.419 . . . . 0.0 111.733 177.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 119.3 -124.13 5.89 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 126.937 2.208 . . . . 0.0 109.592 -176.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.0 m -153.61 147.95 25.93 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 118.314 1.057 . . . . 0.0 110.222 -174.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -139.87 173.87 11.08 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 127.825 2.45 . . . . 0.0 106.912 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -136.15 148.75 48.33 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 126.402 1.881 . . . . 0.0 107.259 174.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -109.47 147.87 32.14 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 172.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.39 150.9 12.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 C-N-CA 125.117 1.367 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 42.6 t -84.75 140.34 31.33 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 169.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -78.08 -20.71 51.75 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -173.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 54.7 mt -61.35 124.38 80.46 Favored Pre-proline 0 CA--C 1.544 0.739 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -25.28 -76.01 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.567 1 C-N-CA 126.011 4.474 . . . . 0.0 117.446 -172.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -77.45 -2.29 79.32 Favored Glycine 0 CA--C 1.525 0.679 0 O-C-N 121.691 -0.631 . . . . 0.0 114.046 -173.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -72.69 -48.29 40.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 119.364 1.582 . . . . 0.0 110.558 -173.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -60.15 -41.86 93.68 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 173.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.76 -48.24 78.29 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.823 0.449 . . . . 0.0 111.51 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 26.3 p -79.38 -58.29 3.28 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -174.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 176.87 37.79 0.05 OUTLIER Glycine 0 C--N 1.339 0.7 0 C-N-CA 119.187 -1.482 . . . . 0.0 115.196 -174.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 10.4 mtp -116.39 72.39 0.81 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 118.193 0.996 . . . . 0.0 108.405 173.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -159.56 -174.72 4.79 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.318 0.647 . . . . 0.0 112.16 -177.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 164.53 171.01 30.26 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 110.032 -1.227 . . . . 0.0 110.032 174.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 42.9 mtmt -99.94 146.86 26.2 Favored 'General case' 0 CA--C 1.528 0.11 0 C-N-CA 124.998 1.319 . . . . 0.0 110.609 -176.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.427 HG23 HD12 ' A' ' 66' ' ' ILE . 15.8 mt -124.59 101.77 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 173.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.5 t -92.42 137.64 21.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 172.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 11.5 t -127.9 123.55 61.05 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -175.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 71.1 mmtt . . . . . 0 N--CA 1.466 0.328 0 CA-C-N 119.823 1.192 . . . . 0.0 111.422 179.481 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.874 0 N-CA-C 111.455 -0.658 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.1 p -63.49 -51.45 65.53 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.287 1.035 . . . . 0.0 110.184 177.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 7.9 mp 54.5 -103.23 0.17 Allowed 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.461 1.105 . . . . 0.0 109.905 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -167.22 152.6 7.47 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 105.901 -1.889 . . . . 0.0 105.901 175.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 25.2 p -135.64 23.15 3.39 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 125.076 1.35 . . . . 0.0 110.829 -174.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.9 m -79.77 64.18 4.55 Favored 'General case' 0 CA--C 1.536 0.409 0 O-C-N 121.161 -0.962 . . . . 0.0 110.277 -174.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -85.91 134.55 33.88 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 126.34 1.856 . . . . 0.0 110.212 -173.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -149.55 173.04 14.05 Favored 'General case' 0 CA--C 1.53 0.2 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -138.77 151.16 46.85 Favored 'General case' 0 N--CA 1.455 -0.212 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 172.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.31 -153.02 0.54 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.898 1.679 . . . . 0.0 106.664 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.7 p -135.65 173.95 11.15 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 119.462 1.028 . . . . 0.0 108.512 172.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.4 tt -39.41 -57.05 2.51 Favored Pre-proline 0 CA--C 1.54 0.575 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -54.76 -34.18 83.54 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 121.963 1.775 . . . . 0.0 113.531 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 21.0 mp0 -67.41 -25.73 66.08 Favored 'General case' 0 N--CA 1.456 -0.172 0 O-C-N 121.134 -0.979 . . . . 0.0 111.258 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.82 -46.91 93.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 174.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.1 -50.11 74.98 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -51.21 -48.36 62.06 Favored 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 111.656 0.243 . . . . 0.0 111.656 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.7 mtm -62.93 -50.63 70.08 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 122.606 0.362 . . . . 0.0 110.516 177.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 43.8 mt -52.08 -41.95 62.8 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.436 0.562 . . . . 0.0 111.875 177.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -56.51 -23.62 40.95 Favored 'General case' 0 CA--C 1.538 0.513 0 O-C-N 121.542 -0.724 . . . . 0.0 112.678 177.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 54.4 mtmt -100.95 12.55 37.46 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 123.653 0.781 . . . . 0.0 111.787 179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -65.85 -46.27 79.1 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -174.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.4 p 63.8 -139.12 0.32 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.455 1.502 . . . . 0.0 109.27 -171.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.48 104.18 0.2 Allowed Glycine 0 CA--C 1.528 0.893 0 CA-C-N 118.593 0.633 . . . . 0.0 111.741 -177.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 37.3 mtpt -78.7 120.26 23.11 Favored 'General case' 0 N--CA 1.451 -0.38 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 62.5 t -63.04 148.51 11.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -148.85 64.17 1.05 Allowed 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.15 -141.26 35.51 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.4 t0 -79.55 54.74 1.82 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 118.603 1.202 . . . . 0.0 109.642 174.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.7 m -161.31 147.12 14.17 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 77.8 t -118.18 137.87 50.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 175.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 93.2 m -120.57 119.22 32.29 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 124.832 1.253 . . . . 0.0 109.623 -173.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -83.07 169.43 15.91 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 122.083 0.944 . . . . 0.0 111.606 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 75.1 m -156.86 152.17 26.48 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.36 166.95 33.05 Favored Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -174.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 35.4 mtmm -82.82 -28.48 30.18 Favored 'General case' 0 CA--C 1.53 0.195 0 O-C-N 122.282 -0.54 . . . . 0.0 112.241 -174.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.2 p -81.59 78.01 8.39 Favored 'General case' 0 N--CA 1.453 -0.29 0 O-C-N 121.484 -0.76 . . . . 0.0 109.588 -178.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -80.07 75.39 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -80.89 93.19 6.24 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.788 -177.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 60.2 t -88.49 102.42 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.526 0.049 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -176.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 43.1 t -83.74 88.42 2.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.08 164.23 12.78 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 125.267 1.427 . . . . 0.0 110.227 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -159.62 169.31 24.05 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 123.96 0.904 . . . . 0.0 109.23 178.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.56 132.7 28.01 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 176.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 26.13 72.73 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 127.263 2.225 . . . . 0.0 113.009 173.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 92.1 mt -77.29 148.27 77.4 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -55.2 111.24 0.69 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.999 2.466 . . . . 0.0 110.519 -175.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 130.77 -40.33 1.67 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 -174.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -87.93 125.08 65.74 Favored Pre-proline 0 N--CA 1.454 -0.272 0 C-N-CA 123.647 0.779 . . . . 0.0 109.453 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -59.08 161.95 14.89 Favored 'Trans proline' 0 N--CA 1.454 -0.84 0 C-N-CA 122.249 1.966 . . . . 0.0 111.744 173.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -62.66 164.6 11.72 Favored Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 116.261 -0.427 . . . . 0.0 109.953 173.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -113.47 -11.92 0.64 Allowed 'Cis proline' 0 CA--C 1.539 0.774 0 CA-C-N 118.947 0.66 . . . . 0.0 113.535 -4.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.5 p -44.68 143.46 1.38 Allowed 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 118.586 2.81 . . . . 0.0 118.586 -170.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -77.27 129.14 35.49 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 168.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -104.33 132.52 50.49 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 177.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.5 t -139.91 123.67 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -175.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -14.74 111.32 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 126.515 1.926 . . . . 0.0 115.37 -173.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.4 t70 89.67 -28.02 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.23 0 C-N-CA 127.309 2.244 . . . . 0.0 113.419 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -136.69 -168.97 2.36 Favored 'General case' 0 CA--C 1.538 0.484 0 CA-C-O 122.524 1.154 . . . . 0.0 111.015 -173.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.5 mttp -137.5 134.88 36.25 Favored 'General case' 0 N--CA 1.446 -0.662 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 171.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 48.82 40.62 0.8 Allowed Pre-proline 0 CA--C 1.548 0.882 0 C-N-CA 124.081 0.952 . . . . 0.0 112.69 -176.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.25 159.67 46.64 Favored 'Trans proline' 0 N--CA 1.45 -1.031 0 CA-C-N 120.993 1.39 . . . . 0.0 113.349 -171.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.58 121.23 25.55 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 127.647 2.379 . . . . 0.0 106.297 173.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 9.2 mp -103.99 117.94 35.5 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 119.862 1.21 . . . . 0.0 111.5 -178.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -93.36 120.09 33.24 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 171.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 14.0 mt -122.32 139.7 31.2 Favored Pre-proline 0 CA--C 1.538 0.514 0 C-N-CA 124.431 1.092 . . . . 0.0 112.906 -170.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -76.34 116.26 4.3 Favored 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 122.805 2.336 . . . . 0.0 108.728 171.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -48.69 139.58 9.43 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 125.12 1.368 . . . . 0.0 112.302 -178.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.25 -9.78 38.7 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-O 119.072 -0.849 . . . . 0.0 113.457 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.47 157.52 20.02 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 119.42 1.61 . . . . 0.0 110.52 174.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 50.2 m -83.71 101.68 11.72 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 175.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.1 t -79.64 99.81 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 174.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -96.59 97.16 9.17 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 174.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -80.02 108.02 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.453 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.2 m -99.7 96.71 7.8 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.009 1.724 . . . . 0.0 107.972 175.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.278 5.7 m-85 -79.26 148.1 32.29 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 118.726 -0.654 . . . . 0.0 110.31 172.66 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.07 79.38 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 102.514 -3.143 . . . . 0.0 102.514 163.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -99.48 104.7 16.55 Favored 'General case' 0 C--O 1.223 -0.296 0 N-CA-C 105.42 -2.067 . . . . 0.0 105.42 172.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.0 m -121.77 38.44 4.11 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 173.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -78.39 73.23 4.94 Favored 'General case' 0 N--CA 1.452 -0.333 0 O-C-N 121.245 -0.91 . . . . 0.0 109.12 175.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 45.4 mttm 0.16 97.32 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 129.126 2.97 . . . . 0.0 114.557 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.05 -34.29 3.62 Favored Glycine 0 CA--C 1.534 1.243 0 O-C-N 121.605 -0.685 . . . . 0.0 114.07 175.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -82.24 88.12 6.52 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 119.073 1.436 . . . . 0.0 110.171 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.29 63.04 0.4 Allowed Glycine 0 CA--C 1.533 1.168 0 C-N-CA 123.785 0.707 . . . . 0.0 112.545 175.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.5 m-70 -51.06 120.78 5.23 Favored 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 118.941 1.37 . . . . 0.0 110.084 175.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -75.87 165.11 25.48 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 123.581 0.752 . . . . 0.0 109.628 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 21.4 t80 -133.15 103.37 5.98 Favored 'General case' 0 C--O 1.232 0.14 0 N-CA-C 106.376 -1.712 . . . . 0.0 106.376 172.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . 0.443 ' HB3' HD12 ' A' ' 105' ' ' ILE . 81.0 m-20 -118.38 137.34 53.19 Favored 'General case' 0 CA--C 1.516 -0.333 0 C-N-CA 123.434 0.694 . . . . 0.0 109.819 -176.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 25.8 mt -110.0 134.71 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.339 0 C-N-CA 126.041 1.737 . . . . 0.0 109.075 -175.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.2 t -158.65 -158.22 0.68 Allowed 'General case' 0 C--O 1.223 -0.301 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.0 mtmm -129.6 6.67 5.21 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 119.564 1.075 . . . . 0.0 112.5 -179.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.9 mtpt -67.51 160.71 27.08 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -104.08 160.06 16.18 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_endo -72.78 159.5 48.29 Favored 'Trans proline' 0 N--CA 1.455 -0.736 0 C-N-CA 122.791 2.327 . . . . 0.0 109.893 174.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -78.79 134.83 34.28 Favored 'Cis proline' 0 N--CA 1.457 -0.635 0 N-CA-C 108.75 -1.288 . . . . 0.0 108.75 -5.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.542 ' HB2' ' HB1' ' A' ' 144' ' ' ALA . 92.9 m-85 -83.13 31.36 0.44 Allowed 'General case' 0 N--CA 1.468 0.463 0 O-C-N 120.979 -1.075 . . . . 0.0 113.377 -173.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . 70.05 156.0 0.14 Allowed 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 127.703 2.401 . . . . 0.0 113.084 177.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.98 -46.25 85.26 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.183 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.386 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.1 mmt -78.92 160.1 72.19 Favored Pre-proline 0 CA--C 1.536 0.422 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 174.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -70.25 59.12 1.85 Allowed 'Trans proline' 0 CA--C 1.538 0.725 0 C-N-CA 123.08 2.52 . . . . 0.0 114.153 -174.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.8 t -82.46 55.79 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 O-C-N 120.238 -1.539 . . . . 0.0 108.664 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -80.88 -38.6 17.17 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 C-N-CA 123.101 0.561 . . . . 0.0 110.998 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -55.48 147.43 38.73 Favored Pre-proline 0 CA--C 1.535 0.374 0 C-N-CA 124.445 1.098 . . . . 0.0 111.826 -174.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 79.1 Cg_endo -74.13 150.38 95.47 Favored 'Cis proline' 0 N--CA 1.459 -0.537 0 CA-C-N 118.851 0.625 . . . . 0.0 111.127 -0.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.443 HD12 ' HB3' ' A' ' 88' ' ' ASP . 20.2 mm -109.45 143.7 19.11 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.118 0 C-N-CA 124.42 1.088 . . . . 0.0 108.406 175.522 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.73 -89.49 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 174.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.89 156.48 16.33 Favored 'General case' 0 C--N 1.332 -0.155 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 173.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.29 173.51 41.11 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 119.063 -1.541 . . . . 0.0 112.817 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.9 p -123.15 137.09 54.99 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.398 1.479 . . . . 0.0 109.625 176.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.47 -164.34 7.49 Favored Glycine 0 CA--C 1.54 1.654 0 N-CA-C 108.136 -1.986 . . . . 0.0 108.136 170.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -67.63 118.66 11.21 Favored 'General case' 0 CA--C 1.537 0.47 0 O-C-N 120.8 -1.412 . . . . 0.0 112.286 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.6 p -69.71 161.08 77.01 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 126.201 1.8 . . . . 0.0 113.413 -173.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -74.4 144.96 33.3 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.023 2.482 . . . . 0.0 107.969 174.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -147.18 80.15 9.49 Favored Pre-proline 0 CA--C 1.536 0.442 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -53.89 164.69 2.29 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 124.627 3.551 . . . . 0.0 112.588 172.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -119.35 -0.05 11.02 Favored 'General case' 0 C--N 1.34 0.173 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -174.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -175.28 148.06 0.94 Allowed 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.191 1.396 . . . . 0.0 109.026 176.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 66.15 -62.85 0.15 Allowed Glycine 0 CA--C 1.527 0.79 0 C-N-CA 126.579 2.038 . . . . 0.0 113.47 177.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -78.66 157.39 28.64 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-O 121.352 0.596 . . . . 0.0 110.018 -177.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -129.55 108.63 10.39 Favored 'General case' 0 CA--C 1.512 -0.481 0 C-N-CA 127.014 2.125 . . . . 0.0 107.943 -174.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.04 123.71 18.63 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 19.8 p90 -130.89 168.57 17.07 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.724 1.25 . . . . 0.0 110.701 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.8 m -155.53 124.68 6.21 Favored 'General case' 0 N--CA 1.444 -0.755 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -109.83 106.63 16.3 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -119.06 150.61 39.68 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.3 m -114.69 145.29 42.21 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.882 0.873 . . . . 0.0 111.007 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 26.1 t90 -145.02 153.23 41.26 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.887 1.275 . . . . 0.0 109.236 174.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.9 93.96 44.96 Favored Pre-proline 0 CA--C 1.53 0.174 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -81.6 146.01 14.93 Favored 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.467 2.112 . . . . 0.0 111.358 -173.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 10.6 p -96.3 156.37 16.37 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 172.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -55.93 144.65 27.56 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -174.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 139.97 -132.58 5.62 Favored Glycine 0 C--N 1.337 0.611 0 C-N-CA 126.215 1.864 . . . . 0.0 109.984 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 33.5 m -150.52 145.07 25.73 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 118.026 0.913 . . . . 0.0 109.132 -174.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -147.02 175.64 10.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.738 2.015 . . . . 0.0 107.181 -175.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -142.57 155.37 44.98 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 125.354 1.462 . . . . 0.0 108.557 179.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -121.46 147.2 46.07 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 124.275 1.03 . . . . 0.0 110.915 175.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 m -150.65 160.66 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 124.855 1.262 . . . . 0.0 112.308 -174.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 7.1 t -102.82 133.49 47.8 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 125.876 1.67 . . . . 0.0 108.738 171.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -70.65 -34.67 72.3 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 113.816 1.043 . . . . 0.0 113.816 -173.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 70.8 mt -48.62 128.38 13.71 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.781 0.832 . . . . 0.0 109.993 -172.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -42.32 142.82 1.61 Allowed 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 124.26 3.307 . . . . 0.0 114.968 -173.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.45 -40.55 1.78 Allowed Glycine 0 CA--C 1.529 0.951 0 C-N-CA 123.995 0.807 . . . . 0.0 112.634 177.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 21.3 m170 -54.6 -47.26 73.6 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.568 0.747 . . . . 0.0 111.624 -173.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . 0.542 ' HB1' ' HB2' ' A' ' 96' ' ' TYR . . . -81.84 -11.67 58.85 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.631 0.65 . . . . 0.0 112.4 175.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.56 -57.82 4.72 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 173.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.5 p -151.63 87.04 1.34 Allowed 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -175.91 -66.47 0.06 OUTLIER Glycine 0 CA--C 1.524 0.631 0 C-N-CA 119.82 -1.181 . . . . 0.0 113.951 178.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.0 ptm -141.59 113.19 7.7 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 117.671 0.736 . . . . 0.0 111.948 -173.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.4 p90 -163.56 -166.73 1.26 Allowed 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 124.716 1.206 . . . . 0.0 108.169 176.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.14 173.33 36.71 Favored Glycine 0 C--N 1.336 0.547 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 175.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 29.9 mttp -109.78 150.31 28.54 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.709 1.204 . . . . 0.0 110.869 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 17.1 mt -128.33 130.01 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 174.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 6.2 t -118.01 135.81 57.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 173.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.03 123.11 64.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -174.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 53.3 mtmt . . . . . 0 N--CA 1.464 0.229 0 CA-C-N 118.81 0.732 . . . . 0.0 111.093 -174.288 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.741 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.1 p -76.43 71.39 3.09 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 176.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.8 mp -55.64 -81.98 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 125.16 1.384 . . . . 0.0 111.239 175.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -176.34 143.35 0.5 Allowed 'General case' 0 C--O 1.235 0.319 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 175.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.0 p -138.18 38.78 2.31 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 123.863 0.727 . . . . 0.0 110.495 -178.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.1 m -79.59 62.62 3.94 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 121.879 0.847 . . . . 0.0 108.729 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.5 OUTLIER -78.48 123.81 27.45 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 125.188 1.395 . . . . 0.0 110.392 -172.428 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.5 mmtp -142.64 173.55 11.44 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 174.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -141.15 148.76 40.54 Favored 'General case' 0 N--CA 1.455 -0.214 0 O-C-N 121.847 -0.533 . . . . 0.0 109.607 171.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.74 -153.77 0.56 Allowed 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 126.633 1.973 . . . . 0.0 106.212 173.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -134.97 172.22 13.32 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 119.084 0.856 . . . . 0.0 108.991 172.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 tt -38.64 -57.44 1.95 Allowed Pre-proline 0 CA--C 1.538 0.511 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -174.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -56.24 -32.46 87.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.473 1.449 . . . . 0.0 113.318 -178.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.6 mp0 -65.7 -31.57 72.64 Favored 'General case' 0 N--CA 1.454 -0.271 0 O-C-N 121.268 -0.895 . . . . 0.0 110.913 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 38.7 t -55.42 -49.74 70.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 CA-C-N 118.954 0.797 . . . . 0.0 109.14 176.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 25.9 mtpp -57.03 -51.39 69.47 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.87 -51.58 39.33 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -61.18 -53.1 61.19 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.219 0.463 . . . . 0.0 110.708 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 58.4 mt -51.7 -40.7 60.6 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 118.672 0.669 . . . . 0.0 111.78 -177.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -59.36 -23.53 62.61 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.842 0.857 . . . . 0.0 112.726 178.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -70.88 -66.31 0.63 Allowed 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 119.315 0.961 . . . . 0.0 109.514 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 58.6 -62.22 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 126.716 2.006 . . . . 0.0 115.622 176.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 19.3 p 53.89 37.66 27.04 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.174 1.79 . . . . 0.0 112.301 179.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -141.6 121.66 1.89 Allowed Glycine 0 CA--C 1.528 0.854 0 C-N-CA 124.88 1.229 . . . . 0.0 110.535 -174.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.3 mtpt -79.81 118.14 21.33 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.892 1.677 . . . . 0.0 108.96 -179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.4 t -68.83 77.48 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 C-N-CA 124.939 1.296 . . . . 0.0 110.257 -174.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 m -81.09 70.08 7.84 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.687 1.195 . . . . 0.0 107.784 -179.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 62.95 -113.55 6.0 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -174.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -78.45 -19.1 53.87 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 117.856 0.828 . . . . 0.0 111.238 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 59.6 m -98.62 110.06 22.72 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -172.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.9 t -79.19 114.17 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 104.298 -2.482 . . . . 0.0 104.298 172.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 98.5 m -106.72 121.48 44.46 Favored 'General case' 0 CA--C 1.522 -0.122 0 C-N-CA 124.577 1.151 . . . . 0.0 111.679 -170.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -81.36 167.68 19.21 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 121.513 0.673 . . . . 0.0 110.752 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.0 m -159.55 46.97 0.28 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 123.992 0.917 . . . . 0.0 109.275 -177.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.52 170.35 42.77 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -78.62 -32.14 47.32 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 117.45 0.625 . . . . 0.0 111.602 -177.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.6 m -78.87 72.94 5.42 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.49 0.662 . . . . 0.0 109.617 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.4 t -80.31 86.08 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 CA-C-O 121.788 0.804 . . . . 0.0 109.118 -174.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 34.5 t-80 -85.69 101.96 13.2 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.938 1.295 . . . . 0.0 110.401 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.3 t -102.79 110.62 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 C-N-CA 124.484 1.114 . . . . 0.0 108.918 -176.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.9 t -95.06 101.64 12.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.306 0 CA-C-N 118.183 0.447 . . . . 0.0 110.267 -176.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -101.93 104.39 15.09 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.437 1.495 . . . . 0.0 111.244 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.6 110.57 21.42 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 125.486 1.514 . . . . 0.0 109.259 175.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -97.48 95.54 7.72 Favored 'General case' 0 N--CA 1.458 -0.068 0 O-C-N 121.79 -0.569 . . . . 0.0 110.826 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 9.2 t 46.68 69.74 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 C-N-CA 127.238 2.215 . . . . 0.0 111.153 173.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 27.3 mt -77.26 152.54 81.75 Favored Pre-proline 0 CA--C 1.532 0.257 0 CA-C-O 118.514 -0.755 . . . . 0.0 109.556 -174.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_exo -43.52 108.83 0.12 Allowed 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 124.139 3.226 . . . . 0.0 111.446 175.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 139.12 -52.27 0.73 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 106.108 -2.797 . . . . 0.0 106.108 -172.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -81.36 121.44 80.14 Favored Pre-proline 0 N--CA 1.451 -0.405 0 N-CA-C 105.592 -2.003 . . . . 0.0 105.592 171.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.98 -59.34 0.09 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.947 0 CA-C-N 120.686 1.281 . . . . 0.0 109.069 175.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -170.77 169.4 3.46 Favored Pre-proline 0 CA--C 1.535 0.398 0 C-N-CA 128.837 2.855 . . . . 0.0 105.558 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -115.7 -21.65 0.15 OUTLIER 'Cis proline' 0 N--CA 1.458 -0.592 0 CA-C-N 120.305 1.145 . . . . 0.0 113.631 -5.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 6.0 p -67.55 148.54 51.32 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 117.765 2.506 . . . . 0.0 117.765 -167.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -75.54 131.48 40.07 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 173.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -102.23 131.1 48.99 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 172.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.4 t -138.33 122.01 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 CA-C-N 119.245 0.93 . . . . 0.0 108.809 -174.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER 12.58 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 127.756 2.422 . . . . 0.0 115.335 -178.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.8 t70 76.21 -32.45 0.2 Allowed 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.078 1.351 . . . . 0.0 113.595 -179.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.2 mmmp? -121.58 -173.29 2.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 122.351 1.072 . . . . 0.0 112.367 -171.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 25.0 mtpp -133.12 125.5 29.66 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 105.332 -2.099 . . . . 0.0 105.332 173.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 43.85 50.18 6.17 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 124.195 0.998 . . . . 0.0 111.83 -173.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.76 157.87 58.91 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 121.717 1.611 . . . . 0.0 110.485 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.414 HG23 ' HB2' ' A' ' 151' ' ' LYS . 50.2 m -84.44 145.88 27.93 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 105.893 -1.892 . . . . 0.0 105.893 170.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.0 mp -114.24 121.47 43.81 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 121.506 -0.747 . . . . 0.0 109.542 -177.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -98.94 118.54 35.95 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 171.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.41 HD12 ' CG2' ' A' ' 152' ' ' ILE . 17.9 mt -122.14 133.68 24.45 Favored Pre-proline 0 N--CA 1.453 -0.289 0 C-N-CA 124.978 1.311 . . . . 0.0 110.448 -172.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.93 118.39 5.02 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.127 1.885 . . . . 0.0 108.137 172.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -50.38 136.37 20.5 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 123.883 0.873 . . . . 0.0 111.196 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -12.71 67.65 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 119.672 -0.516 . . . . 0.0 112.156 -175.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.97 154.14 16.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 118.481 1.14 . . . . 0.0 112.909 174.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 99.5 m -92.15 105.72 17.88 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.472 -2.047 . . . . 0.0 105.472 171.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.2 t -88.04 93.78 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 C-N-CA 124.344 1.058 . . . . 0.0 108.178 -175.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.87 94.9 6.56 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 173.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.9 t -79.6 94.6 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 174.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 96.5 m -86.43 97.06 10.25 Favored 'General case' 0 N--CA 1.444 -0.732 0 C-N-CA 126.085 1.754 . . . . 0.0 108.539 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.403 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.5 m-85 -77.29 156.73 31.17 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 121.169 0.509 . . . . 0.0 111.607 173.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.0 mp -140.59 86.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 100.857 -3.757 . . . . 0.0 100.857 164.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -105.13 113.83 27.66 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 89.7 m -143.4 37.48 1.36 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.304 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -78.96 65.28 4.11 Favored 'General case' 0 CA--C 1.53 0.2 0 O-C-N 121.581 -0.699 . . . . 0.0 109.369 175.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 53.5 mttm 17.7 81.18 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 128.424 2.689 . . . . 0.0 114.688 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 95.15 -29.91 8.82 Favored Glycine 0 CA--C 1.532 1.105 0 CA-C-O 119.608 -0.551 . . . . 0.0 113.885 176.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -78.38 99.02 6.2 Favored 'General case' 0 CA--C 1.53 0.175 0 CA-C-N 119.265 1.532 . . . . 0.0 109.917 -174.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -70.81 60.97 0.94 Allowed Glycine 0 CA--C 1.523 0.591 0 C-N-CA 124.806 1.194 . . . . 0.0 110.614 176.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -33.68 -52.29 0.41 Allowed 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 126.114 1.766 . . . . 0.0 115.411 -172.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 17.5 p 78.43 134.06 0.06 Allowed 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 125.889 1.676 . . . . 0.0 108.742 -172.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.2 t80 -114.44 108.7 17.23 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 103.638 -2.727 . . . . 0.0 103.638 172.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -111.86 139.12 47.61 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -173.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 36.1 mt -124.75 134.42 66.87 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-O 121.838 0.828 . . . . 0.0 110.39 -173.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.2 t -160.22 -163.08 1.06 Allowed 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -175.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -120.97 5.69 10.39 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 123.814 0.846 . . . . 0.0 111.788 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -71.67 130.14 40.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 174.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -96.92 169.18 25.25 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.016 0.817 . . . . 0.0 112.158 -176.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -72.51 167.13 27.86 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.507 2.804 . . . . 0.0 109.698 174.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -68.2 130.74 15.47 Favored 'Cis proline' 0 N--CA 1.459 -0.544 0 CA-C-N 119.483 0.851 . . . . 0.0 111.218 -5.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -79.93 148.72 31.13 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 175.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.27 156.7 24.19 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.347 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 73.9 t -61.26 -34.75 62.05 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 174.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 55.2 mtm -78.05 128.13 79.61 Favored Pre-proline 0 CA--C 1.534 0.344 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 173.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.25 101.91 1.3 Allowed 'Trans proline' 0 N--CA 1.451 -0.971 0 C-N-CA 122.542 2.161 . . . . 0.0 110.602 -173.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 22.0 t -77.69 93.5 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 106.085 -1.82 . . . . 0.0 106.085 177.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.0 pt -78.49 -85.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 123.702 0.801 . . . . 0.0 112.788 -173.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -67.82 150.16 97.92 Favored Pre-proline 0 N--CA 1.454 -0.242 0 O-C-N 121.723 -0.611 . . . . 0.0 112.237 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.61 113.24 2.88 Favored 'Cis proline' 0 CA--C 1.537 0.645 0 CA-C-N 118.579 0.528 . . . . 0.0 112.878 1.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.7 mm -86.66 139.05 17.95 Favored 'Isoleucine or valine' 0 C--N 1.338 0.082 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.5 t -95.76 -87.2 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 174.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -93.64 166.65 12.13 Favored 'General case' 0 N--CA 1.455 -0.179 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 173.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 179.6 41.55 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 174.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.3 p -124.68 124.57 42.47 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.696 1.199 . . . . 0.0 108.984 175.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.27 59.75 4.31 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.564 -0.575 . . . . 0.0 112.809 -173.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 71.17 93.66 0.08 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.244 1.818 . . . . 0.0 110.501 175.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 1.5 p -65.9 161.36 55.11 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 126.875 2.07 . . . . 0.0 115.357 -172.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -67.02 154.88 73.17 Favored 'Trans proline' 0 C--N 1.351 0.709 0 C-N-CA 123.795 2.997 . . . . 0.0 108.995 173.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.4 t -147.19 85.31 6.92 Favored Pre-proline 0 CA--C 1.54 0.561 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -172.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -57.78 165.34 6.55 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.16 2.573 . . . . 0.0 112.722 174.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -101.43 6.39 42.48 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.829 1.048 . . . . 0.0 113.829 -174.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 3.7 p30 143.38 166.45 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 130.355 3.462 . . . . 0.0 109.376 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.3 -66.54 0.95 Allowed Glycine 0 C--N 1.34 0.755 0 C-N-CA 125.431 1.491 . . . . 0.0 111.28 177.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -78.58 155.15 29.8 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 124.075 0.95 . . . . 0.0 108.466 174.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -137.61 109.78 7.3 Favored 'General case' 0 CA--C 1.518 -0.258 0 C-N-CA 125.063 1.345 . . . . 0.0 110.829 -172.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -68.11 114.02 5.79 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 124.63 1.109 . . . . 0.0 111.102 -177.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 22.1 p90 -122.21 164.67 17.42 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-O 122.292 1.044 . . . . 0.0 111.65 178.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 74.3 m -159.57 119.22 2.95 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 26.4 m-20 -95.99 67.95 2.7 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 124.104 0.962 . . . . 0.0 108.501 176.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . 0.254 40.4 p90 -70.81 114.13 8.57 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 118.003 -1.479 . . . . 0.0 108.019 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 60.2 m -91.66 87.08 6.18 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.498 1.519 . . . . 0.0 109.974 -171.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.5 t90 -93.27 143.55 26.16 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.026 0.93 . . . . 0.0 110.951 -175.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.5 m80 -111.23 109.72 56.55 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 105.344 -2.095 . . . . 0.0 105.344 171.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -84.76 178.95 4.57 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 123.884 3.056 . . . . 0.0 111.462 -172.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 58.7 p -124.21 159.97 28.94 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 105.963 -1.865 . . . . 0.0 105.963 170.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -66.61 156.98 33.61 Favored 'General case' 0 CA--C 1.534 0.351 0 N-CA-C 113.823 1.045 . . . . 0.0 113.823 -172.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 114.55 -176.86 17.2 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 126.254 1.883 . . . . 0.0 112.329 174.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 5.5 m -82.76 87.48 6.77 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.115 0.966 . . . . 0.0 110.262 -175.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -78.96 175.31 10.68 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 171.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -150.78 149.34 29.63 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 124.932 1.293 . . . . 0.0 109.541 179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -112.31 146.52 38.1 Favored 'General case' 0 C--O 1.233 0.208 0 C-N-CA 124.233 1.013 . . . . 0.0 108.286 172.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -153.13 150.5 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 C-N-CA 124.872 1.269 . . . . 0.0 110.404 178.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 5.5 t -95.82 106.99 19.19 Favored 'General case' 0 CA--C 1.531 0.215 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 169.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 34.3 mm-40 -75.17 34.32 0.11 Allowed 'General case' 0 CA--C 1.538 0.509 0 N-CA-C 114.695 1.368 . . . . 0.0 114.695 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 25.7 mt -92.21 137.2 25.0 Favored Pre-proline 0 CA--C 1.535 0.383 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 169.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_exo -43.94 129.2 7.54 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.596 2.197 . . . . 0.0 113.207 -178.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.65 -24.73 3.62 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-O 119.361 -0.688 . . . . 0.0 114.095 178.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -65.13 -52.53 54.74 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 119.796 1.798 . . . . 0.0 111.617 -172.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.62 -44.1 80.86 Favored 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 174.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.92 -42.9 99.02 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 122.777 0.431 . . . . 0.0 111.654 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 23.2 p -79.05 -59.93 2.58 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 111.833 0.309 . . . . 0.0 111.833 -174.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -178.9 31.43 0.06 OUTLIER Glycine 0 C--N 1.337 0.621 0 C-N-CA 119.296 -1.43 . . . . 0.0 115.033 -174.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 8.2 mtp -111.39 68.73 0.67 Allowed 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 118.2 1.0 . . . . 0.0 108.531 173.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -158.37 -177.52 6.6 Favored 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.09 165.48 24.56 Favored Glycine 0 C--N 1.34 0.76 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 173.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB2' HG23 ' A' ' 63' ' ' THR . 13.2 mtmm -100.18 149.43 23.55 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.681 0.793 . . . . 0.0 109.492 -174.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.41 ' CG2' HD12 ' A' ' 66' ' ' ILE . 13.3 mt -125.96 93.96 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 C-N-CA 126.102 1.761 . . . . 0.0 107.361 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.97 95.8 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 29.6 t -85.74 91.19 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 95.6 mttt . . . . . 0 C--N 1.332 -0.193 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 177.094 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.677 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.3 p -66.06 -67.18 0.46 Allowed 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 173.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.5 mp -106.19 174.83 5.71 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 127.171 2.188 . . . . 0.0 106.425 171.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -72.83 118.87 16.3 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -176.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.3 p -112.77 31.46 6.36 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.973 1.309 . . . . 0.0 110.627 -174.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 11.4 m -79.01 63.96 3.81 Favored 'General case' 0 CA--C 1.535 0.396 0 O-C-N 121.259 -0.901 . . . . 0.0 109.956 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -78.25 125.57 29.55 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 125.157 1.383 . . . . 0.0 109.511 -173.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.5 mtpt -144.23 -179.74 6.71 Favored 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.918 0.887 . . . . 0.0 108.672 174.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -142.65 154.21 44.15 Favored 'General case' 0 C--N 1.342 0.243 0 CA-C-N 118.671 0.669 . . . . 0.0 111.088 172.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.46 -152.43 0.51 Allowed 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 128.19 2.596 . . . . 0.0 105.65 173.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -138.73 170.81 15.34 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 119.082 0.855 . . . . 0.0 110.042 175.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -38.85 -59.64 1.34 Allowed Pre-proline 0 CA--C 1.538 0.512 0 N-CA-C 115.031 1.493 . . . . 0.0 115.031 -174.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -58.78 -30.73 93.48 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 CA-C-N 121.248 1.481 . . . . 0.0 112.074 -178.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.2 mm100 -67.07 -25.33 66.19 Favored 'General case' 0 N--CA 1.449 -0.523 0 O-C-N 121.819 -0.551 . . . . 0.0 111.254 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.2 t -59.1 -54.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.137 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 174.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -57.73 -49.61 75.98 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.558 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -50.2 -57.91 6.75 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 123.05 0.54 . . . . 0.0 110.953 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.9 mtm -56.82 -50.21 73.07 Favored 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 122.816 0.446 . . . . 0.0 110.096 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 61.1 mt -53.35 -45.31 69.08 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.612 0.642 . . . . 0.0 110.92 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.79 -30.9 70.32 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 118.249 0.477 . . . . 0.0 111.146 177.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 5.3 mmpt? -80.42 1.57 28.6 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 123.214 0.606 . . . . 0.0 112.365 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.43 146.68 50.8 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.926 1.239 . . . . 0.0 110.381 175.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.6 p -109.65 32.4 5.07 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 123.424 0.69 . . . . 0.0 112.155 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.94 113.82 4.75 Favored Glycine 0 CA--C 1.527 0.789 0 C-N-CA 124.678 1.132 . . . . 0.0 110.802 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 47.8 mtmt -79.45 145.72 33.14 Favored 'General case' 0 N--CA 1.455 -0.195 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 174.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 t -73.57 148.73 8.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.769 -0.582 . . . . 0.0 109.623 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 23.6 m -150.76 65.68 0.93 Allowed 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 123.753 0.821 . . . . 0.0 109.611 177.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 64.12 -138.49 41.52 Favored Glycine 0 CA--C 1.528 0.894 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -174.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.2 t0 -79.82 50.58 1.19 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.74 1.27 . . . . 0.0 110.222 174.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 m -161.39 153.73 20.06 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -119.34 149.08 21.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.6 m -134.32 125.34 27.44 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.222 1.009 . . . . 0.0 108.974 -173.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -98.73 167.33 10.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 123.882 0.873 . . . . 0.0 110.0 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.1 m -156.7 161.53 39.84 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.904 1.282 . . . . 0.0 107.661 177.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 73.13 178.36 35.01 Favored Glycine 0 CA--C 1.529 0.969 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -176.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -78.04 -32.3 50.86 Favored 'General case' 0 CA--C 1.533 0.315 0 O-C-N 122.078 -0.66 . . . . 0.0 110.617 178.363 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.8 m -79.06 70.05 5.34 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 123.872 0.869 . . . . 0.0 110.777 -174.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 69.0 t -86.09 92.19 3.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -177.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.0 t-160 -94.49 94.94 8.51 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.852 0.861 . . . . 0.0 110.531 -173.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.4 t -92.26 94.29 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.114 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.124 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 6.2 t -89.83 103.54 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.99 112.23 21.51 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.146 0.978 . . . . 0.0 111.363 -173.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.16 148.44 23.65 Favored 'General case' 0 N--CA 1.45 -0.455 0 O-C-N 121.593 -0.692 . . . . 0.0 109.559 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.52 109.18 16.92 Favored 'General case' 0 CA--C 1.527 0.058 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 174.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.5 t 40.52 81.59 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 126.408 1.883 . . . . 0.0 112.576 175.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 76.8 mt -76.91 147.59 77.62 Favored Pre-proline 0 CA--C 1.534 0.332 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 -175.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -44.51 111.63 0.29 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 123.876 3.051 . . . . 0.0 111.017 174.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.73 -40.71 1.58 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -173.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -88.44 112.57 50.81 Favored Pre-proline 0 CA--C 1.53 0.203 0 CA-C-O 118.661 -0.685 . . . . 0.0 109.349 178.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -78.78 66.29 8.66 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.391 2.061 . . . . 0.0 109.702 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 64.9 170.64 0.1 OUTLIER Pre-proline 0 CA--C 1.539 0.525 0 C-N-CA 124.349 1.06 . . . . 0.0 112.362 -175.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 21.3 Cg_endo -116.73 -19.43 0.14 OUTLIER 'Cis proline' 0 CA--C 1.539 0.733 0 CA-C-N 119.108 0.717 . . . . 0.0 113.394 -6.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -66.52 151.22 47.69 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 118.964 2.95 . . . . 0.0 118.964 -168.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 20.0 m-85 -77.35 128.92 35.11 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 104.249 -2.5 . . . . 0.0 104.249 169.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -111.62 115.34 28.97 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 -173.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 58.2 t -120.49 85.58 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 123.257 0.623 . . . . 0.0 109.517 -171.033 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 45.23 -97.19 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.176 0 C-N-CA 126.177 1.791 . . . . 0.0 112.993 177.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -70.38 -23.61 62.8 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.549 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 68.4 mmtt -134.36 -175.72 3.96 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 123.897 0.879 . . . . 0.0 110.903 -172.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.4 mtpp -131.07 129.58 42.12 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 172.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 50.58 42.95 1.42 Allowed Pre-proline 0 CA--C 1.546 0.819 0 C-N-CA 124.487 1.115 . . . . 0.0 113.115 -175.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -72.51 164.68 34.89 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 121.582 1.522 . . . . 0.0 114.291 -173.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . 0.266 0.2 OUTLIER -84.99 123.07 30.11 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 128.279 2.632 . . . . 0.0 106.088 173.571 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 8.9 mp -109.35 110.19 21.28 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 120.478 1.49 . . . . 0.0 113.221 -176.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -81.59 125.12 30.16 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 12.6 mt -127.29 140.34 37.65 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 124.283 1.033 . . . . 0.0 111.976 -171.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.05 118.18 4.01 Favored 'Trans proline' 0 N--CA 1.452 -0.948 0 C-N-CA 123.287 2.658 . . . . 0.0 109.661 172.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -45.94 138.86 4.7 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 125.326 1.45 . . . . 0.0 112.175 176.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.17 -18.69 9.41 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-O 118.794 -1.004 . . . . 0.0 113.96 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.98 159.48 7.06 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.331 1.565 . . . . 0.0 112.351 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.4 m -84.65 90.15 7.63 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 178.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.02 97.08 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -93.76 98.47 11.12 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.34 104.43 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 177.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 88.3 m -92.39 102.09 14.56 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 3.3 m-85 -77.67 154.91 31.71 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 120.061 -0.656 . . . . 0.0 111.422 173.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.2 mp -133.36 78.03 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 N-CA-C 102.505 -3.146 . . . . 0.0 102.505 163.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -97.86 105.21 17.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 175.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.0 m -146.34 44.89 1.23 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 -82.7 63.54 6.88 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 174.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -6.1 70.34 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 131.273 3.829 . . . . 0.0 114.82 -172.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 141.01 -47.46 0.86 Allowed Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.215 0.912 . . . . 0.0 111.062 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -85.33 100.18 11.65 Favored 'General case' 0 CA--C 1.528 0.13 0 O-C-N 122.076 -0.661 . . . . 0.0 111.125 -174.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -72.2 70.51 1.03 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 173.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -40.5 -49.21 2.9 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 116.164 1.913 . . . . 0.0 116.164 -171.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.7 p 78.22 148.28 0.1 Allowed 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 120.027 1.285 . . . . 0.0 109.687 -172.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 18.9 t80 -138.39 108.31 6.33 Favored 'General case' 0 C--O 1.232 0.17 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -115.52 135.85 53.67 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 118.798 0.727 . . . . 0.0 110.195 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.3 mt -110.26 130.53 63.35 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 126.186 1.794 . . . . 0.0 109.022 -177.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 6.3 t -159.39 -153.68 0.37 Allowed 'General case' 0 N--CA 1.454 -0.25 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -129.71 42.79 3.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 119.662 1.119 . . . . 0.0 110.573 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -91.69 110.92 22.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 123.143 0.577 . . . . 0.0 109.485 178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -72.72 161.81 54.51 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 172.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -65.7 155.69 67.79 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.255 1.97 . . . . 0.0 109.62 174.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.51 167.87 78.0 Favored 'Cis proline' 0 N--CA 1.457 -0.667 0 CA-C-N 119.251 0.768 . . . . 0.0 111.301 -1.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -113.09 155.29 25.18 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.421 1.088 . . . . 0.0 109.106 177.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 156.56 26.68 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-O 121.378 0.608 . . . . 0.0 110.641 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 79.7 t -70.42 -36.9 68.58 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.208 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.743 175.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 1.7 mpt? -78.34 152.04 78.45 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -38.85 111.9 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 124.996 3.797 . . . . 0.0 113.378 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.0 t -85.42 54.04 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 C-N-CA 123.961 0.905 . . . . 0.0 109.021 -173.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.1 pp -88.0 91.05 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 122.519 1.152 . . . . 0.0 109.615 174.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.03 -157.55 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 126.254 1.822 . . . . 0.0 106.852 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -57.28 89.53 0.05 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 121.458 1.438 . . . . 0.0 109.34 153.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.1 mm -78.33 136.22 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 175.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 65.8 t -85.02 -88.81 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.556 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 175.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.42 155.71 16.63 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 171.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 176.51 166.34 33.52 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.312 -1.423 . . . . 0.0 111.438 174.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.6 p -118.44 142.28 47.71 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.251 1.42 . . . . 0.0 108.606 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.44 -161.45 6.79 Favored Glycine 0 CA--C 1.537 1.415 0 N-CA-C 108.174 -1.97 . . . . 0.0 108.174 172.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -67.17 106.38 1.99 Allowed 'General case' 0 CA--C 1.531 0.248 0 O-C-N 120.842 -1.387 . . . . 0.0 109.899 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -62.5 156.68 61.3 Favored Pre-proline 0 CA--C 1.536 0.427 0 C-N-CA 126.731 2.013 . . . . 0.0 112.682 -174.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -67.27 151.28 81.13 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.999 2.466 . . . . 0.0 110.391 -175.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.0 m -129.95 74.5 80.52 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 123.821 0.848 . . . . 0.0 113.031 -175.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_exo -60.91 174.89 1.51 Allowed 'Trans proline' 0 N--CA 1.453 -0.892 0 C-N-CA 122.419 2.079 . . . . 0.0 112.567 173.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 54.9 mttp -140.19 -168.46 2.54 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 124.891 1.277 . . . . 0.0 108.125 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 23.9 t70 55.65 -121.26 1.66 Allowed 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -174.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -112.71 9.98 25.7 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.716 -1.047 . . . . 0.0 112.856 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.1 mtpp -84.36 150.83 25.1 Favored 'General case' 0 C--N 1.341 0.233 0 CA-C-N 118.404 1.102 . . . . 0.0 109.007 175.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -132.87 110.32 10.23 Favored 'General case' 0 CA--C 1.518 -0.269 0 C-N-CA 124.292 1.037 . . . . 0.0 112.119 -173.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -66.88 116.07 7.85 Favored Glycine 0 CA--C 1.521 0.426 0 C-N-CA 125.178 1.37 . . . . 0.0 110.085 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -119.96 167.42 12.18 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-O 122.625 1.202 . . . . 0.0 110.804 175.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 61.7 m -154.69 115.23 3.91 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -92.02 83.6 5.19 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 105.91 -1.885 . . . . 0.0 105.91 172.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 35.6 p90 -90.42 151.52 21.38 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 35.7 m -121.54 145.57 47.83 Favored 'General case' 0 CA--C 1.529 0.135 0 C-N-CA 123.021 0.528 . . . . 0.0 111.058 -173.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 24.0 t90 -143.61 144.17 31.8 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.45 1.1 . . . . 0.0 110.642 177.05 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 67.2 m-70 -109.6 109.93 59.74 Favored Pre-proline 0 CA--C 1.529 0.17 0 N-CA-C 104.857 -2.275 . . . . 0.0 104.857 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -90.73 133.6 1.76 Allowed 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.416 2.744 . . . . 0.0 113.606 -170.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.1 p -82.58 156.02 24.16 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.625 -1.621 . . . . 0.0 106.625 170.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -61.05 169.01 2.18 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 119.438 1.017 . . . . 0.0 112.438 -176.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 106.43 -177.98 22.37 Favored Glycine 0 CA--C 1.527 0.843 0 C-N-CA 125.636 1.589 . . . . 0.0 112.341 175.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 4.1 m -84.39 141.38 30.89 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.828 0.851 . . . . 0.0 110.073 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -137.35 170.11 16.64 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 173.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -142.57 146.83 34.99 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 124.961 1.304 . . . . 0.0 108.023 -178.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 46.8 p90 -115.59 140.87 48.77 Favored 'General case' 0 CA--C 1.528 0.097 0 O-C-N 123.984 0.803 . . . . 0.0 110.616 176.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.4 m -143.93 152.48 15.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 C-N-CA 124.548 1.139 . . . . 0.0 112.03 -174.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.1 t -98.8 125.7 44.24 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.58 1.552 . . . . 0.0 109.035 171.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 16.6 mm-40 -83.98 -4.26 58.59 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -173.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 30.8 mt -61.36 130.43 91.75 Favored Pre-proline 0 CA--C 1.541 0.629 0 CA-C-N 120.342 1.428 . . . . 0.0 108.239 175.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -39.44 125.08 1.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 124.118 3.212 . . . . 0.0 114.456 -174.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.94 -20.37 20.6 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 124.37 0.986 . . . . 0.0 113.226 176.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -66.98 -43.88 81.89 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-N 119.028 1.414 . . . . 0.0 112.303 -172.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -63.22 -48.7 77.17 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 118.703 0.683 . . . . 0.0 110.319 176.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.3 -54.57 43.88 Favored 'General case' 0 C--N 1.34 0.16 0 C-N-CA 123.755 0.822 . . . . 0.0 111.333 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 36.2 p -143.91 81.85 1.7 Allowed 'General case' 0 N--CA 1.451 -0.394 0 C-N-CA 124.226 1.011 . . . . 0.0 108.54 -174.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.49 -63.84 0.07 OUTLIER Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.716 -0.754 . . . . 0.0 113.246 176.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 4.0 ptm -157.9 129.5 6.8 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 117.795 0.797 . . . . 0.0 112.974 -172.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.3 p90 -162.74 -161.59 0.72 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.625 1.17 . . . . 0.0 108.349 175.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 167.49 171.36 33.42 Favored Glycine 0 C--N 1.334 0.452 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 172.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.0 mttm -110.95 153.69 25.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.373 1.069 . . . . 0.0 110.356 -173.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.9 mt -129.01 143.39 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 12.0 t -135.41 100.13 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.8 t -90.03 126.62 42.89 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 45.9 mtmt . . . . . 0 N--CA 1.46 0.052 0 CA-C-N 118.672 0.669 . . . . 0.0 110.828 -179.808 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.802 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 40.2 p -75.87 67.22 2.24 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 123.916 0.887 . . . . 0.0 109.778 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 8.0 mp -61.66 150.34 36.76 Favored 'General case' 0 N--CA 1.455 -0.22 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 174.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 19.3 t0 25.59 82.4 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 127.79 2.436 . . . . 0.0 114.436 -176.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 p -65.19 -26.78 68.29 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 122.534 0.334 . . . . 0.0 110.283 172.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.2 m -78.25 63.91 3.26 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.438 1.095 . . . . 0.0 112.155 -173.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 43.3 m95 -97.9 134.29 41.23 Favored 'General case' 0 CA--C 1.529 0.17 0 C-N-CA 125.154 1.382 . . . . 0.0 109.538 174.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -149.57 -178.4 6.41 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -134.77 128.4 32.78 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 171.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.08 -151.82 0.31 Allowed 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 172.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -142.03 168.13 20.49 Favored 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.3 tt -39.58 -59.49 1.62 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -60.26 -28.74 87.48 Favored 'Trans proline' 0 N--CA 1.46 -0.496 0 CA-C-N 121.028 1.403 . . . . 0.0 112.19 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -66.93 -24.97 66.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 O-C-N 121.471 -0.768 . . . . 0.0 110.728 178.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.428 HG21 ' CD2' ' A' ' 120' ' ' PHE . 24.1 t -62.22 -50.28 80.61 Favored 'Isoleucine or valine' 0 C--N 1.34 0.177 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -58.1 -43.78 87.29 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -55.44 -58.3 8.32 Favored 'General case' 0 CA--C 1.532 0.283 0 O-C-N 121.903 -0.498 . . . . 0.0 110.988 175.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -58.33 -44.61 88.76 Favored 'General case' 0 CA--C 1.53 0.203 0 O-C-N 122.11 -0.369 . . . . 0.0 111.513 -177.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.0 mt -50.52 -47.39 57.49 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.064 0.546 . . . . 0.0 110.746 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -61.89 -14.94 38.67 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 113.045 0.758 . . . . 0.0 113.045 178.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 27.5 mmmt -97.67 5.22 49.63 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 119.313 0.961 . . . . 0.0 111.651 176.034 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -74.65 125.16 28.08 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.051 -1.03 . . . . 0.0 110.507 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.9 p -93.27 29.33 1.94 Allowed 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 123.306 0.642 . . . . 0.0 112.62 -176.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -104.32 111.71 3.91 Favored Glycine 0 C--N 1.339 0.726 0 C-N-CA 125.317 1.437 . . . . 0.0 111.139 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -79.63 159.83 26.61 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 173.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.0 t -81.56 150.73 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.5 m -147.72 65.57 1.12 Allowed 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.411 -0.805 . . . . 0.0 108.99 174.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 61.07 -109.34 2.37 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.546 -1.021 . . . . 0.0 110.546 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.2 p-10 -96.68 37.33 1.29 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 124.848 1.259 . . . . 0.0 110.325 177.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.1 m -160.64 161.98 32.58 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 105.806 -1.924 . . . . 0.0 105.806 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.0 t -120.27 151.65 23.03 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 126.969 2.108 . . . . 0.0 106.939 172.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.0 m -140.29 117.38 11.19 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.495 0.718 . . . . 0.0 109.18 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -83.06 166.99 18.29 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 174.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 57.3 m -152.29 156.17 39.13 Favored 'General case' 0 N--CA 1.453 -0.296 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 175.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 76.37 165.44 20.53 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -173.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -72.64 -27.22 62.0 Favored 'General case' 0 CA--C 1.534 0.358 0 O-C-N 121.838 -0.801 . . . . 0.0 111.02 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -78.95 67.76 4.73 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 124.029 0.932 . . . . 0.0 110.269 -177.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.4 t -79.69 99.36 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.9 t-160 -107.4 94.65 5.21 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t -88.7 107.0 17.27 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.154 0 C-N-CA 123.308 0.643 . . . . 0.0 109.486 -173.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.2 t -93.45 90.74 3.02 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -94.91 111.92 23.67 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.218 1.407 . . . . 0.0 110.282 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.98 143.39 27.12 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 174.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.7 104.41 5.77 Favored 'General case' 0 N--CA 1.454 -0.275 0 CA-C-O 121.23 0.538 . . . . 0.0 110.85 -177.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.427 HG13 ' H ' ' A' ' 51' ' ' PHE . 4.7 t 50.09 63.74 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 C-N-CA 127.203 2.201 . . . . 0.0 111.216 173.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 22.5 mt -76.75 165.26 53.89 Favored Pre-proline 0 CA--C 1.536 0.433 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 175.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 99.7 Cg_exo -47.59 -40.59 30.34 Favored 'Trans proline' 0 CA--C 1.535 0.559 0 C-N-CA 122.888 2.392 . . . . 0.0 113.5 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -61.56 -23.16 62.47 Favored Glycine 0 CA--C 1.534 1.245 0 C-N-CA 123.45 0.548 . . . . 0.0 113.537 177.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -120.6 77.62 28.37 Favored Pre-proline 0 CA--C 1.531 0.25 0 C-N-CA 125.425 1.49 . . . . 0.0 108.923 -179.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -73.46 73.73 3.32 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 123.256 2.638 . . . . 0.0 110.924 -175.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . 0.427 ' H ' HG13 ' A' ' 45' ' ' VAL . 73.3 m-85 71.45 161.61 0.15 Allowed Pre-proline 0 CA--C 1.536 0.425 0 C-N-CA 127.706 2.402 . . . . 0.0 111.925 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -109.32 -21.05 0.36 Allowed 'Cis proline' 0 CA--C 1.536 0.609 0 N-CA-C 114.507 0.926 . . . . 0.0 114.507 -3.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 78.3 p -92.11 170.24 9.99 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 -168.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -77.25 167.21 22.12 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.75 0.82 . . . . 0.0 109.136 178.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -134.29 148.25 50.75 Favored 'General case' 0 CA--C 1.538 0.485 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 173.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.1 t -134.89 79.65 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.211 0 C-N-CA 123.745 0.818 . . . . 0.0 109.456 -170.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 21.7 p80 50.48 -74.51 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 127.821 2.448 . . . . 0.0 114.896 175.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -98.0 -37.38 9.79 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 124.643 1.177 . . . . 0.0 110.964 178.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -111.21 -159.95 0.7 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.876 1.27 . . . . 0.0 108.203 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.2 mtpm? -140.44 -165.27 1.89 Allowed 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.41 ' H ' ' ND2' ' A' ' 61' ' ' ASN . 14.1 m-80 -12.57 -56.38 0.03 OUTLIER Pre-proline 0 N--CA 1.471 0.598 0 C-N-CA 128.433 2.693 . . . . 0.0 115.242 172.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 0.6 OUTLIER -15.5 125.64 0.01 OUTLIER 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.983 3.789 . . . . 0.0 116.272 161.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.44 HG23 ' HB2' ' A' ' 151' ' ' LYS . 55.5 m -31.78 144.04 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 129.911 3.284 . . . . 0.0 117.276 -174.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.42 134.68 54.52 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.907 1.683 . . . . 0.0 108.492 174.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -110.07 140.35 44.22 Favored 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 124.249 1.02 . . . . 0.0 108.685 173.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 17.4 mt -136.71 141.57 35.75 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.256 1.422 . . . . 0.0 110.673 -172.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -78.35 125.7 7.18 Favored 'Trans proline' 0 N--CA 1.451 -1.007 0 C-N-CA 122.796 2.33 . . . . 0.0 108.123 171.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.02 145.45 16.73 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 123.761 0.824 . . . . 0.0 112.553 -177.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.45 2.87 81.45 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-O 119.498 -0.612 . . . . 0.0 112.986 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.88 157.97 20.2 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 118.745 1.273 . . . . 0.0 112.228 174.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 61.2 m -93.6 89.99 6.46 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 172.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 43.2 t -77.58 98.08 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 -173.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -92.51 93.57 8.63 Favored 'General case' 0 N--CA 1.448 -0.575 0 C-N-CA 125.035 1.334 . . . . 0.0 107.88 178.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.95 107.05 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 78.9 m -99.94 103.84 15.43 Favored 'General case' 0 N--CA 1.444 -0.756 0 C-N-CA 125.326 1.45 . . . . 0.0 109.498 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -81.56 152.24 27.33 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 174.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.92 78.99 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 102.159 -3.275 . . . . 0.0 102.159 163.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -101.5 85.08 2.7 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 176.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.471 HG21 ' CD2' ' A' ' 120' ' ' PHE . 76.3 p -112.08 33.51 4.8 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.538 -174.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.6 t-20 -79.61 70.95 6.19 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 177.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -33.49 103.46 0.03 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 127.133 2.173 . . . . 0.0 112.462 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.99 -46.05 1.13 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 125.215 1.388 . . . . 0.0 111.293 -177.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -97.76 107.49 20.0 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.483 1.113 . . . . 0.0 111.938 -173.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.89 -16.29 56.69 Favored Glycine 0 CA--C 1.538 1.503 0 CA-C-O 119.199 -0.779 . . . . 0.0 114.457 174.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 71.6 m-70 46.73 -72.28 0.0 OUTLIER 'General case' 0 C--N 1.343 0.307 0 C-N-CA 129.221 3.008 . . . . 0.0 116.46 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.0 p 88.62 155.98 0.06 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 129.228 3.011 . . . . 0.0 111.867 -172.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -125.13 131.74 53.21 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 103.339 -2.837 . . . . 0.0 103.339 171.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -139.26 116.42 11.08 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 108.569 -0.901 . . . . 0.0 108.569 -173.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -97.19 125.78 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 124.536 1.134 . . . . 0.0 109.392 -178.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.1 t -160.1 -141.94 0.08 Allowed 'General case' 0 N--CA 1.453 -0.311 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 37.0 mtmm -122.91 -110.65 0.32 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 119.143 0.883 . . . . 0.0 110.431 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt 65.62 -65.54 0.17 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.303 1.841 . . . . 0.0 112.397 -174.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.48 162.56 33.36 Favored Glycine 0 CA--C 1.533 1.212 0 N-CA-C 110.291 -1.123 . . . . 0.0 110.291 -173.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -71.79 158.75 52.42 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.79 2.327 . . . . 0.0 109.804 177.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.22 132.38 27.09 Favored 'Cis proline' 0 N--CA 1.455 -0.748 0 CA-C-N 119.146 0.731 . . . . 0.0 110.222 -3.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -79.78 151.97 30.04 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.159 0.504 . . . . 0.0 109.695 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.01 151.65 28.33 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.313 -179.151 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.8 t -61.45 -41.94 91.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 175.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.5 mmm -77.96 128.77 77.97 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 174.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -76.98 75.65 4.48 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.428 2.085 . . . . 0.0 110.397 -174.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.2 t -77.53 76.97 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 175.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.0 pt -77.96 89.66 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 122.394 1.092 . . . . 0.0 109.794 -176.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -55.57 146.69 43.49 Favored Pre-proline 0 CA--C 1.537 0.445 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 171.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -25.63 116.26 0.03 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.698 1 C-N-CA 125.676 4.251 . . . . 0.0 115.625 -166.615 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 30.6 mm -78.46 131.6 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 98.4 t -82.15 -86.07 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 105.376 -2.083 . . . . 0.0 105.376 174.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.87 149.35 21.63 Favored 'General case' 0 C--N 1.333 -0.123 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 172.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.91 165.76 39.07 Favored Glycine 0 C--N 1.332 0.318 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 174.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.9 p -119.04 123.32 44.21 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 123.085 0.554 . . . . 0.0 111.792 -174.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -78.03 57.9 3.95 Favored Glycine 0 CA--C 1.535 1.34 0 CA-C-O 119.082 -0.843 . . . . 0.0 113.646 -175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 65.05 124.73 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 127.382 2.273 . . . . 0.0 113.719 174.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 92.0 p -74.23 136.54 75.64 Favored Pre-proline 0 CA--C 1.532 0.288 0 O-C-N 120.899 -1.125 . . . . 0.0 112.457 -173.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.49 84.96 0.92 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.312 2.008 . . . . 0.0 107.066 172.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 1.3 m -45.06 139.06 4.13 Favored Pre-proline 0 CA--C 1.539 0.533 0 C-N-CA 124.673 1.189 . . . . 0.0 112.851 -174.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -75.74 -178.27 4.2 Favored 'Trans proline' 0 N--CA 1.454 -0.847 0 C-N-CA 123.636 2.891 . . . . 0.0 113.665 -173.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.93 176.73 7.1 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 127.043 2.137 . . . . 0.0 107.19 174.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -36.71 120.98 0.73 Allowed 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.975 1.31 . . . . 0.0 113.269 -174.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 84.53 -27.05 4.85 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.968 0.794 . . . . 0.0 113.738 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 56.5 mttp -85.63 157.4 20.36 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.132 0.966 . . . . 0.0 109.97 -174.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.471 ' CD2' HG21 ' A' ' 79' ' ' THR . 10.1 m-85 -137.18 91.22 2.6 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 124.427 1.091 . . . . 0.0 111.414 -173.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -47.34 121.31 6.33 Favored Glycine 0 CA--C 1.529 0.924 0 C-N-CA 124.716 1.15 . . . . 0.0 111.74 174.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 2.7 p90 -144.24 176.32 9.42 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.312 1.053 . . . . 0.0 111.467 -178.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.16 166.58 32.83 Favored 'General case' 0 N--CA 1.445 -0.703 0 C-N-CA 127.079 2.152 . . . . 0.0 105.757 -176.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 20.2 m-20 -146.68 65.08 1.18 Allowed 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 19.4 p90 -77.99 135.83 37.86 Favored 'General case' 0 C--N 1.34 0.184 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.441 -174.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 14.8 m -99.13 132.6 44.32 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 123.508 0.723 . . . . 0.0 110.021 -175.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 21.6 t90 -137.95 143.25 40.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.459 1.104 . . . . 0.0 109.704 176.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 63.5 m80 -111.36 99.41 43.83 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -76.23 173.79 13.91 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 122.364 2.043 . . . . 0.0 109.397 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 81.3 p -119.06 153.6 34.49 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -57.62 142.26 45.41 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -172.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 135.45 -127.11 4.2 Favored Glycine 0 C--N 1.336 0.555 0 C-N-CA 126.208 1.861 . . . . 0.0 109.411 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 34.7 m -151.95 142.9 23.07 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 118.251 1.026 . . . . 0.0 110.006 -175.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 20.5 m-85 -133.16 -179.28 5.4 Favored 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 126.243 1.817 . . . . 0.0 106.958 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -141.65 147.26 37.27 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 124.301 1.04 . . . . 0.0 108.43 174.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -102.46 145.76 29.09 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.0 m -146.64 160.72 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 C-N-CA 124.842 1.257 . . . . 0.0 110.322 174.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.4 t -99.0 125.89 44.58 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 124.68 1.192 . . . . 0.0 109.691 171.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -59.69 -27.37 66.36 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 116.348 1.981 . . . . 0.0 116.348 -177.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -57.26 128.94 79.25 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 120.541 1.519 . . . . 0.0 109.826 -174.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_exo -43.83 137.68 6.46 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 123.262 2.641 . . . . 0.0 113.15 -179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.59 -27.72 2.49 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-O 119.171 -0.794 . . . . 0.0 113.411 179.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -62.43 -51.53 67.16 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 119.734 1.767 . . . . 0.0 111.639 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.81 -44.0 86.07 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 117.82 0.282 . . . . 0.0 110.764 176.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.95 -43.04 99.27 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 122.135 -0.353 . . . . 0.0 111.364 -179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.6 p -79.14 -41.01 29.53 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 118.877 -0.582 . . . . 0.0 112.175 -174.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 178.26 -15.6 0.03 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 118.725 -1.702 . . . . 0.0 116.977 -176.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 13.3 mtp -79.04 77.03 5.53 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 120.118 1.959 . . . . 0.0 110.456 -174.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -160.17 -174.72 4.67 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.37 164.95 23.93 Favored Glycine 0 C--N 1.341 0.832 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 175.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.44 ' HB2' HG23 ' A' ' 63' ' ' THR . 30.8 mttt -100.99 147.66 25.93 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.9 mt -121.52 100.65 9.04 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.15 121.15 38.92 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.064 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 174.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 60.6 t -109.38 95.06 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 -178.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 96.9 mttt . . . . . 0 C--N 1.332 -0.177 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.286 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.736 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 1.6 p -76.63 59.64 1.55 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.849 1.259 . . . . 0.0 109.616 178.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.6 mp 21.4 -90.15 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 128.189 2.596 . . . . 0.0 115.878 -174.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.34 76.14 2.58 Favored 'General case' 0 N--CA 1.454 -0.239 0 O-C-N 121.306 -0.872 . . . . 0.0 111.427 -172.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.2 p -143.62 -77.44 0.23 Allowed 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -176.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.0 m -77.79 64.13 2.98 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -169.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 71.4 m95 -92.95 156.22 17.06 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 126.645 1.978 . . . . 0.0 110.766 175.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 59.4 mttp -154.68 179.36 9.14 Favored 'General case' 0 CA--C 1.53 0.206 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 172.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -139.68 150.26 44.68 Favored 'General case' 0 C--N 1.341 0.209 0 CA-C-N 119.557 1.072 . . . . 0.0 111.191 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -130.65 -154.52 0.64 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.009 2.123 . . . . 0.0 107.292 174.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 68.3 p -135.94 171.44 14.46 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 123.527 0.731 . . . . 0.0 110.198 176.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -38.67 -59.91 1.23 Allowed Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -174.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -59.77 -30.87 93.05 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 CA-C-N 121.515 1.577 . . . . 0.0 111.964 -178.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -66.97 -22.94 65.9 Favored 'General case' 0 N--CA 1.448 -0.557 0 O-C-N 121.757 -0.589 . . . . 0.0 111.267 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 58.5 t -59.38 -51.5 71.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 173.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.2 mttp -59.78 -49.02 79.35 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -49.81 -55.69 13.19 Favored 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.043 0.214 . . . . 0.0 110.986 177.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 72.6 mtm -57.85 -52.49 65.25 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 123.223 0.609 . . . . 0.0 110.675 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.5 mt -50.67 -44.67 57.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 118.322 0.51 . . . . 0.0 111.057 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -58.81 -25.35 63.07 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 178.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.75 -1.02 36.75 Favored 'General case' 0 CA--C 1.538 0.492 0 CA-C-N 119.934 1.243 . . . . 0.0 112.083 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -60.68 153.42 24.04 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 120.17 1.35 . . . . 0.0 110.782 175.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.2 p -117.94 27.77 8.81 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 123.269 0.628 . . . . 0.0 112.524 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -94.44 116.57 5.32 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 -178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -79.06 154.26 29.56 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 174.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 t -79.74 145.98 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 O-C-N 121.981 -0.449 . . . . 0.0 110.026 -175.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.2 m -149.08 64.32 1.04 Allowed 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.894 0.878 . . . . 0.0 109.404 174.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 65.04 -114.11 6.47 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.4 -17.0 55.28 Favored 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 123.178 0.591 . . . . 0.0 111.246 175.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -103.29 161.55 13.73 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 125.276 1.43 . . . . 0.0 107.841 -175.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.3 t -125.65 148.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.738 -2.319 . . . . 0.0 104.738 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 99.0 m -135.65 131.47 35.8 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -171.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -100.48 168.89 9.45 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-O 121.37 0.605 . . . . 0.0 110.663 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 21.0 m -155.01 155.0 33.38 Favored 'General case' 0 N--CA 1.452 -0.327 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 74.76 174.35 32.96 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -174.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -77.84 -30.49 51.03 Favored 'General case' 0 CA--C 1.531 0.25 0 O-C-N 122.243 -0.563 . . . . 0.0 111.785 -178.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -79.03 74.37 5.56 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 118.502 0.592 . . . . 0.0 109.968 -175.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 78.0 t -84.7 89.36 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -177.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -94.47 100.92 12.82 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.96 0.504 . . . . 0.0 110.642 -174.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t -95.27 100.26 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 C-N-CA 124.89 1.276 . . . . 0.0 108.315 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.1 t -95.7 122.89 47.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 176.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -133.31 116.48 16.19 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 118.621 0.646 . . . . 0.0 112.5 -173.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.85 112.56 24.53 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 123.981 0.913 . . . . 0.0 110.008 175.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.6 92.23 8.49 Favored 'General case' 0 N--CA 1.455 -0.178 0 O-C-N 121.58 -0.7 . . . . 0.0 110.038 -177.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 12.8 t 63.67 97.17 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 C-N-CA 125.195 1.398 . . . . 0.0 111.324 174.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 75.2 mt -74.98 140.85 74.22 Favored Pre-proline 0 CA--C 1.534 0.356 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 -174.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.55 116.87 1.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.629 2.886 . . . . 0.0 111.392 178.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 125.4 -41.06 1.74 Allowed Glycine 0 CA--C 1.527 0.803 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -173.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 16.1 m-85 -74.0 116.19 49.9 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 176.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -81.05 63.9 8.81 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.479 2.119 . . . . 0.0 108.631 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.9 m-30 67.42 174.96 0.08 OUTLIER Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 124.353 1.061 . . . . 0.0 108.988 -172.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -124.45 29.62 0.16 OUTLIER 'Cis proline' 0 CA--C 1.537 0.664 0 CA-C-N 120.722 1.294 . . . . 0.0 109.999 -7.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 31.8 p -92.09 125.25 36.7 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 116.94 2.2 . . . . 0.0 116.94 -171.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -79.69 103.71 9.78 Favored 'General case' 0 C--N 1.342 0.243 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 166.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -88.03 112.03 22.18 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 -176.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -111.49 84.7 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 C-N-CA 125.14 1.376 . . . . 0.0 109.783 -171.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.0 p-80 46.98 -98.97 0.04 OUTLIER 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 125.78 1.632 . . . . 0.0 112.9 176.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -70.73 -24.69 62.68 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.565 0.346 . . . . 0.0 111.877 -176.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -130.57 -178.07 4.62 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.232 1.013 . . . . 0.0 110.679 -173.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.2 mtmp? -130.12 122.32 28.03 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 105.88 -1.896 . . . . 0.0 105.88 172.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 55.33 44.37 1.62 Allowed Pre-proline 0 CA--C 1.541 0.607 0 C-N-CA 124.705 1.202 . . . . 0.0 112.275 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -78.71 172.06 15.69 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.475 2.117 . . . . 0.0 111.567 -176.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 151' ' ' LYS . 28.5 m -91.9 138.86 31.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 170.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 11.0 mp -112.25 126.99 55.83 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 123.83 0.852 . . . . 0.0 110.241 -176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -100.01 119.51 38.38 Favored 'General case' 0 CA--C 1.531 0.241 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 15.3 mt -124.04 142.24 39.2 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.392 1.077 . . . . 0.0 112.95 -171.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.15 118.71 4.07 Favored 'Trans proline' 0 N--CA 1.451 -0.998 0 C-N-CA 122.935 2.423 . . . . 0.0 108.893 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -46.88 142.99 3.1 Favored 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 125.41 1.484 . . . . 0.0 112.31 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 80.49 -22.2 4.81 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 118.982 -0.899 . . . . 0.0 113.706 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.21 158.17 5.56 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.113 1.456 . . . . 0.0 111.969 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -79.84 96.68 6.4 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.5 t -78.68 90.36 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.425 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 174.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -84.36 119.3 24.94 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 174.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -111.79 114.36 46.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -176.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 94.4 m -107.47 104.35 13.9 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.541 1.137 . . . . 0.0 109.473 179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.4 m-85 -79.53 162.9 25.1 Favored 'General case' 0 C--O 1.221 -0.414 0 O-C-N 121.662 -0.649 . . . . 0.0 112.429 174.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.5 mp -137.61 78.78 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 N-CA-C 101.651 -3.462 . . . . 0.0 101.651 163.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -99.94 96.51 7.6 Favored 'General case' 0 N--CA 1.457 -0.111 0 N-CA-C 106.811 -1.552 . . . . 0.0 106.811 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 25.7 m -147.44 59.32 1.15 Allowed 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 174.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -82.3 66.41 7.88 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 173.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 8.72 72.82 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 129.75 3.22 . . . . 0.0 113.927 -171.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.42 -44.83 1.29 Allowed Glycine 0 CA--C 1.527 0.796 0 C-N-CA 124.31 0.957 . . . . 0.0 111.382 178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -79.72 95.62 6.02 Favored 'General case' 0 C--O 1.233 0.233 0 CA-C-O 121.842 0.83 . . . . 0.0 110.091 -175.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.99 61.35 2.58 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.412 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -45.54 124.57 5.09 Favored 'General case' 0 N--CA 1.454 -0.267 0 C-N-CA 124.271 1.028 . . . . 0.0 110.857 173.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 96.8 p -87.2 167.06 14.47 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -134.05 112.5 11.23 Favored 'General case' 0 CA--C 1.516 -0.361 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 172.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -131.27 127.59 38.08 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -173.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 47.5 mt -99.31 127.91 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 C-N-CA 125.818 1.647 . . . . 0.0 108.475 -174.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.48 -149.03 0.18 Allowed 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 51.2 mtmt -129.26 25.28 5.5 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 119.696 1.134 . . . . 0.0 111.994 -178.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.7 mtmt -73.74 94.95 2.3 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 173.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -73.49 171.33 51.69 Favored Glycine 0 CA--C 1.531 1.089 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 173.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.1 150.15 82.27 Favored 'Trans proline' 0 N--CA 1.451 -1.027 0 C-N-CA 122.282 1.988 . . . . 0.0 109.65 175.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -75.31 130.75 22.13 Favored 'Cis proline' 0 N--CA 1.454 -0.807 0 N-CA-C 109.941 -0.83 . . . . 0.0 109.941 -3.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -78.75 145.82 34.21 Favored 'General case' 0 N--CA 1.455 -0.188 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.4 145.59 39.27 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-O 121.382 0.61 . . . . 0.0 112.044 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -67.52 -43.41 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 174.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -78.85 144.95 65.15 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 177.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -64.01 68.83 0.2 Allowed 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.638 2.892 . . . . 0.0 113.685 175.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.43 75.52 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.332 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.4 pt -76.35 86.0 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-O 123.509 1.623 . . . . 0.0 110.816 -172.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.28 155.69 83.9 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 113.125 -1.852 . . . . 0.0 106.913 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -39.57 112.42 0.15 Allowed 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 123.91 3.073 . . . . 0.0 113.986 -176.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 25.1 mm -79.24 132.17 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 94.7 t -82.29 -87.11 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -96.49 156.16 16.46 Favored 'General case' 0 C--N 1.334 -0.106 0 C-N-CA 123.394 0.678 . . . . 0.0 109.365 173.3 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 175.44 178.21 45.1 Favored Glycine 0 C--N 1.335 0.51 0 C-N-CA 118.956 -1.592 . . . . 0.0 113.904 174.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 17.3 p -121.26 155.27 35.01 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 126.464 1.906 . . . . 0.0 109.424 175.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -90.09 -127.55 3.42 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 108.489 -1.844 . . . . 0.0 108.489 173.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -116.2 134.98 54.32 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 118.495 1.148 . . . . 0.0 108.61 176.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 4.5 p -76.58 177.56 2.5 Favored Pre-proline 0 CA--C 1.533 0.295 0 N-CA-C 113.697 0.999 . . . . 0.0 113.697 -172.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.56 -7.08 13.46 Favored 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 123.271 2.648 . . . . 0.0 113.015 172.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m 35.24 67.15 1.46 Allowed Pre-proline 0 CA--C 1.54 0.579 0 C-N-CA 126.285 1.834 . . . . 0.0 115.857 -178.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -60.72 178.59 0.46 Allowed 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.726 2.284 . . . . 0.0 113.796 174.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 23.4 mtpp -142.45 -171.98 3.52 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 124.043 0.937 . . . . 0.0 110.187 -177.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 26.1 t70 62.65 -77.3 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 C-N-CA 126.862 2.065 . . . . 0.0 111.549 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -157.75 15.66 0.3 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 123.966 0.793 . . . . 0.0 111.869 177.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 31.8 mtmm -87.59 155.9 19.75 Favored 'General case' 0 N--CA 1.454 -0.268 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 174.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -140.07 104.07 4.76 Favored 'General case' 0 CA--C 1.517 -0.297 0 C-N-CA 123.765 0.826 . . . . 0.0 112.416 -171.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -67.38 107.85 2.2 Favored Glycine 0 CA--C 1.526 0.725 0 C-N-CA 125.299 1.428 . . . . 0.0 109.841 174.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -103.48 178.62 4.5 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.889 0.852 . . . . 0.0 109.374 173.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -148.87 157.75 43.66 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 -177.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.0 m-20 -139.46 87.5 2.19 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 173.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -100.59 168.78 9.49 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 172.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 16.6 m -151.86 148.94 28.42 Favored 'General case' 0 N--CA 1.455 -0.205 0 O-C-N 120.952 -1.093 . . . . 0.0 108.976 -175.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 22.0 t90 -147.22 149.47 32.98 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 124.627 1.171 . . . . 0.0 110.225 -174.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -113.06 108.32 53.28 Favored Pre-proline 0 CA--C 1.53 0.19 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 172.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -89.8 145.79 4.67 Favored 'Trans proline' 0 N--CA 1.446 -1.274 0 C-N-CA 123.419 2.746 . . . . 0.0 112.693 -171.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 1.8 p -89.55 154.94 19.61 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 124.983 1.313 . . . . 0.0 108.329 172.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.35 169.16 1.26 Allowed 'General case' 0 CA--C 1.538 0.484 0 O-C-N 121.603 -0.686 . . . . 0.0 112.225 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 108.09 -130.61 10.17 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 125.182 1.373 . . . . 0.0 110.192 178.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.7 m -151.56 144.48 24.48 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 118.28 1.04 . . . . 0.0 110.377 -175.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -137.57 174.94 10.05 Favored 'General case' 0 N--CA 1.454 -0.262 0 C-N-CA 126.221 1.809 . . . . 0.0 107.727 178.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -135.79 139.21 43.34 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.482 1.513 . . . . 0.0 108.6 179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -103.36 139.59 38.57 Favored 'General case' 0 N--CA 1.457 -0.116 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 172.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.7 m -147.15 168.62 4.91 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 124.229 1.011 . . . . 0.0 110.701 178.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 10.3 t -106.09 136.85 45.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 126.461 1.905 . . . . 0.0 108.485 173.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -77.49 -26.28 51.1 Favored 'General case' 0 N--CA 1.463 0.18 0 C-N-CA 123.867 0.867 . . . . 0.0 113.22 -173.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 52.7 mt -57.92 130.82 82.97 Favored Pre-proline 0 CA--C 1.543 0.696 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 -178.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 97.9 Cg_exo -43.93 143.56 3.03 Favored 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 124.128 3.219 . . . . 0.0 114.778 -174.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.91 -39.73 1.37 Allowed Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.211 0.91 . . . . 0.0 113.958 174.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 25.0 m170 -50.24 -48.81 54.46 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.591 1.156 . . . . 0.0 114.062 -172.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -62.19 -49.83 74.24 Favored 'General case' 0 C--O 1.225 -0.222 0 CA-C-O 120.736 0.303 . . . . 0.0 110.368 178.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -58.41 -42.1 86.4 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.256 0.622 . . . . 0.0 110.853 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 32.5 p -79.84 -41.29 26.66 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-O 118.129 -0.938 . . . . 0.0 113.196 -174.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -169.46 -41.13 0.03 OUTLIER Glycine 0 C--N 1.342 0.871 0 C-N-CA 118.028 -2.034 . . . . 0.0 117.881 -174.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.268 3.8 ptp -79.91 94.17 5.81 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 120.381 2.09 . . . . 0.0 112.196 -173.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -157.76 -178.28 7.21 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.083 0.953 . . . . 0.0 110.353 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 169.28 161.14 19.07 Favored Glycine 0 C--N 1.338 0.655 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 173.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.467 ' HB2' HG23 ' A' ' 63' ' ' THR . 90.8 mttt -96.31 145.75 25.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.653 1.581 . . . . 0.0 109.553 -175.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.7 mt -122.4 101.09 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 173.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -89.67 132.19 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 25.7 t -123.94 125.98 71.8 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 24.1 mtpp . . . . . 0 N--CA 1.464 0.226 0 CA-C-N 118.898 0.772 . . . . 0.0 111.276 -177.932 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.864 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 16.8 p 65.6 -57.97 0.31 Allowed 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 127.855 2.462 . . . . 0.0 113.557 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 mp -55.17 151.3 9.57 Favored 'General case' 0 N--CA 1.456 -0.132 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 171.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -34.52 106.97 0.05 OUTLIER 'General case' 0 C--O 1.232 0.171 0 C-N-CA 125.691 1.596 . . . . 0.0 112.458 -171.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.5 p -88.8 17.4 5.63 Favored 'General case' 0 N--CA 1.446 -0.654 0 C-N-CA 124.912 1.285 . . . . 0.0 111.645 -176.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 6.2 m -79.71 62.71 4.06 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 119.155 0.889 . . . . 0.0 110.139 -174.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 73.6 m95 -94.49 122.26 36.88 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 125.177 1.391 . . . . 0.0 111.282 -174.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -142.11 -176.47 4.82 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 173.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -136.43 132.32 35.29 Favored 'General case' 0 N--CA 1.452 -0.366 0 O-C-N 121.838 -0.539 . . . . 0.0 109.83 172.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -87.74 -154.56 0.26 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 104.303 -2.48 . . . . 0.0 104.303 169.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.8 p -142.61 165.19 28.09 Favored 'General case' 0 CA--C 1.531 0.245 0 O-C-N 120.921 -1.112 . . . . 0.0 108.713 174.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.3 tt -39.9 -53.02 4.99 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 114.687 1.365 . . . . 0.0 114.687 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -57.54 -31.19 90.91 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.865 1.71 . . . . 0.0 112.572 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -71.13 -33.63 70.28 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 122.995 0.518 . . . . 0.0 110.204 178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.427 HG21 ' CD2' ' A' ' 120' ' ' PHE . 13.6 t -62.74 -48.61 87.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -54.45 -44.96 72.96 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.988 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.91 -48.07 67.52 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 123.25 0.62 . . . . 0.0 111.437 175.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 68.8 mtm -70.1 -30.94 68.28 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-O 118.483 -0.77 . . . . 0.0 112.221 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.57 57.36 1.22 Allowed 'General case' 0 CA--C 1.537 0.452 0 CA-C-O 122.331 1.062 . . . . 0.0 109.757 172.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -137.29 -40.27 0.58 Allowed 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 129.383 3.073 . . . . 0.0 104.839 173.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . 0.294 0.0 OUTLIER 84.72 142.58 0.06 Allowed 'General case' 0 N--CA 1.442 -0.831 0 C-N-CA 128.974 2.91 . . . . 0.0 114.648 170.247 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -101.19 -147.8 0.36 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 111.688 -2.506 . . . . 0.0 109.091 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.2 p -44.16 131.66 5.94 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 126.717 2.007 . . . . 0.0 112.675 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 145.06 90.63 0.11 Allowed Glycine 0 CA--C 1.527 0.821 0 C-N-CA 124.169 0.89 . . . . 0.0 110.928 174.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 90.3 mttt -79.13 137.79 37.63 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 174.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 93.5 t -63.69 146.89 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 33.0 m -148.52 64.66 1.07 Allowed 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 174.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 66.07 -142.99 44.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 107.642 -2.183 . . . . 0.0 107.642 -172.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -80.01 54.85 1.99 Allowed 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 118.721 1.261 . . . . 0.0 109.733 174.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.9 m -160.86 153.9 21.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 178.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 93.5 t -123.46 142.08 41.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.186 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 176.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 92.1 m -125.77 129.44 49.47 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.963 1.305 . . . . 0.0 108.562 -174.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 65.5 m-85 -93.18 167.07 12.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.493 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 30.6 m -156.26 61.58 0.56 Allowed 'General case' 0 CA--C 1.528 0.123 0 C-N-CA 123.552 0.741 . . . . 0.0 109.621 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.87 166.07 38.58 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 108.234 -1.947 . . . . 0.0 108.234 177.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -75.18 -50.4 16.37 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 117.435 0.617 . . . . 0.0 109.659 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.3 p -79.83 93.62 5.66 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 42.5 t -82.82 98.53 4.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 177.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -94.11 116.01 28.38 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t -113.8 122.47 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 C-N-CA 124.864 1.265 . . . . 0.0 108.601 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 95.5 t -92.2 113.82 28.12 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 175.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.83 92.66 3.9 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.871 1.269 . . . . 0.0 110.392 -178.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.33 113.51 24.8 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.273 1.029 . . . . 0.0 109.999 178.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.1 114.45 24.73 Favored 'General case' 0 CA--C 1.531 0.227 0 O-C-N 121.209 -0.932 . . . . 0.0 110.409 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.4 t 32.89 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 126.67 1.988 . . . . 0.0 112.892 173.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 82.5 mt -76.7 142.02 69.55 Favored Pre-proline 0 CA--C 1.533 0.31 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -178.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -56.16 110.4 0.56 Allowed 'Trans proline' 0 N--CA 1.454 -0.802 0 C-N-CA 123.079 2.519 . . . . 0.0 110.429 -174.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 137.65 -42.71 1.27 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 107.917 -2.073 . . . . 0.0 107.917 -173.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -83.01 140.34 42.94 Favored Pre-proline 0 N--CA 1.453 -0.324 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 174.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.99 164.98 30.68 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 122.471 2.114 . . . . 0.0 110.631 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -72.02 166.33 41.77 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 173.17 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -116.64 50.95 0.65 Allowed 'Cis proline' 0 CA--C 1.536 0.591 0 N-CA-C 108.441 -1.407 . . . . 0.0 108.441 -5.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.7 p -93.05 129.3 39.04 Favored 'General case' 0 N--CA 1.453 -0.319 0 N-CA-C 115.109 1.522 . . . . 0.0 115.109 -173.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 42.1 m-85 -77.95 121.69 24.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 N-CA-C 103.247 -2.871 . . . . 0.0 103.247 166.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -91.88 113.99 26.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 105.77 -1.937 . . . . 0.0 105.77 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -120.59 117.79 54.4 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 CA-C-N 119.051 0.841 . . . . 0.0 110.584 -171.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 0.1 OUTLIER 36.93 -104.71 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 126.641 1.976 . . . . 0.0 113.067 -174.751 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.22 -17.68 39.04 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 69.0 mmtt -124.5 -166.93 1.58 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 124.263 1.025 . . . . 0.0 110.833 -172.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 51.2 mttm -133.95 124.74 26.86 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.192 -1.781 . . . . 0.0 106.192 172.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 52.91 44.24 1.91 Allowed Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 124.657 1.183 . . . . 0.0 112.354 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -79.28 173.72 12.91 Favored 'Trans proline' 0 N--CA 1.451 -0.983 0 C-N-CA 122.372 2.048 . . . . 0.0 111.482 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.477 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.8 m -94.62 140.68 29.55 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 172.231 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.4 mp -113.73 121.45 44.11 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.413 1.485 . . . . 0.0 112.305 -171.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -103.46 111.02 23.27 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 123.988 0.915 . . . . 0.0 108.737 173.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.9 mt -112.58 135.45 21.51 Favored Pre-proline 0 CA--C 1.537 0.447 0 C-N-CA 125.739 1.616 . . . . 0.0 110.289 -173.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.67 116.63 4.32 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 122.629 2.22 . . . . 0.0 108.747 172.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.03 133.58 27.21 Favored 'General case' 0 N--CA 1.455 -0.193 0 C-N-CA 123.593 0.757 . . . . 0.0 110.597 177.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 107.98 -26.63 16.75 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 109.986 -1.245 . . . . 0.0 109.986 -173.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.08 32.23 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 117.891 0.846 . . . . 0.0 111.845 174.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 95.2 m -105.08 130.22 53.32 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 172.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 12.1 t -100.53 99.28 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 C-N-CA 124.253 1.021 . . . . 0.0 110.881 -172.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -84.53 93.71 8.4 Favored 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.0 t -83.93 100.64 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 174.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 93.3 m -86.75 100.07 12.23 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.497 1.119 . . . . 0.0 109.109 174.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 2.9 m-85 -76.74 155.7 33.0 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.35 172.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.0 mp -137.96 92.2 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 101.868 -3.382 . . . . 0.0 101.868 163.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -113.54 113.31 24.93 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 172.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 49.1 m -146.17 45.89 1.24 Allowed 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 172.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -75.74 71.02 2.58 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 173.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.2 mtmm -17.74 87.96 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 129.527 3.131 . . . . 0.0 113.929 -173.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.435 ' H ' ' CG1' ' A' ' 114' ' ' VAL . . . 133.32 -45.27 1.13 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.383 0.992 . . . . 0.0 111.507 178.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -97.33 111.99 24.0 Favored 'General case' 0 N--CA 1.456 -0.139 0 CA-C-N 117.506 0.653 . . . . 0.0 112.272 -173.06 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -74.62 54.96 2.5 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.937 0.78 . . . . 0.0 111.475 173.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -48.34 139.84 8.33 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.643 1.221 . . . . 0.0 111.347 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 68.4 p -104.51 165.99 10.69 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.53 1.132 . . . . 0.0 108.435 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 9.0 t80 -131.28 116.52 17.71 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 105.596 -2.002 . . . . 0.0 105.596 171.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . 0.488 ' HB3' HD12 ' A' ' 105' ' ' ILE . 16.8 m-20 -133.03 129.83 38.61 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 118.91 0.777 . . . . 0.0 110.642 -172.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 34.4 mt -104.38 134.04 46.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 C-N-CA 126.016 1.726 . . . . 0.0 108.864 -176.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.2 t -159.13 -154.61 0.42 Allowed 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 48.8 mtmt -126.56 21.88 7.06 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 119.232 0.924 . . . . 0.0 111.804 -179.154 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm -70.37 118.87 13.73 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.05 159.33 43.38 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 174.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -72.5 164.53 35.34 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.969 2.446 . . . . 0.0 109.598 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -71.35 141.46 69.8 Favored 'Cis proline' 0 N--CA 1.459 -0.543 0 CA-C-N 119.333 0.798 . . . . 0.0 110.634 -5.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -79.91 150.86 30.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 121.289 0.566 . . . . 0.0 109.874 175.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.43 151.99 27.63 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.377 177.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 65.9 t -61.1 -39.18 81.47 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.248 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 174.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 92.3 mmm -78.2 133.1 65.02 Favored Pre-proline 0 N--CA 1.452 -0.373 0 N-CA-C 106.809 -1.552 . . . . 0.0 106.809 174.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.87 75.57 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.751 2.301 . . . . 0.0 111.974 -173.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.9 t -79.02 65.5 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 106.318 -1.734 . . . . 0.0 106.318 172.714 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.8 pp -88.43 -43.79 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.84 1.656 . . . . 0.0 111.801 -173.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -64.25 146.52 97.67 Favored Pre-proline 0 CA--C 1.531 0.215 0 C-N-CA 123.119 0.568 . . . . 0.0 111.515 -173.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.26 143.28 74.57 Favored 'Cis proline' 0 N--CA 1.457 -0.668 0 CA-C-N 119.038 0.692 . . . . 0.0 111.261 -2.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.488 HD12 ' HB3' ' A' ' 88' ' ' ASP . 19.4 mm -91.44 143.49 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 173.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 92.2 t -87.05 -92.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 104.432 -2.432 . . . . 0.0 104.432 173.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.17 145.65 24.87 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -178.6 161.5 28.09 Favored Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 119.264 -1.446 . . . . 0.0 111.237 174.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 34.6 p -103.02 149.25 24.74 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 125.186 1.395 . . . . 0.0 108.248 175.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.91 -156.7 8.78 Favored Glycine 0 CA--C 1.534 1.246 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 173.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.9 m-85 -74.74 139.12 43.18 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.506 1.153 . . . . 0.0 109.071 174.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 51.8 p -81.66 163.91 51.74 Favored Pre-proline 0 C--O 1.233 0.216 0 C-N-CA 122.497 0.319 . . . . 0.0 111.547 -174.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -64.97 166.33 18.84 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 N-CA-C 106.395 -2.194 . . . . 0.0 106.395 168.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.435 ' CG1' ' H ' ' A' ' 82' ' ' GLY . 14.4 t -130.55 76.75 77.0 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -172.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -62.76 162.12 26.31 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 122.154 1.903 . . . . 0.0 110.256 172.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 60.6 mttp -137.19 5.95 2.8 Favored 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -178.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -174.33 148.94 1.3 Allowed 'General case' 0 CA--C 1.529 0.158 0 C-N-CA 125.469 1.508 . . . . 0.0 109.102 174.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.94 -66.21 0.13 Allowed Glycine 0 CA--C 1.527 0.832 0 C-N-CA 126.533 2.015 . . . . 0.0 113.935 174.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -79.02 151.53 31.46 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 125.22 1.408 . . . . 0.0 110.525 -176.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.427 ' CD2' HG21 ' A' ' 15' ' ' VAL . 10.1 m-85 -134.76 101.98 5.11 Favored 'General case' 0 N--CA 1.456 -0.153 0 C-N-CA 125.46 1.504 . . . . 0.0 111.096 -174.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.95 112.28 1.87 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 125.272 1.415 . . . . 0.0 111.227 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -130.67 155.23 46.94 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.931 0.893 . . . . 0.0 111.29 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 6.6 m -154.78 114.4 3.74 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -174.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.09 62.55 4.21 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 125.199 1.399 . . . . 0.0 108.525 178.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -70.15 121.82 18.26 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 118.305 -1.358 . . . . 0.0 108.526 -174.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 41.0 m -96.86 84.73 3.63 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.389 -172.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -78.36 124.75 28.46 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -94.02 106.39 22.05 Favored Pre-proline 0 N--CA 1.451 -0.417 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 171.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -83.23 177.85 6.25 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.975 2.45 . . . . 0.0 112.169 -171.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.5 p -131.09 153.88 48.86 Favored 'General case' 0 N--CA 1.448 -0.568 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 172.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -63.38 165.3 7.85 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 119.531 1.06 . . . . 0.0 111.935 -174.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 112.86 -168.18 12.54 Favored Glycine 0 CA--C 1.525 0.676 0 C-N-CA 124.718 1.151 . . . . 0.0 112.297 174.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 28.5 m -98.3 139.89 33.4 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 124.028 0.931 . . . . 0.0 109.08 -176.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -140.35 177.29 8.1 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 125.27 1.428 . . . . 0.0 107.235 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -145.44 152.7 40.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.788 -1.189 . . . . 0.0 107.788 176.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 54.1 p90 -116.74 149.13 40.39 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 123.489 0.716 . . . . 0.0 110.382 174.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 28.6 m -152.78 161.88 2.56 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 C-N-CA 125.052 1.341 . . . . 0.0 111.314 179.288 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 3.1 t -100.14 134.11 43.55 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.406 1.482 . . . . 0.0 107.892 170.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -74.05 -22.17 59.65 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 114.186 1.18 . . . . 0.0 114.186 -173.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 57.1 mt -60.78 126.98 86.6 Favored Pre-proline 0 CA--C 1.542 0.665 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -177.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -44.86 146.89 2.14 Favored 'Trans proline' 0 C--N 1.35 0.654 0 C-N-CA 123.934 3.089 . . . . 0.0 114.056 -174.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.2 -39.01 1.61 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 123.304 0.478 . . . . 0.0 113.055 177.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.1 m170 -54.02 -51.55 63.63 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.491 1.145 . . . . 0.0 111.879 -173.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -57.28 -47.29 81.84 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 117.891 0.314 . . . . 0.0 110.986 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.47 97.27 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 122.783 0.433 . . . . 0.0 111.132 -178.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 40.4 p -79.99 -35.81 36.89 Favored 'General case' 0 N--CA 1.453 -0.283 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -173.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.41 -27.34 0.04 OUTLIER Glycine 0 CA--C 1.528 0.898 0 N-CA-C 117.081 1.592 . . . . 0.0 117.081 -175.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 3.6 mtt -78.12 80.43 4.55 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 120.07 1.935 . . . . 0.0 110.943 -173.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -162.28 -174.38 4.04 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 167.71 163.32 21.41 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 173.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.477 ' HB2' HG23 ' A' ' 63' ' ' THR . 49.2 mttt -99.33 154.1 18.45 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 124.046 0.939 . . . . 0.0 108.954 -175.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.4 mt -130.33 138.1 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 178.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 42.8 t -130.25 101.0 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 173.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 40.1 t -87.0 88.14 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 174.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.3 mttt . . . . . 0 C--N 1.332 -0.182 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 177.109 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.011 0 CA-C-O 120.195 -0.225 . . . . 0.0 112.869 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 6.3 p -72.21 97.76 2.03 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 125.209 1.403 . . . . 0.0 108.687 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.8 mp -44.81 142.18 1.85 Allowed 'General case' 0 CA--C 1.529 0.16 0 CA-C-O 121.293 0.568 . . . . 0.0 111.957 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 20.3 t70 67.59 -31.57 0.18 Allowed 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 127.239 2.216 . . . . 0.0 116.238 174.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 77.3 p -52.36 -43.75 64.84 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 119.243 0.928 . . . . 0.0 111.86 -176.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 36.8 m -98.84 122.33 41.94 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 123.846 0.858 . . . . 0.0 108.871 -179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -155.7 127.1 7.22 Favored 'General case' 0 C--N 1.341 0.233 0 C-N-CA 126.32 1.848 . . . . 0.0 108.417 173.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -150.07 170.62 18.45 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 107.759 -1.201 . . . . 0.0 107.759 173.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -135.91 148.14 48.43 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 172.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -118.24 -155.94 0.62 Allowed 'General case' 0 N--CA 1.446 -0.658 0 C-N-CA 127.862 2.465 . . . . 0.0 106.357 174.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 29.9 p -134.43 173.04 12.07 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.577 0.751 . . . . 0.0 109.49 174.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.0 tt -39.05 -56.81 2.36 Favored Pre-proline 0 CA--C 1.538 0.481 0 N-CA-C 114.508 1.299 . . . . 0.0 114.508 -174.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -56.39 -31.46 85.38 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 121.32 1.347 . . . . 0.0 113.606 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.6 mp0 -68.28 -27.61 66.46 Favored 'General case' 0 N--CA 1.457 -0.115 0 O-C-N 121.177 -0.952 . . . . 0.0 111.249 176.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 t -61.31 -50.54 80.01 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -55.45 -47.11 76.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.889 177.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.68 -59.9 3.91 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 122.438 0.295 . . . . 0.0 110.978 174.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 69.5 mtm -54.59 -47.9 72.8 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 123.209 0.604 . . . . 0.0 111.153 -176.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.9 mt -50.51 -33.51 21.74 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 113.269 0.841 . . . . 0.0 113.269 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -73.09 -31.59 64.46 Favored 'General case' 0 N--CA 1.455 -0.211 0 O-C-N 121.556 -0.715 . . . . 0.0 110.534 178.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt -81.51 60.96 4.74 Favored 'General case' 0 N--CA 1.451 -0.389 0 O-C-N 121.767 -0.583 . . . . 0.0 110.19 -176.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -125.42 102.12 7.26 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.116 0.566 . . . . 0.0 110.632 174.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.3 p -73.86 45.97 0.21 Allowed 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.946 1.698 . . . . 0.0 111.197 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.24 112.6 2.42 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 125.508 1.528 . . . . 0.0 111.152 -174.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 57.1 mttp -79.12 -178.78 6.33 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 71.3 t -113.7 152.18 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.184 0 C-N-CA 123.969 0.907 . . . . 0.0 108.89 177.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 49.7 m -149.1 73.41 1.21 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.373 1.069 . . . . 0.0 108.358 174.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.17 -144.36 39.27 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -172.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -79.46 59.1 2.83 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.653 1.226 . . . . 0.0 109.413 175.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -161.0 146.4 14.28 Favored 'General case' 0 N--CA 1.452 -0.333 0 C-N-CA 125.79 1.636 . . . . 0.0 106.708 -179.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 23.3 t -102.64 147.86 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 174.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 55.4 m -134.3 110.63 9.62 Favored 'General case' 0 CA--C 1.521 -0.172 0 C-N-CA 123.426 0.69 . . . . 0.0 109.954 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -82.8 169.01 16.6 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-O 121.564 0.697 . . . . 0.0 111.4 178.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.3 m -155.04 159.08 40.03 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 124.503 1.121 . . . . 0.0 107.988 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 71.39 -179.54 32.77 Favored Glycine 0 CA--C 1.53 1.019 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 -176.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -85.63 -27.48 25.39 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 122.771 0.428 . . . . 0.0 111.211 179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.6 m -79.18 69.2 5.34 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.107 0.963 . . . . 0.0 110.335 -176.083 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.4 t -88.44 78.55 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.975 0.893 . . . . 0.0 108.935 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 t-80 -83.4 105.61 14.49 Favored 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.9 t -107.36 95.75 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -174.07 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.6 t -83.66 123.32 38.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -174.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -132.52 114.61 14.48 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.461 1.104 . . . . 0.0 111.373 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -93.22 143.21 26.48 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 123.575 0.75 . . . . 0.0 109.819 174.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.421 ' HB3' ' HA ' ' A' ' 78' ' ' ASN . . . -116.25 96.54 5.59 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.012 0.525 . . . . 0.0 110.698 176.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.8 t 49.19 72.14 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.329 0 C-N-CA 128.407 2.683 . . . . 0.0 111.823 175.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.62 142.76 66.67 Favored Pre-proline 0 CA--C 1.533 0.32 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 176.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -41.53 106.2 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 124.362 3.375 . . . . 0.0 112.819 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 133.04 -48.46 0.96 Allowed Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -174.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -75.94 141.02 70.93 Favored Pre-proline 0 CA--C 1.53 0.191 0 CA-C-N 117.182 0.491 . . . . 0.0 109.789 178.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -75.16 155.86 42.23 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 122.352 2.034 . . . . 0.0 111.191 -178.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -75.14 153.6 86.39 Favored Pre-proline 0 N--CA 1.452 -0.336 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 172.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -92.13 -9.13 34.55 Favored 'Cis proline' 0 CA--C 1.538 0.687 0 CA-C-N 118.82 0.614 . . . . 0.0 111.423 -5.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -36.95 121.51 0.78 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 119.478 3.14 . . . . 0.0 119.478 -168.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -77.33 121.67 24.05 Favored 'General case' 0 C--N 1.346 0.447 0 C-N-CA 126.126 1.77 . . . . 0.0 107.161 171.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -94.53 112.07 23.83 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.182 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.47 81.71 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.226 0 C-N-CA 124.357 1.063 . . . . 0.0 109.344 -172.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.434 ' CD2' ' H ' ' A' ' 58' ' ' ASP . 31.9 p-80 44.66 -84.74 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 127.367 2.267 . . . . 0.0 114.629 177.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.434 ' H ' ' CD2' ' A' ' 57' ' ' HIS . 30.1 t70 -75.89 -29.46 58.47 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 123.336 0.654 . . . . 0.0 110.991 -175.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 40.8 mttm -136.72 -173.6 3.48 Favored 'General case' 0 N--CA 1.456 -0.15 0 C-N-CA 123.453 0.701 . . . . 0.0 109.777 -175.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mtmp? -126.03 127.0 45.19 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 174.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 6.9 m-80 50.67 44.08 2.0 Allowed Pre-proline 0 CA--C 1.537 0.459 0 C-N-CA 124.915 1.286 . . . . 0.0 112.575 178.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -83.29 176.07 7.69 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.676 1.584 . . . . 0.0 110.863 -175.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HB2' ' A' ' 151' ' ' LYS . 17.5 m -95.42 144.02 26.28 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 170.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 5.4 mp -117.23 143.97 45.3 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 123.539 0.736 . . . . 0.0 110.806 -177.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 25.6 mm-40 -110.18 125.33 52.94 Favored 'General case' 0 C--O 1.232 0.176 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 170.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 5.6 mt -130.15 138.09 32.31 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 123.464 0.706 . . . . 0.0 111.893 -171.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.65 117.93 4.69 Favored 'Trans proline' 0 N--CA 1.45 -1.044 0 C-N-CA 122.884 2.39 . . . . 0.0 109.233 172.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.73 141.41 10.01 Favored 'General case' 0 N--CA 1.455 -0.202 0 C-N-CA 125.053 1.341 . . . . 0.0 111.724 177.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 75.64 -2.07 55.38 Favored Glycine 0 CA--C 1.531 1.091 0 CA-C-O 118.936 -0.924 . . . . 0.0 113.719 178.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.76 158.77 31.63 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.708 1.754 . . . . 0.0 110.352 173.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 29.6 m -83.18 93.32 7.63 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 174.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 51.8 t -79.38 99.08 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.674 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -91.63 90.72 7.7 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 173.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.9 t -77.18 105.56 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 104.246 -2.501 . . . . 0.0 104.246 176.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 55.4 m -100.63 98.99 9.49 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 125.585 1.554 . . . . 0.0 109.797 -171.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.496 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE . 1.5 m-85 -77.38 158.77 29.92 Favored 'General case' 0 N--CA 1.443 -0.787 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 -179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.38 68.26 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 N-CA-C 101.652 -3.462 . . . . 0.0 101.652 164.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.431 HD22 ' C ' ' A' ' 78' ' ' ASN . 0.2 OUTLIER -87.24 67.06 9.48 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 -174.728 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.2 m -112.61 83.0 1.74 Allowed 'General case' 0 N--CA 1.449 -0.504 0 CA-C-N 114.669 -1.15 . . . . 0.0 110.616 -175.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -120.14 119.91 34.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 172.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.33 72.82 1.31 Allowed 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 123.109 0.564 . . . . 0.0 109.519 -175.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 162.82 -65.64 0.25 Allowed Glycine 0 CA--C 1.522 0.499 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -94.03 112.83 24.7 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.449 -0.442 . . . . 0.0 111.183 -174.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -73.68 38.99 0.91 Allowed Glycine 0 CA--C 1.537 1.418 0 CA-C-O 118.928 -0.929 . . . . 0.0 111.865 172.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.5 m-70 0.95 -78.42 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 129.86 3.264 . . . . 0.0 117.513 -172.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.5 p 99.13 155.08 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.258 0 C-N-CA 129.967 3.307 . . . . 0.0 110.196 -173.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.496 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 6.7 t80 -134.01 110.42 9.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 173.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -122.94 140.94 52.46 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.5 mt -115.64 126.7 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 125.665 1.586 . . . . 0.0 110.257 -172.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -161.05 164.74 30.63 Favored 'General case' 0 N--CA 1.456 -0.142 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -83.86 56.41 3.66 Favored 'General case' 0 CA--C 1.535 0.394 0 O-C-N 121.608 -0.682 . . . . 0.0 110.621 -174.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -105.56 107.91 19.15 Favored 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 175.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.05 160.12 52.62 Favored Glycine 0 CA--C 1.534 1.245 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 175.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.67 162.11 43.31 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.986 2.458 . . . . 0.0 109.81 174.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 158.63 93.88 Favored 'Cis proline' 0 N--CA 1.455 -0.751 0 CA-C-N 119.006 0.681 . . . . 0.0 110.595 -3.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -96.32 153.56 17.75 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.1 151.1 35.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 175.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 60.3 t -60.38 -38.51 77.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 174.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -78.53 133.48 63.21 Favored Pre-proline 0 N--CA 1.451 -0.409 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 174.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -74.75 80.53 2.34 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.409 2.073 . . . . 0.0 109.739 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 70.2 t -77.0 84.24 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 178.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.3 pt -77.58 83.04 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-O 123.065 1.412 . . . . 0.0 111.625 -173.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.5 m-20 -62.12 154.54 69.31 Favored Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 171.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -37.18 112.59 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 124.248 3.299 . . . . 0.0 114.375 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 32.1 mm -79.48 139.44 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 59.6 t -86.0 -88.32 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.42 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 174.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -94.29 146.5 23.98 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.49 -178.9 42.96 Favored Glycine 0 C--N 1.333 0.368 0 CA-C-N 120.153 1.342 . . . . 0.0 112.219 173.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 5.2 p -122.95 -37.96 2.67 Favored 'General case' 0 C--N 1.338 0.083 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -176.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 78.34 -175.45 54.71 Favored Glycine 0 CA--C 1.541 1.701 0 N-CA-C 107.658 -2.177 . . . . 0.0 107.658 -170.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.19 141.71 39.96 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 119.911 1.855 . . . . 0.0 114.513 -171.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 99.0 p -83.82 155.12 64.97 Favored Pre-proline 0 CA--C 1.538 0.482 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -174.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -73.67 75.0 3.17 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 123.458 2.772 . . . . 0.0 110.688 175.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 66.9 t -20.34 96.16 0.05 OUTLIER Pre-proline 0 CA--C 1.542 0.665 0 C-N-CA 128.195 2.598 . . . . 0.0 112.846 175.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.453 ' HG2' ' H ' ' A' ' 121' ' ' GLY . 33.4 Cg_exo -66.47 171.71 10.2 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 123.723 2.948 . . . . 0.0 112.582 -178.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 46.0 mmtm -124.76 151.94 44.48 Favored 'General case' 0 N--CA 1.453 -0.285 0 C-N-CA 124.653 1.181 . . . . 0.0 109.25 177.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 39.23 -103.4 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 127.219 2.208 . . . . 0.0 113.62 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -92.25 -2.11 68.74 Favored Glycine 0 CA--C 1.528 0.851 0 CA-C-O 118.496 -1.169 . . . . 0.0 114.476 -173.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -86.44 153.35 21.95 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 118.687 1.243 . . . . 0.0 110.442 -176.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -138.32 111.37 7.85 Favored 'General case' 0 C--O 1.224 -0.242 0 C-N-CA 124.987 1.315 . . . . 0.0 111.457 -172.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.453 ' H ' ' HG2' ' A' ' 115' ' ' PRO . . . -78.92 113.15 3.6 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 125.459 1.504 . . . . 0.0 110.589 -174.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -121.59 164.46 17.24 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 123.798 0.839 . . . . 0.0 111.796 -176.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.2 m -165.94 115.61 0.99 Allowed 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 124.523 1.129 . . . . 0.0 108.103 178.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -84.99 67.25 10.14 Favored 'General case' 0 C--O 1.234 0.261 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -66.79 122.45 17.7 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 -179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.1 m -97.98 130.12 44.84 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 114.704 -1.135 . . . . 0.0 110.379 -171.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -140.0 145.3 37.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.791 1.236 . . . . 0.0 109.669 -178.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -114.77 94.25 36.71 Favored Pre-proline 0 N--CA 1.454 -0.25 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -80.16 150.43 20.24 Favored 'Trans proline' 0 N--CA 1.447 -1.26 0 C-N-CA 122.573 2.182 . . . . 0.0 111.287 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.3 p -101.31 155.21 18.17 Favored 'General case' 0 CA--C 1.532 0.288 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -53.58 141.56 25.33 Favored 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 -173.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 136.61 176.49 14.39 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 126.198 1.856 . . . . 0.0 111.189 175.351 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.6 m -98.42 109.98 22.64 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 124.143 0.977 . . . . 0.0 110.317 -174.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -101.28 173.56 6.39 Favored 'General case' 0 CA--C 1.521 -0.16 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 172.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -134.63 143.18 47.14 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -104.52 141.64 36.03 Favored 'General case' 0 CA--C 1.522 -0.126 0 CA-C-O 118.569 -0.729 . . . . 0.0 109.682 174.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 5.0 m -147.74 156.57 9.58 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 C-N-CA 123.928 0.891 . . . . 0.0 111.77 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 11.2 t -94.9 131.58 40.66 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 126.595 1.958 . . . . 0.0 109.365 173.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -82.79 -1.39 51.54 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -172.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.33 136.42 93.52 Favored Pre-proline 0 CA--C 1.537 0.444 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 173.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.6 144.74 10.15 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.451 2.101 . . . . 0.0 112.554 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.07 -44.99 2.2 Favored Glycine 0 CA--C 1.527 0.823 0 C-N-CA 123.628 0.632 . . . . 0.0 112.995 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -48.41 -52.73 20.6 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 118.761 1.281 . . . . 0.0 113.989 -173.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -56.87 -52.11 66.41 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 120.877 0.37 . . . . 0.0 110.145 176.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -61.28 -39.74 91.56 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 124.684 1.194 . . . . 0.0 111.686 -175.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 24.2 p -79.01 -36.49 41.09 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 118.473 -0.775 . . . . 0.0 111.31 -174.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 173.33 -22.74 0.07 OUTLIER Glycine 0 C--N 1.342 0.874 0 C-N-CA 117.123 -2.465 . . . . 0.0 118.188 174.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . 0.331 17.8 ptm -80.72 92.8 6.08 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 121.134 2.467 . . . . 0.0 112.93 -173.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.65 -175.1 4.78 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 124.188 0.995 . . . . 0.0 109.332 179.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 176.23 170.6 39.1 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 173.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.421 ' HB2' HG23 ' A' ' 63' ' ' THR . 38.0 mttt -107.08 146.56 31.06 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 124.447 1.099 . . . . 0.0 109.785 -173.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 8.5 mt -121.21 99.12 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 C-N-CA 125.371 1.469 . . . . 0.0 107.062 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.5 t -90.82 100.66 11.47 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 24.1 t -89.62 127.49 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 N-CA-C 107.41 -1.33 . . . . 0.0 107.41 178.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm . . . . . 0 N--CA 1.462 0.167 0 CA-C-N 119.136 0.88 . . . . 0.0 111.132 -178.151 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.851 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 7.7 p -69.63 -63.74 1.01 Allowed 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.437 1.095 . . . . 0.0 109.221 177.528 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 mp 58.17 179.84 0.06 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 125.378 1.471 . . . . 0.0 111.974 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -70.51 126.92 30.99 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.3 p -121.08 39.08 3.9 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 123.659 0.784 . . . . 0.0 109.358 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 m -79.88 60.1 3.37 Favored 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 70.2 m95 -99.66 131.84 45.39 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 126.029 1.732 . . . . 0.0 111.275 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -144.63 -170.89 3.49 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 172.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -136.21 130.12 32.66 Favored 'General case' 0 C--N 1.341 0.202 0 CA-C-N 119.216 0.916 . . . . 0.0 110.098 172.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -89.66 -156.62 0.42 Allowed 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 170.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.4 p -139.33 166.71 23.84 Favored 'General case' 0 CA--C 1.533 0.326 0 O-C-N 121.364 -0.835 . . . . 0.0 109.476 174.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -39.42 -54.97 3.49 Favored Pre-proline 0 CA--C 1.539 0.551 0 N-CA-C 115.594 1.702 . . . . 0.0 115.594 -172.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.75 -33.44 98.4 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 CA-C-N 120.92 1.364 . . . . 0.0 111.759 -177.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.94 -32.02 73.53 Favored 'General case' 0 N--CA 1.446 -0.63 0 C-N-CA 122.769 0.428 . . . . 0.0 110.454 -178.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -56.69 -51.04 71.47 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.231 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -58.22 -49.36 77.35 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.564 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -48.61 -57.15 6.65 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.738 0.415 . . . . 0.0 111.116 178.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -63.1 -45.13 93.52 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 118.432 -0.794 . . . . 0.0 111.605 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 35.4 mt -48.76 -47.77 41.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 119.414 1.007 . . . . 0.0 111.386 179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 77.3 mm-40 -55.35 -21.55 15.65 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 178.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 26.8 mmmt -96.45 7.24 46.99 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 119.156 0.889 . . . . 0.0 112.414 -177.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -71.6 115.06 10.34 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 119.989 1.268 . . . . 0.0 110.226 -179.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 p -83.99 15.13 3.56 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.61 1.164 . . . . 0.0 113.875 -174.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -88.75 115.15 4.38 Favored Glycine 0 CA--C 1.527 0.819 0 O-C-N 121.214 -0.929 . . . . 0.0 111.446 -174.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.7 mtpt -78.89 121.11 24.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 C-N-CA 125.17 1.388 . . . . 0.0 108.995 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.97 122.5 6.27 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 C-N-CA 124.137 0.975 . . . . 0.0 109.592 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -132.12 68.93 1.48 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.689 1.596 . . . . 0.0 108.235 -174.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 67.84 -117.57 8.82 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.335 -1.906 . . . . 0.0 108.335 -174.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -78.89 -33.49 45.63 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.848 0.824 . . . . 0.0 109.559 173.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 27.8 m -78.88 155.96 28.85 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 123.739 0.816 . . . . 0.0 109.215 -173.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 42.7 t -118.67 132.62 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.34 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 173.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -121.14 126.88 50.84 Favored 'General case' 0 CA--C 1.519 -0.215 0 C-N-CA 123.204 0.602 . . . . 0.0 109.969 -173.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.478 ' CB ' HG22 ' A' ' 38' ' ' VAL . 67.7 m-85 -97.84 175.9 5.99 Favored 'General case' 0 C--N 1.329 -0.285 0 C-N-CA 122.826 0.45 . . . . 0.0 110.153 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 60.0 m -156.5 168.21 28.06 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.505 0.722 . . . . 0.0 109.811 -175.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 45.26 43.53 9.71 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 125.354 1.454 . . . . 0.0 113.018 174.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 57.1 mttp 50.55 12.02 0.09 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.093 1.757 . . . . 0.0 115.492 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 45.8 m -103.62 74.78 1.27 Allowed 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -173.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.478 HG22 ' CB ' ' A' ' 33' ' ' TYR . 74.1 t -89.56 96.79 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 12.3 t-160 -105.21 102.62 12.1 Favored 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 173.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.3 t -99.17 103.28 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 17.0 t -88.06 90.48 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 175.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -96.34 159.61 14.85 Favored 'General case' 0 N--CA 1.453 -0.314 0 C-N-CA 125.014 1.326 . . . . 0.0 109.841 -179.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.9 166.44 33.53 Favored 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 124.293 1.037 . . . . 0.0 108.841 177.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -147.69 115.15 6.3 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 122.251 0.22 . . . . 0.0 111.151 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 3.5 t 54.27 53.35 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 125.868 1.667 . . . . 0.0 111.912 172.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 30.9 mt -78.36 151.78 78.19 Favored Pre-proline 0 CA--C 1.532 0.286 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 173.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.0 Cg_exo -47.01 103.88 0.06 OUTLIER 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 123.581 2.854 . . . . 0.0 112.91 -176.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 129.92 -48.8 0.95 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.142 -1.183 . . . . 0.0 110.142 -174.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -79.16 127.56 78.85 Favored Pre-proline 0 CA--C 1.532 0.263 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 178.359 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -82.94 163.85 15.67 Favored 'Trans proline' 0 N--CA 1.45 -1.069 0 C-N-CA 122.311 2.008 . . . . 0.0 112.029 -175.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -63.67 146.16 96.95 Favored Pre-proline 0 N--CA 1.451 -0.397 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -110.44 54.58 0.93 Allowed 'Cis proline' 0 N--CA 1.455 -0.782 0 N-CA-C 106.685 -2.083 . . . . 0.0 106.685 -6.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 85.8 p -79.49 121.59 25.4 Favored 'General case' 0 CA--C 1.53 0.182 0 N-CA-C 115.073 1.509 . . . . 0.0 115.073 -170.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -78.57 115.89 18.58 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 103.284 -2.858 . . . . 0.0 103.284 167.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -100.25 138.52 37.19 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.3 t -135.25 100.35 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 118.354 0.524 . . . . 0.0 110.066 -174.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . 0.295 1.5 p80 35.44 -69.62 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 130.227 3.411 . . . . 0.0 116.378 -173.429 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -101.84 -25.86 13.66 Favored 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 125.004 1.322 . . . . 0.0 112.218 -175.17 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -125.56 -169.85 2.07 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 124.81 1.244 . . . . 0.0 109.957 -173.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? -136.9 133.82 36.16 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 106.163 -1.791 . . . . 0.0 106.163 171.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 48.22 41.76 1.03 Allowed Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 124.235 1.014 . . . . 0.0 112.592 -174.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.59 169.03 22.0 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 CA-C-N 120.742 1.301 . . . . 0.0 112.872 -172.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.0 m -89.58 127.76 35.93 Favored 'General case' 0 N--CA 1.439 -1.024 0 CA-C-N 112.342 -2.208 . . . . 0.0 106.127 172.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 10.3 mp -106.32 128.13 53.77 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.159 0.891 . . . . 0.0 110.101 -177.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 -104.68 117.91 35.26 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 171.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.422 HD12 HG23 ' A' ' 152' ' ' ILE . 14.6 mt -124.22 138.44 30.84 Favored Pre-proline 0 CA--C 1.538 0.496 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.817 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -67.95 125.32 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 122.727 2.284 . . . . 0.0 109.153 168.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -49.32 133.36 19.7 Favored 'General case' 0 C--N 1.332 -0.191 0 O-C-N 121.382 -0.824 . . . . 0.0 111.217 174.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 73.55 12.36 80.34 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.144 -0.809 . . . . 0.0 113.13 -176.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.41 148.7 47.79 Favored 'General case' 0 N--CA 1.455 -0.211 0 CA-C-N 119.375 1.588 . . . . 0.0 110.169 173.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 38.8 m -83.47 90.75 7.25 Favored 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 174.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 85.0 t -77.68 98.67 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 124.746 1.219 . . . . 0.0 108.068 -174.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -96.96 104.38 16.39 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 177.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.3 t -89.44 91.34 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 54.0 m -79.52 87.87 5.1 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CZ ' ' HB2' ' A' ' 87' ' ' PHE 0.275 4.1 m-85 -79.73 138.6 37.35 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 117.876 -1.059 . . . . 0.0 109.934 172.584 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 3.8 mp -117.44 67.89 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.37 0 N-CA-C 101.088 -3.671 . . . . 0.0 101.088 163.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -84.41 56.3 3.74 Favored 'General case' 0 C--O 1.231 0.109 0 O-C-N 121.117 -0.989 . . . . 0.0 108.626 -173.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.522 HG23 ' HG2' ' A' ' 115' ' ' PRO . 53.4 m -85.75 69.99 10.65 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.884 -176.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -97.43 156.82 16.3 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 171.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -93.17 124.14 36.94 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 75.42 -68.64 2.09 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 123.63 0.633 . . . . 0.0 112.392 175.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -79.08 81.07 5.38 Favored 'General case' 0 C--O 1.234 0.28 0 O-C-N 121.873 -0.781 . . . . 0.0 110.001 -174.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -52.85 80.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.848 0 C-N-CA 126.425 1.964 . . . . 0.0 112.52 174.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -57.47 162.52 2.85 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 119.232 1.516 . . . . 0.0 111.468 179.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.3 p -121.85 160.91 23.72 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 125.584 1.554 . . . . 0.0 107.388 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . 0.572 ' HB2' ' CZ ' ' A' ' 76' ' ' PHE . 32.5 t80 -128.26 110.18 12.16 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 172.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -126.64 128.93 47.53 Favored 'General case' 0 N--CA 1.451 -0.401 0 C-N-CA 123.861 0.864 . . . . 0.0 108.716 -172.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 20.5 mt -106.21 134.32 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 C-N-CA 125.964 1.706 . . . . 0.0 110.054 -173.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.6 t -158.04 -152.08 0.33 Allowed 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 176.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -126.58 9.32 7.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 119.689 1.131 . . . . 0.0 113.286 -176.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -64.67 121.44 14.5 Favored 'General case' 0 N--CA 1.456 -0.138 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -80.35 166.45 49.62 Favored Glycine 0 CA--C 1.532 1.117 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -69.62 161.89 44.15 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 122.856 2.37 . . . . 0.0 109.602 173.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -76.92 149.61 90.8 Favored 'Cis proline' 0 N--CA 1.454 -0.825 0 N-CA-C 110.27 -0.704 . . . . 0.0 110.27 -4.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -89.27 152.94 21.28 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 176.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 149.7 29.34 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.86 -42.09 87.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 174.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -78.89 130.35 70.49 Favored Pre-proline 0 N--CA 1.451 -0.391 0 N-CA-C 107.135 -1.431 . . . . 0.0 107.135 174.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -75.02 85.07 1.57 Allowed 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 122.374 2.05 . . . . 0.0 109.829 -175.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 51.4 t -76.77 85.55 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.348 0 N-CA-C 105.799 -1.926 . . . . 0.0 105.799 175.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 pt -75.43 87.43 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 CA-C-O 123.646 1.689 . . . . 0.0 110.653 -172.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -62.83 154.17 76.7 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 112.842 -1.981 . . . . 0.0 106.928 172.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_exo -39.49 108.71 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 124.059 3.173 . . . . 0.0 113.794 -175.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.0 mm -78.46 126.84 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.37 -82.14 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 105.785 -1.932 . . . . 0.0 105.785 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.6 150.17 20.64 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 171.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 178.93 158.66 21.79 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 119.288 -1.434 . . . . 0.0 112.135 174.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.3 p -107.75 145.43 33.52 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.516 1.126 . . . . 0.0 110.544 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -82.63 158.38 37.19 Favored Glycine 0 CA--C 1.535 1.3 0 N-CA-C 107.342 -2.303 . . . . 0.0 107.342 172.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -41.88 133.07 2.95 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.558 1.543 . . . . 0.0 113.884 -173.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.5 p -68.53 158.5 84.99 Favored Pre-proline 0 CA--C 1.535 0.373 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -177.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.3 -177.96 2.66 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 122.075 1.85 . . . . 0.0 108.804 171.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 90.0 t -117.66 98.91 52.14 Favored Pre-proline 0 CA--C 1.537 0.46 0 C-N-CA 125.654 1.582 . . . . 0.0 108.83 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.522 ' HG2' HG23 ' A' ' 79' ' ' THR . 85.9 Cg_exo -62.45 173.59 3.36 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.737 3.625 . . . . 0.0 113.426 174.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -145.57 162.09 38.26 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.54 1.136 . . . . 0.0 109.355 176.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.58 -117.55 0.76 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.883 1.673 . . . . 0.0 110.967 177.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.63 17.43 42.72 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-O 118.899 -0.945 . . . . 0.0 112.445 -177.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -85.72 151.01 24.19 Favored 'General case' 0 C--N 1.341 0.234 0 CA-C-N 118.059 0.93 . . . . 0.0 108.876 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -133.98 93.63 3.13 Favored 'General case' 0 CA--C 1.522 -0.124 0 C-N-CA 124.373 1.069 . . . . 0.0 111.239 -172.37 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.47 ' H ' ' CG ' ' A' ' 115' ' ' PRO . . . -49.03 118.15 4.82 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 125.926 1.726 . . . . 0.0 109.959 173.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.18 159.6 41.76 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 123.919 0.888 . . . . 0.0 112.223 -177.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -143.57 148.46 35.95 Favored 'General case' 0 N--CA 1.446 -0.644 0 C-N-CA 126.537 1.935 . . . . 0.0 107.114 178.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -134.1 65.16 1.58 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 178.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -76.93 150.65 35.94 Favored 'General case' 0 CA--C 1.53 0.198 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 178.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 31.4 m -118.18 142.77 47.1 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 123.872 0.869 . . . . 0.0 109.773 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -145.47 161.28 40.08 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.625 1.17 . . . . 0.0 109.98 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 69.6 m80 -129.81 92.25 37.8 Favored Pre-proline 0 CA--C 1.534 0.359 0 C-N-CA 125.885 1.674 . . . . 0.0 109.001 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -71.64 145.26 46.32 Favored 'Trans proline' 0 N--CA 1.454 -0.852 0 C-N-CA 123.093 2.528 . . . . 0.0 112.178 -175.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.8 p -93.56 155.25 17.42 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 124.834 1.254 . . . . 0.0 108.87 172.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -59.86 146.03 43.49 Favored 'General case' 0 CA--C 1.534 0.348 0 O-C-N 121.808 -0.558 . . . . 0.0 112.493 -174.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 128.41 -125.38 5.02 Favored Glycine 0 C--N 1.334 0.45 0 C-N-CA 126.79 2.138 . . . . 0.0 108.826 -178.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 35.6 m -153.5 144.59 22.91 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 118.226 1.013 . . . . 0.0 109.881 -175.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -134.74 175.27 9.7 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 126.506 1.922 . . . . 0.0 106.962 173.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -141.7 149.96 41.23 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.164 1.386 . . . . 0.0 108.199 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . 0.46 ' CZ ' ' HA3' ' A' ' 150' ' ' GLY . 48.1 p90 -112.89 144.22 42.82 Favored 'General case' 0 C--O 1.231 0.12 0 C-N-CA 123.956 0.903 . . . . 0.0 109.893 175.765 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.1 m -148.71 162.64 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 C-N-CA 125.081 1.352 . . . . 0.0 110.68 178.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 4.3 t -102.29 136.94 41.23 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.643 1.577 . . . . 0.0 107.663 171.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -81.32 -16.5 52.23 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 114.317 1.228 . . . . 0.0 114.317 -172.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 53.7 mt -63.81 129.52 93.86 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_exo -46.79 150.09 2.76 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 123.947 3.098 . . . . 0.0 114.575 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.42 -43.01 2.01 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 124.092 0.853 . . . . 0.0 112.89 174.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 24.0 m170 -50.76 -53.68 29.68 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.671 1.188 . . . . 0.0 111.98 -173.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -54.8 -46.71 74.53 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.77 0.428 . . . . 0.0 111.16 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -65.73 -41.71 91.91 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 123.156 0.583 . . . . 0.0 111.201 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 18.1 p -79.67 -58.94 2.94 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 123.031 0.532 . . . . 0.0 112.124 -173.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -177.81 38.33 0.09 OUTLIER Glycine 0 CA--C 1.525 0.665 0 C-N-CA 119.65 -1.262 . . . . 0.0 114.685 -174.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.1 ttt -126.19 64.75 1.23 Allowed 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 49.2 p90 -151.52 -174.47 4.84 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.806 0.843 . . . . 0.0 111.241 -177.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.46 ' HA3' ' CZ ' ' A' ' 136' ' ' TYR . . . 169.83 174.39 38.06 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 174.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.4 146.67 45.16 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 125.417 1.487 . . . . 0.0 109.805 -170.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.422 HG23 HD12 ' A' ' 66' ' ' ILE . 10.2 mt -128.33 95.81 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 125.461 1.504 . . . . 0.0 107.651 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 11.8 t -88.03 132.22 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.7 t -122.19 120.99 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 -176.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 46.9 mmtm . . . . . 0 N--CA 1.467 0.393 0 CA-C-N 119.671 1.123 . . . . 0.0 110.827 176.711 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.773 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.8 p -74.5 -46.35 40.0 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 124.754 1.222 . . . . 0.0 110.049 175.202 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.3 mm? 39.24 -103.37 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 127.013 2.125 . . . . 0.0 115.038 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -75.2 96.78 3.37 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 118.349 0.522 . . . . 0.0 110.605 -172.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.9 p -52.36 -16.97 0.98 Allowed 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.653 1.181 . . . . 0.0 113.366 174.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.2 m -78.25 53.96 1.31 Allowed 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 119.725 1.148 . . . . 0.0 112.171 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -92.68 142.96 26.79 Favored 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 127.697 2.399 . . . . 0.0 108.405 175.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -152.29 177.08 10.94 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -140.05 140.72 36.21 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 169.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.61 -150.9 0.47 Allowed 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 174.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 19.0 p -136.03 173.43 11.72 Favored 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 172.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 tt -39.56 -56.96 2.66 Favored Pre-proline 0 CA--C 1.538 0.514 0 N-CA-C 114.282 1.216 . . . . 0.0 114.282 -174.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -55.04 -35.31 89.97 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.572 1.515 . . . . 0.0 113.481 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.7 mp0 -65.55 -23.95 66.98 Favored 'General case' 0 N--CA 1.455 -0.184 0 O-C-N 121.339 -0.85 . . . . 0.0 111.379 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 42.7 t -55.72 -46.88 79.77 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 119.27 0.941 . . . . 0.0 108.972 173.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtmt -60.32 -51.25 70.31 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -52.56 -46.99 67.08 Favored 'General case' 0 CA--C 1.533 0.319 0 N-CA-C 111.692 0.256 . . . . 0.0 111.692 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 73.8 mtm -62.65 -54.93 32.08 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 122.721 0.408 . . . . 0.0 110.274 177.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 62.1 mt -49.23 -46.88 46.56 Favored 'General case' 0 CA--C 1.529 0.164 0 C-N-CA 122.883 0.473 . . . . 0.0 111.339 178.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -53.04 -27.0 17.66 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 179.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -90.5 -0.91 57.85 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 119.17 0.896 . . . . 0.0 112.503 -179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -57.02 154.52 9.56 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.897 0.771 . . . . 0.0 112.671 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 37.7 p -128.0 165.59 19.99 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 172.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 122.33 117.67 2.44 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -178.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.4 mtpt -79.08 121.51 25.07 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.31 1.444 . . . . 0.0 108.934 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 47.6 t -61.69 114.25 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 C-N-CA 125.591 1.556 . . . . 0.0 109.485 -176.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 9.1 m -130.57 68.03 1.48 Allowed 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 124.159 0.983 . . . . 0.0 111.435 -174.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 70.18 -94.67 0.47 Allowed Glycine 0 CA--C 1.531 1.043 0 C-N-CA 123.778 0.704 . . . . 0.0 112.476 174.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -101.07 -14.54 17.76 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 124.516 1.127 . . . . 0.0 110.127 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 29.4 m -108.39 151.79 25.55 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 124.811 1.244 . . . . 0.0 109.985 -172.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.44 130.71 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 104.115 -2.55 . . . . 0.0 104.115 170.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.7 m -115.39 119.66 37.0 Favored 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 123.187 0.595 . . . . 0.0 110.404 -170.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.411 ' CD1' HG13 ' A' ' 38' ' ' VAL . 96.7 m-85 -91.8 153.09 19.81 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.9 m -155.79 51.49 0.56 Allowed 'General case' 0 CA--C 1.53 0.185 0 O-C-N 121.884 -0.51 . . . . 0.0 110.157 -175.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.89 166.27 39.46 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 108.276 -1.93 . . . . 0.0 108.276 176.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -73.61 -38.16 65.18 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 117.503 0.651 . . . . 0.0 110.584 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 6.7 p -80.09 103.46 9.99 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 174.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.411 HG13 ' CD1' ' A' ' 33' ' ' TYR . 29.5 t -107.69 128.37 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.549 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 15.2 t-80 -132.15 101.36 5.36 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 123.941 0.897 . . . . 0.0 110.019 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.2 t -92.01 143.02 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 174.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 40.1 t -123.06 114.0 40.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.278 0 N-CA-C 105.495 -2.039 . . . . 0.0 105.495 173.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -120.93 112.17 18.43 Favored 'General case' 0 C--O 1.232 0.138 0 C-N-CA 124.645 1.178 . . . . 0.0 111.976 -172.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -89.86 149.87 22.46 Favored 'General case' 0 N--CA 1.452 -0.36 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 172.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -124.98 109.24 12.72 Favored 'General case' 0 C--O 1.226 -0.162 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 14.0 t 44.34 85.43 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 C-N-CA 125.258 1.423 . . . . 0.0 112.189 -176.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 51.9 mt -76.67 128.95 80.7 Favored Pre-proline 0 CA--C 1.534 0.336 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_exo -42.07 111.24 0.18 Allowed 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 124.071 3.181 . . . . 0.0 111.541 175.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 134.69 -45.91 1.08 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 -173.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -80.03 116.4 61.04 Favored Pre-proline 0 CA--C 1.532 0.259 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -79.45 59.96 7.62 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.759 2.306 . . . . 0.0 111.247 -174.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 63.07 170.3 0.09 OUTLIER Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 124.906 1.282 . . . . 0.0 111.861 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -117.61 34.46 0.58 Allowed 'Cis proline' 0 CA--C 1.536 0.611 0 N-CA-C 109.297 -1.078 . . . . 0.0 109.297 -6.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 17.1 p -90.64 143.13 27.04 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 118.519 2.785 . . . . 0.0 118.519 -168.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . 0.445 ' CD2' ' HB2' ' A' ' 148' ' ' MET . 3.2 m-85 -85.69 103.46 14.51 Favored 'General case' 0 C--N 1.34 0.176 0 N-CA-C 103.276 -2.861 . . . . 0.0 103.276 166.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -93.51 96.07 9.65 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -174.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.8 t -85.2 149.5 4.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -176.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -20.96 -57.31 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 116.732 2.123 . . . . 0.0 116.732 -172.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -114.31 -5.71 12.95 Favored 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -178.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 39.8 mttm -150.34 148.54 28.94 Favored 'General case' 0 C--O 1.223 -0.323 0 CA-C-N 119.845 1.202 . . . . 0.0 109.731 -174.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.5 mttm -97.07 123.79 40.91 Favored 'General case' 0 C--N 1.332 -0.181 0 O-C-N 121.351 -0.843 . . . . 0.0 109.595 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.59 46.29 1.88 Allowed Pre-proline 0 CA--C 1.542 0.658 0 C-N-CA 125.505 1.522 . . . . 0.0 111.435 176.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -83.92 174.29 8.54 Favored 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 122.31 2.007 . . . . 0.0 113.031 -171.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 52.9 m -86.54 148.66 25.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 170.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.5 mp -119.55 133.0 55.86 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 120.892 -1.13 . . . . 0.0 109.421 175.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 18.5 mm-40 -109.82 116.27 31.35 Favored 'General case' 0 CA--C 1.528 0.127 0 N-CA-C 105.539 -2.022 . . . . 0.0 105.539 171.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 6.7 mt -124.56 145.77 50.32 Favored Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 124.29 1.036 . . . . 0.0 112.456 -171.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -85.37 128.48 3.54 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.678 2.252 . . . . 0.0 107.909 171.172 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.26 151.99 2.63 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.859 1.264 . . . . 0.0 112.034 178.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.7 -31.8 2.19 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-O 119.203 -0.776 . . . . 0.0 113.701 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -46.84 148.6 1.02 Allowed 'General case' 0 CA--C 1.532 0.282 0 C-N-CA 124.567 1.147 . . . . 0.0 112.811 -179.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 17.2 m -79.68 96.06 6.11 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 44.4 t -79.53 89.51 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 177.098 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -82.68 133.49 35.16 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 173.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.3 t -132.78 110.83 16.18 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 98.4 m -91.39 125.94 36.3 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 174.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -94.27 158.64 15.49 Favored 'General case' 0 C--O 1.223 -0.327 0 N-CA-C 112.383 0.512 . . . . 0.0 112.383 174.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.6 mp -137.41 67.57 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 N-CA-C 102.577 -3.12 . . . . 0.0 102.577 163.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 20.8 t30 -98.09 76.67 2.39 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 -175.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 48.0 p -94.79 -80.14 0.41 Allowed 'General case' 0 N--CA 1.448 -0.571 0 C-N-CA 124.501 1.12 . . . . 0.0 109.923 -173.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 68.35 -50.71 0.55 Allowed 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 127.253 2.221 . . . . 0.0 114.649 177.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 87.4 mttt 96.42 33.14 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.226 0 C-N-CA 130.079 3.352 . . . . 0.0 111.877 -179.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 171.22 -60.03 0.17 Allowed Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -83.12 91.35 7.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.97 83.39 0.02 OUTLIER Glycine 0 CA--C 1.528 0.9 0 N-CA-C 109.958 -1.257 . . . . 0.0 109.958 173.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -68.87 74.66 0.29 Allowed 'General case' 0 N--CA 1.457 -0.111 0 C-N-CA 125.177 1.391 . . . . 0.0 112.878 -174.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.8 p -42.29 136.38 2.31 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 125.253 1.421 . . . . 0.0 111.281 177.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -107.68 119.95 40.86 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 173.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . 0.538 ' HB3' HD12 ' A' ' 105' ' ' ILE . 5.3 m-20 -129.62 108.79 10.49 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -172.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 32.3 mt -80.72 134.79 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 O-C-N 124.144 0.903 . . . . 0.0 108.824 176.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.0 t -160.33 -160.45 0.78 Allowed 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 125.433 1.493 . . . . 0.0 107.42 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 35.2 mtmm -126.43 13.31 7.61 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 123.692 0.797 . . . . 0.0 111.517 177.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -64.7 121.34 14.28 Favored 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 174.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -86.66 170.72 42.49 Favored Glycine 0 CA--C 1.532 1.114 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -70.85 164.16 36.59 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.208 2.605 . . . . 0.0 109.674 173.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -76.42 139.12 58.36 Favored 'Cis proline' 0 N--CA 1.455 -0.75 0 N-CA-C 110.163 -0.745 . . . . 0.0 110.163 -4.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -79.68 151.27 30.58 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.179 0.514 . . . . 0.0 110.011 178.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -98.96 149.71 22.69 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 124.135 0.974 . . . . 0.0 110.27 -174.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 18.2 t -62.52 -34.62 65.85 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 C-N-CA 123.706 0.803 . . . . 0.0 109.218 173.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 26.6 mmt -78.24 133.97 63.66 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -63.8 63.79 0.21 Allowed 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.889 3.059 . . . . 0.0 115.232 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 13.9 t -80.84 57.5 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 O-C-N 120.254 -1.529 . . . . 0.0 108.325 174.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -38.07 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 C-N-CA 123.529 0.732 . . . . 0.0 111.721 -174.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.04 143.45 32.08 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 125.017 1.327 . . . . 0.0 112.278 -172.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.18 162.45 92.7 Favored 'Cis proline' 0 N--CA 1.46 -0.444 0 N-CA-C 110.281 -0.7 . . . . 0.0 110.281 -6.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 88' ' ' ASP . 14.5 mm -118.18 144.46 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 174.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.7 t -98.56 -86.12 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 174.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -92.41 87.64 6.09 Favored 'General case' 0 CA--C 1.52 -0.207 0 O-C-N 122.024 -0.423 . . . . 0.0 109.977 178.031 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -90.4 125.61 7.99 Favored Glycine 0 N--CA 1.448 -0.552 0 N-CA-C 107.581 -2.208 . . . . 0.0 107.581 172.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 1.7 p -76.01 -41.48 50.97 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.261 1.531 . . . . 0.0 110.039 173.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.2 -170.09 21.25 Favored Glycine 0 CA--C 1.532 1.145 0 N-CA-C 108.673 -1.771 . . . . 0.0 108.673 -174.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -91.17 138.26 31.73 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.332 1.566 . . . . 0.0 109.215 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 26.0 p -83.21 159.31 62.48 Favored Pre-proline 0 CA--C 1.533 0.317 0 N-CA-C 113.478 0.918 . . . . 0.0 113.478 -173.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.87 74.61 3.88 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 123.076 2.518 . . . . 0.0 107.987 172.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.8 m -53.67 128.9 54.1 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 123.278 0.631 . . . . 0.0 111.331 -175.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.98 176.36 9.92 Favored 'Trans proline' 0 N--CA 1.456 -0.725 0 C-N-CA 123.286 2.657 . . . . 0.0 110.078 -179.071 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.32 -29.38 6.24 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 176.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -174.02 155.85 2.6 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 126.715 2.006 . . . . 0.0 108.174 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 71.34 -59.05 1.15 Allowed Glycine 0 CA--C 1.527 0.789 0 C-N-CA 125.466 1.508 . . . . 0.0 113.06 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -78.92 158.77 27.98 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 123.417 0.687 . . . . 0.0 111.344 -174.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -135.23 94.42 3.12 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.804 2.041 . . . . 0.0 108.388 -174.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -53.27 113.29 2.84 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 173.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 20.1 p90 -119.32 177.03 5.05 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 124.537 1.135 . . . . 0.0 109.689 175.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.5 m -158.05 154.17 27.16 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 -177.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -131.82 89.54 2.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 173.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -96.9 170.08 9.41 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 24.8 m -150.79 146.56 26.46 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 23.2 t90 -150.56 153.53 35.94 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.884 0.874 . . . . 0.0 110.423 -176.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -116.47 114.44 40.33 Favored Pre-proline 0 CA--C 1.535 0.384 0 C-N-CA 125.584 1.554 . . . . 0.0 107.116 173.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -89.79 142.26 3.98 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 124.371 3.381 . . . . 0.0 111.503 -172.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 41.2 p -96.02 146.42 24.64 Favored 'General case' 0 CA--C 1.528 0.12 0 C-N-CA 124.363 1.065 . . . . 0.0 108.845 173.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -56.83 149.08 19.08 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.164 0.438 . . . . 0.0 112.092 -179.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 121.74 -123.96 5.63 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 126.754 2.121 . . . . 0.0 109.123 -175.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 46.1 m -153.84 145.7 23.49 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 118.351 1.075 . . . . 0.0 109.972 -174.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -132.95 176.45 8.47 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 127.336 2.254 . . . . 0.0 106.897 173.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -142.31 152.81 43.33 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 125.534 1.533 . . . . 0.0 107.551 175.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 55.1 p90 -114.83 140.59 48.82 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 123.223 0.609 . . . . 0.0 109.905 174.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.36 162.9 14.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.375 1.07 . . . . 0.0 111.093 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 8.8 t -107.69 136.09 48.02 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 127.121 2.169 . . . . 0.0 109.838 173.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 44.8 mt-30 -81.64 -19.0 42.65 Favored 'General case' 0 N--CA 1.463 0.221 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 -170.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 86.9 mt -63.01 130.04 93.82 Favored Pre-proline 0 CA--C 1.544 0.721 0 CA-C-N 119.125 0.875 . . . . 0.0 108.989 -174.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -42.15 133.45 4.52 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.745 2.964 . . . . 0.0 113.424 178.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 90.07 -32.51 4.87 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.099 0.857 . . . . 0.0 111.795 -174.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -75.49 172.84 11.83 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 -176.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . 75.29 -60.6 0.5 Allowed 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -170.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -60.2 -52.27 66.01 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 172.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 25.7 p -78.51 75.47 5.03 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-O 121.829 0.823 . . . . 0.0 112.272 -178.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 70.87 -44.71 0.67 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 118.189 2.035 . . . . 0.0 118.189 169.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . 0.445 ' HB2' ' CD2' ' A' ' 54' ' ' PHE . 4.2 ptp -77.85 87.74 4.07 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 119.857 1.828 . . . . 0.0 114.271 -172.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 36.4 p90 -160.81 -179.91 7.97 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 126.053 1.741 . . . . 0.0 108.839 173.497 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 178.86 168.39 37.96 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 172.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -104.21 138.51 40.57 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 125.049 1.339 . . . . 0.0 108.356 -174.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.1 mt -114.76 100.44 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 175.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 19.6 t -84.16 136.37 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.304 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 21.7 t -123.02 115.65 46.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp . . . . . 0 N--CA 1.462 0.13 0 CA-C-N 119.091 0.86 . . . . 0.0 109.558 174.64 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.829 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 29.1 p -76.61 86.09 3.28 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 175.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.3 mp -57.31 147.67 25.02 Favored 'General case' 0 C--O 1.23 0.056 0 CA-C-O 122.035 0.922 . . . . 0.0 108.907 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.42 143.34 42.76 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.667 -173.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -121.12 12.11 11.03 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.67 1.988 . . . . 0.0 111.337 -174.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 7.2 m -79.16 66.57 4.64 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.568 1.147 . . . . 0.0 112.253 -171.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . . . . . . . . . 0.9 OUTLIER -96.34 146.83 24.4 Favored 'General case' 0 CA--C 1.522 -0.099 0 N-CA-C 114.875 1.435 . . . . 0.0 114.875 177.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -149.13 170.15 19.07 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 129.064 2.946 . . . . 0.0 103.706 171.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -124.8 126.55 45.79 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-N 119.645 1.111 . . . . 0.0 110.063 174.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -88.09 -150.22 0.18 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 172.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 80.9 p -142.39 166.07 25.7 Favored 'General case' 0 CA--C 1.532 0.274 0 O-C-N 121.389 -0.819 . . . . 0.0 109.277 174.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.8 tt -39.45 -58.11 2.1 Favored Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 114.73 1.382 . . . . 0.0 114.73 -175.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -60.06 -28.84 87.9 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 CA-C-N 121.159 1.45 . . . . 0.0 112.224 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -66.83 -24.46 66.16 Favored 'General case' 0 N--CA 1.45 -0.465 0 O-C-N 121.462 -0.774 . . . . 0.0 111.013 177.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.0 t -63.34 -53.84 40.48 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 173.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.5 mtpp -54.29 -42.81 70.47 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.468 178.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -58.25 -66.6 0.46 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.273 -0.267 . . . . 0.0 110.619 174.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 67.9 mtm -47.68 -50.2 25.55 Favored 'General case' 0 CA--C 1.528 0.1 0 C-N-CA 124.766 1.226 . . . . 0.0 112.182 -174.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 51.5 mt -47.14 -40.68 16.18 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.16 0.584 . . . . 0.0 112.192 -179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -67.86 -10.63 54.65 Favored 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 112.747 0.647 . . . . 0.0 112.747 -176.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -106.51 17.55 23.17 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.885 0.766 . . . . 0.0 110.999 175.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -65.6 106.06 1.37 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 119.132 0.878 . . . . 0.0 109.909 174.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.9 p -77.98 82.52 4.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -178.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -171.37 112.71 0.46 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 174.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 33.1 mmtp -78.98 162.78 25.72 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.793 1.237 . . . . 0.0 109.863 -177.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.4 t -69.11 141.42 17.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.653 1.181 . . . . 0.0 109.59 -178.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.5 m -147.85 67.22 1.1 Allowed 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.363 -0.835 . . . . 0.0 109.593 174.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 63.06 -94.66 0.12 Allowed Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.827 0.727 . . . . 0.0 111.785 175.022 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -109.19 25.54 11.68 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 125.856 1.663 . . . . 0.0 110.118 178.202 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.7 m -154.99 163.12 40.75 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -174.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.09 147.17 23.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.137 -1.801 . . . . 0.0 106.137 173.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.6 m -142.15 138.23 31.45 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-N 119.259 0.936 . . . . 0.0 111.168 -171.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -112.07 -167.88 1.24 Allowed 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 118.331 0.514 . . . . 0.0 111.522 173.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.3 m -157.75 -47.77 0.06 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 123.732 0.813 . . . . 0.0 112.268 -173.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -70.08 156.35 53.37 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 177.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 13.4 mmmm -79.18 40.6 0.42 Allowed 'General case' 0 CA--C 1.54 0.595 0 O-C-N 121.289 -1.124 . . . . 0.0 112.323 -174.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 27.3 m -156.18 102.31 2.12 Favored 'General case' 0 N--CA 1.457 -0.112 0 O-C-N 120.771 -1.206 . . . . 0.0 107.877 -178.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.2 t -104.73 84.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -82.47 93.36 7.23 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 173.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 t -93.99 159.65 2.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.4 t -133.68 106.93 9.79 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 C-N-CA 124.97 1.308 . . . . 0.0 108.045 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -112.74 103.48 11.5 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 125.416 1.487 . . . . 0.0 109.836 -174.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.03 112.0 23.71 Favored 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.276 0.63 . . . . 0.0 109.304 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.57 102.87 15.55 Favored 'General case' 0 CA--C 1.53 0.201 0 O-C-N 121.502 -0.749 . . . . 0.0 110.15 -174.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 4.6 t 49.32 82.54 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 125.613 1.565 . . . . 0.0 112.389 178.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 79.3 mt -76.58 141.6 69.41 Favored Pre-proline 0 CA--C 1.533 0.314 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 174.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -56.22 113.85 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 123.093 2.529 . . . . 0.0 110.315 -174.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 128.19 -41.41 1.58 Allowed Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -174.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -81.14 146.05 57.75 Favored Pre-proline 0 N--CA 1.454 -0.238 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 178.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -75.71 152.28 37.37 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.513 2.142 . . . . 0.0 111.628 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -70.29 156.36 91.98 Favored Pre-proline 0 N--CA 1.453 -0.307 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 172.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -109.86 65.09 0.34 Allowed 'Cis proline' 0 N--CA 1.455 -0.766 0 N-CA-C 107.115 -1.917 . . . . 0.0 107.115 -5.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 59.1 p -86.45 123.07 31.27 Favored 'General case' 0 CA--C 1.542 0.654 0 N-CA-C 116.581 2.067 . . . . 0.0 116.581 -171.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -83.47 94.24 7.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 168.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -81.79 115.91 21.23 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -175.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.5 t -114.09 82.55 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 C-N-CA 125.067 1.347 . . . . 0.0 109.479 -173.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.418 ' CG ' ' N ' ' A' ' 58' ' ' ASP . 1.0 OUTLIER 46.83 -69.21 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 130.594 3.557 . . . . 0.0 115.221 176.239 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.418 ' N ' ' CG ' ' A' ' 57' ' ' HIS . 21.2 t70 -95.51 -28.08 15.06 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 126.153 1.781 . . . . 0.0 110.838 -176.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -132.19 -176.92 4.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 123.787 0.835 . . . . 0.0 109.285 -176.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -134.4 121.27 20.9 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 175.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 58.64 43.41 0.9 Allowed Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 124.897 1.279 . . . . 0.0 111.18 -177.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -82.59 177.74 6.71 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 121.711 1.608 . . . . 0.0 111.412 -175.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 20.7 m -93.47 138.04 32.17 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 170.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 6.0 mp -111.3 140.17 46.09 Favored 'General case' 0 CA--C 1.53 0.18 0 C-N-CA 124.111 0.964 . . . . 0.0 109.939 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -112.88 120.9 43.05 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.603 1.161 . . . . 0.0 108.167 172.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 16.5 mt -128.01 146.54 59.6 Favored Pre-proline 0 CA--C 1.539 0.547 0 N-CA-C 113.715 1.005 . . . . 0.0 113.715 -170.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -72.06 123.11 9.01 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.608 2.205 . . . . 0.0 110.587 170.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.39 134.65 28.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 124.22 1.008 . . . . 0.0 110.57 173.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 77.98 0.43 75.76 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 118.764 -1.02 . . . . 0.0 113.157 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.06 146.63 52.82 Favored 'General case' 0 N--CA 1.456 -0.169 0 CA-C-N 119.847 1.824 . . . . 0.0 109.628 173.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 58.5 m -78.37 99.76 6.5 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 173.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 90.2 t -79.25 134.71 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -139.47 95.07 2.86 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 125.754 1.621 . . . . 0.0 106.729 173.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.7 t -80.11 106.02 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 174.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.0 m -79.47 109.0 13.43 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -76.93 150.34 35.95 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.478 172.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.408 ' O ' HG22 ' A' ' 77' ' ' ILE . 1.2 mp -132.74 69.1 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 165.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -102.3 77.94 1.7 Allowed 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 -175.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 5.1 p -118.51 20.21 13.07 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.108 1.763 . . . . 0.0 112.627 -171.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 -70.0 103.36 2.24 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 173.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 30.4 mtpp -46.78 134.81 9.58 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.683 0.793 . . . . 0.0 111.692 -173.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.23 -59.45 3.6 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -174.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -78.89 67.8 4.69 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 123.338 0.655 . . . . 0.0 111.046 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.29 92.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.703 0 N-CA-C 108.267 -1.933 . . . . 0.0 108.267 172.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.6 m-70 -60.53 179.47 0.16 Allowed 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.059 0.944 . . . . 0.0 110.637 178.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 p -137.92 147.9 44.8 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.439 -2.06 . . . . 0.0 105.439 177.315 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -127.02 104.18 7.85 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 173.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASP . . . . . 0.499 ' HB3' HD12 ' A' ' 105' ' ' ILE . 60.3 m-20 -120.62 127.24 51.91 Favored 'General case' 0 N--CA 1.453 -0.291 0 C-N-CA 123.989 0.916 . . . . 0.0 108.877 -174.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 56.2 mt -98.46 129.74 48.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 C-N-CA 125.999 1.719 . . . . 0.0 108.579 -174.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.7 t -160.96 -151.08 0.22 Allowed 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 124.581 1.153 . . . . 0.0 108.153 -173.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 mtmt -133.92 -88.04 0.4 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.821 0.849 . . . . 0.0 109.783 178.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.6 mtmt 49.15 -126.74 2.09 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.216 1.006 . . . . 0.0 109.169 -173.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -175.65 161.88 30.92 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.191 -1.563 . . . . 0.0 109.191 175.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -77.82 154.44 30.17 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.613 2.876 . . . . 0.0 109.75 174.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.14 144.92 82.56 Favored 'Cis proline' 0 N--CA 1.453 -0.872 0 N-CA-C 108.994 -1.194 . . . . 0.0 108.994 -5.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -78.44 163.67 25.42 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-O 121.375 0.607 . . . . 0.0 110.054 -176.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.24 145.13 42.19 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.563 -173.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.25 -49.56 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.336 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 174.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -78.79 149.55 74.34 Favored Pre-proline 0 CA--C 1.534 0.346 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -72.6 73.62 2.84 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.829 2.352 . . . . 0.0 111.494 -179.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 16.6 t -79.28 53.24 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 173.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.2 pt -84.33 68.71 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-O 122.874 1.321 . . . . 0.0 109.787 -176.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -88.48 -72.69 0.06 OUTLIER Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 113.743 -1.571 . . . . 0.0 110.597 -174.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -77.77 57.76 6.17 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 122.208 1.939 . . . . 0.0 111.48 -178.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.499 HD12 ' HB3' ' A' ' 88' ' ' ASP . 24.8 mm -78.41 126.56 38.64 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 O-C-N 121.228 -0.92 . . . . 0.0 108.8 177.392 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 95.1 t -84.78 -88.18 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -95.62 164.29 12.84 Favored 'General case' 0 CA--C 1.521 -0.162 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 173.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 172.26 -179.14 44.04 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 119.297 -1.43 . . . . 0.0 112.556 173.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 6.0 p -130.84 138.82 50.03 Favored 'General case' 0 C--O 1.235 0.307 0 C-N-CA 126.272 1.829 . . . . 0.0 108.749 176.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -75.04 -127.77 0.19 Allowed Glycine 0 CA--C 1.534 1.275 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 174.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -112.15 154.47 25.44 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 119.659 1.729 . . . . 0.0 110.465 176.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 37.6 p -90.31 155.83 46.33 Favored Pre-proline 0 N--CA 1.449 -0.488 0 C-N-CA 124.927 1.291 . . . . 0.0 112.397 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -73.52 98.82 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.192 0 C-N-CA 122.981 2.454 . . . . 0.0 107.468 173.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 40.3 t -37.85 123.49 1.0 Allowed Pre-proline 0 CA--C 1.538 0.502 0 C-N-CA 125.222 1.409 . . . . 0.0 110.421 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -67.79 156.71 64.91 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 122.66 2.24 . . . . 0.0 112.847 -172.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' LYS . . . . . . . . . . . . . 29.2 mmmt -110.2 175.94 5.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 125.717 1.607 . . . . 0.0 106.824 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -36.91 104.02 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 125.119 1.368 . . . . 0.0 114.07 -174.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.31 -8.5 46.33 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-O 118.456 -1.191 . . . . 0.0 115.148 173.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -84.48 156.0 21.92 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 118.866 1.333 . . . . 0.0 109.744 -178.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -139.37 94.17 2.76 Favored 'General case' 0 CA--C 1.53 0.177 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -172.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -51.6 116.14 4.5 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.214 1.387 . . . . 0.0 113.06 174.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -130.46 154.79 47.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 124.26 1.024 . . . . 0.0 111.486 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 1.8 m -145.36 118.84 9.05 Favored 'General case' 0 CA--C 1.518 -0.278 0 C-N-CA 124.419 1.088 . . . . 0.0 109.646 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -95.27 88.28 5.1 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 171.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -89.65 122.97 33.28 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 21.8 m -82.91 142.08 31.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.201 -0.908 . . . . 0.0 110.885 -174.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' TRP . . . . . . . . . . . . . 25.4 t90 -151.38 155.77 39.33 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.458 1.103 . . . . 0.0 109.423 175.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 65.2 m80 -123.78 108.85 30.49 Favored Pre-proline 0 CA--C 1.532 0.288 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 173.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -89.57 144.24 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.909 3.073 . . . . 0.0 111.019 -172.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.8 p -95.86 155.02 16.92 Favored 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 124.052 0.941 . . . . 0.0 109.549 173.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -60.88 149.25 36.82 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -175.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLY . . . . . . . . . . . . . . . 126.67 -128.04 6.17 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 126.39 1.948 . . . . 0.0 108.684 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 32.1 m -152.99 141.95 21.23 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 118.451 1.125 . . . . 0.0 110.201 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -128.29 174.84 8.95 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 125.893 1.677 . . . . 0.0 107.828 173.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -134.74 147.17 49.98 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 125.124 1.37 . . . . 0.0 107.904 174.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -109.06 142.88 39.15 Favored 'General case' 0 N--CA 1.458 -0.052 0 C-N-CA 123.561 0.745 . . . . 0.0 109.291 174.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 33.0 m -143.95 165.3 14.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 124.528 1.131 . . . . 0.0 111.452 -177.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' CYS . . . . . . . . . . . . . 12.2 t -118.76 135.04 54.72 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 126.634 1.974 . . . . 0.0 110.091 173.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLN . . . . . . . . . . . . . 64.9 mt-30 -64.47 -50.9 65.66 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 125.015 1.326 . . . . 0.0 113.49 -174.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 71.4 mt -39.95 121.91 1.55 Allowed Pre-proline 0 CA--C 1.541 0.617 0 C-N-CA 124.711 1.204 . . . . 0.0 111.526 -170.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -31.79 120.22 0.08 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.886 1 C-N-CA 125.472 4.115 . . . . 0.0 115.711 -173.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 86.74 -25.05 7.77 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 118.888 -0.951 . . . . 0.0 113.481 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' HIS . . . . . . . . . . . . . 22.4 m170 -54.68 -59.99 3.97 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 119.203 1.501 . . . . 0.0 111.548 -172.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ALA . . . . . . . . . . . . . . . -49.12 -56.37 9.35 Favored 'General case' 0 C--N 1.34 0.183 0 C-N-CA 123.138 0.575 . . . . 0.0 110.934 177.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -56.27 -46.66 79.59 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 123.914 0.886 . . . . 0.0 112.336 -175.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' THR . . . . . . . . . . . . . 46.7 p -79.23 -36.31 40.22 Favored 'General case' 0 N--CA 1.455 -0.204 0 N-CA-C 113.186 0.809 . . . . 0.0 113.186 -172.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -179.56 -18.82 0.03 OUTLIER Glycine 0 C--N 1.34 0.771 0 C-N-CA 118.442 -1.837 . . . . 0.0 116.443 -175.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 1.4 ttt -79.73 65.11 4.8 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.093 1.446 . . . . 0.0 109.681 -174.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -161.53 167.96 24.47 Favored 'General case' 0 C--O 1.225 -0.236 0 C-N-CA 123.035 0.534 . . . . 0.0 111.53 -178.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -174.22 169.34 42.34 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 108.835 -1.706 . . . . 0.0 108.835 176.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -94.5 151.68 19.16 Favored 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.637 1.175 . . . . 0.0 110.526 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 11.4 mt -125.22 94.0 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 173.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 9.2 t -80.26 136.59 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 173.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . . . . . . . . . 23.2 t -127.39 127.65 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 -176.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 49.8 mttp . . . . . 0 N--CA 1.464 0.243 0 CA-C-N 119.043 0.838 . . . . 0.0 111.383 -176.813 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_